<document page-count="657">
<page number="1">
</page>
<page number="2">
<table id="p2t1" data-filename="pdftables_fromstorage_023782248" data-page="2" data-table="1"><tr><td colspan="3">R A N</td><td>G</td><td>&amp;</td><td>D</td><td>A L</td><td>E</td><td>’S</td></tr><tr><td>R</td><td>A</td><td>N</td><td>G</td><td>A</td><td>ND</td><td>DA</td><td>L</td><td>E’S</td></tr><tr><td colspan="9">Pharmacology</td></tr><tr><td colspan="9">FFllasahs Chacrdas rUdpsdated Edition</td></tr><tr><td>M M Dale</td><td colspan="5">MB BCh PhD</td><td></td><td></td><td></td></tr><tr><td colspan="9">Senior Teaching Fellow, Department of Pharmacology, University of</td></tr><tr><td>Oxford, UK</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">Dennis G Haylett</td><td colspan="3">BSc, PhD</td><td></td></tr><tr><td colspan="9">Honorary Senior Lecturer, Department of Pharmacology,</td></tr><tr><td colspan="6">University College London, UK</td><td></td><td></td><td></td></tr></table>
</page>
<page number="3">
<table id="p3t1" data-filename="pdftables_fromstorage_023782248" data-page="3" data-table="1"><tr><td>CHURCHILL LIVINGSTONE an imprint of Elsevier Limited</td><td>knowledge of their patients, to make diagnoses, to determine dosages</td></tr><tr><td>© 2014, Elsevier Limited. All rights reserved.</td><td>and the best treatment for each individual patient, and to take all</td></tr><tr><td></td><td>appropriate safety precautions.</td></tr><tr><td>No part of this publication may be reproduced or transmitted in any</td><td></td></tr><tr><td>form or by any means, electronic or mechanical, including</td><td>To the fullest extent of the law, neither the Publisher nor the authors,</td></tr><tr><td>photocopying, recording, or any information storage and retrieval</td><td>contributors, or editors, assume any liability for any injury and/or</td></tr><tr><td>system, without permission in writing from the publisher. Details on how</td><td>damage to persons or property as a matter of products liability,</td></tr><tr><td>to seek permission, further information about the Publisher’s permissions</td><td>negligence or otherwise, or from any use or operation of any methods,</td></tr><tr><td>policies and our arrangements with organizations such as the</td><td>products, instructions, or ideas contained in the material herein.</td></tr><tr><td>Copyright Clearance Center and the Copyright Licensing Agency, can</td><td></td></tr><tr><td>be found at our website: www.elsevier.com/permissions.</td><td>ISBN: 9780702059575</td></tr><tr><td>This book and the individual contributions contained in it are protected</td><td>Printed in China</td></tr><tr><td>under copyright by the Publisher (other than as may be noted herein).</td><td>Last digit is the print number: 9 8 7 6 5 4 3 2 1</td></tr><tr><td>Notices</td><td></td></tr><tr><td>Knowledge and best practice in this field are constantly changing. As</td><td>Working together to grow</td></tr><tr><td>new research and experience broaden our understanding, changes in</td><td>libraries in developing countries</td></tr><tr><td>research methods, professional practices, or medical treatment may</td><td></td></tr><tr><td>become necessary. Practitioners and researchers must always rely on</td><td>www.elsevier.com | www.bookaid.org | www.sabre.org</td></tr><tr><td>their own experience and knowledge in evaluating and using any</td><td></td></tr><tr><td>information, methods, compounds, or experiments described herein. In</td><td></td></tr><tr><td>using such information or methods they should be mindful of their own</td><td>VQMPBEFECZ&lt;TUPSNSH&gt;</td></tr><tr><td>safety and the safety of others, including parties for whom they have a</td><td></td></tr><tr><td>professional responsibility.</td><td>Commissioning Editor: Kate Dimock</td></tr><tr><td></td><td>Development Editor: Alexandra Mortimer</td></tr><tr><td>With respect to any drug or pharmaceutical products identified,</td><td>Editorial Assistant: Lora Sickora</td></tr><tr><td>readers are advised to check the most current information provided (i)</td><td>Project Manager: Kerrie-Anne McKinlay</td></tr><tr><td>on procedures featured or (ii) by the manufacturer of each product to</td><td>Design: Stewart Larking</td></tr><tr><td>be administered, to verify the recommended dose or formula, the</td><td>Illustration Manager: Bruce Hogarth</td></tr><tr><td>method and duration of administration, and contraindications. It is the</td><td>Illustrator: Antbits</td></tr><tr><td>responsibility of practitioners, relying on their own experience and</td><td>Marketing Manager(s) (UK/USA): Jeremy Bowes/Amanda Davis</td></tr></table>
</page>
<page number="4">
<table id="p4t1" data-filename="pdftables_fromstorage_023782248" data-page="4" data-table="1"><tr><td colspan="2">CONTENTS</td><td></td><td></td><td></td></tr><tr><td></td><td>Preface</td><td></td><td></td><td></td></tr><tr><td></td><td>Acknowledgements</td><td></td><td></td><td></td></tr><tr><td>Section 1.</td><td>Cholinergic pharmacology</td><td>Section</td><td style="text-align: right">21.</td><td>General anaesthetic</td></tr><tr><td>Section 2.</td><td>Noradrenergic pharmacology</td><td>Section</td><td style="text-align: right">22.</td><td>Anxiolytics and hypnotics</td></tr><tr><td>Section 3.</td><td>Inflammation and anti-inflammatory drugs</td><td>Section</td><td style="text-align: right">23.</td><td>Antipsychotics</td></tr><tr><td>Section 4.</td><td>Drugs affecting immune responses</td><td>Section</td><td style="text-align: right">24.</td><td>Affective disorders</td></tr><tr><td>Section 5.</td><td>Antidysrhythmic drugs</td><td>Section</td><td style="text-align: right">25.</td><td>Antiepileptic drugs</td></tr><tr><td>Section 6.</td><td>CVS antihypertensive drugs</td><td>Section</td><td style="text-align: right">26.</td><td>Analgesic drugs and the control of pain</td></tr><tr><td>Section 7.</td><td>Angina and cardiac infarction</td><td>Section</td><td style="text-align: right">27.</td><td>CNS stimulants and psychotomimetics</td></tr><tr><td>Section 8.</td><td>Heart Failure</td><td>Section</td><td style="text-align: right">28.</td><td>Local anaesthetics</td></tr><tr><td>Section 9.</td><td>Atherosclerosis and lipoproteins</td><td>Section</td><td style="text-align: right">29.</td><td>Antibacterial agents</td></tr><tr><td>Section 10.</td><td>Haemostasis &amp; thrombosis</td><td>Section</td><td style="text-align: right">30.</td><td>Antiviral agents</td></tr><tr><td>Section 11.</td><td>Haemopoietic system</td><td>Section</td><td style="text-align: right">31.</td><td>Antiprotozoal drugs</td></tr><tr><td>Section 12.</td><td>Asthma and antiasthma drugs</td><td>Section</td><td style="text-align: right">32.</td><td>Antifungal agents</td></tr><tr><td>Section 13.</td><td>Kidney</td><td>Section</td><td style="text-align: right">33.</td><td>Anthelminthic drugs</td></tr><tr><td>Section 14.</td><td>GIT drugs</td><td>Section</td><td style="text-align: right">34.</td><td>Anticancer drugs</td></tr><tr><td>Section 15.</td><td>Blood sugar and diabetes</td><td>Section</td><td style="text-align: right">35.</td><td>General principles</td></tr><tr><td>Section 16.</td><td>The ant. pituitary &amp; the adrenal cortex</td><td>Section</td><td style="text-align: right">36.</td><td>The introduction of new drugs</td></tr><tr><td>Section 17.</td><td>Thyroid and antithyroid drugs</td><td>Section</td><td style="text-align: right">37.</td><td>Absorption and distribution of drugs</td></tr><tr><td>Section 18.</td><td>Bone metabolism</td><td>Section</td><td style="text-align: right">38.</td><td>Drug metabolism and excretion</td></tr><tr><td>Section 19.</td><td>Reproductive system</td><td>Section</td><td style="text-align: right">39.</td><td>Pharmacokinetics</td></tr><tr><td>Section 20.</td><td>Neurodegenerative disorders</td><td></td><td></td><td></td></tr></table>
</page>
<page number="5">
<table id="p5t1" data-filename="pdftables_fromstorage_023782248" data-page="5" data-table="1"><tr><td>HOW TO USE THESE CARDS:</td></tr><tr><td>The cards are in sets that accord with the chapters in Rang &amp; Dales’ ‘Pharmacology’</td></tr><tr><td>and Dale &amp; Haylett’s ‘Pharmacology Condensed’ and references to relevant pages in</td></tr><tr><td>these books are given throughout.</td></tr><tr><td>The first card in a set has a diagram of the patho-physiological processes of the chapter</td></tr><tr><td>topic (e.g. thrombosis, analgesia, malaria etc.) and at the top of the card the name of</td></tr><tr><td>a drug (A) that modifies those processes. The back of the card has the essential details</td></tr><tr><td>of drug A – actions, mechanism of action, pharmacokinetic aspects, adverse effects, the</td></tr><tr><td>names of similar drugs and important aspects of clinical use.</td></tr><tr><td>In the second card, drug A is placed in context in the diagram and another drug (B) is</td></tr><tr><td>listed, with its essential details on the back. Drugs are added cumulatively to the diagram</td></tr><tr><td>in subsequent cards in the set.</td></tr><tr><td>The final card in a set will usually include all the drugs mentioned and either allow space</td></tr><tr><td>for personal notes or provide some challenging questions on the uses of the drugs.</td></tr><tr><td>It is expected that students will use the cards for private revision and this is facilitated</td></tr><tr><td>(on trains/ buses etc.) by the provision of a punched hole and ring which allows particu-</td></tr><tr><td>lar sets or batches to be separated and easily carried. The cards can also be used in</td></tr><tr><td>Q/A group sessions.</td></tr></table>
</page>
<page number="6">
<table id="p6t1" data-filename="pdftables_fromstorage_023782248" data-page="6" data-table="1"><tr><td>PREFACE</td><td></td></tr><tr><td colspan="2">Pharmacology is not a conceptually difficult subject like theoretical physics or higher mathematics. The only</td></tr><tr><td colspan="2">problem in studying pharmacology is that a great many facts and hard-to-remember drug names have to be</td></tr><tr><td colspan="2">mastered. To get to grips with the subject it is essential to appreciate how drugs work; and to do this it is</td></tr><tr><td colspan="2">necessary to understand the underlying pathophysiological processes on which they act. Once you’ve covered</td></tr><tr><td colspan="2">the detail from lectures and textbooks, there is then the problem of making sure the information stays securely</td></tr><tr><td colspan="2">and accessibly in your memory for when you need it later in your professional life. And to do this efficiently</td></tr><tr><td colspan="2">you need to know what the essential points about any drug are, so that with these you will be able, by asso-</td></tr><tr><td>ciation, to call up fuller details.</td><td></td></tr><tr><td>Our cards follow fairly closely the sequence of chapters in Rang &amp; Dale (7th</td><td>edition) and Dale and Haylett</td></tr><tr><td colspan="2">(2 nd edition). On the front of each card there is a drug name and a diagram showing the relevant pathophysi-</td></tr><tr><td colspan="2">ological processes it affects (e.g. noradrenergic transmission, heart failure etc); the essential information about</td></tr><tr><td>the drug appears on the back.</td><td></td></tr><tr><td colspan="2">The crucial facts about each drug are thus shown in the context of its mechanism of action, so that the user</td></tr><tr><td colspan="2">can lodge them securely in his/her mind, as pointers to the more detailed material buried ‘deeper’.</td></tr><tr><td>The cards could also (whisper it) help with revising for exams.</td><td></td></tr><tr><td>ACKNOWLEDGEMENTS</td><td></td></tr><tr><td colspan="2">We wish to record our appreciation of the team at Elsevier who worked on this project: Kate Dimock (com-</td></tr><tr><td colspan="2">missioning editor), Alexandra Mortimer (development editor), Kerrie-Anne McKinlay (project manager) and</td></tr><tr><td>Stewart Larking (designer).</td><td></td></tr></table>
</page>
<page number="7">
<table id="p7t1" data-filename="pdftables_fromstorage_023782248" data-page="7" data-table="1"><tr><td colspan="2">DRUG INDEX</td><td></td><td></td><td></td></tr><tr><td>Abciximab 10.03, 10.11</td><td>Anakinra? 3.10</td><td>Benzocaine 28.04</td><td></td><td>Carbimazole 17.01</td></tr><tr><td>Acarbose 15.06</td><td>Aprepitant 14.12</td><td>Benztropine 20.06</td><td></td><td>Carboplatin 34.06</td></tr><tr><td>Aciclovir 30.05</td><td>Arachis oil 14.17</td><td>Benzylpenicillin (Penicillin G)</td><td style="text-align: right">29.01</td><td>Carboprost 19.06</td></tr><tr><td>Adalimumab 3.09</td><td>Aripiprazole 23.07, 23.09</td><td>Bethanechol 1.01</td><td></td><td>Caspofungin 32.04</td></tr><tr><td>Adenosine 5.07</td><td>Artemether 31.07</td><td>Biperiden 20.06</td><td></td><td>Cefaclor 29.05</td></tr><tr><td>Albendazole 33.01</td><td>Articaine 28.05</td><td>Bisacodyl 14.16</td><td></td><td>Cefoperazone 29.06</td></tr><tr><td>Alendronate 18.01, 18.09</td><td>Aspirin 3.02, 10.01, 10.10, 10.11, 26.06,</td><td>Bismuth chelate (tripotassium</td><td></td><td>Ceftazidime 29.06</td></tr><tr><td>Allopurinol 3.11</td><td style="text-align: right">26.10</td><td>dicitratobismuthate) 14.04</td><td></td><td>Ceftriaxone 29.06</td></tr><tr><td>Alteplase 10.05</td><td>Atazanavir 30.03, 30.10</td><td>Bismuth subsalicylate 14.04</td><td></td><td>Cefuroxime 29.05</td></tr><tr><td>Aluminium hydroxide 14.06</td><td>Atenolol 2.02, 5.04, 6.06</td><td>Bleomycin 34.05</td><td></td><td>Celecoxib 26.06, 3.04</td></tr><tr><td>Amantadine 20.05</td><td>Atorvastatin 9.01</td><td>Bromocriptine 20.04</td><td></td><td>Cetirizine 4.06</td></tr><tr><td>Amfetamine 2.08, 27.01</td><td>Atosiban 19.08</td><td>Budesonide 12.06</td><td></td><td>Chloramphenicol 29.11</td></tr><tr><td>Amikacin 29.10</td><td>Atovaquone 31.05, 31.08</td><td>Bumetanide 13.01</td><td></td><td>Chloroquine 31.01, 31.08</td></tr><tr><td>Amiloride 13.03</td><td>Atracurium 1.06</td><td>Bupivacaine 28.02</td><td></td><td>Chlorpromazine (U.S. Thorazine) 14.11,</td></tr><tr><td>Aminophylline 12.03</td><td>Atropine 1.02</td><td>Buprenorphine 26.01</td><td></td><td style="text-align: right">23.01, 23.09</td></tr><tr><td>Amiodarone 5.05</td><td>Auranofin 3.10</td><td>Bupropion 24.07</td><td></td><td>Chlortalidone 13.02</td></tr><tr><td>Amisulpride 23.08, 23.09</td><td>Aurothiomalate 3.10</td><td>Buspirone 22.05</td><td></td><td>Ciclosporin 4.01</td></tr><tr><td>Amitriptyline 24.01, 26.08, 26.10</td><td>Azathioprine 4.02, 34.03</td><td>Calcitonin 18.07, 18.09</td><td></td><td>Cimetidine 14.01</td></tr><tr><td>Amlodipine 6.03, 7.01</td><td>Azithromycin 29.12</td><td>Calcitriol 18.06</td><td></td><td>Cinacalcet 18.08</td></tr><tr><td>Amobarbital 22.04</td><td>Beclometasone 12.06, 12.10, 16.01,</td><td>Calcium carbonate 14.06</td><td></td><td>Cinnarizine 4.08, 14.08</td></tr><tr><td>Amorolfine 32.03</td><td style="text-align: right">16.02, 16.03</td><td>Candesartan 6.02</td><td></td><td>Ciprofloxacin 29.15</td></tr><tr><td>Amoxicillin 14.03, 29.03</td><td>Bemiparin 10.08</td><td>Captopril 6.01, 8.02</td><td></td><td>Cisatracurium 1.06</td></tr><tr><td>Amphotericin 32.01</td><td>Bendroflumethiazide 13.02</td><td>Carbamazepine 25.01, 26.07</td><td></td><td>Cisplatin 34.06</td></tr><tr><td>Ampicillin 29.03</td><td>Benserazide 20.01</td><td>Carbidopa 2.11, 20.01</td><td></td><td>Citalopram 24.02</td></tr></table>
</page>
<page number="8">
<table id="p8t1" data-filename="pdftables_fromstorage_023782248" data-page="8" data-table="1"><tr><td>DRUG INDEX C to F</td><td></td><td></td><td></td></tr><tr><td>Clarithromycin 14.03, 29.12</td><td>Dantron 14.16</td><td>Domperidone 14.11</td><td>Erythromycin 29.12</td></tr><tr><td>Clindamycin 29.13, 31.02</td><td>Demeclocycline 29.09</td><td>Donepezil 20.08</td><td>Escitalopram 24.02</td></tr><tr><td>Clobazam 25.04</td><td>Desferrioxamine 11.05</td><td>Dopamine 2.05</td><td>Esmolol 5.04</td></tr><tr><td>Clomifene 19.02</td><td>Desflurane 21.01</td><td>Doxazosin 2.04</td><td>Etanercept 3.09</td></tr><tr><td>Clomipramine 24.01</td><td>Desipramine 24.01</td><td>Doxorubicin 34.08</td><td>Ethambutol 29.20</td></tr><tr><td>Clonazepam 25.04</td><td>Desogestrol 19.01</td><td>Doxycycline 29.09, 31.02, 31.08</td><td>Ethinylestradiol 19.01</td></tr><tr><td>Clopidogrel 10.02, 10.10, 10.11</td><td>Dexamethasone 14.12, 16.01</td><td>Drospirenone 19.01</td><td>Ethosuximide 25.02</td></tr><tr><td>Clozapine 23.04, 23.09</td><td>Dextropropoxyphene 26.03</td><td>Duloxetine 24.03</td><td>Etomidate 21.03</td></tr><tr><td>Cocaine 2.09, 27.02, 28.03</td><td>Diamorphine (heroin) 26.01</td><td>Dyflos 1.09</td><td>Ezetimibe 9.03</td></tr><tr><td>Codeine 14.18, 26.01</td><td>Diazepam 22.01, 25.04</td><td>Echothiophate 1.09</td><td>Famciclovir 30.05</td></tr><tr><td>Colchicine 3.12</td><td>Diclofenac 3.01</td><td>Edrophonium 1.08</td><td>Famotidine 14.01</td></tr><tr><td>Colestipol 9.04</td><td>Dicycloverine 1.02</td><td>Efavirenz 30.02</td><td>Fentanyl 26.02</td></tr><tr><td>Colestyramine 9.04</td><td>Didanosine 30.01, 30.10</td><td>Eletriptan 26.10</td><td>Ferrous fumarate 11.05</td></tr><tr><td>Co-trimoxazole 29.16</td><td>Digoxin 8.01</td><td>Enalapril 6.01, 8.02</td><td>Ferrous gluconate 11.05</td></tr><tr><td>Crisantaspase 34.16</td><td>Diloxanide 31.10</td><td>Enfuvirtide 30.04, 30.10</td><td>Ferrous sulfate 11.05, 11.06</td></tr><tr><td>Cromoglicate 12.08</td><td>Diltiazem 5.06</td><td>Enoxaparin 10.08</td><td>Filgrastim 11.04</td></tr><tr><td>Cyanocobalamin 11.02</td><td>Dimethyltryptamine (DMT) 27.03</td><td>Entacapone 20.02</td><td>Finasteride 19.10</td></tr><tr><td>Cyclizine 4.08, 14.08</td><td>Diphenoxylate 14.18</td><td>Ephedrine 2.08</td><td>Flecainide 5.03</td></tr><tr><td>Cyclophosphamide 34.07</td><td>Dipyridamole 10.04, 10.11</td><td>Epinephrine (adrenaline) 2.03</td><td>Flucloxacillin 29.02</td></tr><tr><td>Cytarabine 34.04</td><td>Disopyramide 5.01</td><td>Eplerenone 13.04</td><td>Fluconazole 32.02</td></tr><tr><td>Dactinomycin 34.10</td><td>Ditiazem 7.01</td><td>Epoetin 11.03</td><td>Flucytosine 32.06</td></tr><tr><td>Dalfopristin 29.14</td><td>Dobutamine 2.05</td><td>Eptifibatide 10.03</td><td>Fludrocortisone 16.04</td></tr><tr><td>Dalteparin 10.08</td><td>Docusate 14.17</td><td>Ergocalciferol 18.05</td><td>Flumazenil 22.03</td></tr><tr><td>Danazol 19.03</td><td>Dolasetron 14.10</td><td>Ergometrine 19.05</td><td>Fluorouracil 34.02</td></tr></table>
</page>
<page number="9">
<table id="p9t1" data-filename="pdftables_fromstorage_023782248" data-page="9" data-table="1"><tr><td colspan="2">DRUG INDEX F to N</td><td></td><td></td><td></td></tr><tr><td>Fluoxetine 24.02</td><td>Halothane 21.01</td><td>Ivermectin 33.05</td><td>Lubiprostone 14.15</td><td>Methylenedioxymethamfeta-</td></tr><tr><td>Flupentixol 23.03, 23.09</td><td>Heparin 10.07, 10.10</td><td>Ketamine 21.04, 27.04</td><td>Lumefantrine 31.07</td><td>mine (MDMA) 27.01</td></tr><tr><td>Fluphenazine 23.01, 23.09</td><td>Hydralazine 6.05, 8.02</td><td>Ketoprofen 3.01</td><td>Lysergic acid diethylamide</td><td>Methylphenidate 27.01</td></tr><tr><td>Flutamide 19.10</td><td>Hydrochlorothiazide 13.02</td><td>Ketorolac 3.01</td><td>(LSD) 27.03</td><td>Metoclopramide 14.11</td></tr><tr><td>Fluvoxamine 24.02</td><td>Hydrocortisone 12.06, 16.01,</td><td>Lactulose 14.13</td><td>Macrogols 14.13</td><td>Metoprolol 2.02, 6.06</td></tr><tr><td>Folic acid 11.01, 11.06</td><td style="text-align: right">16.02, 16.03</td><td>Lamivudine 30.10</td><td>Magnesium hydroxide 14.06</td><td>Metronidazole 14.03, 31.09</td></tr><tr><td>Formoterol 12.02</td><td>Hydroxocobalamin 11.02</td><td>Lamotrigine 25.07, 26.07</td><td>Magnesium sulfate 5.08,</td><td>Mexiletine 5.02</td></tr><tr><td>Foscarnet 30.06</td><td>Hydroxychloroquine 3.10</td><td>Lansoprazole 14.02</td><td style="text-align: right">14.13</td><td>Micafungin 32.04</td></tr><tr><td>Furosamide 6.06, 8.02, 13.01</td><td>Hyoscine (scopolamine) 4.08</td><td>Leflunomide 3.08</td><td>Mannitol 13.05</td><td>Miglitol 15.06</td></tr><tr><td>Gabapentin 25.11, 26.09</td><td>Ibuprofen 3.01, 26.06, 26.10</td><td>Lenograstim 11.04</td><td>Maprotiline 24.04</td><td>Minocycline 29.09</td></tr><tr><td>Galantamine 20.08</td><td>Ibutilide 5.05</td><td>Levamisole 33.02</td><td>Mebendazole 33.01</td><td>Minoxidil 6.04</td></tr><tr><td>Ganciclovir 30.06</td><td>Imatinib 34.13</td><td>Levetiracetam 25.10</td><td>Meclizine 14.08</td><td>Mirtazapine 24.06</td></tr><tr><td>Gemfibrozil 9.02</td><td>Imipenem 29.07</td><td>Levobupivacaine 28.02</td><td>Mefloquine 31.03, 31.08</td><td>Misoprostol 14.07</td></tr><tr><td>Gentamicin 29.10</td><td>Infliximab 3.09</td><td>Levodopa (L-dopa) 20.01</td><td>Memantine 20.09</td><td>Moclobemide 24.05</td></tr><tr><td>Glibenclamide</td><td>Insulin 15.01</td><td>Levofloxacin 29.15</td><td>Mepivacaine 28.01</td><td>Montelukast 12.04, 12.10</td></tr><tr><td>(glyburide) 15.02</td><td>Interferon alpha 30.09</td><td>Levothyroxine 17.02</td><td>Mercaptopurine 34.03</td><td>Morphine 26.01</td></tr><tr><td>Glimepiride 15.02</td><td>Ipratropium 2.01, 12.05</td><td>Lidocaine (lignocaine) 5.02,</td><td>Meropenem 29.07</td><td>Mycophenolate mofetil</td></tr><tr><td>Glipizide 15.02</td><td>Irinotecan 34.09</td><td style="text-align: right">28.01</td><td>Mescaline 27.03</td><td style="text-align: right">4.03</td></tr><tr><td>Glucagon 15.07</td><td>Iron dextran 11.05</td><td>Liothyronine (T3) 17.02</td><td>Metformin 15.03</td><td>Nabilone 14.12</td></tr><tr><td>Glucocorticoids 3.05, 4.05</td><td>Isocarboxazid 24.05</td><td>Liquid paraffin 14.17</td><td>Methadone 26.03</td><td>Naloxone 26.05</td></tr><tr><td>Glyceryl trinitrate 7.02</td><td>Isoniazid 29.17, 29.20</td><td>Lisinopril 6.01</td><td>Methimazole 17.01</td><td>Naltrexone 26.05</td></tr><tr><td>Granisetron 14.10</td><td>Isosorbide mononitrate 7.02</td><td>Lithium 24.08</td><td>Methotrexate 3.06, 34.01</td><td>Naproxen 3.01, 26.06</td></tr><tr><td>Griseofulvin 32.05</td><td>Ispaghula husk 14.14</td><td>Loperamide 14.18</td><td>Methylcellulose 14.14</td><td>Nateglinide 15.04</td></tr><tr><td>Haloperidol 23.02, 23.09</td><td>Itraconazole 32.02</td><td>Losartan 6.02</td><td>Methyldopa 2.10</td><td>Nedocromil 12.08</td></tr></table>
</page>
<page number="10">
<table id="p10t1" data-filename="pdftables_fromstorage_023782248" data-page="10" data-table="1"><tr><td colspan="2">DRUG INDEX N to S</td><td></td><td></td><td></td></tr><tr><td>Neostigmine 1.07</td><td>Pamidronate 18.01</td><td>Pizotifen 26.10</td><td>Pyrimethamine 31.02, 31.06</td><td>Salmeterol 2.01, 12.02, 12.10</td></tr><tr><td>Nevirapine 30.02, 30.10</td><td>Pancuronium 1.05</td><td>Potassium citrate 13.06</td><td>Quetiapine 23.06, 23.09</td><td>Saquinavir 30.03, 30.10</td></tr><tr><td>Nicotinic acid 9.05</td><td>Paracetamol (acetaminophen)</td><td>Pralidoxime 1.01</td><td>Quinidine 5.01</td><td>Sarin 1.09</td></tr><tr><td>Nifedipine 6.03, 7.01</td><td style="text-align: right">3.03, 26.06</td><td>Pramipexole 20.04</td><td>Quinine 31.02</td><td>Scopolamine (hyoscine) 1.03,</td></tr><tr><td>Nitrazepam 22.01</td><td>Parathyroid hormone 18.02</td><td>Pravastatin 9.01</td><td>Quinupristin 29.14</td><td style="text-align: right">14.09</td></tr><tr><td>Nitrous oxide 21.02</td><td>Paroxetine 24.02</td><td>Praziquantel 33.04</td><td>Radioactive iodide (radioiodine,</td><td>Secobarbital 22.04</td></tr><tr><td>Nizatidine 14.01</td><td>Peginterferon alpha 30.09</td><td>Prazosin 2.04</td><td>I-131) 17.03</td><td>Selegiline 20.03</td></tr><tr><td>Norethisterone 19.01</td><td>Penicillamine 3.10</td><td>Prednisolone 4.05, 12.10,</td><td>Raloxifene 18.03, 18.09</td><td>Senna 14.16</td></tr><tr><td>Norfloxacin 29.15</td><td>Pentostatin 34.03</td><td style="text-align: right">16.01</td><td>Ranitidine 14.01</td><td>Sertraline 24.02</td></tr><tr><td>Nortriptyline 24.01, 26.08</td><td>Pethidine (meperidine) 26.02</td><td>Pregabalin 25.11, 26.09</td><td>Rasagiline 20.03</td><td>Sevoflurane 21.01</td></tr><tr><td>Nystatin 32.01</td><td>Phencyclidine 27.04</td><td>Primaquine 31.04</td><td>Reboxetine 24.04</td><td>Sildenafil 19.11, 19.12</td></tr><tr><td>Olanzapine 23.04, 23.09</td><td>Phenelzine 24.05</td><td>Probenicid 3.11</td><td>Remifentanil 26.02</td><td>Simvastatin 9.01</td></tr><tr><td>Omalizumab 12.07</td><td>Phenobarbital 25.05</td><td>Procainamide 5.01</td><td>Repaglinide 15.04</td><td>Sirolimus (rapamycin) 4.04</td></tr><tr><td>Omeprazole 14.02, 14.03</td><td>Phenoxybenzamine 2.07</td><td>Procaine 28.03</td><td>Reteplase 10.05</td><td>Sodium bicarbonate 14.06</td></tr><tr><td>Ondansetron 14.10</td><td>Phenoxymethylpenicillin 29.01</td><td>Prochlorperazine 14.11</td><td>Rifampicin 29.18, 29.20</td><td>Sodium citrate 13.06</td></tr><tr><td>Oseltamivir 30.07</td><td>Phentolamine 2.07</td><td>Proguanil 31.05, 31.08</td><td>Risperidone 23.05, 23.09</td><td>Sodium stibogluconate 31.11</td></tr><tr><td>Oxazepam 22.01</td><td>Phenylephrine 2.03, 2.06</td><td>Promethazine 4.07, 4.08, 14.08</td><td>Ritodrine 2.01, 19.07</td><td>Sotalol 5.05</td></tr><tr><td>Oxcarbazepine 25.01</td><td>Phenytoin 25.01</td><td>Propafenone 5.03</td><td>Rivastigmine 20.08</td><td>Spironolactone 6.06, 13.04</td></tr><tr><td>Oxprenolol 2.02</td><td>Physostigmine 1.07</td><td>Propofol 21.03</td><td>Rocuronium 1.05</td><td>Sterculia 14.14</td></tr><tr><td>Oxybutinin 1.02</td><td>Pilocarpine 1.01</td><td>Propoxyphene 26.03</td><td>Ropinirole 20.04</td><td>Succinylcholine</td></tr><tr><td>Oxymetazoline 2.03, 2.06</td><td>Pioglitazone 15.05</td><td>Propranolol 2.02, 5.04, 26.10</td><td>Ropivacaine 28.02</td><td>(suxamethonium) 1.04</td></tr><tr><td>Oxytocin 19.04</td><td>Piperacillin 29.04</td><td>Propylthiouracil 17.01</td><td>Rosiglitazone 15.05</td><td>Sucralfate 14.05</td></tr><tr><td>Paclitaxel 34.12</td><td>Piperazine 33.03</td><td>Pyrazinamide 29.19, 29.20</td><td>Salbutamol (Albuterol) 2.01,</td><td>Sufentanil 26.02</td></tr><tr><td>Palivizumab 30.08</td><td>Piroxicam 3.01</td><td>Pyridostigmine 1.07</td><td style="text-align: right">12.01, 12.10, 19.07</td><td>Sulfadoxine 31.02, 31.06</td></tr></table>
</page>
<page number="11">
<table id="p11t1" data-filename="pdftables_fromstorage_023782248" data-page="11" data-table="1"><tr><td colspan="2">DRUG INDEX S to Z</td><td></td><td></td><td></td></tr><tr><td>Sulfamethoxazole 29.16</td><td>Terbutaline 2.01, 12.01, 19.07</td><td>Tocainide 5.02</td><td>Tropisetron 14.10</td><td>Warfarin 10.09, 10.10</td></tr><tr><td>Sulfasalazine 3.07</td><td>Teriparatide 18.02</td><td>Tolbutamide 15.02</td><td>Valaciclovir 30.05</td><td>Xylometazoline 2.06</td></tr><tr><td>Sulpiride 23.08</td><td>Teriparatide 18.09</td><td>Tolfenamic acid 26.10</td><td>Valproate 25.03, 26.10</td><td>Zafirlukast 12.04</td></tr><tr><td>Sumatriptan 26.10</td><td>Testosterone 19.09</td><td>Topiramate 25.09, 26.10</td><td>Valsartan 6.02</td><td>Zaleplon 22.02</td></tr><tr><td>Tacrolimus 4.01</td><td>Tetracaine 28.03</td><td>Tramadol 26.04</td><td>Vancomycin 29.08</td><td>Zanamivir 30.07</td></tr><tr><td>Tadalafil 19.11</td><td>Theophylline 12.03, 12.10</td><td>Tranexamic acid 10.06</td><td>Vardenafil 19.11</td><td>Zidovudine 30.01, 30.10</td></tr><tr><td>Tamoxifen 34.15</td><td>Thiethylperazine 14.11</td><td>Trastuzumab 34.14</td><td>Vecuronium 1.05</td><td>Zolmitriptan 26.10</td></tr><tr><td>Tamsulosin 2.04</td><td>Thiopental 21.03</td><td>Triamcinolone 16.01</td><td>Venlafaxine 24.03</td><td>Zolpidem 22.02</td></tr><tr><td>Temazepam 22.01</td><td>Tiagabine 25.08</td><td>Triamterene 13.03</td><td>Verapamil 5.06, 6.03, 7.01</td><td>Zopiclone 22.02</td></tr><tr><td>Temocillin 29.02</td><td>Ticarcillin 29.04</td><td>Trihexyphenidyl 20.06</td><td>Vigabatrin 25.06</td><td></td></tr><tr><td>Terazosin 2.04, 6.06</td><td>Tinidazole 31.09</td><td>Trimethoprim 29.16</td><td>Vincristine 34.11</td><td></td></tr><tr><td>Terbinafine 32.03</td><td>Tobramycin 29.10</td><td>Tropicamide 1.02</td><td>Voriconazole 32.02</td><td></td></tr></table>
</page>
<page number="12">
<table id="p12t1" data-filename="pdftables_fromstorage_023782248" data-page="12" data-table="1"><tr><td></td><td colspan="2">ABBREVIATIONS</td><td></td><td></td><td></td></tr><tr><td>5-HT</td><td>5-hydroxytryptamine</td><td>CE</td><td>cholesteryl esters</td><td>DOPA</td><td>dihydroxyphenylalanine</td></tr><tr><td>ACE(I)</td><td>angiotensin converting enzyme</td><td>cGMP</td><td>cyclic guanosine monophosphate</td><td>DOPAC</td><td>3,4 dihydroxyphenyl acetic acid</td></tr><tr><td></td><td>(inhibitor)</td><td>CL</td><td>corpus luteum</td><td>dTMP</td><td>thymidylate</td></tr><tr><td>ACh</td><td>Acetylcholine</td><td>CMV</td><td>cytomegalovirus</td><td>dUMP</td><td>uridylate</td></tr><tr><td>AChE(I)</td><td>acetylcholinesterase (inhibitor)</td><td>CNS</td><td>central nervous system</td><td>EPS</td><td>extrapyramidal symptoms</td></tr><tr><td>ACTH</td><td>adrenocorticotropic hormone</td><td>CoA</td><td>Coenzyme A</td><td>FH2</td><td>dihydrofolate</td></tr><tr><td>ADH</td><td>antidiuretic hormone</td><td>COMT</td><td>catechol-O-methyl transferase</td><td>FH4</td><td>tetrahydrofolate.</td></tr><tr><td>ADHD</td><td>Attention Deficit Hyperactivity</td><td>COPD</td><td>Chronic obstructive pulmonary</td><td>FSH</td><td>follicle stimulating hormone</td></tr><tr><td></td><td>Disorder</td><td></td><td>disease</td><td>G N-</td><td>acetylglucosamine</td></tr><tr><td>ADP</td><td>adenosine diphosphate</td><td>COX</td><td>Cyclo-oxygenase</td><td>GABA</td><td>γ-aminobutyric acid</td></tr><tr><td>AIDS</td><td>Acquired immune deficiency</td><td>CSF</td><td>cerebrospinal fluid</td><td>GC</td><td>glucocorticoid</td></tr><tr><td></td><td>syndrome</td><td>CTZ</td><td>chemoreceptor trigger zone</td><td>GC</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>guanylate cyclase</td></tr><tr><td>AMPA</td><td>α-amino-3-hydroxyl-5-methyl-4-</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>CVS</td><td>cardiovascular system</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>GF</td><td>Graafian follicle</td></tr><tr><td></td><td>isoxazole-propionate</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>DA</td><td>dopamine</td><td>GIT</td><td>gastrointestinal tract</td></tr><tr><td>ATP</td><td>adenosine triphosphate</td><td></td><td></td><td></td><td></td></tr><tr><td>AV</td><td>atrio-ventricular</td><td>DAG</td><td>diacylglycerol</td><td>GnRH</td><td>gonadotropin-releasing hormone</td></tr><tr><td></td><td></td><td>DD</td><td>dopamine decarboxylase</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>GP</td><td>glycoprotein</td></tr><tr><td>BP</td><td>blood pressure</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>DHFR</td><td>dihydrofolate reductase</td><td></td><td></td></tr><tr><td>C</td><td>cholesterol</td><td></td><td></td><td>GTP</td><td>guanosine triphosphate</td></tr><tr><td></td><td></td><td>DMARD</td><td>disease-modifying antirheumatoid</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Hb</td><td>haemoglobin</td></tr><tr><td>cAMP</td><td>cyclic adenosine monophosphate</td><td></td><td>drug</td><td></td><td></td></tr><tr><td>CAT</td><td>cholineacetyltransferase</td><td></td><td></td><td>HBV</td><td>Hepatic B virus</td></tr><tr><td></td><td></td><td>DNA</td><td>deoxyribonucleic acid</td><td>HCV</td><td>Hepatic C virus</td></tr></table>
</page>
<page number="13">
<table id="p13t1" data-filename="pdftables_fromstorage_023782248" data-page="13" data-table="1"><tr><td colspan="3">ABBREVIATIONS CONTINUED</td><td></td><td></td><td></td></tr><tr><td>HDL</td><td>high density lipoprotein</td><td>MDMA</td><td>Methylenedioxymethamfetamine</td><td>PAG</td><td>periaqueductal gray</td></tr><tr><td>HIV</td><td>human immunodeficiency virus</td><td>MLCK</td><td>myosin light chain kinase</td><td>PDE(I)</td><td>phosphodiesterase (inhibitor)</td></tr><tr><td>HMG-CoA</td><td>3-Hydroxy-3-methylglutaryl</td><td>Mnp</td><td>mononuclear phagocytes</td><td>PG</td><td>prostaglandin</td></tr><tr><td></td><td>coenzyme A</td><td>MOA</td><td>mechanism of action</td><td>PKA</td><td>Protein kinase A</td></tr><tr><td>HV</td><td>herpes virus</td><td>MRSA</td><td>Methicillin-resistant</td><td>PKG</td><td>protein kinase G</td></tr><tr><td>i.m.</td><td>intramuscular</td><td></td><td>Staphylococcus aureus</td><td>R</td><td>Receptor</td></tr><tr><td>i.v.</td><td>intravenous</td><td>MTX</td><td>methotrexate</td><td>RNA</td><td>ribonucleic acid</td></tr><tr><td>ICSH</td><td>interstitial cell stimulating hormone</td><td>MVA</td><td>mevalonic acid</td><td>RSV</td><td>respiratory syncytial virus</td></tr><tr><td>IL</td><td>interleukin</td><td>NA</td><td>noradrenaline</td><td>s.c.</td><td>subcutaneous</td></tr><tr><td>IP 3</td><td>Inositol trisphosphate</td><td>NMDA</td><td>N-methyl D-aspartate</td><td>SA</td><td>sino-atrial</td></tr><tr><td>LA</td><td>local anaesthetic</td><td>NO</td><td>nitric oxide</td><td>SR</td><td>sarcoplasmic reticulum</td></tr><tr><td>LDL</td><td>low density lipoprotein</td><td>NRM</td><td>nucleus raphe magnus</td><td>SSRI</td><td>Selective serotonin reuptake</td></tr><tr><td>LH</td><td>luteinizing hormone</td><td>NSAID</td><td>non-steroidal anti-inflammatory</td><td></td><td>inhibitors</td></tr><tr><td>LSD</td><td>lysergic acid diethylamide</td><td></td><td>drug</td><td>TB</td><td>tuberculosis</td></tr><tr><td>LT</td><td>leukotriene</td><td>OB</td><td>osteoblast</td><td>TCA</td><td>Tricyclic antidepressant</td></tr><tr><td>M</td><td>acetylmuramic acid</td><td>OC</td><td>osteoclast</td><td>TG</td><td>triglycerides</td></tr><tr><td>M</td><td>muscarinic</td><td>OTC</td><td>over the counter</td><td>TNF</td><td>tumour necrosis factor</td></tr><tr><td>MA</td><td>monoamine</td><td>P450</td><td>cytochrome p450</td><td>TX</td><td>Thromboxane</td></tr><tr><td>MAO(I)</td><td>monoamine oxidase (inhibitor)</td><td>PABA</td><td>p-aminobutyric acid</td><td>VLDL</td><td>very low density lipoprotein</td></tr><tr><td>MC</td><td>mineralocorticoid</td><td>PAF</td><td>platelet activating factor</td><td></td><td></td></tr></table>
</page>
<page number="14">
<table id="p14t1" data-filename="pdftables_fromstorage_023782248" data-page="14" data-table="1"><tr><td colspan="4">USMLE MARKETING CARD</td><td></td></tr><tr><td colspan="3">Try these other great</td><td></td><td></td></tr><tr><td colspan="3">Pharmacology resources!</td><td></td><td></td></tr><tr><td>Rang &amp; Dale’s</td><td>Pharmacology,</td><td>Pharmacology</td><td>Clinical</td><td>Crash Course:</td></tr><tr><td>Pharmacology,</td><td>4th Edition</td><td>Flash Cards,</td><td>Pharmacology,</td><td>Pharmacology,</td></tr><tr><td>7th Edition</td><td>Brenner</td><td>3rd Edition</td><td>11th Edition</td><td>4th Edition</td></tr><tr><td>Rang</td><td>ISBN : 978-1-4557-0282-4</td><td>Brenner</td><td>Bennett</td><td>Battista</td></tr><tr><td>ISBN: 978-0-7020-3471-8</td><td style="text-align: right">2013</td><td>ISBN : 978-1-4557-0281-7</td><td>ISBN : 978-0-7020-4084-9</td><td>ISBN : 978-0-7234-3630-0</td></tr><tr><td style="text-align: right">2012</td><td></td><td style="text-align: right">2013</td><td style="text-align: right">2013</td><td style="text-align: right">2013</td></tr><tr><td></td><td></td><td colspan="2">ORDER YOUR COPIES TODAY!</td><td></td></tr><tr><td></td><td style="text-align: right" colspan="2">1.800.545.2522</td><td colspan="2">us.elsevierhealth.com</td></tr></table>
</page>
<page number="15">
</page>
<page number="16">
<table id="p16t1" data-filename="pdftables_fromstorage_023782248" data-page="16" data-table="1"><tr><td style="text-align: right">1.01</td><td>Pilocarpine</td><td>Cholinergic pharmacology</td><td></td><td></td></tr><tr><td colspan="4">Simple figure of cholinergic transmission with potential sites of drug action</td><td></td></tr><tr><td></td><td></td><td></td><td>CoA</td><td></td></tr><tr><td></td><td></td><td></td><td>ACh</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Choline</td></tr><tr><td></td><td></td><td>ACh</td><td>CAT</td><td>carrier</td></tr><tr><td></td><td></td><td></td><td>AcetylCoA</td><td></td></tr><tr><td></td><td>Acts on, causes,</td><td></td><td></td><td></td></tr><tr><td></td><td>gives rise to</td><td></td><td>ACh</td><td></td></tr><tr><td></td><td>Movement</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Acetylcholinesterase</td><td></td></tr><tr><td></td><td></td><td>Exocytosis</td><td>ACh</td><td>choline + acetate</td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td></td><td>Nicotinic receptors in:</td><td>Muscarinic receptors in:</td><td></td></tr><tr><td></td><td></td><td>neuromuscular junction</td><td>smooth muscle</td><td></td></tr><tr><td></td><td></td><td>autonomic ganglia</td><td>cardiac muscle</td><td></td></tr><tr><td></td><td></td><td>adrenal medulla</td><td>glands</td><td></td></tr><tr><td></td><td></td><td>CNS neurones</td><td>CNS neurones</td><td></td></tr></table>
</page>
<page number="17">
<table id="p17t1" data-filename="pdftables_fromstorage_023782248" data-page="17" data-table="1"><tr><td></td><td>A muscarinic receptor agonist (Similar drug: bethanechol)</td><td>Pilocarpine</td></tr><tr><td>Actions</td><td colspan="2">Parasympathomimetic actions: contracts smooth muscle (e.g. gut, bladder, pupil); decreases rate and</td></tr><tr><td></td><td colspan="2">force of heart beat; glandular secretion (e.g. salivary, sweat, gastric acid); inhibits neurotransmitter</td></tr><tr><td></td><td>release.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Action in glaucoma is due to interaction with M3 receptors which couple to Gq to increase cellular IP3</td></tr><tr><td></td><td colspan="2">and DAG concentrations. Constriction of pupil aids drainage of aqueous humour and lowers</td></tr><tr><td></td><td>intraocular pressure.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">For glaucoma pilocarpine is given as eye drops and actions last for a day. A slow delivery system</td></tr><tr><td></td><td>placed under the eyelid acts for several days.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Glaucoma (narrow and wide angle). Bethanechol to stimulate bladder emptying or to improve gut</td></tr><tr><td></td><td>motility.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Blurred vision (contraction of ciliary muscle). Otherwise few unwanted effects because of very</td></tr><tr><td></td><td colspan="2">limited systemic absorption of topically applied drug. Bethanechol may produce</td></tr><tr><td></td><td>bronchoconstriction.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 13, pp 157-158; D&amp;H 2e Ch 10, pp 28-31</td></tr></table>
</page>
<page number="18">
<table id="p18t1" data-filename="pdftables_fromstorage_023782248" data-page="18" data-table="1"><tr><td style="text-align: right">1.02</td><td>Atropine</td><td>Cholinergic pharmacology</td><td></td><td></td><td></td></tr><tr><td colspan="4">Simple figure of cholinergic transmission with potential sites of drug action</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>CoA</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>ACh</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Choline</td></tr><tr><td></td><td></td><td>ACh</td><td>CAT</td><td></td><td>carrier</td></tr><tr><td></td><td></td><td></td><td>AcetylCoA</td><td></td><td></td></tr><tr><td></td><td>Acts on, causes,</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>gives rise to</td><td></td><td>ACh</td><td></td><td></td></tr><tr><td></td><td>Movement</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Acetylcholinesterase</td><td></td></tr><tr><td></td><td></td><td>Exocytosis</td><td>ACh</td><td></td><td>choline + acetate</td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td style="text-align: right">+</td><td style="text-align: right">+</td><td>Pilocarpine</td></tr><tr><td></td><td></td><td>Nicotinic receptors in:</td><td colspan="2">Muscarinic receptors in:</td><td></td></tr><tr><td></td><td></td><td>neuromuscular junction</td><td colspan="2">smooth muscle</td><td></td></tr><tr><td></td><td></td><td>autonomic ganglia</td><td colspan="2">cardiac muscle</td><td></td></tr><tr><td></td><td></td><td>adrenal medulla</td><td>glands</td><td></td><td></td></tr><tr><td></td><td></td><td>CNS neurones</td><td colspan="2">CNS neurones</td><td></td></tr></table>
</page>
<page number="19">
<table id="p19t1" data-filename="pdftables_fromstorage_023782248" data-page="19" data-table="1"><tr><td></td><td>Muscarinic receptor antagonist (Similar drugs: dicycloverine, oxybutinin, tropicamide)</td><td>Atropine</td></tr><tr><td>Actions</td><td colspan="2">Inhibits secretions (salivary, bronchial, sweat, gastric acid, etc.). Tachycardia. Relaxes smooth muscle</td></tr><tr><td></td><td colspan="2">(causing inhibition of peristalsis, pupillary dilation, paralysis of accommodation, etc.).</td></tr><tr><td></td><td>Antiemetic (CNS effect).</td><td></td></tr><tr><td>MOA</td><td>Competitive reversible antagonism at all muscarinic receptors.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally. Half-life 3h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Paralysis of accommodation and pupil dilation for eye examination (tropicamide). Urinary</td></tr><tr><td></td><td colspan="2">incontinence (oxybutinin). Irritable bowel syndrome (dicycloverine). Antidote for anticholinesterase</td></tr><tr><td></td><td>poisoning. Treatment of cardiac slowing.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Constipation, hyperthermia (reduced sweating), dry mouth, urinary retention, blurred vision, raised</td></tr><tr><td></td><td>intraocular pressure, CNS excitement (delerium, hallucinations).</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 13, pp 159-160; D&amp;H 2e Ch 10, pp 28-31</td></tr></table>
</page>
<page number="20">
<table id="p20t1" data-filename="pdftables_fromstorage_023782248" data-page="20" data-table="1"><tr><td></td><td>Scopolamine</td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">1.03</td><td>(hyoscine)</td><td>Cholinergic pharmacology</td><td></td><td></td><td></td></tr><tr><td colspan="4">Simple figure of cholinergic transmission with potential sites of drug action</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>CoA</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>ACh</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Choline</td></tr><tr><td></td><td></td><td>ACh</td><td>CAT</td><td></td><td>carrier</td></tr><tr><td></td><td></td><td></td><td>AcetylCoA</td><td></td><td></td></tr><tr><td></td><td>Acts on, causes,</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>gives rise to</td><td></td><td>ACh</td><td></td><td></td></tr><tr><td></td><td>Movement</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Acetylcholinesterase</td><td></td></tr><tr><td></td><td></td><td>Exocytosis</td><td>ACh</td><td></td><td>choline + acetate</td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td style="text-align: right">+</td><td style="text-align: right">+</td><td>Pilocarpine</td></tr><tr><td></td><td></td><td>Nicotinic receptors in:</td><td colspan="2">Muscarinic receptors in:</td><td></td></tr><tr><td></td><td></td><td>neuromuscular junction</td><td colspan="2">smooth muscle</td><td></td></tr><tr><td></td><td></td><td>autonomic ganglia</td><td colspan="2">cardiac muscle</td><td>–</td></tr><tr><td></td><td></td><td>adrenal medulla</td><td>glands</td><td></td><td>Atropine</td></tr><tr><td></td><td></td><td>CNS neurones</td><td colspan="2">CNS neurones</td><td></td></tr></table>
</page>
<page number="21">
<table id="p21t1" data-filename="pdftables_fromstorage_023782248" data-page="21" data-table="1"><tr><td></td><td>Muscarinic receptor antagonist (Similar drug: atropine)</td><td>Scopolamine</td></tr><tr><td>Actions</td><td colspan="2">Inhibits secretions (salivary, bronchial, sweat, gastric acid etc.). Tachycardia. Relaxes smooth muscle</td></tr><tr><td></td><td colspan="2">(causing inhibition of peristalsis, pupillary dilation, paralysis of accommodation etc.). CNS actions:</td></tr><tr><td></td><td>antiemetic, amnesic.</td><td></td></tr><tr><td>MOA</td><td>Competitive reversible antagonism at all muscarinic receptors.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Oral admin. T0.5 4h. Also administered as transdermal patch for effects lasting 2–3 days.</td></tr><tr><td>Clinical use</td><td colspan="2">Main use is in motion sickness. Adjunct for anaesthesia (amnesia, inhibition of secretions and of</td></tr><tr><td></td><td colspan="2">bronchoconstriction, reduction of post-operative vomiting). Urinary incontinence.</td></tr><tr><td>Adverse effects</td><td colspan="2">Constipation, dry mouth, urinary retention, blurred vision, raised intraocular pressure, drowsiness.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 13, pp 159-160; D&amp;H 2e Ch 10, pp 28-31</td></tr></table>
</page>
<page number="22">
<table id="p22t1" data-filename="pdftables_fromstorage_023782248" data-page="22" data-table="1"><tr><td></td><td>Succinylcholine</td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">1.04</td><td>(suxamethonium)</td><td>Cholinergic pharmacology</td><td></td><td></td><td></td></tr><tr><td colspan="4">Simple figure of cholinergic transmission with potential sites of drug action</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>CoA</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>ACh</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Choline</td></tr><tr><td></td><td></td><td>ACh</td><td>CAT</td><td colspan="2">carrier</td></tr><tr><td></td><td></td><td></td><td>AcetylCoA</td><td></td><td></td></tr><tr><td></td><td>Acts on, causes,</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>gives rise to</td><td></td><td>ACh</td><td></td><td></td></tr><tr><td></td><td>Movement</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Acetylcholinesterase</td><td></td><td></td></tr><tr><td></td><td></td><td>Exocytosis</td><td>ACh</td><td></td><td>choline + acetate</td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td style="text-align: right">+</td><td style="text-align: right">+</td><td>Pilocarpine</td></tr><tr><td></td><td></td><td>Nicotinic receptors in:</td><td colspan="2">Muscarinic receptors in:</td><td></td></tr><tr><td></td><td></td><td>neuromuscular junction</td><td>smooth muscle</td><td></td><td></td></tr><tr><td></td><td></td><td>autonomic ganglia</td><td>cardiac muscle</td><td>–</td><td></td></tr><tr><td></td><td></td><td>adrenal medulla</td><td>glands</td><td></td><td>Atropine, scopolamine</td></tr><tr><td></td><td></td><td>CNS neurones</td><td>CNS neurones</td><td></td><td></td></tr></table>
</page>
<page number="23">
<table id="p23t1" data-filename="pdftables_fromstorage_023782248" data-page="23" data-table="1"><tr><td></td><td>Nicotinic receptor agonist / depolarizing neuromuscular blocker</td><td>Succinylcholine</td></tr><tr><td>Actions</td><td>Short-lasting paralysis of skeletal muscle.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Action on nicotinic receptors produces a maintained depolarization of the muscle membrane. This</td></tr><tr><td></td><td colspan="2">inactivates the Na+ channels, which propagate the action potential throughout the muscle. Action</td></tr><tr><td></td><td colspan="2">potentials fail to spread along the muscle fibres preventing muscle contraction in response to motor</td></tr><tr><td></td><td>nerve activity.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given i.v. Hydrolysed by plasma cholinesterase within a few minutes. (A small percentage of people</td></tr><tr><td></td><td colspan="2">have an enzyme with much lower activity and action is prolonged.)</td></tr><tr><td>Clinical use</td><td colspan="2">Short-lasting paralysis to aid tracheal intubation and for short operative procedures. Action is not</td></tr><tr><td></td><td>reversed by anticholinesterases.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Hyperkalaemia (with possible cardiac arrhythmia). Hypotension. Bradycardia. Muscle pain (resulting</td></tr><tr><td></td><td colspan="2">from spasm during the initial depolarisation). Raised intraocular pressure. Malignant hyperthermia</td></tr><tr><td></td><td>(rarely, when used with halothane).</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 13, pp 156-157; D&amp;H 2e Ch 10, pp 28-31</td></tr></table>
</page>
<page number="24">
<table id="p24t1" data-filename="pdftables_fromstorage_023782248" data-page="24" data-table="1"><tr><td style="text-align: right">1.05</td><td>Pancuronium</td><td>Cholinergic pharmacology</td><td></td><td></td></tr><tr><td colspan="4">Simple figure of cholinergic transmission with potential sites of drug action</td><td></td></tr><tr><td></td><td></td><td></td><td>CoA</td><td></td></tr><tr><td></td><td></td><td></td><td>ACh</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Choline</td></tr><tr><td></td><td></td><td>ACh</td><td>CAT</td><td>carrier</td></tr><tr><td></td><td></td><td></td><td>AcetylCoA</td><td></td></tr><tr><td></td><td>Acts on, causes,</td><td></td><td></td><td></td></tr><tr><td></td><td>gives rise to</td><td></td><td>ACh</td><td></td></tr><tr><td></td><td>Movement</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Acetylcholinesterase</td><td></td></tr><tr><td></td><td></td><td>Exocytosis</td><td>ACh</td><td>choline + acetate</td></tr><tr><td colspan="2">Succinylcholine</td><td></td><td></td><td>Pilocarpine</td></tr><tr><td></td><td></td><td>Nicotinic receptors in:</td><td>Muscarinic receptors in:</td><td></td></tr><tr><td></td><td></td><td>neuromuscular junction</td><td>smooth muscle</td><td></td></tr><tr><td></td><td></td><td>autonomic ganglia</td><td>cardiac muscle</td><td>–</td></tr><tr><td></td><td></td><td>adrenal medulla</td><td>glands</td><td>Atropine, scopolamine</td></tr><tr><td></td><td></td><td>CNS neurones</td><td>CNS neurones</td><td></td></tr></table>
</page>
<page number="25">
<table id="p25t1" data-filename="pdftables_fromstorage_023782248" data-page="25" data-table="1"><tr><td></td><td>Nicotinic receptor antagonist / non-depolarizing neuromuscular blocker (Similar drugs:</td><td>Pancuronium</td></tr><tr><td></td><td>vecuronium, rocuronium)</td><td></td></tr><tr><td>Actions</td><td>Paralysis of skeletal muscle.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Reversible competitive antagonism at muscle-type nicotinic receptors. Inhibits binding of ACh to the</td></tr><tr><td></td><td colspan="2">receptors at the muscle end-plate. End-plate potential fails to reach threshold for initiation and</td></tr><tr><td></td><td colspan="2">propagation of the action potential along the muscle fibre. Action reversed by anticholinesterases</td></tr><tr><td></td><td>(e.g. neostigmine 1.07).</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given i.v. Half-life 2–3h. Substantial renal excretion (duration increased in renal failure).</td></tr><tr><td>Clinical use</td><td colspan="2">In general anaesthesia – aids tracheal intubation, provides muscle relaxation for general surgery and</td></tr><tr><td></td><td>aids mechanical ventilation.</td><td></td></tr><tr><td>Adverse effects</td><td>Tachycardia (muscarinic antagonist action).</td><td></td></tr><tr><td>Special points</td><td colspan="2">Tubocurarine is the archetypal non-depolarizing neuromuscular blocker, but it has more side effects,</td></tr><tr><td></td><td colspan="2">such as bronchoconstriction due to histamine release, and is now rarely used.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 13, p 164; D&amp;H 2e Ch 10, pp 28-31</td></tr></table>
</page>
<page number="26">
<table id="p26t1" data-filename="pdftables_fromstorage_023782248" data-page="26" data-table="1"><tr><td style="text-align: right">1.06</td><td>Atracurium</td><td>Cholinergic pharmacology</td><td></td><td></td></tr><tr><td colspan="4">Simple figure of cholinergic transmission with potential sites of drug action</td><td></td></tr><tr><td></td><td></td><td></td><td>CoA</td><td></td></tr><tr><td></td><td></td><td></td><td>ACh</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Choline</td></tr><tr><td></td><td></td><td>ACh</td><td>CAT</td><td>carrier</td></tr><tr><td></td><td></td><td></td><td>AcetylCoA</td><td></td></tr><tr><td></td><td>Acts on, causes,</td><td></td><td></td><td></td></tr><tr><td></td><td>gives rise to</td><td></td><td>ACh</td><td></td></tr><tr><td></td><td>Movement</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Acetylcholinesterase</td><td></td></tr><tr><td></td><td></td><td>Exocytosis</td><td>ACh</td><td>choline + acetate</td></tr><tr><td>Succinylcholine</td><td></td><td></td><td></td><td>Pilocarpine</td></tr><tr><td></td><td></td><td>Nicotinic receptors in:</td><td>Muscarinic receptors in:</td><td></td></tr><tr><td></td><td>–</td><td>neuromuscular junction</td><td>smooth muscle</td><td></td></tr><tr><td>Pancuronium</td><td></td><td>autonomic ganglia</td><td>cardiac muscle</td><td>–</td></tr><tr><td></td><td></td><td>adrenal medulla</td><td>glands</td><td>Atropine, scopolamine</td></tr><tr><td></td><td></td><td>CNS neurones</td><td>CNS neurones</td><td></td></tr></table>
</page>
<page number="27">
<table id="p27t1" data-filename="pdftables_fromstorage_023782248" data-page="27" data-table="1"><tr><td colspan="2">Nicotinic receptor antagonist / non-depolarizing neuromuscular blocker (Similar drug: cisatracurium)</td><td>Atracurium</td></tr><tr><td>Actions</td><td>Paralysis of skeletal muscle.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Reversible competitive antagonism at muscle-type nicotinic receptors. Inhibits binding of ACh to the</td></tr><tr><td></td><td colspan="2">receptors at the muscle end-plate. End-plate potential fails to reach threshold for initiation and</td></tr><tr><td></td><td colspan="2">propagation of the action potential along the muscle fibre. Action reversed by anticholinesterases</td></tr><tr><td></td><td>(e.g. neostigmine 1.07).</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given i.v. Half-life 30min. Eliminated mainly by a spontaneous chemical reaction (Hofmann</td></tr><tr><td></td><td colspan="2">elimination) in the plasma which makes duration of action relatively independent of renal function.</td></tr><tr><td>Clinical use</td><td colspan="2">In general anaesthesia – aids tracheal intubation, provides muscle relaxation for general surgery and</td></tr><tr><td></td><td colspan="2">aids mechanical ventilation. Cisatracurium is one of the 10 isomers of atracurium and is replacing it</td></tr><tr><td></td><td>in clinical use.</td><td></td></tr><tr><td>Adverse effects</td><td>Minor effects attributed to histamine release.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 13 p 164; D&amp;H 2e Ch 10, pp 28-31</td></tr></table>
</page>
<page number="28">
<table id="p28t1" data-filename="pdftables_fromstorage_023782248" data-page="28" data-table="1"><tr><td style="text-align: right">1.07</td><td>Neostigmine</td><td>Cholinergic pharmacology</td><td></td><td></td></tr><tr><td colspan="4">Simple figure of cholinergic transmission with potential sites of drug action</td><td></td></tr><tr><td></td><td></td><td></td><td>CoA</td><td></td></tr><tr><td></td><td></td><td></td><td>ACh</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Choline</td></tr><tr><td></td><td></td><td>ACh</td><td>CAT</td><td>carrier</td></tr><tr><td></td><td></td><td></td><td>AcetylCoA</td><td></td></tr><tr><td></td><td>Acts on, causes,</td><td></td><td></td><td></td></tr><tr><td></td><td>gives rise to</td><td></td><td>ACh</td><td></td></tr><tr><td></td><td>Movement</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Acetylcholinesterase</td><td></td></tr><tr><td></td><td></td><td>Exocytosis</td><td>ACh</td><td>choline + acetate</td></tr><tr><td>Succinylcholine</td><td></td><td></td><td></td><td>Pilocarpine</td></tr><tr><td></td><td></td><td>Nicotinic receptors in:</td><td>Muscarinic receptors in:</td><td></td></tr><tr><td></td><td>–</td><td>neuromuscular junction</td><td>smooth muscle</td><td></td></tr><tr><td>Pancuronium,</td><td></td><td>autonomic ganglia</td><td>cardiac muscle</td><td>–</td></tr><tr><td>atracurium</td><td></td><td>adrenal medulla</td><td>glands</td><td>Atropine, scopolamine</td></tr><tr><td></td><td></td><td>CNS neurones</td><td>CNS neurones</td><td></td></tr></table>
</page>
<page number="29">
<table id="p29t1" data-filename="pdftables_fromstorage_023782248" data-page="29" data-table="1"><tr><td></td><td>Anticholinesterase (Similar drugs: pyridostigmine, physostigmine)</td><td>Neostigmine</td></tr><tr><td>Actions</td><td colspan="2">Parasympathomimetic: increased peristalsis; increased secretions; bradycardia; bronchoconstriction;</td></tr><tr><td></td><td colspan="2">decreased intraocular pressure. At the neuromuscular junction – fasciculation and increased twitch</td></tr><tr><td></td><td>tension. CNS – agitation and dreaming.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Reversible inhibition of acetylcholinesterase reduces breakdown of ACh at cholinergic nerve-endings,</td></tr><tr><td></td><td colspan="2">so potentiating transmitter action. Binds to both esteratic and anionic sites in the enzyme. The</td></tr><tr><td></td><td>esterase is carbamylated.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given i.v. (to reverse neuromuscular block), by mouth (for myasthenia gravis). Mostly ionised, so low</td></tr><tr><td></td><td colspan="2">oral bioavailability and poor penetration of the blood–brain-barrier. Half-life 1h.</td></tr><tr><td>Clinical use</td><td colspan="2">Myasthenia gravis. Reversal of non-depolarising neuromuscular block. Post-operative urinary</td></tr><tr><td></td><td colspan="2">retention. Pyridostigmine – myasthenia gravis. Physostigmine – glaucoma.</td></tr><tr><td>Adverse effects</td><td colspan="2">May exacerbate asthma. Unwanted parasympathomimetic actions can be reduced by atropine (1.02).</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 13, p 169; D&amp;H 2e Ch 10, pp 28-31</td></tr></table>
</page>
<page number="30">
<table id="p30t1" data-filename="pdftables_fromstorage_023782248" data-page="30" data-table="1"><tr><td style="text-align: right">1.08</td><td>Edrophonium</td><td>Cholinergic pharmacology</td><td></td><td></td><td></td></tr><tr><td colspan="4">Simple figure of cholinergic transmission with potential sites of drug action</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>CoA</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>ACh</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Choline</td></tr><tr><td></td><td></td><td>ACh</td><td></td><td>CAT</td><td>carrier</td></tr><tr><td></td><td></td><td></td><td>AcetylCoA</td><td></td><td></td></tr><tr><td></td><td>Acts on, causes,</td><td></td><td></td><td></td><td>Neostigmine</td></tr><tr><td></td><td></td><td></td><td></td><td>ACh</td><td></td></tr><tr><td></td><td>gives rise to</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Movement</td><td></td><td></td><td>–</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Acetylcholinesterase</td><td></td></tr><tr><td></td><td></td><td>Exocytosis</td><td></td><td>ACh</td><td>choline + acetate</td></tr><tr><td>Succinylcholine</td><td></td><td></td><td></td><td></td><td>Pilocarpine</td></tr><tr><td></td><td></td><td>Nicotinic receptors in:</td><td colspan="2">Muscarinic receptors in:</td><td></td></tr><tr><td></td><td>–</td><td>neuromuscular junction</td><td colspan="2">smooth muscle</td><td></td></tr><tr><td>Pancuronium,</td><td></td><td>autonomic ganglia</td><td colspan="2">cardiac muscle</td><td>–</td></tr><tr><td>atracurium</td><td></td><td>adrenal medulla</td><td></td><td>glands</td><td>Atropine, scopolamine</td></tr><tr><td></td><td></td><td>CNS neurones</td><td colspan="2">CNS neurones</td><td></td></tr></table>
</page>
<page number="31">
<table id="p31t1" data-filename="pdftables_fromstorage_023782248" data-page="31" data-table="1"><tr><td></td><td>Anticholinesterase (Similar drugs: neostigmine, physostigmine)</td><td>Edrophonium</td></tr><tr><td>Actions</td><td colspan="2">At the neuromuscular junction – fasciculation and increased twitch tension. Parasympathomimetic –</td></tr><tr><td></td><td colspan="2">increased peristalsis, increased secretions, bradycardia, bronchoconstriction.</td></tr><tr><td>MOA</td><td colspan="2">Reversible inhibition of acetylcholinesterase reduces the breakdown of ACh at cholinergic nerve-</td></tr><tr><td></td><td colspan="2">endings, so potentiating neurotransmission. Edrophonium binds only to the anionic site in the</td></tr><tr><td></td><td>esterase. The binding is mainly electrostatic and reverses readily.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given i.v. or i.m. Short duration of action (10min).</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Diagnosis of myasthenia gravis. To confirm that a proper dose of neostigmine or pyridostigmine is</td></tr><tr><td></td><td colspan="2">being used in the treatment of myasthenia gravis. Action too short for therapeutiic use.</td></tr><tr><td>Adverse effects</td><td colspan="2">May exacerbate asthma. Unwanted parasympathomimetic actions can be reduced by atropine (1.02).</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 13, pp 168-169; D&amp;H 2e Ch 10, pp 28-31</td></tr></table>
</page>
<page number="32">
<table id="p32t1" data-filename="pdftables_fromstorage_023782248" data-page="32" data-table="1"><tr><td style="text-align: right">1.09</td><td>Echothiophate</td><td>Cholinergic pharmacology</td><td></td><td></td><td></td></tr><tr><td colspan="4">Simple figure of cholinergic transmission with potential sites of drug action</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>CoA</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>ACh</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Choline</td></tr><tr><td></td><td></td><td>ACh</td><td></td><td>CAT</td><td>carrier</td></tr><tr><td></td><td></td><td></td><td>AcetylCoA</td><td></td><td></td></tr><tr><td></td><td>Acts on, causes,</td><td></td><td></td><td>ACh</td><td>Neostigmine, edrophonium</td></tr><tr><td></td><td>gives rise to</td><td></td><td></td><td>–</td><td></td></tr><tr><td></td><td>Movement</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Acetylcholinesterase</td><td></td></tr><tr><td></td><td></td><td>Exocytosis</td><td></td><td>ACh</td><td>choline + acetate</td></tr><tr><td>Succinylcholine</td><td></td><td></td><td></td><td></td><td>Pilocarpine</td></tr><tr><td></td><td></td><td>Nicotinic receptors in:</td><td colspan="2">Muscarinic receptors in:</td><td></td></tr><tr><td></td><td>–</td><td>neuromuscular junction</td><td colspan="2">smooth muscle</td><td></td></tr><tr><td>Pancuronium,</td><td></td><td>autonomic ganglia</td><td colspan="2">cardiac muscle</td><td>–</td></tr><tr><td>atracurium</td><td></td><td>adrenal medulla</td><td></td><td>glands</td><td>Atropine, scopolamine</td></tr><tr><td></td><td></td><td>CNS neurones</td><td colspan="2">CNS neurones</td><td></td></tr></table>
</page>
<page number="33">
<table id="p33t1" data-filename="pdftables_fromstorage_023782248" data-page="33" data-table="1"><tr><td></td><td>Irreversible (organophosphate) anticholinesterase (Similar drugs: dyflos, sarin)</td><td>Echothiophate</td></tr><tr><td>Actions</td><td colspan="2">Parasympathomimetic – increased peristalsis, increased secretions, bradycardia, bronchoconstriction,</td></tr><tr><td></td><td colspan="2">decreased intraocular pressure. At the neuromuscular junction – fasciculation and increased twitch</td></tr><tr><td></td><td colspan="2">tension. With nerve gases (e.g. sarin) persistent potentiation of ACh action leads to paralysis and death.</td></tr><tr><td>MOA</td><td colspan="2">Irreversible inhibition of acetylcholinesterase potentiates actions of released ACh at cholinergic</td></tr><tr><td></td><td colspan="2">nerve-endings. Binds to enzyme’s esteratic site causing irreversible phosphorylation. (Pralidoxime,</td></tr><tr><td></td><td>a cholinesterase reactivator, can reverse the phosphorylation.)</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Most are readily absorbed through the skin, gut and lungs. (Protective clothing needed to avoid</td></tr><tr><td></td><td>absorption of insecticides and nerve gases.) Long-acting.</td><td></td></tr><tr><td>Clinical use</td><td>Glaucoma.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">May exacerbate asthma. Unwanted parasympathomimetic actions can be reduced by atropine (1.02).</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 13, pp 168-170; D&amp;H 2e Ch 10, pp 28-31</td></tr></table>
</page>
<page number="34">
<table id="p34t1" data-filename="pdftables_fromstorage_023782248" data-page="34" data-table="1"><tr><td style="text-align: right">1.10</td><td>Summary</td><td colspan="2">Cholinergic pharmacology</td><td></td><td></td><td></td></tr><tr><td colspan="5">Simple figure of cholinergic transmission with potential sites of drug action</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>CoA</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>ACh</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Choline</td></tr><tr><td></td><td></td><td></td><td>ACh</td><td>CAT</td><td></td><td>carrier</td></tr><tr><td></td><td></td><td></td><td></td><td>AcetylCoA</td><td></td><td>Neostigmine, edrophonium,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>echothiophate</td></tr><tr><td></td><td colspan="2">Acts on, causes,</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>gives rise to</td><td></td><td></td><td>ACh</td><td>–</td><td></td></tr><tr><td></td><td>Movement</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Acetylcholinesterase</td><td></td></tr><tr><td></td><td></td><td></td><td>Exocytosis</td><td>ACh</td><td></td><td>choline + acetate</td></tr><tr><td colspan="2">Succinylcholine</td><td></td><td></td><td></td><td></td><td>Pilocarpine</td></tr><tr><td></td><td></td><td></td><td>Nicotinic receptors in:</td><td colspan="2">Muscarinic receptors in:</td><td></td></tr><tr><td></td><td></td><td>–</td><td>neuromuscular junction</td><td colspan="2">smooth muscle</td><td></td></tr><tr><td colspan="2">Pancuronium,</td><td></td><td>autonomic ganglia</td><td colspan="2">cardiac muscle</td><td>–</td></tr><tr><td colspan="2">atracurium</td><td></td><td>adrenal medulla</td><td>glands</td><td></td><td>Atropine, scopolamine</td></tr><tr><td></td><td></td><td></td><td>CNS neurones</td><td colspan="2">CNS neurones</td><td></td></tr></table>
</page>
<page number="35">
<table id="p35t1" data-filename="pdftables_fromstorage_023782248" data-page="35" data-table="1"><tr><td>Notes</td></tr><tr><td>Notes</td></tr></table>
</page>
<page number="36">
<table id="p36t1" data-filename="pdftables_fromstorage_023782248" data-page="36" data-table="1"><tr><td></td><td>Salbutamol</td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">2.01</td><td>(Albuterol)</td><td>Noradrenergic transmission</td><td></td><td></td><td></td></tr><tr><td colspan="3">The figure gives a simple outline of noradrenergic transmission</td><td></td><td></td><td></td></tr><tr><td>Tyrosine</td><td></td><td>Dopamine</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Noradrenergic</td><td></td><td></td></tr><tr><td></td><td>Dopa decarboxylase</td><td></td><td></td><td>varicosity</td><td></td></tr><tr><td></td><td></td><td></td><td>Dopamine</td><td></td><td></td></tr><tr><td>TTyyrroossiinnee</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>DOPA</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>NA</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>NA</td><td></td><td></td></tr><tr><td></td><td></td><td>α</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td style="text-align: right">2</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>NA</td><td>Uptake 1</td><td></td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td>NA</td><td></td><td>Acts on, causes,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>gives rise to</td></tr><tr><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Movement</td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td></td><td>β</td><td></td><td>α1</td><td></td><td>β 1</td></tr><tr><td></td><td style="text-align: right">2</td><td></td><td></td><td>↑RATE</td><td></td></tr><tr><td>RELAXATION</td><td></td><td>Smooth muscle cell</td><td>CONTRACTION</td><td>↑FORCE</td><td>Cardiac muscle cell</td></tr></table>
</page>
<page number="37">
<table id="p37t1" data-filename="pdftables_fromstorage_023782248" data-page="37" data-table="1"><tr><td></td><td>A β2-receptor agonist. (Similar drugs: terbutaline, salmeterol, ritodrine)</td><td>Salbutamol</td></tr><tr><td>Actions</td><td colspan="2">Bronchodilatation. (Minimal action on heart: ↑rate and force). Relaxes uterine</td></tr><tr><td></td><td>smooth muscle.</td><td></td></tr><tr><td>MOA</td><td colspan="2">↓calcium-mediated contraction in bronchioles. ↑cAMP which activates protein</td></tr><tr><td></td><td colspan="2">kinase A (PKA). PKA inhibits myosin light chain kinase (MLCK) – the mediator of</td></tr><tr><td></td><td>contraction.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">By inhalation for asthma: Salbutamol: short-acting (3–5h), can be given i.v.</td></tr><tr><td></td><td colspan="2">Salmeterol: long-acting (8–12h). Ritodrine: by infusion for premature labour.</td></tr><tr><td></td><td>All mainly excreted unchanged.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Asthma (main use). Salbutamol and terbutaline for the acute attack; salmeterol</td></tr><tr><td></td><td colspan="2">for nocturnal asthma, exercise-induced asthma and for long-term therapy.</td></tr><tr><td></td><td colspan="2">Chronic obstructive pulmonary disease (COPD): salbutamol, terbutaline or salmeterol</td></tr><tr><td></td><td>(with ipratropium; card 12.05).</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Tremors, tachycardia, sometimes dysrhythmias, nervousness, some peripheral</td></tr><tr><td></td><td>dilatation.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Hypertensive crisis if used with MAO inhibitor. MAOIs also potentiate CNS</td></tr><tr><td></td><td>stimulant actions.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 34, p 428; D&amp;H 2e Ch 11, pp 32-35</td></tr></table>
</page>
<page number="38">
<table id="p38t1" data-filename="pdftables_fromstorage_023782248" data-page="38" data-table="1"><tr><td style="text-align: right">2.02</td><td>Atenolol</td><td>Noradrenergic transmission</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">The figure gives a simple outline of noradrenergic transmission</td><td></td><td></td><td></td></tr><tr><td>Tyrosine</td><td></td><td colspan="2">Dopamine</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Noradrenergic</td><td></td><td></td></tr><tr><td></td><td></td><td>Dopa decarboxylase</td><td></td><td></td><td>varicosity</td><td></td></tr><tr><td>Tyrosine</td><td></td><td></td><td></td><td>Dopamine</td><td></td><td></td></tr><tr><td></td><td>DOPA</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>NA</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>NA</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>α</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">2</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>NA</td><td>Uptake 1</td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td>NA</td><td></td><td>Acts on, causes,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>gives rise to</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Movement</td></tr><tr><td>Salbutamol,</td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td>terbutaline,</td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>salmeterol</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>β</td><td></td><td></td><td>α1</td><td></td><td>β 1</td></tr><tr><td></td><td style="text-align: right">2</td><td></td><td>Smooth</td><td></td><td>↑RATE</td><td></td></tr><tr><td>RELAXATION</td><td></td><td>muscle cell</td><td></td><td>CONTRACTION</td><td>↑FORCE</td><td>Cardiac muscle cell</td></tr></table>
</page>
<page number="39">
<table id="p39t1" data-filename="pdftables_fromstorage_023782248" data-page="39" data-table="1"><tr><td colspan="3">A β1 antagonist (Similar drugs: metoprolol, oxprenolol, propranolol; some selective, some not)</td><td>Atenolol</td><td></td></tr><tr><td>Actions</td><td>Reduces BP in hypertensive patients by</td><td></td><td></td><td></td></tr><tr><td></td><td>↓causing: cardiac output</td><td></td><td></td><td></td></tr><tr><td></td><td>↓renin release</td><td></td><td>Lower part of varicosity</td><td></td></tr><tr><td></td><td>↓CNS-mediated sympathetic activity</td><td></td><td></td><td>Atenolol,</td></tr><tr><td></td><td>In angina slows heart and reduces</td><td></td><td>NA</td><td>metoprolol</td></tr><tr><td></td><td>metabolic demand.</td><td></td><td></td><td>(relatively</td></tr><tr><td></td><td></td><td></td><td>NA</td><td>β1-selective)</td></tr><tr><td>MOA</td><td>Block of the action of endogenous and</td><td></td><td></td><td></td></tr><tr><td></td><td>exogenous agonists on β1 -receptors.</td><td></td><td>Propranolol,</td><td></td></tr><tr><td></td><td></td><td></td><td>oxprenolol</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Absorbed orally; plasma t 1⁄2 4h; metabolised</td><td></td><td>(non-selective)</td><td></td></tr><tr><td></td><td>by liver.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>β 2</td><td></td><td>β 1</td></tr><tr><td>Clinical use</td><td>Hypertension. Angina. Prevention of</td><td>Smooth muscle cell</td><td colspan="2">Cardiac muscle cell</td></tr><tr><td></td><td>dysrhythmia in myocardial infarction.</td><td></td><td></td><td></td></tr><tr><td>Adverse effects</td><td colspan="4">Dangerous: bronchconstriction in asthma, in emphysema; potential heart block or heart failure in</td></tr><tr><td></td><td colspan="4">patients with coronary disease ; decreased sympathetic warning to hypoglycemia in diabetic patients.</td></tr><tr><td></td><td>Inconvenient: cold extremities, fatigue.</td><td></td><td></td><td></td></tr><tr><td>Special points</td><td colspan="4">Atenolol is water-soluble, can enter the CNS and may cause nightmares. Oxprenolol has some intrinsic</td></tr><tr><td></td><td colspan="4">sympathomimetic activity and thus causes less bradycardia and less coldness of hands and feet.</td></tr><tr><td></td><td></td><td colspan="3">R&amp;D 7e Ch 14, p 187-188; D&amp;H 2e Ch 11, pp 32-35</td></tr></table>
</page>
<page number="40">
<table id="p40t1" data-filename="pdftables_fromstorage_023782248" data-page="40" data-table="1"><tr><td></td><td>Epinephrine</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">2.03</td><td>(adrenaline)</td><td colspan="2">Noradrenergic transmission</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">The figure gives a simple outline of noradrenergic transmission</td><td></td><td></td><td></td><td></td></tr><tr><td>Tyrosine</td><td></td><td colspan="2">Dopamine</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Noradrenergic</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Dopa decarboxylase</td><td></td><td></td><td>varicosity</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Dopamine</td><td></td><td></td><td></td><td></td></tr><tr><td>TTyyrroossiinnee</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>DOPA</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td></tr><tr><td></td><td>α</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">2</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td>Uptake 1</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Acts on, causes,</td></tr><tr><td></td><td></td><td></td><td>NA</td><td></td><td>Uptake 1</td><td></td><td>gives rise to</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Movement</td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td></tr><tr><td>Propranolol,</td><td>–</td><td></td><td>NA</td><td></td><td></td><td></td><td></td></tr><tr><td>oxprenolol</td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td>Atenolol,</td></tr><tr><td>Salbutamol,</td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td>metoprolol,</td></tr><tr><td>terbutaline,</td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td><td>–</td><td>propranolol,</td></tr><tr><td>salmeterol</td><td></td><td></td><td></td><td></td><td></td><td></td><td>oxprenolol</td></tr><tr><td></td><td>β</td><td></td><td>α1</td><td></td><td></td><td>β 1</td><td></td></tr><tr><td></td><td style="text-align: right">2</td><td></td><td>Smooth</td><td></td><td>↑RATE</td><td></td><td></td></tr><tr><td>RELAXATION</td><td></td><td>muscle cell</td><td colspan="2">CONTRACTION</td><td>↑FORCE</td><td colspan="2">Cardiac muscle cell</td></tr></table>
</page>
<page number="41">
<table id="p41t1" data-filename="pdftables_fromstorage_023782248" data-page="41" data-table="1"><tr><td></td><td>Agonist at α- and β-receptors</td><td>Epinephrine</td></tr><tr><td>Actions</td><td colspan="2">α1: vasoconstriction (thus ↑BP); contraction of uterus, GIT sphincters, bladder sphincter,</td></tr><tr><td></td><td>radial iris muscle.</td><td></td></tr><tr><td></td><td>α 2: inhibition of lipolysis, inhibition of NA release.</td><td></td></tr><tr><td></td><td colspan="2">β 1: increased heart rate; β2: bronchodilation, vasodilation with decrease in diastolic</td></tr><tr><td></td><td>blood pressure.</td><td></td></tr><tr><td>MOA</td><td colspan="2">At α1 -receptors: Activation of phospholipase C with generation of IP3 (which increases</td></tr><tr><td></td><td>intracellular calcium and thus force of contraction).</td><td></td></tr><tr><td></td><td colspan="2">At β2-receptors: increase cAMP activates protein kinase A. In smooth muscle PKA</td></tr><tr><td></td><td colspan="2">reduces the contractile action; in cardiac muscle it increases intracellular calcium and thus</td></tr><tr><td></td><td>the force of the contraction.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given i.m. or s.c. Plasma t 1⁄2 2min. Metabolised by monoamine oxidase and catechol-O-methyl</td></tr><tr><td></td><td>transferase.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Asthma, anaphylactic shock, cardiac arrest. Also added to local anaesthetic solutions.</td></tr><tr><td>Adverse effects</td><td>Tachycardia, raised BP, anxiety.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Phenylephrine and oxymetazoline are similar drugs except that they are α 1 -selective</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 14, p 174; D&amp;H 2e Ch 11, pp 32-35</td></tr></table>
</page>
<page number="42">
<table id="p42t1" data-filename="pdftables_fromstorage_023782248" data-page="42" data-table="1"><tr><td style="text-align: right">2.04</td><td>Prazosin</td><td>Noradrenergic transmission</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">The figure gives a simple outline of noradrenergic transmission</td><td></td><td></td><td></td><td></td></tr><tr><td>Tyrosine</td><td></td><td>Dopamine</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Noradrenergic</td><td></td><td></td><td></td></tr><tr><td></td><td>Dopa decarboxylase</td><td></td><td>varicosity</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Dopamine</td><td></td><td></td><td></td></tr><tr><td>TTyyrroossiinnee</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>DOPA</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>α</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td style="text-align: right">2</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td>Uptake 1</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Acts on, causes,</td></tr><tr><td></td><td></td><td></td><td>NA</td><td></td><td></td><td>gives rise to</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Movement</td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td></tr><tr><td>Propranolol,</td><td></td><td></td><td>NA</td><td></td><td></td><td></td></tr><tr><td>oxprenolol</td><td>–</td><td style="text-align: right">+</td><td>Epinephrine</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>(adrenaline)</td><td style="text-align: right">+</td><td></td><td>Atenolol,</td></tr><tr><td>Salbutamol,</td><td></td><td style="text-align: right">+</td><td style="text-align: right">+</td><td></td><td></td><td>metoprolol,</td></tr><tr><td>terbutaline,</td><td style="text-align: right">+</td><td></td><td style="text-align: right">+</td><td style="text-align: right">+</td><td>–</td><td>propranolol,</td></tr><tr><td>salmeterol</td><td></td><td></td><td></td><td></td><td></td><td>oxprenolol</td></tr><tr><td></td><td>β2</td><td></td><td>α1</td><td>β 1</td><td></td><td></td></tr></table>
</page>
<page number="43">
<table id="p43t1" data-filename="pdftables_fromstorage_023782248" data-page="43" data-table="1"><tr><td></td><td>An α1-receptor antagonist (Similar drugs: doxazosin, terazosin, tamsulosin)</td><td>Prazosin</td></tr><tr><td>Actions</td><td>Vasodilatation and thus ↓blood pressure</td><td></td></tr><tr><td></td><td>↑Heart rate (a reflex β 1 -receptor response to the ↓BP)</td><td></td></tr><tr><td></td><td>↓Bladder sphincter tone</td><td></td></tr><tr><td></td><td colspan="2">Inhibition of hypertrophy of smooth muscle of bladder neck and prostate capsule.</td></tr><tr><td>MOA</td><td colspan="2">Block of the action of endogenous and exogenous agonists on α1 -receptors. Tamsulosin is</td></tr><tr><td></td><td>an α1A -receptor antagonist.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Prazosin: absorbed orally; plasma half-life 3–4h; metabolised by liver, extensive first-pass metabolism.</td></tr><tr><td></td><td colspan="2">Tamsulosin: absorbed orally; plasma half-life 10–15h; metabolised by liver. Doxazosin half-life 22h.</td></tr><tr><td>Clinical use</td><td colspan="2">For severe hypertension: Prazosin, doxazosin (in combination with other agents; see CVS</td></tr><tr><td></td><td colspan="2">card 6.06). For benign prostatic hypertrophy: tamsulosin; prazosin, doxazosin also used.</td></tr><tr><td>Adverse effects</td><td colspan="2">Prazosin: orthostatic hypotension, dizziness; hypersensitivity reactions; insomnia; sometimes</td></tr><tr><td></td><td colspan="2">priapism. Tamsulosin can also cause abnormal ejaculation and back pain.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 14, p 187; D&amp;H 2e Ch 11, pp 32-35</td></tr></table>
</page>
<page number="44">
<table id="p44t1" data-filename="pdftables_fromstorage_023782248" data-page="44" data-table="1"><tr><td style="text-align: right">2.05</td><td>Dobutamine</td><td>Noradrenergic transmission</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">The figure gives a simple outline of noradrenergic transmission</td><td></td><td></td><td></td><td></td></tr><tr><td>Tyrosine</td><td></td><td>Dopamine</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Noradrenergic</td><td></td><td></td></tr><tr><td></td><td>Dopa decarboxylase</td><td></td><td></td><td>varicosity</td><td></td><td></td></tr><tr><td>Tyrosine</td><td></td><td>Dopamine</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>DOPA</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td></tr><tr><td></td><td>α</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">2</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td>Uptake 1</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Acts on, causes,</td></tr><tr><td></td><td></td><td>NA</td><td></td><td></td><td></td><td>gives rise to</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Movement</td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td></tr><tr><td>Propranolol,</td><td></td><td>NA</td><td></td><td></td><td></td><td></td></tr><tr><td>oxprenolol</td><td>–</td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Epinephrine</td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>(adrenaline)</td><td></td><td></td><td>Atenolol,</td></tr><tr><td>Salbutamol,</td><td></td><td style="text-align: right">+</td><td style="text-align: right">+</td><td style="text-align: right">+</td><td></td><td>metoprolol,</td></tr><tr><td>terbutaline,</td><td style="text-align: right">+</td><td></td><td style="text-align: right">+</td><td>Prazosin,</td><td>–</td><td>propranolol,</td></tr><tr><td>salmeterol</td><td></td><td></td><td>–</td><td>doxazosin,</td><td></td><td>oxprenolol</td></tr><tr><td></td><td></td><td></td><td></td><td>tamsulosin</td><td></td><td></td></tr><tr><td></td><td>β</td><td>α 1</td><td></td><td>β 1</td><td></td><td></td></tr></table>
</page>
<page number="45">
<table id="p45t1" data-filename="pdftables_fromstorage_023782248" data-page="45" data-table="1"><tr><td></td><td colspan="3">A β1-receptor agonist (Similar drug: dopamine)</td><td colspan="2">Dobutamine</td></tr><tr><td>Actions</td><td colspan="5">A cardiac stimulant: it increases contractility and thus cardiac output. It has less effect on</td></tr><tr><td></td><td>heart rate and there is little vasoconstriction.</td><td></td><td></td><td></td><td></td></tr><tr><td>MOA</td><td>Acts mainly on β1 -receptors causing</td><td>Dobutamine</td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td></td><td>G-protein-mediated increase of cAMP</td><td></td><td></td><td></td><td>Ca2+</td></tr><tr><td></td><td>which increases calcium influx in the</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>cardiac myocytes.</td><td></td><td></td><td>β 1</td><td></td></tr><tr><td></td><td></td><td>Adenylyl</td><td>G s</td><td></td><td></td></tr><tr><td></td><td>Minimal effect on β2 -receptors.</td><td>cyclase</td><td></td><td></td><td style="text-align: right">+</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>[ Ca 2+ ] i</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given i.v.; plasma t 1⁄2 2min</td><td>ATP</td><td>cAMP</td><td style="text-align: right">+</td><td>PKA</td></tr><tr><td></td><td>Inactivated by MAO and COMT.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Increased</td></tr><tr><td>Clinical use</td><td>Cardiogenic shock. Decompensated</td><td colspan="2">Cardiac myocyte</td><td></td><td>contractility</td></tr><tr><td></td><td>congestive cardiac failure.</td><td></td><td></td><td></td><td></td></tr><tr><td>Adverse effects</td><td>Dysrhythmias.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="3">R&amp;D 7e Ch 21, p 252; D&amp;H 2e, Ch 11, pp 32-35</td></tr></table>
</page>
<page number="46">
<table id="p46t1" data-filename="pdftables_fromstorage_023782248" data-page="46" data-table="1"><tr><td style="text-align: right">2.06</td><td>Phenylephrine</td><td colspan="2">Noradrenergic transmission</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">The figure gives a simple outline of noradrenergic transmission</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Acts on, causes,</td></tr><tr><td>Tyrosine</td><td></td><td colspan="2">Dopamine</td><td></td><td></td><td></td><td></td><td>gives rise to</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Movement</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Noradrenergic</td><td></td><td></td></tr><tr><td></td><td colspan="2">Dopa decarboxylase</td><td></td><td></td><td></td><td>varicosity</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Dopamine</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TTyyrroossiinnee</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>DOPA</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td>Uptake 1</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td><td>Atenolol,</td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td><td>metoprolol,</td></tr><tr><td>Propranolol,</td><td>–</td><td></td><td>NA</td><td></td><td></td><td></td><td>–</td><td>propranolol,</td></tr><tr><td>oxprenolol</td><td></td><td></td><td style="text-align: right">+</td><td>Epinephrine</td><td></td><td style="text-align: right">+</td><td></td><td>oxprenolol</td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td>(adrenaline)</td><td></td><td></td><td></td><td></td></tr><tr><td>Salbutamol,</td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td style="text-align: right">+</td><td></td><td>Dobutamine,</td></tr><tr><td>terbutaline,</td><td style="text-align: right">+</td><td></td><td></td><td style="text-align: right">+</td><td></td><td>Prazosin,</td><td style="text-align: right">+</td><td>dopamine</td></tr><tr><td>salmeterol</td><td></td><td></td><td></td><td>–</td><td></td><td>doxazosin,</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>tamsulosin</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>α 1</td><td></td><td></td><td></td><td>β 1</td><td></td></tr><tr><td></td><td>β2</td><td></td><td></td><td></td><td>↑RATE</td><td></td><td></td><td></td></tr><tr><td>RELAXATION</td><td></td><td>Smooth muscle cell</td><td colspan="2">CONTRACTION</td><td colspan="2">↑FORCE</td><td colspan="2">Cardiac muscle cell</td></tr></table>
</page>
<page number="47">
<table id="p47t1" data-filename="pdftables_fromstorage_023782248" data-page="47" data-table="1"><tr><td></td><td>An α1-receptor agonist (Similar drugs: oxymetazoline, xylometazoline)</td><td colspan="2">Phenylephrine</td></tr><tr><td>Actions</td><td colspan="3">Vasoconstriction; nasal decongestion; dilatation of pupil without effect on accommodation.</td></tr><tr><td>MOA</td><td>Causes release of calcium from the</td><td>Phenylephine</td><td></td></tr><tr><td></td><td>sarcoplasmic reticulum. The increased</td><td></td><td></td></tr><tr><td></td><td>calcium activates the contractile</td><td></td><td>α 1</td></tr><tr><td></td><td>mechanism.</td><td></td><td>PLC</td></tr><tr><td></td><td></td><td>IP3</td><td>PIP2</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given intranasally or topically in the eye,</td><td>Ca2+</td><td>Smooth muscle</td></tr><tr><td></td><td>plasma half-life 3h, (longer in the elderly).</td><td>Myosin</td><td></td></tr><tr><td></td><td></td><td></td><td>CONTRACTION</td></tr><tr><td></td><td></td><td>Kinase</td><td></td></tr><tr><td>Clinical use</td><td>As nasal decongestant; for opthalmoscopy.</td><td></td><td></td></tr><tr><td></td><td></td><td>MyosinP</td><td></td></tr><tr><td></td><td></td><td>+Actin</td><td></td></tr><tr><td>Adverse effects</td><td>Hypertension, reflex bradycardia.</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">R&amp;D 7e Ch 14, pp 182t-184t; D&amp;H 2e Ch 11, pp 32-35</td></tr></table>
</page>
<page number="48">
<table id="p48t1" data-filename="pdftables_fromstorage_023782248" data-page="48" data-table="1"><tr><td style="text-align: right">2.07</td><td>Phenoxybenzamine</td><td colspan="3">Noradrenergic transmission</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">The figure gives a simple outline of noradrenergic transmission</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Acts on, causes,</td></tr><tr><td>Tyrosine</td><td></td><td colspan="3">Dopamine</td><td></td><td></td><td></td><td></td><td>gives rise to</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Movement</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Noradrenergic</td><td></td><td></td></tr><tr><td></td><td colspan="2">Dopa decarboxylase</td><td></td><td></td><td></td><td></td><td>varicosity</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Dopamine</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TTyyrroossiinnee</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>DOPA</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td>Uptake 1</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td><td>Atenolol,</td></tr><tr><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>metoprolol,</td></tr><tr><td>Propranolol,</td><td>–</td><td></td><td></td><td>NA</td><td></td><td></td><td></td><td>–</td><td>propranolol,</td></tr><tr><td>oxprenolol</td><td style="text-align: right">+</td><td></td><td></td><td></td><td>Epinephrine</td><td></td><td style="text-align: right">+</td><td></td><td>oxprenolol</td></tr><tr><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td>(adrenaline)</td><td></td><td></td><td></td><td></td></tr><tr><td>Salbutamol,</td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td>Dobutamine,</td></tr><tr><td>terbutaline,</td><td style="text-align: right">+</td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td>Prazosin,</td><td style="text-align: right">+</td><td>dopamine</td></tr><tr><td>salmeterol</td><td colspan="2">Phenylephrine</td><td style="text-align: right">+</td><td></td><td>–</td><td></td><td>doxazosin,</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>tamsulosin</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>α 1</td><td></td><td></td><td></td><td>β 1</td><td></td></tr><tr><td></td><td>β2</td><td></td><td></td><td></td><td></td><td>↑RATE</td><td></td><td></td><td></td></tr><tr><td>RELAXATION</td><td colspan="3">Smooth muscle cell</td><td colspan="2">CONTRACTION</td><td colspan="2">↑FORCE</td><td colspan="2">Cardiac muscle cell</td></tr></table>
</page>
<page number="49">
<table id="p49t1" data-filename="pdftables_fromstorage_023782248" data-page="49" data-table="1"><tr><td></td><td>A non-selective α-adrenoceptor antagonist (Similar drug: phentolamine)</td><td>Phenoxybenzamine</td></tr><tr><td>Actions</td><td colspan="2">Block of α1 -receptor effects: vasodilatation and postural hypotension.</td></tr><tr><td></td><td colspan="2">Block of α2 effects: reduced NA action on α2 receptors on the varicosity, increases release of NA</td></tr><tr><td></td><td colspan="2">from varicosity which can cause tachycardia and increased cardiac output.</td></tr><tr><td>MOA</td><td colspan="2">Binds covalently (and therefore irreversibly) to α receptors and blocks NA action, but phentolamine’s</td></tr><tr><td></td><td>action is reversible.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Plasma half-life 3h, (longer in the elderly). Given orally; plasma half-life ~12h; action lasts longer (up</td></tr><tr><td></td><td>to several days) because of irreversible binding to receptor.</td><td></td></tr><tr><td>Clinical use</td><td>Used in the treatment of phaeochromocytoma.</td><td></td></tr><tr><td>Adverse effects</td><td>Postural hypotension and tachycardia.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 14, pp 186-187; D&amp;H 2e Ch 11, pp 32-35</td></tr></table>
</page>
<page number="50">
<table id="p50t1" data-filename="pdftables_fromstorage_023782248" data-page="50" data-table="1"><tr><td style="text-align: right">2.08</td><td>Amfetamine</td><td colspan="2">Noradrenergic transmission</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">The figure gives a simple outline of noradrenergic transmission</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Acts on, causes,</td></tr><tr><td>Tyrosine</td><td></td><td colspan="2">Dopamine</td><td></td><td></td><td></td><td></td><td></td><td>gives rise to</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Movement</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Noradrenergic</td><td></td><td></td></tr><tr><td></td><td colspan="2">Dopa decarboxylase</td><td></td><td></td><td></td><td></td><td>varicosity</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Dopamine</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TTyyrroossiinnee</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>DOPA</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">NA</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td>Uptake 1</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>–</td><td></td><td colspan="2">NA</td><td></td><td></td><td></td><td></td><td>Atenolol,</td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td><td></td><td></td><td>metoprolol,</td></tr><tr><td>Propranolol,</td><td>–</td><td style="text-align: right">+</td><td colspan="2">NA</td><td></td><td></td><td></td><td>–</td><td>propranolol,</td></tr><tr><td>oxprenolol</td><td></td><td>Phenoxybenzamine,</td><td></td><td></td><td>Epinephrine</td><td></td><td style="text-align: right">+</td><td></td><td>oxprenolol</td></tr><tr><td></td><td></td><td>phentolamine</td><td>–</td><td style="text-align: right">+</td><td>(adrenaline)</td><td></td><td></td><td></td><td></td></tr><tr><td>Salbutamol,</td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td style="text-align: right">+</td><td>Dobutamine,</td></tr><tr><td>terbutaline,</td><td style="text-align: right">+</td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td>Prazosin,</td><td></td><td>dopamine</td></tr><tr><td>salmeterol</td><td></td><td>Phenylephrine</td><td style="text-align: right">+</td><td></td><td>–</td><td></td><td>doxazosin,</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>tamsulosin</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>α 1</td><td></td><td></td><td></td><td>β 1</td><td></td></tr><tr><td></td><td>β2</td><td></td><td></td><td></td><td></td><td>↑RATE</td><td></td><td></td><td></td></tr><tr><td>RELAXATION</td><td></td><td>Smooth muscle cell</td><td></td><td colspan="2">CONTRACTION</td><td colspan="2">↑FORCE</td><td colspan="2">Cardiac muscle cell</td></tr></table>
</page>
<page number="51">
<table id="p51t1" data-filename="pdftables_fromstorage_023782248" data-page="51" data-table="1"><tr><td></td><td>An indirectly-acting sympathomimetic (Similar drug: ephedrine)</td><td>Amfetamine</td></tr><tr><td>Actions</td><td colspan="2">Releases NA from the varicosity therefore has similar actions to NA and epinephrine, but weaker:</td></tr><tr><td></td><td>α1 receptor stimulation: →vasoconstriction →increased BP.</td><td></td></tr><tr><td></td><td>β 2 receptor stimulation: →bronchodilatation.</td><td></td></tr><tr><td></td><td>β 1 stimulation: →increased heart rate.</td><td></td></tr><tr><td></td><td>Is also a potent CNS stimulant.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Taken up by Uptake 1 into the varicosity, then into the vesicle by exchange with NA; the NA, now</td></tr><tr><td></td><td colspan="2">loose in the cytoplasm, is then released by exchange with amfetamine at Uptake 1.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Absorbed orally; plasma half-life: ~ 12h. Excreted unchanged in urine.</td></tr><tr><td>Clinical use</td><td>Narcolepsy, hyperactivity in children.</td><td></td></tr><tr><td>Adverse effects</td><td>Increased BP, tachycardia, insomnia, psychosis with excessive doses.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Tolerance, dependence and addiction can develop. (Ephedrine is not addictive).</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 14, p 191; D&amp;H 2e Ch 11, pp 32-35</td></tr></table>
</page>
<page number="52">
<table id="p52t1" data-filename="pdftables_fromstorage_023782248" data-page="52" data-table="1"><tr><td style="text-align: right">2.09</td><td>Cocaine</td><td colspan="2">Noradrenergic transmission</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">The figure gives a simple outline of noradrenergic transmission</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Acts on, causes,</td></tr><tr><td>Tyrosine</td><td></td><td></td><td colspan="2">Dopamine</td><td></td><td></td><td></td><td></td><td>gives rise to</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Movement</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Noradrenergic</td><td></td><td></td></tr><tr><td></td><td colspan="3">Dopa decarboxylase</td><td></td><td></td><td></td><td>varicosity</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Dopamine</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TTyyrroossiinnee</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>DOPA</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>α</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td style="text-align: right">2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td>Uptake 1</td><td></td><td></td><td></td><td></td></tr><tr><td>Amfetamine,</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>ephedrine,</td><td></td><td></td><td>–</td><td></td><td></td><td></td><td></td><td></td><td>Atenolol,</td></tr><tr><td>displace NA</td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td><td></td><td>metoprolol,</td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td>NA</td><td></td><td></td><td></td><td>–</td><td>propranolol,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Epinephrine</td><td></td><td></td><td></td><td>oxprenolol</td></tr><tr><td></td><td></td><td colspan="2">Phenoxybenzamine,</td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td>Propranolol,</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>–</td><td></td><td></td><td></td><td>(adrenaline)</td><td></td><td></td><td></td><td></td></tr><tr><td>oxprenolol</td><td></td><td colspan="2">phentolamine</td><td>–</td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td style="text-align: right">+</td><td style="text-align: right">+</td><td>Dobutamine,</td></tr><tr><td>Salbutamol,</td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td>Prazosin,</td><td></td><td>dopamine</td></tr><tr><td>terbutaline,</td><td style="text-align: right">+</td><td colspan="2">Phenylephrine</td><td style="text-align: right">+</td><td>–</td><td></td><td>doxazosin,</td><td></td><td></td></tr><tr><td>salmeterol</td><td></td><td></td><td></td><td></td><td></td><td></td><td>tamsulosin</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>α 1</td><td></td><td></td><td>β 1</td><td></td></tr><tr><td></td><td>β2</td><td></td><td></td><td></td><td></td><td>↑RATE</td><td></td><td></td><td></td></tr><tr><td>RELAXATION</td><td></td><td colspan="2">Smooth muscle cell</td><td></td><td>CONTRACTION</td><td colspan="2">↑FORCE</td><td colspan="2">Cardiac muscle cell</td></tr></table>
</page>
<page number="53">
<table id="p53t1" data-filename="pdftables_fromstorage_023782248" data-page="53" data-table="1"><tr><td></td><td>Indirectly acting sympathomimetic; also local anaesthetic – see card 28.03.</td><td>Cocaine</td></tr><tr><td>Actions and MOA</td><td colspan="2">Sympathomimetic action: Inhibition of uptake of NA by Uptake 1 leads to increased NA effects</td></tr><tr><td></td><td>(notably vasoconstriction).</td><td></td></tr><tr><td></td><td colspan="2">For mechanism of local anaesthetic action see local anaesthetic card 28.03</td></tr><tr><td>Abs/Distrb/Elim</td><td>See CNS stimulants and psychotomimetics card 27.02.</td><td></td></tr><tr><td>Clinical use</td><td>Local anaesthetic.</td><td></td></tr><tr><td>Adverse effects</td><td>See CNS stimulants and psychotomimetics card 27.02.</td><td></td></tr><tr><td>Drugs with</td><td colspan="2">Other drugs inhibiting Uptake 1: phenoxybenzamine (main action: alpha blocker),</td></tr><tr><td>similar action</td><td colspan="2">tricyclic antidepressants. Other local anaesthetics: see local anaesthetic set (28)</td></tr><tr><td>Special points</td><td colspan="2">Cocaine is a widely used drug of addiction. The vasoconstriction caused by its Uptake 1 blocking</td></tr><tr><td></td><td colspan="2">action can lead to necrosis of the nasal septum in cocaine addicts who snort it.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 47, pp 587-588; D&amp;H 2e Ch 43, p 99</td></tr></table>
</page>
<page number="54">
<table id="p54t1" data-filename="pdftables_fromstorage_023782248" data-page="54" data-table="1"><tr><td style="text-align: right">2.10</td><td>Methyldopa</td><td colspan="2">Noradrenergic transmission</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">The figure gives a simple outline of noradrenergic transmission</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Acts on, causes,</td></tr><tr><td>Tyrosine</td><td></td><td colspan="2">Dopamine</td><td></td><td></td><td></td><td></td><td></td><td>gives rise to</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Movement</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Noradrenergic</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Dopa decarboxylase</td><td></td><td></td><td></td><td></td><td>varicosity</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Dopamine</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TTyyrroossiinnee</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>DOPA</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">NA</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">2</td><td></td><td></td><td></td><td>Uptake 1</td><td></td><td></td><td>Cocaine</td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td>–</td><td colspan="2">tricyclic antidepressants,</td></tr><tr><td>Amfetamine,</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>ephedrine,</td><td>–</td><td></td><td colspan="2">NA</td><td></td><td></td><td></td><td colspan="2">phenoxybenzamine</td></tr><tr><td>displace NA</td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td colspan="2">NA</td><td></td><td></td><td></td><td></td><td>Atenolol,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Epinephrine</td><td></td><td></td><td></td><td>metoprolol,</td></tr><tr><td></td><td></td><td>Phenoxybenzamine,</td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td>Propranolol,</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>–</td><td></td></tr><tr><td></td><td>–</td><td>phentolamine</td><td>–</td><td style="text-align: right">+</td><td>(adrenaline)</td><td></td><td></td><td></td><td>propranolol,</td></tr><tr><td>oxprenolol</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>oxprenolol</td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td>Salbutamol,</td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td>Prazosin,</td><td></td><td>Dobutamine,</td></tr><tr><td>terbutaline,</td><td style="text-align: right">+</td><td>Phenylephrine</td><td style="text-align: right">+</td><td></td><td>–</td><td></td><td>doxazosin,</td><td style="text-align: right">+</td><td>dopamine</td></tr><tr><td>salmeterol</td><td></td><td></td><td></td><td></td><td></td><td></td><td>tamsulosin</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>α 1</td><td></td><td></td><td></td><td>β 1</td><td></td></tr><tr><td></td><td>β2</td><td></td><td></td><td></td><td></td><td>↑RATE</td><td></td><td></td><td></td></tr><tr><td>RELAXATION</td><td></td><td>Smooth muscle cell</td><td></td><td colspan="2">CONTRACTION</td><td colspan="2">↑FORCE</td><td colspan="2">Cardiac muscle cell</td></tr></table>
</page>
<page number="55">
<table id="p55t1" data-filename="pdftables_fromstorage_023782248" data-page="55" data-table="1"><tr><td></td><td>Alpha-2 agonist prodrug</td><td>Methyldopa</td></tr><tr><td>Actions</td><td>Reduces release of NA. Lowers blood pressure..</td><td></td></tr><tr><td>MOA</td><td colspan="2">Acts mainly in the CNS. Is taken up into adrenergic neurones and converted into false transmitter</td></tr><tr><td></td><td colspan="2">methylnoradrenaline (methylnorepinephrine). This is released and acts on the alpha-2</td></tr><tr><td></td><td>adrenoceptors decreasing the release of NA.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally, actively transported into CNS neurones. Plasma half-life ~ 2h; duration of action ~ 24h.</td></tr><tr><td>Clinical use</td><td>Hypertension in pregnancy.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Hypotension, transient sedation, dry mouth, diarrhoea, hypersensitivity reactions.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 14, p 190; D&amp;H 2e Ch 11, p 35</td></tr></table>
</page>
<page number="56">
<table id="p56t1" data-filename="pdftables_fromstorage_023782248" data-page="56" data-table="1"><tr><td style="text-align: right">2.11</td><td>Carbidopa</td><td></td><td>Noradrenergic transmission</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">The figure gives a simple outline of noradrenergic transmission</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Methyldopa</td><td></td><td>Acts on, causes,</td></tr><tr><td>Tyrosine</td><td></td><td></td><td colspan="2">Dopamine</td><td></td><td></td><td></td><td></td><td>gives rise to</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Movement</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Noradrenergic</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="3">Dopa decarboxylase</td><td></td><td></td><td></td><td>varicosity</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Dopamine</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TTyyrroossiinnee</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>DOPA</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>NA</td><td></td><td></td><td>MeNA</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>α 2</td><td></td><td></td><td></td><td></td><td></td><td></td><td>MethylNA</td></tr><tr><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td>Uptake 1</td><td></td><td></td><td></td><td></td></tr><tr><td>Amfetamine,</td><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td><td>Cocaine</td><td></td></tr><tr><td>ephedrine,</td><td></td><td>–</td><td style="text-align: right">+</td><td></td><td></td><td></td><td>–</td><td colspan="2">tricyclic antidepressants,</td></tr><tr><td>displace NA</td><td></td><td></td><td style="text-align: right">+</td><td>NA</td><td></td><td></td><td></td><td colspan="2">phenoxybenzamine</td></tr><tr><td></td><td></td><td></td><td>Phenoxybenzamine,</td><td></td><td>Epinephrine</td><td></td><td></td><td></td><td></td></tr><tr><td>Propranolol,</td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td></td><td></td><td>–</td><td></td><td></td><td>(adrenaline)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Atenolol,</td></tr><tr><td>oxprenolol</td><td></td><td></td><td>phentolamine</td><td>–</td><td style="text-align: right">+</td><td></td><td></td><td>–</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>metoprolol,</td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td>Salbutamol,</td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td>Prazosin,</td><td></td><td>Dobutamine,</td></tr><tr><td>terbutaline,</td><td></td><td style="text-align: right">+</td><td>Phenylephrine</td><td style="text-align: right">+</td><td>–</td><td></td><td>doxazosin,</td><td style="text-align: right">+</td><td>dopamine</td></tr><tr><td>salmeterol</td><td></td><td></td><td></td><td></td><td></td><td></td><td>tamsulosin</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>α 1</td><td></td><td></td><td>β 1</td><td></td></tr><tr><td></td><td></td><td>β2</td><td></td><td></td><td></td><td>↑RATE</td><td></td><td></td><td></td></tr><tr><td>RELAXATION</td><td></td><td></td><td>Smooth muscle cell</td><td></td><td>CONTRACTION</td><td colspan="2">↑FORCE</td><td colspan="2">Cardiac muscle cell</td></tr></table>
</page>
<page number="57">
<table id="p57t1" data-filename="pdftables_fromstorage_023782248" data-page="57" data-table="1"><tr><td></td><td>Adjunct to levodopa treatment</td><td>Carbidopa</td></tr><tr><td>Actions and MOA</td><td colspan="2">Levodopa is used to treat Parkinsonism, but in the GIT and periphery it is metabolised by DOPA</td></tr><tr><td></td><td colspan="2">decarboxylase which reduces the dose available to the CNS. Furthermore, the resulting dopamine</td></tr><tr><td></td><td>has unwanted effects.</td><td></td></tr><tr><td></td><td colspan="2">Carbidopa inhibits DOPA decarboxylase increasing the availabilty of levodopa to the CNS and</td></tr><tr><td></td><td>reducing the its dopamine-mediated side effects. See CNS card 20.01.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Usually given in combination with levodopa in the treatment of Parkinsonism. Carbidopa can’t cross</td></tr><tr><td></td><td colspan="2">the blood – brain barrier so it affects only the peripheral metabolism of levodopa.</td></tr><tr><td>Clinical use</td><td>An adjunct in treatment of Parkinsonism.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Hypotension, transient sedation, dry mouth, diarrhoea, hypersensitivity reactions.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 14, p 190; D&amp;H 2e Ch 11, p 35</td></tr></table>
</page>
<page number="58">
<table id="p58t1" data-filename="pdftables_fromstorage_023782248" data-page="58" data-table="1"><tr><td style="text-align: right">2.12</td><td>Summary</td><td></td><td>Noradrenergic transmission</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">The figure gives a simple outline of noradrenergic transmission</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Carbidopa</td><td>–</td><td></td><td></td><td colspan="2">Methyldopa</td><td></td><td>Acts on, causes,</td></tr><tr><td>Tyrosine</td><td></td><td></td><td colspan="2">Dopamine</td><td></td><td></td><td></td><td></td><td>gives rise to</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Movement</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Noradrenergic</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="3">Dopa decarboxylase</td><td></td><td></td><td></td><td>varicosity</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Dopamine</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TTyyrroossiinnee</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>DOPA</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>NA</td><td></td><td></td><td>MeNA</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>α 2</td><td></td><td></td><td></td><td></td><td></td><td></td><td>MethylNA</td></tr><tr><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td>Uptake 1</td><td></td><td></td><td></td><td></td></tr><tr><td>Amfetamine,</td><td></td><td></td><td></td><td>NA</td><td></td><td></td><td></td><td>Cocaine</td><td></td></tr><tr><td>ephedrine,</td><td></td><td>–</td><td style="text-align: right">+</td><td></td><td></td><td></td><td>–</td><td colspan="2">tricyclic antidepressants,</td></tr><tr><td>displace NA</td><td></td><td></td><td style="text-align: right">+</td><td>NA</td><td></td><td></td><td></td><td colspan="2">phenoxybenzamine</td></tr><tr><td></td><td></td><td></td><td>Phenoxybenzamine,</td><td></td><td>Epinephrine</td><td></td><td></td><td></td><td></td></tr><tr><td>Propranolol,</td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td></td><td></td><td>–</td><td></td><td></td><td>(adrenaline)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Atenolol,</td></tr><tr><td>oxprenolol</td><td></td><td></td><td>phentolamine</td><td>–</td><td style="text-align: right">+</td><td></td><td></td><td>–</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>metoprolol,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Salbutamol,</td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td>Prazosin,</td><td></td><td>Dobutamine,</td></tr><tr><td>terbutaline,</td><td></td><td style="text-align: right">+</td><td>Phenylephrine</td><td style="text-align: right">+</td><td>–</td><td></td><td>doxazosin,</td><td style="text-align: right">+</td><td>dopamine</td></tr><tr><td>salmeterol</td><td></td><td></td><td></td><td></td><td></td><td></td><td>tamsulosin</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>α 1</td><td></td><td></td><td>β 1</td><td></td></tr><tr><td></td><td></td><td>β2</td><td></td><td></td><td></td><td>↑RATE</td><td></td><td></td><td></td></tr><tr><td>RELAXATION</td><td></td><td></td><td>Smooth muscle cell</td><td></td><td>CONTRACTION</td><td colspan="2">↑FORCE</td><td colspan="2">Cardiac muscle cell</td></tr></table>
</page>
<page number="59">
<table id="p59t1" data-filename="pdftables_fromstorage_023782248" data-page="59" data-table="1"><tr><td>Notes</td></tr><tr><td>Notes</td></tr></table>
</page>
<page number="60">
<table id="p60t1" data-filename="pdftables_fromstorage_023782248" data-page="60" data-table="1"><tr><td></td><td>Drugs acting on</td><td></td><td></td><td></td></tr><tr><td style="text-align: right">2.13</td><td>adrenoceptors 1</td><td>Noradrenergic transmission</td><td></td><td></td></tr><tr><td></td><td colspan="3">Add the drugs dealt with in the NA cards in the relevant places</td><td></td></tr><tr><td></td><td></td><td>Adrenoceptor agonists</td><td></td><td></td></tr><tr><td></td><td>α1</td><td>α 2</td><td>β 1</td><td>β2</td></tr><tr><td></td><td>?, ?, ?</td><td>(?)</td><td>?, ?</td><td>?, ?, ?, ?</td></tr><tr><td></td><td>?, ?</td><td></td><td>?</td><td></td></tr><tr><td></td><td></td><td>?, ?</td><td></td><td></td></tr><tr><td></td><td></td><td>(?)</td><td></td><td></td></tr><tr><td></td><td colspan="4">Note that (?) indicates a drug not dealt with in the cards; have a go at giving the names.</td></tr></table>
</page>
<page number="61">
<table id="p61t1" data-filename="pdftables_fromstorage_023782248" data-page="61" data-table="1"><tr><td></td><td></td><td></td><td>Drugs acting on adrenoceptors 1</td></tr><tr><td></td><td colspan="2">Adrenoceptor agonists</td><td></td></tr><tr><td>α1</td><td>α 2</td><td>β1</td><td>β2</td></tr><tr><td>Phenylephrine</td><td>Clonidine</td><td>Dobutamine,</td><td>Salbutamol,</td></tr><tr><td>Oxymetazoline</td><td></td><td>Dopamine</td><td>Terbutaline,</td></tr><tr><td></td><td></td><td></td><td>Ritodrine,</td></tr><tr><td></td><td></td><td></td><td>Salmeterol</td></tr><tr><td>Methoxamine</td><td></td><td></td><td>Isoprenaline</td></tr><tr><td colspan="3">Noradrenaline (Norepinephrine; Methylnoradrenaline)</td><td></td></tr><tr><td></td><td colspan="2">Adrenaline (Epinephrine)</td><td></td></tr></table>
</page>
<page number="62">
<table id="p62t1" data-filename="pdftables_fromstorage_023782248" data-page="62" data-table="1"><tr><td></td><td>Drugs acting on</td><td></td><td></td><td></td></tr><tr><td style="text-align: right">2.14</td><td>adrenoceptors 2</td><td>Noradrenergic transmission</td><td></td><td></td></tr><tr><td></td><td colspan="3">Add the drugs dealt with in the NA cards in the relevant places</td><td></td></tr><tr><td></td><td></td><td>Adrenoceptor antagonists</td><td></td><td></td></tr><tr><td></td><td>α1</td><td>α 2</td><td>β 1</td><td>β2</td></tr><tr><td></td><td>?, ?, ?</td><td>(?)</td><td>?, ?</td><td>(?)</td></tr><tr><td></td><td>?, ?</td><td></td><td>?</td><td></td></tr><tr><td></td><td></td><td>(?)</td><td></td><td></td></tr><tr><td></td><td colspan="4">Note that (?) indicates a drug not dealt with in the cards; have a go at giving the names.</td></tr></table>
</page>
<page number="63">
<table id="p63t1" data-filename="pdftables_fromstorage_023782248" data-page="63" data-table="1"><tr><td></td><td></td><td colspan="2">Drugs acting on adrenoceptors 2</td></tr><tr><td></td><td colspan="2">Adrenoceptor antagonists</td><td></td></tr><tr><td>α1</td><td>α 2</td><td>β1</td><td>β2</td></tr><tr><td>Prazosin,</td><td></td><td></td><td></td></tr><tr><td></td><td>Yohimbine**</td><td>Atenolol,</td><td></td></tr><tr><td>Doxazosin</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Butoxamine**</td></tr><tr><td></td><td></td><td>Metoprolol</td><td></td></tr><tr><td>Tamsulosin</td><td></td><td></td><td></td></tr><tr><td>Phenoxybenzamine</td><td></td><td colspan="2">Propranolol</td></tr><tr><td>Phentolamine</td><td></td><td></td><td></td></tr><tr><td></td><td>Labetalol*</td><td></td><td></td></tr><tr><td colspan="2">* Not dealt with in the cards. **Not used clinically.</td><td></td><td></td></tr></table>
</page>
<page number="64">
<table id="p64t1" data-filename="pdftables_fromstorage_023782248" data-page="64" data-table="1"><tr><td style="text-align: right">3.01</td><td>Ibuprofen</td><td colspan="2">Inflammation and anti-inflammatory drugs</td><td></td><td></td></tr><tr><td colspan="6">Mediators of inflammation 1: prostanoids (in grey boxes), leukotrienes (in dashed boxes) and PAF (in dotted box)</td></tr><tr><td></td><td></td><td></td><td>Phospholipid</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Phospholipase A2</td><td></td><td></td></tr><tr><td></td><td></td><td>Arachidonate</td><td></td><td>Lyso-glyceryl-</td><td>PAF</td></tr><tr><td></td><td></td><td></td><td></td><td>phosphorylcholine</td><td>(vasodilator;</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>↑vasc. permeability;</td></tr><tr><td></td><td colspan="2">Cyclo-oxygenases</td><td></td><td></td><td>bronchoconstrictor;</td></tr><tr><td></td><td colspan="2">(COX-1, COX-2)</td><td></td><td></td><td>chemotaxin)</td></tr><tr><td></td><td></td><td></td><td></td><td>5-Lipoxygenase</td><td></td></tr><tr><td>PGl2</td><td></td><td>Cyclic</td><td>TXA2</td><td>LTA4</td><td></td></tr><tr><td colspan="2">(vasodilator; hyperalgesic;</td><td>endoperoxides</td><td>(thrombotic;</td><td></td><td></td></tr><tr><td colspan="2">↓platelet aggregation)</td><td></td><td>vasoconstrictor)</td><td></td><td>LTB</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>(chemotaxin)</td></tr><tr><td>PGF2α</td><td></td><td>PGD2</td><td>PGE2</td><td>LTC 4</td><td>(bronchoconstrictors;</td></tr><tr><td colspan="2">(bronchoconstrictor;</td><td>(vasodilator;</td><td>(vasodilator;</td><td></td><td>increase vascular</td></tr><tr><td colspan="2">myometrial contraction)</td><td>↓platelet aggregation)</td><td>hyperalgesic)</td><td>LTD</td><td>permeability)</td></tr></table>
</page>
<page number="65">
<table id="p65t1" data-filename="pdftables_fromstorage_023782248" data-page="65" data-table="1"><tr><td></td><td>A non-steroidal anti-inflammatory drug (NSAID)</td><td>Ibuprofen</td></tr><tr><td>Actions</td><td colspan="2">Reduces inflammation, is analgesic for inflammatory pain, is antipyretic (i.e. reduces raised</td></tr><tr><td></td><td>temperature).</td><td></td></tr><tr><td>MOA</td><td>Reversible inhibition of COX-1, weak inhibition of COX-2.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally, half-life 2h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Inflammatory conditions (e.g. rheumatoid disease, osteoarthritis, musculo-skeletal disorders);</td></tr><tr><td></td><td>dysmenorrhoea.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Gastrointestinal disturbances including gastric bleeding; headache, dizziness less commonly,</td></tr><tr><td></td><td>allergic reactions occasionally; renal toxicity rarely.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Increased adverse effects if combined with other NSAIDs. Used to close patent ductus arteriosus.</td></tr><tr><td>Similar drugs</td><td colspan="2">Diclofenac: (moderate potency, half-life 1–2h). Ketoprofen (half-life ~2h;) Naproxen (more potent,</td></tr><tr><td></td><td colspan="2">half-life 10–14h); ketorolac (half-life 4–10h, COX-1 selective); piroxicam (half-life 57h, GIT toxicity</td></tr><tr><td></td><td>common, COX non-selective).</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 26, p 319t; D&amp;H 2e Ch 16, pp 42-43</td></tr></table>
</page>
<page number="66">
<table id="p66t1" data-filename="pdftables_fromstorage_023782248" data-page="66" data-table="1"><tr><td style="text-align: right">3.02</td><td>Aspirin</td><td colspan="2">Inflammation and anti-inflammatory drugs</td><td></td><td></td></tr><tr><td colspan="6">Mediators of inflammation 1: prostanoids (in grey boxes), leukotrienes (in dashed boxes) and PAF (in dotted box)</td></tr><tr><td></td><td></td><td></td><td>Phospholipid</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Phospholipase A2</td><td></td><td></td></tr><tr><td></td><td></td><td>Arachidonate</td><td></td><td>Lyso-glyceryl-</td><td>PAF</td></tr><tr><td>NSAIDs:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>phosphorylcholine</td><td>(vasodilator;</td></tr><tr><td colspan="2">e.g. ibuprofen</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>↑vasc. permeability;</td></tr><tr><td>Others:</td><td></td><td></td><td></td><td></td><td>bronchoconstrictor;</td></tr><tr><td></td><td></td><td>Cyclo-oxygenases</td><td></td><td></td><td></td></tr><tr><td colspan="2">diclofenac</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>chemotaxin)</td></tr><tr><td colspan="2">ketoprofen</td><td>(COX-1, COX-2)</td><td></td><td></td><td></td></tr><tr><td>naproxen</td><td></td><td></td><td></td><td>5-Lipoxygenase</td><td></td></tr><tr><td>ketorolac</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>PGl2</td><td>Cyclic</td><td>TXA2</td><td>LTA4</td><td></td></tr><tr><td colspan="2">(vasodilator; hyperalgesic;</td><td>endoperoxides</td><td>(thrombotic;</td><td></td><td></td></tr><tr><td colspan="2">↓platelet aggregation)</td><td></td><td>vasoconstrictor)</td><td></td><td>LTB</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>(chemotaxin)</td></tr><tr><td colspan="2">PGF2α</td><td>PGD2</td><td>PGE2</td><td>LTC 4</td><td>(bronchoconstrictors;</td></tr><tr><td colspan="2">(bronchoconstrictor;</td><td>(vasodilator;</td><td>(vasodilator;</td><td></td><td>increase vascular</td></tr><tr><td colspan="2">myometrial contraction)</td><td>↓platelet aggregation)</td><td>hyperalgesic)</td><td>LTD</td><td>permeability)</td></tr></table>
</page>
<page number="67">
<table id="p67t1" data-filename="pdftables_fromstorage_023782248" data-page="67" data-table="1"><tr><td></td><td>A non-steroidal anti-inflammatory drug (NSAID)</td><td>Aspirin</td></tr><tr><td>Actions</td><td colspan="2">Reduces inflammation, is analgesic for inflammatory pain, is antipyretic (i.e. reduces raised</td></tr><tr><td></td><td>temperature). Inhibits platelet aggregation (see card 10.01).</td><td></td></tr><tr><td>MOA</td><td>Irreversible acetylation of cyclo-oxygenases; weakly COX-1 selective.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally. Half-life only 30min – rapid hydrolysis to salicylate but effects last</td></tr><tr><td></td><td colspan="2">longer because the COX has been inactivated and new enzyme must be produced.</td></tr><tr><td>Clinical use</td><td colspan="2">Main use: as antithrombotic in myocardial infarction (see card set 7). Other NSAIDs are preferred</td></tr><tr><td></td><td colspan="2">for anti-inflammatory action and analgesia in musculo-skeletal conditions.</td></tr><tr><td>Adverse effects</td><td colspan="2">Gastrointestinal disturbances, especially gastric bleeding. In high dosage can cause ‘salicylism’</td></tr><tr><td></td><td colspan="2">(tinnitus, vertigo, reduced hearing); allergic reactions occasionally; renal toxicity rarely.</td></tr><tr><td></td><td colspan="2">Can cause the potentially fatal Reye’s syndrome (encephalopathy &amp; liver disorder) in children</td></tr><tr><td></td><td>after a viral infection.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Should not be used in children. Can cause increased effect of warfarin resulting in bleeding.</td></tr><tr><td></td><td colspan="2">Should not be used for gout because it reduces urate excretion &amp; interferes with the action</td></tr><tr><td></td><td>of uricosuric agents.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 26, pp323-325; D&amp;H 2e Ch 16, pp 42-43</td></tr></table>
</page>
<page number="68">
<table id="p68t1" data-filename="pdftables_fromstorage_023782248" data-page="68" data-table="1"><tr><td style="text-align: right">3.03</td><td>Paracetamol</td><td colspan="2">Inflammation and anti-inflammatory drugs</td><td></td><td></td></tr><tr><td colspan="6">Mediators of inflammation 1: prostanoids (in grey boxes), leukotrienes (in dashed boxes) and PAF (in dotted box)</td></tr><tr><td></td><td></td><td></td><td>Phospholipid</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Phospholipase A2</td><td></td><td></td></tr><tr><td>NSAIDs:</td><td></td><td>Arachidonate</td><td></td><td>Lyso-glyceryl-</td><td>PAF</td></tr><tr><td colspan="2">e.g. ibuprofen</td><td></td><td></td><td>phosphorylcholine</td><td>(vasodilator;</td></tr><tr><td>Others:</td><td></td><td></td><td></td><td></td><td>↑vasc. permeability;</td></tr><tr><td colspan="2">diclofenac</td><td>Cyclo-oxygenases</td><td></td><td></td><td>bronchoconstrictor;</td></tr><tr><td colspan="2">ketoprofen</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>chemotaxin)</td></tr><tr><td>naproxen</td><td></td><td>(COX-1, COX-2)</td><td></td><td></td><td></td></tr><tr><td>ketorolac</td><td></td><td></td><td></td><td>5-Lipoxygenase</td><td></td></tr><tr><td>aspirin</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>PGl 2</td><td>Cyclic</td><td>TXA2</td><td>LTA4</td><td></td></tr><tr><td colspan="2">(vasodilator; hyperalgesic;</td><td>endoperoxides</td><td>(thrombotic;</td><td></td><td></td></tr><tr><td colspan="2">↓platelet aggregation)</td><td></td><td>vasoconstrictor)</td><td></td><td>LTB</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>(chemotaxin)</td></tr><tr><td colspan="2">PGF2α</td><td>PGD2</td><td>PGE2</td><td>LTC 4</td><td>(bronchoconstrictors;</td></tr><tr><td colspan="2">(bronchoconstrictor;</td><td>(vasodilator;</td><td>(vasodilator;</td><td></td><td>increase vascular</td></tr><tr><td colspan="2">myometrial contraction)</td><td>↓platelet aggregation)</td><td>hyperalgesic)</td><td>LTD</td><td>permeability)</td></tr></table>
</page>
<page number="69">
<table id="p69t1" data-filename="pdftables_fromstorage_023782248" data-page="69" data-table="1"><tr><td></td><td>A non-steroidal anti-inflammatory drug (NSAID)</td><td>Paracetamol</td></tr><tr><td>Actions</td><td colspan="2">Analgesic and antipyretic (i.e. reduces raised temperature). Has little anti-inflammatory action.</td></tr><tr><td>MOA</td><td colspan="2">Inhibition of COX-1, COX-2 and also the recently identified COX-3 which occurs predominantly in the</td></tr><tr><td></td><td>CNS.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally, half-life 2–4h, inactivated in the liver.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Mild to moderate pain, especially headache. It is the most commonly used NSAID.</td></tr><tr><td>Adverse effects</td><td colspan="2">Few and uncommon with therapeutic doses. Toxic doses cause firstly nausea and vomiting and</td></tr><tr><td></td><td>then 24h later potentially fatal liver toxicity.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 26, p 325; D&amp;H 2e Ch 16, pp 42-43</td></tr></table>
</page>
<page number="70">
<table id="p70t1" data-filename="pdftables_fromstorage_023782248" data-page="70" data-table="1"><tr><td style="text-align: right">3.04</td><td>Celecoxib</td><td colspan="2">Inflammation and anti-inflammatory drugs</td><td></td><td></td></tr><tr><td colspan="6">Mediators of inflammation 1: prostanoids (in grey boxes), leukotrienes (in dashed boxes) and PAF (in dotted box)</td></tr><tr><td></td><td></td><td></td><td>Phospholipid</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Phospholipase A2</td><td></td><td></td></tr><tr><td></td><td></td><td>Arachidonate</td><td></td><td>Lyso-glyceryl-</td><td>PAF</td></tr><tr><td>NSAIDs</td><td></td><td></td><td></td><td>phosphorylcholine</td><td>(vasodilator;</td></tr><tr><td>COX-non-</td><td></td><td></td><td></td><td></td><td>↑vasc. permeability;</td></tr><tr><td>selective:</td><td colspan="2">Cyclo-oxygenases</td><td></td><td></td><td>bronchoconstrictor;</td></tr><tr><td>ibuprofen,</td><td colspan="2">(COX-1, COX-2)</td><td></td><td></td><td>chemotaxin)</td></tr><tr><td>aspirin,</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>paracetamol</td><td></td><td></td><td></td><td>5-Lipoxygenase</td><td></td></tr><tr><td>PGl 2</td><td></td><td>Cyclic</td><td>TXA2</td><td>LTA4</td><td></td></tr><tr><td colspan="2">(vasodilator; hyperalgesic;</td><td>endoperoxides</td><td>(thrombotic;</td><td></td><td></td></tr><tr><td colspan="2">↓platelet aggregation)</td><td></td><td>vasoconstrictor)</td><td></td><td>LTB</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>(chemotaxin)</td></tr><tr><td>PGF2α</td><td></td><td>PGD2</td><td>PGE2</td><td>LTC 4</td><td>(bronchoconstrictors;</td></tr><tr><td colspan="2">(bronchoconstrictor;</td><td>(vasodilator;</td><td>(vasodilator;</td><td></td><td>increase vascular</td></tr><tr><td colspan="2">myometrial contraction)</td><td>↓platelet aggregation)</td><td>hyperalgesic)</td><td>LTD</td><td>permeability)</td></tr></table>
</page>
<page number="71">
<table id="p71t1" data-filename="pdftables_fromstorage_023782248" data-page="71" data-table="1"><tr><td></td><td>A ‘coxib’ non-steroidal anti-inammatory drug (Similar drugs: etoricoxib, parecoxib)</td><td>Celecoxib</td></tr><tr><td>Actions</td><td colspan="2">Analgesic, antipyretic and anti-inflammatory actions. No antiplatelet action.</td></tr><tr><td>MOA</td><td colspan="2">Selective inhibition of COX-2 – the enzyme that is induced in areas of inflammation. Celecoxib</td></tr><tr><td></td><td colspan="2">is 10–20 x more active on COX-2 than COX-1 – the constitutive enzyme that generates</td></tr><tr><td></td><td>physiologically important prostaglandins.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally, half-life ~11h, inactivated in the liver.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis. (No cardioprotective effect because</td></tr><tr><td></td><td>no antiplatelet action.)</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Fewer adverse gastrointestinal effects than the traditional NSAIDs. Some renal toxicity because</td></tr><tr><td></td><td>COX-2 occurs constitutively in the kidney.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 26, p 325; D&amp;H 2e Ch 16, pp 42-43</td></tr></table>
</page>
<page number="72">
<table id="p72t1" data-filename="pdftables_fromstorage_023782248" data-page="72" data-table="1"><tr><td style="text-align: right">3.05</td><td>Inflammation and</td><td colspan="3">What group of drugs can inhibit the production of all the inflammatory</td></tr><tr><td></td><td>anti-inflammatory drugs</td><td>mediators below?</td><td></td><td></td></tr><tr><td colspan="5">Mediators of inflammation 1: prostanoids (in grey boxes), leukotrienes (in dashed boxes) and PAF (in dotted box)</td></tr><tr><td></td><td></td><td>Phospholipid</td><td></td><td></td></tr><tr><td></td><td colspan="2">Phospholipase A2</td><td></td><td></td></tr><tr><td>NSAIDs</td><td>Arachidonate</td><td></td><td>Lyso-glyceryl-</td><td>PAF</td></tr><tr><td>COX-non-</td><td></td><td></td><td>phosphorylcholine</td><td>(vasodilator;</td></tr><tr><td>selective:</td><td></td><td></td><td></td><td>↑vasc. permeability;</td></tr><tr><td>ibuprofen,</td><td></td><td></td><td></td><td>bronchoconstrictor;</td></tr><tr><td></td><td>Cyclo-oxygenases</td><td></td><td></td><td></td></tr><tr><td>aspirin,</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>chemotaxin)</td></tr><tr><td>paracetamol</td><td>(COX-1, COX-2)</td><td></td><td></td><td></td></tr><tr><td>COX-2 selective</td><td></td><td></td><td>5-Lipoxygenase</td><td></td></tr><tr><td>Celecoxib</td><td></td><td></td><td></td><td></td></tr><tr><td>PGl 2</td><td>Cyclic</td><td>TXA2</td><td>LTA4</td><td></td></tr><tr><td>(vasodilator; hyperalgesic;</td><td>endoperoxides</td><td>(thrombotic;</td><td></td><td></td></tr><tr><td>↓platelet aggregation)</td><td></td><td>vasoconstrictor)</td><td></td><td>LTB</td></tr><tr><td></td><td></td><td></td><td></td><td>(chemotaxin)</td></tr><tr><td>PGF2α</td><td>PGD2</td><td>PGE2</td><td>LTC 4</td><td>(bronchoconstrictors;</td></tr><tr><td>(bronchoconstrictor;</td><td>(vasodilator;</td><td>(vasodilator;</td><td></td><td>increase vascular</td></tr><tr><td>myometrial contraction)</td><td>↓platelet aggregation)</td><td>hyperalgesic)</td><td>LTD</td><td>permeability)</td></tr></table>
</page>
<page number="73">
<table id="p73t1" data-filename="pdftables_fromstorage_023782248" data-page="73" data-table="1"><tr><td></td><td colspan="4">Glucocorticoids can inhibit the production of all the inflammatory mediators below</td></tr><tr><td>Glucocorticoids also</td><td></td><td>Phospholipid</td><td colspan="2">Glucocorticoids (by inducing</td></tr><tr><td>inhibit induction of:</td><td></td><td></td><td colspan="2">annexin 1). See card 16.02</td></tr><tr><td></td><td colspan="2">Phospholipase A2</td><td></td><td></td></tr><tr><td>NSAIDs</td><td>Arachidonate</td><td></td><td>Lyso-glyceryl-</td><td>PAF</td></tr><tr><td>COX-non-</td><td></td><td></td><td>phosphorylcholine</td><td>(vasodilator;</td></tr><tr><td>selective:</td><td></td><td></td><td></td><td>↑vasc. permeability;</td></tr><tr><td>ibuprofen,</td><td></td><td></td><td></td><td>bronchoconstrictor;</td></tr><tr><td></td><td>Cyclo-oxygenases</td><td></td><td></td><td></td></tr><tr><td>aspirin,</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>chemotaxin)</td></tr><tr><td>paracetamol</td><td>(COX-1, COX-2)</td><td></td><td></td><td></td></tr><tr><td>COX-2 selective</td><td></td><td></td><td>5-Lipoxygenase</td><td></td></tr><tr><td>Celecoxib</td><td></td><td></td><td></td><td></td></tr><tr><td>PGl2</td><td>Cyclic</td><td>TXA2</td><td>LTA4</td><td></td></tr><tr><td>(vasodilator; hyperalgesic;</td><td>endoperoxides</td><td>(thrombotic;</td><td></td><td></td></tr><tr><td>↓platelet aggregation)</td><td></td><td>vasoconstrictor)</td><td></td><td>LTB</td></tr><tr><td></td><td></td><td></td><td></td><td>(chemotaxin)</td></tr><tr><td>PGF2α</td><td>PGD2</td><td>PGE2</td><td>LTC 4</td><td>(bronchoconstrictors;</td></tr><tr><td>(bronchoconstrictor;</td><td>(vasodilator;</td><td>(vasodilator;</td><td></td><td>increase vascular</td></tr><tr><td>myometrial contraction)</td><td>↓platelet aggregation)</td><td>hyperalgesic)</td><td>LTD</td><td>permeability)</td></tr><tr><td></td><td></td><td></td><td colspan="2">R&amp;D 7e Ch 26, pp 318-335; D&amp;H 2e Ch 29, pp 70-71</td></tr></table>
</page>
<page number="74">
<table id="p74t1" data-filename="pdftables_fromstorage_023782248" data-page="74" data-table="1"><tr><td style="text-align: right">3.06</td><td>Methotrexate</td><td colspan="3">Inflammation and anti-inflammatory drugs (antirheumatoid agents)</td></tr><tr><td colspan="4">The figure shows the pathophysiology of rheumatoid joint damage</td><td></td></tr><tr><td colspan="5">CD4 T cells become activated and stimulate macrophages, osteoblasts and fibroblasts</td></tr><tr><td>T</td><td></td><td>Activated</td><td></td><td>Macrophage</td></tr><tr><td></td><td>Th0</td><td></td><td></td><td></td></tr><tr><td>CD4</td><td></td><td>Th1 cell</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>IL-1</td><td>TNF-α</td></tr><tr><td></td><td></td><td></td><td></td><td>Release of other inflammatory</td></tr><tr><td></td><td>Osteoclast</td><td>Fibroblast</td><td></td><td>cytokines and chemokines</td></tr><tr><td></td><td></td><td>Collagenase</td><td colspan="2">Influx of inflammatory cells</td></tr><tr><td></td><td>= gives rise to</td><td></td><td></td><td></td></tr><tr><td></td><td>= releases</td><td colspan="2">Erosion of cartilage and bone: JOINT DAMAGE</td><td></td></tr><tr><td></td><td>= acts on</td><td></td><td></td><td></td></tr><tr><td colspan="5">IL-1 = interleukin-1, TNF-α = tumour necrosis factor-alpha (the main pro-inflammatory cytokines)</td></tr></table>
</page>
<page number="75">
<table id="p75t1" data-filename="pdftables_fromstorage_023782248" data-page="75" data-table="1"><tr><td></td><td>An immunosuppressive disease-modifying antirheumatoid drug (DMARD)</td><td>Methotrexate</td></tr><tr><td>Actions</td><td colspan="2">Has marked anti-inflammatory action in rheumatoid disease. Methotrexate (MTX) is cytotoxic in</td></tr><tr><td></td><td>the larger doses used to treat cancer.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Is a folate antagonist and thus interferes with thymidylate synthesis (which is essential for DNA</td></tr><tr><td></td><td>synthesis).</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally; has active metabolite; both MTX and metabolite are poly-glutamated (PgMTX).</td></tr><tr><td></td><td>Half-life 6–9h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Drug of first choice for rheumatoid arthritis; also used in psoriasis, ankylosing spondylitis,</td></tr><tr><td></td><td>polymyositis and vaculitis. MTX is also an anti-cancer agent.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Gastrointestinal disturbances, dose-related liver toxicity. Bone marrow depression and</td></tr><tr><td></td><td>pneumonitis can occur.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 26, p 327; D&amp;H 2e Ch 46, p 105, Appendix A3</td></tr></table>
</page>
<page number="76">
<table id="p76t1" data-filename="pdftables_fromstorage_023782248" data-page="76" data-table="1"><tr><td style="text-align: right">3.07</td><td>Sulfasalazine</td><td colspan="3">Inflammation and anti-inflammatory drugs (antirheumatoid agents)</td></tr><tr><td colspan="4">The figure shows the pathophysiology of rheumatoid joint damage</td><td></td></tr><tr><td></td><td colspan="2">Immunosuppressant DMARD</td><td></td><td></td></tr><tr><td></td><td>methotrexate</td><td></td><td></td><td></td></tr><tr><td>T</td><td></td><td>Activated</td><td></td><td>Macrophage</td></tr><tr><td></td><td>Th0</td><td></td><td></td><td></td></tr><tr><td>CD4</td><td></td><td>Th1 cell</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>IL-1</td><td>TNF-α</td></tr><tr><td></td><td></td><td></td><td></td><td>Release of other inflammatory</td></tr><tr><td></td><td>Osteoclast</td><td>Fibroblast</td><td></td><td>cytokines and chemokines</td></tr><tr><td></td><td></td><td>Collagenase</td><td colspan="2">Influx of inflammatory cells</td></tr><tr><td></td><td>= gives rise to</td><td></td><td></td><td></td></tr><tr><td></td><td>= releases</td><td colspan="2">Erosion of cartilage and bone: JOINT DAMAGE</td><td></td></tr><tr><td></td><td>= acts on</td><td></td><td></td><td></td></tr></table>
</page>
<page number="77">
<table id="p77t1" data-filename="pdftables_fromstorage_023782248" data-page="77" data-table="1"><tr><td></td><td>A disease-modifying antirheumatoid drug (DMARD)</td><td>Sulfasalazine</td></tr><tr><td>Actions</td><td colspan="2">Produces remission of active rheumatoid arthritis. According to X-rays, disease progression is</td></tr><tr><td></td><td>reduced.</td><td></td></tr><tr><td>MOA</td><td colspan="2">In the colon the salicylic acid moiety is released, is absorbed and has anti-inflammatory action.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally; only ~15% is absorbed in the GIT. Half-life 6–16h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Rheumatoid arthritis, juvenile arthritis, inflammatory bowel disease.</td></tr><tr><td>Adverse effects</td><td colspan="2">Nausea &amp; vomiting, headaches, rashes. Rarely bone marrow dyscrasias, liver dysfunction. About a</td></tr><tr><td></td><td>third of patients discontinue the drug because of adverse effects.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 26, pp 327-328; D&amp;H 2e Ch 17, p 45</td></tr></table>
</page>
<page number="78">
<table id="p78t1" data-filename="pdftables_fromstorage_023782248" data-page="78" data-table="1"><tr><td style="text-align: right">3.08</td><td>Leflunomide</td><td colspan="3">Inflammation and anti-inflammatory drugs (antirheumatoid agents)</td></tr><tr><td colspan="4">The figure shows the pathophysiology of rheumatoid joint damage</td><td></td></tr><tr><td></td><td colspan="2">Immunosuppressant DMARD</td><td></td><td></td></tr><tr><td></td><td>methotrexate</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Macrophage</td></tr><tr><td>T</td><td></td><td>Activated</td><td></td><td></td></tr><tr><td></td><td>Th0</td><td></td><td></td><td></td></tr><tr><td>CD4</td><td></td><td>Th1 cell</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>IL-1</td><td>TNF-α</td></tr><tr><td></td><td></td><td></td><td></td><td>Release of other inflammatory</td></tr><tr><td></td><td>Osteoclast</td><td>Fibroblast</td><td></td><td>cytokines and chemokines</td></tr><tr><td></td><td></td><td>Collagenase</td><td colspan="2">Influx of inflammatory cells</td></tr><tr><td></td><td>= gives rise to</td><td></td><td></td><td></td></tr><tr><td></td><td>= releases</td><td colspan="2">Erosion of cartilage and bone: JOINT DAMAGE</td><td></td></tr><tr><td></td><td>= acts on</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">DMARDS: Methotrexate, sulfasalazine</td><td></td></tr></table>
</page>
<page number="79">
<table id="p79t1" data-filename="pdftables_fromstorage_023782248" data-page="79" data-table="1"><tr><td></td><td>A disease-modifying antirheumatoid drug (DMARD)</td><td>Leflunomide</td></tr><tr><td>Actions</td><td colspan="2">Modifies the immune reaction underlying rheumatoid arthritis through an inhibitory action on</td></tr><tr><td></td><td>activated T cells.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Gives rise to a metabolite that inhibits dihydrooratate dehydrogenase; this results in inhibition of</td></tr><tr><td></td><td colspan="2">T-cell proliferation and decreased production of autoantibodies by B cells.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Absorbed orally. The metabolite undergoes enterohepatic cycling, half-life thus ~18 days.</td></tr><tr><td>Clinical use</td><td colspan="2">Rheumatoid arthritis. Particularly effective in combination with methotrexate.</td></tr><tr><td>Adverse effects</td><td colspan="2">~25% of patients get diarrhoea. Increased BP, weight gain can occur. The long half-life can lead to</td></tr><tr><td></td><td>cumulative toxicity.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 26, p 330</td></tr></table>
</page>
<page number="80">
<table id="p80t1" data-filename="pdftables_fromstorage_023782248" data-page="80" data-table="1"><tr><td style="text-align: right">3.09</td><td>Infliximab</td><td colspan="2">Inflammation and anti-inflammatory drugs (antirheumatoid agents)</td><td></td></tr><tr><td colspan="4">The figure shows the pathophysiology of rheumatoid joint damage</td><td></td></tr><tr><td></td><td colspan="2">Immunosuppressant DMARD</td><td></td><td></td></tr><tr><td></td><td>methotrexate</td><td></td><td></td><td></td></tr><tr><td>T</td><td></td><td>Activated</td><td></td><td>Macrophage</td></tr><tr><td></td><td>Th0</td><td></td><td></td><td></td></tr><tr><td>CD4</td><td></td><td>Th1 cell</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>IL-1</td><td>TNF-α</td></tr><tr><td></td><td></td><td></td><td></td><td>Release of other inflammatory</td></tr><tr><td></td><td>Osteoclast</td><td>Fibroblast</td><td></td><td>cytokines and chemokines</td></tr><tr><td></td><td></td><td>Collagenase</td><td colspan="2">Influx of inflammatory cells</td></tr><tr><td></td><td>= gives rise to</td><td></td><td></td><td></td></tr><tr><td></td><td>= releases</td><td colspan="2">Erosion of cartilage and bone: JOINT DAMAGE</td><td></td></tr><tr><td></td><td>= acts on</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="3">DMARDS: Methotrexate, sulfasalazine, leflunomide</td></tr></table>
</page>
<page number="81">
<table id="p81t1" data-filename="pdftables_fromstorage_023782248" data-page="81" data-table="1"><tr><td></td><td>An anticytokine antirheumatoid drug</td><td>Infliximab</td></tr><tr><td>Actions</td><td colspan="2">Reduces joint inflammation and symptoms of rheumatoid arthritis. Reduces symptoms of Crohn’s</td></tr><tr><td></td><td>disease.</td><td></td></tr><tr><td>MOA</td><td colspan="2">It is a monoclonal antibody against TNF-α that binds with the TNF-α and prevents its interaction</td></tr><tr><td></td><td>with cell surface receptors in inflammatory cells.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given by i.v. infusion every 4 weeks. Half-life 9–12 days.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Active rheumatoid arthritis – usually combined with methotrexate if other DMARDs haven’t</td></tr><tr><td></td><td colspan="2">worked. Ankylosing spondylitis and psoriatic arthritis – if other therapy hasn’t worked.</td></tr><tr><td>Adverse effects</td><td colspan="2">Nausea, vomiting, headache, upper respiratory tract infections with cough. Because of inactivation</td></tr><tr><td></td><td colspan="2">of macrophages latent TB and other conditions (e.g. hepatitis B) could be reactivated. Blood</td></tr><tr><td></td><td>dyscrasias can occur. Antibodies against infliximab may be produced.</td><td></td></tr><tr><td>Similar drugs</td><td colspan="2">Adalimumab is also an anti-TNF-α antibody (half-life 10–20 days, MTX reduces clearance).</td></tr><tr><td></td><td colspan="2">Etanercept another anti-TNF-α antibody (given subcut. twice a week; half-life ~5 days).</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 26, p 330</td></tr></table>
</page>
<page number="82">
<table id="p82t1" data-filename="pdftables_fromstorage_023782248" data-page="82" data-table="1"><tr><td style="text-align: right">3.10</td><td>Other DMARDS</td><td colspan="2">What group of drugs inhibits mediator release from the macrophage?</td><td></td><td></td></tr><tr><td colspan="4">The figure shows the pathophysiology of rheumatoid joint damage</td><td></td><td></td></tr><tr><td></td><td colspan="2">Immunosuppressant DMARD</td><td></td><td></td><td></td></tr><tr><td></td><td>methotrexate</td><td></td><td></td><td>?</td><td></td></tr><tr><td>T</td><td>Th0</td><td>Activated</td><td></td><td>Macrophage</td><td>Anti-TNF agents</td></tr><tr><td>CD4</td><td></td><td>Th1 cell</td><td></td><td></td><td>e.g. infliximab</td></tr><tr><td></td><td></td><td></td><td>IL-1</td><td>TNF-α</td><td>etanercept</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Release of other inflammatory</td></tr><tr><td></td><td>Osteoclast</td><td>Fibroblast</td><td></td><td colspan="2">cytokines and chemokines</td></tr><tr><td></td><td></td><td>Collagenase</td><td colspan="3">Influx of inflammatory cells</td></tr><tr><td></td><td>= gives rise to</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>= releases</td><td colspan="2">Erosion of cartilage and bone: JOINT DAMAGE</td><td></td><td></td></tr><tr><td></td><td>= acts on</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">DMARDS: Methotrexate, sulfasalazine, leflunomide</td><td></td><td></td></tr></table>
</page>
<page number="83">
<table id="p83t1" data-filename="pdftables_fromstorage_023782248" data-page="83" data-table="1"><tr><td></td><td></td><td></td><td></td><td>GLUCOCORTICOIDS;</td></tr><tr><td></td><td></td><td></td><td></td><td>OTHER DMARDS</td></tr><tr><td>Immunosuppressants;</td><td>Anti-IL1 agents</td><td></td><td></td><td></td></tr><tr><td>methotrexate</td><td>e.g. anakinra</td><td></td><td colspan="2">Glucocorticoids (see card 16.01)</td></tr><tr><td>T</td><td>Activated</td><td></td><td>Macrophage</td><td>Anti-TNF agents</td></tr><tr><td>Th0</td><td></td><td></td><td></td><td></td></tr><tr><td>CD4</td><td>Th1 cell</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>IL-1</td><td>TNF-α</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Release of other inflammatory</td></tr><tr><td>Osteoclast</td><td>Fibroblast</td><td></td><td></td><td>cytokines and chemokines</td></tr><tr><td></td><td>Collagenase</td><td colspan="3">Influx of inflammatory cells</td></tr><tr><td>= gives rise to</td><td></td><td></td><td></td><td></td></tr><tr><td>= releases</td><td colspan="3">Erosion of cartilage and bone: JOINT DAMAGE</td><td></td></tr><tr><td>= acts on</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">DMARDS: Methotrexate, sulfasalazine, leflunomide, anticytokine agents, gold</td></tr><tr><td colspan="5">compounds (auranofin, aurothiomalate), hydroxychloroquine, penicillamine</td></tr><tr><td></td><td></td><td></td><td colspan="2">R&amp;D 7e Ch 26, pp 327-328; D&amp;H 2e Ch 17 pp 44-45, Appendix A3</td></tr></table>
</page>
<page number="84">
<table id="p84t1" data-filename="pdftables_fromstorage_023782248" data-page="84" data-table="1"><tr><td style="text-align: right">3.11</td><td>Allopurinol</td><td>Inflammation and anti-inflammatory drugs (antigout agents)</td></tr><tr><td colspan="2">The figure shows the final metabolic pathway in the production of uric acid</td><td></td></tr><tr><td></td><td></td><td>HYPOXANTHINE</td></tr><tr><td></td><td></td><td>Xanthine oxidase</td></tr><tr><td></td><td>GOUT is due to the overproduction of uric acid</td><td></td></tr><tr><td></td><td>leading to arthritis due to deposition of urate</td><td></td></tr><tr><td></td><td>crystals in the joints. Phagocytes engulf the</td><td>XANTHINE</td></tr><tr><td></td><td>crystals and release inflammatory mediators.</td><td></td></tr><tr><td></td><td></td><td>Xanthine oxidase</td></tr><tr><td></td><td></td><td>Uric acid</td></tr></table>
</page>
<page number="85">
<table id="p85t1" data-filename="pdftables_fromstorage_023782248" data-page="85" data-table="1"><tr><td></td><td>A uricosuric agent</td><td>Allopurinol</td></tr><tr><td>Actions</td><td>Reduces uric acid concentration in the body.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits xanthine oxidase and also the biotransformation of purines to xanthine.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally; well absorbed; converted to alloxanthine which has a half-life of ~18–30h and is the</td></tr><tr><td></td><td>moiety that inhibits xanthine oxidase.</td><td></td></tr><tr><td>Clinical use</td><td>To prevent episodes of gout.</td><td></td></tr><tr><td>Adverse effects</td><td>Gastrointestinal disturbances. Rashes and blood dyscrasias can occur.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Allopurinol is not used to treat acute attacks of gout – these are treated with NSAIDs.</td></tr><tr><td></td><td colspan="2">Allopurinol interferes with the metabolism of oral anticoagulants and can increase the effect of</td></tr><tr><td></td><td>azathioprine and cyclophosphamide.</td><td></td></tr><tr><td>Similar drugs</td><td colspan="2">Probenicid is similar in that it is also uricosuric but it acts by increasing uric acid excretion through</td></tr><tr><td></td><td colspan="2">an effect on the proximal tubule in the nephron; only used to prevent gouty attacks.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 26, pp 331-332; D&amp;H 2e Ch 16, p 43</td></tr></table>
</page>
<page number="86">
<table id="p86t1" data-filename="pdftables_fromstorage_023782248" data-page="86" data-table="1"><tr><td style="text-align: right">3.12</td><td>Colchicine</td><td colspan="2">Inflammation and anti-inflammatory drugs (antigout agents)</td></tr><tr><td colspan="4">The figure shows the final metabolic pathway in the production of uric acid</td></tr><tr><td></td><td colspan="3">Gout is due to the overproduction of uric acid leading to arthritis due to deposition of urate crystals</td></tr><tr><td></td><td colspan="3">in the joints. Phagocytes engulf the crystals and release inflammatory mediators.</td></tr><tr><td></td><td></td><td>Allopurinol</td><td></td></tr><tr><td></td><td></td><td></td><td>HYPOXANTHINE</td></tr><tr><td></td><td colspan="2">Xanthine oxidase</td><td></td></tr><tr><td></td><td></td><td></td><td>Xanthine oxidase</td></tr><tr><td></td><td></td><td>Alloxanthine</td><td>↓XANTHINE</td></tr><tr><td></td><td></td><td></td><td>Xanthine oxidase</td></tr><tr><td></td><td></td><td></td><td>↓Uric acid</td></tr></table>
</page>
<page number="87">
<table id="p87t1" data-filename="pdftables_fromstorage_023782248" data-page="87" data-table="1"><tr><td></td><td>An anti-inflammatory antigout agent</td><td>Colchicine</td></tr><tr><td>Actions</td><td>It decreases the pain and inflammation of gouty arthritis.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits migration into gouty joints of neutrophils by binding to tubulin and preventing its</td></tr><tr><td></td><td colspan="2">polymerisation into microtubules. Neutrophils are reduced to moving with a ‘drunken walk’.</td></tr><tr><td></td><td>It also decreases production of the chemokine leukotriene B 4 .</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally, well-absorbed; half-life 9h.</td><td></td></tr><tr><td>Clinical use</td><td>To prevent episodes of gout.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Diarrhoea and sometimes nausea and vomiting. Blood dyscrasias can occur.</td></tr><tr><td>Special points</td><td>It can increase the bone marrow depression caused by other drugs.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 26, p 332; D&amp;H 2e Ch 16, p 43</td></tr></table>
</page>
<page number="88">
<table id="p88t1" data-filename="pdftables_fromstorage_023782248" data-page="88" data-table="1"><tr><td style="text-align: right">4.01</td><td>Ciclosporin</td><td colspan="3">Drugs affecting the immune response</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Antibody-mediated reactions</td></tr><tr><td></td><td></td><td></td><td>B</td><td>P</td><td>Plasma cell</td><td>Releases</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>antibodies</td></tr><tr><td></td><td></td><td>Th2</td><td>BB</td><td></td><td></td><td></td></tr><tr><td></td><td>IL-2</td><td></td><td>B</td><td>MB</td><td>Memory B cell</td><td></td></tr><tr><td></td><td>T</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>CD4</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>IL-2</td><td>Th1</td><td>MT</td><td>Memory T cell</td><td></td></tr><tr><td></td><td>Antigen</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Th1</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Th1</td><td>Th1</td><td colspan="2">Macrophage-activating</td></tr><tr><td></td><td>IL-2</td><td></td><td></td><td></td><td colspan="2">cytokines &amp; other cytokines</td></tr><tr><td></td><td>T</td><td>T</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>CD8</td><td>CD8</td><td></td><td>Tc</td><td colspan="2">Kill virally infected cells</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Cell-mediated reactions</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">T = T cell, Th =T helper cell, B = B cell</td></tr></table>
</page>
<page number="89">
<table id="p89t1" data-filename="pdftables_fromstorage_023782248" data-page="89" data-table="1"><tr><td>Immunosuppressant</td><td>Ciclosporin</td></tr><tr><td colspan="2">Actions Reduces cell-mediated immune (CMI) responses; lesser effect on antibody-mediated responses.</td></tr><tr><td colspan="2">Interferes with antigen-induced T-cell differentiation and the clonal proliferation of T cells and thus</td></tr><tr><td colspan="2">the development &amp; activation of cytotoxic T cells and of other T cells responsible for CMI responses.</td></tr><tr><td colspan="2">MOA It complexes with cyclophilin to inhibit calcineurin which normally activates the transcription of</td></tr><tr><td>interleukin-2 (IL-2).</td><td></td></tr><tr><td colspan="2">Abs/Distrb/Elim Given orally or by i.v. infusion. Tissue concentration is 3 × that in the plasma. Metabolised in the liver</td></tr><tr><td>by the P450 3A enzyme system.</td><td></td></tr><tr><td colspan="2">Clinical use Used to prevent rejection of organ and tissue transplants &amp; for prevention of graft v host disease. Can</td></tr><tr><td colspan="2">be useful in autoimmune diseases. Often used in combination with glucocorticoids or methotrexate.</td></tr><tr><td colspan="2">Adverse effects Nephrotoxicity. Can cause hypertension &amp; hepatotoxicity and sometimes GIT disturbances, tremor,</td></tr><tr><td>hirsutism, paraesthesia, gum hypertrophy.</td><td></td></tr><tr><td>Special points Multiple interactions with other drugs.</td><td></td></tr><tr><td colspan="2">Similar drug Tacrolimus: indirectly inhibits calcineurin; more potent than ciclosporin with similar adverse effects</td></tr><tr><td>– myelosuppression etc. but greater neurotoxicity.</td><td></td></tr><tr><td></td><td>R&amp;D 7e Ch 26, pp 328-329; D&amp;H 2e Ch17, pp 44-45</td></tr></table>
</page>
<page number="90">
<table id="p90t1" data-filename="pdftables_fromstorage_023782248" data-page="90" data-table="1"><tr><td style="text-align: right">4.02</td><td colspan="2">Azathioprine</td><td colspan="4">Drugs affecting the immune response</td><td></td><td></td></tr><tr><td colspan="3">Immunosuppressants:</td><td colspan="2">Ciclosporin</td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">-</td><td style="text-align: right">-</td><td style="text-align: right">-</td><td style="text-align: right">-</td><td></td><td></td><td></td><td colspan="2">Antibody-mediated reactions</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>B</td><td>P</td><td>Plasma cell</td><td>Releases</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>antibodies</td></tr><tr><td></td><td></td><td></td><td>Th2</td><td>BB</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>IL-2</td><td></td><td></td><td></td><td>B</td><td>MB</td><td>Memory B cell</td><td></td></tr><tr><td></td><td>T</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>CD4</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>IL-2</td><td></td><td>Th1</td><td>MT</td><td>Memory T cell</td><td></td></tr><tr><td></td><td>Antigen</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Th1</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Th1</td><td>Th1</td><td colspan="2">Macrophage-activating</td></tr><tr><td></td><td>IL-2</td><td style="text-align: right">-</td><td></td><td></td><td></td><td></td><td colspan="2">cytokines &amp; other cytokines</td></tr><tr><td></td><td>T</td><td style="text-align: right">-</td><td>T</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>CD8</td><td></td><td>CD8</td><td></td><td></td><td>Tc</td><td colspan="2">Kill virally infected cells</td></tr><tr><td></td><td></td><td style="text-align: right">-</td><td></td><td></td><td></td><td></td><td colspan="2">Cell-mediated reactions</td></tr><tr><td></td><td colspan="4">Immunosuppressants:</td><td>Ciclosporin</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">T = T cell, Th =T helper cell, B = B cell</td></tr></table>
</page>
<page number="91">
<table id="p91t1" data-filename="pdftables_fromstorage_023782248" data-page="91" data-table="1"><tr><td>Antiproliferative immunosuppressant</td><td>Azathioprine</td></tr><tr><td colspan="2">Actions Reduces the clonal proliferation of T and B cells during the induction phase of the immune response.</td></tr><tr><td colspan="2">MOA Interferes with purine synthesis and has cytotoxic action on dividing cells.</td></tr><tr><td colspan="2">Abs/Distrb/Elim Given orally or by i.v. infusion. Metabolised to mercaptopurine (mcp) which is the cytotoxic moiety</td></tr><tr><td colspan="2">acting by interfering with purine nucleotide metabolism. Mcp is inactivated by xanthine oxidase.</td></tr><tr><td colspan="2">Clinical use Used to prevent rejection of organ and tissue transplants &amp; for prevention of graft v host disease. Also</td></tr><tr><td colspan="2">used in chronic inflammatory and autoimmune diseases (e.g. rheumatoid arthritis).</td></tr><tr><td colspan="2">Adverse effects Myelotoxicity (dose-related). GIT disturbances, hypersensitivity reactions (skin rashes, arthralgia etc.).</td></tr><tr><td>Special points Blood should be monitored for myelosuppression.</td><td></td></tr><tr><td></td><td>R&amp;D 7e Ch 26, p 330; D&amp;H 2e Ch 17, pp 44-45</td></tr></table>
</page>
<page number="92">
<table id="p92t1" data-filename="pdftables_fromstorage_023782248" data-page="92" data-table="1"><tr><td></td><td colspan="3">Mycophenolate</td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">4.03</td><td colspan="2">mofetil</td><td></td><td colspan="2">Drugs affecting the immune response</td><td></td><td></td></tr><tr><td colspan="3">Immunosuppressants:</td><td colspan="2">Ciclosporin, azathioprine</td><td></td><td></td><td></td></tr><tr><td style="text-align: right">-</td><td style="text-align: right">-</td><td></td><td style="text-align: right">-</td><td style="text-align: right">-</td><td></td><td colspan="2">Antibody-mediated reactions</td></tr><tr><td></td><td></td><td></td><td></td><td>B</td><td>P</td><td>Plasma cell</td><td>Releases</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>antibodies</td></tr><tr><td></td><td></td><td></td><td>Th2</td><td>BB</td><td></td><td></td><td></td></tr><tr><td></td><td>IL-2</td><td></td><td></td><td>B</td><td>MB</td><td>Memory B cell</td><td></td></tr><tr><td></td><td>T</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>CD4</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>IL-2</td><td>Th1</td><td>MT</td><td>Memory T cell</td><td></td></tr><tr><td></td><td colspan="2">Antigen</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Th1</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Th1</td><td>Th1</td><td colspan="2">Macrophage-activating</td></tr><tr><td></td><td>IL-2</td><td></td><td style="text-align: right">-</td><td></td><td></td><td colspan="2">cytokines &amp; other cytokines</td></tr><tr><td></td><td>T</td><td style="text-align: right">-</td><td>T</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>CD8</td><td></td><td>CD8</td><td></td><td>Tc</td><td colspan="2">Kill virally infected cells</td></tr><tr><td></td><td></td><td></td><td style="text-align: right">-</td><td></td><td></td><td colspan="2">Cell-mediated reactions</td></tr><tr><td colspan="4">Immunosuppressants:</td><td colspan="2">Ciclosporin, azathioprine</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">T = T cell, Th =T helper cell, B = B cell</td></tr></table>
</page>
<page number="93">
<table id="p93t1" data-filename="pdftables_fromstorage_023782248" data-page="93" data-table="1"><tr><td></td><td>Mycophenolate</td></tr><tr><td>Antiproliferative Immunosuppressant</td><td>mofetil</td></tr><tr><td colspan="2">Actions Selectively restrains the clonal proliferation of T and B cells and reduces the production of cytotoxic</td></tr><tr><td>T cells.</td><td></td></tr><tr><td colspan="2">MOA Inhibits de novo purine synthesis specifically in T and B lymphocytes (other cells can generate purines</td></tr><tr><td>by another pathway).</td><td></td></tr><tr><td colspan="2">Abs/Distrb/Elim Given orally or by i.v. infusion. Metabolised to mycophenolic acid which is the active moiety</td></tr><tr><td>which interferes with purine nucleotide metabolism.</td><td></td></tr><tr><td colspan="2">Clinical use Used to prevent rejection of organ transplants usually in combination with ciclosporin and</td></tr><tr><td colspan="2">glucocorticoids. Also used in autoimmune diseases (e.g. rheumatoid arthritis).</td></tr><tr><td colspan="2">Adverse effects GIT, CVS &amp; respiratory system disturbances, hepatitis, pancreatitis, tremor, dizziness, flulike syndrome.</td></tr><tr><td>Special points Treatment requires specialist supervision.</td><td></td></tr><tr><td></td><td>R&amp;D 7e Ch 26, p 330; D&amp;H 2e Ch 17, pp 44-45</td></tr></table>
</page>
<page number="94">
<table id="p94t1" data-filename="pdftables_fromstorage_023782248" data-page="94" data-table="1"><tr><td style="text-align: right">4.04</td><td colspan="3">Sirolimus</td><td colspan="3">Drugs affecting the immune response</td><td></td><td></td></tr><tr><td colspan="3">Immunosuppressants:</td><td colspan="6">Ciclosporin, sirolimus, azathioprine, mycophenolate mofetil</td></tr><tr><td style="text-align: right">-</td><td style="text-align: right">-</td><td></td><td style="text-align: right">-</td><td></td><td style="text-align: right">-</td><td></td><td colspan="2">Antibody-mediated reactions</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>B</td><td>P</td><td>Plasma cell</td><td>Releases</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>antibodies</td></tr><tr><td></td><td></td><td></td><td></td><td>Th2</td><td>BB</td><td></td><td></td><td></td></tr><tr><td></td><td>IL-2</td><td></td><td></td><td></td><td>B</td><td>MB</td><td>Memory B cell</td><td></td></tr><tr><td></td><td>T</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>CD4</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>IL-2</td><td>Th1</td><td>MT</td><td>Memory T cell</td><td></td></tr><tr><td></td><td colspan="2">Antigen</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Th1</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Th1</td><td>Th1</td><td colspan="2">Macrophage-activating</td></tr><tr><td></td><td>IL-2</td><td></td><td style="text-align: right">-</td><td></td><td></td><td></td><td colspan="2">cytokines &amp; other cytokines</td></tr><tr><td></td><td>T</td><td style="text-align: right">-</td><td></td><td>T</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>CD8</td><td></td><td></td><td>CD8</td><td></td><td>Tc</td><td colspan="2">Kill virally infected cells</td></tr><tr><td></td><td></td><td></td><td style="text-align: right">-</td><td></td><td></td><td></td><td colspan="2">Cell-mediated reactions</td></tr><tr><td colspan="5">Immunosuppressants:</td><td colspan="4">Ciclosporin, sirolimus, azathioprine, mycophenolate mofetil</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">T = T cell, Th =T helper cell, B = B cell</td></tr></table>
</page>
<page number="95">
<table id="p95t1" data-filename="pdftables_fromstorage_023782248" data-page="95" data-table="1"><tr><td></td><td colspan="2">Antiproliferative immunosuppressant antibiotic (aka rapamycin)</td><td>Sirolimus</td></tr><tr><td>Actions</td><td colspan="3">Inhibits the clonal proliferation of T and – more particularly – B cells; decreases immunoglobulin</td></tr><tr><td></td><td>production.</td><td></td><td></td></tr><tr><td>MOA</td><td colspan="3">Blocks the response of precursor cells to interleukin-2 (IL-2) (by binding a cytosolic protein</td></tr><tr><td></td><td>FK-binding protein 12)</td><td>and thus preventing activation of T &amp; B cells.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="3">Given orally; metabolised by P450 3A in the liver – therefore many drug interactions.</td></tr><tr><td>Clinical use</td><td colspan="3">Used to prevent rejection of organ transplants (particulary renal because, unlike ciclosporin, it has</td></tr><tr><td></td><td colspan="3">no renal toxicity ) usually in combination with ciclosporin or glucocorticoids.</td></tr><tr><td>Adverse effects</td><td colspan="3">Myelosuppression (important), hyperlipidaemia, venous thromboembolism, diarrhoea, rash,</td></tr><tr><td></td><td>osteonecrosis.</td><td></td><td></td></tr><tr><td>Special points</td><td>Drug concentrations in the blood need to be monitored.</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">R&amp;D 7e Ch 26, p 329; D&amp;H 2e Ch 17, pp 44-45</td></tr></table>
</page>
<page number="96">
<table id="p96t1" data-filename="pdftables_fromstorage_023782248" data-page="96" data-table="1"><tr><td></td><td colspan="3">Glucocorticoid</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">4.05</td><td colspan="4">(e.g. prednisolone)</td><td colspan="2">Drugs affecting the immune response</td><td></td><td></td></tr><tr><td colspan="3">Immunosuppressants:</td><td colspan="4">Ciclosporin, sirolimus, azathioprine,</td><td></td><td></td></tr><tr><td colspan="5">mycophenolate mofetil, sirolimus</td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">-</td><td style="text-align: right">-</td><td></td><td style="text-align: right">-</td><td style="text-align: right">-</td><td></td><td></td><td colspan="2">Antibody-mediated reactions</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>B</td><td>P</td><td>Plasma cell</td><td>Releases</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>antibodies</td></tr><tr><td></td><td></td><td></td><td>Th2</td><td></td><td>BB</td><td></td><td></td><td></td></tr><tr><td></td><td>IL-2</td><td></td><td></td><td></td><td>B</td><td>MB</td><td>Memory B cell</td><td></td></tr><tr><td></td><td>T</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>CD4</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>IL-2</td><td></td><td>Th1</td><td>MT</td><td>Memory T cell</td><td></td></tr><tr><td></td><td colspan="2">Antigen</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Th1</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Th1</td><td>Th1</td><td colspan="2">Macrophage-activating</td></tr><tr><td></td><td>IL-2</td><td></td><td style="text-align: right">-</td><td></td><td></td><td></td><td colspan="2">cytokines &amp; other cytokines</td></tr><tr><td></td><td>T</td><td style="text-align: right">-</td><td>T</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>CD8</td><td></td><td>CD8</td><td></td><td></td><td>Tc</td><td colspan="2">Kill virally infected cells</td></tr><tr><td></td><td></td><td></td><td style="text-align: right">-</td><td></td><td></td><td></td><td colspan="2">Cell-mediated reactions</td></tr><tr><td colspan="4">Immunosuppressants:</td><td colspan="3">Ciclosporin, sirolimus, azathioprine,</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="4">mycophenolate mofetil, sirolimus</td><td colspan="2">T = T cell, Th =T helper cell, B = B cell</td></tr></table>
</page>
<page number="97">
<table id="p97t1" data-filename="pdftables_fromstorage_023782248" data-page="97" data-table="1"><tr><td></td><td>An anti-inflammatory/immunosuppressant glucocorticoid (GC)</td><td>Prednisolone</td></tr><tr><td colspan="3">Actions Inhibits clonal proliferation of T &amp; B cells and macrophage activation.</td></tr><tr><td></td><td colspan="2">(Other actions : reduction in chronic inflammation, autoimmune and hypersensitivity reactions;</td></tr><tr><td></td><td colspan="2">various metabolic effects; negative feedback action on ant. pituitary and hypothalamus. (see card</td></tr><tr><td></td><td style="text-align: right">16.01)</td><td></td></tr><tr><td colspan="3">MOA GCs interact with intracellular receptors to inhibit the transcription of specific genes that code for</td></tr><tr><td></td><td>various cytokines esp. IL-2. (see card 16.02)</td><td></td></tr><tr><td colspan="3">Abs/Distrb/Elim Given orally or by injection, topically. The main effects occur only after 2–8 h because protein</td></tr><tr><td></td><td>synthesis of mediators and enzymes is required (see card 16.02).</td><td></td></tr><tr><td colspan="3">Clinical use To prevent rejection of organ transplants and to treat rejection episodes. Also used for inflammatory,</td></tr><tr><td></td><td>see hypersensitivity and autoimmune conditions (see card 16.01)</td><td></td></tr><tr><td>Adverse effects</td><td>Used long-term it causes:</td><td></td></tr><tr><td></td><td>• suppression of response to infection</td><td></td></tr><tr><td></td><td>• suppression of endogenous GC synthesis</td><td></td></tr><tr><td></td><td>• osteoporosis</td><td></td></tr><tr><td></td><td>• growth suppression in children</td><td></td></tr><tr><td></td><td colspan="2">• iatrogenic Cushing’s syndome (see card 16.03 for pictorial expression of Cushing’s syndrome).</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 32, p 401t; D&amp;H 2e Ch 17, pp 44-45</td></tr></table>
</page>
<page number="98">
<table id="p98t1" data-filename="pdftables_fromstorage_023782248" data-page="98" data-table="1"><tr><td style="text-align: right">4.06</td><td colspan="3">Cetirizine</td><td colspan="2">Drugs affecting the immune response</td><td></td><td></td><td></td></tr><tr><td colspan="3">Immunosuppressants:</td><td colspan="4">Ciclosporin, sirolimus, azathioprine,</td><td></td><td></td></tr><tr><td colspan="6">mycophenolate mofetil, sirolimus, glucocorticoids (GCs)</td><td></td><td></td><td></td></tr><tr><td style="text-align: right">-</td><td style="text-align: right">-</td><td></td><td style="text-align: right">-</td><td></td><td style="text-align: right">-</td><td></td><td colspan="2">Antibody-mediated reactions</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>B</td><td>P</td><td>Plasma cell</td><td>Releases</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>antibodies</td></tr><tr><td></td><td></td><td></td><td></td><td>Th2</td><td>BB</td><td></td><td></td><td></td></tr><tr><td></td><td>IL-2</td><td></td><td></td><td></td><td>B</td><td>MB</td><td>Memory B cell</td><td></td></tr><tr><td></td><td>T</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>CD4</td><td></td><td></td><td></td><td></td><td></td><td></td><td>Glucocorticoids</td></tr><tr><td></td><td></td><td></td><td></td><td>IL-2</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Th1</td><td>MT</td><td>Memory T cell</td><td></td></tr><tr><td></td><td colspan="2">Antigen</td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">-</td></tr><tr><td></td><td></td><td></td><td></td><td>Th1</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Th1</td><td>Th1</td><td>Macrophage-activating</td><td></td></tr><tr><td></td><td>IL-2</td><td></td><td style="text-align: right">-</td><td></td><td></td><td></td><td colspan="2">cytokines &amp; other cytokines</td></tr><tr><td></td><td>T</td><td style="text-align: right">-</td><td></td><td>T</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>CD8</td><td></td><td></td><td>CD8</td><td></td><td>Tc</td><td>Kill virally infected cells</td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">-</td><td></td><td></td><td></td><td colspan="2">Cell-mediated reactions</td></tr><tr><td colspan="5">Immunosuppressants:</td><td colspan="2">Ciclosporin, sirolimus, azathioprine,</td><td></td><td></td></tr><tr><td colspan="7">mycophenolate mofetil, sirolimus, glucocorticoids (GCs)</td><td colspan="2">T = T cell, Th =T helper cell, B = B cell</td></tr></table>
</page>
<page number="99">
<table id="p99t1" data-filename="pdftables_fromstorage_023782248" data-page="99" data-table="1"><tr><td></td><td>A histamine H1-receptor antagonist</td><td>Cetirizine</td></tr><tr><td>Actions</td><td colspan="2">Inhibits H 1-receptor actions and thus reduces immediate hypersensivity reactions.</td></tr><tr><td>MOA</td><td>Competitive inhibitor of histamine at H1 -receptors on smooth muscle.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally well absorbed, doesn’t cross the blood–brain barrier, metabolised in the liver , excreted</td></tr><tr><td></td><td>in the urine.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Hypersensitivity reactions – hay fever, urticaria, some drug allergies, insect bites, pruritus.</td></tr><tr><td>Adverse effects</td><td colspan="2">Effects due to action on peripheral muscarinic receptors (dry mouth; sometimes blurred vision,</td></tr><tr><td></td><td>constipation, urine retention).</td><td></td></tr><tr><td>Special points</td><td>It doesn’t cross into the CNS therefore little or no sedation.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 26, p 333t; D&amp;H 2e Ch 17, pp 44-45</td></tr></table>
</page>
<page number="100">
<table id="p100t1" data-filename="pdftables_fromstorage_023782248" data-page="100" data-table="1"><tr><td style="text-align: right">4.07</td><td colspan="3">Promethazine</td><td colspan="3">Drugs affecting the immune response</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">Immunosuppressants:</td><td colspan="4">Ciclosporin, sirolimus, azathioprine,</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6">mycophenolate mofetil, sirolimus, glucocorticoids</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">-</td><td style="text-align: right">-</td><td></td><td style="text-align: right">-</td><td style="text-align: right">-</td><td></td><td></td><td></td><td colspan="2">Antibody-mediated reactions</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>B</td><td></td><td>P</td><td>Plasma cell</td><td></td><td>Releases</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>antibodies</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Th2</td><td>BB</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Memory</td><td></td><td></td><td colspan="2">2. Allergen</td></tr><tr><td></td><td>IL-2</td><td></td><td></td><td>B</td><td></td><td>MB</td><td></td><td></td><td>1. IgE antibodies (abs)</td><td colspan="2">bridges 2</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>B cell</td><td></td><td>attach to mast cell</td><td></td><td>IgE abs</td></tr><tr><td></td><td>T</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>H -antagonists1</td><td></td><td>3. H is</td></tr><tr><td></td><td>CD4</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Memory T</td><td></td><td>cetirizine</td><td></td><td>H released</td></tr><tr><td></td><td></td><td></td><td>IL-2</td><td>Th1</td><td>MT</td><td></td><td></td><td></td><td style="text-align: right">-</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>&amp; acts on</td></tr><tr><td></td><td colspan="2">Antigen</td><td></td><td></td><td></td><td></td><td>cell</td><td></td><td>H</td><td>H</td><td>histamine</td></tr><tr><td></td><td></td><td></td><td>Th1</td><td></td><td></td><td colspan="2">Macrophage-</td><td></td><td>H1</td><td></td><td>receptor</td></tr><tr><td></td><td></td><td></td><td></td><td>Th1</td><td>Th1</td><td colspan="2">activating</td><td colspan="2">Smooth muscle cell</td><td></td><td></td></tr><tr><td></td><td>IL-2</td><td></td><td style="text-align: right">-</td><td></td><td></td><td colspan="2">cytokines &amp;</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>T</td><td style="text-align: right">-</td><td>T</td><td></td><td></td><td colspan="2">other cytokines</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>CD8</td><td></td><td>CD8</td><td></td><td>Tc</td><td></td><td>Kill virally</td><td colspan="3">Glucocorticoids</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>infected cells</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">-</td><td></td><td></td><td></td><td></td><td>Cell-mediated reactions</td><td></td><td></td><td></td></tr><tr><td colspan="4">Immunosuppressants:</td><td colspan="4">Ciclosporin, sirolimus, azathioprine,</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="7">mycophenolate mofetil, sirolimus, glucocorticoids</td><td colspan="4">T = T cell, Th =T helper cell, B = B cell</td></tr></table>
</page>
<page number="101">
<table id="p101t1" data-filename="pdftables_fromstorage_023782248" data-page="101" data-table="1"><tr><td></td><td>A sedating histamine H1-receptor antagonist</td><td>Promethazine</td></tr><tr><td>Actions</td><td colspan="2">Inhibits H 1-receptor actions and thus reduces immediate hypersensivity reactions; has anticholinergic</td></tr><tr><td></td><td colspan="2">action, some local anaesthetic action, weak α-adrenoceptor antagonism and fairly marked sedative</td></tr><tr><td></td><td>effect.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Competitive inhibitor of histamine at H1-receptors on smooth muscle etc.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally or by deep i.m. injection or by slow i.v. injection; enters the CNS.</td></tr><tr><td>Clinical use</td><td colspan="2">Hypersensitivity reactions – hay fever, urticaria; premedication; sedation; emergency treatment of</td></tr><tr><td></td><td>anaphylaxis; motion sickness.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Anticholinergic action on peripheral muscarinic receptors (dry mouth; sometimes blurred vision,</td></tr><tr><td></td><td>constipation, urine retention); headache, drowsiness.</td><td></td></tr><tr><td>Special points</td><td>Injection can be painful.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 26, p 333t; D&amp;H 2e Ch 17, pp 44-45</td></tr></table>
</page>
<page number="102">
<table id="p102t1" data-filename="pdftables_fromstorage_023782248" data-page="102" data-table="1"><tr><td></td><td colspan="3">Drugs affecting the</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">4.08</td><td colspan="3">immune response</td><td colspan="5">What antihistamines are used for motion sickness?</td><td></td><td></td><td></td></tr><tr><td colspan="3">Immunosuppressants:</td><td colspan="4">Ciclosporin, sirolimus, azathioprine,</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6">mycophenolate mofetil, sirolimus, glucocorticoids</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">-</td><td style="text-align: right">-</td><td></td><td style="text-align: right">-</td><td style="text-align: right">-</td><td></td><td></td><td></td><td colspan="2">Antibody-mediated reactions</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>B</td><td></td><td>P</td><td>Plasma cell</td><td>Releases</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>antibodies</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Th2</td><td>BB</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Memory</td><td></td><td></td><td colspan="2">2. Allergen</td></tr><tr><td></td><td>IL-2</td><td></td><td></td><td>B</td><td></td><td>MB</td><td></td><td>1. IgE antibodies (abs)</td><td></td><td colspan="2">bridges 2</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>B cell</td><td>attach to mast cell</td><td></td><td></td><td>IgE abs</td></tr><tr><td></td><td>T</td><td></td><td></td><td></td><td></td><td></td><td></td><td>H 1-antagonists</td><td></td><td></td><td>3. H is</td></tr><tr><td></td><td>CD4</td><td></td><td></td><td></td><td></td><td></td><td>Memory T</td><td>cetirizine,</td><td></td><td></td><td>H released</td></tr><tr><td></td><td></td><td></td><td>IL-2</td><td>Th1</td><td>MT</td><td></td><td></td><td>promethazine</td><td style="text-align: right">-</td><td></td><td>&amp; acts on</td></tr><tr><td></td><td colspan="2">Antigen</td><td></td><td></td><td></td><td></td><td>cell</td><td></td><td>H</td><td>H</td><td>histamine</td></tr><tr><td></td><td></td><td></td><td>Th1</td><td></td><td></td><td colspan="2">Macrophage-</td><td></td><td>H1</td><td></td><td>receptor</td></tr><tr><td></td><td></td><td></td><td></td><td>Th1</td><td>Th1</td><td colspan="2">activating</td><td colspan="2">Smooth muscle cell</td><td></td><td></td></tr><tr><td></td><td>IL-2</td><td></td><td style="text-align: right">-</td><td></td><td></td><td colspan="2">cytokines &amp;</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>T</td><td style="text-align: right">-</td><td>T</td><td></td><td></td><td colspan="2">other cytokines</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>CD8</td><td></td><td>CD8</td><td></td><td>Tc</td><td></td><td>Kill virally</td><td colspan="3">Glucocorticoids</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>infected cells</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">-</td><td></td><td></td><td></td><td></td><td>Cell-mediated reactions</td><td></td><td></td><td></td></tr><tr><td colspan="4">Immunosuppressants:</td><td colspan="4">Ciclosporin, sirolimus, azathioprine,</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="7">mycophenolate mofetil, sirolimus, glucocorticoids</td><td colspan="4">T = T cell, Th =T helper cell, B = B cell</td></tr></table>
</page>
<page number="103">
<table id="p103t1" data-filename="pdftables_fromstorage_023782248" data-page="103" data-table="1"><tr><td>What antihistamines are used for motion sickness?</td></tr><tr><td>Antihistamines</td></tr><tr><td>Promethazine (as specified on cards 4.07 &amp; 14.08)</td></tr><tr><td>Cyclizine</td></tr><tr><td>Cinnarizine</td></tr><tr><td>But a more efficient drug is</td></tr><tr><td>hyoscine, a muscarinic antagonist (see card 1.03)</td></tr><tr><td>which can be given by transdermal patch as well as orally.</td></tr><tr><td>R&amp;D 7e Ch 26, p 333t; D&amp;H 2e Ch 17, pp 44-45</td></tr></table>
</page>
<page number="104">
<table id="p104t1" data-filename="pdftables_fromstorage_023782248" data-page="104" data-table="1"><tr><td style="text-align: right">5.01</td><td>Disopyramide</td><td>Antidysrhythmic drugs</td><td></td><td></td><td></td></tr><tr><td colspan="6">Stylised cardiac action potential. Antidysrhythmic drugs can affect different phases of the action potential.</td></tr><tr><td></td><td style="text-align: right">+30</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Sympathetic</td></tr><tr><td></td><td></td><td></td><td colspan="2">1 Rapid partial repolarisation</td><td>activity</td></tr><tr><td></td><td style="text-align: right">0</td><td></td><td></td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td></td><td></td><td>2 Plateau</td><td></td><td></td></tr><tr><td></td><td></td><td>Sympathetic</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>0 Fast</td><td colspan="2">3 Main repolarisation</td></tr><tr><td></td><td></td><td></td><td>activity</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>depolarisation</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td></td><td>–60</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">4 Pacemaker depolarisation</td><td></td><td style="text-align: right">4</td></tr></table>
</page>
<page number="105">
<table id="p105t1" data-filename="pdftables_fromstorage_023782248" data-page="105" data-table="1"><tr><td></td><td>Class 1a antidysrhythmic (Similar drugs: quinidine and procainamide)</td><td>Disopyramide</td></tr><tr><td>Actions</td><td>Antidysrhythmic.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Belongs to class 1a of the Vaughan Williams classification. Blocks open and inactivated Na+ channels</td></tr><tr><td></td><td colspan="2">in the cell membrane (’use-dependent’ action) to reduce the rate of phase 0 depolarisation thus</td></tr><tr><td></td><td colspan="2">causing an increase in the effective refractory period and slowed AV conduction. Also produces</td></tr><tr><td></td><td>some slowing of action potential repolarisation (a class III action).</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral and i.v. admin. T 0.5 5–10h. Half is excreted unchanged by kidney; half is metabolised in liver.</td></tr><tr><td>Clinical use</td><td>Supraventricular and, more usually, ventricular dysrhythmia.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Atropine-like effects: blurred vision, dry mouth, constipation, urinary retention. Negative inotropic</td></tr><tr><td></td><td colspan="2">action. Procainamide has less antimuscarinic action than either disopyramide or quinidine. The</td></tr><tr><td></td><td>class III actions of these drugs may lead to torsade de pointes.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 21, p 255t; D&amp;H 2e Ch 18, pp 46-47</td></tr></table>
</page>
<page number="106">
<table id="p106t1" data-filename="pdftables_fromstorage_023782248" data-page="106" data-table="1"><tr><td style="text-align: right">5.02</td><td>Lidocaine</td><td>Antidysrhythmic drugs</td><td></td><td></td><td></td></tr><tr><td colspan="6">Stylised cardiac action potential. Antidysrhythmic drugs can affect different phases of the action potential.</td></tr><tr><td></td><td style="text-align: right">+30</td><td>Disopyramide</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Sympathetic</td></tr><tr><td></td><td></td><td></td><td colspan="2">1 Rapid partial repolarisation</td><td>activity</td></tr><tr><td></td><td style="text-align: right">0</td><td></td><td></td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td></td><td></td><td>2 Plateau</td><td></td><td></td></tr><tr><td></td><td></td><td>Sympathetic</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>0 Fast</td><td colspan="2">3 Main repolarisation</td></tr><tr><td></td><td></td><td></td><td>activity</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>depolarisation</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td></td><td>–60</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">4 Pacemaker depolarisation</td><td></td><td style="text-align: right">4</td></tr></table>
</page>
<page number="107">
<table id="p107t1" data-filename="pdftables_fromstorage_023782248" data-page="107" data-table="1"><tr><td></td><td>Class 1b antidysrhythmic (Similar drugs: mexiletine, tocainide)</td><td>Lidocaine</td></tr><tr><td>Actions</td><td>Antidysrhythmic, local anaesthetic (see card 28.01)</td><td></td></tr><tr><td>MOA</td><td colspan="2">Belongs to class 1b of the Vaughan Williams classification. Blocks open and inactivated Na+ channels</td></tr><tr><td></td><td colspan="2">in the cell membrane (shows ‘use-dependence’, so more likely to act in damaged, depolarised</td></tr><tr><td></td><td colspan="2">tissue). Na + channel block reduces the rate of phase 0 depolarisation, increasing the effective</td></tr><tr><td></td><td>refractory period and slowing AV conduction.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Given i.v. (Very high first-pass metabolism precludes oral admin.).</td><td></td></tr><tr><td></td><td colspan="2">Short T0.5 – 2h. Subject to cytochrome P450 metabolism. Mexiletine and tocainide are orally active.</td></tr><tr><td>Clinical use</td><td colspan="2">Treatment and prevention of ventricular fibrillation especially following infarction. Also digoxin-</td></tr><tr><td></td><td>induced dysrhythmias.</td><td></td></tr><tr><td>Adverse effects</td><td>Unwanted CNS effects include drowsiness, tremors and convulsions.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 21, p 256; D&amp;H 2e Ch 18, pp 46-47</td></tr></table>
</page>
<page number="108">
<table id="p108t1" data-filename="pdftables_fromstorage_023782248" data-page="108" data-table="1"><tr><td style="text-align: right">5.03</td><td>Flecainide</td><td>Antidysrhythmic drugs</td><td></td><td></td></tr><tr><td colspan="5">Stylised cardiac action potential. Antidysrhythmic drugs can affect different phases of the action potential.</td></tr><tr><td></td><td></td><td></td><td></td><td>Sympathetic</td></tr><tr><td></td><td style="text-align: right">+30</td><td>Disopyramide, lidocaine</td><td></td><td>activity</td></tr><tr><td></td><td></td><td></td><td>1 Rapid partial</td><td></td></tr><tr><td></td><td></td><td></td><td>repolarisation</td><td style="text-align: right">+</td></tr><tr><td></td><td style="text-align: right">0</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>2 Plateau</td><td></td></tr><tr><td></td><td></td><td>Sympathetic</td><td></td><td></td></tr><tr><td></td><td></td><td>activity</td><td>0 Fast</td><td></td></tr><tr><td></td><td></td><td></td><td>depolarisation</td><td></td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td></td><td>3 Main repolarisation</td></tr><tr><td></td><td>–60</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">4 Pacemaker depolarisation</td><td style="text-align: right">4</td></tr></table>
</page>
<page number="109">
<table id="p109t1" data-filename="pdftables_fromstorage_023782248" data-page="109" data-table="1"><tr><td></td><td>Class 1c antidysrhythmic (Similar drug: propafenone)</td><td>Flecainide</td></tr><tr><td>Actions</td><td>Antidysrhythmic.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Belongs to class 1c of the Vaughan Williams classification. Preferential block of open Na+ channels.</td></tr><tr><td></td><td colspan="2">Reduces the rate of phase 0 depolarisation causing an increase in the effective refractory period and</td></tr><tr><td></td><td colspan="2">slowed AV conduction. Associates with and dissociates from sodium channels more slowly than</td></tr><tr><td></td><td>either Ia or Ib agents.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral admin. T 0.5 20h. Mostly excreted unchanged in urine. Propafenone is metabolised more rapidly</td></tr><tr><td></td><td>by the liver and has a shorter T 0.5 (5–10h).</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Prevention of paroxysmal atrial fibrillation. Severe ventricular dysrhythmia, unresponsive to other</td></tr><tr><td></td><td>agents.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Increases likelihood of dysrhythmia. May increase mortality due to ventricular fibrillation post</td></tr><tr><td></td><td colspan="2">infarction. Needs careful use. Avoid in patients with structural heart disease. Negative inotropic</td></tr><tr><td></td><td>action.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 21, pp 255-256; D&amp;H 2e Ch 18, pp 46-47</td></tr></table>
</page>
<page number="110">
<table id="p110t1" data-filename="pdftables_fromstorage_023782248" data-page="110" data-table="1"><tr><td style="text-align: right">5.04</td><td>Propranolol</td><td>Antidysrhythmic drugs</td><td></td><td></td></tr><tr><td colspan="5">Stylised cardiac action potential. Antidysrhythmic drugs can affect different phases of the action potential.</td></tr><tr><td></td><td></td><td></td><td></td><td>Sympathetic</td></tr><tr><td></td><td style="text-align: right">+30</td><td>Disopyramide, lidocaine,</td><td></td><td>activity</td></tr><tr><td></td><td></td><td>flecainide</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>1 Rapid partial</td><td></td></tr><tr><td></td><td></td><td></td><td>repolarisation</td><td style="text-align: right">+</td></tr><tr><td></td><td style="text-align: right">0</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>2 Plateau</td><td></td></tr><tr><td></td><td></td><td>Sympathetic</td><td></td><td></td></tr><tr><td></td><td></td><td>activity</td><td>0 Fast</td><td></td></tr><tr><td></td><td></td><td></td><td>depolarisation</td><td></td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td></td><td>3 Main repolarisation</td></tr><tr><td></td><td>–60</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">4 Pacemaker depolarisation</td><td style="text-align: right">4</td></tr></table>
</page>
<page number="111">
<table id="p111t1" data-filename="pdftables_fromstorage_023782248" data-page="111" data-table="1"><tr><td></td><td>A class II antidysrhythmic (Similar drugs: esmolol, atenolol.)</td><td>Propranolol</td></tr><tr><td>Actions</td><td colspan="2">Antidysrhythmic. (Also antihypertensive, antianginal.) Blocks actions of catecholamines on</td></tr><tr><td></td><td>β-adrenoceptors (see card 2.02).</td><td></td></tr><tr><td>MOA</td><td colspan="2">Blocks sympathetic drive, reducing pacemaker activity (phase 4) and increasing AV conduction time.</td></tr><tr><td></td><td colspan="2">Reduces the slow inward Ca2+ current which affects phase 2 of the action potential. Propranolol has</td></tr><tr><td></td><td>additional class I action. Esmolol and atenolol are β1 selective.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Oral admin. T0.5 s: propranolol – 4h, atenolol – 6h, esmolol – 10min.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Reduction of mortality after infarct (where dysrhythmias have a sympathetic input). Paroxysmal</td></tr><tr><td></td><td colspan="2">atrial fibrillation. Esmolol’s short T0.5 allows its use by i.v. infusion for emergency treatment of</td></tr><tr><td></td><td>supraventricular dysrhythmias.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Bronchoconstriction in asthmatic patients. Cardiac slowing with possible heart block. Propranolol</td></tr><tr><td></td><td>has CNS effects: depression, sedation and sleep disturbances.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 21, p 257; D&amp;H 2e Ch 18, pp 46-47</td></tr></table>
</page>
<page number="112">
<table id="p112t1" data-filename="pdftables_fromstorage_023782248" data-page="112" data-table="1"><tr><td style="text-align: right">5.05</td><td>Amiodarone</td><td>Antidysrhythmic drugs</td><td></td><td></td><td></td></tr><tr><td colspan="6">Stylised cardiac action potential. Antidysrhythmic drugs can affect different phases of the action potential.</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Sympathetic</td></tr><tr><td></td><td style="text-align: right">+30</td><td colspan="2">Disopyramide, lidocaine,</td><td></td><td>activity</td></tr><tr><td></td><td></td><td>flecainide</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>1 Rapid partial</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>repolarisation</td><td style="text-align: right">+</td></tr><tr><td></td><td style="text-align: right">0</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Propranolol</td><td></td><td>2 Plateau</td><td></td></tr><tr><td></td><td></td><td>Sympathetic</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>activity</td><td>–</td><td>0 Fast</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>depolarisation</td><td></td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td>3 Main repolarisation</td></tr><tr><td></td><td>–60</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="3">4 Pacemaker depolarisation</td><td style="text-align: right">4</td></tr></table>
</page>
<page number="113">
<table id="p113t1" data-filename="pdftables_fromstorage_023782248" data-page="113" data-table="1"><tr><td></td><td>Class III antidysrhythmic (Similar drugs: ibutilide, sotalol)</td><td>Amiodarone</td></tr><tr><td>Actions</td><td>Antidysrhythmic.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Class III drugs block K+ channels in the cell membrane to delay repolarization and increase action</td></tr><tr><td></td><td colspan="2">potential duration. This increases the refractory period. Amiodarone also blocks Na+ channels and</td></tr><tr><td></td><td colspan="2">β-adrenoceptors so has class I and class II actions. Sotalol also has class II actions.</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Long acting; extensive tissue binding, t 1⁄2 several weeks. Sotalol and ibutilide have half-lives of</td></tr><tr><td></td><td>5–10h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">One of the most effective antidysrhythmics. Atrial fibrillation and flutter, ventricular ectopic</td></tr><tr><td></td><td colspan="2">beats and tachyarrhythmias. Ibutilide i.v. for acute treatment of atrial fibrillation and flutter.</td></tr><tr><td>Adverse effects</td><td colspan="2">Torsades de pointes. (Less likely with amiodarone than other class III drugs.) Amiodarone may cause</td></tr><tr><td></td><td colspan="2">pulmonary fibrosis, liver damage, photosensitive skin rashes and thyroid malfunction.</td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 21, p 257; D&amp;H 2e Ch 18, pp 46-47</td></tr></table>
</page>
<page number="114">
<table id="p114t1" data-filename="pdftables_fromstorage_023782248" data-page="114" data-table="1"><tr><td style="text-align: right">5.06</td><td>Verapamil</td><td>Antidysrhythmic drugs</td><td></td><td></td><td></td></tr><tr><td colspan="6">Stylised cardiac action potential. Antidysrhythmic drugs can affect different phases of the action potential.</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Sympathetic</td></tr><tr><td></td><td style="text-align: right">+30</td><td colspan="2">Disopyramide, lidocaine,</td><td></td><td>activity</td></tr><tr><td></td><td></td><td>flecainide</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>1 Rapid partial</td><td style="text-align: right">+</td></tr><tr><td></td><td></td><td></td><td></td><td>repolarisation</td><td></td></tr><tr><td></td><td style="text-align: right">0</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Propranolol</td><td></td><td>2 Plateau</td><td></td></tr><tr><td></td><td></td><td>Sympathetic</td><td></td><td></td><td>Amiodarone</td></tr><tr><td></td><td></td><td>activity</td><td>–</td><td>0 Fast</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>depolarisation</td><td></td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td>3 Main repolarisation</td></tr><tr><td></td><td>–60</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="3">4 Pacemaker depolarisation</td><td style="text-align: right">4</td></tr></table>
</page>
<page number="115">
<table id="p115t1" data-filename="pdftables_fromstorage_023782248" data-page="115" data-table="1"><tr><td></td><td>Class IV antidysrhythmic (Similar drug: diltiazem)</td><td>Verapamil</td></tr><tr><td>Actions</td><td colspan="2">Antidysrhythmic. (Also antianginal and antihypertensive.) Blocks Ca2+ channels in both cardiac and</td></tr><tr><td></td><td colspan="2">smooth muscle so has both negative inotropic and smooth muscle relaxant actions.</td></tr><tr><td>MOA</td><td colspan="2">Blocks L-type, voltage-gated, Ca2+ channels which are important in the action potential plateau and</td></tr><tr><td></td><td colspan="2">in particular affects action potential propagation in the SA and AV nodes. Shows use-dependence so</td></tr><tr><td></td><td colspan="2">is more active in tachyarrythmias. Decreases automaticity and slows AV conduction.</td></tr><tr><td>Abs/Distrib/Elim</td><td>Oral (less commonly i.v.) admin. t1⁄2 6–8h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Supraventricular tachycardias. Control of ventricular rate in atrial fibrillation.</td></tr><tr><td>Adverse effects</td><td colspan="2">Side effects due to smooth muscle relaxation: hypotension and dizziness, ankle oedema,</td></tr><tr><td></td><td colspan="2">constipation. Unwanted cardiac actions include heart block and bradycardia.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 21, p 257-258; D&amp;H 2e Ch 18, pp 46-47</td></tr></table>
</page>
<page number="116">
<table id="p116t1" data-filename="pdftables_fromstorage_023782248" data-page="116" data-table="1"><tr><td style="text-align: right">5.07</td><td>Adenosine</td><td>Antidysrhythmic drugs</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7">Stylised cardiac action potential. Antidysrhythmic drugs can affect different phases of the action potential.</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Sympathetic</td></tr><tr><td></td><td style="text-align: right">+30</td><td colspan="2">Disopyramide, lidocaine,</td><td></td><td>activity</td><td></td></tr><tr><td></td><td></td><td>flecainide</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>1 Rapid partial</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>repolarisation</td><td style="text-align: right">+</td><td>Verapamil</td></tr><tr><td></td><td style="text-align: right">0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Propranolol</td><td></td><td>2 Plateau</td><td></td><td></td></tr><tr><td></td><td></td><td>Sympathetic</td><td></td><td></td><td></td><td>Amiodarone</td></tr><tr><td></td><td></td><td>activity</td><td>–</td><td>0 Fast</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>depolarisation</td><td></td><td></td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td colspan="2">3 Main repolarisation</td></tr><tr><td></td><td>–60</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="3">4 Pacemaker depolarisation</td><td></td><td style="text-align: right">4</td></tr></table>
</page>
<page number="117">
<table id="p117t1" data-filename="pdftables_fromstorage_023782248" data-page="117" data-table="1"><tr><td></td><td>Antidysrhythmic drug</td><td>Adenosine</td></tr><tr><td>Actions</td><td>Antidysrhythmic.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Activates G-protein-coupled adenosine receptors. Action (on A1 receptors) is due to inhibition of</td></tr><tr><td></td><td colspan="2">Ca2+ channel opening and increased K+ channel opening (the effect is analogous to the action of</td></tr><tr><td></td><td colspan="2">ACh on cardiac muscarinic receptors). Important actions are its negative chronotropic action on the</td></tr><tr><td></td><td>SA node and slowed AV conduction.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Given i.v. Short duration of action. T0.5 10secs.</td><td></td></tr><tr><td>Clinical use</td><td>Termination of paroxysmal supraventricular tachycardia.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Side effects (e.g. flushing, chest pain, dyspnoea, bronchospasm) are short-lived because of rapid</td></tr><tr><td></td><td>elimination of adenosine.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 21, p 258; D&amp;H 2e Ch 18, pp 46-47</td></tr></table>
</page>
<page number="118">
<table id="p118t1" data-filename="pdftables_fromstorage_023782248" data-page="118" data-table="1"><tr><td></td><td>Magnesium</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">5.08</td><td>sulfate</td><td colspan="2">Antidysrhythmic drugs</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">Stylised cardiac action potential. Antidysrhythmic drugs can affect different phases of the action potential.</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Sympathetic</td></tr><tr><td></td><td style="text-align: right">+30</td><td colspan="3">Disopyramide, lidocaine,</td><td></td><td>activity</td><td></td></tr><tr><td></td><td></td><td colspan="2">flecainide</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>1 Rapid partial</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>repolarisation</td><td style="text-align: right">+</td><td>Verapamil</td></tr><tr><td></td><td style="text-align: right">0</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Propranolol</td><td></td><td>2 Plateau</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Sympathetic</td><td></td><td></td><td></td><td>Amiodarone</td></tr><tr><td></td><td></td><td colspan="2">activity</td><td>–</td><td>0 Fast</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>depolarisation</td><td></td><td></td></tr><tr><td></td><td></td><td>Adenosine</td><td style="text-align: right">+</td><td></td><td></td><td colspan="2">3 Main repolarisation</td></tr><tr><td></td><td>–60</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="3">4 Pacemaker depolarisation</td><td></td><td style="text-align: right">4</td></tr></table>
</page>
<page number="119">
<table id="p119t1" data-filename="pdftables_fromstorage_023782248" data-page="119" data-table="1"><tr><td></td><td></td><td>Magnesium</td></tr><tr><td></td><td>Antidysrhythmic drug</td><td>sulfate</td></tr><tr><td>Actions</td><td>Antidysrhythmic. Osmotic purgative</td><td></td></tr><tr><td>MOA</td><td colspan="2">Slows AV node conduction. Reduces increased cardiac excitability due to hypomagnesaemia,</td></tr><tr><td></td><td colspan="2">which is common after heart operations. The cellular mechanism of action is not established but is</td></tr><tr><td></td><td>likely to involve effects on membrane ion permeability or transport.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Given i.v.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Prevention of supraventricular tachycardia and ventricular arrhythmias after bypass surgery.</td></tr><tr><td></td><td colspan="2">Ventricular dysrhythmias due to digoxin toxicity. Management of torsades de pointes.</td></tr><tr><td>Adverse effects</td><td>Muscle weakness.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 21, p 368; D&amp;H 2e Ch 18, pp 46-47</td></tr></table>
</page>
<page number="120">
<table id="p120t1" data-filename="pdftables_fromstorage_023782248" data-page="120" data-table="1"><tr><td style="text-align: right">6.01</td><td>Captopril</td><td>CVS antihypertensive drugs</td><td></td><td></td></tr><tr><td colspan="5">The figure shows the homeostatic mechanisms controlling blood pressure. Various pathological factors can</td></tr><tr><td colspan="3">disturb the homeostasis and cause hypertension.</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>CNS</td><td></td></tr><tr><td></td><td>Affects</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Peripheral sympathetic system</td><td></td></tr><tr><td></td><td></td><td colspan="2">releases noradrenaline, which</td><td></td></tr><tr><td colspan="2">Plasma volume, which affects</td><td>Stimulates the heart,</td><td>Constricts blood vessels</td><td></td></tr><tr><td></td><td></td><td>increasing:</td><td>increasing:</td><td></td></tr><tr><td></td><td></td><td>Cardiac output</td><td>Peripheral resistance</td><td></td></tr><tr><td></td><td></td><td colspan="2">together these control</td><td></td></tr><tr><td colspan="2">Baroreceptor discharge</td><td colspan="2">BLOOD PRESSURE,</td><td></td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td></td><td></td><td colspan="2">Renal blood flow,</td><td></td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td></td><td>Affects</td><td colspan="2">Salt and water excretion,</td><td></td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td></td><td>Renin</td><td></td><td>Renin release</td><td></td></tr><tr><td>Angiotensin I (AT I)</td><td></td><td>Angiotensinogen</td><td></td><td></td></tr><tr><td>ACE</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Angiotensin II (AT II), which</td><td>stimulates secretion of</td><td>Aldosterone, which decreases</td></tr><tr><td></td><td></td><td></td><td colspan="2">constricts blood vessels and increases</td></tr></table>
</page>
<page number="121">
<table id="p121t1" data-filename="pdftables_fromstorage_023782248" data-page="121" data-table="1"><tr><td></td><td>An angiotensin-converting enzyme inhibitor (Similar drugs: enalapril, lisinopril)</td><td>Captopril</td></tr><tr><td>Actions</td><td colspan="2">Lowers blood pressure by decreasing vasoconstrictor tone, also by reducing cardias load.</td></tr><tr><td>MOA</td><td colspan="2">Inhibits angiotensin-converting enzyme thus reducing synthesis of vasoconstrictor angiotensin II.</td></tr><tr><td></td><td colspan="2">This decreases aldosterone secretion, resulting in increased salt and water excretion, indirectly</td></tr><tr><td></td><td>decreasing plasma volume and cardiac load (see card 6.02)</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">All are given orally. Captopril: half-life ~2h. Lisinopril: half-life 12h. Enalapril is a prodrug converted</td></tr><tr><td></td><td>to an active moiety by liver enzymes.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Hypertension; heart failure; ventricular dysfunction following myocardial infarction; diabetic</td></tr><tr><td></td><td>nephropathy.</td><td></td></tr><tr><td>Adverse effects</td><td>Hypotension; dry cough, angioedema. Renal failure can occur.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Hyperkalaemia can occur if given with potassium-sparing diuretics. The dry cough and angiooedema</td></tr><tr><td></td><td colspan="2">are due to the drugs producing bradykinin by stimulating the kallikrein-kinin system.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 22, pp 274-275; D &amp;H 2e Ch 17,pp 44–49</td></tr></table>
</page>
<page number="122">
<table id="p122t1" data-filename="pdftables_fromstorage_023782248" data-page="122" data-table="1"><tr><td style="text-align: right">6.02</td><td>Losartan</td><td>CVS antihypertensive drugs</td><td></td><td></td></tr><tr><td colspan="5">The figure shows the homeostatic mechanisms controlling blood pressure. Various pathological factors can</td></tr><tr><td colspan="3">disturb the homeostasis and cause hypertension.</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>CNS</td><td></td></tr><tr><td></td><td>Affects</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Peripheral sympathetic system</td><td></td></tr><tr><td></td><td></td><td colspan="2">releases noradrenaline, which</td><td></td></tr><tr><td colspan="2">Plasma volume, which affects</td><td>Stimulates the heart,</td><td>Constricts blood vessels</td><td></td></tr><tr><td></td><td></td><td>increasing:</td><td>increasing:</td><td></td></tr><tr><td></td><td></td><td>Cardiac output</td><td>Peripheral resistance</td><td></td></tr><tr><td></td><td></td><td colspan="2">together these control</td><td></td></tr><tr><td colspan="2">Baroreceptor discharge</td><td colspan="2">BLOOD PRESSURE,</td><td></td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td></td><td></td><td colspan="2">Renal blood flow,</td><td></td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td></td><td>Affects</td><td colspan="2">Salt and water excretion,</td><td></td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td></td><td>Renin</td><td></td><td>Renin release</td><td></td></tr><tr><td>Angiotensin I (AT I)</td><td></td><td>Angiotensinogen</td><td></td><td></td></tr><tr><td>ACE</td><td></td><td></td><td></td><td></td></tr><tr><td>–</td><td colspan="2">Angiotensin II (AT II), which</td><td>stimulates secretion of</td><td>Aldosterone, which decreases</td></tr><tr><td>ACE Inhibitors (e.g.</td><td></td><td></td><td colspan="2">constricts blood vessels and increases</td></tr><tr><td>captopril, enalapril)</td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="123">
<table id="p123t1" data-filename="pdftables_fromstorage_023782248" data-page="123" data-table="1"><tr><td></td><td>An angiotensin receptor antagonist (Similar drugs: valsartan, candesartan)</td><td>Losartan</td></tr><tr><td>Actions</td><td>Lowers blood pressure by decreasing vasoconstrictor tone.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Blocks the action of angiotensin II on the angiotensin II (AT1 subtype) receptor.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally. Half-life 1–2h; half-life of metabolite 3–4h.</td><td></td></tr><tr><td>Clinical use</td><td>Hypertension; congestive heart failure; nephropathy.</td><td></td></tr><tr><td>Adverse effects</td><td>Hypotension, dizziness. Hyperkalaemia can occur.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Doesn’t cause the dry cough or angioedma seen with the ACE inhibitors.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 22, pp 275-276; D&amp;H 2e Ch 19, pp 48-49</td></tr></table>
</page>
<page number="124">
<table id="p124t1" data-filename="pdftables_fromstorage_023782248" data-page="124" data-table="1"><tr><td style="text-align: right">6.03</td><td>Amlodipine</td><td>CVS antihypertensive drugs</td><td></td><td></td></tr><tr><td colspan="5">The figure shows the homeostatic mechanisms controlling blood pressure. Various pathological factors can</td></tr><tr><td colspan="3">disturb the homeostasis and cause hypertension.</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>CNS</td><td></td></tr><tr><td></td><td>Affects</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Peripheral sympathetic system</td><td></td></tr><tr><td></td><td></td><td colspan="2">releases noradrenaline, which</td><td></td></tr><tr><td colspan="2">Plasma volume, which affects</td><td>Stimulates the heart,</td><td>Constricts blood vessels</td><td></td></tr><tr><td></td><td></td><td>increasing:</td><td>increasing:</td><td></td></tr><tr><td></td><td></td><td>Cardiac output</td><td>Peripheral resistance</td><td></td></tr><tr><td></td><td></td><td colspan="2">together these control</td><td></td></tr><tr><td colspan="2">Baroreceptor discharge</td><td colspan="2">BLOOD PRESSURE,</td><td></td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td></td><td></td><td colspan="2">Renal blood flow,</td><td></td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td></td><td>Affects</td><td colspan="2">Salt and water excretion,</td><td></td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td></td><td>Renin</td><td></td><td>Renin release</td><td></td></tr><tr><td>Angiotensin I (AT I)</td><td></td><td>Angiotensinogen</td><td></td><td></td></tr><tr><td>ACE</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Angiotensin II (AT II), which</td><td>stimulates secretion of</td><td>Aldosterone, which decreases</td></tr><tr><td>ACE Inhibitors (e.g.</td><td></td><td></td><td colspan="2">constricts blood vessels and increases</td></tr><tr><td>captopril, enalapril)</td><td colspan="3">Losartan (AT II receptor antagonist)</td><td></td></tr></table>
</page>
<page number="125">
<table id="p125t1" data-filename="pdftables_fromstorage_023782248" data-page="125" data-table="1"><tr><td></td><td colspan="2">A calcium channel blocker (Similar drugs: nifedipine, verapamil)</td><td>Amlodipine</td><td></td></tr><tr><td>Actions</td><td colspan="4">Vascular dilatation lowers blood pressure. Amlodipine &amp; nifedipine dilate arterial resistance vessels.</td></tr><tr><td></td><td colspan="2">(Verapamil acts mainly on the heart, slowing the rate; see card 5.06).</td><td></td><td></td></tr><tr><td>MOA</td><td>Block voltage-gated calcium channels in vascular</td><td></td><td></td><td></td></tr><tr><td></td><td>smooth muscle inhibiting calcium influx and thus</td><td>Calcium channel</td><td></td><td></td></tr><tr><td></td><td></td><td>blockers</td><td>Ca 2+</td><td></td></tr><tr><td></td><td>contraction.</td><td></td><td></td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally. Half-life of amlodipine 35h, of</td><td></td><td></td><td></td></tr><tr><td></td><td>nifedipine 2h. Verapamil undergoes first-pass</td><td>Ca 2+</td><td></td><td>Voltage-</td></tr><tr><td></td><td>metabolism; half-life ~ 4h.</td><td></td><td></td><td>dependent</td></tr><tr><td></td><td></td><td></td><td></td><td>calcium</td></tr><tr><td>Clinical use</td><td>Hypertension; angina pectoris.</td><td></td><td>Myosin</td><td>channel</td></tr><tr><td></td><td></td><td>Vascular smooth</td><td>Kinase</td><td></td></tr><tr><td>Adverse effects</td><td>Nifedipine &amp; amlodipine: reflex tachycardia,</td><td>muscle cell</td><td></td><td></td></tr><tr><td></td><td>hypotension and headache due to vasodilatation.</td><td></td><td>MyosinP</td><td></td></tr><tr><td></td><td></td><td>Contraction</td><td>+ Actin</td><td></td></tr><tr><td>Special points</td><td>Grapefruit juice increases the effects.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="3">R&amp;D 7e Ch 21, pp 262-263; D&amp;H 2e Ch 19, pp 48-49</td></tr></table>
</page>
<page number="126">
<table id="p126t1" data-filename="pdftables_fromstorage_023782248" data-page="126" data-table="1"><tr><td style="text-align: right">6.04</td><td>Minoxidil</td><td>CVS antihypertensive drugs</td><td></td><td></td></tr><tr><td colspan="5">The figure shows the homeostatic mechanisms controlling blood pressure. Various pathological factors can</td></tr><tr><td colspan="3">disturb the homeostasis and cause hypertension.</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>CNS</td><td></td></tr><tr><td></td><td>Affects</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Peripheral sympathetic system</td><td></td></tr><tr><td></td><td></td><td colspan="2">releases noradrenaline, which</td><td></td></tr><tr><td colspan="2">Plasma volume, which affects</td><td>Stimulates the heart,</td><td>Constricts blood vessels</td><td>Vasodilators:</td></tr><tr><td></td><td></td><td>increasing:</td><td>increasing:</td><td>Calcium channel</td></tr><tr><td></td><td></td><td>Cardiac output</td><td>Peripheral resistance</td><td>blockers (e.g. amlodipine)</td></tr><tr><td></td><td></td><td colspan="2">together these control</td><td></td></tr><tr><td colspan="2">Baroreceptor discharge</td><td colspan="2">BLOOD PRESSURE,</td><td></td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td></td><td></td><td colspan="2">Renal blood flow,</td><td></td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td></td><td>Affects</td><td colspan="2">Salt and water excretion,</td><td></td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td></td><td>Renin</td><td></td><td>Renin release</td><td></td></tr><tr><td>Angiotensin I (AT I)</td><td></td><td>Angiotensinogen</td><td></td><td></td></tr><tr><td>ACE</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Angiotensin II (AT II), which</td><td>stimulates secretion of</td><td>Aldosterone, which decreases</td></tr><tr><td>ACE Inhibitors (e.g.</td><td></td><td></td><td colspan="2">constricts blood vessels and increases</td></tr><tr><td>captopril, enalapril)</td><td colspan="3">Losartan (AT II receptor antagonist)</td><td></td></tr></table>
</page>
<page number="127">
<table id="p127t1" data-filename="pdftables_fromstorage_023782248" data-page="127" data-table="1"><tr><td></td><td></td><td>A potassium channel activator</td><td>Minoxidil</td><td></td></tr><tr><td>Actions</td><td colspan="2">Marked long-lasting vascular dilatation; lowers blood pressure.</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Minoxidil</td><td></td></tr><tr><td>MOA</td><td></td><td></td><td>activates K+ channels</td><td>Ca2+</td></tr><tr><td></td><td></td><td></td><td>which hyperpolarizes</td><td></td></tr><tr><td></td><td></td><td></td><td>the membrane + Actin</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally. Half-life ~ 4h.</td><td></td><td>which inhibits</td><td></td></tr><tr><td></td><td></td><td></td><td>voltage-dependent</td><td></td></tr><tr><td></td><td></td><td></td><td>Ca ++ channels</td><td></td></tr><tr><td>Clinical use</td><td>Very severe hypertension.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>thus</td><td></td></tr><tr><td></td><td></td><td></td><td>reducing</td><td>Myosin</td></tr><tr><td></td><td></td><td>K +</td><td>contraction</td><td></td></tr><tr><td>Adverse effects</td><td>Salt &amp; water retention and tachycardia and</td><td></td><td></td><td>Kinase</td></tr><tr><td></td><td>angina (therefore given with a loop diuretic</td><td></td><td></td><td></td></tr><tr><td></td><td>and a beta blocker). Hirsutism.</td><td>Vascular smooth</td><td>Contraction</td><td>MyosinP</td></tr><tr><td></td><td></td><td>muscle cell</td><td></td><td>+ Actin</td></tr><tr><td>Special points</td><td>Also used topically to treat baldness.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">R&amp;D 7e Ch 22, p 272; D&amp;H 2e Ch 19, p 49</td></tr></table>
</page>
<page number="128">
<table id="p128t1" data-filename="pdftables_fromstorage_023782248" data-page="128" data-table="1"><tr><td style="text-align: right">6.05</td><td>Hydralazine</td><td>CVS antihypertensive drugs</td><td></td><td></td></tr><tr><td colspan="5">The figure shows the homeostatic mechanisms controlling blood pressure. Various pathological factors can</td></tr><tr><td colspan="3">disturb the homeostasis and cause hypertension.</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>CNS</td><td></td></tr><tr><td></td><td>Affects</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Peripheral sympathetic system</td><td></td></tr><tr><td></td><td></td><td colspan="2">releases noradrenaline, which</td><td></td></tr><tr><td colspan="2">Plasma volume, which affects</td><td>Stimulates the heart,</td><td>Constricts blood vessels</td><td>Vasodilators:</td></tr><tr><td></td><td></td><td>increasing:</td><td>increasing:</td><td>Calcium channel</td></tr><tr><td></td><td></td><td>Cardiac output</td><td>Peripheral resistance</td><td>blockers (e.g. amlodipine),</td></tr><tr><td></td><td></td><td></td><td></td><td>minoxidil</td></tr><tr><td></td><td></td><td colspan="2">together these control</td><td></td></tr><tr><td colspan="2">Baroreceptor discharge</td><td colspan="2">BLOOD PRESSURE,</td><td></td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td></td><td></td><td colspan="2">Renal blood flow,</td><td></td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td></td><td>Affects</td><td colspan="2">Salt and water excretion,</td><td></td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td></td><td>Renin</td><td></td><td>Renin release</td><td></td></tr><tr><td>Angiotensin I (AT I)</td><td></td><td>Angiotensinogen</td><td></td><td></td></tr><tr><td>ACE</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Angiotensin II (AT II), which</td><td>stimulates secretion of</td><td>Aldosterone, which decreases</td></tr><tr><td>ACE Inhibitors (e.g.</td><td></td><td></td><td colspan="2">constricts blood vessels and increases</td></tr><tr><td>captopril, enalapril)</td><td colspan="3">Losartan (AT II receptor antagonist)</td><td></td></tr></table>
</page>
<page number="129">
<table id="p129t1" data-filename="pdftables_fromstorage_023782248" data-page="129" data-table="1"><tr><td></td><td>Vasodilator</td><td>Hydralazine</td></tr><tr><td>Actions</td><td>Relaxes arterial smooth muscle lowering blood pressure.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Interferes with the release of Ca++ from the sarcoplasmic reticulum in vascular smooth muscle cells.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally. Half-life ~ 1-3h.</td><td></td></tr><tr><td>Clinical use</td><td>Very severe hypertension – particularly in pregnancy.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Palpitations, hypotension, GIT disturbances, dizziness, allergic reactions (which can be severe with</td></tr><tr><td></td><td>long-term use)</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 22, p 273; D&amp;H 2e Ch 21, p 55</td></tr></table>
</page>
<page number="130">
<table id="p130t1" data-filename="pdftables_fromstorage_023782248" data-page="130" data-table="1"><tr><td style="text-align: right">6.06</td><td colspan="2">Name drug groups that act at the sites</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>CVS antihypertensive drugs</td><td></td></tr><tr><td></td><td colspan="2">marked thus?: Have a go at giving examples</td><td></td><td></td></tr><tr><td colspan="5">The figure shows the homeostatic mechanisms controlling blood pressure. Various pathological factors</td></tr><tr><td colspan="4">can disturb the homeostasis and cause hypertension. Important drugs in bold.</td><td></td></tr><tr><td></td><td>?</td><td></td><td>CNS</td><td>?</td></tr><tr><td></td><td>Affects</td><td colspan="2">Peripheral sympathetic system</td><td>?</td></tr><tr><td></td><td>?</td><td colspan="2">releases noradrenaline, which</td><td></td></tr><tr><td colspan="2">Plasma volume, which affects</td><td>Stimulates the heart,</td><td>Constricts blood vessels</td><td>Vasodilators:</td></tr><tr><td></td><td></td><td>increasing:</td><td>increasing:</td><td>Calcium channel</td></tr><tr><td>Plasma volume, which reduces</td><td></td><td>Cardiac output</td><td>Peripheral resistance</td><td>blockers (e.g. amlodipine),</td></tr><tr><td></td><td></td><td></td><td></td><td>Hydralazine</td></tr><tr><td></td><td></td><td colspan="2">together these control</td><td></td></tr><tr><td></td><td>?</td><td colspan="2">BLOOD PRESSURE,</td><td></td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td>decrease</td><td>increase</td><td colspan="2">Renal blood flow,</td><td>?</td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td></td><td></td><td colspan="2">Salt and water excretion,</td><td></td></tr><tr><td></td><td></td><td></td><td>which affects</td><td></td></tr><tr><td></td><td>Renin</td><td></td><td>Renin release</td><td>?</td></tr><tr><td>Angiotensin I (AT I)</td><td></td><td>Angiotensinogen</td><td></td><td></td></tr><tr><td>ACE</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Angiotensin II (AT II), which</td><td>stimulates secretion of</td><td>Aldosterone, which decreases</td></tr><tr><td></td><td></td><td></td><td>constricts blood vessels and increases</td><td></td></tr><tr><td>ACE Inhibitors (e.g.</td><td></td><td></td><td></td><td></td></tr><tr><td>captopril, enalapril)</td><td colspan="2">Losartan (AT II receptor antagonist)</td><td></td><td></td></tr></table>
</page>
<page number="131">
<table id="p131t1" data-filename="pdftables_fromstorage_023782248" data-page="131" data-table="1"><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">OTHER ANTIHYPERTENSIVE</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">DRUGS</td><td></td><td></td></tr><tr><td colspan="4">Important drugs in bold. For details see the cards specified</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">α2-Adrenoceptor agonists (e.g. methyl- dopa)</td><td>Card</td><td>CNS</td><td colspan="2">Adrenoceptor antagonists (e.g.</td><td></td><td>Card</td></tr><tr><td colspan="2">decrease sympathetic outflow</td><td></td><td style="text-align: right">2.10</td><td></td><td colspan="3">atenolol) decrease sympathetic outflow</td><td style="text-align: right">2.02</td></tr><tr><td>β1-Adrenoceptor blockers</td><td>Card</td><td></td><td colspan="2">Peripheral sympathetic system</td><td>α</td><td colspan="2">-Adrenoceptor</td><td></td></tr><tr><td>(e.g. metoprolol, atenolol)</td><td style="text-align: right">2.02</td><td></td><td colspan="2">releases noradrenaline, which</td><td style="text-align: right">1</td><td colspan="2">antagonists</td><td>Card</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="3">(e.g. terazosin)</td><td style="text-align: right">2.04</td></tr><tr><td colspan="2">Plasma volume, which affects</td><td colspan="2">Stimulates the heart,</td><td>Constricts blood vessels</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">increasing:</td><td></td><td>increasing:</td><td></td><td></td><td></td></tr><tr><td colspan="2">Plasma volume, which reduces</td><td colspan="2">Cardiac output</td><td>Peripheral resistance</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Diuretics (e.g.</td><td>Card</td><td colspan="2">together these control</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">thiazides furosemide )</td><td style="text-align: right">13.02</td><td colspan="2">BLOOD PRESSURE,</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>which affects</td><td colspan="2">Spironolactone blocks</td><td></td><td></td></tr><tr><td>decrease</td><td></td><td>increase</td><td colspan="2">Renal blood flow,</td><td colspan="2">aldosterone receptors</td><td>Card</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">13.04</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>which affects</td><td colspan="2">and thus increases:</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Salt and water excretion,</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>which affects</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Renin</td><td></td><td></td><td>Renin release</td><td>Beta blockers</td><td>Card2.02</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>decrease</td><td></td><td></td><td></td></tr><tr><td>Angiotensin I (AT I)</td><td></td><td colspan="2">Angiotensinogen</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>ACE</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Angiotensin II (AT II), which</td><td></td><td>stimulates secretion of</td><td colspan="4">Aldosterone, which decreases</td></tr><tr><td></td><td></td><td></td><td></td><td>constricts blood vessels and increases</td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="132">
<table id="p132t1" data-filename="pdftables_fromstorage_023782248" data-page="132" data-table="1"><tr><td style="text-align: right">7.01</td><td>Nifedipine</td><td>Angina and myocardial infarction</td><td></td><td></td></tr><tr><td></td><td colspan="4">The figure below outlines the pathophysiology of angina and myocardial infarction</td></tr><tr><td></td><td></td><td colspan="2">Atherosclerotic plaque</td><td></td></tr><tr><td></td><td></td><td>Decreased</td><td colspan="2">Plaque rupture, thrombosis</td></tr><tr><td></td><td></td><td>myocardial</td><td></td><td></td></tr><tr><td></td><td></td><td>perfusion</td><td colspan="2">Block of coronary artery</td></tr><tr><td></td><td>Angina</td><td>Potential</td><td></td><td>Ventricular</td></tr><tr><td></td><td></td><td></td><td>Myocardial</td><td></td></tr><tr><td></td><td></td><td>dysrhythmias</td><td></td><td>dysfunction</td></tr><tr><td></td><td></td><td></td><td>infarction</td><td></td></tr><tr><td></td><td></td><td></td><td>PAIN!</td><td>Shock</td></tr><tr><td></td><td></td><td>Increased</td><td></td><td></td></tr><tr><td></td><td></td><td>sympathetic</td><td></td><td></td></tr><tr><td></td><td></td><td>activity</td><td></td><td></td></tr></table>
</page>
<page number="133">
<table id="p133t1" data-filename="pdftables_fromstorage_023782248" data-page="133" data-table="1"><tr><td></td><td colspan="4">Calcium antagonist (Other calcium antagonists: amlodipine; diltiazem)</td><td>Nifedipine</td><td></td></tr><tr><td>Actions</td><td colspan="6">Dilates and relaxes arterial resistance vessels and coronary arteries and thus (i) reduces cardiac work</td></tr><tr><td></td><td colspan="6">and metabolic demand and (ii) increases the perfusion and oxygenation of heart muscle; see Fig. 1.</td></tr><tr><td>MOA</td><td colspan="5">Inhibits voltage-gated calcium channels and reduces the contractile process; see Fig. 2.</td><td></td></tr><tr><td></td><td></td><td>HEART</td><td></td><td colspan="2">Calcium antagonists</td><td>Ca 2+</td></tr><tr><td></td><td></td><td>Coronary</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>vessels</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Venous</td><td></td><td>Arterial</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Vascular</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>resistance</td><td></td><td></td><td></td></tr><tr><td></td><td>capacitance</td><td></td><td></td><td>smooth</td><td></td><td></td></tr><tr><td></td><td></td><td>vessels</td><td>vessels</td><td>muscle</td><td>Ca 2+</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>cell</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Myosin</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Kinase</td></tr><tr><td></td><td></td><td>Calcium</td><td>and</td><td></td><td>CONTRACTION</td><td></td></tr><tr><td></td><td></td><td>dilate</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>antagonists</td><td>reduce</td><td></td><td></td><td>MyosinP</td></tr><tr><td></td><td></td><td>Fig. 1</td><td>afterload</td><td>Fig. 2</td><td></td><td>+ Actin</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="6">Given orally. Elimination half-lives: nifedipine ~2h, amlodipine ~40h, verapamil 6h, diltiazem 4h.</td></tr><tr><td>Clinical use</td><td colspan="6">To prevent angina (nifedipine, diltiazem). For hypertension; see card 6.03. For dysrhythmias: verapamil</td></tr><tr><td></td><td>(see card 5.06).</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Adverse effects</td><td colspan="6">Nifedipine: flushing &amp; headache and with chronic use – ankle swelling. Verapamil: constipation</td></tr><tr><td></td><td colspan="4">(an effect on GIT smooth muscle) and sometimes heart failure.</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">R&amp;D 7e Ch 18, pp 294-296; D&amp;H 2e Ch 20, pp 294-296</td></tr></table>
</page>
<page number="134">
<table id="p134t1" data-filename="pdftables_fromstorage_023782248" data-page="134" data-table="1"><tr><td style="text-align: right">7.02</td><td>Glyceryl trinitrate</td><td>Angina and myocardial infarction</td><td></td><td></td></tr><tr><td></td><td colspan="4">The figure below outlines the pathophysiology of angina and myocardial infarction</td></tr><tr><td></td><td></td><td colspan="2">Atherosclerotic plaque</td><td></td></tr><tr><td></td><td></td><td>Decreased</td><td colspan="2">Plaque rupture, thrombosis</td></tr><tr><td></td><td></td><td>myocardial</td><td></td><td></td></tr><tr><td></td><td></td><td>perfusion</td><td colspan="2">Block of coronary artery</td></tr><tr><td></td><td>Angina</td><td>Potential</td><td></td><td>Ventricular</td></tr><tr><td></td><td></td><td></td><td>Myocardial</td><td></td></tr><tr><td></td><td></td><td>dysrhythmias</td><td></td><td>dysfunction</td></tr><tr><td></td><td></td><td></td><td>infarction</td><td></td></tr><tr><td></td><td>Nifedipine,</td><td></td><td></td><td></td></tr><tr><td></td><td>Diltiazem</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>PAIN!</td><td>Shock</td></tr><tr><td></td><td></td><td>Increased</td><td></td><td></td></tr><tr><td></td><td></td><td>sympathetic</td><td></td><td></td></tr><tr><td></td><td></td><td>activity</td><td></td><td></td></tr></table>
</page>
<page number="135">
<table id="p135t1" data-filename="pdftables_fromstorage_023782248" data-page="135" data-table="1"><tr><td></td><td colspan="4">Vasodilator drug (Similar drug: isosorbide mononitrate)</td><td colspan="2">Glyceryl trinitrate</td><td></td></tr><tr><td>Actions</td><td colspan="7">Dilates and relaxes vascular (especially venular) smooth muscle and thus (i) reduce cardiac work and</td></tr><tr><td></td><td colspan="7">therefore metabolic demand and (ii) increase the perfusion and oxygenation of heart muscle; see Fig. 1</td></tr><tr><td>MOA</td><td colspan="6">Gives rise to nitric oxide (NO) in the cell which activates protein kinase G (PKG) and reduces</td><td></td></tr><tr><td></td><td>contraction; Fig. 2.</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>HEART</td><td></td><td></td><td></td><td>Nitrates</td><td>Ca 2+</td></tr><tr><td></td><td></td><td>Coronary</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>vessels</td><td></td><td></td><td></td><td></td><td>R</td></tr><tr><td></td><td>Venous</td><td></td><td>Arterial</td><td colspan="2">Guanylyl</td><td>NO</td><td></td></tr><tr><td></td><td>capacitance</td><td></td><td>resistance</td><td colspan="2">cyclase</td><td></td><td></td></tr><tr><td></td><td>vessels</td><td></td><td>vessels</td><td></td><td></td><td>Smooth</td><td>Ca2+</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>muscle cell</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>GTP</td><td>cGMP</td><td></td><td>Myosin</td></tr><tr><td></td><td>these</td><td></td><td>these</td><td></td><td>PKG</td><td>Inhibits</td><td>Kinase</td></tr><tr><td></td><td>and</td><td></td><td>and</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>reduce</td><td>Nitrates</td><td>reduce</td><td></td><td></td><td>Reduces</td><td></td></tr><tr><td></td><td>preload</td><td>dilate</td><td>afterload</td><td></td><td></td><td></td><td>MyosinP</td></tr><tr><td></td><td>Fig. 1</td><td></td><td></td><td>Fig. 2</td><td></td><td>CONTRACTION</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="7">Glyceryl trinitrate: sublingual tablet or spray, acts immediately; effects last ~30 mins. Can be given</td></tr><tr><td></td><td colspan="6">by transdermal patch – effects last 24h. Can be given i.v. Isosorbide mononitrate: given orally;</td><td></td></tr><tr><td></td><td colspan="3">half-life 4h; slow-release preparation available.</td><td></td><td></td><td></td><td></td></tr><tr><td>Clinical use</td><td colspan="7">Given sublingually to prevent/treat stable angina; glyceryl trinitrate is given i.v. to treat unstable</td></tr><tr><td></td><td colspan="5">angina. (Nitrates are also used in chronic heart failure; see card 8.02).</td><td></td><td></td></tr><tr><td>Adverse effects</td><td colspan="7">Headache due to vasodilatation; postural hypotension due to ↓vasomotor tone; prolonged usage</td></tr><tr><td></td><td colspan="6">leads to tolerance; methaemoglobinaemia (rare) with continued high doses.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="3">R&amp;D 7e Ch 21, pp 260-261; D&amp;H 2e Ch 20, pp 50-52</td></tr></table>
</page>
<page number="136">
<table id="p136t1" data-filename="pdftables_fromstorage_023782248" data-page="136" data-table="1"><tr><td style="text-align: right">7.03</td><td>Angina and myocardial infarction</td><td colspan="3">What groups of drugs are used clinically to treat the pathophysiological</td></tr><tr><td></td><td></td><td colspan="2">conditions shown in the dashed box below?</td><td></td></tr><tr><td colspan="4">The figure below outlines the pathophysiology of angina and myocardial infarction</td><td></td></tr><tr><td></td><td></td><td></td><td>Atherosclerotic plaque</td><td></td></tr><tr><td></td><td>Decreased</td><td colspan="3">Plaque rupture, thrombosis</td></tr><tr><td></td><td>myocardial</td><td></td><td></td><td></td></tr><tr><td></td><td>perfusion</td><td colspan="3">Block of coronary artery</td></tr><tr><td></td><td>Angina</td><td></td><td>Potential</td><td>Ventricular</td></tr><tr><td></td><td></td><td></td><td>Myocardial</td><td></td></tr><tr><td></td><td></td><td>dysrhythmias</td><td></td><td>dysfunction</td></tr><tr><td></td><td></td><td></td><td>infarction</td><td></td></tr><tr><td>Nifedipine,</td><td>Glyceryl trinitrate,</td><td></td><td></td><td></td></tr><tr><td>Diltiazem</td><td>isosorbide mononitrate</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>PAIN!</td><td>Shock</td></tr><tr><td></td><td></td><td></td><td>Increased</td><td></td></tr><tr><td></td><td></td><td>sympathetic activity</td><td></td><td></td></tr></table>
</page>
<page number="137">
<table id="p137t1" data-filename="pdftables_fromstorage_023782248" data-page="137" data-table="1"><tr><td colspan="4">The groups of drugs used clinically to treat the pathophysiological conditions shown on front of card.</td></tr><tr><td colspan="4">Myocardial infarction is a medical emergency requiring hospitalisation.</td></tr><tr><td></td><td></td><td></td><td>Anti-platelet</td></tr><tr><td></td><td></td><td></td><td>agents</td></tr><tr><td>Statins</td><td></td><td></td><td>(see section 10)</td></tr><tr><td>(see card 9.01)</td><td colspan="2">Atherosclerotic plaque</td><td></td></tr><tr><td></td><td colspan="2">Plaque rupture, thrombosis</td><td>Anticoagulants</td></tr><tr><td></td><td></td><td></td><td>(see card 10.09)</td></tr><tr><td></td><td colspan="2">Block of coronary artery</td><td></td></tr><tr><td></td><td></td><td></td><td>Thrombolytic</td></tr><tr><td></td><td></td><td></td><td>agents</td></tr><tr><td></td><td></td><td></td><td>(see card 10.05)</td></tr><tr><td>Potential</td><td></td><td>Ventricular</td><td></td></tr><tr><td></td><td>Myocardial</td><td></td><td></td></tr><tr><td>dysrhythmias</td><td></td><td>dysfunction</td><td></td></tr><tr><td></td><td>infarction</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>ACE inhibitors</td></tr><tr><td>β-adrenoceptor</td><td></td><td></td><td>(see card 6.01)</td></tr><tr><td>antagonists</td><td></td><td></td><td></td></tr><tr><td>(see card 2.02)</td><td>PAIN!</td><td>Shock</td><td></td></tr><tr><td>Increased</td><td>Opioids)</td><td></td><td></td></tr><tr><td>sympathetic</td><td colspan="2">(see cards 26.01–26.03)</td><td></td></tr><tr><td>activity</td><td></td><td></td><td>R&amp;D 7e Ch 21, pp 253-254; D&amp;H 2e Ch 20, p 52</td></tr></table>
</page>
<page number="138">
<table id="p138t1" data-filename="pdftables_fromstorage_023782248" data-page="138" data-table="1"><tr><td style="text-align: right">8.01</td><td>Digoxin</td><td>Heart failure</td><td></td><td></td><td></td></tr><tr><td colspan="6">The pathophysiology of heart failure – showing the autocatalytic (positive feedback) mechanisms</td></tr><tr><td></td><td colspan="4">Myocardial disease, hypertension, vascular disease can cause:</td><td></td></tr><tr><td colspan="2">Increased pre-load</td><td>exacerbates</td><td>Cardiac failure</td><td>exacerbates</td><td>Increased after-load</td></tr><tr><td></td><td></td><td></td><td>i.e. reduced cardiac</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>output, which leads</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>to:</td><td></td><td>Increased</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>peripheral</td></tr><tr><td></td><td></td><td></td><td>Decreased</td><td></td><td>resistance</td></tr><tr><td colspan="2">Increased central</td><td></td><td>renal blood</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>flow</td><td>Reduced tissue</td><td></td></tr><tr><td colspan="2">venous pressure</td><td></td><td>Renin</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>perfusion</td><td></td></tr><tr><td></td><td></td><td></td><td>release</td><td>Angiotensinogen</td><td>Vasoconstriction</td></tr><tr><td>Oedema</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">(peripheral and</td><td></td><td></td><td>Renin</td><td></td></tr><tr><td>pulmonary)</td><td></td><td></td><td></td><td>Angiotensin I</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>ACE</td><td></td></tr><tr><td colspan="2">Increased</td><td></td><td>Retention of</td><td></td><td></td></tr><tr><td colspan="2">plasma volume</td><td></td><td>salt and</td><td>Angiotensin II</td><td></td></tr><tr><td></td><td></td><td></td><td>water</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Aldosterone release,</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>which increases</td><td></td></tr></table>
</page>
<page number="139">
<table id="p139t1" data-filename="pdftables_fromstorage_023782248" data-page="139" data-table="1"><tr><td></td><td></td><td colspan="2">A cardiac stimulant</td><td>Digoxin</td><td></td></tr><tr><td>Actions</td><td colspan="4">Slows heart. Slows AV conduction. Prolongs AV node refractory period. Increases force of</td><td></td></tr><tr><td></td><td>contraction in failing heart.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Digoxin</td><td></td><td></td></tr><tr><td>MOA</td><td>Inhibits Na+/K + ATPase in plasma membrane.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>The increased intracellular Na+ reduces</td><td></td><td>2K +</td><td></td><td>Na+</td></tr><tr><td></td><td>Ca++ extrusion thus increasing [Ca++ ] i</td><td></td><td>Na+ /K +</td><td></td><td>Na +/Ca++</td></tr><tr><td></td><td></td><td>ATPase</td><td></td><td>Exchanger</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally, usually with a loading dose;</td><td></td><td>3Na+</td><td></td><td style="text-align: right">++</td></tr><tr><td></td><td>renal excretion; plasma half-life ~36h.</td><td></td><td></td><td>Ca</td><td></td></tr><tr><td>Clinical use</td><td>Atrial fibrillation. Heart failure (if diuretics</td><td></td><td>[Na + ]i</td><td></td><td>[Ca++ ]i</td></tr><tr><td></td><td>and ACE inhibitors haven’t worked).</td><td></td><td></td><td></td><td></td></tr><tr><td>Adverse effects</td><td>Dysrhythymias, due to block of AV</td><td></td><td></td><td colspan="2">IncrCeoansterda cftoirocne of</td></tr><tr><td></td><td>conduction and ectopic pacemaker action;</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>yellow vision; nausea and vomiting.</td><td></td><td></td><td></td><td></td></tr><tr><td>Special points</td><td colspan="5">Narrow margin between effective dose and toxic dose. Decreased plasma K+ increases toxicity</td></tr><tr><td></td><td colspan="3">due to competition between K+ and digoxin for the Na+/K + ATPase.</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="4">R&amp;D 7e Ch 21, p 258; D&amp;H 2e Ch 21, pp 53-55</td></tr></table>
</page>
<page number="140">
<table id="p140t1" data-filename="pdftables_fromstorage_023782248" data-page="140" data-table="1"><tr><td></td><td>Drugs used in the</td><td></td><td></td><td></td></tr><tr><td style="text-align: right">8.02</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Heart Failure</td><td></td><td></td></tr><tr><td></td><td>treatment of heart failure</td><td></td><td></td><td></td></tr><tr><td colspan="5">What groups of drugs would be clinically useful at the sites shown with a question mark. Have a go</td></tr><tr><td>at giving examples.</td><td colspan="3">Myocardial disease, hypertension, vascular disease can cause:</td><td></td></tr><tr><td>Increased pre-load</td><td>exacerbates</td><td>Cardiac failure</td><td>exacerbates</td><td>Increased after-load</td></tr><tr><td></td><td></td><td>i.e. reduced cardiac</td><td></td><td></td></tr><tr><td></td><td>Inotropic agents</td><td>output, which leads</td><td></td><td></td></tr><tr><td>?</td><td>e.g. digoxin</td><td>to:</td><td>?</td><td>Increased</td></tr><tr><td></td><td>increase output</td><td></td><td></td><td>peripheral</td></tr><tr><td></td><td></td><td>Decreased</td><td></td><td>resistance</td></tr><tr><td>Increased central</td><td></td><td>renal blood</td><td></td><td></td></tr><tr><td></td><td></td><td>flow</td><td>Reduced tissue</td><td></td></tr><tr><td>venous pressure</td><td></td><td>Renin</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>perfusion</td><td></td></tr><tr><td></td><td></td><td>release</td><td></td><td>Vasoconstriction</td></tr><tr><td></td><td>?</td><td></td><td>Angiotensinogen</td><td></td></tr><tr><td>Oedema</td><td></td><td></td><td></td><td></td></tr><tr><td>(peripheral and</td><td></td><td></td><td>Renin</td><td></td></tr><tr><td>pulmonary)</td><td></td><td></td><td>Angiotensin I</td><td></td></tr><tr><td></td><td></td><td></td><td>ACE</td><td>?</td></tr><tr><td>Increased</td><td></td><td>Retention of</td><td></td><td></td></tr><tr><td>plasma volume</td><td></td><td>salt and</td><td>Angiotensin II</td><td></td></tr><tr><td></td><td></td><td>water</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Aldosterone release,</td><td></td></tr><tr><td></td><td></td><td></td><td>which increases</td><td></td></tr></table>
</page>
<page number="141">
<table id="p141t1" data-filename="pdftables_fromstorage_023782248" data-page="141" data-table="1"><tr><td></td><td></td><td></td><td colspan="2">Drugs used in the</td></tr><tr><td></td><td></td><td></td><td colspan="2">treatment of heart failure</td></tr><tr><td></td><td colspan="3">Myocardial disease, hypertension, vascular disease can cause:</td><td></td></tr><tr><td>Increased pre-load</td><td>exacerbates</td><td>Cardiac failure</td><td>exacerbates</td><td>Increased after-load</td></tr><tr><td></td><td></td><td>i.e. reduced cardiac</td><td></td><td></td></tr><tr><td></td><td>Inotropic agents *</td><td>output, which leads</td><td>Vasodilators,</td><td></td></tr><tr><td></td><td>e.g. digoxin</td><td>to:</td><td>e.g. hydralazine</td><td>Increased</td></tr><tr><td>Vasodilators</td><td></td><td></td><td></td><td></td></tr><tr><td>e.g. nitrates</td><td>increase output</td><td></td><td>(see Card set 6)</td><td>peripheral</td></tr><tr><td>(see Card set 7</td><td></td><td>Decreased</td><td></td><td>resistance</td></tr><tr><td>Increased central</td><td></td><td>renal blood</td><td></td><td></td></tr><tr><td></td><td></td><td>flow</td><td>Reduced tissue</td><td></td></tr><tr><td>venous pressure</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Renin</td><td></td><td></td></tr><tr><td></td><td>Diuretics:</td><td></td><td>perfusion</td><td></td></tr><tr><td></td><td>Furosemide,</td><td>release</td><td>Angiotensinogen</td><td>Vasoconstriction</td></tr><tr><td>Oedema</td><td>thiazides</td><td></td><td></td><td></td></tr><tr><td>(peripheral and</td><td>(see Card set 13)</td><td></td><td>Renin</td><td></td></tr><tr><td>pulmonary)</td><td></td><td></td><td>Angiotensin I</td><td>ACE inhibitors,</td></tr><tr><td></td><td></td><td></td><td></td><td>e.g. captopril.</td></tr><tr><td></td><td></td><td></td><td>ACE</td><td>enalapril</td></tr><tr><td>Increased</td><td></td><td>Retention of</td><td></td><td>(see card set 6)</td></tr><tr><td>plasma volume</td><td></td><td>salt and</td><td>Angiotensin II</td><td></td></tr><tr><td></td><td></td><td>water</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Aldosterone release,</td><td></td></tr><tr><td colspan="2">* Dobutamine, a β-1 agonist with inotropic action, is used in</td><td></td><td>which increases</td><td></td></tr><tr><td colspan="2">acute heart failure. Beta blockers have negative inotropic actions</td><td></td><td></td><td></td></tr><tr><td colspan="2">but are sometimes used if there is sympathetic over-activity</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">R&amp;D 7e Ch 22, pp 278-280; D&amp;H 2e Ch 21, pp 53-55</td></tr></table>
</page>
<page number="142">
<table id="p142t1" data-filename="pdftables_fromstorage_023782248" data-page="142" data-table="1"><tr><td style="text-align: right">9.01</td><td colspan="2">Simvastatin</td><td colspan="3">Atherosclerosis &amp; lipoproteins</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">Cholesterol and lipoprotein metabolism</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">Endogenous pathway</td><td></td><td></td><td>ACoA</td><td></td><td></td><td colspan="2">Exogenous pathway</td><td></td><td></td></tr><tr><td colspan="3">LDL (low density lipoproteins)</td><td></td><td></td><td colspan="2">HMG-CoA reductase</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">carry cholesterol (C) to the tissues.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">VLDL (very low density lipoproteins)</td><td>Liver</td><td>MVA</td><td></td><td></td><td>Portal vein</td><td></td><td></td></tr><tr><td colspan="3">carry triglycerides (TG) and free</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">fatty acids to the tissues</td><td></td><td></td><td>C</td><td>Bile acids and C</td><td></td><td>Bile duct</td><td colspan="2">Bile acids</td></tr><tr><td colspan="4">HDL = high density lipoproteins;</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">ACoA = acetyl Coenzyme A;</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Endocytosis</td><td>Chylomicron</td><td></td><td></td></tr><tr><td colspan="2">CE = cholesteryl esters)</td><td></td><td></td><td>LDL</td><td></td><td colspan="2">by liver cells</td><td>formation</td><td>C</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>receptors</td><td></td><td></td><td></td><td>Absorption</td><td colspan="2">Dietary</td></tr><tr><td colspan="2">To ↓LDL and ↑HDL</td><td colspan="2">Endocytosis</td><td></td><td></td><td></td><td colspan="2">into lymphatics</td><td></td><td>fat</td></tr><tr><td>slows atheroma</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">by liver cells</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>progress</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td>Fatty</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>C</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">acids</td></tr><tr><td></td><td>CE</td><td></td><td></td><td>VLDL
TG &gt; CE</td><td></td><td></td><td>Chylomicron</td><td></td><td colspan="2">+ Glycerol</td></tr><tr><td></td><td></td><td></td><td>LDL</td><td></td><td></td><td></td><td>remnant</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>CE &gt; TG</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>CE</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>HDL</td><td>CE</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Intestine</td></tr><tr><td>CE</td><td></td><td></td><td></td><td></td><td></td><td></td><td>Chylomicrons</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Lipoprotein lipase</td><td></td><td>TG &gt; CE</td><td></td><td></td><td></td></tr><tr><td>C from cell</td><td></td><td>Uptake</td><td></td><td>Free fatty</td><td></td><td>Free fatty</td><td></td><td colspan="3">Vascular endothelium</td></tr><tr><td>turnover</td><td></td><td>of C</td><td></td><td>acids</td><td></td><td>acids</td><td colspan="2">Peripheral tissues</td><td></td><td></td></tr></table>
</page>
<page number="143">
<table id="p143t1" data-filename="pdftables_fromstorage_023782248" data-page="143" data-table="1"><tr><td></td><td>A lipid-lowering drug (Similar drugs: atorvastatin, pravastatin, lovastatin)</td><td>Simvastatin</td></tr><tr><td>Actions</td><td colspan="2">Lowers LDL-C. Also produces some lowering of plasma triglyceride and some increase in HDL-C.</td></tr><tr><td>MOA</td><td colspan="2">Specific reversible competitive inhibition of the rate-limiting enzyme HMG-CoA-reductase and thus</td></tr><tr><td></td><td colspan="2">↓hepatic C synthesis which up-regulates LDL-receptor synthesis and causes ↑clearance of LDLC</td></tr><tr><td></td><td>from plasma into liver cells.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally; undergoes first-pass metabolism; inactive until biotransformation in the liver. Plasma</td></tr><tr><td></td><td>half-life: 1–3h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Hypercholesterolaemia. Used to prevent atherosclerosis in patients with high C serum levels and</td></tr><tr><td></td><td colspan="2">to prevent cardiac infarction in patients who already have atherosclerosis.</td></tr><tr><td>Adverse effects</td><td>Usually mild: muscle pain, GIT distubances, insomnia, rash.</td><td></td></tr><tr><td></td><td colspan="2">Rarer severe effects: severe myositis (risk increased if given with fibrates); angioedema.</td></tr><tr><td>Special points</td><td>Statin action is increased by Estimibe.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 23, p 289; D&amp;H 2e Ch 22, pp 56-57</td></tr></table>
</page>
<page number="144">
<table id="p144t1" data-filename="pdftables_fromstorage_023782248" data-page="144" data-table="1"><tr><td style="text-align: right">9.02</td><td>Gemfibrozil</td><td>Atherosclerosis &amp; lipoproteins</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">Cholesterol and lipoprotein metabolism</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">Endogenous pathway</td><td>ACoA</td><td></td><td></td><td colspan="2">Exogenous pathway</td><td></td><td></td></tr><tr><td colspan="2">Statins e.g. simvastatin,</td><td></td><td colspan="2">HMG-CoA reductase</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">decrease synthesis of C</td><td></td><td></td><td></td><td></td><td>Portal vein</td><td></td><td></td></tr><tr><td></td><td></td><td>Liver</td><td>MVA</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>C</td><td>Bile acids and C</td><td></td><td></td><td colspan="2">Bile acids</td></tr><tr><td colspan="2">Statins, increase</td><td></td><td></td><td></td><td></td><td>Bile duct</td><td></td><td></td></tr><tr><td colspan="2">uptake of LDL</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Endocytosis</td><td>Chylomicron</td><td></td><td></td></tr><tr><td></td><td></td><td>LDL</td><td></td><td colspan="2">by liver cells</td><td>formation</td><td>C</td><td></td></tr><tr><td></td><td></td><td>receptors</td><td></td><td></td><td></td><td>Absorption</td><td colspan="2">Dietary</td></tr><tr><td></td><td>Endocytosis</td><td></td><td></td><td></td><td colspan="2">into lymphatics</td><td></td><td>fat</td></tr><tr><td></td><td>by liver cells</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td>Fatty</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>C</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">acids</td></tr><tr><td></td><td>CE</td><td>VLDL
TG &gt; CE</td><td></td><td></td><td>Chylomicron</td><td></td><td colspan="2">+ Glycerol</td></tr><tr><td></td><td></td><td>LDL</td><td></td><td></td><td>remnant</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>CE &gt; TG</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>CE</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>HDL</td><td>CE</td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Intestine</td></tr><tr><td>CE</td><td></td><td></td><td></td><td></td><td>Chylomicrons</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Lipoprotein lipase</td><td></td><td>TG &gt; CE</td><td></td><td></td><td></td></tr><tr><td>C from cell</td><td>Uptake</td><td>Free fatty</td><td></td><td>Free fatty</td><td></td><td colspan="3">Vascular endothelium</td></tr><tr><td>turnover</td><td>of C</td><td>acids</td><td></td><td>acids</td><td colspan="2">Peripheral tissues</td><td></td><td></td></tr></table>
</page>
<page number="145">
<table id="p145t1" data-filename="pdftables_fromstorage_023782248" data-page="145" data-table="1"><tr><td></td><td>A lipid-lowering fibrate</td><td>Gemfibrozil</td></tr><tr><td>Actions</td><td colspan="2">Fibrates cause: a marked decrease in plasma VLDL and thus triglyceride; a modest decrease in LDL-C;</td></tr><tr><td></td><td>a small increase in HDL-C.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Fibrates ↑transcription of the genes for lipoprotein lipase and for the apoproteins apoA1 and apoA5</td></tr><tr><td></td><td colspan="2">which are ligands for specific receptors. Fibrates ↑LDL-C uptake by the LDL-C receptors.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally, well absorbed; metabolised to glucuronide conjugates excreted via the kidney.</td></tr><tr><td>Clinical use</td><td colspan="2">Used for mixed dyslipidemia (i.e. ↑in both plasma TGs and C); also in cases with low HDL and thus</td></tr><tr><td></td><td>↑risk of atheroma.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">GIT upsets; rash; moderate increased risk of gall stones; myositis — which can be severe.</td></tr><tr><td>Special points</td><td>Avoid use of statins with fibrates.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 23, p 290; D&amp;H 2e Ch 22, pp 56-57</td></tr></table>
</page>
<page number="146">
<table id="p146t1" data-filename="pdftables_fromstorage_023782248" data-page="146" data-table="1"><tr><td style="text-align: right">9.03</td><td>Ezetimibe</td><td>Atherosclerosis &amp; lipoproteins</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">Cholesterol and lipoprotein metabolism</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">Endogenous pathway</td><td>ACoA</td><td></td><td></td><td colspan="2">Exogenous pathway</td><td></td><td></td></tr><tr><td colspan="2">Statins e.g. simvastatin,</td><td></td><td colspan="2">HMG-CoA reductase</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">decrease synthesis of C</td><td></td><td></td><td></td><td></td><td>Portal vein</td><td></td><td></td></tr><tr><td></td><td></td><td>Liver</td><td>MVA</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>C</td><td>Bile acids and C</td><td></td><td></td><td colspan="2">Bile acids</td></tr><tr><td colspan="2">Statins and</td><td></td><td></td><td></td><td></td><td>Bile duct</td><td></td><td></td></tr><tr><td colspan="2">fibrates increase</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">uptake of LDL</td><td></td><td></td><td></td><td>Endocytosis</td><td>Chylomicron</td><td></td><td></td></tr><tr><td></td><td></td><td>LDL</td><td></td><td></td><td>by liver cells</td><td>formation</td><td>C</td><td></td></tr><tr><td></td><td></td><td>receptors</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Dietary</td></tr><tr><td></td><td>Endocytosis</td><td></td><td></td><td>Fibrates</td><td></td><td></td><td></td><td>fat</td></tr><tr><td></td><td>by liver cells</td><td></td><td></td><td>decrease</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>secretion</td><td></td><td></td><td>C +</td><td>Fatty</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>acids</td></tr><tr><td></td><td>CE</td><td>VLDL
TG &gt; CE</td><td></td><td></td><td>Chylomicron</td><td></td><td colspan="2">+ Glycerol</td></tr><tr><td></td><td></td><td>LDL</td><td colspan="2">Fibrates</td><td>remnant</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>CE</td><td colspan="2">enhance</td><td>CE &gt; TG</td><td></td><td></td><td></td></tr><tr><td>HDL</td><td>CE</td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Intestine</td></tr><tr><td>CE</td><td></td><td></td><td></td><td></td><td>Chylomicrons</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Lipoprotein lipase</td><td>TG &gt; CE</td><td></td><td></td><td></td></tr><tr><td>C from cell</td><td>Uptake</td><td>Free fatty</td><td></td><td>Free fatty</td><td></td><td colspan="3">Vascular endothelium</td></tr><tr><td>turnover</td><td>of C</td><td>acids</td><td></td><td>acids</td><td colspan="2">Peripheral tissues</td><td></td><td></td></tr></table>
</page>
<page number="147">
<table id="p147t1" data-filename="pdftables_fromstorage_023782248" data-page="147" data-table="1"><tr><td></td><td>A cholesterol-lowering drug</td><td>Ezetimibe</td></tr><tr><td>Actions</td><td colspan="2">Specifically inhibits the absorption of cholesterol from the intestine. Main effect: decrease of plasma</td></tr><tr><td></td><td>LDL concentration.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Blocks a sterol carrier protein in the brush border of enterocytes and thus reduces the amount of</td></tr><tr><td></td><td colspan="2">biliary and dietary C delivered to the liver via chylomicrons. This results in a ↓in the liver’s C store,</td></tr><tr><td></td><td colspan="2">an ↑in hepatic LDL absorption and ↑clearance of LDL-C from the plasma.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally, activated in the liver, reaches maximum concentration in 2h after which it undergoes</td></tr><tr><td></td><td colspan="2">enterohepatic cycling and is gradually excreted in the faeces. Plasma half-life: 22h.</td></tr><tr><td>Clinical use</td><td>Hypercholesterolaemia, usually as adjunct to a statin.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">These are few. GIT upsets may occur as may headache, rashes and myalgia.</td></tr><tr><td>Special points</td><td>Plasma concentrations are ↑by fibrates and ↓by colestyramine.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 23, p 291; D&amp;H 2e Ch 22, pp 56-57</td></tr></table>
</page>
<page number="148">
<table id="p148t1" data-filename="pdftables_fromstorage_023782248" data-page="148" data-table="1"><tr><td style="text-align: right">9.04</td><td>Colestyramine</td><td colspan="2">Atherosclerosis &amp; lipoproteins</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">Cholesterol and lipoprotein metabolism</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Endogenous pathway</td><td></td><td>ACoA</td><td></td><td></td><td colspan="2">Exogenous pathway</td><td></td><td></td></tr><tr><td colspan="2">Statins e.g. simvastatin,</td><td></td><td colspan="2">HMG-CoA reductase</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">decrease synthesis of C</td><td></td><td></td><td></td><td></td><td>Portal vein</td><td></td><td></td></tr><tr><td></td><td></td><td>Liver</td><td>MVA</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>C</td><td>Bile acids and C</td><td></td><td></td><td colspan="2">Bile acids</td></tr><tr><td>Statins and</td><td></td><td></td><td></td><td></td><td></td><td>Bile duct</td><td></td><td></td></tr><tr><td>fibrates increase</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>uptake of LDL</td><td></td><td></td><td></td><td></td><td>Endocytosis</td><td>Chylomicron</td><td></td><td></td></tr><tr><td></td><td></td><td>LDL</td><td></td><td></td><td>by liver cells</td><td>formation</td><td>C</td><td></td></tr><tr><td></td><td></td><td>receptors</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Ezetimibe</td><td></td><td>Dietary</td></tr><tr><td></td><td>Endocytosis</td><td></td><td></td><td>Fibrates</td><td></td><td>inhibits</td><td></td><td>fat</td></tr><tr><td></td><td>by liver cells</td><td></td><td></td><td>decrease</td><td></td><td>absorption</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>secretion</td><td colspan="2">of cholesterol</td><td>C +</td><td>Fatty</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>acids</td></tr><tr><td></td><td>CE</td><td>VLDL
TG &gt; CE</td><td></td><td></td><td colspan="2">Chylomicron</td><td colspan="2">+ Glycerol</td></tr><tr><td></td><td>LDL</td><td></td><td colspan="2">Fibrates</td><td>remnant</td><td></td><td></td><td></td></tr><tr><td></td><td>CE</td><td></td><td colspan="2">enhance</td><td>CE &gt; TG</td><td></td><td></td><td></td></tr><tr><td>HDL</td><td>CE</td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Intestine</td></tr><tr><td>CE</td><td></td><td></td><td></td><td></td><td colspan="2">Chylomicrons</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Lipoprotein lipase</td><td></td><td>TG &gt; CE</td><td></td><td></td></tr><tr><td>C from cell</td><td>Uptake</td><td>Free fatty</td><td></td><td>Free fatty</td><td></td><td></td><td colspan="2">Vascular endothelium</td></tr><tr><td>turnover</td><td>of C</td><td>acids</td><td></td><td>acids</td><td colspan="2">Peripheral tissues</td><td></td><td></td></tr></table>
</page>
<page number="149">
<table id="p149t1" data-filename="pdftables_fromstorage_023782248" data-page="149" data-table="1"><tr><td></td><td>A lipid-lowering drug (Similar drug: colestipol)</td><td>Colestyramine</td></tr><tr><td>Actions</td><td colspan="2">This is a bile acid binding resin whose main action is to decrease LDL cholesterol.</td></tr><tr><td>MOA</td><td colspan="2">It is a positively charged drug that binds the negatively charged bile acids inhibiting their</td></tr><tr><td></td><td colspan="2">absorption. This reduces the pool of bile acids in the liver which decreases the hepatic store of C.</td></tr><tr><td></td><td colspan="2">This in turn stimulates the synthesis of LDL receptors which results in increased uptake of LDL into</td></tr><tr><td></td><td colspan="2">liver cells. The drug also lowers C by decreasing its absorption from the GIT.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">It is given orally and is not absorbed so there are no adverse systemic effects.</td></tr><tr><td>Clinical use</td><td>Hypercholesterolaemia, often used with a statin.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances: constipation and bloating, sometimes diarrhoea.</td></tr><tr><td>Special points</td><td colspan="2">Prevents absorption of fat-soluble vitamins, statins, gemfibrozil and other drugs (e.g. digoxin,</td></tr><tr><td></td><td>thiazides, thyroxine, steroids, iron salts, folic acid).</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 23, p 290-291; D&amp;H 2e Ch 22, pp 56-57</td></tr></table>
</page>
<page number="150">
<table id="p150t1" data-filename="pdftables_fromstorage_023782248" data-page="150" data-table="1"><tr><td style="text-align: right">9.05</td><td>Nicotinic acid</td><td colspan="2">Atherosclerosis &amp; lipoproteins</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">Cholesterol and lipoprotein metabolism</td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Colestyramine,</td></tr><tr><td>Endogenous pathway</td><td></td><td>ACoA</td><td></td><td></td><td colspan="2">Exogenous pathway</td><td colspan="2">cobliensdti pbiolle  (raecisidnss)</td></tr><tr><td colspan="2">Statins e.g. simvastatin,</td><td></td><td colspan="2">HMG-CoA reductase</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">decrease synthesis of C</td><td></td><td></td><td></td><td></td><td>Portal vein</td><td></td><td></td></tr><tr><td></td><td></td><td>Liver</td><td>MVA</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>C</td><td>Bile acids and C</td><td></td><td></td><td colspan="2">Bile acids</td></tr><tr><td>Statins and</td><td></td><td></td><td></td><td></td><td></td><td>Bile duct</td><td></td><td></td></tr><tr><td>fibrates increase</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>uptake of LDL</td><td></td><td></td><td></td><td></td><td>Endocytosis</td><td>Chylomicron</td><td></td><td></td></tr><tr><td></td><td></td><td>LDL</td><td></td><td></td><td>by liver cells</td><td>formation</td><td>C</td><td></td></tr><tr><td></td><td></td><td>receptors</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Ezetimibe</td><td></td><td>Dietary</td></tr><tr><td></td><td>Endocytosis</td><td></td><td></td><td>Fibrates</td><td></td><td>inhibits</td><td></td><td>fat</td></tr><tr><td></td><td>by liver cells</td><td></td><td></td><td>decrease</td><td></td><td>absorption</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>secretion</td><td colspan="2">of cholesterol</td><td>C +</td><td>Fatty</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>acids</td></tr><tr><td></td><td>CE</td><td>VLDL
TG &gt; CE</td><td></td><td></td><td colspan="2">Chylomicron</td><td colspan="2">+ Glycerol</td></tr><tr><td></td><td>LDL</td><td></td><td colspan="2">Fibrates</td><td>remnant</td><td></td><td></td><td></td></tr><tr><td></td><td>CE</td><td></td><td colspan="2">enhance</td><td>CE &gt; TG</td><td></td><td></td><td></td></tr><tr><td>HDL</td><td>CE</td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Intestine</td></tr><tr><td>CE</td><td></td><td></td><td></td><td></td><td colspan="2">Chylomicrons</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Lipoprotein lipase</td><td></td><td>TG &gt; CE</td><td></td><td></td></tr><tr><td>C from cell</td><td>Uptake</td><td>Free fatty</td><td></td><td>Free fatty</td><td></td><td></td><td colspan="2">Vascular endothelium</td></tr><tr><td>turnover</td><td>of C</td><td>acids</td><td></td><td>acids</td><td colspan="2">Peripheral tissues</td><td></td><td></td></tr></table>
</page>
<page number="151">
<table id="p151t1" data-filename="pdftables_fromstorage_023782248" data-page="151" data-table="1"><tr><td></td><td>A vitamin (B3) that has lipid-lowering action</td><td>Nicotinic acid</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Increases HDL. Decreases plasma triglyceride synthesis and reduces the release of VLDL from the</td></tr><tr><td></td><td colspan="2">liver which results in decreased plasma triglycerides and LDL levels.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally; excreted in the urine.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">As an adjunct to a statin in dyslipidaemia, or when a statin is contraindicated.</td></tr><tr><td>Adverse effects</td><td colspan="2">Vasodilatation (with uncomfortable flushing); GIT disturbances, pruritus, rashes. Less commonly:</td></tr><tr><td></td><td colspan="2">palpitations, dyspnoea, headache, giddiness, peripheral oedema. High doses can impair liver</td></tr><tr><td></td><td>function as well as glucose tolerance and can precipitate gout.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Unwanted effects can limit its clinical use. Pretreatment with ibuprofen can reduce the flushing.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 23, pp 291-292</td></tr></table>
</page>
<page number="152">
<table id="p152t1" data-filename="pdftables_fromstorage_023782248" data-page="152" data-table="1"><tr><td style="text-align: right">9.06</td><td>Summary</td><td>Atherosclerosis &amp; lipoproteins</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">Cholesterol and lipoprotein metabolism</td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Colestyramine,</td></tr><tr><td colspan="2">Endogenous pathway</td><td>ACoA</td><td></td><td></td><td colspan="2">Exogenous pathway</td><td colspan="2">cobliensdti pbiolle  (raecisidnss)</td></tr><tr><td colspan="2">Statins e.g. simvastatin,</td><td></td><td colspan="2">HMG-CoA reductase</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">decrease synthesis of C</td><td></td><td></td><td></td><td></td><td>Portal vein</td><td></td><td></td></tr><tr><td></td><td></td><td>Liver</td><td>MVA</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>C</td><td>Bile acids and C</td><td></td><td></td><td colspan="2">Bile acids</td></tr><tr><td colspan="2">Statins and</td><td></td><td></td><td></td><td></td><td>Bile duct</td><td></td><td></td></tr><tr><td colspan="2">fibrates increase</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">uptake of LDL</td><td></td><td></td><td colspan="2">Endocytosis</td><td>Chylomicron</td><td></td><td></td></tr><tr><td></td><td></td><td>LDL</td><td></td><td colspan="2">by liver cells</td><td>formation</td><td>C</td><td></td></tr><tr><td></td><td></td><td>receptors</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Fibrates and</td><td></td><td>Ezetimibe</td><td></td><td>Dietary</td></tr><tr><td></td><td>Endocytosis</td><td></td><td></td><td>nicotinic acid</td><td></td><td>inhibits</td><td></td><td>fat</td></tr><tr><td></td><td>by liver cells</td><td></td><td></td><td>decrease</td><td></td><td>absorption</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>secretion</td><td colspan="2">of cholesterol</td><td>C +</td><td>Fatty</td></tr><tr><td></td><td>CE</td><td>TG &gt; CE</td><td></td><td></td><td colspan="2">Chylomicron</td><td colspan="2">+ Glycerol</td></tr><tr><td></td><td></td><td>LDL</td><td>Fibrates</td><td></td><td>remnant</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>CE</td><td>enhance</td><td></td><td>CE &gt; TG</td><td></td><td></td><td></td></tr><tr><td>HDL</td><td>CE</td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Intestine</td></tr><tr><td>CE</td><td></td><td></td><td></td><td></td><td colspan="2">Chylomicrons</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Lipoprotein lipase</td><td></td><td>TG &gt; CE</td><td></td><td></td></tr><tr><td>C from cell</td><td>Uptake</td><td>Free fatty</td><td></td><td>Free fatty</td><td></td><td></td><td colspan="2">Vascular endothelium</td></tr><tr><td>turnover</td><td>of C</td><td>acids</td><td></td><td>acids</td><td colspan="2">Peripheral tissues</td><td></td><td></td></tr></table>
</page>
<page number="153">
<table id="p153t1" data-filename="pdftables_fromstorage_023782248" data-page="153" data-table="1"><tr><td>Notes</td></tr><tr><td>Notes</td></tr></table>
</page>
<page number="154">
<table id="p154t1" data-filename="pdftables_fromstorage_023782248" data-page="154" data-table="1"><tr><td style="text-align: right">10.01</td><td>Aspirin</td><td>Thrombosis</td><td></td><td></td><td></td></tr><tr><td colspan="6">The basic processes involved in the formation of a thrombus and its dissolution by fibrinolysis</td></tr><tr><td colspan="3">Aggregation involves, inter</td><td>AtherosclerotiPcla pqluae qruupeture</td><td></td><td>Thrombus</td></tr><tr><td colspan="3">alia, linking of platelets by</td><td></td><td></td><td></td></tr><tr><td colspan="3">fibrinogen binding to</td><td></td><td></td><td></td></tr><tr><td colspan="2">platelet GPIIb/GPIIIa</td><td></td><td>Platelet</td><td>Activation of</td><td></td></tr><tr><td colspan="2">receptors (GP,</td><td></td><td>adhesion</td><td>clotting factors,</td><td></td></tr><tr><td colspan="2">glycoprotein)</td><td></td><td>activation</td><td>tissue factor,</td><td></td></tr><tr><td></td><td></td><td></td><td>aggregation</td><td>XIIa, Xa, IIa, etc.</td><td></td></tr><tr><td></td><td></td><td></td><td>Trapped</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>blood</td><td>FIBRIN forms the</td><td></td></tr><tr><td></td><td></td><td></td><td>cells</td><td>framework of the</td><td>Fibrin</td></tr><tr><td></td><td></td><td></td><td></td><td>THROMBUS</td><td>degradation</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>products</td></tr><tr><td></td><td></td><td></td><td>Plasminogen</td><td>Plasmin</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Plasminogen</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>activator</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Artery wall</td></tr></table>
</page>
<page number="155">
<table id="p155t1" data-filename="pdftables_fromstorage_023782248" data-page="155" data-table="1"><tr><td></td><td colspan="2">A non-steroidal drug with antithrombotic and anti-inflammatory properties</td><td>Aspirin</td></tr><tr><td></td><td></td><td>Arachidonate</td><td></td></tr><tr><td>Actions</td><td>Antiplatelet (also analgesic and anti-inflammatory).</td><td></td><td></td></tr><tr><td></td><td></td><td>ASPIRIN</td><td>COX-1</td></tr><tr><td>MOA</td><td>Irreversibly inactivates (COX-1); alters balance between</td><td colspan="2">Cyclic endoperoxides</td></tr><tr><td></td><td>TXA2 and PGI2 in the platelet/vascular endothelium axis.</td><td></td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Given orally in small doses. Excretion in urine, increased</td><td>inPhiGbIi2t:or</td><td>TXA2:</td></tr><tr><td></td><td>if urine is alkalinised.</td><td>of platelet</td><td>thrombotic,</td></tr><tr><td></td><td></td><td>aggregation</td><td>aggregator</td></tr><tr><td>Clinical use</td><td colspan="3">To reduce risk of myocardial infarction or transient ischaemic attacks; intermittent small doses</td></tr><tr><td>in the context</td><td colspan="3">given orally decrease platelet TXA2 without significantly reducing endothelial PGI2 . Also used to</td></tr><tr><td>of thrombosis</td><td>treat acute stroke.</td><td></td><td></td></tr><tr><td>Adverse effects</td><td colspan="3">Gastrointestinal bleeding because the cytoprotective action of PGs (namely ↓ acid secretion,</td></tr><tr><td></td><td colspan="3">↑ mucus &amp; bicarbonate) is decreased; bronchospasm in some individuals. Toxic doses cause</td></tr><tr><td></td><td>respiratory alkalosis followed by acidosis.</td><td></td><td></td></tr><tr><td>Special points</td><td colspan="2">Interactions: effects increased by anticoagulants &amp; thrombolytic drugs.</td><td></td></tr><tr><td></td><td></td><td colspan="2">R&amp;D 7e Ch 24, pp 302-304; D&amp;H 2e Ch 23, pp 58-59</td></tr></table>
</page>
<page number="156">
<table id="p156t1" data-filename="pdftables_fromstorage_023782248" data-page="156" data-table="1"><tr><td style="text-align: right">10.02</td><td>Clopidogrel</td><td>Thrombosis</td><td></td><td></td><td></td></tr><tr><td colspan="6">The basic processes involved in the formation of a thrombus and its dissolution by fibrinolysis</td></tr><tr><td colspan="2">Aggregation involves, inter</td><td></td><td>AtherosclerotiPcla pqluae qruupeture</td><td></td><td>Thrombus</td></tr><tr><td colspan="2">alia, linking of platelets by</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">fibrinogen binding to</td><td></td><td></td><td></td><td></td></tr><tr><td>platelet GPIIb/GPIIIa</td><td></td><td></td><td>Platelet</td><td>Activation of</td><td></td></tr><tr><td>receptors (GP,</td><td></td><td></td><td>adhesion</td><td>clotting factors,</td><td></td></tr><tr><td>glycoprotein)</td><td></td><td>-–</td><td>activation</td><td>tissue factor,</td><td></td></tr><tr><td></td><td>Antiplatelet</td><td></td><td>aggregation</td><td>XIIa, Xa, IIa, etc.</td><td></td></tr><tr><td></td><td>agents:</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>aspirin</td><td></td><td>Trapped</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>blood</td><td>FIBRIN forms the</td><td></td></tr><tr><td></td><td></td><td></td><td>cells</td><td>framework of the</td><td>Fibrin</td></tr><tr><td></td><td></td><td></td><td></td><td>THROMBUS</td><td>degradation</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>products</td></tr><tr><td></td><td></td><td></td><td>Plasminogen</td><td>Plasmin</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Plasminogen</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>activator</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Artery wall</td></tr></table>
</page>
<page number="157">
<table id="p157t1" data-filename="pdftables_fromstorage_023782248" data-page="157" data-table="1"><tr><td></td><td></td><td>An antiplatelet antithrombotic drug</td><td colspan="2">Clopidogrel</td></tr><tr><td>Actions</td><td>It prevents platelet activation.</td><td></td><td></td><td></td></tr><tr><td>MOA</td><td colspan="4">It irreversibly inhibits the binding of ADP to the purine receptor on platelets thus inhibiting ADP-</td></tr><tr><td></td><td colspan="4">mediated platelet activation and interfering with GpIIb/IIIa-mediated platelet aggregation.</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="4">Given orally, loading dose first then once daily. Metabolised to an active compound.</td></tr><tr><td></td><td colspan="4">Because action is irreversible, the effects last several days until platelets are replaced.</td></tr><tr><td>Clinical use</td><td colspan="4">Prevention &amp; treatment of myocardial infarction &amp; other vascular disorders. Often given with aspirin.</td></tr><tr><td>Adverse effects</td><td colspan="3">Unwanted effects: bleeding; GIT discomfort; rashes. Rarely neutropaenia.</td><td></td></tr><tr><td>Special points</td><td colspan="4">Effects ↑ by other antithrombotic drugs. Interactions: inhibits metabolism of NSAIDs, phenytoin.</td></tr><tr><td>Platelets, activated</td><td colspan="3">Clopidogrel selectively blocks ADP receptors</td><td></td></tr><tr><td>by adherence,</td><td></td><td></td><td></td><td></td></tr><tr><td>release</td><td>ADP</td><td>ADP</td><td>ADP</td><td>IIb/IIIa</td></tr><tr><td>ADP, 5-HT, TXA2</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">ADP acts on ADP receptors in other platelets activating them to express GP IIb/IIIa receptors</td></tr><tr><td></td><td></td><td></td><td colspan="2">R&amp;D 7e Ch 24, pp 304-305; D&amp;H 2e Ch 23, pp 58-59</td></tr></table>
</page>
<page number="158">
<table id="p158t1" data-filename="pdftables_fromstorage_023782248" data-page="158" data-table="1"><tr><td style="text-align: right">10.03</td><td>Abciximab</td><td>Thrombosis</td><td></td><td></td><td></td></tr><tr><td colspan="6">The basic processes involved in the formation of a thrombus and its dissolution by fibrinolysis</td></tr><tr><td colspan="2">Aggregation involves, inter</td><td></td><td>AtherosclerotiPcla pqluae qruupeture</td><td></td><td>Thrombus</td></tr><tr><td colspan="2">alia, linking of platelets by</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">fibrinogen binding to</td><td></td><td></td><td></td><td></td></tr><tr><td>platelet GPIIb/GPIIIa</td><td></td><td></td><td>Platelet</td><td>Activation of</td><td></td></tr><tr><td>receptors (GP,</td><td></td><td></td><td>adhesion</td><td>clotting factors,</td><td></td></tr><tr><td>glycoprotein)</td><td></td><td>-–</td><td>activation</td><td>tissue factor,</td><td></td></tr><tr><td></td><td>Antiplatelet</td><td></td><td>aggregation</td><td>XIIa, Xa, IIa, etc.</td><td></td></tr><tr><td></td><td>agents:</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>aspirin,</td><td></td><td>Trapped</td><td></td><td></td></tr><tr><td></td><td>clopidogrel</td><td></td><td>blood</td><td>FIBRIN forms the</td><td></td></tr><tr><td></td><td></td><td></td><td>cells</td><td>framework of the</td><td>Fibrin</td></tr><tr><td></td><td></td><td></td><td></td><td>THROMBUS</td><td>degradation</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>products</td></tr><tr><td></td><td></td><td></td><td>Plasminogen</td><td>Plasmin</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Plasminogen</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>activator</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Artery wall</td></tr></table>
</page>
<page number="159">
<table id="p159t1" data-filename="pdftables_fromstorage_023782248" data-page="159" data-table="1"><tr><td></td><td></td><td></td><td colspan="3">An antiplatelet antithrombotic drug</td><td>Abciximab</td></tr><tr><td>Actions</td><td colspan="2">It inhibits platelet activation.</td><td></td><td></td><td></td><td></td></tr><tr><td>MOA</td><td colspan="6">Abciximab is a monoclonal antibody Fab fragment against the platelet GP IIb/IIIa receptor. It binds</td></tr><tr><td></td><td colspan="6">and inactivates the receptor preventing the binding of fibrinogen thus inhibiting platelet aggregation.</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Given by i.v. injection. Half life 10–30min.</td><td></td><td></td><td></td><td></td></tr><tr><td>Clinical use</td><td colspan="6">Adjunct to heparin and aspirin in high-risk patients undergoing coronary angioplasty (an operation to</td></tr><tr><td></td><td colspan="5">unblock coronary artery). Prevents restenosis and reinfarction.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Bleeding; thrombocytopaenia.</td><td></td><td></td><td></td><td></td></tr><tr><td>Special points</td><td colspan="6">For specialist use. Used just once because of immunogenicity. Drug with similar action: eptifibatide,</td></tr><tr><td></td><td colspan="4">a peptide sequence from a GPIIb/IIIa receptor ligand.</td><td></td><td></td></tr><tr><td></td><td colspan="2">Clopidogrel selectively blocks ADP receptors</td><td></td><td colspan="3">Abciximab, eptifibatide block GP IIB/IIIa</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="3">receptors preventing fibrinogen binding</td></tr><tr><td>Activated</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>platelets</td><td>ADP</td><td>ADP</td><td>ADP</td><td>IIb/IIIa</td><td>Fibrinogen</td><td>IIb/IIIa</td></tr><tr><td>release ADP</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7">ADP acts on ADP receptors in other platelets activating them to express GP IIb/IIIa receptors for fibrinogen</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">R&amp;D 7e Ch 24, p 305; D&amp;H 2e Ch 23, pp 58-59</td></tr></table>
</page>
<page number="160">
<table id="p160t1" data-filename="pdftables_fromstorage_023782248" data-page="160" data-table="1"><tr><td style="text-align: right">10.04</td><td>Dipyridamole</td><td>Thrombosis</td><td></td><td></td><td></td></tr><tr><td colspan="6">The basic processes involved in the formation of a thrombus and its dissolution by fibrinolysis</td></tr><tr><td colspan="2">Aggregation involves, inter</td><td></td><td>AtherosclerotiPcla pqluae qruupeture</td><td></td><td>Thrombus</td></tr><tr><td colspan="2">alia, linking of platelets by</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">fibrinogen binding to</td><td></td><td></td><td></td><td></td></tr><tr><td>platelet GPIIb/GPIIIa</td><td></td><td></td><td>Platelet</td><td>Activation of</td><td></td></tr><tr><td>receptors (GP,</td><td></td><td></td><td>adhesion</td><td>clotting factors,</td><td></td></tr><tr><td>glycoprotein)</td><td></td><td>-–</td><td>activation</td><td>tissue factor,</td><td></td></tr><tr><td></td><td>Antiplatelet</td><td></td><td>aggregation</td><td>XIIa, Xa, IIa, etc.</td><td></td></tr><tr><td></td><td>agents:</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>aspirin,</td><td></td><td>Trapped</td><td></td><td></td></tr><tr><td></td><td>clopidogrel,</td><td></td><td>blood</td><td>FIBRIN forms the</td><td></td></tr><tr><td></td><td>abciximab</td><td></td><td>cells</td><td>framework of the</td><td>Fibrin</td></tr><tr><td></td><td></td><td></td><td></td><td>THROMBUS</td><td>degradation</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>products</td></tr><tr><td></td><td></td><td></td><td>Plasminogen</td><td>Plasmin</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Plasminogen</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>activator</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Artery wall</td></tr></table>
</page>
<page number="161">
<table id="p161t1" data-filename="pdftables_fromstorage_023782248" data-page="161" data-table="1"><tr><td></td><td>An antiplatelet antithrombotic drug</td><td>Dipyridamole</td></tr><tr><td>Actions</td><td>It inhibits platelet aggregation.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Has vasodilator activity; prevents platelet adenosine uptake &amp; cyclic GMP phosphodiesterase action.</td></tr><tr><td>Abs/Distrib/Elim</td><td>Given orally, usually as a modified release preparation.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Used with aspirin for secondary prevention of ischaemic stroke &amp; transient ischaemic attacks.</td></tr><tr><td>Adverse effects</td><td colspan="2">Headache (common); GIT disturbances; hypotension, hypersensitivity reactions.</td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 24, p 304; D&amp;H 2e Ch 23, pp 58-59</td></tr></table>
</page>
<page number="162">
<table id="p162t1" data-filename="pdftables_fromstorage_023782248" data-page="162" data-table="1"><tr><td style="text-align: right">10.05</td><td>Alteplase</td><td>Thrombosis</td><td></td><td></td><td></td></tr><tr><td colspan="6">The basic processes involved in the formation of a thrombus and its dissolution by fibrinolysis</td></tr><tr><td colspan="2">Aggregation involves, inter</td><td></td><td>AtherosclerotiPcla pqluae qruupeture</td><td></td><td>Thrombus</td></tr><tr><td colspan="2">alia, linking of platelets by</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">fibrinogen binding to</td><td></td><td></td><td></td><td></td></tr><tr><td>platelet GPIIb/GPIIIa</td><td></td><td></td><td>Platelet</td><td>Activation of</td><td></td></tr><tr><td>receptors (GP,</td><td></td><td></td><td>adhesion</td><td>clotting factors,</td><td></td></tr><tr><td>glycoprotein)</td><td></td><td>-–</td><td>activation</td><td>tissue factor,</td><td></td></tr><tr><td></td><td>Antiplatelet</td><td></td><td>aggregation</td><td>XIIa, Xa, IIa, etc.</td><td></td></tr><tr><td></td><td>agents:</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>aspirin,</td><td></td><td>Trapped</td><td></td><td></td></tr><tr><td></td><td>clopidogrel,</td><td></td><td>blood</td><td>FIBRIN forms the</td><td></td></tr><tr><td></td><td>abciximab,</td><td></td><td>cells</td><td>framework of the</td><td>Fibrin</td></tr><tr><td></td><td>dipyridamole</td><td></td><td></td><td>THROMBUS</td><td>degradation</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>products</td></tr><tr><td></td><td></td><td></td><td>Plasminogen</td><td>Plasmin</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Plasminogen</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>activator</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Artery wall</td></tr></table>
</page>
<page number="163">
<table id="p163t1" data-filename="pdftables_fromstorage_023782248" data-page="163" data-table="1"><tr><td></td><td>A thrombolytic drug</td><td>Alteplase</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">It enzymically activates plasminogen to give plasmin which digests fibrin &amp; fibrinogen, lysing the clot.</td></tr><tr><td>Abs/Distrib/Elim</td><td>Given by i.v. injection or infusion; short half-life.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Myocardial infarction, deep vein thrombosis, pulmonary embolism, acute ischaemic stroke.</td></tr><tr><td>Adverse effects</td><td colspan="2">Bleeding (most important), reperfusion dysrhythmias, nausea &amp; vomiting, hypersensitivity reactions.</td></tr><tr><td>Special points</td><td colspan="2">It needs to be given within 12 hours of the onset of the condition, preferably within 1 hour.</td></tr><tr><td>Similar drug</td><td>Reteplase (long half-life).</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 24, p 307; D&amp;H 2e Ch 23, pp 58-59</td></tr></table>
</page>
<page number="164">
<table id="p164t1" data-filename="pdftables_fromstorage_023782248" data-page="164" data-table="1"><tr><td style="text-align: right">10.06</td><td>Tranexamic acid</td><td>Thrombosis</td><td></td><td></td><td></td></tr><tr><td colspan="6">The basic processes involved in the formation of a thrombus and its dissolution by fibrinolysis</td></tr><tr><td colspan="2">Aggregation involves, inter</td><td></td><td colspan="2">AtherosclerotiPcla pqluae qruupeture</td><td>Thrombus</td></tr><tr><td colspan="2">alia, linking of platelets by</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">fibrinogen binding to</td><td></td><td></td><td></td><td></td></tr><tr><td>platelet GPIIb/GPIIIa</td><td></td><td></td><td>Platelet</td><td>Activation of</td><td></td></tr><tr><td>receptors (GP,</td><td></td><td></td><td>adhesion</td><td>clotting factors,</td><td></td></tr><tr><td>glycoprotein)</td><td></td><td>-–</td><td>activation</td><td>tissue factor,</td><td></td></tr><tr><td></td><td>Antiplatelet</td><td></td><td>aggregation</td><td>XIIa, Xa, IIa, etc.</td><td></td></tr><tr><td></td><td>agents:</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>aspirin,</td><td></td><td>Trapped</td><td></td><td></td></tr><tr><td></td><td>clopidogrel,</td><td></td><td>blood</td><td>FIBRIN forms the</td><td></td></tr><tr><td></td><td>abciximab,</td><td></td><td>cells</td><td>framework of the</td><td>Fibrin</td></tr><tr><td></td><td>dipyridamole</td><td></td><td></td><td>THROMBUS</td><td>degradation</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>products</td></tr><tr><td></td><td colspan="2">Fibrinolytic</td><td style="text-align: right">+-</td><td></td><td></td></tr><tr><td></td><td colspan="2">Agents</td><td></td><td>Plasminogen</td><td>Plasmin</td></tr><tr><td></td><td colspan="2">alteplase,</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">reteplase</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Plasminogen</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>activator</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Artery wall</td></tr></table>
</page>
<page number="165">
<table id="p165t1" data-filename="pdftables_fromstorage_023782248" data-page="165" data-table="1"><tr><td></td><td>An antifibrinolytic agent</td><td>Tranexamic acid</td></tr><tr><td>Actions &amp; MOA</td><td>It inhibits plasminogen activation and thus prevents fibrinolysis.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Given orally and by i.v. injection or infusion.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">To reduce haemorrhage following dental extraction or prostatectomy. For menorrhagia, epistaxis,</td></tr><tr><td></td><td>hereditary angioedema, thrombolytic overdose.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances. Rare: hypersensitivity skin reactions, disturbed colour vision.</td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 24, p 307; D&amp;H 2e Ch 23, pp 58-59</td></tr></table>
</page>
<page number="166">
<table id="p166t1" data-filename="pdftables_fromstorage_023782248" data-page="166" data-table="1"><tr><td style="text-align: right">10.07</td><td>Heparin</td><td>Thrombosis</td><td></td><td></td><td></td></tr><tr><td colspan="6">The basic processes involved in the formation of a thrombus and its dissolution by fibrinolysis</td></tr><tr><td colspan="2">Aggregation involves, inter</td><td></td><td colspan="2">AtherosclerotiPcla pqluae qruupeture</td><td>Thrombus</td></tr><tr><td colspan="2">alia, linking of platelets by</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">fibrinogen binding to</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">platelet GPIIb/GPIIIa</td><td></td><td>Platelet</td><td>Activation of</td><td></td></tr><tr><td>receptors (GP,</td><td></td><td></td><td>adhesion</td><td>clotting factors,</td><td></td></tr><tr><td>glycoprotein)</td><td></td><td>-–</td><td>activation</td><td>tissue factor,</td><td></td></tr><tr><td></td><td></td><td>Antiplatelet</td><td>aggregation</td><td>XIIa, Xa, IIa, etc.</td><td></td></tr><tr><td></td><td></td><td>agents:</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>aspirin,</td><td>Trapped</td><td></td><td></td></tr><tr><td></td><td></td><td>clopidogrel,</td><td>blood</td><td>FIBRIN forms the</td><td></td></tr><tr><td></td><td></td><td>abciximab,</td><td>cells</td><td>framework of the</td><td>Fibrin</td></tr><tr><td></td><td>dipyridamole</td><td></td><td></td><td>THROMBUS</td><td>degradation</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>products</td></tr><tr><td></td><td></td><td>Fibrinolytic</td><td style="text-align: right">+-</td><td></td><td></td></tr><tr><td></td><td></td><td>Agents</td><td></td><td>Plasminogen</td><td>Plasmin</td></tr><tr><td></td><td></td><td>alteplase,</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>reteplase</td><td></td><td>-–</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Plasminogen</td></tr><tr><td></td><td></td><td></td><td>Antifibrinolytic agent</td><td></td><td>activator</td></tr><tr><td></td><td></td><td></td><td>tranexamic acid</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Artery wall</td></tr></table>
</page>
<page number="167">
<table id="p167t1" data-filename="pdftables_fromstorage_023782248" data-page="167" data-table="1"><tr><td></td><td></td><td>An injectable anticoagulant</td><td>Heparin</td><td></td></tr><tr><td>Action</td><td>It inhibits blood coagulation.</td><td>BLOOD COAGULATION</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="3">Atherosclerotic plaque or damaged endothelium</td></tr><tr><td>MOA</td><td>Accelerates action of antithrombin III (ATIII)</td><td>The in vivo</td><td colspan="2">The in vitro</td></tr><tr><td></td><td>increasing its inactivation mainly of factors IIa</td><td>pathway</td><td colspan="2">contact system</td></tr><tr><td></td><td>(thrombin) &amp; Xa; also affects IXa, XIa, &amp; XIIa.</td><td>VIIa</td><td></td><td>XIIa</td></tr><tr><td></td><td></td><td></td><td></td><td>Heparin</td></tr><tr><td></td><td></td><td></td><td></td><td>XIa</td></tr><tr><td></td><td></td><td>(tissue</td><td></td><td>+ ATIII</td></tr><tr><td></td><td></td><td>factor)</td><td></td><td>IXa</td></tr><tr><td>Abs/Distrib/Elim</td><td>Given by subcut. or by i.v. injection. Elimination</td><td></td><td></td><td></td></tr><tr><td></td><td>half-life 40–90min; renal excretion.</td><td>Factor X</td><td></td><td>Xa</td></tr><tr><td></td><td></td><td>Ca 2+ + Factor Va</td><td></td><td></td></tr><tr><td></td><td></td><td>+ phospholipid</td><td></td><td></td></tr><tr><td>Clinical use</td><td>To treat deep vein thrombosis, pulmonary</td><td>(proFtahcrtoorm IIbin)</td><td></td><td>IIa (thrombin)</td></tr><tr><td></td><td>embolism, unstable angina, acute peripheral</td><td></td><td></td><td></td></tr><tr><td></td><td>arterial occlusion.</td><td>Fibrinogen</td><td colspan="2">FIBRIN</td></tr><tr><td></td><td></td><td>a = activated</td><td></td><td></td></tr><tr><td>Adverse effects</td><td colspan="4">Main adverse effect: bleeding. Thrombocytopaenia, hypersensitivity reactions, osteoporosis.</td></tr><tr><td>Special points</td><td colspan="4">Dosage is adjusted according to the activated partial thromboplastin time. Overdose treated with</td></tr><tr><td></td><td>protamine sulfate.</td><td></td><td></td><td></td></tr><tr><td>Similar drugs</td><td>Low molecular weight heparins.</td><td colspan="3">R&amp;D 7e Ch 24, pp 298-300; D&amp;H 2e Ch 23, pp 58-59</td></tr></table>
</page>
<page number="168">
<table id="p168t1" data-filename="pdftables_fromstorage_023782248" data-page="168" data-table="1"><tr><td style="text-align: right">10.08</td><td>Enoxaparin</td><td>Thrombosis</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7">The basic processes involved in the formation of a thrombus and its dissolution by fibrinolysis</td></tr><tr><td colspan="2">Aggregation involves, inter</td><td></td><td colspan="2">AtherosclerotiPcla pqluae qruupeture</td><td></td><td>Thrombus</td></tr><tr><td colspan="2">alia, linking of platelets by</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">fibrinogen binding to</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>platelet GPIIb/GPIIIa</td><td></td><td></td><td>Platelet</td><td>Activation of</td><td>-–</td><td>An</td></tr><tr><td>receptors (GP,</td><td></td><td></td><td>adhesion</td><td>clotting factors,</td><td></td><td>tic</td></tr><tr><td>glycoprotein)</td><td></td><td>-–</td><td>activation</td><td>tissue factor,</td><td></td><td>he</td></tr><tr><td></td><td>Antiplatelet</td><td></td><td>aggregation</td><td>XIIa, Xa, IIa, etc.</td><td></td><td></td></tr><tr><td></td><td>agents:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>aspirin,</td><td></td><td>Trapped</td><td></td><td></td><td></td></tr><tr><td></td><td>clopidogrel,</td><td></td><td>blood</td><td>FIBRIN forms the</td><td></td><td></td></tr><tr><td></td><td>abciximab,</td><td></td><td>cells</td><td>framework of the</td><td></td><td>Fibrin</td></tr><tr><td></td><td>dipyridamole</td><td></td><td></td><td>THROMBUS</td><td></td><td>degradation</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>products</td></tr><tr><td></td><td></td><td>Fibrinolytic</td><td style="text-align: right">+-</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Agents</td><td></td><td>Plasminogen</td><td>Plasmin</td><td></td></tr><tr><td></td><td></td><td>alteplase,</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>reteplase</td><td></td><td>-–</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Plasminogen</td><td></td></tr><tr><td></td><td></td><td></td><td>Antifibrinolytic agent</td><td></td><td>activator</td><td></td></tr><tr><td></td><td></td><td></td><td>tranexamic acid</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Artery wall</td></tr></table>
</page>
<page number="169">
<table id="p169t1" data-filename="pdftables_fromstorage_023782248" data-page="169" data-table="1"><tr><td></td><td colspan="3">An injectable anticoagulant; a low molecular weight heparin</td><td>Enoxaparin</td><td></td></tr><tr><td>Action</td><td>It inhibits blood coagulation.</td><td colspan="2">BLOOD COAGULATION</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="3">Atherosclerotic plaque or damaged endothelium</td><td></td></tr><tr><td>MOA</td><td>Accelerates action of antithrombin III (ATIII)</td><td>The in vivo</td><td></td><td></td><td>The in vitro</td></tr><tr><td></td><td>increasing its inactivation of Factor Xa.</td><td>pathway</td><td></td><td></td><td>contact system</td></tr><tr><td></td><td></td><td></td><td></td><td>XIIa</td><td></td></tr><tr><td></td><td></td><td></td><td>VIIa</td><td></td><td>Heparin</td></tr><tr><td></td><td></td><td></td><td></td><td>XIa</td><td></td></tr><tr><td></td><td></td><td></td><td>(tissue</td><td></td><td>+ ATIII</td></tr><tr><td>Abs/Distrib/Elim</td><td>Given by subcut. injection. Elimination half-life</td><td></td><td>factor)</td><td>IXa</td><td></td></tr><tr><td></td><td>130–180 min; renal excretion.</td><td>Factor X</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Ca 2+ + Factor Va</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">+ phospholipid</td><td></td><td></td></tr><tr><td>Clinical use</td><td>To prevent venous thromboembolism.</td><td></td><td></td><td></td><td>Enoxaparin</td></tr><tr><td></td><td>To treat deep vein thrombosis, pulmonary</td><td>Factor II</td><td></td><td></td><td>IIa (thrombin)</td></tr><tr><td></td><td>embolism, myocardial infarction, unstable</td><td colspan="2">(prothrombin)</td><td></td><td></td></tr><tr><td></td><td>angina.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Fibrinogen</td><td>FIBRIN</td></tr><tr><td></td><td></td><td>a = activated</td><td></td><td></td><td></td></tr><tr><td>Adverse effects</td><td colspan="5">Main adverse effect: bleeding. Less likely than heparin to cause thrombocytopaenia, hypersensitivity</td></tr><tr><td></td><td>reactions, osteoporosis.</td><td></td><td></td><td></td><td></td></tr><tr><td>Special points</td><td colspan="5">No need to monitor the activated partial thromboplastin time. Overdose treated with protamine</td></tr><tr><td></td><td>sulfate.</td><td></td><td></td><td></td><td></td></tr><tr><td>Similar drugs</td><td colspan="2">Other low molecular weight heparins: e.g. bemiparin, dalteparin.</td><td colspan="3">R&amp;D 7e Ch 24, p 299; D&amp;H 2e Ch 23, pp 58-59</td></tr></table>
</page>
<page number="170">
<table id="p170t1" data-filename="pdftables_fromstorage_023782248" data-page="170" data-table="1"><tr><td style="text-align: right">10.09</td><td>Warfarin</td><td>Thrombosis</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7">The basic processes involved in the formation of a thrombus and its dissolution by fibrinolysis</td></tr><tr><td colspan="2">Aggregation involves, inter</td><td></td><td colspan="2">AtherosclerotiPcla pqluae qruupeture</td><td></td><td>Thrombus</td></tr><tr><td colspan="2">alia, linking of platelets by</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">fibrinogen binding to</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>platelet GPIIb/GPIIIa</td><td></td><td></td><td>Platelet</td><td>Activation of</td><td>-–</td><td>An</td></tr><tr><td>receptors (GP,</td><td></td><td></td><td>adhesion</td><td>clotting factors,</td><td></td><td>t ic</td></tr><tr><td>glycoprotein)</td><td></td><td>-–</td><td>activation</td><td>tissue factor,</td><td></td><td>eno xhep</td></tr><tr><td></td><td>Antiplatelet</td><td></td><td>aggregation</td><td>XIIa, Xa, IIa, etc.</td><td></td><td></td></tr><tr><td></td><td></td><td>agents:</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>aspirin,</td><td>Trapped</td><td></td><td></td><td></td></tr><tr><td></td><td>clopidogrel,</td><td></td><td>blood</td><td>FIBRIN forms the</td><td></td><td></td></tr><tr><td></td><td>abciximab,</td><td></td><td>cells</td><td>framework of the</td><td></td><td>Fibrin</td></tr><tr><td></td><td>dipyridamole</td><td></td><td></td><td>THROMBUS</td><td></td><td>degradation</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>products</td></tr><tr><td></td><td></td><td>Fibrinolytic</td><td style="text-align: right">+-</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Agents</td><td></td><td>Plasminogen</td><td>Plasmin</td><td></td></tr><tr><td></td><td></td><td>alteplase,</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>reteplase</td><td></td><td>-–</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Plasminogen</td><td></td></tr><tr><td></td><td></td><td></td><td>Antifibrinolytic agent</td><td></td><td>activator</td><td></td></tr><tr><td></td><td></td><td></td><td>tranexamic acid</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Artery wall</td></tr></table>
</page>
<page number="171">
<table id="p171t1" data-filename="pdftables_fromstorage_023782248" data-page="171" data-table="1"><tr><td></td><td></td><td></td><td></td><td>An oral anticoagulant</td><td>Warfarin</td><td></td></tr><tr><td>Action</td><td colspan="2">It inhibits blood coagulation.</td><td></td><td colspan="2">BLOOD COAGULATION</td><td></td></tr><tr><td>MOA</td><td colspan="3">Inhibits the reduction of vitamin K and thus prevents</td><td colspan="3">Atherosclerotic plaque or damaged endothelium</td></tr><tr><td></td><td colspan="3">the γ-carboxylation of the glutamate residues in</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="3">factors II, VII, IX &amp; X – shown in red in the figure.</td><td>The in vivo</td><td></td><td>The in vitro</td></tr><tr><td></td><td></td><td></td><td></td><td>pathway</td><td></td><td>contact system</td></tr><tr><td>Glutamic acid</td><td></td><td></td><td>γ-Carboxyglutamic acid</td><td></td><td>VIIa</td><td>XIIa</td></tr><tr><td></td><td>O2</td><td>CO2</td><td></td><td></td><td></td><td>XIa</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>(tissue</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>factor)</td><td>IXa</td></tr><tr><td colspan="2">Vit. K (hydroquinone)</td><td></td><td>Vit. K (epoxide)</td><td>Factor X</td><td></td><td>Xa</td></tr><tr><td colspan="2">Vit. K reductase</td><td>Vit. K (quinone)</td><td>Vit. K reductase</td><td colspan="2">C+a  p2h+ o+s pFhacotliopri dVa</td><td></td></tr><tr><td>Warfarin</td><td></td><td></td><td>Warfarin</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Factor II</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>IIa (thrombin)</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">(prothrombin)</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="3">Given orally. Onset slow because the circulating</td><td></td><td>Fibrinogen</td><td>FIBRIN</td></tr><tr><td></td><td colspan="2">γ-carboxylated factors have to be degraded.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>a = activated</td><td></td><td></td></tr><tr><td>Clinical use</td><td colspan="6">To treat deep vein thrombosis, pulmonary embolism. To prevent embolisation in atrial fibrillation.</td></tr><tr><td>Adverse effects</td><td colspan="6">Bleeding; treated by giving natural Vit K or fresh plasma or coagulation factor concentrates.</td></tr><tr><td>Special points</td><td colspan="6">Prothrombin time must be monitored. Action increased (with ↑ risk of bleeding) by many drugs e.g.</td></tr><tr><td></td><td colspan="6">ciprofloxacin, aspirin. Action decreased (with ↓ risk of clotting) by many drugs e.g. rifampicin.</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="3">R&amp;D 7e Ch 24, pp 300-301; D&amp;H 2e Ch 23, pp 58-59</td></tr></table>
</page>
<page number="172">
<table id="p172t1" data-filename="pdftables_fromstorage_023782248" data-page="172" data-table="1"><tr><td style="text-align: right">10.10</td><td>Thrombosis</td><td colspan="6">Anticoagulants are used mainly for thromboembolism in ... ? ... vessels because ... ... ?</td><td></td></tr><tr><td></td><td></td><td colspan="6">Antiplatelet drugs are used mainly for thromboembolism in ... ? ... because ... ... ?</td><td></td></tr><tr><td colspan="9">The basic processes involved in the formation of a thrombus and its dissolution by fibrinolysis</td></tr><tr><td colspan="2">Aggregation involves, inter</td><td></td><td colspan="2">AtherosclerotiPcla pqluae qruupeture</td><td></td><td></td><td colspan="2">Thrombus</td></tr><tr><td colspan="2">alia, linking of platelets by</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">fibrinogen binding to</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>platelet GPIIb/GPIIIa</td><td></td><td></td><td>Platelet</td><td>Activation of</td><td>-–</td><td>he</td><td colspan="2">An</td></tr><tr><td>receptors (GP,</td><td></td><td></td><td>adhesion</td><td>clotting factors,</td><td></td><td></td><td>parin</td><td>tic</td></tr><tr><td>glycoprotein)</td><td></td><td>-–</td><td>activation</td><td>tissue factor,</td><td></td><td colspan="2">wa ,r</td><td></td></tr><tr><td></td><td>Antiplatelet</td><td></td><td>aggregation</td><td>XIIa, Xa, IIa, etc.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>agents:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>aspirin,</td><td></td><td>Trapped</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>clopidogrel,</td><td></td><td>blood</td><td>FIBRIN forms the</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>abciximab,</td><td></td><td>cells</td><td>framework of the</td><td></td><td colspan="2">Fibrin</td><td></td></tr><tr><td></td><td>dipyridamole</td><td></td><td></td><td>THROMBUS</td><td></td><td colspan="3">degradation</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">products</td></tr><tr><td></td><td></td><td>Fibrinolytic</td><td style="text-align: right">+-</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Agents</td><td></td><td>Plasminogen</td><td>Plasmin</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>alteplase,</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>reteplase</td><td></td><td>-–</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Plasminogen</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Antifibrinolytic agent</td><td></td><td>activator</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>tranexamic acid</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">Artery wall</td></tr></table>
</page>
<page number="173">
<table id="p173t1" data-filename="pdftables_fromstorage_023782248" data-page="173" data-table="1"><tr><td>Simplified summary of the main differences between anticoagulants and antiplatelet agents.</td></tr><tr><td>The diagram used on the front faces of this set of cards was a schematic diagram of an arterial thrombus showing</td></tr><tr><td>– for simplicity – both platelet aggregation/activation and blood coagulation contributing to the thrombus.</td></tr><tr><td>Anticoagulants (e.g. warfarin, heparin, low molecular weight heparins which modify blood coagulation</td></tr><tr><td>and inhibit the formation of fibrin) are used mainly for thromboembolism in veins because venous thrombi</td></tr><tr><td>consist largely of a fibrin mesh with platelets and blood cells trapped inside it.</td></tr><tr><td>Antiplatelet drugs (e.g. aspirin, clopidogrel which modify platelet aggregation and activation) are used</td></tr><tr><td>mainly for thromboembolism in arteries because arterial thrombi have a large platelet component with not</td></tr><tr><td>much contribution from blood coagulation. Anticoagulants have little effect on arterial thrombi.</td></tr><tr><td>R&amp;D 7e Ch 24, pp 298-302; D&amp;H 2e Ch 23, pp 58-59</td></tr></table>
</page>
<page number="174">
<table id="p174t1" data-filename="pdftables_fromstorage_023782248" data-page="174" data-table="1"><tr><td style="text-align: right">10.11</td><td>What drugs affect platelet</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Thrombosis</td><td></td><td></td></tr><tr><td></td><td>aggregation at the sites indicated?</td><td></td><td></td><td></td></tr><tr><td colspan="2">The diagram shows the events leading up to platelet aggregation.</td><td></td><td></td><td></td></tr><tr><td></td><td>Platelet adhesion</td><td></td><td></td><td></td></tr><tr><td></td><td>and activation</td><td></td><td>-–</td><td>?</td></tr><tr><td></td><td></td><td>?</td><td>Synthesis</td><td></td></tr><tr><td></td><td></td><td></td><td>of TXA 2</td><td></td></tr><tr><td></td><td>GPIIb/IIIa receptor activation</td><td></td><td>-–</td><td></td></tr><tr><td></td><td></td><td>-–</td><td></td><td></td></tr><tr><td></td><td></td><td>?</td><td></td><td></td></tr><tr><td></td><td></td><td>-–</td><td></td><td></td></tr><tr><td></td><td></td><td>Release of ADP</td><td>AGGREGATION</td><td></td></tr></table>
</page>
<page number="175">
<table id="p175t1" data-filename="pdftables_fromstorage_023782248" data-page="175" data-table="1"><tr><td colspan="2">The main examples of drugs that affect platelet aggregation at the site indicated.</td><td></td></tr><tr><td>There are, of course, others.</td><td></td><td></td></tr><tr><td>Platelet adhesion</td><td></td><td>Aspirin</td></tr><tr><td>and activation</td><td></td><td>-–</td></tr><tr><td></td><td>Dipyridamole</td><td>Synthesis</td></tr><tr><td>Clopidogrel</td><td></td><td>of TXA 2</td></tr><tr><td>GPIIb/IIIa receptor activation</td><td></td><td>-–</td></tr><tr><td>–</td><td></td><td></td></tr><tr><td style="text-align: right">-</td><td>Abciximab</td><td></td></tr><tr><td></td><td>-–</td><td></td></tr><tr><td>Release of ADP</td><td></td><td>AGGREGATION</td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 24, pp 302-305; D&amp;H 2e Ch 23, pp 58-59</td></tr></table>
</page>
<page number="176">
<table id="p176t1" data-filename="pdftables_fromstorage_023782248" data-page="176" data-table="1"><tr><td style="text-align: right">11.01</td><td>Folic acid</td><td>Haemopoietic system</td><td></td><td></td></tr><tr><td colspan="2">Synthesis of nucleotide thymidylate (dTMP)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>DHFR</td><td></td></tr><tr><td></td><td></td><td></td><td>FH 4</td><td></td></tr><tr><td></td><td></td><td>FH2</td><td>FH 4 + 1-carbon unit</td><td></td></tr><tr><td></td><td></td><td></td><td>Thymidylate</td><td></td></tr><tr><td></td><td></td><td>dTMP</td><td>synthetase</td><td>dUMP</td></tr><tr><td></td><td></td><td></td><td></td><td>dTMP (aka TMP) = thymidylate</td></tr><tr><td></td><td></td><td></td><td></td><td>DHFR = dihydrofolate reductase</td></tr><tr><td></td><td></td><td></td><td></td><td>FH2 = dihydrofolate</td></tr><tr><td></td><td></td><td></td><td></td><td>FH 4 = tetrahydrofolate</td></tr><tr><td></td><td></td><td></td><td></td><td>dUMP (aka UMP)= uridylate</td></tr></table>
</page>
<page number="177">
<table id="p177t1" data-filename="pdftables_fromstorage_023782248" data-page="177" data-table="1"><tr><td></td><td>A haematinic agent</td><td>Folic acid</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Folic acid is essential for DNA synthesis and cell proliferation. In the tetrahydrofolate (FH 4 ) form it</td></tr><tr><td></td><td colspan="2">is a cofactor in the synthesis of purines and pyrimidines being particularly important in thymidylate</td></tr><tr><td></td><td>synthesis.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Given orally, it is absorbed by active transport into intestinal mucosal cells where it is reduced to FH 4</td></tr><tr><td></td><td colspan="2">then methylated to methyl-FH4 which passes into the plasma and from thence into cells. The</td></tr><tr><td></td><td colspan="2">functionally inactive methyl-FH4 is demethylated in a Vit B12-dependent reaction (see card 11.03).</td></tr><tr><td>Clinical use</td><td colspan="2">To treat megaloblastic anaemias caused by folate deficiency. To prevent the development of folate</td></tr><tr><td></td><td colspan="2">deficiency in susceptible individuals (e.g. pregnant women, premature infants, patients with severe</td></tr><tr><td></td><td colspan="2">chronic haemolytic anaemias). To treat toxicity caused by methotrexate (a folate antagonist).</td></tr><tr><td>Adverse effects</td><td>Rare; occasionally GIT disturbances.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Should not be used in undiagnosed megaloblastic anaemias because if the anaemia is due to Vit B12 -</td></tr><tr><td></td><td colspan="2">deficiency the anemia may improve but the neurological lesions will persist and could get worse.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 25, pp 311-314; D&amp;H 2e Ch 24, pp 60-61</td></tr></table>
</page>
<page number="178">
<table id="p178t1" data-filename="pdftables_fromstorage_023782248" data-page="178" data-table="1"><tr><td style="text-align: right">11.02</td><td>Hydroxocobalamin</td><td>Haemopoietic system</td><td></td><td></td></tr><tr><td colspan="2">Synthesis of nucleotide thymidylate (dTMP)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>DHFR</td><td>DHFR</td><td></td></tr><tr><td></td><td></td><td></td><td>FH 4</td><td></td></tr><tr><td></td><td>Folic acid</td><td>FH2</td><td>FH 4 + 1-carbon unit</td><td></td></tr><tr><td></td><td></td><td></td><td>Thymidylate</td><td></td></tr><tr><td></td><td></td><td>dTMP</td><td>synthetase</td><td>dUMP</td></tr><tr><td></td><td></td><td></td><td></td><td>dTMP (aka TMP) = thymidylate</td></tr><tr><td></td><td></td><td></td><td></td><td>DHFR = dihydrofolate reductase</td></tr><tr><td></td><td></td><td></td><td></td><td>FH2 = dihydrofolate</td></tr><tr><td></td><td></td><td></td><td></td><td>FH 4 = tetrahydrofolate</td></tr><tr><td></td><td></td><td></td><td></td><td>dUMP (aka UMP)= uridylate</td></tr></table>
</page>
<page number="179">
<table id="p179t1" data-filename="pdftables_fromstorage_023782248" data-page="179" data-table="1"><tr><td></td><td>A vitamin B12 haematinic preparation</td><td>Hydroxocobalamin</td></tr><tr><td>Actions</td><td colspan="2">Restores the blood picture in megaloblastic anaemias (e.g pernicious anaemia) and results in partial</td></tr><tr><td></td><td colspan="2">to full recovery of the neurological syndrome (subacute combined degeneration of the spinal cord).</td></tr><tr><td>MOA</td><td colspan="2">It is necessary for the conversion of methyl-tetrahydrofolate (methyl-FH4 ) to tetrahydrofolate (FH4 )</td></tr><tr><td></td><td colspan="2">which is essential for thymidylate synthesis and thus for DNA synthesis.</td></tr><tr><td>Abs/Distrib/Elim</td><td>Given by i.m. injection.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">To treat pernicious anaemia and other causes of vitamin B12 deficiency.</td></tr><tr><td>Adverse effects</td><td colspan="2">Nausea, dizziness, headache and hypersensitivity reactions; hypokalaemia at start of treatment.</td></tr><tr><td>Drug with</td><td>Cyanocobalamin.</td><td></td></tr><tr><td>similar action</td><td></td><td>R&amp;D 7e Ch 25, pp 311-314; D&amp;H 2e Ch 24, pp 60-61</td></tr></table>
</page>
<page number="180">
<table id="p180t1" data-filename="pdftables_fromstorage_023782248" data-page="180" data-table="1"><tr><td style="text-align: right">11.03</td><td>Epoetin</td><td>Haemopoietic system</td><td></td><td></td><td></td></tr><tr><td colspan="6">Role of Vit B12 (hydroxocobalamin) in reactions necessary for synthesis of thymidylate (dTMP)</td></tr><tr><td></td><td></td><td>Methyl-FH4</td><td>Folic acid</td><td></td><td>Plasma</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Cell membrane</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Cytosol</td></tr><tr><td></td><td></td><td>Methyl-FH4</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>FH 4</td><td></td><td></td></tr><tr><td></td><td>Vit B12</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>DHFR</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>FH 4</td><td></td></tr><tr><td></td><td></td><td>Methyl-Vit B12</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>FH2</td><td>FH4 + 1-carbon unit</td><td></td></tr><tr><td></td><td></td><td>Homocysteine</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Thymidylate</td><td></td></tr><tr><td></td><td></td><td>Methionine</td><td>dTMP</td><td>synthetase</td><td>dUMP</td></tr><tr><td colspan="2">DHFR = dehydrofolate reductase,</td><td colspan="4">FH2 = dihydrofolate, FH4 = tetrahydrofolate. dUMP = uridylate, dTMP= thymidylate</td></tr></table>
</page>
<page number="181">
<table id="p181t1" data-filename="pdftables_fromstorage_023782248" data-page="181" data-table="1"><tr><td></td><td>A recombinant growth factor controlling erythropoiesis</td><td>Epoetin</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">It binds to receptors on committed erythrocyte progenitor cells stimulating proliferation and</td></tr><tr><td></td><td>differentiation.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Given by subcut. or i.v. injection.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">To treat the anaemia of chronc renal failure and of AIDS; to alleviate anaemia caused by cytotoxic</td></tr><tr><td></td><td>anticancer drugs; to prevent anaemia in premature infants.</td><td></td></tr><tr><td>Adverse effects</td><td>GIT disturbances; hypertension.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 25, p 314; D&amp;H 2e Ch 24, p 61</td></tr></table>
</page>
<page number="182">
<table id="p182t1" data-filename="pdftables_fromstorage_023782248" data-page="182" data-table="1"><tr><td style="text-align: right">11.04</td><td>Filgrastim</td><td>Haemopoietic system</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">Growth factors controlling haemopoiesis</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>IL = interleukin</td></tr><tr><td></td><td></td><td>Committed</td><td></td><td></td><td></td><td>SCF = stem cell factor</td></tr><tr><td></td><td></td><td>progenitor</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>SCF,</td><td></td><td>cells</td><td></td><td></td><td></td></tr><tr><td></td><td>IL-3,</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>IL-6,</td><td colspan="2">Thrombopoietin</td><td></td><td></td><td></td></tr><tr><td></td><td>IL-1</td><td></td><td style="text-align: right">-+</td><td>Megakaryocyte</td><td></td><td>Platelets</td></tr><tr><td></td><td></td><td></td><td>Erythropoietin</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">-+</td><td>Epoetin</td><td style="text-align: right">-+</td><td>Erythrocytes</td></tr><tr><td></td><td></td><td></td><td>Monocyte-</td><td></td><td style="text-align: right">-+</td><td>Monocytes</td></tr><tr><td colspan="2">Stem</td><td></td><td>granulocyte</td><td></td><td></td><td>Neutrophils</td></tr><tr><td colspan="2">cell</td><td></td><td>precursor</td><td></td><td style="text-align: right">-+</td><td>Eosinophils</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Basophils</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>IL-2</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>T lymphocytes</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>B lymphocytes</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>IL- 4</td><td></td></tr></table>
</page>
<page number="183">
<table id="p183t1" data-filename="pdftables_fromstorage_023782248" data-page="183" data-table="1"><tr><td></td><td>Recombinant human granulocyte-colony-stimulating factor</td><td>Filgrastim</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Interacts with specific receptors on myeloid progenitor cells causing proliferation and differentiation.</td></tr><tr><td></td><td>It can mobilise haemopoietic stem cells from bone marrow to blood.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Given by subcut. injection, subcut infusion or i.v. injection.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Neutropenia associated with cytotoxic cancer chemotherapy, bone marrow transplantation</td></tr><tr><td></td><td>or HIV infection.</td><td></td></tr><tr><td>Adverse effects</td><td>GIT disturbances, bone pain, muscle pain, fever, rash, alopecia.</td><td></td></tr><tr><td>Similar drug</td><td>Lenograstim.</td><td></td></tr><tr><td>Special points</td><td>For use only by experienced clinicians.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 25, pp 314-315; D&amp;H 2e Ch 24, p 61</td></tr></table>
</page>
<page number="184">
<table id="p184t1" data-filename="pdftables_fromstorage_023782248" data-page="184" data-table="1"><tr><td style="text-align: right">11.05</td><td colspan="2">Ferrous sulfate</td><td>Haemopoietic system</td><td></td><td></td><td></td></tr><tr><td colspan="3">Growth factors controlling haemopoiesis</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>IL = interleukin</td></tr><tr><td></td><td></td><td>Committed</td><td></td><td></td><td></td><td>SCF = stem cell factor</td></tr><tr><td></td><td></td><td>progenitor</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>SCF,</td><td>cells</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>IL-3,</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>IL-6,</td><td></td><td>Thrombopoietin</td><td></td><td></td><td></td></tr><tr><td></td><td>IL-1</td><td></td><td style="text-align: right">-+</td><td>Megakaryocyte</td><td></td><td>Platelets</td></tr><tr><td></td><td></td><td></td><td>Erythropoietin</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">-+</td><td>Epoetin</td><td style="text-align: right">-+</td><td>Erythrocytes</td></tr><tr><td></td><td></td><td></td><td>Monocyte-</td><td></td><td></td><td>Monocytes</td></tr><tr><td colspan="2">Stem</td><td></td><td>granulocyte</td><td>Filgrastim</td><td style="text-align: right">-+</td><td>Neutrophils</td></tr><tr><td colspan="2">cell</td><td></td><td>precursor</td><td></td><td style="text-align: right">-+</td><td>Eosinophils</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Basophils</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>IL-2</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>T lymphocytes</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>B lymphocytes</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>IL- 4</td><td></td></tr></table>
</page>
<page number="185">
<table id="p185t1" data-filename="pdftables_fromstorage_023782248" data-page="185" data-table="1"><tr><td></td><td>A haematinic agent</td><td>Ferrous sulfate</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">It is used in haemoglobin production in red blood cell precursors in the bone marrow.</td></tr><tr><td>Abs/Distrib/Elim</td><td>Given orally.</td><td></td></tr><tr><td>Clinical use</td><td>Iron-deficiency anaemia.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Dose-related GIT disturbances – nausea, epigastric pain, abdominal cramps, diarrhoea.</td></tr><tr><td>Drugs with</td><td colspan="2">Ferrous fumarate, ferrous gluconate – given orally. Iron dextran given by deep i.m. injection or slow</td></tr><tr><td>similar action</td><td>i.v. infusion.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Iron toxicity both acute (due to excessive ingestion of iron salts) or chronic (e.g. from repeated blood</td></tr><tr><td></td><td>transfusions) is treated with the iron chelator desferrioxamine.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 25, p 311; D&amp;H 2e Ch 24, p 60</td></tr></table>
</page>
<page number="186">
<table id="p186t1" data-filename="pdftables_fromstorage_023782248" data-page="186" data-table="1"><tr><td style="text-align: right">11.06</td><td>Haemopoietic system</td><td colspan="4">Which haematinic agent(s) should be given as supplement(s) to pregnant women and why?</td></tr><tr><td colspan="2">Ferric iron (Fe3+) enters the body in the</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">diet, is converted in the GIT into ferrous</td><td>Absorption in food</td><td style="text-align: right">-+</td><td colspan="2">Ferrous sulfate</td></tr><tr><td colspan="2">iron (Fe2+), which is absorbed into the</td><td>1mg per day</td><td></td><td></td><td></td></tr><tr><td colspan="2">mucosal cells by active transport and</td><td></td><td></td><td colspan="2">In the plasma, iron is bound to</td></tr><tr><td colspan="2">from thence into the plasma</td><td></td><td></td><td colspan="2">transferrin and most is used</td></tr><tr><td></td><td></td><td>Plasma (4mg)</td><td></td><td colspan="2">in rbc generation in the</td></tr><tr><td></td><td></td><td>5mg</td><td></td><td></td><td>bone marrow</td></tr><tr><td></td><td></td><td>Tissues (150mg)</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="4">(Iron is present in myoglobin, in cytochromes and other enzymes)</td><td></td></tr><tr><td>30mg</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="4">The body cannot excrete iron but 1mg per day is lost mainly</td><td>30mg</td></tr><tr><td></td><td colspan="4">through sloughing of ferritin-containing GIT mucosal cells</td><td></td></tr><tr><td>Bone marrow:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>in rbc precursors</td><td></td><td>6mg</td><td></td><td></td><td>Stores in mnp</td></tr><tr><td>(150mg)</td><td></td><td></td><td></td><td></td><td>(1000mg)</td></tr><tr><td></td><td>24mg</td><td></td><td></td><td>24mg</td><td></td></tr><tr><td></td><td></td><td colspan="2">Hb in rbc (3000mg)</td><td></td><td></td></tr><tr><td></td><td colspan="5">Iron is stored as ferritin or haemosiderin, mainly in mononuclear phagocytes (mnp) and liver</td></tr></table>
</page>
<page number="187">
<table id="p187t1" data-filename="pdftables_fromstorage_023782248" data-page="187" data-table="1"><tr><td>Which haematinic agent(s) should be given in supplement form to pregnant women and why?</td></tr><tr><td>Folic acid is usually given to pregnant women as a supplement –</td></tr><tr><td>to prevent the development of neural tube defects (e.g spina bifida) in the foetus.</td></tr><tr><td>Iron is also important in pregnant women but whether it should be given as a supplement is controversial;</td></tr><tr><td>there are two schools of thought:</td></tr><tr><td>• Some authorities believe that a good diet contaning iron-rich foods is preferable to using oral iron</td></tr><tr><td>salts because these can result in adverse effects to both mother and foetus, and that iron supplements</td></tr><tr><td>should not be given unless iron levels are low due to dietary factors or blood loss (e.g from</td></tr><tr><td>haemorrhoids, GIT ulcers etc.)</td></tr><tr><td>• Some authorities recommend that all pregnant women take 27mg a day of iron as a supplement.</td></tr><tr><td>R&amp;D 7e Ch 25, p 309; D&amp;H 2e Ch 24, p 60</td></tr></table>
</page>
<page number="188">
<table id="p188t1" data-filename="pdftables_fromstorage_023782248" data-page="188" data-table="1"><tr><td></td><td>Salbutamol</td><td></td><td></td><td></td></tr><tr><td style="text-align: right">12.01</td><td>(Albuterol)</td><td>Asthma and antiasthma drugs</td><td></td><td></td></tr><tr><td colspan="5">Pathobiology of asthma: bronchial hyper-reactivity, bronchial spasm and inflammation of the airways</td></tr><tr><td colspan="2">Immediate phase of the asthma attack</td><td></td><td colspan="2">Delayed phase of the asthma attack</td></tr><tr><td colspan="2">(bronchial hyper-reactivity and spasm)</td><td></td><td colspan="2">(bronchial hyper-reactivity, spasm and</td></tr><tr><td></td><td></td><td></td><td>airway inflammation)</td><td></td></tr><tr><td>Triggers:</td><td>Allergen (e.g. pollen,</td><td>Air pollutants,</td><td></td><td></td></tr><tr><td></td><td>animal dander)</td><td>viral infection</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Influx /activation of inflammatory cells,</td></tr><tr><td></td><td></td><td>release</td><td colspan="2">(eosinophils, monocytes, T cells etc.)</td></tr><tr><td></td><td></td><td></td><td colspan="2">which release leukotrienes,</td></tr><tr><td colspan="2">Mast cell spasmogens</td><td>Chemotaxins</td><td colspan="2">cytokines, eosinophil proteins etc.</td></tr><tr><td colspan="2">(e.g. histamine,</td><td>(e.g. LTB 4 ,</td><td colspan="2">which cause:</td></tr><tr><td colspan="2">LTC 4 , LTD4 etc.)</td><td>cytokines etc.)</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Bronchospasm</td><td>↑of hyper-reactivity</td></tr><tr><td></td><td></td><td></td><td>wheezing, cough</td><td>&amp; inflammation</td></tr><tr><td colspan="2">Smooth muscle</td><td></td><td></td><td></td></tr><tr><td></td><td>Mucosa</td><td>Bronchospasm</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Mucus</td></tr><tr><td colspan="2">Normal bronchiole</td><td></td><td></td><td></td></tr></table>
</page>
<page number="189">
<table id="p189t1" data-filename="pdftables_fromstorage_023782248" data-page="189" data-table="1"><tr><td></td><td>A selective β2-agonist (Similar drug: terbutaline. See also card 2.01)</td><td>Salbutamol</td></tr><tr><td>Actions</td><td colspan="2">Bronchodilatation – a physiological antagonist of spasmogenic mediators;</td></tr><tr><td></td><td>minimal action on heart: ↑rate and force.</td><td></td></tr><tr><td>MOA</td><td colspan="2">↓calcium-mediated contraction in bronchioles. ↑cAMP which activates protein kinase A (PKA).</td></tr><tr><td></td><td colspan="2">PKA inhibits myosin light chain kinase (MLCK) – the mediator of contraction.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">By inhalation for asthma. Short-acting (3–5h); can be given i.v. in acute severe asthma.</td></tr><tr><td></td><td>Mainly excreted unchanged.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">For the acute asthmatic attack – used ‘as needed’. To prevent exercise-induced asthma. For chronic</td></tr><tr><td></td><td>obstructive airways disease.</td><td></td></tr><tr><td>Unwanted</td><td colspan="2">Tremors, tachycardia, sometimes dysrhythmias, nervousness, some peripheral dilatation.</td></tr><tr><td>effects</td><td></td><td></td></tr><tr><td>Special points</td><td colspan="2">Selective β2-agonists are first-line drugs for the the immediate phase i.e. the acute attack; ineffective</td></tr><tr><td></td><td>on the delayed phase.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 27, pp 341; D&amp;H 2e Ch 25, pp 62-63</td></tr></table>
</page>
<page number="190">
<table id="p190t1" data-filename="pdftables_fromstorage_023782248" data-page="190" data-table="1"><tr><td style="text-align: right">12.02</td><td>Salmeterol</td><td>Asthma and antiasthma drugs</td><td></td><td></td></tr><tr><td colspan="5">Pathobiology of asthma: bronchial hyper-reactivity, bronchial spasm and inflammation of the airways</td></tr><tr><td colspan="2">Immediate phase of the asthma attack</td><td></td><td colspan="2">Delayed phase of the asthma attack</td></tr><tr><td colspan="2">(bronchial hyper-reactivity and spasm)</td><td></td><td colspan="2">(bronchial hyper-reactivity, spasm and</td></tr><tr><td></td><td></td><td></td><td>airway inflammation)</td><td></td></tr><tr><td>Triggers:</td><td>Allergen (e.g. pollen,</td><td>Air pollutants,</td><td></td><td></td></tr><tr><td></td><td>animal dander)</td><td>viral infection</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Influx /activation of inflammatory cells,</td></tr><tr><td></td><td></td><td>release</td><td colspan="2">(eosinophils, monocytes, T cells etc.)</td></tr><tr><td></td><td></td><td></td><td colspan="2">which release leukotrienes,</td></tr><tr><td colspan="2">Mast cell spasmogens</td><td>Chemotaxins</td><td colspan="2">cytokines, eosinophil proteins etc.</td></tr><tr><td colspan="2">(e.g histamine,</td><td>(e.g. LTB4 ,</td><td colspan="2">which cause:</td></tr><tr><td colspan="2">LTC 4 , LTD4 etc.)</td><td>cytokines etc.)</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Bronchospasm</td><td>↑of hyper-reactivity</td></tr><tr><td></td><td></td><td></td><td>wheezing, cough</td><td>&amp; inflammation</td></tr><tr><td colspan="2">Smooth muscle</td><td></td><td></td><td></td></tr><tr><td></td><td>Mucosa</td><td>Bronchospasm</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Mucus</td></tr><tr><td></td><td></td><td>Salbutamol reverses</td><td></td><td></td></tr><tr><td colspan="2">Normal bronchiole</td><td>the bronchospasm</td><td></td><td></td></tr></table>
</page>
<page number="191">
<table id="p191t1" data-filename="pdftables_fromstorage_023782248" data-page="191" data-table="1"><tr><td></td><td>A long-acting selective β2-agonist (similar drug: formoterol. See also card 2.01)</td><td>Salmeterol</td></tr><tr><td>Actions</td><td colspan="2">Bronchodilatation – a physiological antagonist of spasmogenic mediators.</td></tr><tr><td></td><td>(Minimal action on heart: ↑rate and force).</td><td></td></tr><tr><td>MOA</td><td colspan="2">↓calcium-mediated contraction in bronchioles. ↑cAMP which activates protein</td></tr><tr><td></td><td colspan="2">kinase A (PKA). PKA inhibits myosin light chain kinase (MLCK) – the mediator of</td></tr><tr><td></td><td>contraction.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">By inhalation for asthma. Long-acting (8–12h); Mostly metabolised by P450 with</td></tr><tr><td></td><td>significant amount lost in faeces.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">To prevent bronchconstriction with exercise-induced asthma or at night in patients needing</td></tr><tr><td></td><td colspan="2">prolonged bronchodilator therapy. For chronic obstructive pulmonary disease.</td></tr><tr><td>Unwanted</td><td colspan="2">Tremors, tachycardia, sometimes dysrhythmias, nervousness, some peripheral vasodilatation.</td></tr><tr><td>effects</td><td></td><td></td></tr><tr><td>Special points</td><td colspan="2">Not used for the acute attack; not given ‘as needed’ but regularly as adjunct to corticosteroids.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 27, pp 340-341; D&amp;H 2e Ch 25, pp 62-63</td></tr></table>
</page>
<page number="192">
<table id="p192t1" data-filename="pdftables_fromstorage_023782248" data-page="192" data-table="1"><tr><td style="text-align: right">12.03</td><td>Theophylline</td><td>Asthma and antiasthma drugs</td><td></td><td></td></tr><tr><td colspan="5">Pathobiology of asthma: bronchial hyper-reactivity, bronchial spasm and inflammation of the airways</td></tr><tr><td colspan="2">Immediate phase of the asthma attack</td><td></td><td colspan="2">Delayed phase of the asthma attack</td></tr><tr><td colspan="2">(bronchial hyper-reactivity and spasm)</td><td></td><td colspan="2">(bronchial hyper-reactivity, spasm and</td></tr><tr><td></td><td></td><td></td><td>airway inflammation)</td><td></td></tr><tr><td>Triggers:</td><td>Allergen (e.g. pollen,</td><td>Air pollutants,</td><td></td><td></td></tr><tr><td></td><td>animal dander)</td><td>viral infection</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Influx /activation of inflammatory cells,</td></tr><tr><td></td><td></td><td>release</td><td colspan="2">(eosinophils, monocytes, T cells etc.)</td></tr><tr><td></td><td></td><td></td><td colspan="2">which release leukotrienes,</td></tr><tr><td colspan="2">Mast cell spasmogens</td><td>Chemotaxins</td><td colspan="2">cytokines, eosinophil proteins etc.</td></tr><tr><td colspan="2">(e.g histamine,</td><td>(e.g. LTB 4 ,</td><td colspan="2">which cause:</td></tr><tr><td colspan="2">LTC 4 , LTD4 etc.)</td><td>cytokines etc.)</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Bronchospasm</td><td>↑of hyper-reactivity</td></tr><tr><td></td><td></td><td></td><td>wheezing, cough</td><td>&amp; inflammation</td></tr><tr><td colspan="2">Smooth muscle</td><td></td><td></td><td></td></tr><tr><td></td><td>Mucosa</td><td>Bronchospasm</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Mucus</td></tr><tr><td></td><td></td><td>Salbutamol &amp; salmeterol</td><td></td><td></td></tr><tr><td colspan="2">Normal bronchiole</td><td>reverse bronchospasm</td><td></td><td></td></tr></table>
</page>
<page number="193">
<table id="p193t1" data-filename="pdftables_fromstorage_023782248" data-page="193" data-table="1"><tr><td></td><td>A xanthine (Similar drug: aminophylline theophylline ethylene diamine)</td><td>Theophylline</td></tr><tr><td>Actions</td><td>Bronchodilatation. (Also stimulates CNS and CVS.)</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits phosphodiesterase PDE4 thus ↑cAMP (and ?cGMP) thus relaxing smooth muscle.</td></tr><tr><td></td><td>Inhibition of PDE4 in inflammatory cells can ↓mediator release.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Sustained-release preparations given orally. Plasma half-life (~8h) is ↑by liver</td></tr><tr><td></td><td colspan="2">disease cardiac failure &amp; viral infection and ↓by heavy smoking &amp; drinking.</td></tr><tr><td></td><td colspan="2">Plasma level is ↓by rifampicin, phenytoin, carbamazepine and ↑by erythromycin,</td></tr><tr><td></td><td>diltiazem, fluconazole and caffeine. Aminophylline can be given i.v.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">A second-line drug for chronic asthma not adequately controlled by β2-agonists.</td></tr><tr><td></td><td>Aminophylline i.v. is used for severe acute asthma.</td><td></td></tr><tr><td>Unwanted</td><td colspan="2">GIT disturbances, tachycardia, anxiety. High plasma levels can cause serious dysrhythymia</td></tr><tr><td>effects</td><td>or seizures.</td><td></td></tr><tr><td>Special points</td><td>Plasma levels should be monitored.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e, Ch 27, pp 340-341; D&amp;H 2e Ch 25, p 63</td></tr></table>
</page>
<page number="194">
<table id="p194t1" data-filename="pdftables_fromstorage_023782248" data-page="194" data-table="1"><tr><td style="text-align: right">12.04</td><td>Montelukast</td><td>Asthma and antiasthma drugs</td><td></td><td></td></tr><tr><td colspan="5">Pathobiology of asthma: bronchial hyper-reactivity, bronchial spasm and inflammation of the airways</td></tr><tr><td colspan="2">Immediate phase of the asthma attack</td><td></td><td colspan="2">Delayed phase of the asthma attack</td></tr><tr><td colspan="2">(bronchial hyper-reactivity and spasm)</td><td></td><td colspan="2">(bronchial hyper-reactivity, spasm and</td></tr><tr><td></td><td></td><td></td><td>airway inflammation)</td><td></td></tr><tr><td>Triggers:</td><td>Allergen (e.g. pollen,</td><td>Air pollutants,</td><td></td><td></td></tr><tr><td></td><td>animal dander)</td><td>viral infection</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Influx /activation of inflammatory cells,</td></tr><tr><td></td><td></td><td>release</td><td colspan="2">(eosinophils, monocytes, T cells etc.)</td></tr><tr><td></td><td></td><td></td><td colspan="2">which release leukotrienes,</td></tr><tr><td colspan="2">Mast cell spasmogens</td><td>Chemotaxins</td><td colspan="2">cytokines, eosinophil proteins etc.</td></tr><tr><td colspan="2">(e.g histamine,</td><td>(e.g. LTB4 ,</td><td colspan="2">which cause:</td></tr><tr><td colspan="2">LTC4 , LTD4 etc.)</td><td>cytokines etc.)</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Bronchospasm</td><td>↑of hyper-reactivity</td></tr><tr><td></td><td></td><td></td><td>wheezing, cough</td><td>&amp; inflammation</td></tr><tr><td colspan="2">Smooth muscle</td><td></td><td></td><td></td></tr><tr><td></td><td>Mucosa</td><td>Bronchospasm</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Mucus</td></tr><tr><td></td><td></td><td>Salbutamol, salmeterol, theophylline</td><td></td><td></td></tr><tr><td colspan="2">Normal bronchiole</td><td>reverse bronchospasm</td><td></td><td></td></tr></table>
</page>
<page number="195">
<table id="p195t1" data-filename="pdftables_fromstorage_023782248" data-page="195" data-table="1"><tr><td></td><td>A leukotriene receptor antagonist (Similar drug: zafirlukast)</td><td>Montelukast</td></tr><tr><td>Actions</td><td colspan="2">Reverses bronchoconstriction. Relaxes airway smooth muscle in mild asthma.</td></tr><tr><td>MOA</td><td colspan="2">The drug is an antagonist at the cysteinyl leukotriene receptor, (CysLT1 ) on which the</td></tr><tr><td></td><td colspan="2">bronchospasmic mediators LTC4 , LTD4 and LTE 4 act. It can ↓both the early- and late-phase</td></tr><tr><td></td><td>responses to inhaled allergen.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally. Metabolised in liver and excreted mainly in bile; half-life 3–5h.</td></tr><tr><td>Clinical use</td><td colspan="2">A third-line drug for asthma, used as adjunct to inhaled corticosteroids and long-acting</td></tr><tr><td></td><td>β2-agonists. Effective in aspirin-induced asthma.</td><td></td></tr><tr><td>Unwanted</td><td>Few.</td><td></td></tr><tr><td>effects</td><td></td><td></td></tr><tr><td>Special points</td><td>Easy for children to take.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e, Ch 27, p 340; D&amp;H 2e Ch 25, p 63</td></tr></table>
</page>
<page number="196">
<table id="p196t1" data-filename="pdftables_fromstorage_023782248" data-page="196" data-table="1"><tr><td style="text-align: right">12.05</td><td>Ipratropium</td><td>Asthma and antiasthma drugs</td><td></td><td></td></tr><tr><td colspan="5">Pathobiology of asthma: bronchial hyper-reactivity, bronchial spasm and inflammation of the airways</td></tr><tr><td colspan="2">Immediate phase of the asthma attack</td><td></td><td colspan="2">Delayed phase of the asthma attack</td></tr><tr><td colspan="2">(bronchial hyper-reactivity and spasm)</td><td></td><td colspan="2">(bronchial hyper-reactivity, spasm and</td></tr><tr><td></td><td></td><td></td><td>airway inflammation)</td><td></td></tr><tr><td>Triggers:</td><td>Allergen (e.g. pollen,</td><td>Air pollutants,</td><td></td><td></td></tr><tr><td></td><td>animal dander)</td><td>viral infection</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Influx /activation of inflammatory cells,</td></tr><tr><td></td><td></td><td>release</td><td colspan="2">(eosinophils, monocytes, T cells etc.)</td></tr><tr><td></td><td></td><td></td><td colspan="2">which release leukotrienes,</td></tr><tr><td colspan="2">Mast cell spasmogens</td><td>Chemotaxins</td><td colspan="2">cytokines, eosinophil proteins etc.</td></tr><tr><td colspan="2">(e.g histamine,</td><td>(e.g. LTB 4 ,</td><td colspan="2">which cause:</td></tr><tr><td colspan="2">LTC 4 , LTD4 etc.)</td><td>cytokines etc.)</td><td></td><td></td></tr><tr><td></td><td></td><td>Montelukast</td><td>Bronchospasm</td><td>↑of hyper-reactivity</td></tr><tr><td></td><td></td><td></td><td>wheezing, cough</td><td>&amp; inflammation</td></tr><tr><td colspan="2">Smooth muscle</td><td></td><td></td><td></td></tr><tr><td></td><td>Mucosa</td><td>Bronchospasm</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Mucus</td></tr><tr><td></td><td></td><td>Salbutamol, salmeterol theophylline</td><td></td><td></td></tr><tr><td colspan="2">Normal bronchiole</td><td>reverse bronchospasm</td><td></td><td></td></tr></table>
</page>
<page number="197">
<table id="p197t1" data-filename="pdftables_fromstorage_023782248" data-page="197" data-table="1"><tr><td></td><td>A muscarinic receptor antagonist</td><td>Ipratropium</td></tr><tr><td>Actions</td><td colspan="2">Bronchodilatation by inhibiting acetylcholine-mediated bronchoconstriction</td></tr><tr><td></td><td>and mucus secretion. No effect on the late phase.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Competitively antagonises acetylcholine action on muscarinc receptors.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given by inhalation; the action lasts for 3–5h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">For asthma as adjunct to β2 -agonist &amp; corticosteroids; for chronic obstructive pulmonary disease.</td></tr><tr><td>Unwanted</td><td>Few.</td><td></td></tr><tr><td>effects</td><td></td><td></td></tr><tr><td>Special points</td><td>Useful in patients intolerant of β2-agonists.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 27, p 342; D&amp;H 2e Ch 25, pp 62-63</td></tr></table>
</page>
<page number="198">
<table id="p198t1" data-filename="pdftables_fromstorage_023782248" data-page="198" data-table="1"><tr><td style="text-align: right">12.06</td><td>Beclometasone</td><td>Asthma and antiasthma drugs</td><td></td><td></td></tr><tr><td colspan="5">Pathobiology of asthma: bronchial hyper-reactivity, bronchial spasm and inflammation of the airways</td></tr><tr><td colspan="2">Immediate phase of the asthma attack</td><td></td><td colspan="2">Delayed phase of the asthma attack</td></tr><tr><td colspan="2">(bronchial hyper-reactivity and spasm)</td><td></td><td colspan="2">(bronchial hyper-reactivity, spasm and</td></tr><tr><td></td><td></td><td></td><td>airway inflammation)</td><td></td></tr><tr><td>Triggers:</td><td>Allergen (e.g. pollen,</td><td>Air pollutants,</td><td></td><td></td></tr><tr><td></td><td>animal dander)</td><td>viral infection</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Influx /activation of inflammatory cells,</td></tr><tr><td></td><td></td><td>release</td><td colspan="2">(eosinophils, monocytes, T cells etc.)</td></tr><tr><td></td><td></td><td></td><td colspan="2">which release leukotrienes,</td></tr><tr><td colspan="2">Mast cell spasmogens</td><td>Chemotaxins</td><td colspan="2">cytokines, eosinophil proteins etc.</td></tr><tr><td colspan="2">(e.g histamine,</td><td>(e.g. LTB 4 ,</td><td colspan="2">which cause:</td></tr><tr><td>LTC 4 , LTD4</td><td>etc.)</td><td>cytokines etc.)</td><td></td><td></td></tr><tr><td></td><td></td><td>Montelukast</td><td>Bronchospasm</td><td>↑of hyper-reactivity</td></tr><tr><td></td><td></td><td></td><td>wheezing, cough</td><td>&amp; inflammation</td></tr><tr><td>Smooth muscle</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Mucosa</td><td>Bronchospasm</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Mucus</td></tr><tr><td></td><td></td><td>Salbutamol, salmeterol, theophylline,</td><td></td><td></td></tr><tr><td colspan="2">Normal bronchiole</td><td>ipratropium reverse bronchospasm</td><td></td><td></td></tr></table>
</page>
<page number="199">
<table id="p199t1" data-filename="pdftables_fromstorage_023782248" data-page="199" data-table="1"><tr><td></td><td>An antiasthmatic corticosteroid (Similar: budesonide; fluticasone, hydrocortisone)</td><td>Beclometasone</td></tr><tr><td>Actions</td><td colspan="2">Reduces hyper-reactivity and decreases the inflammatory delayed phase. No effect on the</td></tr><tr><td></td><td>immediate phase. (See also card 16.01.)</td><td></td></tr><tr><td>MOA</td><td colspan="2">Reduces the activation of inflammatory cells and the release of mediators especially cytokines</td></tr><tr><td></td><td>(see cards 4.05 &amp; 16.02).</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given by inhalation with metered-dose inhaler; the full action takes weeks to occur.</td></tr><tr><td>Clinical use</td><td colspan="2">Added to bronchodilator therapy if this is inadequate. An i.v. glucocorticoid (e.g. hydrocortisone)</td></tr><tr><td></td><td>is life-saving in acute severe asthma (status asthmaticus).</td><td></td></tr><tr><td>Unwanted</td><td>Hoarse voice; oral candidiasis (thrush).</td><td></td></tr><tr><td>effects</td><td></td><td></td></tr><tr><td>Special points</td><td colspan="2">Regular high doses of inhaled corticosteroids can be absorbed and cause adrenal suppression</td></tr><tr><td></td><td>and other adverse effects (see card 16.03).</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 27, p 343; D&amp;H 2e Ch 25, pp 62- 63</td></tr></table>
</page>
<page number="200">
<table id="p200t1" data-filename="pdftables_fromstorage_023782248" data-page="200" data-table="1"><tr><td style="text-align: right">12.07</td><td>Omalizumab</td><td colspan="2">Asthma and antiasthma drugs</td><td></td><td></td></tr><tr><td colspan="6">Pathobiology of asthma: bronchial hyper-reactivity, bronchial spasm and inflammation of the airways</td></tr><tr><td colspan="2">Immediate phase of the asthma attack</td><td></td><td colspan="3">Delayed phase of the asthma attack</td></tr><tr><td colspan="2">(bronchial hyper-reactivity and spasm)</td><td></td><td colspan="3">(bronchial hyper-reactivity, spasm and</td></tr><tr><td></td><td></td><td></td><td colspan="2">airway inflammation)</td><td></td></tr><tr><td>Triggers:</td><td>Allergen (e.g. pollen,</td><td>Air pollutants,</td><td></td><td></td><td></td></tr><tr><td></td><td>animal dander)</td><td>viral infection</td><td>Beclometasone</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>inhibits</td><td colspan="2">Influx /activation of inflammatory cells,</td></tr><tr><td></td><td></td><td>release</td><td></td><td colspan="2">(eosinophils, monocytes, T cells etc.)</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">which release leukotrienes,</td></tr><tr><td colspan="2">Mast cell spasmogens</td><td colspan="2">Chemotaxins</td><td colspan="2">cytokines, eosinophil proteins etc.</td></tr><tr><td colspan="2">(e.g histamine,</td><td colspan="2">(e.g. LTB4 ,</td><td colspan="2">which cause:</td></tr><tr><td>LTC4 , LTD4</td><td>etc.)</td><td colspan="2">cytokines etc.)</td><td></td><td></td></tr><tr><td></td><td></td><td>Montelukast</td><td></td><td>Bronchospasm</td><td>↑of hyper-reactivity</td></tr><tr><td></td><td></td><td></td><td></td><td>wheezing, cough</td><td>&amp; inflammation</td></tr><tr><td>Smooth muscle</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Mucosa</td><td>Bronchospasm</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Mucus</td></tr><tr><td></td><td></td><td colspan="2">Salbutamol, salmeterol, theophylline,</td><td></td><td></td></tr><tr><td colspan="2">Normal bronchiole</td><td colspan="2">ipratropium reverse bronchospasm</td><td>Beclometasone</td><td></td></tr></table>
</page>
<page number="201">
<table id="p201t1" data-filename="pdftables_fromstorage_023782248" data-page="201" data-table="1"><tr><td></td><td>An inhibitor of mast cell mediator release</td><td>Omalizumab</td></tr><tr><td>Actions</td><td>Reduces plasma IgE levels and decreases magnitude of both early and late phases.</td><td></td></tr><tr><td>MOA</td><td colspan="2">It is a monoclonal antibody that inhibits the binding of IgE to mast cells (and eosinophils)</td></tr><tr><td></td><td>thus reducing mediator release.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given subcutaneously at 2–4 week intervals.</td><td></td></tr><tr><td>Clinical use</td><td>For persistent allergic asthma not completely controlled with inhaled corticosteroid</td><td></td></tr><tr><td></td><td>plus long-acting β2 -agonist.</td><td></td></tr><tr><td>Unwanted</td><td>Hypersensitivity reactions.</td><td></td></tr><tr><td>effects</td><td></td><td></td></tr><tr><td>Special points</td><td>Needs expert administration.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 27, p 338</td></tr></table>
</page>
<page number="202">
<table id="p202t1" data-filename="pdftables_fromstorage_023782248" data-page="202" data-table="1"><tr><td style="text-align: right">12.08</td><td>Cromoglicate</td><td colspan="3">Asthma and antiasthma drugs</td><td></td><td></td></tr><tr><td colspan="7">Pathobiology of asthma: bronchial hyper-reactivity, bronchial spasm and inflammation of the airways</td></tr><tr><td colspan="3">Immediate phase of the asthma attack</td><td></td><td colspan="3">Delayed phase of the asthma attack</td></tr><tr><td colspan="2">(bronchial hyper-reactivity and spasm)</td><td></td><td></td><td colspan="3">(bronchial hyper-reactivity, spasm and</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">airway inflammation)</td><td></td></tr><tr><td>Triggers:</td><td>Allergen (e.g. pollen,</td><td colspan="2">Air pollutants,</td><td></td><td></td><td></td></tr><tr><td></td><td>animal dander)</td><td></td><td>viral infection</td><td>Beclometasone</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>inhibits</td><td colspan="2">Influx /activation of inflammatory cells,</td></tr><tr><td></td><td></td><td>release</td><td></td><td></td><td colspan="2">(eosinophils, monocytes, T cells etc.)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">which release leukotrienes,</td></tr><tr><td colspan="2">Mast cell spasmogens</td><td></td><td colspan="2">Chemotaxins</td><td colspan="2">cytokines, eosinophil proteins etc.</td></tr><tr><td colspan="2">(e.g histamine,</td><td>Omalizumab</td><td colspan="2">(e.g. LTB 4 ,</td><td colspan="2">which cause:</td></tr><tr><td colspan="2">LTC 4 , LTD4 etc.)</td><td></td><td colspan="2">cytokines etc.)</td><td></td><td></td></tr><tr><td></td><td></td><td>Montelukast</td><td></td><td></td><td>Bronchospasm</td><td>↑of hyper-reactivity</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>wheezing, cough</td><td>&amp; inflammation</td></tr><tr><td colspan="2">Smooth muscle</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Mucosa</td><td>Bronchospasm</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Mucus</td></tr><tr><td></td><td></td><td colspan="3">Salbutamol, salmeterol, theophylline,</td><td></td><td></td></tr><tr><td colspan="2">Normal bronchiole</td><td colspan="3">ipratropium reverse bronchospasm</td><td>Beclometasone</td><td></td></tr></table>
</page>
<page number="203">
<table id="p203t1" data-filename="pdftables_fromstorage_023782248" data-page="203" data-table="1"><tr><td></td><td>A prophylactic antiasthma drug (Similar drug: nedocromil)</td><td>Cromoglicate</td></tr><tr><td>Actions</td><td colspan="2">Moderate inhibition of allergen – and exercise-induced asthma and bronchial hyperreactivity –</td></tr><tr><td></td><td>but not in all patients. No effect on bronchial spasm.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits mast cell degranulation and the response of sensory C fibres to irritants (early phase) and</td></tr><tr><td></td><td colspan="2">eosinophil activation (delayed phase) possibly by an action on chloride channels in the plasma</td></tr><tr><td></td><td>membranes.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given by powder inhalation.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Prophylaxis of asthma, mainly in older children. To reduce symptoms of allergic rhinitis.</td></tr><tr><td>Unwanted</td><td>Irritation of throat by the powder.</td><td></td></tr><tr><td>effects</td><td></td><td></td></tr><tr><td>Special points</td><td>None.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 27, p 343; D&amp;H 2e Ch 25, p 63</td></tr></table>
</page>
<page number="204">
<table id="p204t1" data-filename="pdftables_fromstorage_023782248" data-page="204" data-table="1"><tr><td style="text-align: right">12.09</td><td colspan="3">Asthma and antiasthma drugs</td><td colspan="3">How might the main drugs given here be introduced gradually, in five steps, in</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">a patient whose asthma is difficult to control?</td><td></td></tr><tr><td colspan="7">Pathobiology of asthma: bronchial hyper-reactivity, bronchial spasm and inflammation of the airways</td></tr><tr><td colspan="3">Immediate phase of the asthma attack</td><td>Crcoamn ionghliibcitate</td><td colspan="2">Delayed phase of the asthma attack</td><td></td></tr><tr><td colspan="2">(bronchial hyper-reactivity and spasm)</td><td></td><td></td><td colspan="2">(bronchial hyper-reactivity, spasm and</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">airway inflammation)</td><td>Cromoglicate</td></tr><tr><td>Triggers:</td><td>Allergen (e.g. pollen,</td><td colspan="2">Air pollutants,</td><td></td><td></td><td>can inhibit</td></tr><tr><td></td><td>animal dander)</td><td></td><td>viral infection</td><td>Beclometasone</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>inhibits</td><td colspan="2">Influx /activation of inflammatory cells,</td></tr><tr><td></td><td></td><td>release</td><td></td><td></td><td colspan="2">(eosinophils, monocytes, T cells etc.)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">which release leukotrienes,</td></tr><tr><td colspan="2">Mast cell spasmogens</td><td></td><td>Chemotaxins</td><td></td><td colspan="2">cytokines, eosinophil proteins etc.</td></tr><tr><td colspan="2">(e.g histamine,</td><td>Omalizumab</td><td>(e.g. LTB 4 ,</td><td></td><td colspan="2">which cause:</td></tr><tr><td>LTC 4 , LTD4</td><td>etc.)</td><td></td><td>cytokines etc.)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Montelukast</td><td></td><td></td><td>Bronchospasm</td><td>↑of hyper-reactivity</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>wheezing, cough</td><td>&amp; inflammation</td></tr><tr><td>Smooth muscle</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">Mucosa</td><td>Bronchospasm</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Mucus</td></tr><tr><td></td><td></td><td colspan="2">Salbutamol, salmeterol, theophylline,</td><td></td><td></td><td></td></tr><tr><td colspan="2">Normal bronchiole</td><td colspan="2">ipratropium reverse bronchospasm</td><td></td><td>Beclometasone</td><td></td></tr></table>
</page>
<page number="205">
<table id="p205t1" data-filename="pdftables_fromstorage_023782248" data-page="205" data-table="1"><tr><td></td><td>Based on the cards you’ve done, work out the possible names of drugs A, B, C etc, in the five-step programme given</td></tr><tr><td></td><td>below, and specify the mode of administration.</td></tr><tr><td>Step 1</td><td>Patient is started on Drug A. How would A be given?</td></tr><tr><td>Step 2</td><td>If drug A is needed more often than specified in Step 1, add Drug B.</td></tr><tr><td></td><td>How would B be given?</td></tr><tr><td>Step 3</td><td>If asthma is not adequately controlled, add Drug C. How would it be given?</td></tr><tr><td>Step 4</td><td>If asthma is still not adequately controlled, add other drug(s). How would it/they be given?</td></tr><tr><td>Step 5</td><td>If asthma is still not adequately controlled, add another drug. How would it be given?</td></tr><tr><td></td><td>R&amp;D 7e Ch 27, pp 340-343; D&amp;H 2e Ch 25, p 63</td></tr></table>
</page>
<page number="206">
<table id="p206t1" data-filename="pdftables_fromstorage_023782248" data-page="206" data-table="1"><tr><td style="text-align: right">12.10</td><td colspan="2">Asthma and antiasthma drugs</td><td colspan="3">How might the main drugs given here be introduced gradually in a patient</td></tr><tr><td></td><td></td><td></td><td colspan="2">whose asthma is difficult to control?</td><td></td></tr><tr><td colspan="6">Pathobiology of asthma: bronchial hyper-reactivity, bronchial spasm and inflammation of the airways</td></tr><tr><td colspan="2">Immediate phase of the asthma attack</td><td>Crcoanm ionghliibcitate</td><td colspan="2">Delayed phase of the asthma attack</td><td></td></tr><tr><td colspan="2">(bronchial hyper-reactivity and spasm)</td><td></td><td colspan="2">(bronchial hyper-reactivity, spasm and</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">airway inflammation)</td><td>Cromoglicate</td></tr><tr><td>Triggers:</td><td>Allergen (e.g. pollen,</td><td>Air pollutants,</td><td></td><td></td><td>can inhibit</td></tr><tr><td></td><td>animal dander)</td><td>viral infection</td><td>Beclometasone</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>inhibits</td><td colspan="2">Influx /activation of inflammatory cells,</td></tr><tr><td></td><td>release</td><td></td><td></td><td colspan="2">(eosinophils, monocytes, T cells etc.)</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">which release leukotrienes,</td></tr><tr><td>Mast cell spasmogens</td><td></td><td>Chemotaxins</td><td></td><td colspan="2">cytokines, eosinophil proteins etc.</td></tr><tr><td>(e.g histamine,</td><td>Omalizumab</td><td>(e.g. LTB4 ,</td><td></td><td colspan="2">which cause:</td></tr><tr><td>LTC4 , LTD4 etc.)</td><td></td><td>cytokines etc.)</td><td></td><td></td><td></td></tr><tr><td></td><td>Montelukast</td><td></td><td></td><td>Bronchospasm</td><td>↑of hyper-reactivity</td></tr><tr><td></td><td></td><td></td><td></td><td>wheezing, cough</td><td>&amp; inflammation</td></tr><tr><td>Smooth muscle</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Mucosa</td><td>Bronchospasm</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Mucus</td></tr><tr><td></td><td colspan="2">Salbutamol, salmeterol, theophylline,</td><td></td><td></td><td></td></tr><tr><td>Normal bronchiole</td><td colspan="2">ipratropium reverse bronchospasm</td><td></td><td>Beclometasone</td><td></td></tr></table>
</page>
<page number="207">
<table id="p207t1" data-filename="pdftables_fromstorage_023782248" data-page="207" data-table="1"><tr><td></td><td>Step-wise introduction of drugs in patient with chronic asthma based on advice given by the British Thoracic Society</td></tr><tr><td>Step 1</td><td>Patient is started on a short-acting bronchodilator such as salbutamol. Taken by inhalation</td></tr><tr><td></td><td>‘as needed’ – up to once daily.</td></tr><tr><td>Step 2</td><td>If inhalation of the short-acting bronchodilator is needed more than once a day, regular inhaled</td></tr><tr><td></td><td>beclometasone is added.</td></tr><tr><td>Step 3</td><td>If the asthma is not adequately controlled, a long-acting bronchodilator (salmeterol) taken</td></tr><tr><td></td><td>regularly by inhalation is added rather than increasing the doses of beclometasone.</td></tr><tr><td>Step 4</td><td>If the asthma is still not adequately controlled, oral theophylline or montelukast is added –</td></tr><tr><td></td><td>or the dose of inhaled beclometasone is increased.</td></tr><tr><td>Step 5</td><td>If the asthma is still not adequately controlled, a regular single daily dose of an oral corticosteroid</td></tr><tr><td></td><td>(e.g. prednisolone) is added.</td></tr><tr><td></td><td>R&amp;D 7e Ch 27, p 340</td></tr></table>
</page>
<page number="208">
<table id="p208t1" data-filename="pdftables_fromstorage_023782248" data-page="208" data-table="1"><tr><td style="text-align: right">13.01</td><td colspan="2">Furosemide</td><td colspan="2">Kidney</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="9">Diagram of the nephron with 3 tubular cells shown enlarged as a basis for specifying drug action</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Distal convoluted tubule</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>(shown straightened out)</td><td>P</td><td>C</td></tr><tr><td colspan="3">Bowman’s capsule</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>K+</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Na+</td><td>Cl-</td></tr><tr><td colspan="2">Proximal tubule</td><td></td><td></td><td></td><td></td><td>Ascending</td><td></td><td></td></tr><tr><td colspan="3">(shown straightened</td><td></td><td></td><td></td><td>loop (thick</td><td>C</td><td></td></tr><tr><td>out)</td><td></td><td></td><td></td><td></td><td></td><td>segment)</td><td></td><td></td></tr><tr><td>Na+/K+ ATPase</td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Co-transporter</td></tr><tr><td colspan="2">moving Na + out into</td><td></td><td></td><td></td><td></td><td></td><td colspan="2">moving Na+ and Cl-</td></tr><tr><td colspan="2">the interstitium and</td><td></td><td></td><td></td><td></td><td>Collecting</td><td colspan="2">from lumen into cell</td></tr><tr><td>K+ into the cell</td><td></td><td></td><td></td><td></td><td></td><td>tubule</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Na + channel</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Medullary</td><td></td><td>K +</td><td></td></tr><tr><td>P</td><td>Na+</td><td></td><td>Na +</td><td></td><td>loop</td><td>P</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Na +</td><td></td></tr><tr><td></td><td>K+
Cl-</td><td>C</td><td>K +
2Cl-</td><td></td><td></td><td>Na + /K + ATPase</td><td style="text-align: right">-</td><td>Aldosterone</td></tr><tr><td>C</td><td>Cl-</td><td></td><td></td><td></td><td></td><td>moving Na + out</td><td>Cl</td><td>mediator</td></tr><tr><td></td><td></td><td></td><td colspan="3">Symporter moving</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>activates</td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td style="text-align: right">+</td><td style="text-align: right">-</td><td>into the</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Na</td><td>, K</td><td>and 2Cl</td><td></td><td>H 2O</td><td></td></tr><tr><td colspan="2">Symporter moving K + and</td><td></td><td colspan="3">from lumen into cell</td><td>interstitium and</td><td>H2 O</td><td>ADH acts on V 2 receptors</td></tr><tr><td colspan="3">Cl- out of cell into interstitium</td><td></td><td></td><td></td><td>K+ into the cell</td><td>channel</td><td>to increase permeability</td></tr></table>
</page>
<page number="209">
<table id="p209t1" data-filename="pdftables_fromstorage_023782248" data-page="209" data-table="1"><tr><td></td><td>A loop diuretic (Similar drug: bumetanide)</td><td>Furosemide</td></tr><tr><td>Actions</td><td colspan="2">Causes copious urine production by inhibiting NaCl reabsorption in the thick ascending loop.</td></tr><tr><td></td><td colspan="2">Increases excretion of Ca2+ and Mg 2+ , decreases excretion of uric acid.</td></tr><tr><td>MOA</td><td colspan="2">Inhibits the Na +/K+ /2Cl - co-transporter in the luminal membrane by combining with the chloride</td></tr><tr><td></td><td>binding site.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally (can be given i.v. in emergencies), well absorbed, reaches site of action by being</td></tr><tr><td></td><td>secreted into the proximal tubule. Half-life 90min.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Pulmonary oedema, chronic heart failure, ascites due to liver cirrhosis, hypercalcaemia,</td></tr><tr><td></td><td>hyperkalaemia.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Hypokalaemic alkalosis; hyperuricaemia (can precipitate gout); hypovolaemia and hypotension in</td></tr><tr><td></td><td>elderly patients; reversible ototoxicity.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 28, pp 353-354; D&amp;H 2e Ch 26, pp 64-65</td></tr></table>
</page>
<page number="210">
<table id="p210t1" data-filename="pdftables_fromstorage_023782248" data-page="210" data-table="1"><tr><td style="text-align: right" colspan="2">13.02</td><td colspan="2">Hydrochlorothiazide</td><td>Kidney</td><td></td><td></td></tr><tr><td colspan="7">Diagram of the nephron with 3 tubular cells shown enlarged as a basis for specifying drug action</td></tr><tr><td></td><td></td><td></td><td></td><td>Distal convoluted tubule</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>(shown straightened out)</td><td>P</td><td>C</td></tr><tr><td colspan="4">Bowman’s capsule</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>K +</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Na +</td><td>Cl -</td></tr><tr><td colspan="4">Proximal tubule</td><td>Ascending</td><td></td><td></td></tr><tr><td colspan="4">(shown straightened</td><td>loop (thick</td><td>C</td><td></td></tr><tr><td>out)</td><td></td><td></td><td></td><td>segment)</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Collecting</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>tubule</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Na+ channel</td></tr><tr><td></td><td>+
Na</td><td></td><td></td><td>Medullary</td><td>K +</td><td></td></tr><tr><td>P</td><td></td><td></td><td>Na +</td><td>loop</td><td>P</td><td></td></tr><tr><td></td><td>K+</td><td>C</td><td>K +</td><td></td><td>Na+</td><td></td></tr><tr><td>C</td><td>Cl-</td><td></td><td>2Cl-</td><td></td><td></td><td>Aldosterone</td></tr><tr><td></td><td>Cl-</td><td></td><td></td><td></td><td>Cl-</td><td>mediator</td></tr><tr><td></td><td></td><td></td><td style="text-align: right">-</td><td></td><td></td><td>activates</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>H 2O</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>H2 O</td><td>ADH acts on V 2 receptors</td></tr><tr><td></td><td></td><td></td><td>Furosemide</td><td></td><td>channel</td><td>to increase permeability</td></tr></table>
</page>
<page number="211">
<table id="p211t1" data-filename="pdftables_fromstorage_023782248" data-page="211" data-table="1"><tr><td></td><td>Diuretic (Similar drugs: bendroflumethiazide, chlortalidone)</td><td>Hydrochlorothiazide</td></tr><tr><td>Actions</td><td colspan="2">Causes moderate degree of diuresis by inhibiting NaCl reabsorption in the distal tubule.</td></tr><tr><td></td><td colspan="2">Increases K+ and H + excretion. Decreases excretion of Ca2+ and uric acid; increases excretion of</td></tr><tr><td></td><td>Mg 2+. Some vasodilator action.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits the Na + /Cl- co-transporter in the luminal membrane of the distal convoluted tubule.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally; reaches site of action by being secreted into the proximal tubule. Half-life 90min.</td></tr><tr><td>Clinical use</td><td colspan="2">Hypertension. Also mild heart failure; nephrogenic diabetes insipidus; kidney stones.</td></tr><tr><td>Adverse effects</td><td colspan="2">Potassium loss; metabolic alkalosis; hyperuricaemia (can precipitate gout); increased insulin</td></tr><tr><td></td><td>requirement; erectile dysfunction.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 28, p 354; D&amp;H 2e Ch 26, pp 64-65</td></tr></table>
</page>
<page number="212">
<table id="p212t1" data-filename="pdftables_fromstorage_023782248" data-page="212" data-table="1"><tr><td style="text-align: right" colspan="2">13.03</td><td colspan="2">Amiloride</td><td>Kidney</td><td></td><td></td></tr><tr><td colspan="7">Diagram of the nephron with 3 tubular cells shown enlarged as a basis for specifying drug action</td></tr><tr><td></td><td></td><td></td><td></td><td>Distal convoluted tubule</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>(shown straightened out)</td><td>P</td><td>C</td></tr><tr><td colspan="4">Bowman’s capsule</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>K +</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Na +</td><td>Cl -</td></tr><tr><td colspan="4">Proximal tubule</td><td>Ascending</td><td></td><td></td></tr><tr><td colspan="4">(shown straightened</td><td>loop (thick</td><td>C</td><td></td></tr><tr><td>out)</td><td></td><td></td><td></td><td>segment)</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">-</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Hydrochlorothiazide,</td></tr><tr><td></td><td></td><td></td><td></td><td>Collecting</td><td></td><td>bendroflumethiazide</td></tr><tr><td></td><td></td><td></td><td></td><td>tubule</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Na+ channel</td></tr><tr><td></td><td>+
Na</td><td></td><td></td><td>Medullary</td><td>K +</td><td></td></tr><tr><td>P</td><td></td><td></td><td>Na +</td><td>loop</td><td>P</td><td></td></tr><tr><td></td><td>K+</td><td>C</td><td>K+</td><td></td><td>Na+</td><td></td></tr><tr><td>C</td><td>Cl-</td><td></td><td>2Cl-</td><td></td><td></td><td>Aldosterone</td></tr><tr><td></td><td>Cl-</td><td></td><td></td><td></td><td>Cl-</td><td>mediator</td></tr><tr><td></td><td></td><td></td><td style="text-align: right">-</td><td></td><td></td><td>activates</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>H 2 O</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>H2 O</td><td>ADH acts on V2 receptors</td></tr><tr><td></td><td></td><td></td><td>Furosemide</td><td></td><td>channel</td><td>to increase permeability</td></tr></table>
</page>
<page number="213">
<table id="p213t1" data-filename="pdftables_fromstorage_023782248" data-page="213" data-table="1"><tr><td></td><td>Potassium-sparing diuretic (Similar drug triamterene)</td><td>Amiloride</td></tr><tr><td>Actions</td><td colspan="2">Inhibits sodium reabsorption in the distal nephron; has limited diuretic effficacy.</td></tr><tr><td></td><td>Reduces K+ excretion.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits the sodium channel in the luminal membrane of the collecting tubule, reducing sodium</td></tr><tr><td></td><td>influx.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally. Triamterene has more rapid onset and shorter duration of action than amiloride.</td></tr><tr><td>Clinical use</td><td>Given with K+ -losing diuretics (thiazides, loop diuretics) to limit K+ loss.</td><td></td></tr><tr><td>Adverse effects</td><td>Hyperkalaemia; may cause acidosis.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 28, p 356; D&amp;H 2e Ch 26, pp 64-65</td></tr></table>
</page>
<page number="214">
<table id="p214t1" data-filename="pdftables_fromstorage_023782248" data-page="214" data-table="1"><tr><td style="text-align: right" colspan="2">13.04</td><td colspan="2">Spironolactone</td><td>Kidney</td><td></td><td></td><td></td></tr><tr><td colspan="7">Diagram of the nephron with 3 tubular cells shown enlarged as a basis for specifying drug action</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Distal convoluted tubule</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>(shown straightened out)</td><td>P</td><td>C</td><td></td></tr><tr><td colspan="4">Bowman’s capsule</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>K +</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Na +</td><td>Cl -</td><td></td></tr><tr><td colspan="4">Proximal tubule</td><td>Ascending</td><td></td><td></td><td></td></tr><tr><td colspan="4">(shown straightened</td><td>loop (thick</td><td>C</td><td></td><td></td></tr><tr><td>out)</td><td></td><td></td><td></td><td>segment)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">-</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Hydrochlorothiazide,</td></tr><tr><td></td><td></td><td></td><td></td><td>Collecting</td><td></td><td colspan="2">bendroflumethiazide</td></tr><tr><td></td><td></td><td></td><td></td><td>tubule</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Na+ channel</td></tr><tr><td></td><td>Na+</td><td></td><td></td><td>Medullary</td><td>K +</td><td></td><td>Amiloride,</td></tr><tr><td>P</td><td></td><td></td><td>Na +</td><td>loop</td><td>P</td><td style="text-align: right">-</td><td>triamterene</td></tr><tr><td></td><td>K+</td><td>C</td><td>K+</td><td></td><td>Na+</td><td></td><td></td></tr><tr><td>C</td><td>Cl-</td><td></td><td>2Cl-</td><td></td><td></td><td></td><td>Aldosterone</td></tr><tr><td></td><td>Cl-</td><td></td><td></td><td></td><td>Cl-</td><td></td><td>mediator</td></tr><tr><td></td><td></td><td></td><td style="text-align: right">-</td><td></td><td></td><td></td><td>activates</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>H 2 O</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>H2 O</td><td colspan="2">ADH acts on V2 receptors</td></tr><tr><td></td><td></td><td></td><td>Furosemide</td><td></td><td>channel</td><td colspan="2">to increase permeability</td></tr></table>
</page>
<page number="215">
<table id="p215t1" data-filename="pdftables_fromstorage_023782248" data-page="215" data-table="1"><tr><td></td><td>Potassium-sparing diuretic (Similar drug eplerenone)</td><td>Spironolactone</td></tr><tr><td>Actions</td><td colspan="2">Inhibits sodium reabsorption in the distal nephron; has limited diuretic effficacy.</td></tr><tr><td></td><td>Reduces K+ excretion.</td><td></td></tr><tr><td>MOA</td><td colspan="2">It is a competitive antagonist of aldosterone; causes diuresis by preventing the production of the</td></tr><tr><td></td><td colspan="2">aldosterone mediator that normally causes influx of sodium by activating the sodium channel in the</td></tr><tr><td></td><td>luminal membrane of the collecting tubule.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally, gives rise to active metabolite, canrenone, which has a plasma half-life of 16h.</td></tr><tr><td></td><td>Eplerenone has no active metabolite and a shorter half-life.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Hypertension, given with K+ -losing diuretics (thiazides, loop diuretics) to limit K+ loss.</td></tr><tr><td></td><td>Primary and secondary hyperaldosteronism.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Hyperkalaemia; hyperchloraemic acidosis. Can cause gynaecomastia (less likely with eplerenone).</td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 28, p 355; D&amp;H 2e Ch 26, pp 64-65</td></tr></table>
</page>
<page number="216">
<table id="p216t1" data-filename="pdftables_fromstorage_023782248" data-page="216" data-table="1"><tr><td style="text-align: right" colspan="2">13.05</td><td colspan="2">Mannitol</td><td>Kidney</td><td></td><td></td><td></td></tr><tr><td colspan="8">Diagram of the nephron with 3 tubular cells shown enlarged as a basis for specifying drug action</td></tr><tr><td></td><td></td><td></td><td></td><td>Distal convoluted tubule</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>(shown straightened out)</td><td>P</td><td>C</td><td></td></tr><tr><td colspan="4">Bowman’s capsule</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>K +</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Na +</td><td>Cl -</td><td></td></tr><tr><td colspan="4">Proximal tubule</td><td>Ascending</td><td></td><td></td><td></td></tr><tr><td colspan="4">(shown straightened</td><td>loop (thick</td><td>C</td><td></td><td></td></tr><tr><td>out)</td><td></td><td></td><td></td><td>segment)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">-</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Hydrochlorothiazide,</td></tr><tr><td></td><td></td><td></td><td></td><td>Collecting</td><td></td><td colspan="2">bendroflumethiazide</td></tr><tr><td></td><td></td><td></td><td></td><td>tubule</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Na + channel</td></tr><tr><td></td><td>Na+</td><td></td><td></td><td>Medullary</td><td>K+</td><td></td><td>Amiloride,</td></tr><tr><td>P</td><td></td><td></td><td>Na +</td><td>loop</td><td>P</td><td style="text-align: right">-</td><td>triamterene</td></tr><tr><td></td><td>K+</td><td>C</td><td>K+</td><td></td><td>Na+</td><td></td><td></td></tr><tr><td></td><td>Cl-</td><td></td><td>2Cl-</td><td></td><td></td><td></td><td>Spironolactone</td></tr><tr><td>C</td><td>Cl-</td><td></td><td></td><td></td><td>Cl-</td><td></td><td>is an aldosterone</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>antagonist</td></tr><tr><td></td><td></td><td></td><td style="text-align: right">-</td><td></td><td>H 2 O</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Furosemide</td><td></td><td>H 2 O</td><td colspan="2">Aldosterone mediator</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>channel</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>activates</td></tr></table>
</page>
<page number="217">
<table id="p217t1" data-filename="pdftables_fromstorage_023782248" data-page="217" data-table="1"><tr><td></td><td>Osmotic diuretic</td><td>Mannitol</td></tr><tr><td>Actions</td><td colspan="2">Increases the amount or water excreted by the kidney; has a smaller effect on sodium excretion.</td></tr><tr><td>MOA</td><td colspan="2">It is an inert compound that passes across into the filtrate at the glomerulus and is not resorbed.</td></tr><tr><td></td><td>Acts in those parts of the nephron that are freely permeable to water.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given intravenously, not metabolised, excreted in about 30min.</td><td></td></tr><tr><td>Clinical use</td><td>Cerebral oedema; increased intraocular pressure.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Temporary expansion of the extracellur fluid compartment and hyponatraemia due to osmotic</td></tr><tr><td></td><td>extraction of intracellular water. Pulmonary oedema may occur.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 28, p 356; D&amp;H 2e Ch 26, pp 64-65</td></tr></table>
</page>
<page number="218">
<table id="p218t1" data-filename="pdftables_fromstorage_023782248" data-page="218" data-table="1"><tr><td style="text-align: right" colspan="2">13.06</td><td>Kidney</td><td>What drug will turn the urine alkaline?</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">Diagram of the nephron with 3 tubular cells shown enlarged</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Distal convoluted tubule</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>(shown straightened out)</td><td>P</td><td>C</td><td></td></tr><tr><td colspan="3">Bowman’s capsule</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>K +</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Na +</td><td>Cl -</td><td></td></tr><tr><td colspan="3">Proximal tubule</td><td>Mannitol</td><td>Ascending</td><td></td><td></td><td></td></tr><tr><td colspan="3">(shown straightened</td><td></td><td></td><td>C</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>increases</td><td>loop (thick</td><td></td><td></td><td></td></tr><tr><td>out)</td><td></td><td></td><td>osmotic</td><td>segment)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>pressure</td><td></td><td style="text-align: right">-</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Hydrochlorothiazide,</td></tr><tr><td></td><td></td><td></td><td></td><td>Collecting</td><td></td><td colspan="2">bendroflumethiazide</td></tr><tr><td></td><td></td><td></td><td></td><td>tubule</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Na + channel</td></tr><tr><td></td><td>Na+</td><td></td><td>Medullary</td><td></td><td>K +</td><td></td><td>Amiloride,</td></tr><tr><td>P</td><td></td><td>Na +</td><td>loop</td><td>P</td><td></td><td style="text-align: right">-</td><td>triamterene</td></tr><tr><td></td><td>K+</td><td>C</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Cl-</td><td>K+2Cl-</td><td></td><td></td><td>Na +</td><td></td><td>Spironolactone</td></tr><tr><td>C</td><td>Cl-</td><td></td><td></td><td></td><td>Cl-</td><td></td><td>is an aldosterone</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>antagonist</td></tr><tr><td></td><td></td><td style="text-align: right">-</td><td></td><td></td><td>H 2 O</td><td></td><td></td></tr><tr><td></td><td></td><td>Furosemide</td><td></td><td></td><td>H 2O</td><td colspan="2">Aldosterone mediator</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>channel</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>activates</td></tr></table>
</page>
<page number="219">
<table id="p219t1" data-filename="pdftables_fromstorage_023782248" data-page="219" data-table="1"><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Alkalinization of the urine</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Distal convoluted tubule</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>(shown straightened out)</td><td>P</td><td>C</td><td></td></tr><tr><td colspan="3">Bowman’s capsule</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>K +</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Na+</td><td>Cl -</td><td></td></tr><tr><td colspan="3">Proximal tubule</td><td>Mannitol</td><td>Ascending</td><td></td><td></td><td></td></tr><tr><td colspan="3">(shown straightened</td><td></td><td></td><td>C</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>increases</td><td>loop (thick</td><td></td><td></td><td></td></tr><tr><td>out)</td><td></td><td></td><td>osmotic</td><td>segment)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>pressure</td><td></td><td style="text-align: right">-</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Hydrochlorothiazide,</td></tr><tr><td></td><td></td><td></td><td></td><td>Collecting</td><td></td><td colspan="2">bendroflumethiazide</td></tr><tr><td></td><td></td><td></td><td></td><td>tubule</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Na + channel</td></tr><tr><td></td><td>Na+</td><td></td><td>Medullary</td><td></td><td>K +</td><td></td><td>Amiloride,</td></tr><tr><td>P</td><td></td><td>Na +</td><td>loop</td><td>P</td><td></td><td style="text-align: right">-</td><td>triamterene</td></tr><tr><td></td><td>K+</td><td>C</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Cl-</td><td>K +2Cl-</td><td></td><td></td><td>Na +</td><td></td><td>Spironolactone</td></tr><tr><td>C</td><td>Cl-</td><td></td><td></td><td>Potassium or</td><td>Cl-</td><td></td><td>is an aldosterone</td></tr><tr><td></td><td></td><td></td><td></td><td>sodium citrate*</td><td></td><td></td><td>antagonist</td></tr><tr><td></td><td></td><td style="text-align: right">-</td><td></td><td>turns urine alkaline</td><td>H 2O</td><td></td><td></td></tr><tr><td></td><td></td><td>Furosemide</td><td>*Given orally. Adverse effects: mild</td><td></td><td>H2 O</td><td colspan="2">Aldosterone mediator</td></tr><tr><td></td><td></td><td></td><td>diuresis, hyperkalaemia with high doses</td><td></td><td>channel</td><td></td><td>activates</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">R&amp;D 7e Ch 28, pp 356-357</td></tr></table>
</page>
<page number="220">
<table id="p220t1" data-filename="pdftables_fromstorage_023782248" data-page="220" data-table="1"><tr><td style="text-align: right">14.01</td><td>Cimetidine</td><td>GIT drugs</td><td>Gastric Ulcer</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6">Factors influencing gastric HCl secretion and the development of gastric ulcers</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Gastrin</td><td></td><td>G</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td>Helicobacter pylori</td><td colspan="2">Gastrin release</td><td></td><td></td><td></td><td>‘Mast cell’</td></tr><tr><td></td><td></td><td></td><td></td><td>G</td><td>Histamine</td><td></td><td>M</td></tr><tr><td></td><td></td><td colspan="2">Gastric lumen</td><td>Parietal cell</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td>Mucosal</td><td>K +</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>damage</td><td></td><td>C</td><td></td><td></td><td>H 2</td><td></td></tr><tr><td></td><td></td><td>Cl-</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ulcer</td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>H +</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>PP</td><td>K+</td><td></td><td>M</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td>ACh</td></tr><tr><td></td><td></td><td></td><td></td><td>PG</td><td></td><td></td><td></td></tr><tr><td></td><td>PP proton pump</td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Parietal cell</td><td></td><td></td><td></td></tr><tr><td></td><td>C K+-Cl- symport carrier</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>G gastrin receptor</td><td></td><td></td><td></td><td>PGE 2</td><td></td><td></td></tr><tr><td></td><td>H2 histamine receptor</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>M muscarinic receptor</td><td></td><td></td><td>NSAIDs</td><td></td><td></td><td></td></tr><tr><td></td><td>PG prostaglandin receptor</td><td></td><td></td><td>(NSAIDS are ulcerogenic)</td><td>Arachidonate</td><td></td><td>Vagus nerve</td></tr></table>
</page>
<page number="221">
<table id="p221t1" data-filename="pdftables_fromstorage_023782248" data-page="221" data-table="1"><tr><td></td><td>Histamine H2 receptor antagonist (Similar drugs: ranitidine, famotidine and nizatidine)</td><td>Cimetidine</td></tr><tr><td>Actions</td><td colspan="2">Inhibits gastric acid secretion. Inhibits action of histamine released from mast cell-like cells in the</td></tr><tr><td></td><td colspan="2">gastric mucosa. Partially inhibits acid secretion stimulated by gastrin or vagal stimulation.</td></tr><tr><td>MOA</td><td colspan="2">Selective, reversible, competitive antagonism of histamine H2 receptors on parietal cells.</td></tr><tr><td>Abs/Distrib/Elim</td><td>Oral administration. (T 0.5,2h, ranitidine 3h).</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Peptic and duodenal ulcers. Gastro-oesophageal reflux disease. NSAID-induced ulcers (with</td></tr><tr><td></td><td>discontinuation of NSAID).</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Uncommon. Headache, GIT disturbances. Confusion, disorientation in elderly. Antiandrogenic effects</td></tr><tr><td></td><td colspan="2">with cimetidine but not other H 2 blockers – gynaecomastia in men and galactorrhoea in women.</td></tr><tr><td>Special points</td><td colspan="2">Cimetidine (but not the other H2 antagonists) is a potent cytochrome P450 inhibitor. Many</td></tr><tr><td></td><td colspan="2">interactions due to increased plasma concentration of other drugs (e.g. propranolol,</td></tr><tr><td></td><td colspan="2">benzodiazepines, phenytoin, warfarin). Cimetidine and ranitidine also inhibit renal tubular secretion</td></tr><tr><td></td><td>of other drugs.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 29, p 363; D&amp;H 2e Ch 27, p 66</td></tr></table>
</page>
<page number="222">
<table id="p222t1" data-filename="pdftables_fromstorage_023782248" data-page="222" data-table="1"><tr><td style="text-align: right">14.02</td><td>Omeprazole</td><td>GIT drugs</td><td>Gastric Ulcer</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6">Factors influencing gastric HCl secretion and the development of gastric ulcers</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Gastrin</td><td></td><td></td><td>G</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td>Helicobacter pylori</td><td colspan="2">Gastrin release</td><td></td><td></td><td></td><td></td><td>‘Mast cell’</td></tr><tr><td></td><td></td><td></td><td></td><td>G</td><td colspan="2">Histamine</td><td></td><td>M</td></tr><tr><td></td><td></td><td colspan="2">Gastric lumen</td><td>Parietal cell</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td></td><td>Mucosal</td><td>K+</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>damage</td><td></td><td>C</td><td></td><td>H 2</td><td>–</td><td>Cimetidine, ranitidine</td><td></td></tr><tr><td></td><td></td><td>Cl-</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ulcer</td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>H +</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>PP</td><td>K+</td><td>M</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td>ACh</td></tr><tr><td></td><td></td><td></td><td></td><td>PG</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>PP proton pump</td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Parietal cell</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>C K+-Cl- symport carrier</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>G gastrin receptor</td><td></td><td></td><td></td><td>PGE 2</td><td></td><td></td><td></td></tr><tr><td></td><td>H2 histamine receptor</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>M muscarinic receptor</td><td></td><td></td><td>NSAIDs</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>PG prostaglandin receptor</td><td></td><td></td><td>(NSAIDS are ulcerogenic)</td><td colspan="2">Arachidonate</td><td></td><td>Vagus nerve</td></tr></table>
</page>
<page number="223">
<table id="p223t1" data-filename="pdftables_fromstorage_023782248" data-page="223" data-table="1"><tr><td></td><td>Proton pump inhibitor (PPI) (Similar drug: lansoprazole)</td><td>Omeprazole</td></tr><tr><td>Actions</td><td>Inhibition of gastric acid secretion.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Binds irreversibly to the H+ /K+ -ATPase (proton pump) in the gastric parietal cells to inhibit H+</td></tr><tr><td></td><td colspan="2">transport. Omeprazole (like other PPIs) is a prodrug. The acidic conditions in the parietal cell</td></tr><tr><td></td><td>canaliculi convert the drug to the active form.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Mainly eliminated by rapid P450 metabolism in liver (T0.5 ,1–2h), but duration of action is long</td></tr><tr><td></td><td colspan="2">(2–3days) because of covalent binding. The production of new PP molecules determines the</td></tr><tr><td></td><td colspan="2">rate of recovery. Needs enteric coating to prevent action of acid before absorption.</td></tr><tr><td>Clinical use</td><td colspan="2">Duodenal and peptic ulcer. Gastro-oesophageal reflux disease. Zollinger-Ellison syndrome. As part of</td></tr><tr><td></td><td colspan="2">the triple therapy for Helicobacter pylori-dependent ulcers. Treatment of NSAID-associated ulcers.</td></tr><tr><td></td><td>PPIs are more effective than H2 antagonists.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Generally very safe. Occasionally, headache, abdominal pain, diarrhoea, flatulence and nausea.</td></tr><tr><td></td><td colspan="2">Long-term use can cause hypergastrinaemia which may increase risk of gastric carcinoid tumours.</td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 29, p 363; D&amp;H 2e Ch 27, p 66</td></tr></table>
</page>
<page number="224">
<table id="p224t1" data-filename="pdftables_fromstorage_023782248" data-page="224" data-table="1"><tr><td style="text-align: right">14.03</td><td colspan="3">Clarithromycin/amoxicillin/omeprazole triple therapy</td><td colspan="2">GIT drugs</td><td>Gastric Ulcer</td><td></td></tr><tr><td colspan="5">Factors influencing gastric HCl secretion and the development of gastric ulcers</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Gastrin</td><td></td><td>G</td></tr><tr><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td>Helicobacter pylori</td><td>Gastrin release</td><td></td><td></td><td></td><td></td><td>‘Mast cell’</td></tr><tr><td></td><td></td><td></td><td>G</td><td colspan="2">Histamine</td><td></td><td>M</td></tr><tr><td></td><td></td><td>Gastric lumen</td><td>Parietal cell</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td>Mucosal</td><td>K +</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>damage</td><td>C</td><td></td><td>H 2</td><td>–</td><td>Cimetidine, ranitidine</td><td></td></tr><tr><td></td><td></td><td>Cl-</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ulcer</td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>H +</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>PP</td><td>K+</td><td>M</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td>ACh</td></tr><tr><td></td><td>Omeprazole, lansoprazole</td><td></td><td>PG</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>PP proton pump</td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Parietal cell</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>C K+-Cl- symport carrier</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>G gastrin receptor</td><td></td><td></td><td>PGE 2</td><td></td><td></td><td></td></tr><tr><td></td><td>H2 histamine receptor</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>M muscarinic receptor</td><td></td><td>NSAIDs</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>PG prostaglandin receptor</td><td></td><td>(NSAIDS are ulcerogenic)</td><td colspan="2">Arachidonate</td><td></td><td>Vagus nerve</td></tr></table>
</page>
<page number="225">
<table id="p225t1" data-filename="pdftables_fromstorage_023782248" data-page="225" data-table="1"><tr><td></td><td>Macrolide antibiotic for eradication of Helicobacter pylori</td><td>Clarithromycin</td></tr><tr><td>Actions</td><td>Bactericidal.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Kills bacteria by binding to their ribosomes to inhibit protein synthesis.</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Active orally. Metabolised by liver (with significant first-pass metabolism). t1⁄2 3–4h.</td></tr><tr><td>Clinical use</td><td colspan="2">Many peptic ulcers occur secondary to H. pylori infection. Triple therapy (a combination of two</td></tr><tr><td></td><td colspan="2">antibiotics with a proton pump inhibitor or H2 antagonist) is an effective treatment. Amoxicillin may</td></tr><tr><td></td><td>be replaced by metronidazole in patients allergic to penicillins.</td><td></td></tr><tr><td>Adverse effects</td><td>Gastrointestinal upsets – diarrhoea, nausea.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 29, pp 364-365; D&amp;H 2e Ch 27, p 66</td></tr></table>
</page>
<page number="226">
<table id="p226t1" data-filename="pdftables_fromstorage_023782248" data-page="226" data-table="1"><tr><td style="text-align: right">14.04</td><td colspan="3">Bismuth chelate (tripotassium dicitratobismuthate,</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>GIT drugs</td><td colspan="2">Gastric Ulcer</td><td></td></tr><tr><td></td><td colspan="2">bismuth subsalicylate used in USA)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6">Factors influencing gastric HCl secretion and the development of gastric ulcers</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Metronidazole, clarithromycin,</td><td></td><td>Gastrin</td><td></td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td>–</td><td>amoxicillin</td><td></td><td></td><td></td><td></td><td></td><td>G</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td>Helicobacter pylori</td><td>Gastrin release</td><td></td><td></td><td></td><td></td><td></td><td>‘Mast cell’</td></tr><tr><td></td><td></td><td></td><td></td><td>G</td><td colspan="2">Histamine</td><td></td><td>M</td></tr><tr><td></td><td></td><td>Gastric lumen</td><td></td><td>Parietal cell</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td></td><td>Mucosal</td><td>K +</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>damage</td><td>C</td><td></td><td></td><td>H 2</td><td>–</td><td>Cimetidine, ranitidine</td><td></td></tr><tr><td></td><td></td><td>Cl-</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ulcer</td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>H +</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>PP</td><td></td><td>K+</td><td>M</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td>ACh</td></tr><tr><td></td><td>Omeprazole, lansoprazole</td><td></td><td></td><td>PG</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>PP proton pump</td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Parietal cell</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>C K+-Cl- symport carrier</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>G gastrin receptor</td><td></td><td></td><td></td><td>PGE 2</td><td></td><td></td><td></td></tr><tr><td></td><td>H2 histamine receptor</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Mmuscarinic receptor</td><td></td><td></td><td>NSAIDs</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>PG prostaglandin receptor</td><td></td><td>(NSAIDS are ulcerogenic)</td><td></td><td colspan="2">Arachidonate</td><td></td><td>Vagus nerve</td></tr></table>
</page>
<page number="227">
<table id="p227t1" data-filename="pdftables_fromstorage_023782248" data-page="227" data-table="1"><tr><td></td><td>Mucosal protectant and antibacterial agent</td><td>Bismuth chelate</td></tr><tr><td>Actions</td><td>Antidiarrhoea / antiulcer.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Antibacterial action against H. pylori plus a protective effect on the gastric mucosa. Coats</td></tr><tr><td></td><td colspan="2">ulcer/mucosa to reduce action of acid and pepsin and may increase mucus and bicarbonate</td></tr><tr><td></td><td>secretion. May also enhance prostaglandin synthesis.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Very little (1%) of oral dose is absorbed into the systemic circulation.</td></tr><tr><td>Clinical use</td><td colspan="2">(I) Duodenal ulcers (in combination with metronidazole and tetracycline). Ranitidine bismuth citrate</td></tr><tr><td></td><td colspan="2">is used with antibiotics to eradicate H. pylori infection. (II) Diarrhoea (including travellers’, binds</td></tr><tr><td></td><td>enterotoxins).</td><td></td></tr><tr><td>Adverse effects</td><td>Low frequency of side effects: nausea, vomiting, black stools.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 29, p 365; D&amp;H 2e Ch 27, p 66</td></tr></table>
</page>
<page number="228">
<table id="p228t1" data-filename="pdftables_fromstorage_023782248" data-page="228" data-table="1"><tr><td style="text-align: right">14.05</td><td colspan="2">Sucralfate</td><td>GIT drugs</td><td>Gastric Ulcer</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7">Factors influencing gastric HCl secretion and the development of gastric ulcers</td><td></td><td></td><td></td></tr><tr><td colspan="2">Bismuth chelate</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Metronidazole, clarithromycin,</td><td></td><td>Gastrin</td><td></td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td>–</td><td>–</td><td colspan="2">amoxicillin</td><td></td><td></td><td></td><td></td><td>G</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td>–</td><td colspan="2">Helicobacter pylori</td><td colspan="2">Gastrin release</td><td></td><td></td><td></td><td></td><td>‘Mast cell’</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>G</td><td colspan="2">Histamine</td><td></td><td>M</td></tr><tr><td></td><td></td><td></td><td colspan="2">Gastric lumen</td><td>Parietal cell</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td></td><td>Mucosal</td><td></td><td>K +</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>damage</td><td></td><td></td><td>C</td><td></td><td>H 2</td><td>-–</td><td>Cimetidine, ranitidine</td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">-</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Cl</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ulcer</td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>H +</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>PP</td><td>K+</td><td>M</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td>ACh</td></tr><tr><td></td><td colspan="3">Omeprazole, lansoprazole</td><td></td><td>PG</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">PP proton pump</td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Parietal cell</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">C K+-Cl- symport carrier</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">G gastrin receptor</td><td></td><td></td><td></td><td>PGE 2</td><td></td><td></td><td></td></tr><tr><td colspan="3">H2 histamine receptor</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">M muscarinic receptor</td><td></td><td></td><td>NSAIDs</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">PG prostaglandin receptor</td><td></td><td>(NSAIDS are ulcerogenic)</td><td colspan="2">Arachidonate</td><td></td><td>Vagus nerve</td></tr></table>
</page>
<page number="229">
<table id="p229t1" data-filename="pdftables_fromstorage_023782248" data-page="229" data-table="1"><tr><td></td><td>Mucosal protectant</td><td>Sucralfate</td></tr><tr><td>Actions</td><td colspan="2">Prevents damage to gut mucosa by HCl, pepsin and bile acids. Stimulates mucosal secretion of</td></tr><tr><td></td><td>mucus, bicarbonate and prostaglandins.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Sucralfate is a complex of aluminium hydroxide and sulfated sucrose. This forms a viscous paste</td></tr><tr><td></td><td colspan="2">which adheres to ulcer bases to provide a protective barrier. Antacids and drugs reducing acid</td></tr><tr><td></td><td>secretion will inhibit its action.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Given orally. Local action, virtually no absorption.</td><td></td></tr><tr><td>Clinical use</td><td>Gastric and duodenal ulcer. Gastro-oesophageal reflux disease.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Constipation. Formation of solid complexes (bezoars) within stomach. Aluminium toxicity in patients</td></tr><tr><td></td><td>with renal impairment.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Sucralfate will reduce the absorption of many drugs and food substances. This can be minimised by</td></tr><tr><td></td><td>taking them 2h before sucralfate.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 29, p 365; D&amp;H 2e Ch 27, p 66</td></tr></table>
</page>
<page number="230">
<table id="p230t1" data-filename="pdftables_fromstorage_023782248" data-page="230" data-table="1"><tr><td style="text-align: right">14.06</td><td colspan="3">Aluminium hydroxide</td><td>GIT drugs</td><td>Gastric Ulcer</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7">Factors influencing gastric HCl secretion and the development of gastric ulcers</td><td></td><td></td><td></td></tr><tr><td colspan="2">Bismuth chelate</td><td></td><td colspan="2">Metronidazole, clarithromycin,</td><td></td><td>Gastrin</td><td></td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td>–</td><td>–</td><td>amoxicillin</td><td></td><td></td><td></td><td></td><td></td><td>G</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td>–</td><td colspan="2">Helicobacter pylori</td><td colspan="2">Gastrin release</td><td></td><td></td><td></td><td></td><td>‘Mast cell’</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>G</td><td colspan="2">Histamine</td><td></td><td>M</td></tr><tr><td></td><td></td><td></td><td>Gastric lumen</td><td></td><td>Parietal cell</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td></td><td>Mucosal</td><td></td><td>K +</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>damage</td><td></td><td></td><td>C</td><td></td><td>H 2</td><td>–</td><td>Cimetidine, ranitidine</td><td></td></tr><tr><td></td><td></td><td></td><td>Cl-</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ulcer</td><td>–</td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>H +</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Sucralfate</td><td></td><td>K+</td><td></td><td>M</td><td></td><td></td><td style="text-align: right">+</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td>ACh</td></tr><tr><td></td><td colspan="3">Omeprazole, lansoprazole</td><td></td><td>PG</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">PP proton pump</td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Parietal cell</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">C K+-Cl- symport carrier</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">G gastrin receptor</td><td></td><td></td><td></td><td>PGE 2</td><td></td><td></td><td></td></tr><tr><td colspan="3">H2 histamine receptor</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">M muscarinic receptor</td><td></td><td></td><td>NSAIDs</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">PG prostaglandin receptor</td><td colspan="2">(NSAIDS are ulcerogenic)</td><td colspan="2">Arachidonate</td><td></td><td>Vagus nerve</td></tr></table>
</page>
<page number="231">
<table id="p231t1" data-filename="pdftables_fromstorage_023782248" data-page="231" data-table="1"><tr><td colspan="2">Antacid (Similar drugs: magnesium hydroxide, sodium bicarbonate, calcium carbonate)</td><td>Aluminium hydroxide</td></tr><tr><td>Actions</td><td>Lowers pH in gut lumen.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Antacids are weak bases that neutralise the HCl secreted in the stomach. The elevation of pH also</td></tr><tr><td></td><td colspan="2">usefully reduces the activity of pepsin. Stimulates prostaglandin synthesis.</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Aluminium and magnesium hydroxides are poorly absorbed from the gut (no systemic actions).</td></tr><tr><td></td><td colspan="2">NaHCO 3 and CaCO3 are absorbed and may have significant systemic actions.</td></tr><tr><td>Clinical use</td><td colspan="2">Short-term symptom relief for duodenal ulcers. Gastro-oesophageal reflux disease.Needs to be taken</td></tr><tr><td></td><td>5–7 times daily.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Al(OH)3 causes constipation. Mg(OH)2 has a strong laxative action (osmotic purgative). NaHCO3 and</td></tr><tr><td></td><td colspan="2">CaCO 3 release CO2 which causes belching and also metabolic alkalosis.</td></tr><tr><td></td><td>CaCO3 causes hypercalcaemia.</td><td></td></tr><tr><td>Special point</td><td colspan="2">Calcium and aluminium salts complex with orally administered tetracyclines to prevent their</td></tr><tr><td></td><td>absorption.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 29, p 364; D&amp;H 2e Ch 27, p 66</td></tr></table>
</page>
<page number="232">
<table id="p232t1" data-filename="pdftables_fromstorage_023782248" data-page="232" data-table="1"><tr><td style="text-align: right">14.07</td><td colspan="2">Misoprostol</td><td></td><td>GIT drugs</td><td>Gastric Ulcer</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">Factors influencing gastric HCl secretion and the development of gastric ulcers</td><td></td><td></td><td></td></tr><tr><td colspan="2">Bismuth chelate</td><td></td><td colspan="3">Metronidazole, clarithromycin,</td><td></td><td>Gastrin</td><td></td><td></td><td style="text-align: right">+</td></tr><tr><td></td><td>–</td><td>–</td><td></td><td>amoxicillin</td><td></td><td></td><td></td><td></td><td></td><td>G</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td>–</td><td colspan="3">Helicobacter pylori</td><td colspan="2">Gastrin release</td><td></td><td></td><td></td><td></td><td>‘Mast cell’</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>G</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Histamine</td><td></td><td>M</td></tr><tr><td></td><td></td><td></td><td></td><td>Gastric lumen</td><td></td><td>Parietal cell</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td></td><td>Mucosal</td><td></td><td></td><td>K +</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>damage</td><td></td><td></td><td></td><td></td><td>C</td><td>H 2</td><td>–</td><td>Cimetidine, ranitidine</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Cl-</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ulcer</td><td>–</td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>H +</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Sucralfate</td><td>–</td><td></td><td></td><td>K+</td><td>M</td><td></td><td></td><td style="text-align: right">+</td></tr><tr><td></td><td colspan="2">Antacids</td><td></td><td>–</td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>ACh</td></tr><tr><td></td><td colspan="3">Omeprazole, lansoprazole</td><td></td><td></td><td>PG</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">PP proton pump</td><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Parietal cell</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">C K+-Cl- symport carrier</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">G gastrin receptor</td><td></td><td></td><td></td><td></td><td>PGE 2</td><td></td><td></td><td></td></tr><tr><td colspan="3">H2 histamine receptor</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">M muscarinic receptor</td><td></td><td></td><td></td><td>NSAIDs</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">P G prostaglandin receptor</td><td></td><td colspan="2">(NSAIDS are ulcerogenic)</td><td colspan="2">Arachidonate</td><td></td><td>Vagus nerve</td></tr></table>
</page>
<page number="233">
<table id="p233t1" data-filename="pdftables_fromstorage_023782248" data-page="233" data-table="1"><tr><td></td><td>Prostaglandin E receptor agonist</td><td>Misoprostol</td></tr><tr><td>Actions</td><td colspan="2">Promotes gastric ulcer healing. Combats the ulcerogenic action of NSAIDs.</td></tr><tr><td>MOA</td><td colspan="2">Activates prostaglandin receptors (EP3 subtype ) to inhibit acid secretion. Effects mediated by</td></tr><tr><td></td><td colspan="2">Gi -mediated inhibition of adenylate cyclase. Additionally stimulates bicarbonate and mucus</td></tr><tr><td></td><td>secretion.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Well absorbed orally. Rapidly hydrolysed to free acid which is the active moiety. T0.5 30–40min.</td></tr><tr><td>Clinical use</td><td colspan="2">Gastric ulcers – particularly those caused by NSAIDs and where the NSAIDs cannot be</td></tr><tr><td></td><td>withdrawn. Abortifacient.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Diarrhoea, abdominal cramps. Should be avoided in pregnancy because of contractile action on</td></tr><tr><td></td><td>uterus.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 29, p 362; D&amp;H 2e Ch 27, p 66</td></tr></table>
</page>
<page number="234">
<table id="p234t1" data-filename="pdftables_fromstorage_023782248" data-page="234" data-table="1"><tr><td style="text-align: right">14.08</td><td>Promethazine</td><td>GIT drugs</td><td>Antiemetics</td><td></td></tr><tr><td colspan="3">The central control of vomiting and stimuli resulting in emesis</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">CTZ = chemoreceptor trigger zone</td></tr><tr><td></td><td>Disorienting motion</td><td>Unpleasant/emotional</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>sensations</td><td></td></tr><tr><td></td><td></td><td>(repulsive experiences)</td><td></td><td></td></tr><tr><td></td><td>Labyrinth</td><td></td><td>Higher centres</td><td></td></tr><tr><td></td><td>Vestibular nuclei</td><td></td><td>Vomiting centre</td><td></td></tr><tr><td></td><td></td><td></td><td>in medulla</td><td></td></tr><tr><td></td><td></td><td></td><td>CTZ in</td><td></td></tr><tr><td>CNS</td><td></td><td></td><td>area postrema</td><td></td></tr><tr><td>Periphery</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Muscles involved</td></tr><tr><td></td><td>Stimuli to pharynx/stomach</td><td></td><td>Toxins/drugs</td><td>in vomiting</td></tr><tr><td></td><td>via vagus and nucleus of</td><td></td><td></td><td></td></tr><tr><td></td><td>solitary tract</td><td></td><td></td><td></td></tr></table>
</page>
<page number="235">
<table id="p235t1" data-filename="pdftables_fromstorage_023782248" data-page="235" data-table="1"><tr><td></td><td>Histamine H1-receptor antagonist (Similar drugs: cyclizine, meclizine, cinnarizine)</td><td>Promethazine</td></tr><tr><td>Actions</td><td colspan="2">Antiemetic. Sedative. (Also prevents histamine’s actions in the periphery, e.g. Use in hay fever</td></tr><tr><td></td><td>(see card 4.07).</td><td></td></tr><tr><td>MOA</td><td colspan="2">Reversible competitive antagonist at H1 receptors. Antiemetic action is due to blocking H1</td></tr><tr><td></td><td>receptors in the vestibular nuclei and in the ‘vomiting centre’.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>T 0.5 10h. Significant first-pass metabolism. Meclizine longer T0.5.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Motion sickness and other emesis of vestibular origin (e.g. Meniere’s disease). Vomiting in early</td></tr><tr><td></td><td colspan="2">pregnancy. Emesis due to local stimuli in the gut acting via the vagus.</td></tr><tr><td>Adverse effects</td><td colspan="2">Sedative action may not be desirable – contraindicated for driving etc. Confusion in elderly. Cyclizine</td></tr><tr><td></td><td colspan="2">and cinnarizine are less sedating. Dry mouth (anticholinergic action). Potentially fatal respiratory</td></tr><tr><td></td><td>depression in infants under 2y.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 29, p 366; D&amp;H Ch 27, p 67</td></tr></table>
</page>
<page number="236">
<table id="p236t1" data-filename="pdftables_fromstorage_023782248" data-page="236" data-table="1"><tr><td style="text-align: right">14.09</td><td>Scopolamine (hyoscine)</td><td>GIT drugs</td><td>Antiemetics</td><td></td></tr><tr><td colspan="3">The central control of vomiting and stimuli resulting in emesis</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">CTZ = chemoreceptor trigger zone</td></tr><tr><td></td><td>Disorienting motion</td><td>Unpleasant/emotional</td><td></td><td></td></tr><tr><td></td><td></td><td>sensations</td><td></td><td></td></tr><tr><td></td><td></td><td>(repulsive experiences)</td><td></td><td></td></tr><tr><td></td><td>Labyrinth</td><td>Higher centres</td><td></td><td></td></tr><tr><td></td><td>Vestibular nuclei</td><td>Vomiting centre</td><td></td><td></td></tr><tr><td></td><td></td><td>in medulla</td><td></td><td></td></tr><tr><td></td><td>-–</td><td></td><td></td><td></td></tr><tr><td></td><td>-–</td><td></td><td></td><td></td></tr><tr><td></td><td>Promethazine, cyclizine,</td><td></td><td>CTZ in</td><td></td></tr><tr><td>CNS</td><td>meclizine, cinnarizine</td><td></td><td>area postrema</td><td></td></tr><tr><td>Periphery</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Muscles involved</td></tr><tr><td></td><td>Stimuli to pharynx/stomach</td><td></td><td>Toxins/drugs</td><td>in vomiting</td></tr><tr><td></td><td>via vagus and nucleus of</td><td></td><td></td><td></td></tr><tr><td></td><td>solitary tract</td><td></td><td></td><td></td></tr></table>
</page>
<page number="237">
<table id="p237t1" data-filename="pdftables_fromstorage_023782248" data-page="237" data-table="1"><tr><td></td><td>Muscarinic-receptor antagonist</td><td>Scopolamine</td></tr><tr><td>Actions</td><td colspan="2">Antiemetic. Other actions consistent with antagonism of parasympathetic nervous system (see card</td></tr><tr><td></td><td style="text-align: right">1.03).</td><td></td></tr><tr><td>MOA</td><td colspan="2">Reversible competitive antagonism of muscarinic receptors. Antiemetic effects due to blockade of</td></tr><tr><td></td><td>receptors in vestibular nucleus and in the vomiting centre.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Active orally (t1⁄2 5h). A transdermal patch applied behind ear is particularly effective, lasting for up</td></tr><tr><td></td><td>to 3 days.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Particularly effective, when given prophylactically, against motion sickness. No efficacy against</td></tr><tr><td></td><td colspan="2">chemotherapy-induced emesis mediated via the CTZ. Effective against local gut stimuli.</td></tr><tr><td>Adverse effects</td><td colspan="2">Drowsiness. Amnesia. Actions attributable to muscarinic receptor block (dry mouth, tachycardia,</td></tr><tr><td></td><td>blurred vision, urinary retention). Avoid in closed-angle glaucoma.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 29, p 366; D&amp;H 2e Ch 27, p 67</td></tr></table>
</page>
<page number="238">
<table id="p238t1" data-filename="pdftables_fromstorage_023782248" data-page="238" data-table="1"><tr><td style="text-align: right">14.10</td><td>Ondansetron</td><td>GIT drugs</td><td>Antiemetics</td><td></td><td></td></tr><tr><td colspan="4">The central control of vomiting and stimuli resulting in emesis</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">CTZ = chemoreceptor trigger zone</td></tr><tr><td></td><td>Disorienting motion</td><td></td><td>Unpleasant/emotional</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>sensations</td><td></td></tr><tr><td></td><td></td><td></td><td>(repulsive experiences)</td><td></td><td></td></tr><tr><td></td><td>Labyrinth</td><td></td><td></td><td>Higher centres</td><td></td></tr><tr><td></td><td>–</td><td>Scopolamine</td><td></td><td>–</td><td></td></tr><tr><td></td><td>Vestibular nuclei</td><td></td><td></td><td>Vomiting centre</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>in medulla</td><td></td></tr><tr><td></td><td></td><td>–</td><td></td><td></td><td></td></tr><tr><td></td><td>-–</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Promethazine, cyclizine,</td><td></td><td></td><td>CTZ in</td><td></td></tr><tr><td>CNS</td><td>meclizine, cinnarizine</td><td></td><td></td><td>area postrema</td><td></td></tr><tr><td>Periphery</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Muscles involved</td></tr><tr><td></td><td>Stimuli to pharynx/stomach</td><td></td><td></td><td>Toxins/drugs</td><td>in vomiting</td></tr><tr><td></td><td>via vagus and nucleus of</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>solitary tract</td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="239">
<table id="p239t1" data-filename="pdftables_fromstorage_023782248" data-page="239" data-table="1"><tr><td></td><td>5-HT3-receptor antagonist (Similar drugs: granisetron, dolasetron, tropisetron)</td><td>Ondansetron</td></tr><tr><td>Actions</td><td>Antiemetic.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Reversible competitive antagonism at 5-HT3 receptors in the CTZ and at the sensory endings of</td></tr><tr><td></td><td>vagal afferents in the GIT.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Given orally or i.v. (if vomiting). T0.5 4–6h. Metabolised by cytochrome P450 system in liver.</td></tr><tr><td>Clinical use</td><td colspan="2">Main agents for nausea and vomiting due to cytotoxic, anticancer drugs. Often given a short</td></tr><tr><td></td><td colspan="2">time before starting chemotherapy. Nausea and vomiting arising postoperatively or after radiation</td></tr><tr><td></td><td>treatment . Limited effectiveness in motion sickness.</td><td></td></tr><tr><td>Adverse effects</td><td>Well tolerated. Headache, GIT upsets.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 29, pp 366-367; D&amp;H 2e Ch 27, p 67</td></tr></table>
</page>
<page number="240">
<table id="p240t1" data-filename="pdftables_fromstorage_023782248" data-page="240" data-table="1"><tr><td style="text-align: right">14.11</td><td colspan="2">Chlorpromazine</td><td>GIT drugs</td><td>Antiemetics</td><td></td><td></td></tr><tr><td colspan="4">The central control of vomiting and stimuli resulting in emesis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">CTZ = chemoreceptor trigger zone</td></tr><tr><td></td><td>Disorienting motion</td><td></td><td>Unpleasant/emotional</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>sensations</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>(repulsive experiences)</td><td></td><td></td><td></td></tr><tr><td></td><td>Labyrinth</td><td></td><td></td><td>Higher centres</td><td></td><td></td></tr><tr><td></td><td>–</td><td>Scopolamine</td><td>–</td><td></td><td></td><td></td></tr><tr><td></td><td>Vestibular nuclei</td><td></td><td></td><td>Vomiting centre</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>in medulla</td><td></td><td></td></tr><tr><td></td><td></td><td>–</td><td></td><td>–</td><td></td><td></td></tr><tr><td></td><td>–</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Promethazine, cyclizine,</td><td></td><td colspan="2">Ondansetron, dolasetron,</td><td>CTZ in</td><td></td></tr><tr><td>CNS</td><td>meclizine, cinnarizine</td><td></td><td colspan="2">granisetron, tropisetron</td><td>area postrema</td><td></td></tr><tr><td>Periphery</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>–</td><td></td><td>Muscles involved</td></tr><tr><td></td><td>Stimuli to pharynx/stomach</td><td></td><td></td><td></td><td>Toxins/drugs</td><td>in vomiting</td></tr><tr><td></td><td>via vagus and nucleus of</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>solitary tract</td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="241">
<table id="p241t1" data-filename="pdftables_fromstorage_023782248" data-page="241" data-table="1"><tr><td></td><td>Dopamine D2-receptor antagonist (Similar drugs: domperidone, prochlorperazine,</td><td>Chlorpromazine</td></tr><tr><td></td><td>metoclopramide thiethylperazine)</td><td></td></tr><tr><td>Actions</td><td>Antiemetic. Antipsychotic (see card 23.01).</td><td></td></tr><tr><td>MOA</td><td colspan="2">Reversible competitive antagonism of dopamine D2 receptors in CTZ. Some of the side effects are</td></tr><tr><td></td><td colspan="2">due to antagonism of other receptors (e.g. adrenoceptors and histamine receptors).</td></tr><tr><td>Abs/Distrib/Elim</td><td>Oral administration. T0.5 15–30h. (P450 metabolism in liver.)</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Nausea and vomiting associated with cancer chemotherapy, radiation therapy and general</td></tr><tr><td></td><td>anaesthesia.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Extrapyramidal effects – Parkinsonian symptoms (avoid in patients with Parkinson’s disease).</td></tr><tr><td></td><td colspan="2">Prolactin release – galactorrhoea. Sedation. Hypotension. Antihistamine and antimuscarinic actions</td></tr><tr><td></td><td>(e.g. dry mouth).</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 29, p 367; D&amp;H 2e Ch 27, p 67</td></tr></table>
</page>
<page number="242">
<table id="p242t1" data-filename="pdftables_fromstorage_023782248" data-page="242" data-table="1"><tr><td style="text-align: right">14.12</td><td>GIT drugs</td><td>Antiemetics</td><td colspan="3">What other groups of drugs have useful antiemetic action?</td><td></td></tr><tr><td colspan="4">The central control of vomiting and stimuli resulting in emesis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">CTZ = chemoreceptor trigger zone</td></tr><tr><td></td><td>Disorienting motion</td><td></td><td>Unpleasant/emotional</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>sensations</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>(repulsive experiences)</td><td></td><td></td><td></td></tr><tr><td></td><td>Labyrinth</td><td></td><td></td><td>Higher centres</td><td></td><td></td></tr><tr><td></td><td>–</td><td>Scopolamine</td><td></td><td>–</td><td colspan="2">Chlorpromazine, domperidone,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">prochlorperazine, metoclopramide</td></tr><tr><td></td><td>Vestibular nuclei</td><td></td><td></td><td>Vomiting centre</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>in medulla</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>–</td><td></td></tr><tr><td></td><td></td><td>–</td><td></td><td>–</td><td></td><td></td></tr><tr><td></td><td>–</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Promethazine, cyclizine,</td><td></td><td colspan="2">Ondansetron, dolasetron,</td><td>CTZ in</td><td></td></tr><tr><td>CNS</td><td>meclizine, cinnarizine</td><td></td><td colspan="2">granisetron, tropisetron</td><td>area postrema</td><td></td></tr><tr><td>Periphery</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>–</td><td></td><td>Muscles involved</td></tr><tr><td></td><td>Stimuli to pharynx/stomach</td><td></td><td></td><td></td><td>Toxins/drugs</td><td>in vomiting</td></tr><tr><td></td><td>via vagus and nucleus of</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>solitary tract</td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="243">
<table id="p243t1" data-filename="pdftables_fromstorage_023782248" data-page="243" data-table="1"><tr><td></td><td>Glucocorticoids, NK1 antagonists, cannabinoids</td><td>Other antiemetics</td></tr><tr><td>Dexamethasone</td><td colspan="2">Mechanism of antiemetic action is not established. High doses used for nausea and vomiting of</td></tr><tr><td></td><td colspan="2">chemotherapy (esp. cisplatin). Generally used in combination with other antiemetics.</td></tr><tr><td>Cannabinoids</td><td colspan="2">Action via CB1 receptors. Used for nausea and vomiting associated with cancer chemotherapy.</td></tr><tr><td></td><td colspan="2">Dronabinol is the main active ingredient (tetrahydrocannabinol) of cannabis; nabilone is a synthetic</td></tr><tr><td></td><td colspan="2">analogue. May cause dependence. Nabilone is active by mouth; T0.5 2h.</td></tr><tr><td>Neurokinin</td><td colspan="2">E.g. aprepitant blocks substance P receptors in the vomiting centre. Adjunct for treatment of</td></tr><tr><td>receptor</td><td colspan="2">chemotherapy-induced and post-operative nausea and vomiting. Orally active.</td></tr><tr><td>antagonists</td><td>Metabolised by cytochrome P450 system in liver. T 0.5 12h.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 29, p 367; D&amp;H 2e Ch 27, p 67</td></tr></table>
</page>
<page number="244">
<table id="p244t1" data-filename="pdftables_fromstorage_023782248" data-page="244" data-table="1"><tr><td style="text-align: right">14.13</td><td>Magnesium sulfate</td><td>GIT drugs</td><td>Control of motility</td></tr><tr><td colspan="4">Processes in the GIT involved in constipation and diarrhoea which are potential targets for drug action</td></tr><tr><td>Viruses / bacteria (acute)</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Toxins e.g. Cholera toxin</td><td></td></tr><tr><td>(Antibacterials)</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Fluid secretion</td><td>Reduced fluid / solids volume</td></tr><tr><td>Osmotic load</td><td colspan="2">Increased fluid volume</td><td></td></tr><tr><td>Malabsorption</td><td colspan="2">Diarrhoea</td><td>Constipation</td></tr><tr><td></td><td colspan="2">Increased peristalsis</td><td></td></tr><tr><td></td><td></td><td></td><td>Decreased peristalsis (stasis)</td></tr><tr><td></td><td></td><td></td><td>Drug side effects</td></tr><tr><td colspan="3">Parasympathetic / enteric nervous system</td><td>e.g. opioids, anticholinergics</td></tr><tr><td colspan="2">Underlying disease, anxiety</td><td></td><td></td></tr></table>
</page>
<page number="245">
<table id="p245t1" data-filename="pdftables_fromstorage_023782248" data-page="245" data-table="1"><tr><td></td><td>Osmotic laxative (Similar drugs: lactulose, macrogols)</td><td>Magnesium sulfate</td></tr><tr><td>Actions</td><td>Purgative.</td><td></td></tr><tr><td>MOA</td><td colspan="2">These agents are poorly absorbed and raise the osmotic load within the gut lumen. This causes</td></tr><tr><td></td><td colspan="2">ingested water to be retained and water also to be withdrawn from the blood stream. The increased</td></tr><tr><td></td><td colspan="2">fluid volume promotes movement along the gut. Purgation occurs within 2h.</td></tr><tr><td>Abs/Distrib/Elim</td><td>Taken orally. Not absorbed.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Bowel cleansing prior to surgery or examination (MgSO4). Constipation (macrogols and lactulose).</td></tr><tr><td></td><td>The effects of lactulose develop after 2–3 days.</td><td></td></tr><tr><td>Adverse effects</td><td>Abdominal cramps. Few systemic actions because of low absorption.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 29, p 368; D&amp;H 2e Ch 27, p 67</td></tr></table>
</page>
<page number="246">
<table id="p246t1" data-filename="pdftables_fromstorage_023782248" data-page="246" data-table="1"><tr><td style="text-align: right">14.14</td><td>Methylcellulose</td><td>GIT drugs</td><td>Control of motility</td></tr><tr><td colspan="4">Processes in the GIT involved in constipation and diarrhoea which are potential targets for drug action</td></tr><tr><td></td><td></td><td></td><td>Magnesium sulfate,</td></tr><tr><td>Viruses / bacteria (acute)</td><td></td><td></td><td>lactulose, macrogols</td></tr><tr><td></td><td colspan="2">Toxins e.g. Cholera toxin</td><td>–</td></tr><tr><td>(Antibacterials)</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Fluid secretion</td><td>Reduced fluid / solids volume</td></tr><tr><td>Osmotic load</td><td colspan="2">Increased fluid volume</td><td></td></tr><tr><td>Malabsorption</td><td></td><td>Diarrhoea</td><td>Constipation</td></tr><tr><td></td><td colspan="2">Increased peristalsis</td><td></td></tr><tr><td></td><td></td><td></td><td>Decreased peristalsis (stasis)</td></tr><tr><td></td><td></td><td></td><td>Drug side effects</td></tr><tr><td colspan="3">Parasympathetic / enteric nervous system</td><td>e.g. opioids, anticholinergics</td></tr><tr><td colspan="2">Underlying disease, anxiety</td><td></td><td></td></tr></table>
</page>
<page number="247">
<table id="p247t1" data-filename="pdftables_fromstorage_023782248" data-page="247" data-table="1"><tr><td></td><td>Bulk laxative (Similar drugs: ispaghula husk, sterculia)</td><td>Methylcellulose</td></tr><tr><td>Actions</td><td>Purgative.</td><td></td></tr><tr><td>MOA</td><td colspan="2">These agents are poorly absorbed and, being hygroscopic, form a soft faecal mass which</td></tr><tr><td></td><td>distends the gut to promote peristalsis.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Taken orally. Not absorbed.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Constipation. Used if increasing dietary fibre is inadequate. Beneficial in various bowel disorders (e.g.</td></tr><tr><td></td><td colspan="2">haemorrhoids, irritable bowel syndrome). Maintain fluid intake to prevent intestinal obstruction.</td></tr><tr><td>Adverse effects</td><td colspan="2">Flatulence. Few systemic actions because of low absorption. Obstruction.</td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 29, p 368; D&amp;H 2e Ch 27, p 67</td></tr></table>
</page>
<page number="248">
<table id="p248t1" data-filename="pdftables_fromstorage_023782248" data-page="248" data-table="1"><tr><td style="text-align: right">14.15</td><td>Lubiprostone</td><td>GIT drugs</td><td></td><td>Control of motility</td></tr><tr><td colspan="5">Processes in the GIT involved in constipation and diarrhoea which are potential targets for drug action</td></tr><tr><td></td><td></td><td></td><td>Magnesium sulfate,</td><td></td></tr><tr><td>Viruses / bacteria (acute)</td><td></td><td></td><td>lactulose, macrogols</td><td></td></tr><tr><td></td><td colspan="2">Toxins e.g. Cholera toxin</td><td></td><td>–</td></tr><tr><td>(Antibacterials)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Fluid secretion</td><td colspan="2">Reduced fluid / solids volume</td></tr><tr><td>Osmotic load</td><td colspan="2">Increased fluid volume</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>–</td></tr><tr><td></td><td></td><td></td><td></td><td>Methylcellulose, dietry</td></tr><tr><td>Malabsorption</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Diarrhoea</td><td></td><td>Constipation</td></tr><tr><td></td><td></td><td></td><td></td><td>fibre (bran), ispaghula husk</td></tr><tr><td></td><td colspan="2">Increased peristalsis</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Decreased peristalsis (stasis)</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Drug side effects</td></tr><tr><td colspan="3">Parasympathetic / enteric nervous system</td><td></td><td>e.g. opioids, anticholinergics</td></tr><tr><td colspan="2">Underlying disease, anxiety</td><td></td><td></td><td></td></tr></table>
</page>
<page number="249">
<table id="p249t1" data-filename="pdftables_fromstorage_023782248" data-page="249" data-table="1"><tr><td></td><td>Chloride channel activator</td><td>Lubiprostone</td></tr><tr><td>Actions</td><td>Increases fluid content of gut, thus aiding propulsive movements.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Activates the CIC-2 chloride channel in the apical membrane of the gastrointestinal epithelium.</td></tr><tr><td></td><td colspan="2">The enhanced secretion of chloride ion is accompanied by water leading to an increase in</td></tr><tr><td></td><td>intraluminal fluid.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Oral administration. Local action in the gut – little systemic absorption.</td><td></td></tr><tr><td>Clinical use</td><td>Chronic constipation. Irritable bowel syndrome with constipation.</td><td></td></tr><tr><td>Adverse effects</td><td>Nausea. Diarrhoea.</td><td></td></tr><tr><td></td><td></td><td>(Too new to be in R&amp;D or D&amp;H)</td></tr></table>
</page>
<page number="250">
<table id="p250t1" data-filename="pdftables_fromstorage_023782248" data-page="250" data-table="1"><tr><td style="text-align: right">14.16</td><td>Bisacodyl</td><td>GIT drugs</td><td>Control of motility</td><td></td><td></td><td></td></tr><tr><td colspan="7">Processes in the GIT involved in constipation and diarrhoea which are potential targets for drug action</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Magnesium sulfate,</td><td></td></tr><tr><td>Viruses / bacteria (acute)</td><td></td><td></td><td></td><td colspan="2">lactulose, macrogols</td><td></td></tr><tr><td></td><td colspan="3">Toxins e.g. Cholera toxin</td><td>–</td><td>–</td><td>Lubiprostone</td></tr><tr><td>(Antibacterials)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="3">Fluid secretion</td><td colspan="3">Reduced fluid / solids volume</td></tr><tr><td>Osmotic load</td><td></td><td colspan="2">Increased fluid volume</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>–</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Methylcellulose, dietry</td></tr><tr><td>Malabsorption</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Diarrhoea</td><td>Constipation</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>fibre (bran), ispaghula husk</td></tr><tr><td></td><td></td><td colspan="2">Increased peristalsis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Decreased peristalsis (stasis)</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Drug side effects</td></tr><tr><td colspan="4">Parasympathetic / enteric nervous system</td><td></td><td></td><td>e.g. opioids, anticholinergics</td></tr><tr><td colspan="2">Underlying disease, anxiety</td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="251">
<table id="p251t1" data-filename="pdftables_fromstorage_023782248" data-page="251" data-table="1"><tr><td></td><td>Stimulant laxative (Similar drugs: senna, dantron)</td><td>Bisacodyl</td></tr><tr><td>Actions</td><td>Laxative.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Active metabolite of bisacodyl stimulates peristalsis by irritation of mucosa and/or an effect on the</td></tr><tr><td></td><td colspan="2">enteric nervous system. Also increases fluid volume by promoting net fluid secretion.</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral or rectal administration. T0.5 16h. Senna is activated in the colon by bacteria.</td></tr><tr><td>Clinical use</td><td colspan="2">Chronic constipation. Bowel cleansing prior to surgery/investigation. Action of bisacodyl is more</td></tr><tr><td></td><td>rapid rectally (30min) than orally (6h).</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Abdominal cramps. Tolerance to action with atony of the colon if used excessively.</td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 29, p 368; D&amp;H 2e Ch 27, p 67</td></tr></table>
</page>
<page number="252">
<table id="p252t1" data-filename="pdftables_fromstorage_023782248" data-page="252" data-table="1"><tr><td style="text-align: right">14.17</td><td>Docusate</td><td>GIT drugs</td><td>Control of motility</td><td></td><td></td><td></td></tr><tr><td colspan="7">Processes in the GIT involved in constipation and diarrhoea which are potential targets for drug action</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Magnesium sulfate,</td><td></td></tr><tr><td>Viruses / bacteria (acute)</td><td></td><td></td><td></td><td colspan="2">lactulose, macrogols</td><td></td></tr><tr><td></td><td colspan="3">Toxins e.g. Cholera toxin</td><td>–</td><td>–</td><td>Lubiprostone</td></tr><tr><td>(Antibacterials)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="3">Fluid secretion</td><td colspan="3">Reduced fluid / solids volume</td></tr><tr><td>Osmotic load</td><td></td><td colspan="2">Increased fluid volume</td><td></td><td>–</td><td>Methylcellulose, dietry</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>fibre (bran), ispaghula husk</td></tr><tr><td>Malabsorption</td><td></td><td></td><td>Diarrhoea</td><td>Constipation</td><td>–</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>-–</td><td>BiBsisaaccooddyyll,, sseennnnaa</td></tr><tr><td></td><td></td><td colspan="2">Increased peristalsis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Decreased peristalsis (stasis)</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Drug side effects</td></tr><tr><td colspan="4">Parasympathetic / enteric nervous system</td><td></td><td></td><td>e.g. opioids, anticholinergics</td></tr><tr><td colspan="2">Underlying disease, anxiety</td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="253">
<table id="p253t1" data-filename="pdftables_fromstorage_023782248" data-page="253" data-table="1"><tr><td></td><td>Laxative, faecal softener (Similar drugs: liquid paraffin, arachis oil)</td><td>Docusate</td></tr><tr><td>Actions</td><td colspan="2">Softens/lubricates the stool to allow easier passage along gut and defaecation.</td></tr><tr><td>MOA</td><td>Surfactant with emulsifying action.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Docusate is given orally or rectally, arachis oil rectally.</td><td></td></tr><tr><td>Clinical use</td><td>Constipation. Haemorrhoids.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Well-tolerated – possible abdominal cramping. Liquid paraffin may impair the absorption of fat-soluble</td></tr><tr><td></td><td>vitamins.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 29, p 368; D&amp;H 2e Ch 27, p 67</td></tr></table>
</page>
<page number="254">
<table id="p254t1" data-filename="pdftables_fromstorage_023782248" data-page="254" data-table="1"><tr><td style="text-align: right">14.18</td><td>Loperamide</td><td>GIT drugs</td><td>Control of motility</td><td></td><td></td><td></td></tr><tr><td colspan="7">Processes in the GIT involved in constipation and diarrhoea which are potential targets for drug action.</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Magnesium sulfate,</td><td></td></tr><tr><td>Viruses / bacteria (acute)</td><td></td><td></td><td></td><td colspan="2">lactulose, macrogols</td><td></td></tr><tr><td></td><td colspan="3">Toxins e.g. Cholera toxin</td><td>–</td><td>–</td><td>Lubiprostone</td></tr><tr><td>(Antibacterials)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="3">Fluid secretion</td><td colspan="3">Reduced fluid / solids volume</td></tr><tr><td>Osmotic load</td><td colspan="3">Increased fluid volume</td><td></td><td>–</td><td>Methylcellulose, dietry</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>fibre (bran), ispaghula husk</td></tr><tr><td>Malabsorption</td><td></td><td colspan="2">Diarrhoea</td><td>Constipation</td><td>–</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>-–</td><td>Bisacodyl, senna</td></tr><tr><td></td><td colspan="3">Increased peristalsis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Decreased peristalsis (stasis)</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Drug side effects</td></tr><tr><td colspan="4">Parasympathetic / enteric nervous system</td><td></td><td></td><td>e.g. opioids, anticholinergics</td></tr><tr><td></td><td></td><td></td><td></td><td>–</td><td colspan="2">Docusate,</td></tr><tr><td colspan="2">Underlying disease, anxiety</td><td></td><td></td><td></td><td colspan="2">liquid paraffin</td></tr></table>
</page>
<page number="255">
<table id="p255t1" data-filename="pdftables_fromstorage_023782248" data-page="255" data-table="1"><tr><td></td><td>Antidiarrhoeal agent (Similar drugs: diphenoxylate, codeine)</td><td>Loperamide</td></tr><tr><td>Actions</td><td colspan="2">Reduces gut motility and secretions. The slower transit time allows for more fluid absorption and</td></tr><tr><td></td><td>more solid stools.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Agonist action at μ opioid receptors in myenteric plexus of gut inhibits peristalsis. Effects can be</td></tr><tr><td></td><td colspan="2">reversed by naloxone. Loperamide and diphenoxylate, but not codeine, achieve low concentrations</td></tr><tr><td></td><td colspan="2">in CNS, so have few central effects (including analgesia and addiction).</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral administration. Metabolised by hepatic cytochrome P450 system. t1⁄2 10h. Diphenoxylate is</td></tr><tr><td></td><td>hydrolysed to an active metabolite.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Acute diarrhoea. Chronic diarrhoea associated with inflammatory bowel disease. Diphenoxylate is</td></tr><tr><td></td><td>commonly administered in a combined preparation with atropine.</td><td></td></tr><tr><td>Adverse effects</td><td>Drowsiness and nausea. Constipation and abdominal cramps.</td><td></td></tr><tr><td></td><td>CNS depression may occur in overdose.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 29, p 369; D&amp;H 2e Ch 27, p 67</td></tr></table>
</page>
<page number="256">
<table id="p256t1" data-filename="pdftables_fromstorage_023782248" data-page="256" data-table="1"><tr><td style="text-align: right">14.19</td><td>Summary of drugs influencing gut motility</td><td>GIT drugs</td><td colspan="3">Control of motility</td></tr><tr><td colspan="6">Processes in the GIT involved in constipation and diarrhoea which are potential targets for drug action</td></tr><tr><td></td><td></td><td colspan="3">Magnesium sulfate,</td><td></td></tr><tr><td>Viruses / bacteria (acute)</td><td></td><td colspan="3">lactulose, macrogols</td><td></td></tr><tr><td></td><td>Toxins e.g. Cholera toxin</td><td></td><td>–</td><td>–</td><td>Lubiprostone</td></tr><tr><td>(Antibacterials)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Fluid secretion</td><td colspan="4">Reduced fluid / solids volume</td></tr><tr><td>Osmotic load</td><td>Increased fluid volume</td><td></td><td></td><td>–</td><td>Methylcellulose, dietry</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>fibre (bran), ispaghula husk</td></tr><tr><td>Malabsorption</td><td>Diarrhoea</td><td colspan="2">Constipation</td><td>–</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>–</td><td>Bisacodyl, senna</td></tr><tr><td></td><td>Increased peristalsis</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="3">Decreased peristalsis (stasis)</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Drug side effects</td></tr><tr><td colspan="2">Parasympathetic / enteric nervous system</td><td></td><td></td><td colspan="2">e.g. opioids, anticholinergics</td></tr><tr><td></td><td>–</td><td></td><td>–</td><td colspan="2">Docusate,</td></tr><tr><td>Underlying disease, anxiety</td><td>Loperamide, codeine,</td><td></td><td></td><td colspan="2">liquid paraffin</td></tr><tr><td></td><td>diphenoxylate</td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="257">
<table id="p257t1" data-filename="pdftables_fromstorage_023782248" data-page="257" data-table="1"><tr><td>Notes</td></tr><tr><td>NOTES</td></tr></table>
</page>
<page number="258">
<table id="p258t1" data-filename="pdftables_fromstorage_023782248" data-page="258" data-table="1"><tr><td style="text-align: right">15.01</td><td>Insulin</td><td>Blood sugar and diabetes</td></tr><tr><td colspan="2">The main processes determining blood glucose concentrations</td><td></td></tr><tr><td></td><td>Absorption of</td><td>Uptake and utilisation</td></tr><tr><td></td><td>glucose from GIT</td><td>of glucose by tissues</td></tr><tr><td></td><td>Glycogenolysis in</td><td></td></tr><tr><td></td><td></td><td>Blood glucose</td></tr><tr><td></td><td>muscle and liver</td><td></td></tr><tr><td></td><td>Gluconeogenesis</td><td>Glycogen synthesis in</td></tr><tr><td></td><td>in liver</td><td>muscle and liver</td></tr></table>
</page>
<page number="259">
<table id="p259t1" data-filename="pdftables_fromstorage_023782248" data-page="259" data-table="1"><tr><td></td><td>Agonist at insulin receptors; the major regulator of blood glucose concentration</td><td>Insulin</td></tr><tr><td>Actions</td><td colspan="2">Promotes tissue uptake and storage of glucose, amino acids and fats. Acutely lowers blood glucose.</td></tr><tr><td></td><td colspan="2">Inhibits hepatic glycogenolysis and gluconeogenesis. Increases glycogen synthesis in muscle/liver.</td></tr><tr><td></td><td colspan="2">Inhibits lipolysis. Stimulates protein synthesis. Longer-term effects on growth and gene expression.</td></tr><tr><td>MOA</td><td colspan="2">Binding to its receptor (tyrosine kinase type) causes autophosphorylation of the receptor.</td></tr><tr><td></td><td colspan="2">Subsequent tyrosine phosphorylation of ‘insulin receptor substrates’ leads to activation of SH2</td></tr><tr><td></td><td colspan="2">domain proteins which regulate the action of various intracellular enzymes and cell membrane</td></tr><tr><td></td><td>glucose transporters.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Free insulin in the blood has a T0.5 of only 10min so slow-release preparations are needed for regular</td></tr><tr><td></td><td colspan="2">use. Given s.c. or i.v. Short-acting (3–5h) – soluble (regular) insulin, insulin lispro, insulin aspart.</td></tr><tr><td></td><td colspan="2">Intermediate-acting (10–12h) – isophane insulin. Long-acting (24h) – insulin zinc suspension</td></tr><tr><td></td><td>(crystalline), insulin glargine.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Life-long treatment of type 1 diabetes. Also for type 2 diabetes not controlled by oral hypoglycaemic</td></tr><tr><td></td><td colspan="2">agents. Soluble insulin also for emergency i.v. treatment of diabetic ketoacidosis.</td></tr><tr><td>Adverse</td><td colspan="2">Hypoglycaemia – treated by glucose administration (by mouth, if conscious, otherwise i.v.) or</td></tr><tr><td>effects</td><td>glucagon (i.m.). Weight gain.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Recombinant human insulin is preferred to animal insulins which may cause antibody formation.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 30, pp 372-376; D&amp;H 2e Ch 28, pp 68-69</td></tr></table>
</page>
<page number="260">
<table id="p260t1" data-filename="pdftables_fromstorage_023782248" data-page="260" data-table="1"><tr><td></td><td>Glibenclamide</td><td></td></tr><tr><td style="text-align: right">15.02</td><td>(glyburide)</td><td>Blood sugar and diabetes</td></tr><tr><td colspan="2">The main processes determining blood glucose concentrations</td><td></td></tr><tr><td></td><td></td><td>Uptake and utilisation</td></tr><tr><td colspan="2">Absorption of</td><td>of glucose by tissues</td></tr><tr><td colspan="2">glucose from GIT</td><td></td></tr><tr><td colspan="2">Glycogenolysis in</td><td>Insulin</td></tr><tr><td></td><td></td><td>Blood glucose</td></tr><tr><td colspan="2">muscle and liver</td><td></td></tr><tr><td></td><td>Insulin</td><td>Glycogen synthesis in</td></tr><tr><td></td><td></td><td>muscle and liver</td></tr><tr><td colspan="2">Gluconeogenesis</td><td></td></tr><tr><td></td><td>in liver</td><td>Insulin release from</td></tr><tr><td></td><td></td><td>B cells in pancreas</td></tr></table>
</page>
<page number="261">
<table id="p261t1" data-filename="pdftables_fromstorage_023782248" data-page="261" data-table="1"><tr><td></td><td>Oral hypoglycaemic agent (Similar drugs: tolbutamide, glipizide, glimepiride)</td><td>Glibenclamide</td></tr><tr><td>Actions</td><td colspan="2">Increases insulin release from functioning B cells, thus producing the effects of insulin indicated on</td></tr><tr><td></td><td>card 15.01.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Interaction with the sulphonylurea receptor, which is a subunit of the KATP channel in the cell</td></tr><tr><td></td><td colspan="2">membrane of B cells, causes the K+ channel to close. This causes the cell to depolarise and activates</td></tr><tr><td></td><td colspan="2">voltage-dependent Ca2+ channels. Ca2+ entry stimulates exocytosis of insulin.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally they bind extensively to plasma proteins. Half-lives: glibenclamide 10h, tolbutamide 4h,</td></tr><tr><td></td><td colspan="2">glipizide 4h, glimepiride 5h. Actions prolonged in patients with renal disease.</td></tr><tr><td>Clinical use</td><td>Type 2 diabetes mellitus, effective in 30% of patients.</td><td></td></tr><tr><td>Adverse</td><td colspan="2">Hypoglycaemia (more likely in elderly and with longer-acting sulphonylureas). Weight gain.</td></tr><tr><td>effects</td><td></td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 30, p 380; D&amp;H 2e Ch 28, p 69</td></tr></table>
</page>
<page number="262">
<table id="p262t1" data-filename="pdftables_fromstorage_023782248" data-page="262" data-table="1"><tr><td style="text-align: right">15.03</td><td>Metformin</td><td>Blood sugar and diabetes</td><td></td></tr><tr><td colspan="3">The main processes determining blood glucose concentrations</td><td></td></tr><tr><td></td><td></td><td></td><td>Uptake and utilisation</td></tr><tr><td colspan="2">Absorption of</td><td></td><td>of glucose by tissues</td></tr><tr><td colspan="2">glucose from GIT</td><td></td><td></td></tr><tr><td colspan="2">Glycogenolysis in</td><td></td><td>Insulin</td></tr><tr><td></td><td></td><td>Blood glucose</td><td></td></tr><tr><td colspan="2">muscle and liver</td><td></td><td></td></tr><tr><td></td><td>Insulin</td><td>Glibenclamide, glipizide</td><td>Glycogen synthesis in</td></tr><tr><td></td><td></td><td></td><td>muscle and liver</td></tr><tr><td colspan="2">Gluconeogenesis</td><td></td><td></td></tr><tr><td></td><td>in liver</td><td>Insulin release from</td><td></td></tr><tr><td></td><td></td><td>B cells in pancreas</td><td></td></tr></table>
</page>
<page number="263">
<table id="p263t1" data-filename="pdftables_fromstorage_023782248" data-page="263" data-table="1"><tr><td></td><td>Oral hypoglycaemic agent</td><td>Metformin</td></tr><tr><td>Actions</td><td>Lowers blood glucose concentration.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits gluconeogenesis in liver by activating AMP-activated protein kinase. May also enhance</td></tr><tr><td></td><td>tissue sensitivity to insulin. Increases glucose uptake into tissues.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given by mouth. Half-life 3h. Mostly excreted unchanged in urine (avoid in patients with renal</td></tr><tr><td></td><td>insufficiency).</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Type 2 diabetes (alone or with other oral hypoglycaemic agents). Particularly useful in obese patients.</td></tr><tr><td>Adverse</td><td colspan="2">Anorexia and gastrointestinal upset including diarrhoea (leading to weight loss). May rarely cause</td></tr><tr><td>effects</td><td colspan="2">potentially fatal lactic acidosis. (Unlike sulphonylureas does not cause hypoglycaemia.)</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 30, pp 379-380; D&amp;H Ch 28, p 69</td></tr></table>
</page>
<page number="264">
<table id="p264t1" data-filename="pdftables_fromstorage_023782248" data-page="264" data-table="1"><tr><td style="text-align: right">15.04</td><td>Repaglinide</td><td>Blood sugar and diabetes</td><td></td></tr><tr><td colspan="3">The main processes determining blood glucose concentrations</td><td></td></tr><tr><td></td><td></td><td></td><td>Uptake and utilisation</td></tr><tr><td colspan="2">Absorption of</td><td></td><td>of glucose by tissues</td></tr><tr><td colspan="2">glucose from GIT</td><td></td><td></td></tr><tr><td colspan="2">Glycogenolysis in</td><td></td><td>Insulin</td></tr><tr><td></td><td></td><td>Blood glucose</td><td></td></tr><tr><td colspan="2">muscle and liver</td><td></td><td></td></tr><tr><td></td><td>Insulin</td><td>Glibenclamide, glipizide</td><td>Glycogen synthesis in</td></tr><tr><td></td><td></td><td></td><td>muscle and liver</td></tr><tr><td colspan="2">Gluconeogenesis</td><td></td><td></td></tr><tr><td></td><td>in liver</td><td>Insulin release from</td><td></td></tr><tr><td></td><td></td><td>B cells in pancreas</td><td></td></tr><tr><td colspan="2">Metformin</td><td></td><td></td></tr></table>
</page>
<page number="265">
<table id="p265t1" data-filename="pdftables_fromstorage_023782248" data-page="265" data-table="1"><tr><td></td><td>Oral hypoglycaemic agent (a meglitinide) (Similar drug: nateglinide)</td><td>Repaglinide</td></tr><tr><td>Actions</td><td colspan="2">Lowers blood glucose concentration. Stimulates insulin release from B cells in pancreatic islets.</td></tr><tr><td>MOA</td><td colspan="2">Similar to sulphonylureas. Interaction with the sulphonylurea receptor, a subunit of the KATP</td></tr><tr><td></td><td colspan="2">channel in the cell membrane of B cells, causes the K+ channel to close. This depolarises the cell</td></tr><tr><td></td><td colspan="2">membrane and activates voltage-dependent Ca2+ channels. Ca2+ entry promotes exocytosis</td></tr><tr><td></td><td>of insulin.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Quick onset and short duration of action. Half-life 1h. (Its actions can be reduced by drugs that</td></tr><tr><td></td><td colspan="2">induce hepatic P450 enzymes, e.g. carbamazepine.) Nateglinide half-life 1.5h.</td></tr><tr><td>Clinical use</td><td colspan="2">Type 2 diabetes mellitus. Rapid action allows good control of postprandial hyperglycaemia.</td></tr><tr><td></td><td colspan="2">May be combined with metformin or a glitazone. Mainly metabolised in liver, so useful in patients</td></tr><tr><td></td><td>with renal insufficiency.</td><td></td></tr><tr><td>Adverse</td><td colspan="2">Hypoglycaemia (uncommon unless its metabolism is inhibited by other drugs, e.g. gemfibrozil).</td></tr><tr><td>effects</td><td></td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 30, p 381; D&amp;H 2e Ch 28, p 69</td></tr></table>
</page>
<page number="266">
<table id="p266t1" data-filename="pdftables_fromstorage_023782248" data-page="266" data-table="1"><tr><td style="text-align: right">15.05</td><td>Rosiglitazone</td><td>Blood sugar and diabetes</td><td></td></tr><tr><td colspan="3">The main processes determining blood glucose concentrations</td><td></td></tr><tr><td></td><td></td><td></td><td>Uptake and utilisation</td></tr><tr><td colspan="2">Absorption of</td><td></td><td>of glucose by tissues</td></tr><tr><td colspan="2">glucose from GIT</td><td></td><td></td></tr><tr><td colspan="2">Glycogenolysis in</td><td></td><td>Insulin</td></tr><tr><td></td><td></td><td>Blood glucose</td><td></td></tr><tr><td colspan="2">muscle and liver</td><td></td><td></td></tr><tr><td></td><td></td><td>Glibenclamide, glipizide,</td><td></td></tr><tr><td></td><td>Insulin</td><td>repaglinide, nateglinide</td><td>Glycogen synthesis in</td></tr><tr><td></td><td></td><td></td><td>muscle and liver</td></tr><tr><td colspan="2">Gluconeogenesis</td><td></td><td></td></tr><tr><td></td><td>in liver</td><td>Insulin release from</td><td></td></tr><tr><td></td><td></td><td>B cells in pancreas</td><td></td></tr><tr><td>Metformin</td><td></td><td></td><td></td></tr></table>
</page>
<page number="267">
<table id="p267t1" data-filename="pdftables_fromstorage_023782248" data-page="267" data-table="1"><tr><td></td><td>Oral hypoglycaemic agent (thiazolidinedione) (Similar drug: pioglitazone)</td><td>Rosiglitazone</td></tr><tr><td>Actions</td><td>Lowers blood glucose concentration.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Activates the peroxisomal proliferator – activated receptor – γ in adipose tissue, liver and skeletal</td></tr><tr><td></td><td colspan="2">muscle to promote transcription of genes coding for proteins important in insulin action.</td></tr><tr><td></td><td colspan="2">Important effects in control of blood glucose are: reduced glucose release from the liver, increased</td></tr><tr><td></td><td colspan="2">uptake into muscle and increased sensitivity (reduced resistance) to insulin. The effects develop over</td></tr><tr><td></td><td>2–3 months.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Rapid oral absorption, highly bound to plasma proteins. Eliminated mainly by P450 metabolism</td></tr><tr><td></td><td colspan="2">in liver. (Interactions may occur with drugs inhibiting or inducing cytochrome P450.) Short half-life</td></tr><tr><td></td><td>(7h) but some activity of metabolites.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Type 2 diabetes mellitus. Generally used with a sulphonylurea or metformin.</td></tr><tr><td>Adverse</td><td colspan="2">Weight gain, fluid retention (may precipitate heart failure). Risk of hypoglycaemia is low. Some</td></tr><tr><td>effects</td><td colspan="2">glitazones are hepatotoxic so the group as a whole is avoided in patients with liver disease.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 30, pp 381-382; D&amp;H 2e Ch 28, p 69</td></tr></table>
</page>
<page number="268">
<table id="p268t1" data-filename="pdftables_fromstorage_023782248" data-page="268" data-table="1"><tr><td style="text-align: right">15.06</td><td>Acarbose</td><td>Blood sugar and diabetes</td><td></td><td></td></tr><tr><td colspan="4">The main processes determining blood glucose concentrations</td><td></td></tr><tr><td></td><td></td><td></td><td>Rosiglitazone, pioglitazone</td><td>Uptake and utilisation</td></tr><tr><td colspan="2">Absorption of</td><td></td><td></td><td>of glucose by tissues</td></tr><tr><td colspan="2">glucose from GIT</td><td></td><td></td><td></td></tr><tr><td colspan="2">Glycogenolysis in</td><td></td><td></td><td>Insulin</td></tr><tr><td></td><td></td><td></td><td>Blood glucose</td><td></td></tr><tr><td colspan="2">muscle and liver</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Glibenclamide, glipizide,</td><td></td></tr><tr><td></td><td></td><td>Insulin</td><td>repaglinide, nateglinide</td><td>Glycogen synthesis in</td></tr><tr><td></td><td></td><td></td><td></td><td>muscle and liver</td></tr><tr><td colspan="2">Gluconeogenesis</td><td></td><td></td><td></td></tr><tr><td></td><td>in liver</td><td></td><td>Insulin release from</td><td></td></tr><tr><td></td><td></td><td></td><td>B cells in pancreas</td><td></td></tr><tr><td>Metformin</td><td></td><td>Rosiglitazone, pioglitazone</td><td></td><td></td></tr></table>
</page>
<page number="269">
<table id="p269t1" data-filename="pdftables_fromstorage_023782248" data-page="269" data-table="1"><tr><td></td><td>Oral hypoglycaemic agent (Similar drug: miglitol)</td><td>Acarbose</td></tr><tr><td>Actions</td><td>Delays carbohydrate absorption from intestine.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits intestinal α-glucosidase and pancreatic α-amylase so reduces the rise in blood glucose</td></tr><tr><td></td><td colspan="2">which follows a meal. α-glucosidase is the enzyme responsible for breaking down starches and</td></tr><tr><td></td><td>oligosaccharides to yield the absorbable monosaccharides.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Metabolised in GIT by bacteria and digestive enzymes. Half-life 2h.</td><td></td></tr><tr><td>Clinical use</td><td>Type 2 diabetes mellitus not controlled by other drugs.</td><td></td></tr><tr><td>Adverse</td><td>Gastrointestinal discomfort – flatulence, diarrhoea.</td><td></td></tr><tr><td>effects</td><td></td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 30, p 382; D&amp;H 2e Ch 28, p 69</td></tr></table>
</page>
<page number="270">
<table id="p270t1" data-filename="pdftables_fromstorage_023782248" data-page="270" data-table="1"><tr><td style="text-align: right">15.07</td><td>Glucagon</td><td colspan="2">Blood sugar and diabetes</td><td></td><td></td></tr><tr><td colspan="5">The main processes determining blood glucose concentrations</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Complex</td><td></td></tr><tr><td colspan="2">Glucose in intestine</td><td></td><td></td><td>carbohydrates in food</td><td></td></tr><tr><td colspan="2">Absorption of</td><td></td><td>Acarbose</td><td>Rosiglitazone, pioglitazone</td><td>Uopft galkuec aosned  buyt itliisssautieosn</td></tr><tr><td colspan="2">glucose from GIT</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">Glycogenolysis in</td><td></td><td></td><td></td><td>Insulin</td></tr><tr><td></td><td></td><td></td><td></td><td>Blood glucose</td><td></td></tr><tr><td colspan="2">muscle and liver</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Glibenclamide, glipizide,</td><td></td></tr><tr><td></td><td></td><td>Insulin</td><td colspan="2">repaglinide, nateglinide</td><td>Glycogen synthesis in</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>muscle and liver</td></tr><tr><td colspan="2">Gluconeogenesis</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>in liver</td><td></td><td></td><td>Insulin release from</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>B cells in pancreas</td><td></td></tr><tr><td>Metformin</td><td></td><td>Rosiglitazone, pioglitazone</td><td></td><td></td><td></td></tr></table>
</page>
<page number="271">
<table id="p271t1" data-filename="pdftables_fromstorage_023782248" data-page="271" data-table="1"><tr><td></td><td>Hyperglycaemic agent; agonist at glucagon receptors</td><td>Glucagon</td></tr><tr><td>Actions</td><td colspan="2">Elevates blood glucose concentration. Increases rate and force of heart contraction.</td></tr><tr><td>MOA</td><td colspan="2">Glucagon activates adenylate cyclase by acting on G-protein coupled receptors linked to Gs . Its</td></tr><tr><td></td><td colspan="2">actions thus mimic those of adrenaline activating β-adrenoceptors. It elevates blood glucose by</td></tr><tr><td></td><td colspan="2">stimulating hepatic gluconeogenesis and glycogenolysis and by inhibiting glycogen synthesis.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Glucagon is a peptide hormone which must be given by injection. Plasma half-life 5min.</td></tr><tr><td>Clinical use</td><td colspan="2">Emergency treatment of hypoglycaemic emergency (caused by insulin overdose), when oral or i.v.</td></tr><tr><td></td><td colspan="2">glucose administration is not possible. (Also used to treat heart failure precipitated by</td></tr><tr><td></td><td>β-adrenoceptor antagonists.)</td><td></td></tr><tr><td>Adverse</td><td colspan="2">Uncommon. Cardiac stimulation in patients taking β-blockers or with phaeochromocytoma.</td></tr><tr><td>effects</td><td></td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 30, pp 376-377; D&amp;H 2e Ch 28, p 69</td></tr></table>
</page>
<page number="272">
<table id="p272t1" data-filename="pdftables_fromstorage_023782248" data-page="272" data-table="1"><tr><td style="text-align: right">15.08</td><td>Summary</td><td colspan="2">Blood sugar and diabetes</td><td></td></tr><tr><td colspan="4">The main processes determining blood glucose concentrations</td><td></td></tr><tr><td></td><td></td><td></td><td>Complex</td><td></td></tr><tr><td colspan="2">Glucose in intestine</td><td></td><td>carbohydrates in food</td><td></td></tr><tr><td colspan="2">Absorption of</td><td>Acarbose</td><td>Rosiglitazone, pioglitazone</td><td>Uopft galkuec aosned  buyt itliisssautieosn</td></tr><tr><td colspan="2">glucose from GIT</td><td></td><td></td><td></td></tr><tr><td colspan="2">Glycogenolysis in</td><td></td><td></td><td>Insulin</td></tr><tr><td></td><td></td><td></td><td>Blood glucose</td><td></td></tr><tr><td colspan="2">muscle and liver</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Glibenclamide, glipizide,</td><td></td></tr><tr><td>Glucagon</td><td></td><td>Insulin</td><td>repaglinide, nateglinide</td><td>Glycogen synthesis in</td></tr><tr><td></td><td></td><td></td><td></td><td>muscle and liver</td></tr><tr><td colspan="2">Gluconeogenesis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Glucagon</td></tr><tr><td></td><td>in liver</td><td></td><td>Insulin release from</td><td></td></tr><tr><td></td><td></td><td></td><td>B cells in pancreas</td><td></td></tr><tr><td>Metformin</td><td></td><td>Rosiglitazone, pioglitazone</td><td></td><td></td></tr></table>
</page>
<page number="273">
<table id="p273t1" data-filename="pdftables_fromstorage_023782248" data-page="273" data-table="1"><tr><td>Notes</td></tr><tr><td>Notes</td></tr></table>
</page>
<page number="274">
<table id="p274t1" data-filename="pdftables_fromstorage_023782248" data-page="274" data-table="1"><tr><td style="text-align: right">16.01</td><td>Hydrocortisone</td><td colspan="2">The ant. pituitary &amp; the adrenal cortex</td><td></td></tr><tr><td colspan="4">The figure outlines the synthesis and release of the endogenous corticosteroids.</td><td></td></tr><tr><td></td><td></td><td></td><td>Neural factors</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Acts on</td></tr><tr><td></td><td></td><td>Hypothalamus</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Releases</td></tr><tr><td></td><td>Long</td><td colspan="2">Corticotrophin-releasing factor</td><td>Short</td></tr><tr><td></td><td>negative</td><td></td><td></td><td>negative</td></tr><tr><td></td><td>feedback</td><td></td><td></td><td>feedback</td></tr><tr><td></td><td>loop</td><td>Anterior pituitary</td><td></td><td>loop</td></tr><tr><td></td><td></td><td>Corticotrophin (ACTH)</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Renin-angiotensin</td><td></td></tr><tr><td></td><td></td><td>Adrenal cortex</td><td>system</td><td></td></tr><tr><td></td><td></td><td>Glucocorticoids</td><td>Mineralocorticoids</td><td></td></tr></table>
</page>
<page number="275">
<table id="p275t1" data-filename="pdftables_fromstorage_023782248" data-page="275" data-table="1"><tr><td></td><td></td><td>An anti-inflammatory/immunosuppressant glucocorticoid (GC)</td><td colspan="2">Hydrocortisone</td></tr><tr><td>Actions</td><td colspan="4">Reduction in chronic inflammation and in autoimmune and hypersensitivity reactions.</td></tr><tr><td></td><td>Metabolic:</td><td>uptake &amp; utilisation of glucose; gluconeogenesis;</td><td>catabolism and</td><td>synthesis</td></tr><tr><td></td><td>of protein; permissive effect on lipolytic hormones.</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Negative feedback action on ant. pituitary and hypothalamus.</td><td></td><td></td></tr><tr><td>MOA</td><td colspan="4">GCs interact with intracellular receptors that control transcription of specific genes (see card 16.02).</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="4">Short-acting. Given orally, by injection, topically. The main effects occur only after 2–8 h because</td></tr><tr><td></td><td colspan="2">protein synthesis of mediators and enzymes is required.</td><td></td><td></td></tr><tr><td>Similar drugs</td><td colspan="4">Prednisolone (short-acting; oral, injectable). Triamcinolone (intermediate-acting; i.m. injection,</td></tr><tr><td></td><td colspan="4">topical). Dexamethasone (longer-acting; oral, injectable) . Beclometasone (given by inhalation).</td></tr><tr><td>Clinical use</td><td colspan="4">Inflammatory, hypersensitivity and autoimmune diseases (rheumatoid arthritis, asthma,</td></tr><tr><td></td><td colspan="3">anaphylactic shock etc.); to prevent graft rejection; in some cancers.</td><td></td></tr><tr><td></td><td>Replacement therapy in adrenal failure.</td><td></td><td></td><td></td></tr><tr><td>Adverse effects</td><td>See card 16.03.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="3">R&amp;D 7e Ch 32, pp 400-401; D&amp;H 2e Ch 29, pp 70-71</td></tr></table>
</page>
<page number="276">
<table id="p276t1" data-filename="pdftables_fromstorage_023782248" data-page="276" data-table="1"><tr><td></td><td>Action of glucocorticoids</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">16.02</td><td>at the cellular level?</td><td colspan="2">The ant. pituitary &amp; the adrenal cortex</td><td></td><td></td><td></td></tr><tr><td colspan="4">The figure outlines the synthesis and release of the endogenous corticosteroids.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Neural factors</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Hypothalamus</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Short</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>negative</td><td></td><td></td></tr><tr><td></td><td>Long</td><td>Corticotrophin-releasing factor</td><td></td><td>feedback</td><td></td><td></td></tr><tr><td></td><td>negative</td><td></td><td></td><td>loop</td><td></td><td></td></tr><tr><td></td><td>feedback</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>loop</td><td>Anterior pituitary</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Glucocorticoid</td><td>GC</td><td>Plasma</td></tr><tr><td></td><td></td><td>Corticotrophin (ACTH)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Renin-</td><td></td><td></td><td>Cytoplasm</td></tr><tr><td></td><td></td><td></td><td>angiotensin</td><td>R</td><td></td><td></td></tr><tr><td>Prednisolone,</td><td></td><td>Adrenal cortex</td><td>system</td><td></td><td></td><td></td></tr><tr><td>beclometasone</td><td></td><td></td><td></td><td>GC receptor</td><td></td><td></td></tr><tr><td></td><td></td><td>Glucocorticoids</td><td>Mineralocorticoids</td><td></td><td colspan="2">Nucleus</td></tr><tr><td></td><td>Peripheral actions:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Metabolic</td><td></td><td>Acts on</td><td></td><td></td><td></td></tr><tr><td></td><td>anti-inflammatory</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>immunosuppressive</td><td></td><td>Releases</td><td></td><td></td><td></td></tr></table>
</page>
<page number="277">
<table id="p277t1" data-filename="pdftables_fromstorage_023782248" data-page="277" data-table="1"><tr><td></td><td></td><td></td><td></td><td colspan="2">Action of glucocorticoids at the cellular level</td></tr><tr><td>(1) All GC (apart from</td><td></td><td>CBG</td><td></td><td>CBG</td><td></td></tr><tr><td colspan="2">synthetic compounds) are</td><td>GC</td><td></td><td></td><td></td></tr><tr><td>bound to corticosteroid-</td><td></td><td></td><td></td><td>GC</td><td></td></tr><tr><td>binding globulin (CBG)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>in the plasma</td><td>(2) Released</td><td>GC</td><td></td><td></td><td></td></tr><tr><td></td><td>from CBG</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Plasma</td><td></td></tr><tr><td></td><td>(3) Diffusion</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>into cell and</td><td>GC</td><td></td><td>GC</td><td>(4) Receptor changes</td></tr><tr><td></td><td>interaction</td><td></td><td></td><td></td><td>conformation</td></tr><tr><td></td><td></td><td>R</td><td></td><td>R</td><td></td></tr><tr><td></td><td>with receptor</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Receptor</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>GC</td><td>(5) Complex interacts with</td></tr><tr><td></td><td></td><td>Cytoplasm</td><td>Nucleus</td><td>R</td><td>DNA and alters gene</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>expression</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>(6a) Inhibition of transcription of</td></tr><tr><td></td><td></td><td>(7) Synthesis</td><td>(6b)Transcription</td><td></td><td>some genes (e.g. for COX-2, some</td></tr><tr><td>e.g. cAMP-dependent</td><td></td><td>of mediator</td><td></td><td></td><td>cytokines &amp; interleukins etc).</td></tr><tr><td>kinase, annexin-1 etc.</td><td></td><td>proteins</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>R&amp;D 7e Ch 32, pp 402-405; D&amp;H 2e Ch 29, pp 70-71</td></tr></table>
</page>
<page number="278">
<table id="p278t1" data-filename="pdftables_fromstorage_023782248" data-page="278" data-table="1"><tr><td></td><td>Adverse effects of</td><td></td><td></td><td></td></tr><tr><td style="text-align: right">16.03</td><td>the corticosteroids</td><td colspan="2">The ant. pituitary &amp; the adrenal cortex</td><td></td></tr><tr><td colspan="4">The figure outlines the synthesis and release of the endogenous corticosteroids.</td><td></td></tr><tr><td></td><td></td><td></td><td>Neural factors</td><td></td></tr><tr><td></td><td></td><td>Hypothalamus</td><td></td><td></td></tr><tr><td></td><td>Long</td><td colspan="2">Corticotrophin-releasing factor</td><td>Short</td></tr><tr><td></td><td>negative</td><td></td><td></td><td>negative</td></tr><tr><td></td><td>feedback</td><td></td><td></td><td>feedback</td></tr><tr><td></td><td>loop</td><td>Anterior pituitary</td><td></td><td>loop</td></tr><tr><td></td><td></td><td>Corticotrophin (ACTH)</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Renin-angiotensin</td><td></td></tr><tr><td>Prednisolone,</td><td></td><td>Adrenal cortex</td><td>system</td><td></td></tr><tr><td>beclometasone</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Glucocorticoids</td><td>Mineralocorticoids</td><td></td></tr><tr><td></td><td>Peripheral actions:</td><td></td><td></td><td></td></tr><tr><td></td><td>Metabolic</td><td></td><td>Acts on</td><td>Before prolonged</td></tr><tr><td></td><td>anti-inflammatory</td><td></td><td></td><td>corticosteroid therapy</td></tr><tr><td></td><td></td><td></td><td>Releases</td><td></td></tr><tr><td></td><td>immunosuppressive</td><td></td><td></td><td></td></tr></table>
</page>
<page number="279">
<table id="p279t1" data-filename="pdftables_fromstorage_023782248" data-page="279" data-table="1"><tr><td></td><td></td><td>Adverse effects of the corticosteroids</td></tr><tr><td></td><td></td><td>Euphoria (though</td></tr><tr><td></td><td>Cataracts</td><td>sometimes depression,</td></tr><tr><td></td><td></td><td>sometimes psychosis)</td></tr><tr><td>A. Used long-term in inflammatory or</td><td></td><td></td></tr><tr><td>hypersensitivity or autoimmune conditions*:</td><td>Buffalo hump</td><td>Moon face</td></tr><tr><td>• suppression of response to infection</td><td></td><td></td></tr><tr><td>• suppression of endogenous GC synthesis</td><td></td><td></td></tr><tr><td>• osteoporosis</td><td></td><td>Abdominal fat</td></tr><tr><td>• growth suppression in children</td><td></td><td></td></tr><tr><td>• iatrogenic Cushing’s syndome</td><td></td><td>Easy bruising</td></tr><tr><td>* When used thus, the metbolic actions</td><td>Thin arms and legs</td><td></td></tr><tr><td>are unwanted</td><td>(muscle wasting)</td><td></td></tr><tr><td></td><td></td><td>Poor wound</td></tr><tr><td></td><td></td><td>healing</td></tr><tr><td>B. Used in corticosteroid deficiency</td><td></td><td></td></tr><tr><td>there are few adverse actions</td><td></td><td></td></tr><tr><td></td><td colspan="2">Iatrogenic Cushing’s syndrome (after</td></tr><tr><td></td><td colspan="2">prolonged glucocorticoid therapy)</td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 32, pp 403- 406; D&amp;H 2e, Ch 29, pp 70-71</td></tr></table>
</page>
<page number="280">
<table id="p280t1" data-filename="pdftables_fromstorage_023782248" data-page="280" data-table="1"><tr><td style="text-align: right">16.04</td><td>Fludrocortisone</td><td>The ant. pituitary &amp; the adrenal cortex</td><td></td><td></td></tr><tr><td colspan="3">The figure outlines the synthesis and release of the corticosteroids.</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Neural factors</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Acts on</td></tr><tr><td></td><td></td><td>Hypothalamus</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Releases</td></tr><tr><td></td><td>Long</td><td colspan="2">Corticotrophin-releasing factor</td><td>Short</td></tr><tr><td></td><td>negative</td><td></td><td></td><td>negative</td></tr><tr><td></td><td>feedback</td><td></td><td></td><td>feedback</td></tr><tr><td></td><td>loop</td><td>Anterior pituitary</td><td></td><td>loop</td></tr><tr><td></td><td></td><td>Corticotrophin (ACTH)</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Renin-angiotensin</td><td></td></tr><tr><td>Prednisolone,</td><td></td><td>Adrenal cortex</td><td>system</td><td></td></tr><tr><td>beclometasone</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Glucocorticoids</td><td>Mineralocorticoids</td><td></td></tr><tr><td></td><td>Peripheral actions:</td><td></td><td></td><td>Peripheral actions</td></tr><tr><td></td><td>Metabolic</td><td></td><td></td><td>on salt and water</td></tr><tr><td></td><td>anti-inflammatory</td><td></td><td></td><td>metabolism</td></tr><tr><td></td><td>immunosuppressive</td><td></td><td></td><td></td></tr></table>
</page>
<page number="281">
<table id="p281t1" data-filename="pdftables_fromstorage_023782248" data-page="281" data-table="1"><tr><td></td><td colspan="2">A mineralocorticoid (MC) regulating water and electrolyte balance</td><td>Fludrocortisone</td><td></td></tr><tr><td>Actions</td><td colspan="3">Acts on the distal renal tubule to increase Na+ reabsorption and increase excretion</td><td></td></tr><tr><td></td><td>of K+ and H+ .</td><td></td><td></td><td></td></tr><tr><td>MOA</td><td>MCs interact with intracellular</td><td></td><td></td><td></td></tr><tr><td></td><td>receptors in the kidney controlling</td><td></td><td>K +</td><td></td></tr><tr><td></td><td>transcription of specific genes (see</td><td></td><td></td><td></td></tr><tr><td></td><td>card 16.02) that cause:</td><td>P</td><td style="text-align: right">+</td><td>Sodium</td></tr><tr><td></td><td>number of Na+ channels</td><td></td><td>Na</td><td>channel</td></tr><tr><td></td><td>number of Na+ pumps (P).</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Collecting</td></tr><tr><td></td><td></td><td></td><td></td><td>tubule</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally.</td><td></td><td></td><td></td></tr><tr><td>Clinical use</td><td colspan="3">Used (with a glucocorticoid) for replacement therapy in adrenal insufficiency.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="3">Few; hypokalaemia can occur and is increased by thiazides and loop diuretics.</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">R&amp;D 7e Ch 32, p 401t; D&amp;H 2e Ch 29, pp 70-71</td></tr></table>
</page>
<page number="282">
<table id="p282t1" data-filename="pdftables_fromstorage_023782248" data-page="282" data-table="1"><tr><td style="text-align: right">17.01</td><td>Carbimazole</td><td>Thyroid and antithyroid drugs</td><td></td><td></td></tr><tr><td></td><td colspan="4">Outline of the control and actions of thyroid hormone system</td></tr><tr><td></td><td></td><td></td><td></td><td>Hypothalamus</td></tr><tr><td></td><td></td><td>acts on</td><td></td><td></td></tr><tr><td></td><td></td><td>releases</td><td></td><td></td></tr><tr><td></td><td></td><td>is released</td><td></td><td>Thyrotrophin-releasing</td></tr><tr><td></td><td>(thicker lines mean</td><td></td><td>Protirelin</td><td>hormone (TRH)</td></tr><tr><td></td><td>greater quantity)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Anterior pituitary</td></tr><tr><td></td><td></td><td></td><td></td><td>Thyrotrophin</td></tr><tr><td></td><td></td><td>T4</td><td>Thyroid</td><td>Thyroid</td></tr><tr><td></td><td></td><td>T 3</td><td>hormones</td><td></td></tr><tr><td></td><td></td><td colspan="3">↑Metabolism of carbohydrates,</td></tr><tr><td></td><td></td><td colspan="3">proteins, fat; ↑basal metabolic rate</td></tr></table>
</page>
<page number="283">
<table id="p283t1" data-filename="pdftables_fromstorage_023782248" data-page="283" data-table="1"><tr><td></td><td>An antithyroid drug (Similar drugs propylthiouracil, methimazole)</td><td>Carbimazole</td></tr><tr><td>Actions</td><td colspan="2">Gradually decreases thyroid hormone output and thus reduces signs &amp; symptoms of thyrotoxicosis.</td></tr><tr><td>MOA</td><td colspan="2">Reduces the synthesis of thyroid hormones by inhibiting thyroperoxidase which normally</td></tr><tr><td></td><td colspan="2">iodinates tyrosyl residues in thyroglobulin to give the precursors of T3 and T 4 .</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally. Carbimazole is converted to methimazole, plasma half-life 6–15h.</td></tr><tr><td>Clinical use</td><td>Hyperthyroidism; to control the disease before surgery.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Agranulocytosis (rare; incidence 0.1–1.2%); rashes (more common); joint pains.</td></tr><tr><td>Special points</td><td colspan="2">The clinical response may take several weeks because the thyroid stores of hormone need to be</td></tr><tr><td></td><td>depleted and T4 has a long half-life.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 33, pp 414- 415; D&amp;H 2e Ch30, p 73</td></tr></table>
</page>
<page number="284">
<table id="p284t1" data-filename="pdftables_fromstorage_023782248" data-page="284" data-table="1"><tr><td style="text-align: right">17.02</td><td>Levothyroxine</td><td colspan="2">Thyroid and antithyroid drugs</td><td></td><td></td></tr><tr><td colspan="5">Outline of the control and actions of thyroid hormone system</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Hypothalamus</td><td></td></tr><tr><td></td><td>acts on</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>releases</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>is released</td><td></td><td></td><td>Thyrotrophin-releasing</td><td></td></tr><tr><td colspan="2">(thicker lines mean</td><td></td><td>Protirelin</td><td>hormone (TRH)</td><td></td></tr><tr><td colspan="2">greater quantity)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Anterior pituitary</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Thyrotrophin</td><td></td></tr><tr><td></td><td></td><td style="text-align: right">4</td><td>hTohrymrooindes</td><td>Thyroid</td><td>Carbimazole</td></tr><tr><td></td><td></td><td colspan="3">↑Metabolism of carbohydrates,</td><td></td></tr><tr><td></td><td></td><td colspan="3">proteins, fat; ↑basal metabolic rate</td><td></td></tr></table>
</page>
<page number="285">
<table id="p285t1" data-filename="pdftables_fromstorage_023782248" data-page="285" data-table="1"><tr><td></td><td>Synthetic T4 (Similar drug: liothyronine (T3))</td><td>Levothyroxine</td></tr><tr><td>Actions</td><td colspan="2">Increased metabolism of carbohydrates, proteins and fats; increase in basal metabolic rate.</td></tr><tr><td>MOA</td><td colspan="2">The drug enters cells and is converted to T 3 which enters the nucleus and binds to a thyroid</td></tr><tr><td></td><td colspan="2">hormone receptor. The complex activates transcription resulting in the generation of mRNA</td></tr><tr><td></td><td colspan="2">and the synthesis of proteins &amp; enzymes responsible for the metabolic actions of T 4 .</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally. Has long half-life.</td><td></td></tr><tr><td>Clinical use</td><td>Hypothyroidism. Liothyronine is used for myxoedema coma.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Nervousness, palpitations, insomnia, heat intolerance, weight loss.</td></tr><tr><td>Special points</td><td colspan="2">Best given on an empty stomach since some foods can interfere with absorption.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 33, p 415; D&amp;H 2e Ch 30, pp 72-73</td></tr></table>
</page>
<page number="286">
<table id="p286t1" data-filename="pdftables_fromstorage_023782248" data-page="286" data-table="1"><tr><td></td><td>Radioactive iodide</td><td></td><td></td><td></td></tr><tr><td style="text-align: right">17.03</td><td>(radioiodine)</td><td colspan="2">Thyroid and antithyroid drugs</td><td></td></tr><tr><td colspan="4">Outline of the control and actions of thyroid hormone system</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Hypothalamus</td></tr><tr><td></td><td>acts on</td><td></td><td></td><td></td></tr><tr><td></td><td>releases</td><td></td><td></td><td></td></tr><tr><td></td><td>is released</td><td></td><td></td><td>Thyrotrophin-releasing</td></tr><tr><td colspan="2">(thicker lines mean</td><td></td><td>Protirelin</td><td>hormone (TRH)</td></tr><tr><td colspan="2">greater quantity)</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Anterior pituitary</td></tr><tr><td></td><td></td><td></td><td></td><td>Thyrotrophin</td></tr><tr><td></td><td></td><td>T4</td><td>Thyroid</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Thyroid</td></tr><tr><td></td><td></td><td></td><td>hormones</td><td>Carbimazole</td></tr><tr><td></td><td>Levothyroxine</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">↑Metabolism of carbohydrates,</td><td></td></tr><tr><td></td><td></td><td colspan="2">proteins, fat; ↑basal metabolic rate</td><td></td></tr></table>
</page>
<page number="287">
<table id="p287t1" data-filename="pdftables_fromstorage_023782248" data-page="287" data-table="1"><tr><td></td><td></td><td></td><td></td><td>Radioactive</td></tr><tr><td></td><td></td><td></td><td></td><td>iodine</td></tr><tr><td></td><td></td><td></td><td></td><td>Radioactive iodine (131I ):</td></tr><tr><td>acts on</td><td></td><td>Hypothalamus</td><td>MOA</td><td>Emits both X-rays (which do no</td></tr><tr><td>releases</td><td></td><td></td><td></td><td>damage) and β radiation which has</td></tr><tr><td>is released</td><td></td><td></td><td></td><td>a very short range and is cytotoxic</td></tr><tr><td></td><td></td><td>Thyrotrophin-releasing</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>to local thyroid cells.</td></tr><tr><td>(thicker lines mean</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>hormone (TRH)</td><td></td><td></td></tr><tr><td>greater quantity)</td><td>Protirelin</td><td></td><td>Abs &amp;</td><td>Given orally as a single dose, taken</td></tr><tr><td></td><td></td><td></td><td>Distrb</td><td>up by thyroid cells, incorporated into</td></tr><tr><td></td><td></td><td></td><td></td><td>thyroglobulin. 131I half-life is 8 days.</td></tr><tr><td></td><td></td><td></td><td>Clin. use</td><td>Thyrotoxicosis. Maximum effect</td></tr><tr><td></td><td></td><td>Anterior pituitary</td><td></td><td>takes ~ 4 months.</td></tr><tr><td></td><td></td><td></td><td>Adverse</td><td>Hypothyroidism will eventually</td></tr><tr><td></td><td></td><td>Thyrotrophin</td><td>effects</td><td>occur.</td></tr><tr><td>T 4</td><td>Thyroid</td><td>Thyroid</td><td colspan="2">131I (radioiodine)</td></tr><tr><td></td><td>hormones</td><td></td><td></td><td></td></tr><tr><td>T 3</td><td></td><td></td><td colspan="2">Carbimazole</td></tr><tr><td>Levothyroxine</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">↑Metabolism of carbohydrates,</td><td></td><td></td></tr><tr><td colspan="3">proteins, fat; ↑basal metabolic rate</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>R&amp;D 7e Ch 33, pp 413-415; D&amp;H 2e Ch 30, pp 72-73</td></tr></table>
</page>
<page number="288">
<table id="p288t1" data-filename="pdftables_fromstorage_023782248" data-page="288" data-table="1"><tr><td style="text-align: right">18.01</td><td>Alendronate</td><td>Bone metabolism</td><td></td><td></td></tr><tr><td colspan="2">Schematic outline of bone formation</td><td></td><td></td><td></td></tr><tr><td colspan="2">The bone remodelling cycle:</td><td colspan="2">OC precursor cell</td><td>OB precursor cell</td></tr><tr><td colspan="2">Bone resorption</td><td></td><td></td><td></td></tr><tr><td colspan="2">1. The precursor cells differentiate</td><td></td><td></td><td></td></tr><tr><td colspan="2">to osteoclasts (OCs) or osteoblasts</td><td></td><td>Diffetroe nOtCiastion</td><td>Diffetroe nOtBiastion</td></tr><tr><td>(OBs).</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">2. OCs digest bone.</td><td></td><td></td><td></td></tr><tr><td colspan="2">Bone formation</td><td></td><td></td><td></td></tr><tr><td colspan="2">3. OBs secrete osteoid (bone matrix).</td><td></td><td></td><td></td></tr><tr><td colspan="2">4. Mineralisation of the osteoid</td><td></td><td></td><td></td></tr><tr><td colspan="2">occurs, i.e. complex calcium</td><td></td><td>OCs</td><td>OBs</td></tr><tr><td colspan="2">phosphate crystals</td><td></td><td></td><td>New</td></tr><tr><td colspan="2">(hydroxyapatite) are deposited.</td><td></td><td></td><td>osteoid</td></tr><tr><td></td><td></td><td>Quiescent</td><td>Bone</td><td>Bone</td></tr><tr><td></td><td></td><td>bone</td><td>resorption</td><td>formation</td></tr></table>
</page>
<page number="289">
<table id="p289t1" data-filename="pdftables_fromstorage_023782248" data-page="289" data-table="1"><tr><td></td><td>A bisphosphonate that modifies bone remodelling (Similar drug: pamidronate)</td><td>Alendronate</td></tr><tr><td>Actions</td><td>It decreases bone resorption and increases bone density.</td><td></td></tr><tr><td>MOA</td><td colspan="2">It prevents osteoclast-mediated bone resorption. Also it is incorporated into the bone</td></tr><tr><td></td><td colspan="2">matrix and ingested by osteoclasts, promoting osteoclast apoptosis.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally with a large amount of water 1 hour before eating, it localizes at sites of</td></tr><tr><td></td><td colspan="2">bone mineralisation. Being an analogue of pyrophosphate, it binds to the hydroxyapatite</td></tr><tr><td></td><td>in bone matrix.</td><td></td></tr><tr><td>Clinical use</td><td>Postmenopausal osteoporosis (either alone or with an oestrogen).</td><td></td></tr><tr><td></td><td>Paget’s disease of bone.</td><td></td></tr><tr><td></td><td>Glucocorticoid-induced osteoporosis.</td><td></td></tr><tr><td></td><td>Malignant hypercalcaemia.</td><td></td></tr><tr><td></td><td>Bone secondaries in breast cancer.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances particularly oesophagitis; bone pain. Osteonecrosis of the jaw (rare).</td></tr><tr><td>Special points</td><td colspan="2">Patient needs to remain upright for ~1 hour after administration to avoid reflux.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 35, p 438; D&amp;H 2e Ch 31, pp 74-75</td></tr></table>
</page>
<page number="290">
<table id="p290t1" data-filename="pdftables_fromstorage_023782248" data-page="290" data-table="1"><tr><td style="text-align: right">18.02</td><td>Teriparatide</td><td>Bone metabolism</td><td></td><td></td></tr><tr><td colspan="2">Schematic outline of bone formation</td><td></td><td></td><td></td></tr><tr><td colspan="2">The bone remodelling cycle:</td><td colspan="2">OC precursor cell</td><td>OB precursor cell</td></tr><tr><td colspan="2">Bone resorption</td><td></td><td></td><td></td></tr><tr><td colspan="2">1. The precursor cells differentiate</td><td></td><td></td><td></td></tr><tr><td colspan="2">to osteoclasts (OCs) or osteoblasts</td><td></td><td>Diffetroe nOtCiastion</td><td>Diffetroe nOtBiastion</td></tr><tr><td>(OBs).</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">2. OCs digest bone.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Alendronate</td><td></td></tr><tr><td colspan="2">Bone formation</td><td></td><td></td><td></td></tr><tr><td colspan="2">3. OBs secrete osteoid (bone matrix).</td><td></td><td></td><td></td></tr><tr><td colspan="2">4. Mineralisation of the osteoid</td><td></td><td></td><td></td></tr><tr><td colspan="2">occurs, i.e. complex calcium</td><td></td><td>OCs</td><td>OBs</td></tr><tr><td colspan="2">phosphate crystals</td><td></td><td></td><td>New</td></tr><tr><td colspan="2">(hydroxyapatite) are deposited.</td><td></td><td></td><td>osteoid</td></tr><tr><td></td><td></td><td>Quiescent</td><td>Bone</td><td>Bone</td></tr><tr><td></td><td></td><td>bone</td><td>resorption</td><td>formation</td></tr></table>
</page>
<page number="291">
<table id="p291t1" data-filename="pdftables_fromstorage_023782248" data-page="291" data-table="1"><tr><td></td><td>A recombinant form of parathyroid hormone (Similar drug: parathyroid hormone)</td><td>Teriparatide</td></tr><tr><td>Actions</td><td colspan="2">It has anabolic effects on bone, increasing bone mass, structural integrity and strength.</td></tr><tr><td>MOA</td><td colspan="2">It increases the number of osteoblasts in bone and activates the OBs already there.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given subcut. once daily.</td><td></td></tr><tr><td>Clinical use</td><td>Osteoporosis in postmenpausal women and in men.</td><td></td></tr><tr><td></td><td>Glucocorticoid-induced osteoporosis.</td><td></td></tr><tr><td>Adverse effects</td><td>GIT disturbances, dizziness, muscle cramps.</td><td></td></tr><tr><td>Special points</td><td>Should be given by experts in osteoporosis treatment.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 35, p 439; D&amp;H 2e Ch 31, pp 74-75</td></tr></table>
</page>
<page number="292">
<table id="p292t1" data-filename="pdftables_fromstorage_023782248" data-page="292" data-table="1"><tr><td style="text-align: right">18.03</td><td>Raloxifene</td><td>Bone metabolism</td><td></td><td></td></tr><tr><td colspan="2">Schematic outline of bone formation</td><td></td><td></td><td></td></tr><tr><td colspan="2">The bone remodelling cycle:</td><td colspan="2">OC precursor cell</td><td>OB precursor cell</td></tr><tr><td colspan="2">Bone resorption</td><td></td><td></td><td>Teriparatide</td></tr><tr><td colspan="2">1. The precursor cells differentiate</td><td></td><td></td><td></td></tr><tr><td colspan="2">to osteoclasts (OCs) or osteoblasts</td><td></td><td>Diffetroe nOtCiastion</td><td>Diffetroe nOtBiastion</td></tr><tr><td>(OBs).</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">2. OCs digest bone.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Alendronate</td><td></td></tr><tr><td colspan="2">Bone formation</td><td></td><td></td><td></td></tr><tr><td colspan="2">3. OBs secrete osteoid (bone matrix).</td><td></td><td></td><td></td></tr><tr><td colspan="2">4. Mineralisation of the osteoid</td><td></td><td></td><td></td></tr><tr><td colspan="2">occurs, i.e. complex calcium</td><td></td><td>OCs</td><td>OBs</td></tr><tr><td colspan="2">phosphate crystals</td><td></td><td></td><td>New</td></tr><tr><td colspan="2">(hydroxyapatite) are deposited.</td><td></td><td></td><td>osteoid</td></tr><tr><td></td><td></td><td>Quiescent</td><td>Bone</td><td>Bone</td></tr><tr><td></td><td></td><td>bone</td><td>resorption</td><td>formation</td></tr></table>
</page>
<page number="293">
<table id="p293t1" data-filename="pdftables_fromstorage_023782248" data-page="293" data-table="1"><tr><td></td><td>A selective oestrogen receptor modulator (SERM)</td><td>Raloxifene</td></tr><tr><td>Actions</td><td colspan="2">It has agonist effects on bone and on the CVS but antagonist action on mammary glands</td></tr><tr><td></td><td>and the uterus.</td><td></td></tr><tr><td>MOA</td><td>Like the oestrogens, it inhibits the cytokines that recruit osteoclasts.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally, undergoes first-pass metabolism. Bioavailability ~2%. Plasma half-life ~32h.</td></tr><tr><td>Clinical use</td><td>Prophylaxis for postmenopausal osteoporosis and breast cancer.</td><td></td></tr><tr><td>Adverse effects</td><td>Risk of thromboembolism.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 35, pp 438-439; D&amp;H 2e Ch 31, pp 74-75</td></tr></table>
</page>
<page number="294">
<table id="p294t1" data-filename="pdftables_fromstorage_023782248" data-page="294" data-table="1"><tr><td style="text-align: right">18.04</td><td colspan="2">What are the main hormones that affect bone</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Bone metabolism</td><td></td></tr><tr><td></td><td colspan="2">metabolism and what is their clinical importance?</td><td></td><td></td></tr><tr><td>Schematic outline of bone formation</td><td></td><td></td><td></td><td></td></tr><tr><td>The bone remodelling cycle:</td><td colspan="2">OC precursor cell</td><td></td><td>OB precursor cell</td></tr><tr><td>Bone resorption</td><td></td><td></td><td>Raloxifene</td><td>Teriparatide</td></tr><tr><td>1. The precursor cells differentiate</td><td></td><td></td><td></td><td></td></tr><tr><td>to osteoclasts (OCs) or</td><td></td><td>Differentiation</td><td>Differentiation</td><td></td></tr><tr><td></td><td></td><td>to OCs</td><td>to OBs</td><td></td></tr><tr><td>osteoblasts (OBs).</td><td></td><td></td><td></td><td></td></tr><tr><td>2. OCs digest bone.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Alendronate</td><td></td><td></td></tr><tr><td>Bone formation</td><td></td><td></td><td></td><td></td></tr><tr><td>3. OBs secrete osteoid (bone matrix).</td><td></td><td></td><td></td><td></td></tr><tr><td>4. Mineralisation of the osteoid</td><td></td><td></td><td></td><td></td></tr><tr><td>occurs, i.e. complex calcium</td><td></td><td>OCs</td><td>OBs</td><td></td></tr><tr><td>phosphate crystals</td><td></td><td></td><td></td><td>New</td></tr><tr><td>(hydroxyapatite) are deposited.</td><td></td><td></td><td></td><td>osteoid</td></tr><tr><td></td><td>Quiescent</td><td>Bone</td><td></td><td>Bone</td></tr><tr><td></td><td>bone</td><td>resorption</td><td></td><td>formation</td></tr></table>
</page>
<page number="295">
<table id="p295t1" data-filename="pdftables_fromstorage_023782248" data-page="295" data-table="1"><tr><td>The main hormones that affect bone metabolism and their clinical importance</td></tr></table>
</page>
<page number="296">
<table id="p296t1" data-filename="pdftables_fromstorage_023782248" data-page="296" data-table="1"><tr><td style="text-align: right">18.05</td><td>Ergocalciferol</td><td>Bone metabolism</td><td></td><td></td></tr><tr><td colspan="3">The vitamin D family, parathyroid and calcium metabolism</td><td></td><td></td></tr><tr><td colspan="2">Cholesterol gives rise</td><td></td><td>7-Dehydrocholesterol</td><td></td></tr><tr><td colspan="2">to 7-dehydrocholesterol</td><td>Skin</td><td>UV</td><td></td></tr><tr><td colspan="2">which gives rise to Vit D3</td><td></td><td>Vit D 3 (cholecalciferol)</td><td></td></tr><tr><td colspan="2">then to the hormones:</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Liver</td><td>Vit D3</td><td></td></tr><tr><td></td><td>Calcifediol</td><td></td><td>Calcifediol</td><td></td></tr><tr><td></td><td>and</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Calcifediol</td><td></td></tr><tr><td></td><td></td><td>Kidney</td><td>Parathormone</td><td></td></tr><tr><td></td><td>Calcitriol</td><td></td><td>Calcitriol</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>↓Blood</td></tr><tr><td></td><td></td><td></td><td></td><td>calcium</td></tr><tr><td></td><td></td><td></td><td>Calcitriol</td><td></td></tr><tr><td></td><td></td><td></td><td>in blood</td><td>Parathyroid</td></tr><tr><td></td><td></td><td></td><td>↑Blood</td><td></td></tr><tr><td></td><td></td><td></td><td>calcium</td><td></td></tr><tr><td></td><td></td><td></td><td>Biological actions:</td><td></td></tr><tr><td></td><td></td><td>Intracellular actions:</td><td>Calcium and</td><td></td></tr><tr><td></td><td></td><td>cell growth and differentiation</td><td>phosphate homeostasis</td><td></td></tr></table>
</page>
<page number="297">
<table id="p297t1" data-filename="pdftables_fromstorage_023782248" data-page="297" data-table="1"><tr><td></td><td>A preparation of vitamin D2</td><td>Ergocalciferol</td></tr><tr><td>Actions</td><td colspan="2">A prehormone that gives rise to true hormones, calcifediol and calcitriol, needed in</td></tr><tr><td></td><td>calcium and phosphate homeostasis and in bone metabolism.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Calcifediol and calcitriol act on receptors belonging to the steroid superfamily of receptors</td></tr><tr><td></td><td colspan="2">to increase serum calcium by increasing calcium and phosphate absorption from the intestine</td></tr><tr><td></td><td>and decreasing their excretion by the kidney.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally it needs bile salts for absorption.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Rickets; the hypocalcaemia of hypoparathyroidism; the osteodystrophy of renal failure.</td></tr><tr><td>Adverse effects</td><td colspan="2">Excessive intake can cause hypercalcaemia; if this persists renal calculi may result.</td></tr><tr><td>Special points</td><td>Serum calcium levels should be monitored.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 35, p 439; D&amp;H 2e Ch 31, pp 74-75</td></tr></table>
</page>
<page number="298">
<table id="p298t1" data-filename="pdftables_fromstorage_023782248" data-page="298" data-table="1"><tr><td style="text-align: right">18.06</td><td>Calcitriol</td><td>Bone metabolism</td><td></td><td></td></tr><tr><td colspan="3">The vitamin D family, parathyroid and calcium metabolism</td><td></td><td></td></tr><tr><td colspan="2">Cholesterol gives rise</td><td></td><td>7-Dehydrocholesterol</td><td></td></tr><tr><td colspan="2">to 7-dehydrocholesterol</td><td>Skin</td><td>UV</td><td></td></tr><tr><td colspan="2">which gives rise to Vit D3</td><td></td><td>Vit D 3 (cholecalciferol)</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Converted in the</td></tr><tr><td colspan="2">then to the hormones:</td><td></td><td>Ergocalciferol</td><td>liver to calcfediol</td></tr><tr><td></td><td></td><td>Liver</td><td>Vit D3</td><td>actions are thus</td></tr><tr><td></td><td></td><td></td><td></td><td>those of calcitriol</td></tr><tr><td colspan="2">Calcifediol</td><td></td><td>Calcifediol</td><td></td></tr><tr><td colspan="2">and</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Calcifediol</td><td></td></tr><tr><td></td><td></td><td>Kidney</td><td>Parathormone</td><td></td></tr><tr><td colspan="2">Calcitriol</td><td></td><td>Calcitriol</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>↓Blood</td></tr><tr><td></td><td></td><td></td><td></td><td>calcium</td></tr><tr><td></td><td></td><td></td><td>Calcitriol</td><td></td></tr><tr><td></td><td></td><td></td><td>in blood</td><td>Parathyroid</td></tr><tr><td></td><td></td><td></td><td>↑Blood</td><td></td></tr><tr><td></td><td></td><td></td><td>calcium</td><td></td></tr><tr><td></td><td></td><td></td><td>Biological actions:</td><td></td></tr><tr><td></td><td></td><td>Intracellular actions:</td><td>Calcium and</td><td></td></tr><tr><td></td><td></td><td>cell growth and differentiation</td><td>phosphate homeostasis</td><td></td></tr></table>
</page>
<page number="299">
<table id="p299t1" data-filename="pdftables_fromstorage_023782248" data-page="299" data-table="1"><tr><td></td><td>A secosteroid that has all the actions of vitamin D2 and vitamin D3</td><td>Calcitriol</td></tr><tr><td>Actions</td><td>Increases serum calcium and phosphate levels.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Calcitriol acts on receptors belonging to the steroid superfamily of receptors to give mediator</td></tr><tr><td></td><td colspan="2">proteins that increase calcium and phosphate absorption from the intestine and decrease their</td></tr><tr><td></td><td>excretion by the kidney.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally it needs bile salts for absorption. Can be given by i.v. injection.</td></tr><tr><td>Clinical use</td><td colspan="2">The osteodystrophy of chronic renal failure which is due to decreased calcitriol;</td></tr><tr><td></td><td>postmenopausal osteoporosis.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Excessive intake can cause hypercalcaemia; if this persists renal calculi may result.</td></tr><tr><td>Special points</td><td colspan="2">Serum calcium, phosphate and and creatinine levels should be monitored.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e , p 439; D&amp;H 2e Ch 31, pp 74-75</td></tr></table>
</page>
<page number="300">
<table id="p300t1" data-filename="pdftables_fromstorage_023782248" data-page="300" data-table="1"><tr><td style="text-align: right">18.07</td><td>Calcitonin</td><td>Bone metabolism</td><td></td><td></td></tr><tr><td colspan="4">Calcium homeostasis, parathyroid and bone</td><td></td></tr><tr><td></td><td></td><td>A fall in the plasma</td><td></td><td>A rise in the plasma</td></tr><tr><td></td><td colspan="2">Ca2+ concentration</td><td></td><td>Ca2+ concentration</td></tr><tr><td></td><td></td><td>causes:</td><td></td><td>decreases:</td></tr><tr><td></td><td></td><td></td><td>Secretion of parathormone</td><td></td></tr><tr><td></td><td></td><td></td><td>from the parathyroid,</td><td></td></tr><tr><td></td><td></td><td></td><td>which causes:</td><td></td></tr><tr><td></td><td></td><td></td><td>Conversion of</td><td></td></tr><tr><td></td><td></td><td></td><td>calcifediol to calcitriol,</td><td></td></tr><tr><td></td><td></td><td></td><td>which causes:</td><td></td></tr><tr><td></td><td colspan="2">Decreased excretion</td><td>Increased Ca 2+</td><td>Mobilisation of</td></tr><tr><td></td><td colspan="2">of Ca2+ by the kidney</td><td>absorption in the</td><td>Ca 2+ from bone</td></tr><tr><td></td><td></td><td>which causes:</td><td>intestine which causes:</td><td>which causes:</td></tr></table>
</page>
<page number="301">
<table id="p301t1" data-filename="pdftables_fromstorage_023782248" data-page="301" data-table="1"><tr><td></td><td>Synthetic or recombinant form of salmon calcitonin</td><td>Calcitonin</td></tr><tr><td>Actions</td><td>Lowers serum calcium levels and decreases bone resorption.</td><td></td></tr><tr><td>MOA</td><td colspan="2">It decreases the reabsorption of both calcium and phosphate in the kidney; it inhibits</td></tr><tr><td></td><td colspan="2">bone resorption by binding to a specific receptor on osteoclasts, inhibiting their action.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given by subcut. or i.m. injection or by nasal spray. Plasma half-life is 4–12min; action lasts</td></tr><tr><td></td><td>several hours.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Hypercalcaemia; Paget’s disease; the prevention of postmenopausal osteoporosis.</td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disorders; facial flushing; taste disturbances; dizziness; muscle pain.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 35, p 437; D&amp;H 2e Ch 31, pp 74-75</td></tr></table>
</page>
<page number="302">
<table id="p302t1" data-filename="pdftables_fromstorage_023782248" data-page="302" data-table="1"><tr><td style="text-align: right">18.08</td><td>Cinacalcet</td><td>Bone metabolism</td><td></td><td></td></tr><tr><td colspan="4">Calcium homeostasis, parathyroid and bone</td><td></td></tr><tr><td></td><td colspan="2">A fall in the plasma</td><td></td><td>A rise in the plasma</td></tr><tr><td></td><td colspan="2">Ca2+ concentration</td><td></td><td>Ca2+ concentration</td></tr><tr><td></td><td></td><td>causes:</td><td></td><td>decreases:</td></tr><tr><td></td><td></td><td></td><td>Secretion of parathormone</td><td></td></tr><tr><td></td><td></td><td></td><td>from the parathyroid,</td><td></td></tr><tr><td></td><td></td><td></td><td>which causes:</td><td></td></tr><tr><td></td><td></td><td></td><td>Conversion of</td><td></td></tr><tr><td></td><td>Calcitonin</td><td></td><td>calcifediol to calcitriol,</td><td>Calcitonin</td></tr><tr><td></td><td></td><td></td><td>which causes:</td><td></td></tr><tr><td></td><td colspan="2">Decreased excretion</td><td>Increased Ca 2+</td><td>Mobilisation of</td></tr><tr><td></td><td colspan="2">of Ca2+ by the kidney</td><td>absorption in the</td><td>Ca 2+ from bone</td></tr><tr><td></td><td></td><td>which causes:</td><td>intestine which causes:</td><td>which causes:</td></tr></table>
</page>
<page number="303">
<table id="p303t1" data-filename="pdftables_fromstorage_023782248" data-page="303" data-table="1"><tr><td></td><td>A calcimimetic drug</td><td>Cinacalcet</td></tr><tr><td>Actions</td><td colspan="2">Decreases the secretion of parathyroid hormone resulting in a rise in plasma calcium by:</td></tr><tr><td></td><td>• decreasing the conversion of calcifediol to calcitriol,</td><td></td></tr><tr><td></td><td>• decreasing the excretion of calcium by the kidney,</td><td></td></tr><tr><td></td><td>• increasing the absorption of calcium from the intestine,</td><td></td></tr><tr><td></td><td>• mobilising calcium from bone.</td><td></td></tr><tr><td>MOA</td><td>It activates the calcium-sensing receptor in parathyroid cells.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally it needs bile salts for absorption. Can be given by i.v. injection.</td></tr><tr><td>Clinical use</td><td>Hyperparathyroidism.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Excessive intake can cause hypercalcaemia; if this persists renal calculi may result.</td></tr><tr><td>Special points</td><td colspan="2">Serum calcium, phosphate and and creatinine levels should be monitored.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 35, p 440; D&amp;H 2e Ch 31, pp 74-75</td></tr></table>
</page>
<page number="304">
<table id="p304t1" data-filename="pdftables_fromstorage_023782248" data-page="304" data-table="1"><tr><td style="text-align: right">18.09</td><td colspan="2">A 69-year-old woman slips on her front steps, falls and breaks her</td><td></td></tr><tr><td></td><td></td><td></td><td>Bone metabolism</td></tr><tr><td></td><td colspan="2">arm. Probable diagnosis? Drug treatment? Which drugs and why?</td><td></td></tr><tr><td colspan="2">Calcium homeostasis, parathyroid and bone</td><td></td><td></td></tr><tr><td></td><td>A fall in the plasma</td><td></td><td>A rise in the plasma</td></tr><tr><td></td><td>Ca2+ concentration</td><td>Cinacalcet</td><td>Ca2+ concentration</td></tr><tr><td></td><td>causes:</td><td></td><td>decreases:</td></tr><tr><td></td><td></td><td>Secretion of parathormone</td><td></td></tr><tr><td></td><td></td><td>from the parathyroid,</td><td></td></tr><tr><td></td><td></td><td>which causes:</td><td></td></tr><tr><td></td><td></td><td>Conversion of</td><td></td></tr><tr><td></td><td>Calcitonin</td><td>calcifediol to calcitriol,</td><td>Calcitonin</td></tr><tr><td></td><td></td><td>which causes:</td><td></td></tr><tr><td></td><td>Decreased excretion</td><td>Increased Ca 2+</td><td>Mobilisation of</td></tr><tr><td></td><td>of Ca2+ by the kidney</td><td>absorption in the</td><td>Ca 2+ from bone</td></tr><tr><td></td><td>which causes:</td><td>intestine which causes:</td><td>which causes:</td></tr></table>
</page>
<page number="305">
<table id="p305t1" data-filename="pdftables_fromstorage_023782248" data-page="305" data-table="1"><tr><td>A 69-year-old woman slips on her front steps, falls and breaks her arm. Probable diagnosis?</td></tr><tr><td>Drug treatment? Which drugs and why?</td></tr><tr><td>Probable diagnosis</td></tr><tr><td>Fracture due to established postmenopausal osteoporosis</td></tr><tr><td>(but whether or not the patient is on glucocorticoids needs to be checked).</td></tr><tr><td>Treatment</td></tr><tr><td>1. The primary treatment would be surgical, of course.</td></tr><tr><td>2. Drug treatment of the osteoporosis would also be needed.</td></tr><tr><td>Drugs to be considered:</td></tr><tr><td>A drug which decreases bone resorption and thus prevents futher loss of bone density,</td></tr><tr><td>e.g. a bisphosphonate (e.g. alendronate) which has primarily antiosteoclast action.</td></tr><tr><td>Calcitonin also decreases bone resorption.</td></tr><tr><td>A drug which enhances bone formation. Both raloxifene and teriparatide do this.</td></tr><tr><td>Raloxifene increases osteoblast action and decreases osteoclast activity; teriparatide has</td></tr><tr><td>anabolic actions on bone increasing the number and activity of osteoblasts.</td></tr><tr><td>R&amp;D 7e Ch 35 ; D&amp;H 2e Ch 31, pp 74-75</td></tr></table>
</page>
<page number="306">
<table id="p306t1" data-filename="pdftables_fromstorage_023782248" data-page="306" data-table="1"><tr><td></td><td>Ethinylestradiol</td><td></td><td></td><td></td></tr><tr><td style="text-align: right">19.01</td><td>+ norethisterone</td><td>Female Reproductive System</td><td></td><td></td></tr><tr><td colspan="4">The figure shows the hormonal control of the menstrual cycle</td><td></td></tr><tr><td colspan="2">1. The menstrual cycle starts with bleeding. When this ceases,</td><td colspan="2">Hypothalamus</td><td>11. If the ovum does not implant,</td></tr><tr><td colspan="2">the endometrium is regenerated during the rest of the cycle.</td><td></td><td></td><td>progesterone secretion ceases,</td></tr><tr><td></td><td></td><td></td><td></td><td>triggering menstruation; in the</td></tr><tr><td colspan="2">2. Gonadotrophin-releasing hormone</td><td></td><td></td><td>absence of the negative feedback</td></tr><tr><td colspan="2">(GnRH) is released from the hypothalamus</td><td>GnRH</td><td></td><td>action the cycle begins again.</td></tr><tr><td colspan="2">. . . to act on GnRH receptors in the ant. pit to stimulate</td><td></td><td></td><td>10. Progesterone acts on the</td></tr><tr><td colspan="2">release of follicle-stimulating hormone (FSH) and</td><td></td><td></td><td>hypothalamus and anterior pituitary,</td></tr><tr><td colspan="2">luteinising hormone (LH) from the anterior pituitary.</td><td>GnRHR</td><td></td><td>reducing the secretion of GnRH and</td></tr><tr><td></td><td></td><td></td><td></td><td>LH. It also raises body temperature by</td></tr><tr><td></td><td></td><td colspan="2">Anterior pituitary</td><td></td></tr><tr><td colspan="2">3. In the first part of the cycle, FSH stimulates</td><td></td><td></td><td>about 0.5 °C.</td></tr><tr><td colspan="2">the development of the Graafian follicle ,</td><td></td><td></td><td></td></tr><tr><td colspan="2">which contains the ovum.</td><td></td><td></td><td>9. The ruptured follicle, under LH</td></tr><tr><td></td><td></td><td></td><td></td><td>action, develops into the corpus</td></tr><tr><td></td><td></td><td>FSH</td><td>LH</td><td>luteum, which secretes both</td></tr><tr><td colspan="2">4. FSH stimulates the granulosa cells surrounding</td><td></td><td></td><td>oestrogen and progesterone.</td></tr><tr><td colspan="2">the ovum to produce oestrogens whose level</td><td></td><td></td><td></td></tr><tr><td colspan="2">peaks at mid-cycle. The oestrogens control the</td><td></td><td></td><td></td></tr><tr><td colspan="2">proliferative phase of endometrium renewal</td><td></td><td></td><td>8. These sex steroids act on nuclear</td></tr><tr><td colspan="2">(till mid cycle) and also act on the anterior</td><td>Ovary</td><td></td><td>receptors in target tissues,</td></tr><tr><td colspan="2">pituitary to reduce gonadotrophin release.</td><td>GF</td><td>CL</td><td>activating transcription of some</td></tr><tr><td></td><td></td><td></td><td></td><td>genes and inhibiting transcription</td></tr><tr><td colspan="2">5. At mid cycle, a surge of LH</td><td></td><td></td><td>of others.</td></tr><tr><td colspan="2">secretion stimulates ovulation.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Oestrogens</td><td>Progesterone</td><td>7. Progesterone, acting on oestrogen-induced</td></tr><tr><td colspan="2">6. Oestrogens promote progesterone</td><td></td><td></td><td>receptors, stimulates the secretory phase of</td></tr><tr><td colspan="2">receptor synthesis in peripheral target</td><td></td><td></td><td>endometrium regeneration, preparing it for</td></tr><tr><td colspan="2">tissues, including the endometrium.</td><td colspan="2">Peripheral tissues</td><td>implantation of the ovum.</td></tr></table>
</page>
<page number="307">
<table id="p307t1" data-filename="pdftables_fromstorage_023782248" data-page="307" data-table="1"><tr><td></td><td></td><td>Ethinylestradiol</td></tr><tr><td></td><td>Oral contraceptive combining an oestrogen and a progestogen</td><td>+ norethisterone</td></tr><tr><td>Action and Use</td><td>Prevention of pregnancy.</td><td></td></tr><tr><td>MOA</td><td colspan="2">The ethinylestradiol suppresses the development of the ovarian follicle by inhibiting follicle-</td></tr><tr><td></td><td colspan="2">stimulating hormone (FSH) release from the anterior pituitary. The norethisterone prevents</td></tr><tr><td></td><td colspan="2">ovulation by inhibiting luteinizing hormone (LH) release. Together they make the endometrium</td></tr><tr><td></td><td>unsuitable for implantation of the ovum.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Infrequent; but may cause weight gain, flushing, mood changes, dizziness and sometimes acne or</td></tr><tr><td></td><td colspan="2">skin pigmentation and a transient rise of blood pressure. Some risk of thromboembolism.</td></tr><tr><td>Special points</td><td colspan="2">Other combinations: ethinylestradiol + desogestrel; ethinylestradiol + drospirenone.</td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 34, pp 425-426; D&amp;H 2e Ch 32, pp 76-77</td></tr></table>
</page>
<page number="308">
<table id="p308t1" data-filename="pdftables_fromstorage_023782248" data-page="308" data-table="1"><tr><td style="text-align: right">19.02</td><td>Clomifene</td><td>Female Reproductive System</td><td></td></tr><tr><td></td><td colspan="3">The figure shows the hormonal control of the menstrual cycle</td></tr><tr><td></td><td></td><td colspan="2">Hypothalamus</td></tr><tr><td></td><td></td><td>GnRH</td><td></td></tr><tr><td></td><td></td><td>GnRHR</td><td></td></tr><tr><td></td><td></td><td colspan="2">Anterior pituitary</td></tr><tr><td></td><td></td><td>FSH</td><td>LH</td></tr><tr><td></td><td></td><td>Ovary</td><td></td></tr><tr><td></td><td></td><td>GF</td><td>CL</td></tr><tr><td></td><td></td><td>Oestrogens</td><td>Progesterone</td></tr><tr><td></td><td></td><td>Ethinylestradiol</td><td>Norethisterone</td></tr></table>
</page>
<page number="309">
<table id="p309t1" data-filename="pdftables_fromstorage_023782248" data-page="309" data-table="1"><tr><td></td><td>An ovulation-inducing antioestrogen</td><td>Clomifene</td></tr><tr><td>Action &amp; MOA</td><td colspan="2">Acts on the anterior pituitary to inhibit the negative feedback action of endogenous oestrogens</td></tr><tr><td></td><td>thus increasing gonadotrophin release.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally.</td><td></td></tr><tr><td>Clinical use</td><td>Treatment of infertility.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Menopausal-like hot flushes; ovarian enlargement. Sometimes visual symptoms (after images).</td></tr><tr><td></td><td>GIT disturbances may occur.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 34, pp 424-425; D&amp;H 2e Ch 32, pp 76-77</td></tr></table>
</page>
<page number="310">
<table id="p310t1" data-filename="pdftables_fromstorage_023782248" data-page="310" data-table="1"><tr><td style="text-align: right">19.03</td><td>Danazol</td><td></td><td>Female Reproductive System</td><td></td></tr><tr><td></td><td colspan="4">The figure shows the hormonal control of the menstrual cycle</td></tr><tr><td></td><td></td><td colspan="3">Hypothalamus</td></tr><tr><td></td><td></td><td colspan="2">GnRH</td><td></td></tr><tr><td></td><td></td><td colspan="2">GnRHR</td><td></td></tr><tr><td></td><td></td><td colspan="3">Anterior pituitary</td></tr><tr><td></td><td></td><td colspan="2">FSH</td><td>LH</td></tr><tr><td></td><td></td><td></td><td>Clomifene</td><td></td></tr><tr><td></td><td></td><td></td><td>Ovary</td><td></td></tr><tr><td></td><td></td><td></td><td>GF</td><td>CL</td></tr><tr><td></td><td></td><td>Oestrogens</td><td></td><td>Progesterone</td></tr><tr><td></td><td></td><td>Ethinylestradiol</td><td></td><td>Norethisterone</td></tr></table>
</page>
<page number="311">
<table id="p311t1" data-filename="pdftables_fromstorage_023782248" data-page="311" data-table="1"><tr><td></td><td></td><td>A gonadotrophin inhibitor</td><td>Danazol</td></tr><tr><td></td><td></td><td colspan="2">Hypothalamus</td></tr><tr><td>Action &amp; MOA</td><td>Inhibits gonadal function by suppressing</td><td></td><td></td></tr><tr><td></td><td>the mid-cycle surge of gonadotrophins.</td><td></td><td></td></tr><tr><td></td><td></td><td>GnRH</td><td>Danazol</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally, T0.5 &gt;15h.</td><td>GnRHR</td><td></td></tr><tr><td></td><td></td><td colspan="2">Anterior pituitary</td></tr><tr><td>Clinical use</td><td>Treatment of endometriosis.</td><td>FSH</td><td>LH</td></tr><tr><td></td><td></td><td>Clomifene</td><td></td></tr><tr><td></td><td></td><td></td><td>Ovary</td></tr><tr><td>Adverse effects</td><td>Moderate effects are common: weight</td><td>GF</td><td>CL</td></tr><tr><td></td><td>gain, acne, hot flushes, amenorrhoea,</td><td></td><td></td></tr><tr><td></td><td>masculinisation (hirsutism, deepening</td><td></td><td></td></tr><tr><td></td><td>of voice etc.).</td><td>Oestrogens</td><td>Progesterone</td></tr><tr><td></td><td></td><td>Ethinylestradiol</td><td>Norethisterone</td></tr><tr><td></td><td></td><td colspan="2">R&amp;D 7e Ch 34, pp 424-425; D&amp;H 2e Ch 32, pp 76-77</td></tr></table>
</page>
<page number="312">
<table id="p312t1" data-filename="pdftables_fromstorage_023782248" data-page="312" data-table="1"><tr><td style="text-align: right">19.04</td><td>Oxytocin</td><td>Female Reproductive System</td><td></td></tr><tr><td></td><td colspan="3">The diagram shows a cross-section of the uterus, the Fallopian tubes and the ovaries</td></tr><tr><td></td><td></td><td>Fallopian</td><td></td></tr><tr><td></td><td></td><td>tubes</td><td></td></tr><tr><td></td><td></td><td></td><td>Uterus</td></tr><tr><td></td><td></td><td>Ovary</td><td></td></tr><tr><td></td><td></td><td>Cervix</td><td>Vagina</td></tr></table>
</page>
<page number="313">
<table id="p313t1" data-filename="pdftables_fromstorage_023782248" data-page="313" data-table="1"><tr><td></td><td>Uterine stimulant</td><td>Oxytocin</td></tr><tr><td>Actions</td><td colspan="2">Contracts the uterus causing coordinated contractions that travel from fundus to cervix</td></tr><tr><td></td><td>with complete relaxation between contractions. Has vasodilator action.</td><td></td></tr><tr><td>MOA</td><td>Acts on oxytocin receptors in the smooth muscle of the myometrium.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Usually given by i.v. infusion; can be given i.m. Inactivated by liver and kidneys and by</td></tr><tr><td></td><td>circulating oxytocinase.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">To induce or augment labour when the uterine muscle is not functioning adequately.</td></tr><tr><td></td><td>To prevent or treat post-partum bleeding due to uterine atony.</td><td></td></tr><tr><td></td><td>To treat haemorrhage due to incomplete abortion.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Dose-related hypotension due to vasodilatation. Can cause water retention due to an</td></tr><tr><td></td><td>antidiuretic hormone-like effect.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Oxytocin contracts the myoepithelial cells in the post-partum mammary gland causing</td></tr><tr><td></td><td>‘milk let down’.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 34, p 427; D&amp;H 2e Ch 32, pp 76-77</td></tr></table>
</page>
<page number="314">
<table id="p314t1" data-filename="pdftables_fromstorage_023782248" data-page="314" data-table="1"><tr><td style="text-align: right">19.05</td><td>Ergometrine</td><td>Female Reproductive System</td><td></td></tr><tr><td colspan="3">The diagram shows a cross-section of the uterus, the Fallopian tubes and the ovaries</td><td></td></tr><tr><td></td><td></td><td>Fallopian</td><td></td></tr><tr><td></td><td></td><td>tubes</td><td></td></tr><tr><td></td><td>Uterine</td><td></td><td></td></tr><tr><td></td><td>stimulants</td><td></td><td></td></tr><tr><td></td><td>Oxytocin</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Uterus</td></tr><tr><td></td><td></td><td>Ovary</td><td></td></tr><tr><td></td><td></td><td>Cervix</td><td>Vagina</td></tr></table>
</page>
<page number="315">
<table id="p315t1" data-filename="pdftables_fromstorage_023782248" data-page="315" data-table="1"><tr><td></td><td>Uterine stimulant</td><td>Ergometrine</td></tr><tr><td>Actions</td><td>Contracts the relaxed uterus. Has vasoconstrictor action.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Not understood; may act partly on α-adrenoceptors, partly on 5-HT receptors.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally, i.m. or i.v. Rapid onset of action. Duration: 3–6h.</td><td></td></tr><tr><td>Clinical use</td><td>To treat post-partum haemorrhage.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances; increase in BP and in some cases angina (due to vasoconstriction);</td></tr><tr><td></td><td>headache, dizziness; dysrhythmias.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 34, pp 427-428; D&amp;H 2e Ch 32, p 77</td></tr></table>
</page>
<page number="316">
<table id="p316t1" data-filename="pdftables_fromstorage_023782248" data-page="316" data-table="1"><tr><td style="text-align: right">19.06</td><td>Carboprost</td><td>Female Reproductive System</td><td></td></tr><tr><td colspan="3">The diagram shows a cross-section of the uterus, the Fallopian tubes and the ovaries</td><td></td></tr><tr><td></td><td></td><td>Fallopian</td><td></td></tr><tr><td></td><td>Uterine</td><td>tubes</td><td></td></tr><tr><td></td><td>stimulants</td><td></td><td></td></tr><tr><td></td><td>Oxytocin</td><td></td><td></td></tr><tr><td></td><td>Ergometrine</td><td></td><td>Uterus</td></tr><tr><td></td><td></td><td>Ovary</td><td></td></tr><tr><td></td><td></td><td>Cervix</td><td>Vagina</td></tr></table>
</page>
<page number="317">
<table id="p317t1" data-filename="pdftables_fromstorage_023782248" data-page="317" data-table="1"><tr><td></td><td>A PGF2α analogue that is a uterine stimulant</td><td>Carboprost</td></tr><tr><td>Actions</td><td colspan="2">Causes coordinated contractions of the pregnant uterus; relaxes the cervix.</td></tr><tr><td>MOA</td><td>Activates PGF2α (FP) receptors on uterine smooth muscle.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given by deep intramuscular injection.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">To treat post-partum haemorrhage unresponsive to oxytocin or ergometrine.</td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances, bronchospasm, fever. Sometimes headache, dizziness, hypertension.</td></tr><tr><td>Similar drugs</td><td colspan="2">Dinoprostone (PGE2); used intravaginally to augment or induce labour. Gemeprost</td></tr><tr><td></td><td colspan="2">(a PGE 1 analogue), used in pessary form for medical induction of abortion.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 34, p 428; D&amp;H 2e Ch 32, pp 76-77</td></tr></table>
</page>
<page number="318">
<table id="p318t1" data-filename="pdftables_fromstorage_023782248" data-page="318" data-table="1"><tr><td style="text-align: right">19.07</td><td>Ritodrine</td><td>Female Reproductive System</td><td></td></tr><tr><td colspan="3">The diagram shows a cross-section of the uterus, the Fallopian tubes and the ovaries</td><td></td></tr><tr><td></td><td></td><td>Fallopian</td><td></td></tr><tr><td colspan="2">Uterine</td><td>tubes</td><td>Uterine</td></tr><tr><td colspan="2">stimulants</td><td></td><td>relaxants</td></tr><tr><td colspan="2">Oxytocin</td><td></td><td></td></tr><tr><td colspan="2">Ergometrine</td><td></td><td>Uterus</td></tr><tr><td colspan="2">Carboprost</td><td>Ovary</td><td>Carboprost</td></tr><tr><td></td><td></td><td>Cervix</td><td>Vagina</td></tr></table>
</page>
<page number="319">
<table id="p319t1" data-filename="pdftables_fromstorage_023782248" data-page="319" data-table="1"><tr><td></td><td>A β-adrenoceptor agonist (Similar drugs: salbutamol, terbutaline (see card 2.01))</td><td>Ritodrine</td></tr><tr><td>Actions</td><td colspan="2">Inhibits spontaneous and oxytocin-induced contractions of the pregnant uterus.</td></tr><tr><td>MOA</td><td colspan="2">Activates β-adrenoceptors on uterine smooth muscle causing relaxation.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given by i.v. infusion.</td><td></td></tr><tr><td>Clinical use</td><td>To delay pre-term labour.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances; headache, dysrhythmias, vasodilatation, hypersensitivity reactions.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 34, p 428; D&amp;H 2e Ch 32, p 77</td></tr></table>
</page>
<page number="320">
<table id="p320t1" data-filename="pdftables_fromstorage_023782248" data-page="320" data-table="1"><tr><td style="text-align: right">19.08</td><td>Atosiban</td><td>Female Reproductive System</td><td></td></tr><tr><td colspan="3">The diagram shows a cross-section of the uterus, the Fallopian tubes and the ovaries</td><td></td></tr><tr><td></td><td></td><td>Fallopian</td><td></td></tr><tr><td colspan="2">Uterine</td><td>tubes</td><td>Uterine</td></tr><tr><td colspan="2">stimulants</td><td></td><td>relaxants</td></tr><tr><td colspan="2">Oxytocin</td><td></td><td>Ritodrine</td></tr><tr><td colspan="2">Ergometrine</td><td></td><td>Uterus</td></tr><tr><td colspan="2">Carboprost</td><td>Ovary</td><td>Carboprost</td></tr><tr><td></td><td></td><td>Cervix</td><td>Vagina</td></tr></table>
</page>
<page number="321">
<table id="p321t1" data-filename="pdftables_fromstorage_023782248" data-page="321" data-table="1"><tr><td></td><td></td><td>An oxytocin antagonist</td><td>Atosiban</td></tr><tr><td>Uterine</td><td>Fallopian</td><td></td><td>Uterine</td></tr><tr><td></td><td>tubes</td><td></td><td></td></tr><tr><td>stimulants</td><td></td><td></td><td>relaxants</td></tr><tr><td>Oxytocin</td><td></td><td></td><td>Ritodrine</td></tr><tr><td>Ergometrine</td><td></td><td>Uterus</td><td>Atosiban</td></tr><tr><td>Carboprost</td><td>Ovary</td><td>Vagina</td><td>Carboprost</td></tr><tr><td></td><td>Cervix</td><td></td><td></td></tr><tr><td>Actions</td><td colspan="2">Inhibits oxytocin-induced contractions of the pregnant uterus.</td><td></td></tr><tr><td>MOA</td><td colspan="3">Antagonises oxytocin action on oxytocin receptors on uterine smooth muscle causing</td></tr><tr><td></td><td>relaxation.</td><td></td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given by i.v. injection.</td><td></td><td></td></tr><tr><td>Clinical use</td><td>To delay pre-term labour.</td><td></td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances, tachycardia, hypotension, dizziness, headache.</td><td></td></tr><tr><td></td><td></td><td colspan="2">R&amp;D 7e Ch 34, p 428; D&amp;H 2e Ch 32, p 77</td></tr></table>
</page>
<page number="322">
<table id="p322t1" data-filename="pdftables_fromstorage_023782248" data-page="322" data-table="1"><tr><td style="text-align: right">19.09</td><td>Testosterone</td><td>Male Reproductive System</td><td></td><td></td></tr><tr><td></td><td colspan="2">Hormonal control of the male reproductive system</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Hypothalamus</td><td></td></tr><tr><td></td><td></td><td></td><td>GnRH</td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td></td><td></td><td>Anterior pituitary</td><td></td></tr><tr><td></td><td></td><td></td><td>FSH</td><td>ICSH</td></tr><tr><td></td><td></td><td>Sertoli</td><td style="text-align: right">+</td><td style="text-align: right">+</td></tr><tr><td></td><td></td><td>cell</td><td>Testis</td><td></td></tr><tr><td></td><td></td><td>Spermatozoa</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Interstitial</td></tr><tr><td></td><td></td><td></td><td></td><td>cells</td></tr><tr><td></td><td></td><td>Gametogenesis</td><td style="text-align: right">+</td><td>Testosterone</td></tr><tr><td></td><td></td><td>in the seminifer-</td><td>5α-Reductase</td><td></td></tr><tr><td></td><td></td><td>ous tubules</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Dihydrotestosterone</td></tr><tr><td></td><td></td><td></td><td colspan="2">Peripheral effects</td></tr><tr><td></td><td></td><td></td><td colspan="2">secondary sex organs</td></tr></table>
</page>
<page number="323">
<table id="p323t1" data-filename="pdftables_fromstorage_023782248" data-page="323" data-table="1"><tr><td></td><td>Male sex hormone</td><td>Testosterone</td></tr><tr><td>Actions</td><td colspan="2">Has the same actions as endogenous testosterone; the effects will depend on the age of the patient.</td></tr><tr><td>MOA</td><td colspan="2">Converted to dihydrotestosterone which enters cells and interacts with nuclear receptors to initiate</td></tr><tr><td></td><td colspan="2">transcription of some genes (resulting in DNA-directed RNA and protein synthesis) and repression</td></tr><tr><td></td><td>of others.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Administration can be oral, buccal, by i.m. injection or transdermally.</td></tr><tr><td>Clinical use</td><td>Replacement therapy in hypogonadism.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Eventual decrease of gonadotrophin release resulting in infertility; oedema due to salt and water</td></tr><tr><td></td><td>retention.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 34, pp 422-423; D&amp;H 2e Ch 32, pp 77-78</td></tr></table>
</page>
<page number="324">
<table id="p324t1" data-filename="pdftables_fromstorage_023782248" data-page="324" data-table="1"><tr><td style="text-align: right">19.10</td><td>Finasteride</td><td>Male Reproductive System</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Hormonal control of the male reproductive system</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Hypothalamus</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">GnRH</td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right" colspan="2">+</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Anterior pituitary</td><td></td></tr><tr><td></td><td></td><td></td><td>FSH</td><td>ICSH</td><td></td></tr><tr><td></td><td></td><td>Sertoli</td><td style="text-align: right">+</td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td></td><td>cell</td><td colspan="2">Testis</td><td>–</td></tr><tr><td></td><td></td><td>Spermatozoa</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Interstitial</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>cells</td></tr><tr><td></td><td></td><td>Gametogenesis</td><td style="text-align: right">+</td><td>Testosterone</td><td></td></tr><tr><td></td><td></td><td>in the seminifer-</td><td colspan="2">5α-Reductase</td><td>Testosterone</td></tr><tr><td></td><td></td><td>ous tubules</td><td></td><td></td><td>5α-Reductase</td></tr><tr><td></td><td></td><td></td><td colspan="2">Dihydrotestosterone</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Peripheral effects</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">secondary sex organs</td><td></td></tr></table>
</page>
<page number="325">
<table id="p325t1" data-filename="pdftables_fromstorage_023782248" data-page="325" data-table="1"><tr><td></td><td colspan="3">Antiandrogen; flutamide is another antiandrogen</td><td>Finasteride</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Hypothalamus</td><td></td></tr><tr><td>Action &amp; MOA</td><td>Finasteride inhibits the 5α-reductase</td><td></td><td colspan="2">GnRH</td><td></td></tr><tr><td></td><td>that converts testosterone to dihydro-</td><td></td><td style="text-align: right" colspan="2">+</td><td></td></tr><tr><td></td><td>testosterone which has greater affinity</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>for the androgen receptor than the</td><td></td><td colspan="2">Anterior pituitary</td><td></td></tr><tr><td></td><td>parent molecule.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>(Flutamide is an androgen-receptor</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>antagonist.)</td><td></td><td>FSH</td><td>ICSH</td><td></td></tr><tr><td></td><td></td><td>Sertoli</td><td style="text-align: right">+</td><td style="text-align: right">+</td><td></td></tr><tr><td></td><td></td><td>cell</td><td colspan="2">Testis</td><td>–</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally; T0.5 ~7h</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Spermatozoa</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Interstitial</td></tr><tr><td>Clinical use</td><td>Benign prostatic hyperplasia (but note</td><td>Gametogenesis</td><td style="text-align: right">+</td><td></td><td>cells</td></tr><tr><td></td><td>that α-adrenoceptor blockers are more</td><td>in the</td><td></td><td>Testosterone</td><td></td></tr><tr><td></td><td>effective). Flutamide is used to treat</td><td>seminiferous</td><td colspan="2">5α-Reductase</td><td>Testosterone</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>5α-Reductase</td></tr><tr><td></td><td>prostate cancer.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>tubules</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>–</td><td colspan="2">Dihydrotestosterone</td><td></td></tr><tr><td></td><td></td><td>Finasteride</td><td colspan="2">Peripheral effects</td><td></td></tr><tr><td>Adverse effects</td><td>Erectile dysfunction; libido loss.</td><td></td><td colspan="2">secondary sex organs</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">R&amp;D 7e Ch 34, p 424; D&amp;H 2e Ch 32, p 77</td></tr></table>
</page>
<page number="326">
<table id="p326t1" data-filename="pdftables_fromstorage_023782248" data-page="326" data-table="1"><tr><td style="text-align: right" colspan="2">19.11</td><td>Sildenafil</td><td>Male Reproductive System</td><td></td><td></td><td></td></tr><tr><td colspan="7">The mechanisms controlling the contraction and relaxation of the smooth muscle of the corpora cavernosa</td></tr><tr><td colspan="2">1. Nitrergic nerves</td><td></td><td></td><td></td><td></td><td>NO = nitric oxide</td></tr><tr><td colspan="2">release nitric oxide</td><td></td><td></td><td>Ca2+</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>GC = guanylate cyclase</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>MLCK = myosin light</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>chain kinase</td></tr><tr><td style="text-align: right">2.</td><td>NO</td><td></td><td>SR</td><td>Ca2+</td><td></td><td></td></tr><tr><td></td><td>activates</td><td></td><td></td><td></td><td></td><td>PKG = protein kinase G</td></tr><tr><td></td><td></td><td></td><td>Ca 2+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td style="text-align: right">5.</td><td></td><td></td><td></td><td>SR = sarcoplasmic</td></tr><tr><td></td><td>GC</td><td>Phosphodiesterase V</td><td></td><td colspan="2">Ca 2+ + calmodulin</td><td>reticulum</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">activate</td><td></td></tr><tr><td>GTP</td><td></td><td>cGMP</td><td>5 ́GMP</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>activates</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">3.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td style="text-align: right">4.</td><td></td><td></td></tr><tr><td></td><td></td><td>PKG which</td><td>inhibits</td><td></td><td>MLCK</td><td></td></tr><tr><td></td><td colspan="2">and thus results in:</td><td></td><td>MyosinP</td><td>Myosin</td><td></td></tr><tr><td></td><td colspan="2">RELAXATION</td><td>CONTRACTION</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>and</td><td></td><td>+ actin</td><td></td><td></td></tr><tr><td></td><td colspan="2">DILATATION</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Smooth muscle cell</td><td></td><td></td><td></td></tr></table>
</page>
<page number="327">
<table id="p327t1" data-filename="pdftables_fromstorage_023782248" data-page="327" data-table="1"><tr><td></td><td>Enhances penile erection (Similar drugs: tadalafil, vardenafil)</td><td>Sildenafil</td></tr><tr><td>Actions</td><td colspan="2">Relaxes the non-vascular smooth muscle of the copora cavernosa. Blood at virtually arterial</td></tr><tr><td></td><td colspan="2">pressure then flows into the cavenosa sinuses resulting in swelling and erection of the penis.</td></tr><tr><td>MOA</td><td colspan="2">It inhibits phosphodiesterase type V – an enzyme that normally converts cGMP to 5’-GMP.</td></tr><tr><td></td><td colspan="2">This increases the concentration of cGMP which inhibits the contractile mechanisms</td></tr><tr><td></td><td>of the muscle allowing relaxation (see front of card).</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally, peak action occurs in 30–120min.</td><td></td></tr><tr><td>Clinical use</td><td>For erectile dysfunction.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">These are due to the action of the drug on other vascular beds and include fall in blood</td></tr><tr><td></td><td>pressure, headache and flushing.</td><td></td></tr><tr><td>Special points</td><td colspan="2">The drugs increase the action of the organic nitrates which also work by increasing cGMP.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 34, pp 429-430; D&amp;H 2e Ch 32, p 78</td></tr></table>
</page>
<page number="328">
<table id="p328t1" data-filename="pdftables_fromstorage_023782248" data-page="328" data-table="1"><tr><td style="text-align: right" colspan="2">19.12</td><td colspan="2">Male Reproductive System</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">The mechanisms controlling the contraction and relaxation of the smooth muscle of the corpora cavernosa</td></tr><tr><td colspan="2">1. Nitrergic nerves</td><td></td><td></td><td></td><td></td><td></td><td>NO = nitric oxide</td></tr><tr><td colspan="2">release nitric oxide</td><td></td><td>Sildenafil</td><td></td><td>Ca2+</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>GC = guanylate cyclase</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>MLCK = myosin light</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>chain kinase</td></tr><tr><td style="text-align: right">2.</td><td>NO</td><td></td><td>–</td><td>SR</td><td>Ca2+</td><td></td><td></td></tr><tr><td></td><td>activates</td><td></td><td></td><td style="text-align: right">2+</td><td></td><td></td><td>PKG = protein kinase G</td></tr><tr><td></td><td></td><td style="text-align: right">5.</td><td></td><td></td><td></td><td></td><td>SR = sarcoplasmic</td></tr><tr><td></td><td>GC</td><td colspan="2">Phosphodiesterase V</td><td></td><td colspan="2">Ca 2+ + calmodulin</td><td>reticulum</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">activate</td><td></td></tr><tr><td>GTP</td><td></td><td>cGMP</td><td></td><td>5 ́GMP</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>activates</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">3.</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">4.</td><td></td><td></td></tr><tr><td></td><td></td><td>PKG which</td><td>inhibits</td><td></td><td></td><td>MLCK</td><td></td></tr><tr><td></td><td colspan="2">and thus results in:</td><td></td><td></td><td>MyosinP</td><td>Myosin</td><td></td></tr><tr><td></td><td colspan="2">RELAXATION</td><td colspan="2">CONTRACTION</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>and</td><td></td><td></td><td>+ actin</td><td></td><td></td></tr><tr><td></td><td colspan="2">DILATATION</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Smooth muscle cell</td><td></td><td></td><td></td></tr></table>
</page>
<page number="329">
<table id="p329t1" data-filename="pdftables_fromstorage_023782248" data-page="329" data-table="1"><tr><td>Notes on the female and male reproductive systems</td></tr><tr><td>Notes on the female and male reproductive systems</td></tr></table>
</page>
<page number="330">
<table id="p330t1" data-filename="pdftables_fromstorage_023782248" data-page="330" data-table="1"><tr><td></td><td>Levodopa (L-dopa)</td><td></td><td></td></tr><tr><td style="text-align: right">20.01</td><td>– carbidopa</td><td>Neurodegenerative disorders: Parkinson’s</td><td></td></tr><tr><td colspan="3">Transmitter systems in the striatum providing targets for antiparkinsonian drugs</td><td></td></tr><tr><td></td><td></td><td></td><td>Cholinergic nerve</td></tr><tr><td></td><td></td><td></td><td>in striatum</td></tr><tr><td>L-dopa</td><td>DD</td><td></td><td></td></tr><tr><td>Nigrostriatal</td><td>Dopamine</td><td></td><td></td></tr><tr><td>dopaminergic</td><td>MAO</td><td></td><td></td></tr><tr><td>neuron</td><td></td><td></td><td></td></tr><tr><td></td><td>Aldehyde</td><td></td><td>ACh</td></tr><tr><td></td><td>intermediate</td><td></td><td>M</td></tr><tr><td></td><td>DOPAC</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Dopamine</td></tr><tr><td></td><td></td><td></td><td>Postsynaptic neuron</td></tr><tr><td colspan="2">COMT = catechol-O-methyl transferase</td><td></td><td>in striatum</td></tr><tr><td>DD = DOPA decarboxylase</td><td></td><td></td><td></td></tr><tr><td colspan="2">DOPAC = 3,4-dihydroxyphenyl acetic acid</td><td></td><td></td></tr><tr><td colspan="2">MAO = monoamine oxidase</td><td></td><td></td></tr></table>
</page>
<page number="331">
<table id="p331t1" data-filename="pdftables_fromstorage_023782248" data-page="331" data-table="1"><tr><td></td><td>Levodopa – precursor of dopamine</td><td>Levodopa/</td></tr><tr><td></td><td>Carbidopa – peripheral DOPA decarboxylase inhibitor (Similar drug: benserazide)</td><td>Carbidopa</td></tr><tr><td>Actions</td><td>Antiparkinsonian.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Decarboxylation of levodopa to dopamine restores some activity in nigrostriatal pathway. Carbidopa</td></tr><tr><td></td><td colspan="2">inhibits levodopa decarboxylation outside the brain, allowing the use of smaller doses and reducing</td></tr><tr><td></td><td>peripheral side effects of dopamine (e.g. postural hypotension).</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral admin. Levodopa T0.5 1–2h when co-administered with carbidopa.</td></tr><tr><td>Clinical use</td><td colspan="2">Cornerstone of therapy in Parkinson’s disease. Levodopa is usually given with a peripheral DOPA</td></tr><tr><td></td><td colspan="2">decarboxylase inhibitor. More effective against akinesia and rigidity than against tremor.</td></tr><tr><td></td><td>Effectiveness diminishes over some months to a few years.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Anorexia, nausea and vomiting. Postural hypotension. Acute schizophrenia-like syndrome. Confusion,</td></tr><tr><td></td><td colspan="2">anxiety, disorientation and insomnia or nightmares. More slowly developing effects: dyskinesia (in</td></tr><tr><td></td><td colspan="2">most patients after 2 years) and 'on-off' effects (rapid fluctuations between dyskinesia and</td></tr><tr><td></td><td>hypokinesia/rigidity).</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 39, pp 487-488; D&amp;H 2e Ch 36, p 85</td></tr></table>
</page>
<page number="332">
<table id="p332t1" data-filename="pdftables_fromstorage_023782248" data-page="332" data-table="1"><tr><td style="text-align: right">20.02</td><td colspan="2">Entacapone</td><td>Neurodegenerative disorders: Parkinson’s</td><td></td></tr><tr><td colspan="4">Transmitter systems in the striatum providing targets for antiparkinsonian drugs</td><td></td></tr><tr><td colspan="2">L-dopa</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>DD in periphery</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Cholinergic nerve</td></tr><tr><td></td><td style="text-align: right">+</td><td>-–</td><td></td><td>in striatum</td></tr><tr><td></td><td></td><td>Carbidopa</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Dopamine</td></tr><tr><td colspan="2">L-dopa</td><td>DD</td><td></td><td></td></tr><tr><td>Nigrostriatal</td><td></td><td>Dopamine</td><td></td><td></td></tr><tr><td>dopaminergic</td><td>MAO</td><td></td><td></td><td></td></tr><tr><td>neuron</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Aldehyde</td><td></td><td></td><td>ACh</td></tr><tr><td></td><td>intermediate</td><td></td><td></td><td>M</td></tr><tr><td></td><td></td><td>DOPAC</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Dopamine</td></tr><tr><td></td><td></td><td></td><td>Postsynaptic neuron</td><td></td></tr><tr><td colspan="3">COMT = catechol-O-methyl transferase</td><td></td><td>in striatum</td></tr><tr><td colspan="2">DD = DOPA decarboxylase</td><td></td><td></td><td></td></tr><tr><td colspan="3">DOPAC = 3,4-dihydroxyphenyl acetic acid</td><td></td><td></td></tr><tr><td colspan="3">MAO = monoamine oxidase</td><td></td><td></td></tr></table>
</page>
<page number="333">
<table id="p333t1" data-filename="pdftables_fromstorage_023782248" data-page="333" data-table="1"><tr><td></td><td>Catechol-O-methyl transferase inhibitor</td><td>Entacapone</td></tr><tr><td>Actions</td><td colspan="2">Synergises with the antiparkinsonian effects of levodopa/carbidopa. Potentiates actions of</td></tr><tr><td></td><td>catecholamines.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Reversible inhibition of COMT in the periphery reduces levodopa breakdown (like peripheral dopa</td></tr><tr><td></td><td colspan="2">decarboxylase inhibitors) allowing more of levodopa dose to penetrate brain.</td></tr><tr><td>Abs/Distrib/Elim</td><td>Oral admin. Short T0.5 (1h) necessitates dosing several times/day.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Adjunct to levodopa/carbidopa therapy – especially for patients showing ‘end of dose’ symptoms.</td></tr><tr><td></td><td>(No antiparkinsonian effect by itself.)</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Exacerbates adverse effects of levodopa/carbidopa taken at the same time. Dyskinesia, nausea,</td></tr><tr><td></td><td colspan="2">diarrhoea. Postural hypotension. Hallucinations. Anxiety and sleepiness.</td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 39, p 487; D&amp;H 2e Ch 36, p 85</td></tr></table>
</page>
<page number="334">
<table id="p334t1" data-filename="pdftables_fromstorage_023782248" data-page="334" data-table="1"><tr><td style="text-align: right">20.03</td><td colspan="2">Selegiline</td><td colspan="2">Neurodegenerative disorders: Parkinson’s</td><td></td><td></td><td></td></tr><tr><td colspan="6">Transmitter systems in the striatum providing targets for antiparkinsonian drugs</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">COMT in periphery</td><td>-–</td><td>Entacapone</td><td></td><td></td></tr><tr><td colspan="2">L-dopa</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">DD in periphery</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>3-methoxy-</td><td></td><td>Cholinergic nerve</td></tr><tr><td></td><td></td><td>-–</td><td></td><td></td><td></td><td>4-hydroxy-</td><td>in striatum</td></tr><tr><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td>L-phenylalanine</td><td></td><td></td></tr><tr><td></td><td></td><td>Carbidopa</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Dopamine</td><td></td></tr><tr><td colspan="2">L-dopa</td><td>DD</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Nigrostriatal</td><td></td><td>Dopamine</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>dopaminergic</td><td>MAO</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>neuron</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Aldehyde</td><td></td><td></td><td></td><td></td><td>ACh</td><td></td></tr><tr><td></td><td>intermediate</td><td></td><td></td><td></td><td></td><td>M</td><td></td></tr><tr><td></td><td></td><td>DOPAC</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Dopamine</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Postsynaptic neuron</td><td></td><td></td></tr><tr><td colspan="3">COMT = catechol-O-methyl transferase</td><td></td><td></td><td></td><td>in striatum</td><td></td></tr><tr><td colspan="2">DD = DOPA decarboxylase</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">DOPAC = 3,4-dihydroxyphenyl acetic acid</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">MAO = monoamine oxidase</td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="335">
<table id="p335t1" data-filename="pdftables_fromstorage_023782248" data-page="335" data-table="1"><tr><td></td><td>MAOB inhibitor (Similar drug; rasagiline)</td><td>Selegiline</td></tr><tr><td>Actions</td><td>Antiparkinsonian.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Selective irreversible inhibition of MAOB , the isozyme which has dopamine as a preferred substrate.</td></tr><tr><td></td><td colspan="2">Potentiates action of endogenous dopamine and dopamine formed from administered levodopa.</td></tr><tr><td>Abs/Distrib/Elim</td><td>Oral admin. (but low bioavailability), t1⁄2 2h. Rasagiline T0.5 3h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Adjunct to levodopa/carbidopa, as their effect wanes, in Parkinson’s disease. Irreversible nature of</td></tr><tr><td></td><td colspan="2">MAO inhibition prolongs effects of drug for some days. Also approved for major depression.</td></tr><tr><td>Adverse effects</td><td colspan="2">Adverse effects mainly due to increased action of levodopa taken concurrently: nausea, dyskinesia</td></tr><tr><td></td><td colspan="2">depression, insomnia, postural hypotension, hallucinations, confusion. At clinical doses, spares MAOA</td></tr><tr><td></td><td colspan="2">so less likely to provoke the ‘cheese reaction’ than non-selective MAO inhibitors. Severe interactions</td></tr><tr><td></td><td>may occur with tricyclic and SSRI antidepressants.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 39, p 488; D&amp;H 2e Ch 36, p 85</td></tr></table>
</page>
<page number="336">
<table id="p336t1" data-filename="pdftables_fromstorage_023782248" data-page="336" data-table="1"><tr><td style="text-align: right">20.04</td><td colspan="2">Bromocriptine</td><td colspan="2">Neurodegenerative disorders: Parkinson’s</td><td></td><td></td><td></td></tr><tr><td colspan="6">Transmitter systems in the striatum providing targets for antiparkinsonian drugs</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">COMT in periphery</td><td>-–</td><td>Entacapone</td><td></td><td></td></tr><tr><td colspan="2">L-dopa</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">DD in periphery</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>3-methoxy-</td><td></td><td>Cholinergic nerve</td></tr><tr><td></td><td></td><td>-–</td><td></td><td></td><td></td><td>4-hydroxy-</td><td>in striatum</td></tr><tr><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td>L-phenylalanine</td><td></td><td></td></tr><tr><td></td><td></td><td>Carbidopa</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Dopamine</td><td></td></tr><tr><td colspan="2">L-dopa</td><td>DD</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Nigrostriatal</td><td></td><td>Dopamine</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>dopaminergic</td><td>MAO</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>neuron</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Aldehyde</td><td></td><td></td><td></td><td></td><td>ACh</td><td></td></tr><tr><td>-–</td><td>intermediate</td><td></td><td></td><td>D</td><td></td><td>M</td><td></td></tr><tr><td>Selegiline</td><td></td><td>DOPAC</td><td>Dopamine</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Postsynaptic neuron</td><td></td><td></td></tr><tr><td colspan="3">COMT = catechol-O-methyl transferase</td><td></td><td></td><td></td><td>in striatum</td><td></td></tr><tr><td colspan="2">DD = DOPA decarboxylase</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">DOPAC = 3,4-dihydroxyphenyl acetic acid</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">MAO = monoamine oxidase</td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="337">
<table id="p337t1" data-filename="pdftables_fromstorage_023782248" data-page="337" data-table="1"><tr><td></td><td>Dopamine receptor agonist (Similar drugs: pramipexole, ropinirole)</td><td>Bromocriptine</td></tr><tr><td>Actions</td><td>Antiparkinsonian. Inhibits prolactin secretion from pituitary.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Activation of D2 receptors on striatal neurones counters impairment of dopaminergic transmission.</td></tr><tr><td></td><td colspan="2">Actions on D 1 receptors may be important in ameliorating the non-Parkinsonian symptoms associated</td></tr><tr><td></td><td>with disease.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Dopamine agonists have longer T0.5s than levodopa and provide a more continuous control of</td></tr><tr><td></td><td colspan="2">symptoms. T 0.5: bromocriptine 12h, pramipexole 12h, ropinirole 6h.</td></tr><tr><td>Clinical use</td><td colspan="2">Used alone or as adjuvants to levodopa therapy in Parkinson’s. Often used in early stages before use</td></tr><tr><td></td><td colspan="2">of levodopa. Bromocriptine’s effect on prolactin secretion is used for amenorrhoea and acromegaly.</td></tr><tr><td>Adverse effects</td><td colspan="2">Hallucinations and sleepiness (more than with levodopa). Postural hypotension. Dyskinesias – but</td></tr><tr><td></td><td colspan="2">less than with levodopa. Bromocriptine (and other ergot derivatives) rarely cause fibrotic reactions.</td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 39, p 488; D&amp;H 2e Ch 36, p 85</td></tr></table>
</page>
<page number="338">
<table id="p338t1" data-filename="pdftables_fromstorage_023782248" data-page="338" data-table="1"><tr><td style="text-align: right">20.05</td><td colspan="2">Amantadine</td><td colspan="2">Neurodegenerative disorders: Parkinson’s</td><td></td><td></td><td></td></tr><tr><td colspan="6">Transmitter systems in the striatum providing targets for antiparkinsonian drugs</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">COMT in periphery</td><td>-–</td><td>Entacapone</td><td></td><td></td></tr><tr><td colspan="2">L-dopa</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">DD in periphery</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>3-methoxy-</td><td></td><td>Cholinergic nerve</td></tr><tr><td></td><td></td><td>-–</td><td></td><td></td><td></td><td>4-hydroxy-</td><td>in striatum</td></tr><tr><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td>L-phenylalanine</td><td></td><td></td></tr><tr><td></td><td></td><td>Carbidopa</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Dopamine</td><td></td></tr><tr><td colspan="2">L-dopa</td><td>DD</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Nigrostriatal</td><td></td><td>Dopamine</td><td></td><td>Bromocriptine</td><td></td><td></td><td></td></tr><tr><td>dopaminergic</td><td>MAO</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>neuron</td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td>Aldehyde</td><td></td><td></td><td></td><td></td><td>ACh</td><td></td></tr><tr><td>-–</td><td>intermediate</td><td></td><td></td><td>D</td><td></td><td>M</td><td></td></tr><tr><td>Selegiline</td><td></td><td>DOPAC</td><td>Dopamine</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Postsynaptic neuron</td><td></td><td></td></tr><tr><td colspan="3">COMT = catechol-O-methyl transferase</td><td></td><td></td><td></td><td>in striatum</td><td></td></tr><tr><td colspan="2">DD = DOPA decarboxylase</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">DOPAC = 3,4-dihydroxyphenyl acetic acid</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">MAO = monoamine oxidase</td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="339">
<table id="p339t1" data-filename="pdftables_fromstorage_023782248" data-page="339" data-table="1"><tr><td></td><td>Antiviral agent with unrelated use in Parkinson’s disease</td><td>Amantadine</td></tr><tr><td>Actions</td><td>Antiparkinsonian. Antiviral.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Thought to act by increasing dopamine release from nerve endings in striatum. Antimuscarinic</td></tr><tr><td></td><td>actions, like those of benztropine, may also contribute.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Oral admin. Most excreted unchanged in urine. T0.5 17h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Parkinson’s disease. Generally less effective than levodopa, dopamine agonists or MAOB inhibitors.</td></tr><tr><td></td><td colspan="2">Also effective against the dyskinesia associated with levodopa therapy. (Antiviral action used for</td></tr><tr><td></td><td>influenza infection.)</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Nausea, dizziness, insomnia. Postural hypotension. Anxiety, confusion, hallucinations.</td></tr><tr><td></td><td colspan="2">Antimuscarinic action is important contributor to death from overdose .</td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 39, p 489; D&amp;H 2e Ch 36, p 85</td></tr></table>
</page>
<page number="340">
<table id="p340t1" data-filename="pdftables_fromstorage_023782248" data-page="340" data-table="1"><tr><td style="text-align: right">20.06</td><td colspan="2">Benztropine</td><td colspan="2">Neurodegenerative disorders: Parkinson’s</td><td></td><td></td><td></td></tr><tr><td colspan="6">Transmitter systems in the striatum providing targets for antiparkinsonian drugs</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">COMT in periphery</td><td>-–</td><td>Entacapone</td><td></td><td></td></tr><tr><td colspan="2">L-dopa</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>DD in periphery</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>3-methoxy-</td><td></td><td>Cholinergic nerve</td></tr><tr><td></td><td></td><td>-–</td><td></td><td></td><td></td><td>4-hydroxy-</td><td>in striatum</td></tr><tr><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td>L-phenylalanine</td><td></td><td></td></tr><tr><td></td><td></td><td>Carbidopa</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Dopamine</td><td></td></tr><tr><td colspan="2">L-dopa</td><td>DD</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Nigrostriatal</td><td></td><td>Dopamine</td><td></td><td>Bromocriptine</td><td></td><td></td><td></td></tr><tr><td>dopaminergic</td><td>MAO</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>neuron</td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td>Aldehyde</td><td></td><td></td><td></td><td></td><td>ACh</td><td></td></tr><tr><td>-–</td><td>intermediate</td><td></td><td></td><td>D</td><td></td><td>M</td><td></td></tr><tr><td>Selegiline</td><td></td><td>DOPAC</td><td>Dopamine</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Postsynaptic neuron</td><td></td><td></td></tr><tr><td colspan="3">COMT = catechol-O-methyl transferase</td><td></td><td></td><td></td><td>in striatum</td><td></td></tr><tr><td colspan="2">DD = DOPA decarboxylase</td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">DOPAC = 3,4-dihydroxyphenyl acetic acid</td><td></td><td>Amantadine</td><td></td><td></td><td></td></tr><tr><td colspan="3">MAO = monoamine oxidase</td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="341">
<table id="p341t1" data-filename="pdftables_fromstorage_023782248" data-page="341" data-table="1"><tr><td></td><td>Centrally acting muscarinic antagonist (Similar drugs: trihexyphenidyl, biperiden)</td><td>Benztropine</td></tr><tr><td>Actions</td><td>Antiparkinsonian.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Reduces muscarinic actions of ACh in striatum. (Restores ‘balance’ between dopaminergic and</td></tr><tr><td></td><td>cholinergic activities.) Action is probably on M1 receptors</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Orally active. Long T0.5 – 36h. Trihexyphenidyl T0.5 3–4h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Second-line drug for Parkinson’s disease. Much less effective than those drugs increasing</td></tr><tr><td></td><td colspan="2">dopaminergic transmission but has value in treating tremor. Used as adjunct with other agents and</td></tr><tr><td></td><td>in drug (antipsychotic)-induced Parkinsonism.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Effects due to parasympathetic block – dry mouth, inhibition of peristalsis, raised intraocular</td></tr><tr><td></td><td colspan="2">pressure (avoid in narrow-angle glaucoma), blurred vision, urinary retention, tachycardia, etc.</td></tr><tr><td></td><td>Confusion, hallucinations.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 39, p 489; D&amp;H 2e Ch 36, p 85</td></tr></table>
</page>
<page number="342">
<table id="p342t1" data-filename="pdftables_fromstorage_023782248" data-page="342" data-table="1"><tr><td style="text-align: right">20.07</td><td colspan="2">Summary</td><td colspan="2">Neurodegenerative disorders: Parkinson’s</td><td></td><td></td><td></td></tr><tr><td colspan="6">Transmitter systems in the striatum providing targets for antiparkinsonian drugs</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">COMT in periphery</td><td>-–</td><td>Entacapone</td><td></td><td></td></tr><tr><td colspan="2">L-dopa</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>DD in periphery</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>3-methoxy-</td><td></td><td>Cholinergic nerve</td></tr><tr><td></td><td></td><td>-–</td><td></td><td></td><td></td><td>4-hydroxy-</td><td>in striatum</td></tr><tr><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td>L-phenylalanine</td><td></td><td></td></tr><tr><td></td><td></td><td>Carbidopa</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Dopamine</td><td></td></tr><tr><td colspan="2">L-dopa</td><td>DD</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Nigrostriatal</td><td></td><td>Dopamine</td><td></td><td>Bromocriptine</td><td></td><td></td><td></td></tr><tr><td>dopaminergic</td><td>MAO</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>neuron</td><td></td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td>Aldehyde</td><td></td><td></td><td></td><td></td><td>ACh</td><td></td></tr><tr><td></td><td>intermediate</td><td></td><td></td><td></td><td></td><td>M</td><td></td></tr><tr><td>–</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">-</td><td></td><td></td><td></td><td>D</td><td></td><td>–</td><td>Benztropine</td></tr><tr><td>Selegiline</td><td></td><td>DOPAC</td><td>Dopamine</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Postsynaptic neuron</td><td></td><td></td></tr><tr><td colspan="3">COMT = catechol-O-methyl transferase</td><td></td><td></td><td></td><td>in striatum</td><td></td></tr><tr><td colspan="2">DD = DOPA decarboxylase</td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">DOPAC = 3,4-dihydroxyphenyl acetic acid</td><td></td><td>Amantadine</td><td></td><td></td><td></td></tr><tr><td colspan="3">MAO = monoamine oxidase</td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="343">
<table id="p343t1" data-filename="pdftables_fromstorage_023782248" data-page="343" data-table="1"><tr><td>Notes</td></tr><tr><td>Notes</td></tr></table>
</page>
<page number="344">
<table id="p344t1" data-filename="pdftables_fromstorage_023782248" data-page="344" data-table="1"><tr><td style="text-align: right">20.08</td><td>Donepezil</td><td>Neurodegenerative Disorders: Alzheimer’s</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6">Cholinergic and glutamatergic transmission are targets for drug action in Alzheimer’s disease.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Neuronal glutamate</td></tr><tr><td colspan="2">Cholinergic neurons in</td><td>Alzheimer’s disease</td><td></td><td></td><td></td><td>release</td></tr><tr><td colspan="2">forebrain nuclei</td><td>Loss of neurons</td><td>Excess</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>ive</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>glut</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td>am</td><td colspan="2">Action on NMDA</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">ate</td><td></td></tr><tr><td colspan="2">Acetylcholine</td><td></td><td></td><td></td><td>act</td><td>receptor</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>io</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">n</td></tr><tr><td></td><td></td><td>AC</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>hE</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Ca 2+ entry and</td></tr><tr><td></td><td></td><td>Choline + acetic acid</td><td></td><td></td><td colspan="2">excitotoxicity</td></tr><tr><td colspan="2">Action on nicotinic /</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">muscarinic receptors</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Neuronal death</td></tr><tr><td colspan="7">Alzheimer’s disease is associated with a loss of neurons and shrinkage of brain tissue, particularly in the hippocampus</td></tr><tr><td colspan="7">and basal forebrain. The loss of cholinergic neurons in particular is believed to be associated with the impairment of</td></tr><tr><td colspan="7">learning and memory. Excitotoxicity, mediated by NMDA receptors, may also be important in neuronal death.</td></tr><tr><td colspan="2">AChE = acetylcholinesterase</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">NMDA = N-methyl D-aspartate</td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="345">
<table id="p345t1" data-filename="pdftables_fromstorage_023782248" data-page="345" data-table="1"><tr><td></td><td>Centrally acting anticholinesterase (Similar drugs: rivastigmine, galantamine)</td><td>Donepezil</td></tr><tr><td>Actions</td><td>Ameliorates symptoms of Alzheimer’s disease.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Reversible inhibition of acetylcholinesterase. Enhances cholinergic transmission in the cerebral cortex</td></tr><tr><td></td><td>and hippocampus.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Orally active. Donepezil has long T0.5 of 70h. Galantamine T0.5 7h. Rivastigmine has a short half-life</td></tr><tr><td></td><td>1.5h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Mild to moderate Alzheimer’s disease, providing limited relief from the symptoms but having no</td></tr><tr><td></td><td>effect on the progression of the disease.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Predictable parasympathomimetic side effects: nausea, diarrhoea, vomiting, bradycardia, increased</td></tr><tr><td></td><td colspan="2">gastric acid secretion. Anorexia with weight loss and insomnia also occur.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 39, pp 283-284; D&amp;H 2e Ch 36, pp 84-85</td></tr></table>
</page>
<page number="346">
<table id="p346t1" data-filename="pdftables_fromstorage_023782248" data-page="346" data-table="1"><tr><td style="text-align: right">20.09</td><td>Memantine</td><td>Neurodegenerative disorders: Alzheimer’s</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6">Cholinergic and glutamatergic transmission are targets for drug action in Alzheimer’s disease.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Neuronal glutamate</td></tr><tr><td>Cholinergic neurons in</td><td></td><td>Alzheimer’s disease</td><td></td><td></td><td></td><td>release</td></tr><tr><td>forebrain nuclei</td><td></td><td>Loss of neurons</td><td>Excess</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Donepezil</td><td>ive</td><td>gl</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>ut</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">+</td><td>am</td><td colspan="2">Action on NMDA</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">ate</td><td></td></tr><tr><td>Acetylcholine</td><td></td><td>-–</td><td></td><td></td><td>act</td><td>receptor</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>io</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">n</td></tr><tr><td></td><td>AC</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>hE</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Ca 2+ entry and</td></tr><tr><td></td><td></td><td>Choline + acetic acid</td><td></td><td></td><td colspan="2">excitotoxicity</td></tr><tr><td>Action on nicotinic /</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>muscarinic receptors</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Neuronal death</td></tr><tr><td colspan="7">Alzheimer’s disease is associated with a loss of neurons and shrinkage of brain tissue, particularly in the hippocampus</td></tr><tr><td colspan="7">and basal forebrain. The loss of cholinergic neurons in particular is believed to be associated with the impairment of</td></tr><tr><td colspan="7">learning and memory. Excitotoxicity, mediated by NMDA receptors, may also be important in neuronal death.</td></tr><tr><td colspan="2">AChE = acetylcholinesterase</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">NMDA = N-methyl D-aspartate</td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="347">
<table id="p347t1" data-filename="pdftables_fromstorage_023782248" data-page="347" data-table="1"><tr><td></td><td>NMDA receptor antagonist</td><td>Memantine</td></tr><tr><td>Actions</td><td>Ameliorates symptoms of Alzheimer’s disease.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Open channel block of NMDA receptors. Prevents Na+ and, more importantly, Ca2+ entry into the</td></tr><tr><td></td><td colspan="2">neurone, so reducing glutamate excitotoxicity. Normal glutamatergic transmission continues.</td></tr><tr><td>Abs/Distrib/Elim</td><td>Oral admin. T0.5 60–80h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Moderate to severe Alzheimer’s disease. Provides only symptomatic relief of the cognitive and</td></tr><tr><td></td><td colspan="2">memory impairment of the disease. No effect on the degenerative process. Can be used in</td></tr><tr><td></td><td>combination with centrally acting anticholinesterases.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Usually well tolerated. Confusion, dizziness, drowsiness, headache, insomnia, agitation,</td></tr><tr><td></td><td>hallucinations.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 39, pp 483-485; D&amp;H 2e Ch 36, p 85</td></tr></table>
</page>
<page number="348">
<table id="p348t1" data-filename="pdftables_fromstorage_023782248" data-page="348" data-table="1"><tr><td style="text-align: right">20.10</td><td>Summary</td><td>Neurodegenerative disorders: Alzheimer’s</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7">Cholinergic and glutamatergic transmission are targets for drug action in Alzheimer’s disease.</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Neuronal glutamate</td></tr><tr><td colspan="2">Cholinergic neurons in</td><td></td><td>Alzheimer’s disease</td><td></td><td></td><td></td><td>release</td></tr><tr><td colspan="2">forebrain nuclei</td><td></td><td>Loss of neurons</td><td>Excess</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>ive</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Donepezil</td><td></td><td>gl</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>ut</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td style="text-align: right">+</td><td>am</td><td colspan="2">Action on NMDA</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">ate</td><td></td></tr><tr><td colspan="2">Acetylcholine</td><td></td><td>-–</td><td></td><td></td><td>act</td><td>receptor</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>io</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">n</td></tr><tr><td></td><td></td><td></td><td>AC</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>hE</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>-–</td><td></td><td></td><td colspan="2">Ca 2+ entry and</td></tr><tr><td></td><td></td><td></td><td>Choline + acetic acid</td><td></td><td></td><td colspan="2">excitotoxicity</td></tr><tr><td colspan="2">Action on nicotinic /</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Memantine</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">muscarinic receptors</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Neuronal death</td></tr><tr><td colspan="8">Alzheimer’s disease is associated with a loss of neurons and shrinkage of brain tissue, particularly in the hippocampus</td></tr><tr><td colspan="8">and basal forebrain. The loss of cholinergic neurons in particular is believed to be associated with the impairment of</td></tr><tr><td colspan="8">learning and memory. Excitotoxicity, mediated by NMDA receptors, may also be important in neuronal death.</td></tr><tr><td colspan="2">AChE = acetylcholinesterase</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">NMDA = N-methyl D-aspartate</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="349">
<table id="p349t1" data-filename="pdftables_fromstorage_023782248" data-page="349" data-table="1"><tr><td>NOTES</td></tr><tr><td>Notes</td></tr></table>
</page>
<page number="350">
<table id="p350t1" data-filename="pdftables_fromstorage_023782248" data-page="350" data-table="1"><tr><td style="text-align: right">21.01</td><td>Halothane</td><td>General anaesthetics</td><td></td></tr><tr><td colspan="4">Established/possible targets for anaesthetic agents are indicated in the diagram.</td></tr><tr><td colspan="2">Target in brain</td><td>Effect on target</td><td></td></tr><tr><td></td><td>GABAA receptors</td><td>Increased response to GABA</td><td></td></tr><tr><td></td><td></td><td></td><td>Reduced neuronal excitabilty /</td></tr><tr><td></td><td>Two-pore domain (TREK)</td><td>Increased channel opening</td><td>depression of CNS activity /</td></tr><tr><td></td><td>potassium channel</td><td></td><td>unconsciousness / anaesthesia</td></tr><tr><td></td><td>NMDA receptors</td><td>Reduced response to glutamate</td><td></td></tr><tr><td colspan="2">Glycine and nicotinic</td><td></td><td></td></tr><tr><td colspan="2">receptors are also potential</td><td></td><td></td></tr><tr><td colspan="2">sites of anaesthetic action.</td><td></td><td></td></tr><tr><td colspan="4">Inhalation anaesthetic agents in general act at high (mM) concentrations and have less well-defined targets than the</td></tr><tr><td colspan="2">more potent intravenous agents.</td><td></td><td></td></tr></table>
</page>
<page number="351">
<table id="p351t1" data-filename="pdftables_fromstorage_023782248" data-page="351" data-table="1"><tr><td></td><td>Volatile inhalational general anaesthetic (Similar drugs: desflurane, sevoflurane)</td><td>Halothane</td></tr><tr><td>Actions</td><td>CNS depressant. Causes unconsciousness. Only weakly analgesic.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Potentiates GABA action on GABAA receptors and opens K+ channels (TREK type) to reduce neuronal</td></tr><tr><td></td><td colspan="2">activity, especially in cerebral cortex, thalamus and hippocampus. Lipid solubility important for</td></tr><tr><td></td><td>action.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Given by inhalation with oxygen. Rate of equilibration with body and onset of anaesthesia depends</td></tr><tr><td></td><td colspan="2">on the ‘blood/gas solubility’. Halothane has a medium onset of action – desflurane and sevoflurane</td></tr><tr><td></td><td colspan="2">(with lower blood/gas solubilities) a fast onset. Mostly eliminated unchanged by the lungs.</td></tr><tr><td>Clinical use</td><td>Maintenance, and less frequently induction, of general anaesthesia.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Cardiac and respiratory depression. Cardiac dysrhythmias. Post-operative nausea and vomiting.</td></tr><tr><td></td><td colspan="2">Rarely malignant hyperthermia and liver damage (due to metabolites). Sevoflurane may produce</td></tr><tr><td></td><td>kidney damage.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 40, pp 498-500; D&amp;H 2e Ch 37, p 86</td></tr></table>
</page>
<page number="352">
<table id="p352t1" data-filename="pdftables_fromstorage_023782248" data-page="352" data-table="1"><tr><td style="text-align: right">21.02</td><td>Nitrous oxide</td><td>General anaesthetics</td><td></td></tr><tr><td colspan="4">Established/possible targets for anaesthetic agents are indicated in the diagram.</td></tr><tr><td colspan="2">Target in brain</td><td>Effect on target</td><td></td></tr><tr><td></td><td></td><td></td><td>Halothane</td></tr><tr><td></td><td>GABAA receptors</td><td>Increased response to GABA</td><td></td></tr><tr><td></td><td></td><td></td><td>Reduced neuronal excitabilty /</td></tr><tr><td></td><td>Two-pore domain (TREK)</td><td>Increased channel opening</td><td>depression of CNS activity /</td></tr><tr><td></td><td>potassium channel</td><td></td><td>unconsciousness / anaesthesia</td></tr><tr><td></td><td>NMDA receptors</td><td>Reduced response to glutamate</td><td></td></tr><tr><td colspan="2">Glycine and nicotinic</td><td></td><td></td></tr><tr><td colspan="2">receptors are also potential</td><td></td><td></td></tr><tr><td colspan="2">sites of anaesthetic action.</td><td></td><td></td></tr><tr><td colspan="4">Inhalation anaesthetic agents in general act at high (mM) concentrations and have less well-defined targets than the</td></tr><tr><td colspan="2">more potent intravenous agents.</td><td></td><td></td></tr></table>
</page>
<page number="353">
<table id="p353t1" data-filename="pdftables_fromstorage_023782248" data-page="353" data-table="1"><tr><td></td><td>Gaseous general anaesthetic</td><td>Nitrous oxide</td></tr><tr><td>Actions</td><td colspan="2">CNS depression, unconsciousness (in combination with other anaesthetics). Analgesia. Euphoria.</td></tr><tr><td>MOA</td><td colspan="2">Reduces opening of NMDA receptor channels. Increases opening of TREK-1 potassium channels. (No</td></tr><tr><td></td><td colspan="2">action on GABAA receptors.) Analgesic action inhibited by opioid antagonists, suggesting release of</td></tr><tr><td></td><td>endogenous opioids.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Administered by inhalation. Low blood/gas partition coefficient results in rapid onset and offset of</td></tr><tr><td></td><td>action. Eliminated unchanged via lungs. No metabolism.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">General anaesthesia. Because of low potency will not produce full surgical anaesthesia by itself;</td></tr><tr><td></td><td colspan="2">must be combined with more potent agents. In subanaesthetic doses used as analgesic for childbirth</td></tr><tr><td></td><td>and emergency pain relief (e.g. by paramedics).</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Few side effects. Oxygen may be required during recovery due to possibility of ‘diffusion anoxia’.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 40, pp 500-501; D&amp;H 2e Ch 37, pp 86-87</td></tr></table>
</page>
<page number="354">
<table id="p354t1" data-filename="pdftables_fromstorage_023782248" data-page="354" data-table="1"><tr><td style="text-align: right">21.03</td><td>Thiopental</td><td>General anaesthetics</td><td></td></tr><tr><td colspan="4">Established/possible targets for anaesthetic agents are indicated in the diagram.</td></tr><tr><td colspan="2">Target in brain</td><td>Effect on target</td><td></td></tr><tr><td></td><td></td><td></td><td>Halothane</td></tr><tr><td></td><td>GABAA receptors</td><td>Increased response to GABA</td><td></td></tr><tr><td></td><td></td><td></td><td>Reduced neuronal excitabilty /</td></tr><tr><td></td><td>Two-pore domain (TREK)</td><td>Increased channel opening</td><td>depression of CNS activity /</td></tr><tr><td></td><td>potassium channel</td><td></td><td>unconsciousness / anaesthesia</td></tr><tr><td></td><td>NMDA receptors</td><td>Reduced response to glutamate</td><td></td></tr><tr><td colspan="2">Glycine and nicotinic</td><td></td><td></td></tr><tr><td colspan="2">receptors are also potential</td><td></td><td></td></tr><tr><td colspan="2">sites of anaesthetic action.</td><td></td><td>Nitrous oxide</td></tr><tr><td colspan="4">Inhalation anaesthetic agents in general act at high (mM) concentrations and have less well-defined targets than the</td></tr><tr><td colspan="2">more potent intravenous agents.</td><td></td><td></td></tr></table>
</page>
<page number="355">
<table id="p355t1" data-filename="pdftables_fromstorage_023782248" data-page="355" data-table="1"><tr><td></td><td>Intravenous general anaesthetic (Similar drugs: etomidate, propofol)</td><td>Thiopental</td></tr><tr><td>Actions</td><td>Ultrashort-acting anaesthetics. All have only weak analgesic action.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Binds to particular site (different to benzodiazepine binding site) on GABAA receptor to enhance</td></tr><tr><td></td><td colspan="2">opening of intrinsic Cl- channel by GABA. Higher concentrations directly activate receptor.</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">I.v. injection. Very lipid soluble allowing rapid CNS penetration. Rapid onset (20s) and short acting</td></tr><tr><td></td><td colspan="2">(5–10min). Short duration due to rapid redistribution in body, particularly to muscle. Thiopental is</td></tr><tr><td></td><td colspan="2">slowly metabolised (T0.5 8–10h) and may produce a ‘hangover’. Propofol is rapidly metabolised and</td></tr><tr><td></td><td colspan="2">lack of hangover makes it suitable for day case surgery. Etomidate T0.5 2h.</td></tr><tr><td>Clinical use</td><td colspan="2">Anaesthesia for short procedures and to induce anaesthesia for subsequent maintenance with</td></tr><tr><td></td><td>volatile agents.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Cardiorespiratory depression: less with etomidate. Post-operative vomiting and adrenocortical</td></tr><tr><td></td><td>suppression with etomidate.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 40, pp 495-496; D&amp;H 2e Ch 37, pp 86-87</td></tr></table>
</page>
<page number="356">
<table id="p356t1" data-filename="pdftables_fromstorage_023782248" data-page="356" data-table="1"><tr><td style="text-align: right">21.04</td><td>Ketamine</td><td>General anaesthetics</td><td></td></tr><tr><td colspan="4">Established/possible targets for anaesthetic agents are indicated in the diagram.</td></tr><tr><td colspan="2">Target in brain</td><td>Effect on target</td><td></td></tr><tr><td></td><td></td><td>Thiopentone</td><td>Halothane</td></tr><tr><td></td><td>GABAA receptors</td><td>Increased response to GABA</td><td></td></tr><tr><td></td><td></td><td></td><td>Reduced neuronal excitabilty /</td></tr><tr><td></td><td>Two-pore domain (TREK)</td><td>Increased channel opening</td><td>depression of CNS activity /</td></tr><tr><td></td><td>potassium channel</td><td></td><td>unconsciousness / anaesthesia</td></tr><tr><td></td><td>NMDA receptors</td><td>Reduced response to glutamate</td><td></td></tr><tr><td colspan="2">Glycine and nicotinic</td><td></td><td></td></tr><tr><td colspan="2">receptors are also potential</td><td></td><td></td></tr><tr><td colspan="2">sites of anaesthetic action.</td><td></td><td>Nitrous oxide</td></tr><tr><td colspan="4">Inhalation anaesthetic agents in general act at high (mM) concentrations and have less well-defined targets than the</td></tr><tr><td colspan="2">more potent intravenous agents.</td><td></td><td></td></tr></table>
</page>
<page number="357">
<table id="p357t1" data-filename="pdftables_fromstorage_023782248" data-page="357" data-table="1"><tr><td></td><td>Intravenous dissociative anaesthetic</td><td>Ketamine</td></tr><tr><td>Actions</td><td colspan="2">Dissociative anaesthesia, in which the patient may remain conscious but have good pain relief and</td></tr><tr><td></td><td>short-term amnesia. Analgesia at subanaesthetic doses.</td><td></td></tr><tr><td>MOA</td><td>Blocks NMDA type glutamate receptor ion channel.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">I.v. or i.m. admin. Rapid onset and short duration of action following i.v. dosing. Metabolised in liver;</td></tr><tr><td></td><td>T0.5 2.5h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Induction and maintenance of anaesthesia for brief surgical/diagnostic procedures. Mainly used for</td></tr><tr><td></td><td colspan="2">minor procedures in children, who exhibit fewer untoward psychotic side effects.</td></tr><tr><td>Adverse effects</td><td colspan="2">Increased heart rate and blood pressure (by activation of sympathetic system). Involuntary muscle</td></tr><tr><td></td><td colspan="2">movement. Hallucinations, delerium and dysphoria during recovery. Respiratory depression in</td></tr><tr><td></td><td>overdose.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 40, pp 496-497; D&amp;H 2e Ch 37, pp 86-87</td></tr></table>
</page>
<page number="358">
<table id="p358t1" data-filename="pdftables_fromstorage_023782248" data-page="358" data-table="1"><tr><td style="text-align: right">21.05</td><td>Summary</td><td>General anaesthetics</td><td></td></tr><tr><td colspan="4">Established/possible targets for anaesthetic agents are indicated in the diagram.</td></tr><tr><td colspan="2">Target in brain</td><td>Effect on target</td><td></td></tr><tr><td></td><td></td><td>Thiopentone</td><td>Halothane</td></tr><tr><td></td><td>GABAA receptors</td><td>Increased response to GABA</td><td></td></tr><tr><td></td><td></td><td></td><td>Reduced neuronal excitabilty /</td></tr><tr><td></td><td>Two-pore domain (TREK)</td><td>Increased channel opening</td><td>depression of CNS activity /</td></tr><tr><td></td><td>potassium channel</td><td></td><td>unconsciousness / anaesthesia</td></tr><tr><td></td><td>NMDA receptors</td><td>Reduced response to glutamate</td><td></td></tr><tr><td colspan="2">Glycine and nicotinic</td><td></td><td></td></tr><tr><td colspan="2">receptors are also potential</td><td></td><td></td></tr><tr><td colspan="2">sites of anaesthetic action.</td><td>Ketamine</td><td>Nitrous oxide</td></tr><tr><td colspan="4">Inhalation anaesthetic agents in general act at high (mM) concentrations and have less well-defined targets than the</td></tr><tr><td colspan="2">more potent intravenous agents.</td><td></td><td></td></tr></table>
</page>
<page number="359">
<table id="p359t1" data-filename="pdftables_fromstorage_023782248" data-page="359" data-table="1"><tr><td>Notes</td></tr><tr><td>Notes</td></tr></table>
</page>
<page number="360">
<table id="p360t1" data-filename="pdftables_fromstorage_023782248" data-page="360" data-table="1"><tr><td style="text-align: right">22.01</td><td colspan="2">Diazepam</td><td>Anxiolytics and hypnotics</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">The important anxiolytic and hypnotic drugs act on GABA A or 5HT1A receptors.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Cl-</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5-HT binding</td><td></td><td></td><td></td></tr><tr><td colspan="2">GABA</td><td>GABA</td><td></td><td></td><td>between</td><td></td><td></td></tr><tr><td colspan="2">binding</td><td></td><td></td><td>transmembrane</td><td></td><td></td><td></td></tr><tr><td></td><td>site</td><td></td><td></td><td></td><td>segments</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>benzodiazepine</td><td></td><td>N</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>binding site</td><td style="text-align: right">3</td><td style="text-align: right">2</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">4</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">1</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">5</td><td style="text-align: right">6</td><td style="text-align: right">7</td></tr><tr><td colspan="2">barbiturate</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">binding site</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Cell membrane</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>C</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">G-protein</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>5-HT1A receptor</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">(A 7-transmembrane</td></tr><tr><td></td><td></td><td>GABAA receptor</td><td></td><td></td><td></td><td colspan="2">segment receptor)</td></tr></table>
</page>
<page number="361">
<table id="p361t1" data-filename="pdftables_fromstorage_023782248" data-page="361" data-table="1"><tr><td colspan="2">Benzodiazepine agonist (Similar drugs: oxazepam, nitrazepam, temazepam, and many more)</td><td>Diazepam</td></tr><tr><td>Actions</td><td colspan="2">Anxiolytic, hypnotic, amnestic, anticonvulsant and reduction in muscle tone.</td></tr><tr><td>MOA</td><td colspan="2">Binds to benzodiazepine binding site on GABAA receptor to enhance channel opening by GABA.</td></tr><tr><td></td><td>The increased Cl– conductance reduces neuronal excitability.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally. Diazepam is long acting due to active metabolite with long T0.5 . Nitrazepam and</td></tr><tr><td></td><td>temazepam have a medium duration. Oxazepam is short acting.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Anxiety and insomnia. Temazepam &amp; nitrazepam are used as hypnotics. Diazepam is also used for</td></tr><tr><td></td><td>premedication and status epilepticus (see card 25.04).</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Drowsiness and confusion. Tolerance and dependence (with withdrawal symptoms) can occur as</td></tr><tr><td></td><td colspan="2">can severe respiratory depression in combination with other CNS depressants (e.g. alcohol).</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 43, p 535; D&amp;H 2e Ch 38, p 88</td></tr></table>
</page>
<page number="362">
<table id="p362t1" data-filename="pdftables_fromstorage_023782248" data-page="362" data-table="1"><tr><td style="text-align: right">22.02</td><td>Zolpidem</td><td>Anxiolytics and hypnotics</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">The important anxiolytic and hypnotic drugs act on GABA A or 5HT1A receptors.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Cl-</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>5-HT binding</td><td></td><td></td><td></td></tr><tr><td colspan="2">GABA</td><td>Diazepam</td><td></td><td>between</td><td></td><td></td></tr><tr><td colspan="2">binding</td><td></td><td>transmembrane</td><td></td><td></td><td></td></tr><tr><td></td><td>site</td><td></td><td></td><td>segments</td><td></td><td></td></tr><tr><td></td><td></td><td>benzodiazepine</td><td></td><td></td><td></td><td>N</td></tr><tr><td></td><td></td><td>binding site</td><td></td><td></td><td style="text-align: right">3</td><td style="text-align: right">2</td></tr><tr><td></td><td></td><td></td><td></td><td style="text-align: right">4</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">1</td></tr><tr><td></td><td></td><td></td><td></td><td style="text-align: right">5</td><td style="text-align: right">6</td><td style="text-align: right">7</td></tr><tr><td colspan="2">barbiturate</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">binding site</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Cell membrane</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>C</td></tr><tr><td></td><td></td><td></td><td colspan="2">G-protein</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>5-HT1A receptor</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">(A 7-transmembrane</td></tr><tr><td></td><td></td><td>GABAA receptor</td><td></td><td></td><td colspan="2">segment receptor)</td></tr></table>
</page>
<page number="363">
<table id="p363t1" data-filename="pdftables_fromstorage_023782248" data-page="363" data-table="1"><tr><td></td><td>Non-benzodiazepine agonist at benzodiazepine receptor (Similar drugs: zopiclone, zaleplon)</td><td>Zolpidem</td></tr><tr><td>Actions</td><td colspan="2">Hypnotic (less anxiolytic, amnestic and muscle relaxant activity than benzodiazepines).</td></tr><tr><td>MOA</td><td colspan="2">Binds to benzodiazepine binding site on GABAA receptor (the more limited actions are due to</td></tr><tr><td></td><td colspan="2">selective action on BZ1 receptors) to enhance the channel opening activity of GABA. Reduces</td></tr><tr><td></td><td>electrical excitability of neuronal cell membrane.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Oral admin. Zolpidem and zopiclone are short acting (t1⁄2 2–3 and 6h respectively): zaleplon very</td></tr><tr><td></td><td>short acting.</td><td></td></tr><tr><td>Clinical use</td><td>Insomnia.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Well tolerated. Some drowsiness, confusion and dizziness. Tolerance and dependence (with</td></tr><tr><td></td><td colspan="2">withdrawal symptoms) may develop. Allergic reactions. Enhances CNS depression caused by other</td></tr><tr><td></td><td>drugs (e.g. ethanol).</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 43, pp 532-533; D&amp;H 2e Ch 38, p 88</td></tr></table>
</page>
<page number="364">
<table id="p364t1" data-filename="pdftables_fromstorage_023782248" data-page="364" data-table="1"><tr><td style="text-align: right">22.03</td><td>Flumazenil</td><td>Anxiolytics and hypnotics</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">The important anxiolytic and hypnotic drugs act on GABA A or 5HT1A receptors.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Zolpidem</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Cl-</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5-HT binding</td><td></td><td></td><td></td></tr><tr><td colspan="2">GABA</td><td></td><td>Diazepam</td><td></td><td>between</td><td></td><td></td></tr><tr><td colspan="2">binding</td><td></td><td></td><td>transmembrane</td><td></td><td></td><td></td></tr><tr><td></td><td>site</td><td></td><td></td><td></td><td>segments</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">benzodiazepine</td><td></td><td></td><td></td><td>N</td></tr><tr><td></td><td></td><td colspan="2">binding site</td><td></td><td></td><td style="text-align: right">3</td><td style="text-align: right">2</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">4</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">1</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">5</td><td style="text-align: right">6</td><td style="text-align: right">7</td></tr><tr><td colspan="2">barbiturate</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">binding site</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Cell membrane</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>C</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">G-protein</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>5-HT1A receptor</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">(A 7-transmembrane</td></tr><tr><td></td><td></td><td></td><td>GABAA receptor</td><td></td><td></td><td colspan="2">segment receptor)</td></tr></table>
</page>
<page number="365">
<table id="p365t1" data-filename="pdftables_fromstorage_023782248" data-page="365" data-table="1"><tr><td></td><td>Antagonist at benzodiazepine binding site</td><td>Flumazenil</td></tr><tr><td>Actions</td><td>Antagonises actions of benzodiazepines and zolpidem-like drugs.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Competitive binding to the benzodiazepine binding site on GABA A receptor.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given intravenously. Short T0.5 1–2h, so will need repeat doses to antagonise the longer-acting</td></tr><tr><td></td><td>benzodiazepines.</td><td></td></tr><tr><td>Clinical use</td><td>Treatment of overdose of benzodiazepines or zolpidem.</td><td></td></tr><tr><td>Adverse effects</td><td>Anxiety, palpitations, insomnia. Convulsions.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 43, pp 535-537; D&amp;H 2e Ch 38, p 88</td></tr></table>
</page>
<page number="366">
<table id="p366t1" data-filename="pdftables_fromstorage_023782248" data-page="366" data-table="1"><tr><td style="text-align: right">22.04</td><td>Amobarbital</td><td colspan="2">Anxiolytics and hypnotics</td><td></td><td></td><td></td></tr><tr><td colspan="4">The important anxiolytic and hypnotic drugs act on GABA A or 5HT1A receptors.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Zolpidem</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Cl-</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5-HT binding</td><td></td><td></td></tr><tr><td colspan="2">GABA</td><td></td><td>Diazepam</td><td></td><td>between</td><td></td></tr><tr><td colspan="2">binding</td><td></td><td></td><td>transmembrane</td><td></td><td></td></tr><tr><td></td><td>site</td><td></td><td></td><td></td><td>segments</td><td></td></tr><tr><td></td><td></td><td></td><td>benzodiazepine</td><td></td><td></td><td>N</td></tr><tr><td></td><td></td><td></td><td>binding site</td><td></td><td style="text-align: right">3</td><td style="text-align: right">2</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">4</td><td></td></tr><tr><td></td><td></td><td></td><td>Flumazenil</td><td></td><td style="text-align: right">5</td><td style="text-align: right">1</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">6</td><td style="text-align: right">7</td></tr><tr><td colspan="2">barbiturate</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">binding site</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Cell membrane</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>C</td></tr><tr><td></td><td></td><td></td><td></td><td>G-protein</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>5-HT1A receptor</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">(A 7-transmembrane</td></tr><tr><td></td><td></td><td>GABAA receptor</td><td></td><td></td><td colspan="2">segment receptor)</td></tr></table>
</page>
<page number="367">
<table id="p367t1" data-filename="pdftables_fromstorage_023782248" data-page="367" data-table="1"><tr><td></td><td>Barbiturate (Similar drug: secobarbital)</td><td>Amobarbital</td></tr><tr><td>Actions</td><td>CNS depressant. Hypnotic, anxiolytic.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Binds to barbiturate binding site on GABAA receptor to increase action of GABA. At higher</td></tr><tr><td></td><td>concentration can increase channel opening in absence of GABA.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Orally active. Metabolised by hepatic P450 system. T0.5 24–36h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Severe insomnia unresponsive to other, safer drugs. Much less used nowadays. (Barbiturates also</td></tr><tr><td></td><td>find use as general anaesthetics and antiepileptic agents.)</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Cardiorespiratory depression. Daytime sedation, impaired motor function. Dependence with severe</td></tr><tr><td></td><td colspan="2">withdrawal symptoms. Potent inducer of hepatic P450 system, leading to many drug interactions.</td></tr><tr><td></td><td colspan="2">D&amp;H 2e Ch 38, p 88</td></tr></table>
</page>
<page number="368">
<table id="p368t1" data-filename="pdftables_fromstorage_023782248" data-page="368" data-table="1"><tr><td style="text-align: right">22.05</td><td>Buspirone</td><td>Anxiolytics and hypnotics</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">The important anxiolytic and hypnotic drugs act on GABA A or 5HT1A receptors.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Zolpidem</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Cl-</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5-HT binding</td><td></td><td></td></tr><tr><td colspan="2">GABA</td><td></td><td>Diazepam</td><td></td><td>between</td><td></td></tr><tr><td colspan="2">binding</td><td></td><td></td><td>transmembrane</td><td></td><td></td></tr><tr><td></td><td>site</td><td></td><td></td><td></td><td>segments</td><td></td></tr><tr><td></td><td></td><td></td><td>benzodiazepine</td><td></td><td></td><td>N</td></tr><tr><td colspan="2">Amobarbital</td><td></td><td>binding site</td><td></td><td style="text-align: right">3</td><td style="text-align: right">2</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">4</td><td></td></tr><tr><td></td><td></td><td></td><td>Flumazenil</td><td></td><td style="text-align: right">5</td><td style="text-align: right">1</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">6</td><td style="text-align: right">7</td></tr><tr><td colspan="2">barbiturate</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">binding site</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Cell membrane</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>C</td></tr><tr><td></td><td></td><td></td><td></td><td>G-protein</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>5-HT1A receptor</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">(A 7-transmembrane</td></tr><tr><td></td><td></td><td>GABAA receptor</td><td></td><td></td><td colspan="2">segment receptor)</td></tr></table>
</page>
<page number="369">
<table id="p369t1" data-filename="pdftables_fromstorage_023782248" data-page="369" data-table="1"><tr><td></td><td>Non-sedating anxiolytic</td><td>Buspirone</td></tr><tr><td>Actions</td><td>Anxiolytic.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Partial agonist at 5-HT1A receptors. Acts presynaptically to inhibit firing of serotonergic neurons,</td></tr><tr><td></td><td colspan="2">particularly in the dorsal raphe nucleus. (Actions on postsynaptic 5-HT1A receptors in amygdala also</td></tr><tr><td></td><td colspan="2">likely.) Clinical response is not seen for 1–2 weeks, suggesting effects may require more complex,</td></tr><tr><td></td><td>plastic changes.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally, but significant first-pass metabolism. T0.5 2–3h, but effects are longer lasting, possibly</td></tr><tr><td></td><td>due to metabolite with similar action.</td><td></td></tr><tr><td>Clinical use</td><td>Generalised anxiety disorder.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Nausea, dizziness, nervousness, headache. Blurred vision. (Does not cause dependence, nor cause</td></tr><tr><td></td><td>the sedation and motor incoordination seen with benzodiazepines.)</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 43, pp 438-439; D&amp;H 2e Ch 38, p 88</td></tr></table>
</page>
<page number="370">
<table id="p370t1" data-filename="pdftables_fromstorage_023782248" data-page="370" data-table="1"><tr><td style="text-align: right">22.06</td><td>Summary</td><td>Anxiolytics and hypnotics</td><td></td><td></td><td></td></tr><tr><td colspan="3">The important anxiolytic and hypnotic drugs act on GABA A or 5HT1A receptors.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Zolpidem</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Cl-</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>5-HT binding</td><td></td><td></td></tr><tr><td colspan="2">GABA</td><td></td><td>between</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Diazepam</td><td></td><td></td></tr><tr><td colspan="2">binding</td><td></td><td>transmembrane</td><td></td><td>Buspirone</td></tr><tr><td></td><td>site</td><td></td><td>segments</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>benzodiazepine</td><td></td><td>N</td></tr><tr><td colspan="2">Amobarbital</td><td></td><td>binding site</td><td style="text-align: right">3</td><td style="text-align: right">2</td></tr><tr><td></td><td></td><td></td><td style="text-align: right">4</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Flumazenil</td><td style="text-align: right">5</td><td style="text-align: right">1</td></tr><tr><td></td><td></td><td></td><td></td><td style="text-align: right">6</td><td style="text-align: right">7</td></tr><tr><td colspan="2">barbiturate</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">binding site</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Cell membrane</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>C</td></tr><tr><td></td><td></td><td></td><td>G-protein</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>5-HT1A receptor</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">(A 7-transmembrane</td></tr><tr><td></td><td></td><td>GABAA receptor</td><td></td><td colspan="2">segment receptor)</td></tr></table>
</page>
<page number="371">
<table id="p371t1" data-filename="pdftables_fromstorage_023782248" data-page="371" data-table="1"><tr><td>Notes</td></tr><tr><td>Notes</td></tr></table>
</page>
<page number="372">
<table id="p372t1" data-filename="pdftables_fromstorage_023782248" data-page="372" data-table="1"><tr><td>Chlorpromazine</td><td></td><td></td><td></td></tr><tr><td style="text-align: right">23.01</td><td></td><td></td><td></td></tr><tr><td>(U.S. Thorazine)</td><td>Antipsychotics</td><td></td><td></td></tr><tr><td colspan="3">Diagram illustrating the effects of first- and second-generation antipsychotics</td><td></td></tr><tr><td colspan="2">First-generation agents</td><td>Second-generation agents</td><td></td></tr><tr><td colspan="2">(‘Typical’ neuroleptics)</td><td>(‘Atypical’ neuroleptics)</td><td></td></tr><tr><td colspan="2">D2 receptor antagonism</td><td>D 2 receptor antagonism</td><td></td></tr><tr><td></td><td></td><td>+ effects on other receptors</td><td></td></tr><tr><td></td><td></td><td>e.g. 5-HT2A</td><td></td></tr><tr><td>Extrapyramidal</td><td>↑ Prolactin secretion</td><td>↓ +ve symptoms</td><td>↓ -ve symptoms</td></tr><tr><td>symptoms (EPS)</td><td>from pituitary</td><td>of schizophrenia</td><td>of schizophrenia</td></tr><tr><td>(dystonias, akathisia,</td><td>(galactorrhoea,</td><td>(delusions,</td><td>(withdrawal,</td></tr><tr><td>bradykinesia,</td><td>amenorrhoea,</td><td>hallucinations,</td><td>apathy,</td></tr><tr><td>dyskinesias)</td><td>gynaecomastia)</td><td>aggression)</td><td>demotivation)</td></tr><tr><td colspan="2">Unwanted side effects</td><td></td><td>Wanted effects</td></tr></table>
</page>
<page number="373">
<table id="p373t1" data-filename="pdftables_fromstorage_023782248" data-page="373" data-table="1"><tr><td></td><td>First-generation, phenothiazine, antipsychotic drug (Similar drug: fluphenazine)</td><td>Chlorpromazine</td></tr><tr><td>Actions</td><td colspan="2">Antipsychotic. Apathy and inertia. Reduced aggression. Antiemetic.</td></tr><tr><td>MOA</td><td colspan="2">Competitive antagonism of dopamine D2 receptors in the mesolimbic/mesocortical pathways. Clinical</td></tr><tr><td></td><td colspan="2">benefits are delayed although receptor block is immediate, suggesting that slower changes in</td></tr><tr><td></td><td>neurotransmission occur.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Given orally or by i.m. injection. t1⁄2 16–32h. Fluphenazine decanoate available as i.m. depot</td></tr><tr><td></td><td>formulation.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Schizophrenia (less effective against –ve symptoms) and other psychotic states. Manic phase of</td></tr><tr><td></td><td colspan="2">bipolar disorder. Tourette’s syndrome. Nausea &amp; vomiting. Aggression in children. Persistent hiccups.</td></tr><tr><td>Adverse effects</td><td colspan="2">Marked sedation. EPS (dystonias and Parkinsonian symptoms) reduced by antimuscarinic action.</td></tr><tr><td></td><td colspan="2">Endocrine effects (e.g. galactorrhoea, gynaecomastia, weight gain). Antimuscarinic effects (e.g</td></tr><tr><td></td><td colspan="2">constipation, dry mouth). Hypotension (α-adrenoceptor antagonism). Rare, but serious, neuroleptic</td></tr><tr><td></td><td colspan="2">malignant syndrome. Hypersensitivity reactions. Agranulocytosis. Hepatotoxicity.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 45, pp 555-556; D&amp;H 2e Ch 39, pp 90-91</td></tr></table>
</page>
<page number="374">
<table id="p374t1" data-filename="pdftables_fromstorage_023782248" data-page="374" data-table="1"><tr><td style="text-align: right">23.02</td><td>Haloperidol</td><td>Antipsychotics</td><td></td><td></td></tr><tr><td colspan="4">Diagram illustrating the effects of first- and second-generation antipsychotics</td><td></td></tr><tr><td></td><td colspan="2">Chlorpromazine</td><td></td><td></td></tr><tr><td></td><td colspan="2">First-generation agents</td><td>Second-generation agents</td><td></td></tr><tr><td></td><td colspan="2">(‘Typical’ neuroleptics)</td><td>(‘Atypical’ neuroleptics)</td><td></td></tr><tr><td></td><td colspan="2">D2 receptor antagonism</td><td>D 2 receptor antagonism</td><td></td></tr><tr><td></td><td></td><td></td><td>+ effects on other receptors</td><td></td></tr><tr><td></td><td></td><td></td><td>e.g. 5-HT2A</td><td></td></tr><tr><td>Extrapyramidal</td><td></td><td>↑ Prolactin secretion</td><td>↓ +ve symptoms</td><td>↓ -ve symptoms</td></tr><tr><td>symptoms (EPS)</td><td></td><td>from pituitary</td><td>of schizophrenia</td><td>of schizophrenia</td></tr><tr><td>(dystonias, akathisia,</td><td></td><td>(galactorrhoea,</td><td>(delusions,</td><td>(withdrawal,</td></tr><tr><td>bradykinesia,</td><td></td><td>amenorrhoea,</td><td>hallucinations,</td><td>apathy,</td></tr><tr><td>dyskinesias)</td><td></td><td>gynaecomastia)</td><td>aggression)</td><td>demotivation)</td></tr><tr><td></td><td colspan="2">Unwanted side effects</td><td></td><td>Wanted effects</td></tr></table>
</page>
<page number="375">
<table id="p375t1" data-filename="pdftables_fromstorage_023782248" data-page="375" data-table="1"><tr><td></td><td>First-generation, butyrophenone, antipsychotic drug</td><td>Haloperidol</td></tr><tr><td>Actions</td><td>Antipsychotic. Apathy. Reduced aggression. Antiemetic</td><td></td></tr><tr><td>MOA</td><td colspan="2">Competitive antagonism of dopamine D2 receptors in the mesolimbic/mesocortical pathways.</td></tr><tr><td></td><td colspan="2">Clinical benefits are delayed although receptor block is immediate, suggesting that more complex</td></tr><tr><td></td><td colspan="2">changes in neurotransmission occur. Higher potency compared to chlorpromazine.</td></tr><tr><td>Abs/Distrib/Elim</td><td>Oral or i.m. admin. (Also i.m. depot.) t1⁄2 12–36h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Schizophrenia (less effective against negative symptoms) and other psychotic states. Mania.</td></tr><tr><td></td><td colspan="2">Aggressive behaviour. Tourette’s syndrome. Nausea &amp; vomiting. Persistent hiccup.</td></tr><tr><td>Adverse effects</td><td colspan="2">Marked EPS. Hyperprolactinaemia. Little sedative, hypotensive or antimuscarinic actions. Neuroleptic</td></tr><tr><td></td><td>malignant syndrome.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 45, pp 555-556; D&amp;H 2e Ch 39, pp 90-91</td></tr></table>
</page>
<page number="376">
<table id="p376t1" data-filename="pdftables_fromstorage_023782248" data-page="376" data-table="1"><tr><td style="text-align: right">23.03</td><td>Flupentixol</td><td>Antipsychotics</td><td></td><td></td></tr><tr><td colspan="4">Diagram illustrating the effects of first- and second-generation antipsychotics</td><td></td></tr><tr><td>Haloperidol</td><td colspan="2">Chlorpromazine</td><td></td><td></td></tr><tr><td></td><td colspan="2">First-generation agents</td><td>Second-generation agents</td><td></td></tr><tr><td></td><td colspan="2">(‘Typical’ neuroleptics)</td><td>(‘Atypical’ neuroleptics)</td><td></td></tr><tr><td></td><td colspan="2">D2 receptor antagonism</td><td>D 2 receptor antagonism</td><td></td></tr><tr><td></td><td></td><td></td><td>+ effects on other receptors</td><td></td></tr><tr><td></td><td></td><td></td><td>e.g. 5-HT2A</td><td></td></tr><tr><td>Extrapyramidal</td><td></td><td>↑ Prolactin secretion</td><td>↓ +ve symptoms</td><td>↓ -ve symptoms</td></tr><tr><td>symptoms (EPS)</td><td></td><td>from pituitary</td><td>of schizophrenia</td><td>of schizophrenia</td></tr><tr><td>(dystonias, akathisia,</td><td></td><td>(galactorrhoea,</td><td>(delusions,</td><td>(withdrawal,</td></tr><tr><td>bradykinesia,</td><td></td><td>amenorrhoea,</td><td>hallucinations,</td><td>apathy,</td></tr><tr><td>dyskinesias)</td><td></td><td>gynaecomastia)</td><td>aggression)</td><td>demotivation)</td></tr><tr><td></td><td colspan="2">Unwanted side effects</td><td></td><td>Wanted effects</td></tr></table>
</page>
<page number="377">
<table id="p377t1" data-filename="pdftables_fromstorage_023782248" data-page="377" data-table="1"><tr><td></td><td>First-generation, thioxanthene, antipsychotic drug</td><td>Flupentixol</td></tr><tr><td>Actions</td><td>Antipsychotic. Antidepressant (tricyclic-like) activity.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Competitive antagonism of dopamine D2 receptors in the mesolimbic/mesocortical pathways.</td></tr><tr><td></td><td colspan="2">Clinical benefits are delayed although receptor block is immediate, suggesting that more complex</td></tr><tr><td></td><td>changes in neurotransmission occur.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Effective orally but most often used as i.m. depot formulation. T0.5 19–39h.</td></tr><tr><td>Clinical use</td><td colspan="2">Schizophrenia and other psychotic states. Bipolar disorder. Depression.</td></tr><tr><td>Adverse effects</td><td>EPS. Hyperprolactinaemia. Neuroleptic malignant syndrome.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 45, p 556t; D&amp;H 2e Ch 39, pp 90-91</td></tr></table>
</page>
<page number="378">
<table id="p378t1" data-filename="pdftables_fromstorage_023782248" data-page="378" data-table="1"><tr><td style="text-align: right">23.04</td><td>Clozapine</td><td>Antipsychotics</td><td></td><td></td></tr><tr><td colspan="4">Diagram illustrating the effects of first- and second-generation antipsychotics</td><td></td></tr><tr><td>Haloperidol</td><td></td><td>Chlorpromazine</td><td></td><td></td></tr><tr><td>Flupentixol</td><td colspan="2">First-generation agents</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Second-generation agents</td><td></td></tr><tr><td></td><td colspan="2">(‘Typical’ neuroleptics)</td><td>(‘Atypical’ neuroleptics)</td><td></td></tr><tr><td></td><td colspan="2">D2 receptor antagonism</td><td>D 2 receptor antagonism</td><td></td></tr><tr><td></td><td></td><td></td><td>+ effects on other receptors</td><td></td></tr><tr><td></td><td></td><td></td><td>e.g. 5-HT2A</td><td></td></tr><tr><td>Extrapyramidal</td><td></td><td>↑ Prolactin secretion</td><td>↓ +ve symptoms</td><td>↓ -ve symptoms</td></tr><tr><td>symptoms (EPS)</td><td></td><td>from pituitary</td><td>of schizophrenia</td><td>of schizophrenia</td></tr><tr><td>(dystonias, akathisia,</td><td></td><td>(galactorrhoea,</td><td>(delusions,</td><td>(withdrawal,</td></tr><tr><td>bradykinesia,</td><td></td><td>amenorrhoea,</td><td>hallucinations,</td><td>apathy,</td></tr><tr><td>dyskinesias)</td><td></td><td>gynaecomastia)</td><td>aggression)</td><td>demotivation)</td></tr><tr><td></td><td colspan="2">Unwanted side effects</td><td></td><td>Wanted effects</td></tr></table>
</page>
<page number="379">
<table id="p379t1" data-filename="pdftables_fromstorage_023782248" data-page="379" data-table="1"><tr><td></td><td>Second-generation (‘atypical’) antipsychotic drug (Similar drug: olanzapine)</td><td>Clozapine</td></tr><tr><td>Actions</td><td>Antipsychotic – effective against +ve and -ve symptoms.</td><td></td></tr><tr><td>MOA</td><td colspan="2">MOA less well established than for typical agents. Action on 5HT2A receptors may be important.</td></tr><tr><td></td><td colspan="2">Antagonist action at muscarinic, 5HT 2 , α1 adrenoceptors, and H1 histamine receptors. Higher affinity</td></tr><tr><td></td><td>for D4 than other dopamine receptors.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Orally active. t1⁄2 12h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Schizophrenia. Because of toxicity, used mainly in patients resistant to other drugs, for whom it is</td></tr><tr><td></td><td>very effective.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Little EPS (reduced D2 antagonism coupled with antimuscarinic action). Antimuscarinic actions (e.g.</td></tr><tr><td></td><td colspan="2">constipation). Agranulocytosis (not with olanzapine) – blood testing needed. Sedation. Epileptic</td></tr><tr><td></td><td colspan="2">seizures. Weight gain (more than with other antipsychotics). Hyperglycaemia.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 45, pp 560-561; D&amp;H 2e Ch 39, pp 90-91</td></tr></table>
</page>
<page number="380">
<table id="p380t1" data-filename="pdftables_fromstorage_023782248" data-page="380" data-table="1"><tr><td style="text-align: right">23.05</td><td>Risperidone</td><td>Antipsychotics</td><td></td><td></td></tr><tr><td colspan="4">Diagram illustrating the effects of first- and second-generation antipsychotics</td><td></td></tr><tr><td>Haloperidol</td><td colspan="2">Chlorpromazine</td><td>Clozapine</td><td></td></tr><tr><td>Flupentixol</td><td colspan="2">First-generation agents</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Second-generation agents</td><td></td></tr><tr><td></td><td colspan="2">(‘Typical’ neuroleptics)</td><td>(‘Atypical’ neuroleptics)</td><td></td></tr><tr><td></td><td colspan="2">D2 receptor antagonism</td><td>D 2 receptor antagonism</td><td></td></tr><tr><td></td><td></td><td></td><td>+ effects on other receptors</td><td></td></tr><tr><td></td><td></td><td></td><td>e.g. 5-HT2A</td><td></td></tr><tr><td>Extrapyramidal</td><td></td><td>↑ Prolactin secretion</td><td>↓ +ve symptoms</td><td>↓ -ve symptoms</td></tr><tr><td>symptoms (EPS)</td><td></td><td>from pituitary</td><td>of schizophrenia</td><td>of schizophrenia</td></tr><tr><td>(dystonias, akathisia,</td><td></td><td>(galactorrhoea,</td><td>(delusions,</td><td>(withdrawal,</td></tr><tr><td>bradykinesia,</td><td></td><td>amenorrhoea,</td><td>hallucinations,</td><td>apathy,</td></tr><tr><td>dyskinesias)</td><td></td><td>gynaecomastia)</td><td>aggression)</td><td>demotivation)</td></tr><tr><td></td><td colspan="2">Unwanted side effects</td><td></td><td>Wanted effects</td></tr></table>
</page>
<page number="381">
<table id="p381t1" data-filename="pdftables_fromstorage_023782248" data-page="381" data-table="1"><tr><td></td><td>Second-generation (‘atypical’) antipsychotic drug</td><td>Risperidone</td></tr><tr><td>Actions</td><td colspan="2">Antipsychotic. Effective against +ve and -ve symptoms of schizophrenia.</td></tr><tr><td>MOA</td><td colspan="2">Potent antagonist of D 2 and 5HT2A receptors and α1 adrenoceptors. As for other atypical agents, a</td></tr><tr><td></td><td colspan="2">combination of D2 and 5HT2A antagonism may be important in modifying activity in the mesolimbic</td></tr><tr><td></td><td>and mesocortical pathways.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral and i.m. depot admin. Hepatic P450 metabolism. t1⁄2 3–20h. Active metabolite is longer acting.</td></tr><tr><td>Clinical use</td><td colspan="2">Schizophrenia and other psychotic states. Manic phase of bipolar disorder.</td></tr><tr><td>Adverse effects</td><td colspan="2">EPS (more than with other atypicals). Insomnia and sedation. Anxiety. Hyperprolactinaemia. Weight</td></tr><tr><td></td><td>gain. Hypotension.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 45, p 557t; D&amp;H 2e Ch 39, pp 90-91</td></tr></table>
</page>
<page number="382">
<table id="p382t1" data-filename="pdftables_fromstorage_023782248" data-page="382" data-table="1"><tr><td style="text-align: right">23.06</td><td>Quetiapine</td><td>Antipsychotics</td><td></td><td></td><td></td></tr><tr><td colspan="5">Diagram illustrating the effects of first- and second-generation antipsychotics</td><td></td></tr><tr><td>Haloperidol</td><td></td><td>Chlorpromazine</td><td>Clozapine</td><td>Risperidone</td><td></td></tr><tr><td>Flupentixol</td><td colspan="2">First-generation agents</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Second-generation agents</td><td></td></tr><tr><td></td><td colspan="2">(‘Typical’ neuroleptics)</td><td colspan="2">(‘Atypical’ neuroleptics)</td><td></td></tr><tr><td></td><td colspan="2">D2 receptor antagonism</td><td colspan="2">D 2 receptor antagonism</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">+ effects on other receptors</td><td></td></tr><tr><td></td><td></td><td></td><td>e.g. 5-HT2A</td><td></td><td></td></tr><tr><td>Extrapyramidal</td><td></td><td>↑ Prolactin secretion</td><td colspan="2">↓ +ve symptoms</td><td>↓ -ve symptoms</td></tr><tr><td>symptoms (EPS)</td><td></td><td>from pituitary</td><td colspan="2">of schizophrenia</td><td>of schizophrenia</td></tr><tr><td>(dystonias, akathisia,</td><td></td><td>(galactorrhoea,</td><td>(delusions,</td><td></td><td>(withdrawal,</td></tr><tr><td>bradykinesia,</td><td></td><td>amenorrhoea,</td><td>hallucinations,</td><td></td><td>apathy,</td></tr><tr><td>dyskinesias)</td><td></td><td>gynaecomastia)</td><td>aggression)</td><td></td><td>demotivation)</td></tr><tr><td></td><td colspan="2">Unwanted side effects</td><td></td><td colspan="2">Wanted effects</td></tr></table>
</page>
<page number="383">
<table id="p383t1" data-filename="pdftables_fromstorage_023782248" data-page="383" data-table="1"><tr><td></td><td>Second-generation (‘atypical’) antipsychotic drug</td><td>Quetiapine</td></tr><tr><td>Actions</td><td>Antipsychotic. Effective against +ve and -ve symptoms.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Competitive antagonism of dopamine D2 and 5HT2A receptors in the mesolimbic/mesocortical</td></tr><tr><td></td><td colspan="2">pathways is likely to be important. Antagonism of histamine H1 receptors may underlie sedative</td></tr><tr><td></td><td>action.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Oral admin. Short (6h) half-life.</td><td></td></tr><tr><td>Clinical use</td><td>Schizophrenia and other psychotic states. Bipolar disorder.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Weight gain. Minor EPS and hyperprolactinaemia. Sedation. Postural hypotension. Constipation, dry</td></tr><tr><td></td><td colspan="2">mouth (antimuscarinic actions). Rarely, neuroleptic malignant syndrome.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 45, p 557t; D&amp;H 2e Ch 39, pp 90-91</td></tr></table>
</page>
<page number="384">
<table id="p384t1" data-filename="pdftables_fromstorage_023782248" data-page="384" data-table="1"><tr><td style="text-align: right">23.07</td><td>Aripiprazole</td><td>Antipsychotics</td><td></td><td></td><td></td></tr><tr><td colspan="5">Diagram illustrating the effects of first- and second-generation antipsychotics</td><td></td></tr><tr><td>Haloperidol</td><td colspan="2">Chlorpromazine</td><td>Clozapine</td><td>Risperidone</td><td>Quetiapine</td></tr><tr><td>Flupentixol</td><td colspan="2">First-generation agents</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Second-generation agents</td><td></td></tr><tr><td></td><td colspan="2">(‘Typical’ neuroleptics)</td><td colspan="2">(‘Atypical’ neuroleptics)</td><td></td></tr><tr><td></td><td colspan="2">D2 receptor antagonism</td><td colspan="2">D 2 receptor antagonism</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">+ effects on other receptors</td><td></td></tr><tr><td></td><td></td><td></td><td>e.g. 5-HT2A</td><td></td><td></td></tr><tr><td>Extrapyramidal</td><td></td><td>↑ Prolactin secretion</td><td colspan="2">↓ +ve symptoms</td><td>↓ -ve symptoms</td></tr><tr><td>symptoms (EPS)</td><td></td><td>from pituitary</td><td colspan="2">of schizophrenia</td><td>of schizophrenia</td></tr><tr><td>(dystonias, akathisia,</td><td></td><td>(galactorrhoea,</td><td>(delusions,</td><td></td><td>(withdrawal,</td></tr><tr><td>bradykinesia,</td><td></td><td>amenorrhoea,</td><td>hallucinations,</td><td></td><td>apathy,</td></tr><tr><td>dyskinesias)</td><td></td><td>gynaecomastia)</td><td>aggression)</td><td></td><td>demotivation)</td></tr><tr><td></td><td colspan="2">Unwanted side effects</td><td></td><td colspan="2">Wanted effects</td></tr></table>
</page>
<page number="385">
<table id="p385t1" data-filename="pdftables_fromstorage_023782248" data-page="385" data-table="1"><tr><td></td><td>Second-generation (‘atypical’) antipsychotic drug</td><td>Aripiprazole</td></tr><tr><td>Actions</td><td>Antipsychotic. Effective against +ve and -ve symptoms.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Modification of dopaminergic transmission in the mesolimbic/mesocortical pathways. Aripiprazole</td></tr><tr><td></td><td colspan="2">binds strongly to dopamine D2 receptors but has partial agonist activity which may explain its low</td></tr><tr><td></td><td>incidence of EPS. 5HT 2A antagonism is probably important.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Oral admin. Long (75h) half-life.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Schizophrenia and other psychotic states. Manic phase of bipolar disorder.</td></tr><tr><td>Adverse effects</td><td colspan="2">Fewer side effects than many other antipsychotics (e.g. minor EPS (some akathisia), less weight gain,</td></tr><tr><td></td><td colspan="2">less antimuscarinic, less prolactin secretion). Some hypotension and nausea &amp; vomiting.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 45, p 557t; D&amp;H 2e Ch 39, pp 90-91</td></tr></table>
</page>
<page number="386">
<table id="p386t1" data-filename="pdftables_fromstorage_023782248" data-page="386" data-table="1"><tr><td style="text-align: right">23.08</td><td>Amisulpride</td><td>Antipsychotics</td><td></td><td></td><td></td></tr><tr><td colspan="5">Diagram illustrating the effects of first- and second-generation antipsychotics</td><td></td></tr><tr><td>Haloperidol</td><td colspan="2">Chlorpromazine</td><td>Clozapine</td><td>Risperidone</td><td>Quetiapine</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Aripiprazole</td></tr><tr><td>Flupentixol</td><td colspan="2">First-generation agents</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Second-generation agents</td><td></td></tr><tr><td></td><td colspan="2">(‘Typical’ neuroleptics)</td><td colspan="2">(‘Atypical’ neuroleptics)</td><td></td></tr><tr><td></td><td colspan="2">D2 receptor antagonism</td><td colspan="2">D 2 receptor antagonism</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">+ effects on other receptors</td><td></td></tr><tr><td></td><td></td><td></td><td>e.g. 5-HT2A</td><td></td><td></td></tr><tr><td>Extrapyramidal</td><td></td><td>↑ Prolactin secretion</td><td colspan="2">↓ +ve symptoms</td><td>↓ -ve symptoms</td></tr><tr><td>symptoms (EPS)</td><td></td><td>from pituitary</td><td colspan="2">of schizophrenia</td><td>of schizophrenia</td></tr><tr><td>(dystonias, akathisia,</td><td></td><td>(galactorrhoea,</td><td>(delusions,</td><td></td><td>(withdrawal,</td></tr><tr><td>bradykinesia,</td><td></td><td>amenorrhoea,</td><td>hallucinations,</td><td></td><td>apathy,</td></tr><tr><td>dyskinesias)</td><td></td><td>gynaecomastia)</td><td>aggression)</td><td></td><td>demotivation)</td></tr><tr><td></td><td colspan="2">Unwanted side effects</td><td></td><td colspan="2">Wanted effects</td></tr></table>
</page>
<page number="387">
<table id="p387t1" data-filename="pdftables_fromstorage_023782248" data-page="387" data-table="1"><tr><td></td><td>Second-generation (‘atypical’) antipsychotic drug (Similar drug: sulpiride)</td><td>Amisulpride</td></tr><tr><td>Actions</td><td colspan="2">Antipsychotic. Effective against +ve and -ve symptoms of schizophrenia.</td></tr><tr><td>MOA</td><td colspan="2">Dopamine D2 and D3 receptor antagonist. Preferential action on dopamine autoreceptors may</td></tr><tr><td></td><td colspan="2">explain lower incidence of EPS and effectiveness against -ve symptoms. Low affinity for 5HT,</td></tr><tr><td></td><td>histamine, muscarinic and α1 adrenergic receptors.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Mostly excreted unchanged in kidney. t1⁄2 12h.</td><td></td></tr><tr><td>Clinical use</td><td>Schizophrenia.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Hyperprolactinaemia. Insomnia. Anxiety. Weight gain. Constipation and dry mouth.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 45, p 562; D&amp;H 2e Ch 39, pp 90-91</td></tr></table>
</page>
<page number="388">
<table id="p388t1" data-filename="pdftables_fromstorage_023782248" data-page="388" data-table="1"><tr><td style="text-align: right">23.09</td><td>Summary</td><td>Antipsychotics</td><td></td><td></td><td></td></tr><tr><td colspan="5">Diagram illustrating the effects of first- and second-generation antipsychotics</td><td></td></tr><tr><td>Haloperidol</td><td colspan="2">Chlorpromazine</td><td>Clozapine</td><td>Risperidone</td><td>Quetiapine</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Aripiprazole</td></tr><tr><td>Flupentixol</td><td colspan="2">First-generation agents</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Second-generation agents</td><td></td></tr><tr><td></td><td colspan="2">(‘Typical’ neuroleptics)</td><td colspan="2">(‘Atypical’ neuroleptics)</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Amisulpride</td></tr><tr><td></td><td colspan="2">D2 receptor antagonism</td><td colspan="2">D 2 receptor antagonism</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">+ effects on other receptors</td><td></td></tr><tr><td></td><td></td><td></td><td>e.g. 5-HT2A</td><td></td><td></td></tr><tr><td>Extrapyramidal</td><td></td><td>↑ Prolactin secretion</td><td colspan="2">↓ +ve symptoms</td><td>↓ -ve symptoms</td></tr><tr><td>symptoms (EPS)</td><td></td><td>from pituitary</td><td colspan="2">of schizophrenia</td><td>of schizophrenia</td></tr><tr><td>(dystonias, akathisia,</td><td></td><td>(galactorrhoea,</td><td>(delusions,</td><td></td><td>(withdrawal,</td></tr><tr><td>bradykinesia,</td><td></td><td>amenorrhoea,</td><td>hallucinations,</td><td></td><td>apathy,</td></tr><tr><td>dyskinesias)</td><td></td><td>gynaecomastia)</td><td>aggression)</td><td></td><td>demotivation)</td></tr><tr><td></td><td colspan="2">Unwanted side effects</td><td></td><td colspan="2">Wanted effects</td></tr></table>
</page>
<page number="389">
<table id="p389t1" data-filename="pdftables_fromstorage_023782248" data-page="389" data-table="1"><tr><td></td><td></td><td></td><td colspan="4">Comparison of pharmacological activity of antipsychotic drugs</td><td></td></tr><tr><td></td><td>↓+ve</td><td>↓-ve</td><td></td><td>Prolactin</td><td>Anti-</td><td>Anti-</td><td></td></tr><tr><td>Drug</td><td></td><td></td><td>EPS</td><td></td><td></td><td></td><td>α-block</td></tr><tr><td></td><td>symptoms</td><td>symptoms</td><td></td><td>secretion</td><td>muscarinic</td><td>histamine</td><td></td></tr><tr><td>Chlorpromazine</td><td style="text-align: right">+++</td><td style="text-align: right">+</td><td style="text-align: right">+++</td><td style="text-align: right">++</td><td style="text-align: right">+++</td><td style="text-align: right">+++</td><td style="text-align: right">++++</td></tr><tr><td>Haloperidol</td><td style="text-align: right">+++</td><td style="text-align: right">+</td><td style="text-align: right">+++++</td><td style="text-align: right">++</td><td style="text-align: right">+</td><td style="text-align: right">+</td><td style="text-align: right">+</td></tr><tr><td>Fluphenazine</td><td style="text-align: right">+++</td><td style="text-align: right">+</td><td style="text-align: right">++++</td><td style="text-align: right">++</td><td style="text-align: right">++</td><td style="text-align: right">+</td><td style="text-align: right">+</td></tr><tr><td>Flupentixol</td><td style="text-align: right">+++</td><td style="text-align: right">+</td><td style="text-align: right">++++</td><td style="text-align: right">++</td><td style="text-align: right">+</td><td style="text-align: right">+++</td><td style="text-align: right">+</td></tr><tr><td>Clozapine</td><td style="text-align: right">++++</td><td style="text-align: right">++++</td><td style="text-align: right">+</td><td style="text-align: right">0</td><td style="text-align: right">++++</td><td style="text-align: right">++++</td><td style="text-align: right">+++</td></tr><tr><td>Risperidone</td><td style="text-align: right">+++</td><td style="text-align: right">+</td><td style="text-align: right">++</td><td style="text-align: right">++</td><td style="text-align: right">+</td><td style="text-align: right">++</td><td style="text-align: right">++</td></tr><tr><td>Olanzapine</td><td style="text-align: right">+++</td><td style="text-align: right">+</td><td style="text-align: right">+</td><td style="text-align: right">+</td><td style="text-align: right">+++</td><td style="text-align: right">+++</td><td style="text-align: right">++</td></tr><tr><td>Quetiapine</td><td style="text-align: right">++</td><td style="text-align: right">+</td><td style="text-align: right">+</td><td style="text-align: right">0</td><td style="text-align: right">+</td><td style="text-align: right">+++</td><td style="text-align: right">+</td></tr><tr><td>Aripiprazole</td><td style="text-align: right">++</td><td style="text-align: right">+</td><td style="text-align: right">+</td><td style="text-align: right">0</td><td style="text-align: right">+</td><td style="text-align: right">++</td><td style="text-align: right">++</td></tr><tr><td>Amisulpride</td><td style="text-align: right">++</td><td style="text-align: right">+</td><td style="text-align: right">++</td><td style="text-align: right">++</td><td style="text-align: right">+</td><td style="text-align: right">+</td><td style="text-align: right">+</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">R&amp;D 7e Ch 45, pp 555-563; D&amp;H 2e Ch 39, pp 90-91</td></tr></table>
</page>
<page number="390">
<table id="p390t1" data-filename="pdftables_fromstorage_023782248" data-page="390" data-table="1"><tr><td style="text-align: right">24.01</td><td>Amitriptyline</td><td>Affective disorders – Major Depressive Disorder</td><td></td><td></td></tr><tr><td colspan="5">Potential sites for antidepressant drug action in noradrenergic and serotonergic neurotransmission in CNS</td></tr><tr><td>Noradrenergic</td><td></td><td></td><td></td><td>Serotonergic</td></tr><tr><td>neuron</td><td></td><td></td><td></td><td>neuron</td></tr><tr><td></td><td></td><td></td><td>5-HT transporter</td><td></td></tr><tr><td></td><td>NA transporter</td><td></td><td></td><td></td></tr><tr><td></td><td>NA aldehyde</td><td></td><td></td><td>5-HT aldehyde</td></tr><tr><td></td><td>MAO-A</td><td>NA</td><td>5-HT</td><td>MAO-A</td></tr><tr><td></td><td></td><td></td><td>–</td><td></td></tr><tr><td></td><td></td><td>NA</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>5-HT</td><td>α 2 -adrenoceptor</td></tr><tr><td>NA, noradrenaline</td><td></td><td>Adrenoceptor</td><td>5-HT receptor</td><td style="text-align: right">-+</td></tr><tr><td colspan="2">5-HT, 5-hydroxytryptamine</td><td>on forebrain neuron</td><td>on forebrain neuron</td><td>Noradrenaline</td></tr><tr><td colspan="2">MAO-A, monoamineoxidase-A</td><td></td><td></td><td></td></tr></table>
</page>
<page number="391">
<table id="p391t1" data-filename="pdftables_fromstorage_023782248" data-page="391" data-table="1"><tr><td colspan="2">Tricyclic antidepressant (TCA) (Similar drugs: nortriptyline, desipramine, clomipramine)</td><td>Amitriptyline</td></tr><tr><td>Actions</td><td>Antidepressant.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits reuptake of noradrenaline into noradrenergic neurons and 5-HT into serotonergic neurons,</td></tr><tr><td></td><td colspan="2">so potentiating transmitter action. The clinical effects are not seen for a few weeks, meaning that</td></tr><tr><td></td><td colspan="2">longer-term changes (e.g. down-regulation of receptors) are required.</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral administration. Metabolised in liver by cytochrome P450 system with subsequent conjugation</td></tr><tr><td></td><td colspan="2">reactions. Plasma half-life 12–24h (influenced by P450 inhibitors or inducers). Strong protein binding.</td></tr><tr><td>Clinical use</td><td>Depression. Panic disorder. Neuropathic pain(see set 26). Enuresis.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Sedation (antihistamine action, less with nortriptyline and desipramine). Blurred vision, dry mouth,</td></tr><tr><td></td><td colspan="2">constipation, urinary retention (antimuscarinic action). Postural hypotension (α1 -adrenoceptor</td></tr><tr><td></td><td colspan="2">antagonism). Overdose potentially fatal due to cardiac dysrhythmia, severe hypotension,</td></tr><tr><td></td><td colspan="2">seizure and CNS depression. Not given with MAOIs. Increased risk of suicide in young patients.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 46, pp 574-576; D&amp;H 2e Ch 40, pp 92-93</td></tr></table>
</page>
<page number="392">
<table id="p392t1" data-filename="pdftables_fromstorage_023782248" data-page="392" data-table="1"><tr><td style="text-align: right">24.02</td><td>Fluoxetine</td><td>Affective disorders – Major Depressive Disorder</td><td></td><td></td></tr><tr><td colspan="5">Potential sites for antidepressant drug action in noradrenergic and serotonergic neurotransmission in CNS</td></tr><tr><td></td><td colspan="2">Amitriptyline, nortriptyline,</td><td></td><td></td></tr><tr><td></td><td colspan="2">desipramine, clomipramine</td><td></td><td></td></tr><tr><td>Noradrenergic</td><td></td><td></td><td></td><td>Serotonergic</td></tr><tr><td>neuron</td><td></td><td>-–</td><td>Arrow thickness indicates</td><td>neuron</td></tr><tr><td></td><td></td><td></td><td>strength of action</td><td></td></tr><tr><td></td><td></td><td></td><td>5-HT transporter</td><td></td></tr><tr><td></td><td>NA transporter</td><td></td><td></td><td></td></tr><tr><td></td><td>NA aldehyde</td><td></td><td></td><td>5-HT aldehyde</td></tr><tr><td></td><td>MAO-A</td><td>NA</td><td>5-HT</td><td>MAO-A</td></tr><tr><td></td><td></td><td></td><td>–</td><td></td></tr><tr><td></td><td></td><td>NA</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>5-HT</td><td>α 2-adrenoceptor</td></tr><tr><td>NA, noradrenaline</td><td></td><td>Adrenoceptor</td><td>5-HT receptor</td><td style="text-align: right">-+</td></tr><tr><td colspan="2">5-HT, 5-hydroxytryptamine</td><td>on forebrain neuron</td><td>on forebrain neuron</td><td>Noradrenaline</td></tr><tr><td colspan="2">MAO-A, monoamineoxidase-A</td><td></td><td></td><td></td></tr></table>
</page>
<page number="393">
<table id="p393t1" data-filename="pdftables_fromstorage_023782248" data-page="393" data-table="1"><tr><td colspan="2">Selective serotonin reuptake inhibitor (SSRI) (Similar drugs: paroxetine, citalopram, escitalopram,</td><td>Fluoxetine</td></tr><tr><td></td><td>sertraline, fluvoxamine)</td><td></td></tr><tr><td>Actions</td><td>Antidepressant.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits the reuptake 5-HT into serotonergic neurons, so potentiating transmitter action. The</td></tr><tr><td></td><td colspan="2">antidepressant action is not seen for a few weeks, because longer-term changes (e.g. down-</td></tr><tr><td></td><td colspan="2">regulation of receptors) are required for this. (Less marked antimuscarinic and antihistaminergic</td></tr><tr><td></td><td>actions than the TCAs.)</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral administration. Brain concentration rises over a few days. Hepatic P450 metabolism followed by</td></tr><tr><td></td><td colspan="2">conjugation reactions. T0.5 1–3 days. Longer-lasting active metabolite. (Half-lives of other SSRIs:</td></tr><tr><td></td><td colspan="2">paroxetine, 18–24h, fluvoxamine, 18–24h, escitalopram, 24–36h, sertraline, 24–36h.) Strongly bound.</td></tr><tr><td>Clinical use</td><td colspan="2">Widely prescribed. Depression. Obsessive–compulsive disorder. Panic disorder. Bulimia nervosa.</td></tr><tr><td>Adverse effects</td><td colspan="2">Anxiety and insomnia; can cause nausea, diarrhoea and headache. Sexual dysfunction. Increased</td></tr><tr><td></td><td colspan="2">risk of suicide in young patients. Not prescribed with MAOIs (risk of serotonin syndrome).</td></tr><tr><td></td><td>Hyponatraemia in elderly. Overdose toxicity much less than for TCAs.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Escitalopram is the active enantiomer of citalopram. Sertraline and escitalopram are the SSRIs which</td></tr><tr><td></td><td>are most selective for 5-HT uptake inhibition.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 46, pp 573-574; D&amp;H 2e Ch 40, pp 92-93</td></tr></table>
</page>
<page number="394">
<table id="p394t1" data-filename="pdftables_fromstorage_023782248" data-page="394" data-table="1"><tr><td style="text-align: right">24.03</td><td>Venlafaxine</td><td>Affective disorders – Major Depressive Disorder</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7">Potential sites for antidepressant drug action in noradrenergic and serotonergic neurotransmission in CNS</td></tr><tr><td></td><td colspan="2">Amitriptyline, nortriptyline,</td><td colspan="3">Fluoxetine, paroxetine,</td><td></td></tr><tr><td>Noradrenergic</td><td colspan="2">desipramine, clomipramine</td><td colspan="3">citalopram, sertraline</td><td></td></tr><tr><td>neuron</td><td></td><td>-–</td><td></td><td></td><td></td><td>neuron</td></tr><tr><td></td><td></td><td></td><td></td><td>-–</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">5-HT transporter</td><td></td></tr><tr><td></td><td>NA transporter</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>NA aldehyde</td><td></td><td></td><td></td><td>5-HT aldehyde</td><td></td></tr><tr><td></td><td>MAO-A</td><td>NA</td><td></td><td>5-HT</td><td>MAO-A</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>–</td><td></td><td></td></tr><tr><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5-HT</td><td></td><td>α 2-adrenoceptor</td></tr><tr><td>NA, noradrenaline</td><td></td><td>Adrenoceptor</td><td>5-HT receptor</td><td></td><td></td><td style="text-align: right">-+</td></tr><tr><td colspan="2">5-HT, 5-hydroxytryptamine</td><td>on forebrain neuron</td><td>on forebrain neuron</td><td></td><td colspan="2">Noradrenaline</td></tr><tr><td colspan="2">MAO-A, monoamineoxidase-A</td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="395">
<table id="p395t1" data-filename="pdftables_fromstorage_023782248" data-page="395" data-table="1"><tr><td></td><td>Serotonin/noradrenaline reuptake inhibitor (SNRI) (Similar drug: duloxetine)</td><td>Venlafaxine</td></tr><tr><td>Actions</td><td>Antidepressant.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits the reuptake of noradrenaline into noradrenergic neurons and 5-HT into serotonergic</td></tr><tr><td></td><td colspan="2">neurons, so potentiating transmitter action. The antidepressant action is not seen until a few weeks</td></tr><tr><td></td><td colspan="2">later. No important effects on histamine, muscarinic or adrenergic receptors.</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral administration. Half-life 5h (active metabolite – desmethylvenlafaxine. T0.5 11h) Metabolised in</td></tr><tr><td></td><td>liver by cytochrome P450 system. T0.5 of duloxetine 12–24h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Depression (reported to be effective in cases resistant to SSRIs). Panic disorder. Generalised anxiety</td></tr><tr><td></td><td>disorder. Social phobia.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Nausea, headache, sleep problems and sexual dysfunction. Not given with MAOIs (induces serotonin</td></tr><tr><td></td><td colspan="2">syndrome). Increased risk of suicide in young patients. Overdose causes CNS depression, seizures,</td></tr><tr><td></td><td>cardiac dysrhythmias.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch, pp 576-577; D&amp;H 2e Ch 40, pp 92-93</td></tr></table>
</page>
<page number="396">
<table id="p396t1" data-filename="pdftables_fromstorage_023782248" data-page="396" data-table="1"><tr><td style="text-align: right">24.04</td><td>Reboxetine</td><td colspan="3">Affective disorders – Major Depressive Disorder</td><td></td><td></td><td></td></tr><tr><td colspan="8">Potential sites for antidepressant drug action in noradrenergic and serotonergic neurotransmission in CNS</td></tr><tr><td></td><td colspan="2">Amitriptyline, nortriptyline,</td><td colspan="2">Venlafaxine,</td><td colspan="2">Fluoxetine, paroxetine,</td><td></td></tr><tr><td>Noradrenergic</td><td colspan="2">desipramine, clomipramine</td><td>duloxetine</td><td></td><td colspan="2">citalopram, sertraline</td><td></td></tr><tr><td>neuron</td><td></td><td>-–</td><td></td><td></td><td></td><td></td><td>neuron</td></tr><tr><td></td><td></td><td></td><td>–</td><td>–</td><td>–</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td style="text-align: right">-</td><td style="text-align: right">--</td><td style="text-align: right">-</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">5-HT transporter</td><td></td></tr><tr><td></td><td>NA transporter</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>NA aldehyde</td><td></td><td></td><td></td><td></td><td>5-HT aldehyde</td><td></td></tr><tr><td></td><td>MAO-A</td><td>NA</td><td></td><td></td><td>5-HT</td><td>MAO-A</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>–</td><td></td><td></td></tr><tr><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5-HT</td><td></td><td></td><td>α 2-adrenoceptor</td></tr><tr><td>NA, noradrenaline</td><td></td><td>Adrenoceptor</td><td></td><td>5-HT receptor</td><td></td><td></td><td style="text-align: right">-+</td></tr><tr><td colspan="2">5-HT, 5-hydroxytryptamine</td><td colspan="2">on forebrain neuron</td><td>on forebrain neuron</td><td></td><td colspan="2">Noradrenaline</td></tr><tr><td colspan="2">MAO-A, monoamineoxidase-A</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="397">
<table id="p397t1" data-filename="pdftables_fromstorage_023782248" data-page="397" data-table="1"><tr><td></td><td>Noradrenaline reuptake inhibitor (NRI) (Similar drug: maprotiline)</td><td>Reboxetine</td></tr><tr><td>Actions</td><td>Antidepressant.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits selectively the reuptake of noradrenaline into noradrenergic neurons. (No effect on 5-HT</td></tr><tr><td></td><td colspan="2">and dopamine transmission.) The antidepressant action is not seen for a few weeks, indicating that</td></tr><tr><td></td><td colspan="2">other changes (e.g. down-regulation of receptors) are required for the clinical effects.</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral administration. Metabolised in liver by cytochrome P450 system. Plasma half-life 15h (influenced</td></tr><tr><td></td><td>by P450 inhibitors or inducers).</td><td></td></tr><tr><td>Clinical use</td><td>Depression. Panic disorder. Proposed for ADHD.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Insomnia, headache, effects due to antagonism of muscarinic and histamine receptors, e.g. sweating,</td></tr><tr><td></td><td colspan="2">dry mouth, constipation. Unlike SSRIs does not increase risk of suicide in young patients. Maprotiline</td></tr><tr><td></td><td colspan="2">has similar side effects, consistent with block of receptors, to the TCAs. Not given with MAOIs.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch p 577; D&amp;H 2e Ch 40, pp 92-93</td></tr></table>
</page>
<page number="398">
<table id="p398t1" data-filename="pdftables_fromstorage_023782248" data-page="398" data-table="1"><tr><td style="text-align: right">24.05</td><td>Phenelzine</td><td colspan="3">Affective disorders – Major Depressive Disorder</td><td></td><td></td><td></td></tr><tr><td colspan="8">Potential sites for antidepressant drug action in noradrenergic and serotonergic neurotransmission in CNS</td></tr><tr><td></td><td colspan="2">Amitriptyline, nortriptyline,</td><td colspan="2">Venlafaxine,</td><td colspan="2">Fluoxetine, paroxetine,</td><td></td></tr><tr><td>Noradrenergic</td><td colspan="2">desipramine, clomipramine</td><td>duloxetine</td><td></td><td colspan="2">citalopram, sertraline</td><td></td></tr><tr><td>neuron</td><td>Reboxetine</td><td>-–</td><td></td><td></td><td></td><td></td><td>neuron</td></tr><tr><td></td><td></td><td>–</td><td>-–</td><td>--–</td><td>-–</td><td></td><td></td></tr><tr><td></td><td></td><td style="text-align: right">-</td><td></td><td></td><td colspan="2">5-HT transporter</td><td></td></tr><tr><td></td><td>NA transporter</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>NA aldehyde</td><td></td><td></td><td></td><td></td><td>5-HT aldehyde</td><td></td></tr><tr><td></td><td>MAO-A</td><td>NA</td><td></td><td></td><td>5-HT</td><td>MAO-A</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>–</td><td></td><td></td></tr><tr><td></td><td></td><td>NA</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5-HT</td><td></td><td></td><td>α 2-adrenoceptor</td></tr><tr><td>NA, noradrenaline</td><td></td><td>Adrenoceptor</td><td></td><td>5-HT receptor</td><td></td><td></td><td style="text-align: right">-+</td></tr><tr><td colspan="2">5-HT, 5-hydroxytryptamine</td><td colspan="2">on forebrain neuron</td><td>on forebrain neuron</td><td></td><td colspan="2">Noradrenaline</td></tr><tr><td colspan="2">MAO-A, monoamineoxidase-A</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="399">
<table id="p399t1" data-filename="pdftables_fromstorage_023782248" data-page="399" data-table="1"><tr><td></td><td>Monoamine oxidase inhibitor (MAOI) (Similar drugs: isocarboxazid, moclobemide)</td><td>Phenelzine</td></tr><tr><td>Actions</td><td>Antidepressant.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Phenelzine and isocarboxacid irreversibly inhibit both the A &amp; B forms of monoamine oxidase. MAO</td></tr><tr><td></td><td colspan="2">is found in nerve endings, MAO-A acting preferentially on noradrenaline and 5-HT and MAO-B</td></tr><tr><td></td><td colspan="2">acting mainly on dopamine. MAO inhibition increases the amount of transmitter in the nerve-</td></tr><tr><td></td><td colspan="2">ending. Antidepressant action is due to MAO-A inhibition. Moclobemide is a selective, reversible</td></tr><tr><td></td><td colspan="2">inhibitor of MAO-A. (MAO-B inhibitors are used for Parkinson’s disease (see card 20.03).)</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral administration. Plasma half-life 1–2h, but action lasts much longer because of irreversible</td></tr><tr><td></td><td>inhibition of MAO. Moclobemide T0.5 1–2h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Depression; may have particular value for atypical depression. Social phobia. Clinical effect takes</td></tr><tr><td></td><td>some days to develop.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Postural hypotension. Headache. Insomnia. Sexual dysfunction. Dry mouth, urinary retention.</td></tr><tr><td></td><td colspan="2">Convulsions with overdose. Increased risk of suicide in young patients. Cheese reaction with dietary</td></tr><tr><td></td><td colspan="2">tyramine – hypertensive crisis. Cheese reaction is less pronounced with moclobemide (since MAO-B</td></tr><tr><td></td><td>is still functional).</td><td></td></tr><tr><td>Special points</td><td colspan="2">Adverse effects are more frequent than with the TCAs or SSRIs so MAOIs are second-line treatment for</td></tr><tr><td></td><td>depression.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 46, pp 577-578; D&amp;H 2e Ch 40, pp 92-93</td></tr></table>
</page>
<page number="400">
<table id="p400t1" data-filename="pdftables_fromstorage_023782248" data-page="400" data-table="1"><tr><td style="text-align: right">24.06</td><td>Mirtazapine</td><td colspan="3">Affective disorders – Major Depressive Disorder</td><td></td><td></td><td></td></tr><tr><td colspan="8">Potential sites for antidepressant drug action in noradrenergic and serotonergic neurotransmission in CNS</td></tr><tr><td></td><td colspan="2">Amitriptyline, nortriptyline,</td><td colspan="2">Venlafaxine,</td><td>Fluoxetine, paroxetine,</td><td></td><td></td></tr><tr><td>Noradrenergic</td><td colspan="2">desipramine, clomipramine</td><td>duloxetine</td><td></td><td>citalopram, sertraline</td><td></td><td></td></tr><tr><td>neuron</td><td>Reboxetine</td><td>-–</td><td></td><td></td><td></td><td></td><td>neuron</td></tr><tr><td></td><td></td><td>–</td><td>-–</td><td>--–</td><td>-–</td><td></td><td></td></tr><tr><td></td><td></td><td style="text-align: right">-</td><td></td><td></td><td colspan="2">5-HT transporter</td><td></td></tr><tr><td></td><td>NA transporter</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>NA aldehyde</td><td></td><td></td><td></td><td></td><td>5-HT aldehyde</td><td></td></tr><tr><td></td><td>MAO-A</td><td>NA</td><td></td><td></td><td>5-HT</td><td></td><td>MAO-A</td></tr><tr><td></td><td>-–</td><td></td><td></td><td></td><td></td><td></td><td>-–</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>–</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Phenelzine, isocarboxazid</td></tr><tr><td colspan="2">Phenelzine, isocarboxazid</td><td>NA</td><td></td><td></td><td></td><td colspan="2">moclobamide</td></tr><tr><td>moclobamide</td><td></td><td></td><td></td><td>5-HT</td><td></td><td colspan="2">α 2-adrenoceptor</td></tr><tr><td>NA, noradrenaline</td><td></td><td>Adrenoceptor</td><td></td><td>5-HT receptor</td><td></td><td></td><td style="text-align: right">-+</td></tr><tr><td colspan="2">5-HT, 5-hydroxytryptamine</td><td colspan="2">on forebrain neuron</td><td>on forebrain neuron</td><td></td><td colspan="2">Noradrenaline</td></tr><tr><td colspan="2">MAO-A, monoamineoxidase-A</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="401">
<table id="p401t1" data-filename="pdftables_fromstorage_023782248" data-page="401" data-table="1"><tr><td></td><td>α-adrenoceptor and 5-HT receptor antagonist</td><td>Mirtazapine</td></tr><tr><td>Actions</td><td>Antidepressant.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Antagonist at presynaptic α 2-adrenoceptors so preventing the inhibitory effect of noradrenaline on</td></tr><tr><td></td><td colspan="2">5-HT and perhaps also on noradrenaline release from CNS neurons, thus enhancing monoaminergic</td></tr><tr><td></td><td colspan="2">transmission. Antagonism of 5-HT 2 and 5-HT3 receptors may be beneficial in reducing side effects</td></tr><tr><td></td><td colspan="2">due to potentiation of serotonergic transmission (e.g. the sexual dysfunction and nausea produced</td></tr><tr><td></td><td>by uptake inhibitors).</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral admin. Subject to hepatic cytochrome P450 metabolism. t1⁄2 30h. Longer in elderly and those</td></tr><tr><td></td><td>with liver/ renal impairment.</td><td></td></tr><tr><td>Clinical use</td><td>Major depression. Post-traumatic stress disorder.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Devoid of many side effects associated with muscarinic or adrenoceptor block, but does have</td></tr><tr><td></td><td colspan="2">antihistamine actions, e.g. sedation (useful if insomnia accompanies depression). Increased appetite</td></tr><tr><td></td><td>and weight gain. Agranulocytosis is rare but serious.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 46, p 577; D&amp;H 2e Ch 40, pp 92-93</td></tr></table>
</page>
<page number="402">
<table id="p402t1" data-filename="pdftables_fromstorage_023782248" data-page="402" data-table="1"><tr><td style="text-align: right">24.07</td><td>Bupropion</td><td colspan="3">Affective disorders – Major Depressive Disorder</td><td></td><td></td><td></td></tr><tr><td colspan="8">Potential sites for antidepressant drug action in noradrenergic and serotonergic neurotransmission in CNS</td></tr><tr><td></td><td colspan="2">Amitriptyline, nortriptyline,</td><td colspan="2">Venlafaxine,</td><td colspan="2">Fluoxetine, paroxetine,</td><td></td></tr><tr><td>Noradrenergic</td><td colspan="2">desipramine, clomipramine</td><td>duloxetine</td><td></td><td colspan="2">citalopram, sertraline</td><td></td></tr><tr><td>neuron</td><td>Reboxetine</td><td>-–</td><td></td><td></td><td></td><td></td><td>neuron</td></tr><tr><td></td><td></td><td>–</td><td>-–</td><td>--–</td><td>-–</td><td></td><td></td></tr><tr><td></td><td></td><td style="text-align: right">-</td><td></td><td></td><td colspan="2">5-HT transporter</td><td></td></tr><tr><td></td><td>NA transporter</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>NA aldehyde</td><td></td><td></td><td></td><td></td><td>5-HT aldehyde</td><td></td></tr><tr><td></td><td>MAO-A</td><td>NA</td><td></td><td></td><td>5-HT</td><td>MAO-A</td><td></td></tr><tr><td></td><td>-–</td><td></td><td></td><td></td><td></td><td></td><td>-–</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>–</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Phenelzine, isocarboxazid</td></tr><tr><td>Phenelzine, isocarboxazid</td><td></td><td>NA</td><td></td><td></td><td></td><td></td><td>moclobamide</td></tr><tr><td>moclobamide</td><td></td><td></td><td></td><td>5-HT</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>α 2-adrenoceptor</td></tr><tr><td>NA, noradrenaline</td><td></td><td>Adrenoceptor</td><td></td><td>5-HT receptor</td><td></td><td>-–</td><td>Noradrenaline</td></tr><tr><td>5-HT, 5-hydroxytryptamine</td><td></td><td colspan="2">on forebrain neuron</td><td>on forebrain neuron</td><td></td><td></td><td>Mirtazapine</td></tr><tr><td>MAO-A, monoamineoxidase-A</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="403">
<table id="p403t1" data-filename="pdftables_fromstorage_023782248" data-page="403" data-table="1"><tr><td></td><td>Bupropion – Dopamine reuptake inhibitor</td><td>Bupropion</td></tr><tr><td>Actions</td><td>‘Atypical’ antidepressant. Elevates mood.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Relatively selective inhibitor of neuronal dopamine reuptake with a lesser effect on noradrenaline</td></tr><tr><td></td><td colspan="2">and little effect on 5-HT uptake. Also antagonist at neuronal nicotinic receptors.</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral admin. Extensive hepatic metabolism by Cyt P450 yields active metabolites which contribute</td></tr><tr><td></td><td>to antidepressant action. T0.5 20h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Alone or in combination with SSRIs for major depression. Also used to help people give up tobacco</td></tr><tr><td></td><td>smoking. Clinical effects take some weeks to develop.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Side effects include: agitation, tremor, dry mouth, nausea, insomnia and skin rashes. It does not cause</td></tr><tr><td></td><td colspan="2">the weight gain or sexual dysfunction common with other antidepressants. Seizures may be induced</td></tr><tr><td></td><td>with larger doses.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 46, p 577; D&amp;H 2e Ch 40, pp 92-93</td></tr></table>
</page>
<page number="404">
<table id="p404t1" data-filename="pdftables_fromstorage_023782248" data-page="404" data-table="1"><tr><td style="text-align: right">24.08</td><td>Lithium</td><td>Affective disorders – Bipolar Disorder</td></tr><tr><td colspan="3">Bipolar disorder (manic-depressive illness) is characterised by mood changes which swing between mania</td></tr><tr><td colspan="2">and depression.</td><td></td></tr><tr><td colspan="2">Severe mania</td><td></td></tr><tr><td></td><td></td><td>Each phase may last for some weeks or months</td></tr><tr><td colspan="2">Severe depression</td><td></td></tr></table>
</page>
<page number="405">
<table id="p405t1" data-filename="pdftables_fromstorage_023782248" data-page="405" data-table="1"><tr><td></td><td>A group 1 metallic element</td><td>Lithium</td></tr><tr><td>Actions</td><td>Mood ‘stabiliser’.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Not well established. Being a group 1 element like Na+ and K +, one proposal is that Li+ interferes with</td></tr><tr><td></td><td colspan="2">membrane ion transport, perhaps including neurotransmitter reuptake. Actions on phosphatidyl</td></tr><tr><td></td><td colspan="2">inositol metabolism and on glycogen synthase kinase are other possible mechanisms.</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral admin. Uptake of lithium into cells leads to accumulation in the body over a period of 2 weeks.</td></tr><tr><td>Clinical use</td><td colspan="2">Bipolar (manic-depressive) disorder, mania and as adjunct to other agents in unipolar depression.</td></tr><tr><td></td><td>Clinical effect develops over 3–4 weeks.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Diarrhoea, tremor, confusion. Renal toxicity, including nephrogenic diabetes insipidus – dehydration.</td></tr><tr><td></td><td colspan="2">Depresses thyroid function. Overdose results in convulsions, coma and death. Many drug</td></tr><tr><td></td><td>interactions (e.g. with diuretics).</td><td></td></tr><tr><td>Special points</td><td colspan="2">Because of a low therapeutic index, it is essential to measure the serum Li+ concentration to ensure</td></tr><tr><td></td><td colspan="2">an effective therapeutic concentration with minimal toxicity. Other treatments: antipsychotics</td></tr><tr><td></td><td>(olanzapine) and some antiepileptics (lamotrigine, valproate).</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 46, pp 581-582; D&amp;H 2e Ch 40, p 93</td></tr></table>
</page>
<page number="406">
<table id="p406t1" data-filename="pdftables_fromstorage_023782248" data-page="406" data-table="1"><tr><td style="text-align: right">25.01</td><td>Carbamazepine</td><td>Antiepileptic drugs</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">Potential sites of action of antiepileptic drugs</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Glutamatergic nerve</td><td></td><td></td><td></td><td></td><td>GABAergic</td></tr><tr><td></td><td></td><td></td><td colspan="3">GABA transporter</td><td>nerve</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Succinic</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">semialdehyde</td><td></td></tr><tr><td>Ca 2+ channel</td><td></td><td></td><td></td><td>GABA</td><td>GABA-T</td><td></td></tr><tr><td>Na + channel</td><td></td><td>Glutamate</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>sites</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Glutamate</td><td>GABA</td><td colspan="2">GABA binding site</td><td></td></tr><tr><td></td><td>Glycine site</td><td></td><td>Barbiturate site</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Benzodiazepine site</td><td></td></tr><tr><td colspan="2">NMDA receptor</td><td>+ AMPA receptor</td><td></td><td colspan="2">GABA receptor</td><td></td></tr><tr><td></td><td></td><td>Depolarisation</td><td>Hyperpolarisation</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="3">T-type Ca 2+ channel</td><td></td></tr><tr><td></td><td></td><td>Excitation</td><td>Inhibition</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Na + channel</td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="407">
<table id="p407t1" data-filename="pdftables_fromstorage_023782248" data-page="407" data-table="1"><tr><td></td><td>Antiepileptic (Similar drugs: phenytoin, oxcarbazepine)</td><td>Carbamazepine</td></tr><tr><td>Actions</td><td>Anticonvulsant. Relieves neuropathic pain.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Blocks Na+ channels to inhibit action potential initiation and propagation. Use-dependence of block</td></tr><tr><td></td><td colspan="2">means that action is preferentially on rapidly firing neurons in the epileptic focus.</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral admin. Metabolised by P450 system in liver to give an active metabolite. T0.5 30h. Phenytoin T0.5</td></tr><tr><td></td><td>20h but increases with dose due to saturation kinetics.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Partial and generalised seizures (tonic-clonic), but not absence seizures. Also neuropathic pain and</td></tr><tr><td></td><td colspan="2">bipolar disorder. Phenytoin also used for status epilepticus. Saturable elimination of phenytoin</td></tr><tr><td></td><td>makes it useful to monitor its plasma concentration.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Drowsiness, headache, mental disorientation, motor disturbances. Rare, but serious: liver damage,</td></tr><tr><td></td><td colspan="2">agranulocytosis, aplastic anaemia, skin reaction. Teratogenic effects (e.g. cleft palate with phenytoin).</td></tr><tr><td></td><td>Phenytoin may cause thickening of the gums and hirsutism.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Induction of cytochrome P450 enzymes causes many drug interactions (e.g. ineffectiveness</td></tr><tr><td></td><td colspan="2">of oestrogenic contraceptives). Oxcarbazepine much weaker P450 inducer.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 44, p 546; D&amp;H 2e Ch 41, pp 94-95</td></tr></table>
</page>
<page number="408">
<table id="p408t1" data-filename="pdftables_fromstorage_023782248" data-page="408" data-table="1"><tr><td style="text-align: right">25.02</td><td>Ethosuximide</td><td>Antiepileptic drugs</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">Potential sites of action of antiepileptic drugs</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Glutamatergic nerve</td><td></td><td></td><td></td><td></td><td>GABAergic</td></tr><tr><td></td><td></td><td></td><td colspan="3">GABA transporter</td><td>nerve</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Succinic</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">semialdehyde</td><td></td></tr><tr><td>Ca 2+ channel</td><td></td><td></td><td></td><td>GABA</td><td>GABA-T</td><td></td></tr><tr><td>Na + channel</td><td></td><td>Glutamate</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>sites</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Glutamate</td><td>GABA</td><td colspan="2">GABA binding site</td><td></td></tr><tr><td>-–</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Glycine site</td><td></td><td>Barbiturate site</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Benzodiazepine site</td><td></td></tr><tr><td></td><td>NMDA receptor</td><td>+ AMPA receptor</td><td></td><td colspan="2">GABA receptor</td><td></td></tr><tr><td>Carbamazepine</td><td></td><td>Depolarisation</td><td>Hyperpolarisation</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="3">T-type Ca 2+ channel</td><td></td></tr><tr><td></td><td></td><td>Excitation</td><td>Inhibition</td><td></td><td></td><td></td></tr><tr><td></td><td>-–</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Na + channel</td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="409">
<table id="p409t1" data-filename="pdftables_fromstorage_023782248" data-page="409" data-table="1"><tr><td></td><td>Antiepileptic</td><td>Ethosuximide</td></tr><tr><td>Actions</td><td>Anticonvulsant with specific action on absence seizures.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Blocks T-type Ca2+ channels in thalamic neurons to counteract the slow (3Hz), spike and wave, firing</td></tr><tr><td></td><td>pattern thought to be important in absence epilepsy.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Oral admin. Oxidised by cytochrome P450 system. T0.5 50h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Drug of choice for absence seizures (not effective against partial or tonic-clonic seizures).</td></tr><tr><td>Adverse effects</td><td colspan="2">Anorexia, GIT upset, pancytopaenia. Rash, drowsiness, fatigue. Overdose can cause coma and</td></tr><tr><td></td><td>respiratory depression.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 44, p 548; D&amp;H 2e Ch 41, pp 94-95</td></tr></table>
</page>
<page number="410">
<table id="p410t1" data-filename="pdftables_fromstorage_023782248" data-page="410" data-table="1"><tr><td style="text-align: right">25.03</td><td>Valproate</td><td>Antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">Potential sites of action of antiepileptic drugs</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Glutamatergic nerve</td><td></td><td></td><td></td><td></td><td></td><td>GABAergic</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="3">GABA transporter</td><td>nerve</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Succinic</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">semialdehyde</td><td></td></tr><tr><td>Ca 2+ channel</td><td></td><td></td><td></td><td></td><td>GABA</td><td>GABA-T</td><td></td></tr><tr><td>Na + channel</td><td></td><td colspan="2">Glutamate</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>sites</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Glutamate</td><td>GABA</td><td colspan="2">GABA binding site</td><td></td></tr><tr><td>-–</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Glycine site</td><td></td><td></td><td>Barbiturate site</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Benzodiazepine site</td><td></td></tr><tr><td></td><td>NMDA receptor</td><td></td><td>+ AMPA receptor</td><td></td><td colspan="2">GABA receptor</td><td></td></tr><tr><td colspan="2">Carbamazepine</td><td colspan="2">Depolarisation</td><td>Hyperpolarisation</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="3">T-type Ca 2+ channel</td><td></td></tr><tr><td></td><td></td><td></td><td>Excitation</td><td>Inhibition</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>-–</td><td>-–</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Ethosuximide</td><td></td></tr><tr><td></td><td></td><td></td><td>Na + channel</td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="411">
<table id="p411t1" data-filename="pdftables_fromstorage_023782248" data-page="411" data-table="1"><tr><td></td><td>Antiepileptic</td><td>Valproate</td></tr><tr><td>Actions</td><td>Anticonvulsant. Mood stabiliser.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Several actions may contribute to the antiepileptic action: block of voltage-gated Na+ channels to</td></tr><tr><td></td><td colspan="2">inhibit action potential initiation and propagation; inhibition of GABA transaminase to reduce GABA</td></tr><tr><td></td><td>breakdown; various effects on second messenger pathways.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral admin. Subject to glucuronidation and mitochondrial oxidation. T0.5 9–16h.</td></tr><tr><td>Clinical use</td><td colspan="2">Most forms of epilepsy (esp. useful in myoclonic seizures). Manic phase of bipolar disorder. Migraine.</td></tr><tr><td>Adverse effects</td><td colspan="2">Nausea &amp; vomiting. Tremor. Weight gain. Reproductive dysfunction. Hepatic (especially in infants)</td></tr><tr><td></td><td colspan="2">and pancreatic toxicity. Teratogenic effects (e.g. neural tube defects including spina bifida).</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 44, pp 547-548; D&amp;H 2e Ch 41, pp 94-95</td></tr></table>
</page>
<page number="412">
<table id="p412t1" data-filename="pdftables_fromstorage_023782248" data-page="412" data-table="1"><tr><td style="text-align: right">25.04</td><td>Diazepam</td><td>Antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">Potential sites of action of antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Glutamatergic nerve</td><td></td><td></td><td></td><td></td><td></td><td>GABAergic</td></tr><tr><td></td><td></td><td></td><td colspan="3">GABA transporter</td><td></td><td>nerve</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Succinic</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">semialdehyde</td><td></td><td></td></tr><tr><td>Ca 2+ channel</td><td></td><td></td><td></td><td>GABA</td><td>GABA-T</td><td>-–</td><td>Valproate</td></tr><tr><td>Na + channel</td><td></td><td>Glutamate</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>sites</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Glutamate</td><td>GABA</td><td colspan="2">GABA binding site</td><td></td><td></td></tr><tr><td>-–</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Glycine site</td><td></td><td>Barbiturate site</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="3">Benzodiazepine site</td><td></td></tr><tr><td></td><td>NMDA receptor</td><td>+ AMPA receptor</td><td></td><td colspan="2">GABA receptor</td><td></td><td></td></tr><tr><td colspan="2">Carbamazepine, valproate</td><td>Depolarisation</td><td>Hyperpolarisation</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="3">T-type Ca 2+ channel</td><td></td><td></td></tr><tr><td></td><td></td><td>Excitation</td><td>Inhibition</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>-–</td><td>-–</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="3">Ethosuximide</td><td></td></tr><tr><td></td><td></td><td>Na + channel</td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="413">
<table id="p413t1" data-filename="pdftables_fromstorage_023782248" data-page="413" data-table="1"><tr><td></td><td>Benzodiazepine (Similar drugs: clonazepam, clobazam)</td><td>Diazepam</td></tr><tr><td>Actions</td><td>Anticonvulsant. Also hypnotic and anxiolytic (see set 22).</td><td></td></tr><tr><td>MOA</td><td colspan="2">Interacts with benzodiazepine binding site on GABAA receptor to enhance channel opening by GABA.</td></tr><tr><td></td><td colspan="2">Increased Cl - permeability reduces electrical excitability. Clonazepam and clobazam said to be more</td></tr><tr><td></td><td>selective anticonvulsants with less sedation.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Given orally ( i.v. for status epilepticus). Active metabolite of diazepam has a longer half-life (60h) and</td></tr><tr><td></td><td colspan="2">contributes significantly to actions. Metabolised by P450 system and glucuronide conjugation.</td></tr><tr><td>Clinical use</td><td colspan="2">Diazepam given i.v. for status epilepticus. Clonazepam used for tonic-clonic and absence seizures.</td></tr><tr><td></td><td colspan="2">Clobazam as an adjunctive anticonvulsant. Tolerance to anticonvulsant activity develops.</td></tr><tr><td>Adverse effects</td><td colspan="2">Benzodiazepines are safe drugs. Unwanted effect in treating epilepsy is sedation. Severe respiratory</td></tr><tr><td></td><td>depression in combination with other CNS depressants (e.g. alcohol).</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 44, p 548; D&amp;H 2e Ch 41, pp 94-95</td></tr></table>
</page>
<page number="414">
<table id="p414t1" data-filename="pdftables_fromstorage_023782248" data-page="414" data-table="1"><tr><td style="text-align: right">25.05</td><td>Phenobarbital</td><td>Antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">Potential sites of action of antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Glutamatergic nerve</td><td></td><td></td><td></td><td></td><td></td><td>GABAergic</td></tr><tr><td></td><td></td><td></td><td colspan="3">GABA transporter</td><td></td><td>nerve</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Succinic</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">semialdehyde</td><td></td><td></td></tr><tr><td>Ca 2+ channel</td><td></td><td></td><td></td><td>GABA</td><td>GABA-T</td><td>-–</td><td>Valproate</td></tr><tr><td>Na + channel</td><td></td><td>Glutamate</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>sites</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Glutamate</td><td>GABA</td><td colspan="2">GABA binding site</td><td></td><td></td></tr><tr><td>-–</td><td></td><td></td><td></td><td></td><td colspan="2">Diazepam</td><td></td></tr><tr><td></td><td>Glycine site</td><td></td><td>Barbiturate site</td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="3">Benzodiazepine site</td><td></td></tr><tr><td></td><td>NMDA receptor</td><td style="text-align: right">+</td><td>AMPA receptor</td><td colspan="2">GABA receptor</td><td></td><td></td></tr><tr><td colspan="2">Carbamazepine, valproate</td><td>Depolarisation</td><td>Hyperpolarisation</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="3">T-type Ca 2+ channel</td><td></td><td></td></tr><tr><td></td><td></td><td>Excitation</td><td>Inhibition</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>-–</td><td>-–</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="3">Ethosuximide</td><td></td></tr><tr><td></td><td></td><td>Na + channel</td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="415">
<table id="p415t1" data-filename="pdftables_fromstorage_023782248" data-page="415" data-table="1"><tr><td></td><td>Barbiturate</td><td>Phenobarbital</td></tr><tr><td>Actions</td><td>Anticonvulsant. Hypnotic (at higher doses).</td><td></td></tr><tr><td>MOA</td><td colspan="2">Binds to the barbiturate site on the GABAA receptor to enhance the activity of GABA in opening the</td></tr><tr><td></td><td colspan="2">Cl– channel. This reduces neuronal excitability and action potential frequency at the epileptic focus.</td></tr><tr><td></td><td colspan="2">Effects on Na+ and Ca2+ channels may contribute to the anticonvulsant activity.</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral admin. Some drug is excreted unchanged, but majority of drug is oxidised in liver. T0.5 50–100h.</td></tr><tr><td>Clinical use</td><td>Tonic-clonic and simple partial seizures, particularly in children.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Highly sedative. Megaloblastic anaemia, hypersensitivity reactions. In overdose coma and</td></tr><tr><td></td><td colspan="2">respiratory and circulatory failure. Induces dependence. Drug interactions due to hepatic enzyme</td></tr><tr><td></td><td>induction.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 44, p 548; D&amp;H 2e Ch 41, pp 94-95</td></tr></table>
</page>
<page number="416">
<table id="p416t1" data-filename="pdftables_fromstorage_023782248" data-page="416" data-table="1"><tr><td style="text-align: right">25.06</td><td>Vigabatrin</td><td>Antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">Potential sites of action of antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Glutamatergic nerve</td><td></td><td></td><td></td><td></td><td></td><td>GABAergic</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">GABA transporter</td><td></td><td>nerve</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Succinic</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>semialdehyde</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Phenobarbital</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>GABA-T</td><td></td><td></td></tr><tr><td>2+ Ca  channel</td><td></td><td></td><td></td><td></td><td>GABA</td><td>-–</td><td>Valproate</td></tr><tr><td>Na + channel</td><td></td><td>Glutamate</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>sites</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Glutamate</td><td style="text-align: right">+</td><td>GABA</td><td>GABA binding site</td><td></td><td></td></tr><tr><td>-–</td><td></td><td></td><td></td><td></td><td colspan="2">Diazepam</td><td></td></tr><tr><td></td><td>Glycine site</td><td></td><td>Barbiturate site</td><td></td><td style="text-align: right">+</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Benzodiazepine site</td><td></td></tr><tr><td></td><td>NMDA receptor</td><td style="text-align: right">+</td><td>AMPA receptor</td><td></td><td>GABA receptor</td><td></td><td></td></tr><tr><td colspan="2">Carbamazepine, valproate</td><td>Depolarisation</td><td>Hyperpolarisation</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">T-type Ca 2+ channel</td><td></td><td></td></tr><tr><td></td><td></td><td>Excitation</td><td>Inhibition</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>-–</td><td></td><td>-–</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Ethosuximide</td><td></td></tr><tr><td></td><td></td><td>Na + channel</td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="417">
<table id="p417t1" data-filename="pdftables_fromstorage_023782248" data-page="417" data-table="1"><tr><td></td><td>Antiepileptic</td><td>Vigabatrin</td></tr><tr><td>Actions</td><td>Anticonvulsant.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Irreversible inhibition of GABA transaminase in GABAergic nerves increases the GABA concentration</td></tr><tr><td></td><td colspan="2">in the nerve terminal. Synaptic GABA concentration probably rises as a consequence of reverse</td></tr><tr><td></td><td colspan="2">operation of the GABA transporter. Action potential mediated release is also increased.</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral admin. Mostly excreted unchanged. T0.5 10h, though irreversible enzyme inhibition prolongs</td></tr><tr><td></td><td>drug action.</td><td></td></tr><tr><td>Clinical use</td><td>As an adjunct to other anticonvulsants.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Sedation. Fatigue. Hyperactivity in children. Long-term use may produce visual field defects in a high</td></tr><tr><td></td><td>percentage of patients.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 44, p 549; D&amp;H 2e Ch 41, pp 94-95</td></tr></table>
</page>
<page number="418">
<table id="p418t1" data-filename="pdftables_fromstorage_023782248" data-page="418" data-table="1"><tr><td style="text-align: right">25.07</td><td>Lamotrigine</td><td>Antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">Potential sites of action of antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Glutamatergic nerve</td><td></td><td></td><td></td><td></td><td></td><td></td><td>GABAergic</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="3">GABA transporter</td><td></td><td>nerve</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Succinic</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">semialdehyde</td><td></td><td></td></tr><tr><td></td><td></td><td>Phenobarbital</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ca 2+ channel</td><td></td><td></td><td></td><td></td><td>GABA</td><td>GABA-T</td><td>-–</td><td>Valproate,</td></tr><tr><td>Na + channel</td><td></td><td>Glutamate</td><td></td><td></td><td></td><td></td><td></td><td>vigabatrin</td></tr><tr><td></td><td></td><td>sites</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Glutamate</td><td style="text-align: right">+</td><td>GABA</td><td colspan="2">GABA binding site</td><td></td><td></td></tr><tr><td>-–</td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Diazepam</td><td></td></tr><tr><td></td><td>Glycine site</td><td></td><td>Barbiturate site</td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="3">Benzodiazepine site</td><td></td></tr><tr><td></td><td>NMDA receptor</td><td style="text-align: right">+</td><td>AMPA receptor</td><td></td><td colspan="2">GABA receptor</td><td></td><td></td></tr><tr><td colspan="2">Carbamazepine, valproate</td><td>Depolarisation</td><td>Hyperpolarisation</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="3">T-type Ca 2+ channel</td><td></td><td></td></tr><tr><td></td><td></td><td>Excitation</td><td>Inhibition</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>-–</td><td></td><td>-–</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="3">Ethosuximide</td><td></td></tr><tr><td></td><td></td><td>Na + channel</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="419">
<table id="p419t1" data-filename="pdftables_fromstorage_023782248" data-page="419" data-table="1"><tr><td></td><td>Antiepileptic</td><td>Lamotrigine</td></tr><tr><td>Actions</td><td colspan="2">Anticonvulsant. Reduces frequency of mood episodes in bipolar disorder.</td></tr><tr><td>MOA</td><td colspan="2">Inhibition of glutamate release decreases postsynaptic neuronal excitation. This may be due to Na+</td></tr><tr><td></td><td>(and perhaps Ca2+ ) channel inhibition in the nerve ending.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Oral admin. Subject to hepatic glucuronidation. T0.5 24–36h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Partial and generalised seizures, including absence. Bipolar disorder.</td></tr><tr><td>Adverse effects</td><td colspan="2">Dizziness, headache, double vision and sedation. Serious skin rashes may occur in a small</td></tr><tr><td></td><td>percentage of patients, particularly children.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 44, p 549; D&amp;H 2e Ch 41, pp 94-95</td></tr></table>
</page>
<page number="420">
<table id="p420t1" data-filename="pdftables_fromstorage_023782248" data-page="420" data-table="1"><tr><td style="text-align: right">25.08</td><td>Tiagabine</td><td>Antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">Potential sites of action of antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Glutamatergic nerve</td><td></td><td></td><td></td><td></td><td></td><td></td><td>GABAergic</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="3">GABA transporter</td><td></td><td>nerve</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Succinic</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">semialdehyde</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Phenobarbital</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ca 2+ channel</td><td></td><td></td><td></td><td></td><td></td><td>GABA</td><td>GABA-T</td><td>-–</td><td>Valproate,</td></tr><tr><td>Na + channel</td><td></td><td></td><td>Glutamate</td><td></td><td></td><td></td><td></td><td></td><td>vigabatrin</td></tr><tr><td></td><td></td><td></td><td>sites</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>-–</td><td>-–</td><td>Glutamate</td><td style="text-align: right">+</td><td>GABA</td><td colspan="2">GABA binding site</td><td></td><td></td></tr><tr><td>–</td><td>Lamotrigine</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">-</td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Diazepam</td><td></td></tr><tr><td></td><td colspan="2">Glycine site</td><td></td><td>Barbiturate site</td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">Benzodiazepine site</td><td></td></tr><tr><td></td><td>NMDA receptor</td><td></td><td style="text-align: right">+</td><td>AMPA receptor</td><td></td><td colspan="2">GABA receptor</td><td></td><td></td></tr><tr><td colspan="2">Carbamazepine, valproate</td><td></td><td>Depolarisation</td><td>Hyperpolarisation</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="3">T-type Ca 2+ channel</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Excitation</td><td>Inhibition</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>-–</td><td></td><td>-–</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">Ethosuximide</td><td></td></tr><tr><td></td><td></td><td></td><td>Na + channel</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="421">
<table id="p421t1" data-filename="pdftables_fromstorage_023782248" data-page="421" data-table="1"><tr><td></td><td>Antiepileptic</td><td>Tiagabine</td></tr><tr><td>Actions</td><td>Anticonvulsant.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits the reuptake of GABA (by GAT-1) into GABAergic nerve endings and glia, thus raising</td></tr><tr><td></td><td>synaptic GABA concentration and inhibiting neuronal activity.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Orally active. P450 metabolism in liver. T0.5 7h.</td><td></td></tr><tr><td>Clinical use</td><td>Adjunct to other agents in treatment of partial seizures.</td><td></td></tr><tr><td>Adverse effects</td><td>Dizziness, sedation, confusion, fatigue. Nausea.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 44, p 549; D&amp;H 2e Ch 41, pp 94-95</td></tr></table>
</page>
<page number="422">
<table id="p422t1" data-filename="pdftables_fromstorage_023782248" data-page="422" data-table="1"><tr><td style="text-align: right">25.09</td><td>Topiramate</td><td>Antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">Potential sites of action of antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Glutamatergic nerve</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>GABAergic</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">GABA transporter</td><td></td><td>nerve</td></tr><tr><td></td><td></td><td></td><td></td><td>Tiagabine</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>-–</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Succinic</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">semialdehyde</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Phenobarbital</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ca 2+ channel</td><td></td><td></td><td></td><td></td><td></td><td></td><td>GABA</td><td>GABA-T</td><td>-–</td><td>Valproate,</td></tr><tr><td>Na + channel</td><td></td><td></td><td>Glutamate</td><td></td><td></td><td></td><td></td><td></td><td></td><td>vigabatrin</td></tr><tr><td></td><td></td><td></td><td>sites</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>-–</td><td>-–</td><td>Glutamate</td><td></td><td style="text-align: right">+</td><td>GABA</td><td colspan="2">GABA binding site</td><td></td><td></td></tr><tr><td>–</td><td>Lamotrigine</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Diazepam</td><td></td></tr><tr><td></td><td>Glycine site</td><td></td><td></td><td>Barbiturate site</td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">Benzodiazepine site</td><td></td></tr><tr><td></td><td>NMDA receptor</td><td></td><td style="text-align: right">+</td><td>AMPA receptor</td><td></td><td></td><td colspan="2">GABA receptor</td><td></td><td></td></tr><tr><td colspan="2">Carbamazepine, valproate</td><td></td><td>Depolarisation</td><td colspan="2">Hyperpolarisation</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">T-type Ca 2+ channel</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Excitation</td><td></td><td>Inhibition</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>-–</td><td></td><td></td><td>-–</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">Ethosuximide</td><td></td></tr><tr><td></td><td></td><td></td><td>Na + channel</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="423">
<table id="p423t1" data-filename="pdftables_fromstorage_023782248" data-page="423" data-table="1"><tr><td></td><td>Antiepileptic</td><td>Topiramate</td></tr><tr><td>Actions</td><td>Anticonvulsant.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Most likely channel block of AMPA/kainate receptors for glutamate but topiramate also blocks</td></tr><tr><td></td><td colspan="2">voltage-dependent Na+ channels and potentiates GABA action on GABAA receptors.</td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral admin. Mostly excreted unchanged in urine with some hepatic metabolism. T0.5 21h.</td></tr><tr><td>Clinical use</td><td colspan="2">Generalised tonic-clonic and partial seizures. Used as frequently for migraine.</td></tr><tr><td>Adverse effects</td><td colspan="2">Psychomotor slowing, motor incoordination, memory impairment, paraesthesia, sedation, fatigue,</td></tr><tr><td></td><td colspan="2">confusion. Loss of appetite and weight loss. Rarely serious vision loss. Metabolic acidosis.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 44, p 549; D&amp;H 2e Ch 41, pp 94-95</td></tr></table>
</page>
<page number="424">
<table id="p424t1" data-filename="pdftables_fromstorage_023782248" data-page="424" data-table="1"><tr><td style="text-align: right">25.10</td><td colspan="2">Levetiracetam</td><td>Antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">Potential sites of action of antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Glutamatergic nerve</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>GABAergic</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">GABA transporter</td><td></td><td>nerve</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Tiagabine</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>-–</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Succinic</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">semialdehyde</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Phenobarbital</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ca 2+ channel</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>GABA</td><td>GABA-T</td><td>-–</td><td>Valproate,</td></tr><tr><td>Na + channel</td><td></td><td></td><td colspan="2">Glutamate</td><td></td><td></td><td></td><td></td><td></td><td></td><td>vigabatrin</td></tr><tr><td></td><td></td><td></td><td>sites</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Topiramate</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>-–</td><td>-–</td><td>Glutamate</td><td>-–</td><td></td><td style="text-align: right">+</td><td>GABA</td><td colspan="2">GABA binding site</td><td></td><td></td></tr><tr><td>–</td><td>Lamotrigine</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Diazepam</td><td></td></tr><tr><td></td><td colspan="2">Glycine site</td><td></td><td colspan="2">Barbiturate site</td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">Benzodiazepine site</td><td></td></tr><tr><td></td><td colspan="2">NMDA receptor</td><td style="text-align: right">+</td><td colspan="2">AMPA receptor</td><td></td><td></td><td colspan="2">GABA receptor</td><td></td><td></td></tr><tr><td colspan="3">Carbamazepine, valproate</td><td>Depolarisation</td><td></td><td colspan="2">Hyperpolarisation</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">T-type Ca 2+ channel</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Excitation</td><td></td><td>Inhibition</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>-–</td><td></td><td></td><td></td><td>-–</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">Ethosuximide</td><td></td></tr><tr><td></td><td></td><td></td><td>Na + channel</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="425">
<table id="p425t1" data-filename="pdftables_fromstorage_023782248" data-page="425" data-table="1"><tr><td></td><td>Antiepileptic</td><td>Levetiracetam</td></tr><tr><td>Actions</td><td>Anticonvulsant.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Activity is thought to be due to binding to synaptic vesicle protein SV2A – how this modifies the</td></tr><tr><td></td><td>release of neurotransmitter (e.g. glutamate) is not established.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Oral admin. Mostly excreted unchanged. T0.5 7h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">As an adjunct to other anticonvulsants in the treatment of partial seizures.</td></tr><tr><td>Adverse effects</td><td>Sedation, dizziness, paraesthesia. Few drug interactions.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 44, p 549; D&amp;H 2e Ch 41, pp 94-95</td></tr></table>
</page>
<page number="426">
<table id="p426t1" data-filename="pdftables_fromstorage_023782248" data-page="426" data-table="1"><tr><td style="text-align: right">25.11</td><td>Gabapentin</td><td colspan="3">Antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">Potential sites of action of antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Glutamatergic nerve</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>GABAergic</td></tr><tr><td></td><td></td><td></td><td colspan="2">Levetiracetam</td><td></td><td></td><td></td><td colspan="3">GABA transporter</td><td></td><td>nerve</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Tiagabine</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>-–</td><td></td><td></td><td>-–</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Succinic</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">semialdehyde</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Phenobarbital</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ca 2+ channel</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>GABA</td><td>GABA-T</td><td>-–</td><td>Valproate,</td></tr><tr><td>Na + channel</td><td></td><td></td><td></td><td>Glutamate</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>vigabatrin</td></tr><tr><td></td><td></td><td></td><td></td><td>sites</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Topiramate</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>-–</td><td>-–</td><td>Glutamate</td><td></td><td>-–</td><td></td><td style="text-align: right">+</td><td>GABA</td><td colspan="2">GABA binding site</td><td></td><td></td></tr><tr><td>–</td><td>Lamotrigine</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Diazepam</td><td></td></tr><tr><td></td><td>Glycine site</td><td></td><td></td><td></td><td colspan="2">Barbiturate site</td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">Benzodiazepine site</td><td></td></tr><tr><td></td><td>NMDA receptor</td><td></td><td></td><td style="text-align: right">+</td><td colspan="2">AMPA receptor</td><td></td><td></td><td colspan="2">GABA receptor</td><td></td><td></td></tr><tr><td colspan="2">Carbamazepine, valproate</td><td></td><td colspan="2">Depolarisation</td><td></td><td colspan="2">Hyperpolarisation</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">T-type Ca 2+ channel</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Excitation</td><td></td><td>Inhibition</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>-–</td><td></td><td></td><td></td><td>-–</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">Ethosuximide</td><td></td></tr><tr><td></td><td></td><td></td><td>Na + channel</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="427">
<table id="p427t1" data-filename="pdftables_fromstorage_023782248" data-page="427" data-table="1"><tr><td></td><td>Antiepileptic (Similar drug: pregabalin)</td><td>Gabapentin</td></tr><tr><td>Actions</td><td>Anticonvulsant. Analgesic.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Action is attributed to binding to the α 2 -δ-1 and α2 -δ-2 subunits of voltage-activated Ca2+ channels</td></tr><tr><td></td><td colspan="2">(P/Q or N-type) to block Ca2+ entry and exocytosis of transmitter (glutamate) from nerve endings.</td></tr><tr><td></td><td>(Enhanced release of GABA has also been suggested.)</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Oral admin. Excreted unchanged. T0.5 6h (longer with renal impairment).</td></tr><tr><td>Clinical use</td><td colspan="2">Adjunctive treatment for partial seizures. Widely used to treat neuropathic pain (see set 26).</td></tr><tr><td>Adverse effects</td><td>Sedation, dizziness and unsteadiness.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 44, p 549; D&amp;H 2e Ch 41, pp 94-95</td></tr></table>
</page>
<page number="428">
<table id="p428t1" data-filename="pdftables_fromstorage_023782248" data-page="428" data-table="1"><tr><td style="text-align: right">25.12</td><td>Summary</td><td colspan="2">Antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="5">Potential sites of action of antiepileptic drugs</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Glutamatergic nerve</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>GABAergic</td></tr><tr><td></td><td></td><td></td><td colspan="2">Levetiracetam</td><td></td><td></td><td></td><td colspan="3">GABA transporter</td><td></td><td>nerve</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Tiagabine</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>-–</td><td></td><td></td><td>-–</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Gabapentin</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Succinic</td><td></td><td></td></tr><tr><td></td><td>–</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">semialdehyde</td><td></td><td></td></tr><tr><td></td><td style="text-align: right">-</td><td></td><td></td><td colspan="2">Phenobarbital</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Ca2+ channel</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>GABA</td><td>GABA-T</td><td>-–</td><td>Valproate,</td></tr><tr><td>Na+ channel</td><td></td><td></td><td></td><td colspan="2">Glutamate</td><td></td><td></td><td></td><td></td><td></td><td></td><td>vigabatrin</td></tr><tr><td></td><td></td><td></td><td></td><td>sites</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Topiramate</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>-–</td><td>-–</td><td>Glutamate</td><td></td><td>-–</td><td></td><td style="text-align: right">+</td><td>GABA</td><td colspan="2">GABA binding site</td><td></td><td></td></tr><tr><td>–</td><td>Lamotrigine</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Diazepam</td><td></td></tr><tr><td></td><td colspan="2">Glycine site</td><td></td><td></td><td colspan="2">Barbiturate site</td><td></td><td></td><td style="text-align: right">+</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">Benzodiazepine site</td><td></td></tr><tr><td></td><td>NMDA receptor</td><td></td><td></td><td style="text-align: right">+</td><td colspan="2">AMPA receptor</td><td></td><td></td><td colspan="2">GABA receptor</td><td></td><td></td></tr><tr><td colspan="3">Carbamazepine, valproate</td><td colspan="2">Depolarisation</td><td></td><td colspan="2">Hyperpolarisation</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">T-type Ca 2+ channel</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Excitation</td><td></td><td>Inhibition</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>-–</td><td></td><td></td><td></td><td>-–</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">Ethosuximide</td><td></td></tr><tr><td></td><td></td><td></td><td>Na + channel</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="429">
<table id="p429t1" data-filename="pdftables_fromstorage_023782248" data-page="429" data-table="1"><tr><td>Notes</td></tr><tr><td>Notes</td></tr></table>
</page>
<page number="430">
<table id="p430t1" data-filename="pdftables_fromstorage_023782248" data-page="430" data-table="1"><tr><td style="text-align: right">26.01</td><td>Morphine</td><td>Analgesic drugs and the control of pain</td><td></td><td></td><td></td></tr><tr><td colspan="3">Simplified diagram of pain pathway from periphery to brain</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>PAG</td><td>Sensory cortex</td></tr><tr><td></td><td></td><td></td><td>Brain</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Locus ceruleus</td><td>NRM</td><td>Thalamus</td></tr><tr><td></td><td></td><td>Descending</td><td></td><td></td><td>Descending</td></tr><tr><td></td><td></td><td>noradrenergic</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">serotonergic/</td></tr><tr><td></td><td></td><td>inhibition</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">enkephalinergic</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>inhibition</td></tr><tr><td>Tissue damage</td><td></td><td>Interneuron in</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>dorsal horn</td><td></td><td></td><td></td></tr><tr><td></td><td>Prostaglandins</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>GABA/</td><td></td><td></td><td></td></tr><tr><td>Bradykinin, ATP, H+</td><td></td><td>enkephalin</td><td></td><td></td><td></td></tr><tr><td></td><td>Nociceptive C or A d</td><td colspan="2">Spinothalamic tract</td><td></td><td></td></tr><tr><td></td><td>pain afferent</td><td>Glutamate/</td><td>neuron</td><td></td><td></td></tr><tr><td>Periphery</td><td></td><td>substance P</td><td>Spinal cord</td><td></td><td></td></tr><tr><td></td><td></td><td>Neuropathic pain</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Nerve inflammation /chemokines</td><td></td><td></td><td></td></tr></table>
</page>
<page number="431">
<table id="p431t1" data-filename="pdftables_fromstorage_023782248" data-page="431" data-table="1"><tr><td></td><td>Opioid receptor agonist (Similar drugs: diamorphine (heroin), buprenorphine, codeine)</td><td>Morphine</td></tr><tr><td>Actions</td><td colspan="2">Analgesia. Sedation. Euphoria/reduced anxiety. Physical/psychological dependence. Cough</td></tr><tr><td></td><td>suppression and respiratory depression. Inhibition of gut motility.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Activates μ opioid receptors in the brain and spinal cord to inhibit pain transmission and modify</td></tr><tr><td></td><td colspan="2">the central perception of pain. Activation of κ receptors may exert an additional effect on pain</td></tr><tr><td></td><td colspan="2">transmission in the spinal cord. May inhibit the activation of sensory nerve endings. Opioid</td></tr><tr><td></td><td colspan="2">receptors are G-protein coupled receptors which inhibit adenylate cyclase activity, open K+</td></tr><tr><td></td><td>channels and inhibit the opening of Ca2+ channels in nerve endings.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Oral or s.c., i.m. injection. Glucuronic acid conjugation in liver: t 0.5 3–4h. The actions of diamorphine</td></tr><tr><td></td><td colspan="2">and codeine are due, at least in part, to metabolism to morphine. Buprenorphine T0.5 12h.</td></tr><tr><td>Clinical use</td><td colspan="2">Moderate to severe chronic and post-operative pain (codeine – mild pain). Epidural anaesthesia.</td></tr><tr><td></td><td>Neuropathic pain. Treatment of painful cough. Diarrhoea.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Hypotension. Constipation, nausea, vomiting, drowsiness, dizziness. Tolerance, dependence and</td></tr><tr><td></td><td colspan="2">withdrawal effects (much less with codeine). Larger doses – coma with respiratory depression.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 41, pp 510-513; D&amp;H 2e Ch 42, p 96</td></tr></table>
</page>
<page number="432">
<table id="p432t1" data-filename="pdftables_fromstorage_023782248" data-page="432" data-table="1"><tr><td></td><td>Pethidine</td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">26.02</td><td>(Meperidine)</td><td>Analgesic drugs and the control of pain</td><td></td><td></td><td></td></tr><tr><td colspan="3">Simplified diagram of pain pathway from periphery to brain</td><td></td><td></td><td></td></tr><tr><td></td><td>Morphine, diamorphine,</td><td></td><td></td><td>PAG</td><td>Sensory cortex</td></tr><tr><td></td><td>buprenorphine, codeine</td><td></td><td>Brain</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Locus ceruleus</td><td>NRM</td><td>Thalamus</td></tr><tr><td></td><td></td><td>Descending</td><td></td><td></td><td>Descending</td></tr><tr><td></td><td></td><td>noradrenergic</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">serotonergic/</td></tr><tr><td></td><td></td><td>inhibition</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">enkephalinergic</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>inhibition</td></tr><tr><td>Tissue damage</td><td></td><td>Interneuron in</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>dorsal horn</td><td></td><td></td><td></td></tr><tr><td></td><td>Prostaglandins</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>GABA/</td><td></td><td></td><td></td></tr><tr><td>Bradykinin, ATP, H+</td><td></td><td>enkephalin</td><td></td><td></td><td></td></tr><tr><td></td><td>Nociceptive C or A d</td><td colspan="2">Spinothalamic tract</td><td></td><td></td></tr><tr><td></td><td>pain afferent</td><td>Glutamate/</td><td>neuron</td><td></td><td></td></tr><tr><td>Periphery</td><td></td><td>substance P</td><td>Spinal cord</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="3">Morphine, diamorphine,</td></tr><tr><td></td><td></td><td></td><td colspan="3">buprenorphine, codeine</td></tr><tr><td></td><td></td><td>Neuropathic pain</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Nerve inflammation /chemokines</td><td></td><td></td><td></td></tr></table>
</page>
<page number="433">
<table id="p433t1" data-filename="pdftables_fromstorage_023782248" data-page="433" data-table="1"><tr><td></td><td>Opioid receptor agonist (Similar drugs: fentanyl, remifentanil, sufentanil)</td><td>Pethidine</td></tr><tr><td>Actions</td><td colspan="2">Analgesia. Euphoria. Physical/psychological dependence. Respiratory depression. Inhibition of</td></tr><tr><td></td><td>gut motility. (Antimuscarinic effects of pethidine cause tachycardia.)</td><td></td></tr><tr><td>MOA</td><td colspan="2">Activates μ opioid receptors in the brain and spinal cord to inhibit pain transmission. Activation</td></tr><tr><td></td><td colspan="2">of κ receptors may exert an additional effect on pain transmission in the spinal cord. May inhibit</td></tr><tr><td></td><td colspan="2">activation of the sensory nerve endings. (See also ‘Morphine’ – card 26.01).</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Oral/ i.m. admin. Subject to hydrolysis and P450 oxidation – T0.5 3–5h. Fentanyl is also available as a</td></tr><tr><td></td><td colspan="2">patch for transdermal admin. for long-term effects. Remifentanil has a very short half-life (0.1h).</td></tr><tr><td>Clinical use</td><td colspan="2">Moderate to severe pain. Does not reduce uterine contractions so favoured for labour pain.</td></tr><tr><td></td><td>Remifentanil and sufentanil are given i.v. for surgical analgesia.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Constipation (less than morphine), nausea, vomiting, drowsiness, dizziness. Tolerance, dependence</td></tr><tr><td></td><td colspan="2">and withdrawal effects. Larger doses – coma with respiratory depression.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 41, p 520; D&amp;H 2e Ch 42, p 96</td></tr></table>
</page>
<page number="434">
<table id="p434t1" data-filename="pdftables_fromstorage_023782248" data-page="434" data-table="1"><tr><td style="text-align: right">26.03</td><td>Methadone</td><td>Analgesic drugs and the control of pain</td><td></td><td></td><td></td></tr><tr><td colspan="3">Simplified diagram of pain pathway from periphery to brain</td><td></td><td></td><td></td></tr><tr><td></td><td>Morphine, diamorphine,</td><td></td><td></td><td>PAG</td><td>Sensory cortex</td></tr><tr><td></td><td>buprenorphine, codeine</td><td></td><td>Brain</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Locus ceruleus</td><td>NRM</td><td>Thalamus</td></tr><tr><td></td><td>Pethidine, fentanyl</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Descending</td><td></td><td></td><td>Descending</td></tr><tr><td></td><td></td><td>noradrenergic</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">serotonergic/</td></tr><tr><td></td><td></td><td>inhibition</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">enkephalinergic</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>inhibition</td></tr><tr><td>Tissue damage</td><td></td><td>Interneuron in</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>dorsal horn</td><td></td><td></td><td></td></tr><tr><td></td><td>Prostaglandins</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>GABA/</td><td></td><td></td><td></td></tr><tr><td>Bradykinin, ATP, H+</td><td></td><td>enkephalin</td><td></td><td></td><td></td></tr><tr><td></td><td>Nociceptive C or A d</td><td colspan="2">Spinothalamic tract</td><td></td><td></td></tr><tr><td></td><td>pain afferent</td><td>Glutamate/</td><td>neuron</td><td></td><td></td></tr><tr><td>Periphery</td><td></td><td>substance P</td><td>Spinal cord</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Pethidine, fentanyl</td></tr><tr><td></td><td></td><td>Neuropathic pain</td><td></td><td colspan="2">Morphine, diamorphine,</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">buprenorphine, codeine</td></tr><tr><td></td><td></td><td>Nerve inflammation /chemokines</td><td></td><td></td><td></td></tr></table>
</page>
<page number="435">
<table id="p435t1" data-filename="pdftables_fromstorage_023782248" data-page="435" data-table="1"><tr><td colspan="2">Opioid receptor agonist (Similar drug: propoxyphene (active d-isomer-dextropropoxyphene))</td><td>Methadone</td></tr><tr><td>Actions</td><td colspan="2">Analgesia (methadone strong, propoxyphene weak). Euphoria. Physical/psychological dependence.</td></tr><tr><td></td><td>Respiratory depression. Inhibition of gut motility.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Activation of μ opioid receptors in the brain and spinal cord to inhibit pain transmission. Also</td></tr><tr><td></td><td colspan="2">modifies the central perception of pain. Opioids may also inhibit the activation of sensory nerve</td></tr><tr><td></td><td>endings. (See also ‘Morphine’ – card 26.01.)</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Oral absorption. Long duration of action. P450 metabolism in liver T0.5 15–40h. Propoxyphene T0.5 6h.</td></tr><tr><td>Clinical use</td><td colspan="2">Analgesia (propoxyphene only copes with mild to moderate pain). Maintenance of opioid addicts</td></tr><tr><td></td><td colspan="2">and assistance in withdrawal program. Cough suppression. Propoxyphene is often combined with</td></tr><tr><td></td><td>paracetamol.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Constipation, nausea, vomiting, drowsiness, dizziness. Tolerance, dependence and withdrawal</td></tr><tr><td></td><td colspan="2">effects. Larger doses – coma with respiratory depression and possible cardiac dysrhythmia.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 41, pp 519-520; D&amp;H 2e Ch 42, p 96</td></tr></table>
</page>
<page number="436">
<table id="p436t1" data-filename="pdftables_fromstorage_023782248" data-page="436" data-table="1"><tr><td style="text-align: right">26.04</td><td>Tramadol</td><td>Analgesic drugs and the control of pain</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">Simplified diagram of pain pathway from periphery to brain</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Morphine, diamorphine,</td><td></td><td></td><td></td><td>PAG</td><td>Sensory cortex</td></tr><tr><td></td><td>buprenorphine, codeine</td><td></td><td>Brain</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Locus ceruleus</td><td>NRM</td><td>Thalamus</td></tr><tr><td></td><td>Pethidine, fentanyl</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Descending</td><td></td><td></td><td></td><td>Descending</td></tr><tr><td></td><td></td><td>noradrenergic</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Methadone,</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">serotonergic/</td></tr><tr><td></td><td>propoxyphene</td><td>inhibition</td><td></td><td></td><td colspan="2">enkephalinergic</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>inhibition</td></tr><tr><td>Tissue damage</td><td></td><td></td><td>Interneuron in</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>dorsal horn</td><td></td><td></td><td></td></tr><tr><td></td><td>Prostaglandins</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>GABA/</td><td></td><td></td><td></td></tr><tr><td>Bradykinin, ATP, H+</td><td></td><td></td><td>enkephalin</td><td></td><td></td><td></td></tr><tr><td></td><td>Nociceptive C or A d</td><td colspan="3">Spinothalamic tract</td><td></td><td></td></tr><tr><td></td><td>pain afferent</td><td></td><td colspan="2">neuron</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Glutamate/</td><td></td><td></td><td></td></tr><tr><td>Periphery</td><td></td><td></td><td>substance P</td><td>Spinal cord</td><td></td><td>Methadone,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>propoxyphene</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>Pethidine, fentanyl</td></tr><tr><td></td><td></td><td></td><td>Neuropathic pain</td><td></td><td colspan="2">Morphine, diamorphine,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">buprenorphine, codeine</td></tr><tr><td></td><td></td><td colspan="2">Nerve inflammation /chemokines</td><td></td><td></td><td></td></tr></table>
</page>
<page number="437">
<table id="p437t1" data-filename="pdftables_fromstorage_023782248" data-page="437" data-table="1"><tr><td></td><td>Atypical narcotic analgesic</td><td>Tramadol</td></tr><tr><td>Actions</td><td>Analgesia.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Weak agonist action at μ opioid receptors but main action is attributed to enhancement of</td></tr><tr><td></td><td colspan="2">monoamine neurotransmission by inhibition of 5-HT and noradrenaline reuptake into nerve</td></tr><tr><td></td><td colspan="2">endings. Analgesic action is reported to be inhibited by 5-HT 3 receptor antagonists.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Oral admin. Subject to hepatic demethylation and conjugation, T0.5 6h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Moderate/moderately severe pain. Used post-operatively. Neuropathic pain.</td></tr><tr><td>Adverse effects</td><td colspan="2">Dizziness, nausea and vomiting. Respiratory depression, constipation and addiction (but less than</td></tr><tr><td></td><td>with morphine). Convulsions.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 41, p 520; D&amp;H 2e Ch 42, p 96</td></tr></table>
</page>
<page number="438">
<table id="p438t1" data-filename="pdftables_fromstorage_023782248" data-page="438" data-table="1"><tr><td style="text-align: right">26.05</td><td>Naloxone</td><td>Analgesic drugs and the control of pain</td><td></td><td></td><td></td></tr><tr><td colspan="3">Simplified diagram of pain pathway from periphery to brain</td><td></td><td></td><td></td></tr><tr><td></td><td>Morphine, diamorphine,</td><td></td><td></td><td>PAG</td><td>Sensory cortex</td></tr><tr><td></td><td>buprenorphine, codeine</td><td></td><td>Brain</td><td></td><td></td></tr><tr><td></td><td>Pethidine, fentanyl</td><td></td><td>Locus ceruleus</td><td>NRM</td><td>Thalamus</td></tr><tr><td></td><td></td><td>Descending</td><td></td><td></td><td></td></tr><tr><td></td><td>Methadone,</td><td></td><td></td><td colspan="2">Descending</td></tr><tr><td></td><td></td><td>noradrenergic</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">serotonergic/</td></tr><tr><td></td><td>propoxyphene</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>inhibition</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">enkephalinergic</td></tr><tr><td></td><td></td><td>Tramadol</td><td></td><td colspan="2">inhibition</td></tr><tr><td>Tissue damage</td><td></td><td>Interneuron in</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>dorsal horn</td><td></td><td></td><td></td></tr><tr><td></td><td>Prostaglandins</td><td></td><td></td><td>?</td><td></td></tr><tr><td></td><td></td><td>GABA/</td><td></td><td></td><td></td></tr><tr><td>Bradykinin, ATP, H+</td><td></td><td>enkephalin</td><td></td><td></td><td></td></tr><tr><td></td><td>Nociceptive C or A d</td><td colspan="2">Spinothalamic tract</td><td></td><td>Tramadol</td></tr><tr><td></td><td>pain afferent</td><td>Glutamate/</td><td>neuron</td><td></td><td></td></tr><tr><td>Periphery</td><td></td><td>substance P</td><td>Spinal cord</td><td></td><td>Methadone,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>propoxyphene</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Pethidine, fentanyl</td></tr><tr><td></td><td></td><td>Neuropathic pain</td><td></td><td colspan="2">Morphine, diamorphine,</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">buprenorphine, codeine</td></tr><tr><td></td><td></td><td>Nerve inflammation /chemokines</td><td></td><td></td><td></td></tr></table>
</page>
<page number="439">
<table id="p439t1" data-filename="pdftables_fromstorage_023782248" data-page="439" data-table="1"><tr><td></td><td>Opioid receptor antagonist (Similar drug: naltrexone)</td><td>Naloxone</td></tr><tr><td>Actions</td><td colspan="2">Antagonises the actions of opioid drugs. May cause hyperalgesia under conditions, such as stress,</td></tr><tr><td></td><td>where endogenous opioids may be operative.</td><td></td></tr><tr><td>MOA</td><td>Competitive antagonist of opioids at μ, δ and κ-receptors.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given by injection (i.v., i.m. or s.c.) (very low oral bioavailability). Conjugated with glucuronic acid in</td></tr><tr><td></td><td colspan="2">liver, short t1⁄2:1–2h. Naltrexone is orally active and has a t1⁄2 of 4h though action is extended by an</td></tr><tr><td></td><td>active metabolite with t 1⁄2 of 13h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Treatment of respiratory depression and coma caused by opioid overdose. The longer-acting</td></tr><tr><td></td><td>naltrexone is used to aid in treating opioid and alcohol addiction.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Free of important side effects. May cause withdrawal symptoms in opiate addicts.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 41, p 520; D&amp;H 2e Ch 42, p 96</td></tr></table>
</page>
<page number="440">
<table id="p440t1" data-filename="pdftables_fromstorage_023782248" data-page="440" data-table="1"><tr><td style="text-align: right">26.06</td><td>Ibuprofen</td><td colspan="2">Analgesic drugs and the control of pain</td><td></td><td></td><td></td></tr><tr><td colspan="4">Simplified diagram of pain pathway from periphery to brain</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Morphine, diamorphine,</td><td></td><td></td><td>PAG</td><td>Sensory cortex</td></tr><tr><td></td><td colspan="2">buprenorphine, codeine</td><td></td><td>Brain</td><td></td><td></td></tr><tr><td></td><td colspan="2">Pethidine, fentanyl</td><td></td><td>Locus ceruleus</td><td>NRM</td><td>Thalamus</td></tr><tr><td></td><td colspan="2">Methadone,</td><td></td><td></td><td colspan="2">Descending</td></tr><tr><td></td><td></td><td></td><td>noradrenergic</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">serotonergic/</td></tr><tr><td></td><td colspan="2">propoxyphene</td><td>inhibition</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">enkephalinergic</td></tr><tr><td></td><td></td><td>Tramadol</td><td></td><td></td><td colspan="2">inhibition</td></tr><tr><td>Tissue damage</td><td></td><td></td><td>Interneuron in</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>dorsal horn</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Prostaglandins</td><td></td><td></td><td>?</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>GABA/</td><td></td><td></td></tr><tr><td>Bradykinin, ATP, H+</td><td></td><td></td><td></td><td>enkephalin</td><td></td><td></td></tr><tr><td></td><td colspan="2">Nociceptive C or A d</td><td></td><td>Spinothalamic tract</td><td></td><td>Tramadol</td></tr><tr><td></td><td>pain afferent</td><td></td><td>Glutamate/</td><td>neuron</td><td></td><td></td></tr><tr><td>Periphery</td><td></td><td></td><td>substance P</td><td>Spinal cord</td><td></td><td>Methadone,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>propoxyphene</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Pethidine, fentanyl</td></tr><tr><td></td><td></td><td></td><td>Neuropathic pain</td><td>Naloxone</td><td colspan="2">Morphine, diamorphine,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">buprenorphine, codeine</td></tr><tr><td></td><td></td><td colspan="3">Nerve inflammation /chemokines</td><td></td><td></td></tr></table>
</page>
<page number="441">
<table id="p441t1" data-filename="pdftables_fromstorage_023782248" data-page="441" data-table="1"><tr><td>Cyclo-oxygenase (COX) inhibitor (Similar drugs: naproxen, aspirin, celecoxib, paracetamol (acetaminophen))</td><td>Ibuprofen</td></tr><tr><td>Actions</td><td>Anti-inflammatory (except paracetamol) (see card 3.01). Analgesic. Antipyretic.</td></tr><tr><td>MOA</td><td>Inhibit cyclo-oxygenase iso-enzymes. Ibuprofen, naproxen and aspirin are non-selective inhibitors,</td></tr><tr><td></td><td>celecoxib is COX-2 selective and paracetamol is COX-3 selective. (See cards 3.01–3.04.) Inhibit</td></tr><tr><td></td><td>production of prostaglandins at the site of inflammation; this prevents an increase in sensitivity of</td></tr><tr><td></td><td>pain receptors. Also act within the CNS. Paracetamol may utilise additional mechanisms.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Oral admin. Metabolised by P450 system, T0.5 2h. Aspirin is rapidly hydrolysed to yield salicylate</td></tr><tr><td></td><td>which is also a COX inhibitor. Naproxen T0.5 14h. Paracetamol T0.5 2–3h.</td></tr><tr><td>Clinical use</td><td>Mild to moderate pain due to inflammatory disease, surgery, dysmenorrhoea and headache</td></tr><tr><td></td><td>(including migraine). Naproxen is used for chronic pain. Paracetamol is ineffective in rheumatic pain.</td></tr><tr><td>Adverse effects</td><td>GIT bleeding and ulceration (less with COX-2 selective agents). Tinnitus. Skin rashes. Celecoxib (and</td></tr><tr><td></td><td>other selective COX-2 inhibitors) may provoke myocardial infarction or stroke and should be</td></tr><tr><td></td><td>avoided in patients with heart disease. Paracetamol is hepatotoxic in overdose.</td></tr><tr><td></td><td>R&amp;D 7e Ch 41, p 521; D&amp;H 2e Ch 42, p 96</td></tr></table>
</page>
<page number="442">
<table id="p442t1" data-filename="pdftables_fromstorage_023782248" data-page="442" data-table="1"><tr><td style="text-align: right">26.07</td><td>Carbamazepine</td><td colspan="2">Analgesic drugs and the control of pain</td><td></td><td></td></tr><tr><td colspan="3">Simplified diagram of pain pathway from periphery to brain</td><td></td><td></td><td></td></tr><tr><td></td><td>Morphine, diamorphine,</td><td></td><td></td><td>PAG</td><td>Sensory cortex</td></tr><tr><td></td><td>buprenorphine, codeine</td><td></td><td>Brain</td><td></td><td></td></tr><tr><td></td><td>Pethidine, fentanyl</td><td></td><td>Locus ceruleus</td><td>NRM</td><td>Thalamus</td></tr><tr><td></td><td>Methadone,</td><td></td><td></td><td colspan="2">Descending</td></tr><tr><td></td><td></td><td>noradrenergic</td><td></td><td></td><td></td></tr><tr><td></td><td>propoxyphene</td><td></td><td></td><td colspan="2">serotonergic/</td></tr><tr><td>Ibuprofen</td><td></td><td>inhibition</td><td></td><td colspan="2">enkephalinergic</td></tr><tr><td></td><td>Tramadol</td><td></td><td></td><td colspan="2">inhibition</td></tr><tr><td>Tissue damage</td><td></td><td>Interneuron in</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>dorsal horn</td><td></td><td></td><td></td></tr><tr><td></td><td>Prostaglandins</td><td></td><td></td><td>?</td><td></td></tr><tr><td></td><td></td><td></td><td>GABA/</td><td></td><td></td></tr><tr><td>Bradykinin, ATP, H+</td><td></td><td></td><td>enkephalin</td><td></td><td></td></tr><tr><td></td><td>Nociceptive C or A d</td><td></td><td>Spinothalamic tract</td><td></td><td>Tramadol</td></tr><tr><td></td><td>pain afferent</td><td>Glutamate/</td><td>neuron</td><td></td><td></td></tr><tr><td>Periphery</td><td></td><td>substance P</td><td>Spinal cord</td><td></td><td>Methadone,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>propoxyphene</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Pethidine, fentanyl</td></tr><tr><td></td><td></td><td>Neuropathic pain</td><td>Naloxone</td><td colspan="2">Morphine, diamorphine,</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">buprenorphine, codeine</td></tr><tr><td></td><td></td><td colspan="2">Nerve inflammation /chemokines</td><td></td><td></td></tr></table>
</page>
<page number="443">
<table id="p443t1" data-filename="pdftables_fromstorage_023782248" data-page="443" data-table="1"><tr><td></td><td>Antiepileptic drug used for neuropathic pain (Similar drug: lamotrigine)</td><td>Carbamazepine</td></tr><tr><td>Actions</td><td colspan="2">Reduction of neuropathic pain. (For antiepileptic action see cards 25.01 &amp; 25.07.)</td></tr><tr><td>MOA</td><td colspan="2">Inhibits the opening of neuronal voltage-gated Na+ channels to reduce nociceptive transmission</td></tr><tr><td></td><td>from site of nerve injury.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Oral administration. Active P450 metabolite.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Second- or third-line treatment of neuropathic pain. Main use in trigeminal neuralgia and diabetic</td></tr><tr><td></td><td>neuropathy.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Drowsiness, headache, mental disorientation, motor disturbances. Rare, but serious, adverse effects</td></tr><tr><td></td><td colspan="2">are liver damage, agranulocytosis and aplastic anaemia. Serious dermatological reaction in</td></tr><tr><td></td><td colspan="2">genetically susceptible patients. Strong inducer of cytochrome P450 enzymes leading to many</td></tr><tr><td></td><td colspan="2">drug interactions. Lamotrigine may cause a skin rash, particularly in children.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 41, p 521; D&amp;H 2e Ch 42, p 96</td></tr></table>
</page>
<page number="444">
<table id="p444t1" data-filename="pdftables_fromstorage_023782248" data-page="444" data-table="1"><tr><td style="text-align: right">26.08</td><td>Amitriptyline</td><td>Analgesic drugs and the control of pain</td><td></td><td></td><td></td></tr><tr><td colspan="3">Simplified diagram of pain pathway from periphery to brain</td><td></td><td></td><td></td></tr><tr><td></td><td>Morphine, diamorphine,</td><td></td><td></td><td>PAG</td><td>Sensory cortex</td></tr><tr><td></td><td>buprenorphine, codeine</td><td></td><td>Brain</td><td></td><td></td></tr><tr><td></td><td>Pethidine, fentanyl</td><td></td><td>Locus ceruleus</td><td>NRM</td><td>Thalamus</td></tr><tr><td></td><td>Methadone,</td><td>Descending</td><td></td><td colspan="2">Descending</td></tr><tr><td></td><td></td><td>noradrenergic</td><td></td><td></td><td></td></tr><tr><td></td><td>propoxyphene</td><td></td><td></td><td colspan="2">serotonergic/</td></tr><tr><td>Ibuprofen</td><td></td><td>inhibition</td><td></td><td colspan="2">enkephalinergic</td></tr><tr><td></td><td>Tramadol</td><td></td><td></td><td colspan="2">inhibition</td></tr><tr><td>Tissue damage</td><td></td><td>Interneuron in</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>dorsal horn</td><td></td><td></td><td></td></tr><tr><td></td><td>Prostaglandins</td><td></td><td></td><td>?</td><td></td></tr><tr><td></td><td></td><td></td><td>GABA/</td><td></td><td></td></tr><tr><td>Bradykinin, ATP, H+</td><td></td><td></td><td>enkephalin</td><td></td><td></td></tr><tr><td></td><td>Nociceptive C or A d</td><td></td><td>Spinothalamic tract</td><td></td><td>Tramadol</td></tr><tr><td></td><td>pain afferent</td><td>Glutamate/</td><td>neuron</td><td></td><td></td></tr><tr><td>Periphery</td><td></td><td>substance P</td><td>Spinal cord</td><td></td><td>Methadone,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>propoxyphene</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Pethidine, fentanyl</td></tr><tr><td>Carbamazepine</td><td></td><td>Neuropathic pain</td><td>Naloxone</td><td colspan="2">Morphine, diamorphine,</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">buprenorphine, codeine</td></tr><tr><td></td><td></td><td colspan="2">Nerve inflammation /chemokines</td><td></td><td></td></tr></table>
</page>
<page number="445">
<table id="p445t1" data-filename="pdftables_fromstorage_023782248" data-page="445" data-table="1"><tr><td></td><td>Antidepressant used for neuropathic pain (Similar drug: nortriptyline)</td><td>Amitriptyline</td></tr><tr><td>Actions</td><td colspan="2">Reduction of neuropathic pain. (For antidepressant action see set 24).</td></tr><tr><td>MOA</td><td colspan="2">Analgesic action of antidepressants is mainly due to inhibition of the opening of neuronal</td></tr><tr><td></td><td colspan="2">voltage-gated Na+ channels (Nav 1.7 subtype) rather than to inhibition of monoamine reuptake. Na+</td></tr><tr><td></td><td>channel block reduces pain transmission from site of nerve injury.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Oral administration. Hepatic P450 metabolism (nortriptyline is a metabolite of amitriptyline).</td></tr><tr><td></td><td>T0.5 12–24h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Postherpetic neuralgia, diabetic peripheral neuropathy, neuropathic cancer pain.</td></tr><tr><td>Adverse effects</td><td colspan="2">Sedation (antihistamine action, less with nortriptyline). Blurred vision, dry mouth, constipation,</td></tr><tr><td></td><td colspan="2">urinary retention (antimuscarinic action). Postural hypotension (α1-adrenoceptor antagonism).</td></tr><tr><td></td><td colspan="2">Overdose potentially fatal due to cardiac dysrhythmia, severe hypotension, seizure and CNS</td></tr><tr><td></td><td>depression. Increased risk of suicide in young patients.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 41, p 521; D&amp;H 2e Ch 42, p 96</td></tr></table>
</page>
<page number="446">
<table id="p446t1" data-filename="pdftables_fromstorage_023782248" data-page="446" data-table="1"><tr><td style="text-align: right">26.09</td><td>Gabapentin</td><td>Analgesic drugs and the control of pain</td><td></td><td></td><td></td></tr><tr><td colspan="3">Simplified diagram of pain pathway from periphery to brain</td><td></td><td></td><td></td></tr><tr><td></td><td>Morphine, diamorphine,</td><td></td><td></td><td>PAG</td><td>Sensory cortex</td></tr><tr><td></td><td>buprenorphine, codeine</td><td></td><td>Brain</td><td></td><td></td></tr><tr><td></td><td>Pethidine, fentanyl</td><td></td><td>Locus ceruleus</td><td>NRM</td><td>Thalamus</td></tr><tr><td></td><td>Methadone,</td><td>Descending</td><td></td><td colspan="2">Descending</td></tr><tr><td></td><td></td><td>noradrenergic</td><td></td><td></td><td></td></tr><tr><td></td><td>propoxyphene</td><td></td><td></td><td colspan="2">serotonergic/</td></tr><tr><td>Ibuprofen</td><td></td><td>inhibition</td><td></td><td colspan="2">enkephalinergic</td></tr><tr><td></td><td>Tramadol</td><td></td><td></td><td colspan="2">inhibition</td></tr><tr><td>Tissue damage</td><td></td><td>Interneuron in</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>dorsal horn</td><td></td><td></td><td></td></tr><tr><td></td><td>Prostaglandins</td><td></td><td></td><td>?</td><td></td></tr><tr><td></td><td></td><td></td><td>GABA/</td><td></td><td></td></tr><tr><td>Bradykinin, ATP, H+</td><td></td><td></td><td>enkephalin</td><td></td><td></td></tr><tr><td></td><td>Nociceptive C or A d</td><td></td><td>Spinothalamic tract</td><td></td><td>Tramadol</td></tr><tr><td></td><td>pain afferent</td><td>Glutamate/</td><td>neuron</td><td></td><td></td></tr><tr><td>Periphery</td><td></td><td>substance P</td><td>Spinal cord</td><td></td><td>Methadone,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>propoxyphene</td></tr><tr><td>Amitriptyline</td><td></td><td></td><td></td><td colspan="2">Pethidine, fentanyl</td></tr><tr><td>Carbamazepine</td><td></td><td>Neuropathic pain</td><td>Naloxone</td><td colspan="2">Morphine, diamorphine,</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">buprenorphine, codeine</td></tr><tr><td></td><td></td><td colspan="2">Nerve inflammation /chemokines</td><td></td><td></td></tr></table>
</page>
<page number="447">
<table id="p447t1" data-filename="pdftables_fromstorage_023782248" data-page="447" data-table="1"><tr><td></td><td>Antiepileptic drug used for neuropathic pain (Similar drug: pregabalin)</td><td>Gabapentin</td></tr><tr><td>Actions</td><td>Reduction of neuropathic pain. (For antiepileptic action see set 25).</td><td></td></tr><tr><td>MOA</td><td colspan="2">Effectiveness in neuropathic pain is due to binding to the α2 -δ-1 and α2 -δ-2 subunits of voltage-</td></tr><tr><td></td><td colspan="2">activated Ca2+ channels (P/Q or N-type) to block Ca2+ entry and exocytosis of transmitter</td></tr><tr><td></td><td>(glutamate) from pain nerve endings.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Oral admin. Excreted unchanged. t1⁄2 6h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Postherpetic and trigeminal neuralgia. Pregabalin is also used for painful diabetic peripheral</td></tr><tr><td></td><td>neuropathy.</td><td></td></tr><tr><td>Adverse effects</td><td>Sedation, dizziness and unsteadiness.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 41, p 521; D&amp;H 2e Ch 42, p 96</td></tr></table>
</page>
<page number="448">
<table id="p448t1" data-filename="pdftables_fromstorage_023782248" data-page="448" data-table="1"><tr><td></td><td>Sumatriptan and the</td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">26.10</td><td>treatment of migraine</td><td colspan="2">Analgesic drugs and the control of pain</td><td></td><td></td></tr><tr><td colspan="3">Simplified diagram of pain pathway from periphery to brain</td><td></td><td></td><td></td></tr><tr><td></td><td>Morphine, diamorphine,</td><td></td><td></td><td>PAG</td><td>Sensory cortex</td></tr><tr><td></td><td>buprenorphine, codeine</td><td></td><td>Brain</td><td></td><td></td></tr><tr><td></td><td>Pethidine, fentanyl</td><td></td><td>Locus ceruleus</td><td>NRM</td><td>Thalamus</td></tr><tr><td></td><td>Methadone,</td><td>Descending</td><td></td><td colspan="2">Descending</td></tr><tr><td></td><td></td><td>noradrenergic</td><td></td><td></td><td></td></tr><tr><td></td><td>propoxyphene</td><td></td><td></td><td colspan="2">serotonergic/</td></tr><tr><td>Ibuprofen</td><td></td><td>inhibition</td><td></td><td colspan="2">enkephalinergic</td></tr><tr><td></td><td>Tramadol</td><td></td><td></td><td colspan="2">inhibition</td></tr><tr><td>Tissue damage</td><td></td><td>Interneuron in</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>dorsal horn</td><td></td><td></td><td></td></tr><tr><td></td><td>Prostaglandins</td><td></td><td></td><td>?</td><td></td></tr><tr><td></td><td></td><td></td><td>GABA/</td><td></td><td></td></tr><tr><td>Bradykinin, ATP, H+</td><td></td><td></td><td>enkephalin</td><td></td><td></td></tr><tr><td></td><td>Nociceptive C or A d</td><td></td><td>Spinothalamic tract</td><td></td><td>Tramadol</td></tr><tr><td></td><td>pain afferent</td><td>Glutamate/</td><td>neuron</td><td></td><td></td></tr><tr><td>Periphery</td><td></td><td>substance P</td><td>Spinal cord</td><td></td><td>Methadone,</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>propoxyphene</td></tr><tr><td></td><td>Gabapentin</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Pethidine, fentanyl</td></tr><tr><td></td><td>Amitriptyline</td><td>Neuropathic pain</td><td>Naloxone</td><td colspan="2">Morphine, diamorphine,</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">buprenorphine, codeine</td></tr><tr><td></td><td>Carbamazepine</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Nerve inflammation /chemokines</td><td></td><td></td></tr></table>
</page>
<page number="449">
<table id="p449t1" data-filename="pdftables_fromstorage_023782248" data-page="449" data-table="1"><tr><td></td><td>Antimigraine drug (Similar drugs: zolmitriptan, eletriptan et al.)</td><td>Sumatriptan</td></tr><tr><td colspan="3">The pathophysiology of migraine is likely to involve inflammatory vasodilatation in extracerebral</td></tr><tr><td colspan="3">cranial blood vessels and stimulation of trigeminal nerve terminals (which might induce further</td></tr><tr><td colspan="2">inflammation by the release of neuropeptides).</td><td></td></tr><tr><td colspan="3">Treatment of acute attack is with NSAIDS (aspirin, ibuprofen, tolfenamic acid, etc.) or paracetamol.</td></tr><tr><td colspan="2">If this is inadequate, ‘triptans’ are used.</td><td></td></tr><tr><td></td><td>Sumatriptan is the standard triptan.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Triptans are agonists at 5-HT1B and 5-HT1D receptors. Activation of 5-HT1D receptors causes</td></tr><tr><td></td><td colspan="2">vasoconstriction of cranial blood vessels (with little effect on peripheral vessels). They also inhibit</td></tr><tr><td></td><td>trigeminal nerve stimulation and peptide release.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Orally active, but low bioavailability. T0.5 1.5h. May be given s.c. if migraine is accompanied by</td></tr><tr><td></td><td>vomiting.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Acute migraine attack. Sumatriptan is also effective in cluster headache.</td></tr><tr><td>Adverse effects</td><td colspan="2">Sumatriptan has adverse cardiac effects and is contraindicated in heart disease.</td></tr><tr><td colspan="3">Prophylaxis employs other drugs: β-adrenoceptor antagonists (e.g. propranolol), tricyclic</td></tr><tr><td colspan="3">antidepressants (e.g. amitriptyline), some antiepileptics (topiramate, valproate), pizotifen (5-HT2</td></tr><tr><td colspan="2">receptor antagonist).</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 15, pp 201-202; D&amp;H 2e Ch 12, p 36</td></tr></table>
</page>
<page number="450">
<table id="p450t1" data-filename="pdftables_fromstorage_023782248" data-page="450" data-table="1"><tr><td style="text-align: right">27.01</td><td>Amfetamine</td><td colspan="2">CNS stimulants and psychotomimetics</td><td></td><td></td></tr><tr><td colspan="6">Dopaminergic, noradrenergic and serotonergic transmission as targets for CNS stimulants and psychotomimetics</td></tr><tr><td colspan="2">-Dopaminergic neuron in</td><td></td><td></td><td>Monoamine</td><td></td></tr><tr><td colspan="2">ventral tegmental area</td><td></td><td></td><td>transporter</td><td></td></tr><tr><td colspan="2">-Serotonergic neuron in dorsal</td><td></td><td></td><td></td><td></td></tr><tr><td>raphe nuclei</td><td></td><td>Aldehyde</td><td></td><td></td><td></td></tr><tr><td colspan="2">-Noradrenergic neuron in locus ceruleus</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>MAO-A</td><td>MA</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>MA</td><td></td></tr><tr><td></td><td></td><td></td><td>5-HT</td><td>NA</td><td>DA</td></tr><tr><td></td><td></td><td colspan="3">5-HT receptors and adrenoceptors</td><td>Dopamine receptors in nucleus</td></tr><tr><td colspan="2">MA, monoamine</td><td colspan="3">in reticular formation, prefrontal cortex</td><td>accumbens/prefrontal cortex</td></tr><tr><td colspan="2">DA, dopamine</td><td colspan="2">and hypothalamus</td><td></td><td></td></tr><tr><td colspan="2">NA, noradrenaline</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">5-HT, 5-hydroxytryptamine</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">MAO-A, monoamineoxidase-A</td><td colspan="3">Arousal, effects on mood</td><td>Reward, pleasure</td></tr></table>
</page>
<page number="451">
<table id="p451t1" data-filename="pdftables_fromstorage_023782248" data-page="451" data-table="1"><tr><td colspan="2">CNS stimulant, sympathomimetic (Similar drugs: methylenedioxymethamfetamine (MDMA), methylphenidate)</td><td>Amfetamine</td></tr><tr><td>Actions</td><td colspan="2">CNS stimulation: arousal, alertness, concentration. Euphoria/excitement. Stereotyped behaviour.</td></tr><tr><td></td><td colspan="2">Anxiety. Reduced appetite. Sympathomimetic actions: tachycardia, pupillary dilation, etc.</td></tr><tr><td>MOA</td><td colspan="2">Inhibition of neuronal reuptake of MA, inhibition of MAO, inhibition of the vesicular monoamine</td></tr><tr><td></td><td colspan="2">transporter. Raised cytosolic levels of MAs and release from nerve terminals, mainly by reverse</td></tr><tr><td></td><td colspan="2">operation of the MA transporter. Increased MA levels in synapse. Sympathomimetic actions due to</td></tr><tr><td></td><td>release of NA in the periphery.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Orally active. T0.5 10h. Renal excretion enhanced by urine acidification. Methylphenidate also</td></tr><tr><td></td><td>administered by patch.</td><td></td></tr><tr><td>Clinical use</td><td>Attention deficit hyperactivity disorder (ADHD), narcolepsy.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Aggression, restlessness, insomnia, paranoia. Anorexia, weight loss. Psychotic states/ hallucinations.</td></tr><tr><td></td><td colspan="2">Dependence. Dehydration/hyperthermia (MDMA). Hypertension. Sudden death in patients with</td></tr><tr><td></td><td>pre-existing cardiac abnormalities.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 47, pp 584-586; D&amp;H 2e Ch 43, p 99</td></tr></table>
</page>
<page number="452">
<table id="p452t1" data-filename="pdftables_fromstorage_023782248" data-page="452" data-table="1"><tr><td style="text-align: right">27.02</td><td>Cocaine</td><td>CNS stimulants and psychotomimetics</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7">Dopaminergic, noradrenergic and serotonergic transmission as targets for CNS stimulants and psychotomimetics</td></tr><tr><td></td><td></td><td></td><td></td><td>–</td><td>Amfetamine</td><td></td></tr><tr><td colspan="2">-Dopaminergic neuron in</td><td></td><td></td><td style="text-align: right">-</td><td style="text-align: right">+</td><td></td></tr><tr><td colspan="2">ventral tegmental area</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">-Serotonergic neuron in dorsal</td><td></td><td></td><td></td><td>-–</td><td>Monoamine</td></tr><tr><td>raphe nuclei</td><td></td><td>Aldehyde</td><td></td><td></td><td></td><td>transporter</td></tr><tr><td colspan="2">-Noradrenergic neuron in locus ceruleus</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>MAO-A</td><td>MA</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Release by reversed action of</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">monoamine transporter</td></tr><tr><td></td><td></td><td></td><td></td><td>MA</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>5-HT</td><td>NA</td><td>DA</td><td></td></tr><tr><td></td><td></td><td colspan="3">5-HT receptors and adrenoceptors</td><td colspan="2">Dopamine receptors in nucleus</td></tr><tr><td colspan="2">MA, monoamine</td><td colspan="3">in reticular formation, prefrontal cortex</td><td colspan="2">accumbens/prefrontal cortex</td></tr><tr><td colspan="2">DA, dopamine</td><td colspan="2">and hypothalamus</td><td></td><td></td><td></td></tr><tr><td colspan="2">NA, noradrenaline</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">5-HT, 5-hydroxytryptamine</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">MAO-A, monoamineoxidase-A</td><td colspan="3">Arousal, effects on mood</td><td colspan="2">Reward, pleasure</td></tr></table>
</page>
<page number="453">
<table id="p453t1" data-filename="pdftables_fromstorage_023782248" data-page="453" data-table="1"><tr><td></td><td>CNS stimulant, sympathomimetic</td><td>Cocaine</td></tr><tr><td>Actions</td><td colspan="2">Euphoria, alertness and other effects like amfetamine. Sympathomimetic actions: tachycardia,</td></tr><tr><td></td><td>vasoconstriction with increased blood pressure etc. Local anaesthesia.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits action of monoamine transporters (but unlike amfetamine-like drugs is not transported</td></tr><tr><td></td><td colspan="2">and does not provoke monoamine release). Local anaesthetic action due to Na+ channel block</td></tr><tr><td></td><td>(see card 28.03).</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Abusers favour i.v. or nasal admin. (The free base ‘crack cocaine’ is volatile and is smoked.) T0.5 1h.</td></tr><tr><td>Clinical use</td><td>Important as drug of abuse. Limited use as surface anaesthetic.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Cardiac toxicity. Hypertension. Hyperthermia. Addiction. Taken intranasally, vasoconstriction may</td></tr><tr><td></td><td>cause necrosis of nasal tissue.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 47, p 587; D&amp;H 2e Ch 43, p 99</td></tr></table>
</page>
<page number="454">
<table id="p454t1" data-filename="pdftables_fromstorage_023782248" data-page="454" data-table="1"><tr><td></td><td>Lysergic acid</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">27.03</td><td>diethylamide (LSD)</td><td colspan="3">CNS stimulants and psychotomimetics</td><td></td><td></td></tr><tr><td colspan="7">Dopaminergic, noradrenergic and serotonergic transmission as targets for CNS stimulants and psychotomimetics</td></tr><tr><td></td><td></td><td>Cocaine</td><td>–</td><td>–</td><td>Amfetamine</td><td></td></tr><tr><td colspan="2">-Dopaminergic neuron in</td><td></td><td style="text-align: right">-</td><td style="text-align: right">-</td><td style="text-align: right">+</td><td></td></tr><tr><td colspan="2">ventral tegmental area</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">-Serotonergic neuron in dorsal</td><td></td><td></td><td></td><td>-–</td><td>Monoamine</td></tr><tr><td>raphe nuclei</td><td></td><td>Aldehyde</td><td></td><td></td><td></td><td>transporter</td></tr><tr><td colspan="2">-Noradrenergic neuron in locus ceruleus</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>MAO-A</td><td>MA</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Release by reversed action of</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">monoamine transporter</td></tr><tr><td></td><td></td><td></td><td></td><td>MA</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>5-HT</td><td>NA</td><td>DA</td><td></td></tr><tr><td></td><td></td><td colspan="3">5-HT receptors and adrenoceptors</td><td colspan="2">Dopamine receptors in nucleus</td></tr><tr><td colspan="2">MA, monoamine</td><td colspan="3">in reticular formation, prefrontal cortex</td><td colspan="2">accumbens/prefrontal cortex</td></tr><tr><td colspan="2">DA, dopamine</td><td colspan="2">and hypothalamus</td><td></td><td></td><td></td></tr><tr><td colspan="2">NA, noradrenaline</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">5-HT, 5-hydroxytryptamine</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">MAO-A, monoamineoxidase-A</td><td colspan="3">Arousal, effects on mood</td><td colspan="2">Reward, pleasure</td></tr></table>
</page>
<page number="455">
<table id="p455t1" data-filename="pdftables_fromstorage_023782248" data-page="455" data-table="1"><tr><td></td><td>Psychotomimetic (hallucinogen) (Similar drugs: mescaline, dimethyltryptamine (DMT))</td><td>LSD</td></tr><tr><td>Actions</td><td colspan="2">Mood alteration, perceptual changes (psychedelic effects), cognitive impairment. Paranoid delusions</td></tr><tr><td></td><td>(‘bad trips’ ). Hallucinations at higher doses.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Agonist at several 5-HT receptors but psychotomimetic action is attributed to 5-HT2A receptors</td></tr><tr><td></td><td colspan="2">enhancing glutamatergic transmission in cerebral cortex. Additional actions may be inhibition of</td></tr><tr><td></td><td colspan="2">5-HT release in the Raphe nucei by 5-HT1A receptors and modulation of dopaminergic activity in the</td></tr><tr><td></td><td>mesolimbic pathway. Mescaline acts partly by inhibiting MA reuptake.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Effective orally. LSD T0.5 3h. DMT has a low oral bioavailability so may be smoked.</td></tr><tr><td>Clinical use</td><td>No clinical use. Important only as a drug of abuse.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Some sympathomimetic actions (e.g. pupil dilatation, tachycardia). Unlike other drugs of abuse they</td></tr><tr><td></td><td colspan="2">produce little dependence or withdrawal effects. LSD is non-fatal in overdose.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 47, p 589; D&amp;H 2e Ch 43, p 99</td></tr></table>
</page>
<page number="456">
<table id="p456t1" data-filename="pdftables_fromstorage_023782248" data-page="456" data-table="1"><tr><td style="text-align: right">27.04</td><td>Phencyclidine</td><td colspan="2">CNS stimulants and psychotomimetics</td><td></td><td></td><td></td></tr><tr><td colspan="7">Dopaminergic, noradrenergic and serotonergic transmission as targets for CNS stimulants and psychotomimetics</td></tr><tr><td></td><td></td><td>Cocaine</td><td>–</td><td>–</td><td>Amfetamine</td><td></td></tr><tr><td>-Dopaminergic neuron in</td><td></td><td></td><td style="text-align: right">-</td><td style="text-align: right">-</td><td style="text-align: right">+</td><td></td></tr><tr><td>ventral tegmental area</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="2">-Serotonergic neuron in dorsal</td><td></td><td></td><td></td><td>-–</td><td>Monoamine</td></tr><tr><td>raphe nuclei</td><td></td><td>Aldehyde</td><td></td><td></td><td></td><td>transporter</td></tr><tr><td colspan="2">-Noradrenergic neuron in locus ceruleus</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>MAO-A</td><td>MA</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td colspan="2">Release by reversed action of</td></tr><tr><td></td><td>LSD</td><td></td><td></td><td></td><td colspan="2">monoamine transporter</td></tr><tr><td></td><td></td><td></td><td></td><td>MA</td><td></td><td></td></tr><tr><td></td><td></td><td style="text-align: right">+</td><td>5-HT</td><td>NA</td><td>DA</td><td></td></tr><tr><td></td><td></td><td colspan="3">5-HT receptors and adrenoceptors</td><td colspan="2">Dopamine receptors in nucleus</td></tr><tr><td>MA, monoamine</td><td></td><td colspan="3">in reticular formation, prefrontal cortex</td><td colspan="2">accumbens/prefrontal cortex</td></tr><tr><td>DA, dopamine</td><td></td><td colspan="2">and hypothalamus</td><td></td><td></td><td></td></tr><tr><td>NA, noradrenaline</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>5-HT, 5-hydroxytryptamine</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>MAO-A, monoamineoxidase-A</td><td></td><td colspan="3">Arousal, effects on mood</td><td colspan="2">Reward, pleasure</td></tr></table>
</page>
<page number="457">
<table id="p457t1" data-filename="pdftables_fromstorage_023782248" data-page="457" data-table="1"><tr><td></td><td>Psychotomimetic (hallucinogen) (Similar drug: ketamine)</td><td>Phencyclidine</td></tr><tr><td>Actions</td><td colspan="2">Euphoria, sensory distortion, hallucinations. Schizophrenia-like psychosis. Like ketamine, it produces</td></tr><tr><td></td><td colspan="2">analgesia and amnesia which confers action as a dissociative anaesthetic.</td></tr><tr><td>MOA</td><td colspan="2">Blocks the ion channel of NMDA-type glutamate receptor. How this leads to the behavioural effects</td></tr><tr><td></td><td colspan="2">is not fully established, but effects on dopaminergic transmission are likely. Phencyclidine also blocks</td></tr><tr><td></td><td>σ receptors.</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td colspan="2">Most commonly absorbed by inhalation of smoke but also orally active. T0.5 10–90h.</td></tr><tr><td>Clinical use</td><td colspan="2">Use of phencyclidine as anaesthetic now stopped, though ketamine is still used for this purpose</td></tr><tr><td></td><td>(see card 21.04). Dangerous drug of abuse.</td><td></td></tr><tr><td>Adverse effects</td><td>In overdose: hypertension and seizures.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 47, p 590; D&amp;H 2e Ch 43, p 99</td></tr></table>
</page>
<page number="458">
<table id="p458t1" data-filename="pdftables_fromstorage_023782248" data-page="458" data-table="1"><tr><td></td><td>Lidocaine</td><td></td><td></td><td></td></tr><tr><td style="text-align: right">28.01</td><td>(Lignocaine)</td><td>Local anaesthetics</td><td></td><td></td></tr><tr><td colspan="5">Local anaesthetics may be administered in a variety of ways to reduce the transmission of pain to the CNS.</td></tr><tr><td></td><td></td><td>Nerve</td><td></td><td></td></tr><tr><td></td><td></td><td>block</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Epidural</td><td>Spinal</td></tr><tr><td></td><td></td><td></td><td>anaesthesia</td><td>anaesthesia</td></tr><tr><td></td><td>Infiltration</td><td></td><td></td><td></td></tr><tr><td></td><td>anaesthesia</td><td></td><td></td><td></td></tr><tr><td>Surface</td><td></td><td></td><td></td><td></td></tr><tr><td>anaesthesia</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Sensory</td><td></td><td></td></tr><tr><td></td><td></td><td>nerve</td><td>Arachnoid mater</td><td></td></tr><tr><td></td><td></td><td></td><td>Dura mater</td><td></td></tr><tr><td></td><td></td><td></td><td>Vertebra</td><td></td></tr></table>
</page>
<page number="459">
<table id="p459t1" data-filename="pdftables_fromstorage_023782248" data-page="459" data-table="1"><tr><td></td><td>Local anaesthetic (similar drug: mepivacaine)</td><td colspan="2">Lidocaine</td><td></td></tr><tr><td>Actions</td><td colspan="4">Prevents the propagation of nerve action potentials. Blocks small-diameter pain fibres at lower</td></tr><tr><td></td><td>concentration than large fibres.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">B + H +</td><td>BH+</td></tr><tr><td>MOA</td><td>Use-dependent block of voltage-gated Na+ channels from inside</td><td>out</td><td></td><td></td></tr><tr><td></td><td>of cell membrane. Penetrates cell membrane in its lipid-soluble,</td><td>α</td><td></td><td></td></tr><tr><td></td><td>uncharged form. (See fig.) Less active in inflamed tissue, where</td><td>β</td><td></td><td>β</td></tr><tr><td></td><td>the lower pH increases ionisation of the weakly basic local</td><td></td><td></td><td></td></tr><tr><td></td><td>anaesthetic (LA).</td><td>in</td><td></td><td></td></tr><tr><td></td><td></td><td>B + H+</td><td>BH+</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Topical application (gel, solution, patch) or injection. Penetrates</td><td colspan="3">(B = unionised drug;</td></tr><tr><td></td><td>membranes readily. Lidocaine, like other amide LAs, is metabolised</td><td colspan="3">BH+ = ionised drug)</td></tr><tr><td></td><td>mainly in the liver by P450 system. t1⁄2 2h.</td><td></td><td></td><td></td></tr><tr><td>Clinical use</td><td colspan="4">Surface and infiltration anaesthesia, nerve block (e.g. dentistry) and epidural and spinal anaesthesia</td></tr><tr><td></td><td colspan="4">(sometimes combined with an opioid). Adrenaline may be added to reduce loss to blood stream.</td></tr><tr><td></td><td colspan="4">EMLA (eutectic mixture of LA) is a widely used topical combination of lidocaine with prilocaine.</td></tr><tr><td></td><td>Ventricular dysrhythmia (see card 5.02).</td><td></td><td></td><td></td></tr><tr><td>Adverse effects</td><td colspan="4">Few adverse effects. High plasma concentration may cause seizures and cardiac depression.</td></tr><tr><td></td><td colspan="4">Transient neurologic symptoms are more prevalent with lidocaine than bupivacaine following</td></tr><tr><td></td><td>epidural use.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="3">R&amp;D 7e Ch 42, pp 526-529; D&amp;H 2e Ch 44, p 100</td></tr></table>
</page>
<page number="460">
<table id="p460t1" data-filename="pdftables_fromstorage_023782248" data-page="460" data-table="1"><tr><td style="text-align: right">28.02</td><td>Bupivacaine</td><td>Local anaesthetics</td><td></td><td></td></tr><tr><td colspan="5">Local anaesthetics may be administered in a variety of ways to reduce the transmission of pain to the CNS.</td></tr><tr><td></td><td></td><td></td><td>Lidocaine</td><td></td></tr><tr><td></td><td>Lidocaine</td><td>Lidocaine</td><td>Lidocaine</td><td></td></tr><tr><td></td><td></td><td>Nerve</td><td></td><td></td></tr><tr><td></td><td></td><td>block</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Spinal</td></tr><tr><td></td><td></td><td></td><td>Epidural</td><td>anaesthesia</td></tr><tr><td>Lidocaine, EMLA</td><td>Infiltration</td><td></td><td>anaesthesia</td><td></td></tr><tr><td></td><td>anaesthesia</td><td></td><td></td><td></td></tr><tr><td>Surface</td><td></td><td></td><td></td><td></td></tr><tr><td>anaesthesia</td><td></td><td>Sensory</td><td></td><td></td></tr><tr><td></td><td></td><td>nerve</td><td>Arachnoid mater</td><td></td></tr><tr><td></td><td></td><td></td><td>Dura mater</td><td></td></tr><tr><td></td><td></td><td></td><td>Vertebra</td><td></td></tr></table>
</page>
<page number="461">
<table id="p461t1" data-filename="pdftables_fromstorage_023782248" data-page="461" data-table="1"><tr><td></td><td colspan="2">Local anaesthetic (Similar drug: levobupivacaine, ropivacaine)</td><td colspan="3">Bupivacaine</td><td></td></tr><tr><td>Actions</td><td colspan="6">Prevents the propagation of nerve action potentials. Blocks small-diameter pain fibres at lower</td></tr><tr><td></td><td>concentration than large fibres.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">B + H+</td><td>BH+</td></tr><tr><td></td><td></td><td></td><td>out</td><td></td><td></td><td></td></tr><tr><td>MOA</td><td>Use-dependent block of voltage-gated Na+</td><td>channels from inside</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">of cell membrane. Penetrates cell membrane in its lipid-soluble,</td><td></td><td>β</td><td>α</td><td>β</td></tr><tr><td></td><td colspan="2">uncharged form. (See fig.) Less active in inflamed tissue, where</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">the lower pH increases ionisation of the weakly basic local</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>anaesthetic (LA).</td><td></td><td>in</td><td>B + H+</td><td>BH+</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="3">(B = unionised drug;</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">These drugs are amides metabolised by P450 system in liver,</td><td></td><td colspan="3">BH+ = ionised drug)</td></tr><tr><td></td><td colspan="2">eventually yielding glucuronides. They are longer acting than</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>other LAs. Bupivacaine T0.5 2–3h.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Clinical use</td><td colspan="6">Infiltration, nerve block, epidural, and spinal anaesthesia. Used when longer action is required.</td></tr><tr><td></td><td colspan="4">May be combined with adrenaline to prolong action and fentanyl for epidural use.</td><td></td><td></td></tr><tr><td>Adverse effects</td><td colspan="6">At normal doses few adverse effects. More cardiotoxic than other LAs. (Levobupivacaine and</td></tr><tr><td></td><td>ropivacaine less cardiotoxic.)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="5">R&amp;D 7e Ch 42, pp 526-528; D&amp;H 2e Ch 44, p 100</td></tr></table>
</page>
<page number="462">
<table id="p462t1" data-filename="pdftables_fromstorage_023782248" data-page="462" data-table="1"><tr><td style="text-align: right">28.03</td><td>Procaine</td><td>Local anaesthetics</td><td></td><td></td><td></td></tr><tr><td colspan="6">Local anaesthetics may be administered in a variety of ways to reduce the transmission of pain to the CNS.</td></tr><tr><td></td><td></td><td></td><td></td><td>Lidocaine,</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>bupivacaine,</td><td></td></tr><tr><td></td><td colspan="2">Lidocaine,</td><td>Lidocaine,</td><td>Lidocaine,</td><td></td></tr><tr><td></td><td colspan="2">bupivacaine,</td><td>bupivacaine,</td><td>bupivacaine,</td><td></td></tr><tr><td></td><td colspan="2">ropivacaine</td><td>ropivacaine</td><td>ropivacaine</td><td></td></tr><tr><td></td><td></td><td></td><td>Nerve</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>block</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Spinal</td></tr><tr><td></td><td></td><td></td><td></td><td>Epidural</td><td>anaesthesia</td></tr><tr><td>Lidocaine, EMLA</td><td></td><td>Infiltration</td><td></td><td>anaesthesia</td><td></td></tr><tr><td></td><td></td><td>anaesthesia</td><td></td><td></td><td></td></tr><tr><td>Surface</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>anaesthesia</td><td></td><td></td><td>Sensory</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>nerve</td><td>Arachnoid mater</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Dura mater</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Vertebra</td><td></td></tr></table>
</page>
<page number="463">
<table id="p463t1" data-filename="pdftables_fromstorage_023782248" data-page="463" data-table="1"><tr><td></td><td>Ester-type local anaesthetic (Similar drugs: cocaine, tetracaine)</td><td colspan="2">Procaine</td><td></td></tr><tr><td>Actions</td><td colspan="4">Prevents the propagation of nerve action potentials. Blocks small-diameter pain fibres at lower</td></tr><tr><td></td><td>concentration than large fibres.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">B + H +</td><td>BH+</td></tr><tr><td>MOA</td><td>Use-dependent block of voltage-gated Na+ channels from inside</td><td>out</td><td></td><td></td></tr><tr><td></td><td>of cell membrane. Penetrates cell membrane in its lipid-soluble,</td><td>α</td><td></td><td></td></tr><tr><td></td><td>uncharged form. (See fig.) Less active in inflamed tissue, where</td><td>β</td><td></td><td>β</td></tr><tr><td></td><td>the lower pH increases ionisation of the weakly basic local</td><td></td><td></td><td></td></tr><tr><td></td><td>anaesthetic (LA).</td><td>in</td><td></td><td></td></tr><tr><td></td><td></td><td>B + H+</td><td>BH+</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Ester-type LAs are in general shorter acting than lidocaine or</td><td colspan="3">(B = unionised drug;</td></tr><tr><td></td><td>bupivacaine, being mainly hydrolysed by plasma esterases. (Plasma</td><td colspan="3">BH+ = ionised drug)</td></tr><tr><td></td><td>T 0.5 is only a few minutes, but duration of action is increased due</td><td></td><td></td><td></td></tr><tr><td></td><td>to slower removal from site of injection, especially so for the very lipid-</td><td></td><td></td><td></td></tr><tr><td></td><td>soluble tetracaine.)</td><td></td><td></td><td></td></tr><tr><td>Clinical use</td><td colspan="4">Cocaine’s vasoconstrictor action is useful when applied topically for nose and throat surgery.</td></tr><tr><td></td><td colspan="4">Tetracaine is used mainly for surface (skin, cornea – sometimes combined with lidocaine) and spinal</td></tr><tr><td></td><td>anaesthesia.</td><td></td><td></td><td></td></tr><tr><td>Adverse effects</td><td colspan="4">Cardiac depression. Procaine has more central effects than other LAs and is rarely used. Ester LAs are</td></tr><tr><td></td><td colspan="4">more likely than amides to cause an allergic reaction. Cocaine is a CNS stimulant (see card 27.02).</td></tr><tr><td></td><td colspan="4">R&amp;D 7e Ch 42, pp 526-529; D&amp;H 2e Ch 44, p 100</td></tr></table>
</page>
<page number="464">
<table id="p464t1" data-filename="pdftables_fromstorage_023782248" data-page="464" data-table="1"><tr><td style="text-align: right">28.04</td><td>Benzocaine</td><td>Local anaesthetics</td><td></td><td></td></tr><tr><td colspan="5">Local anaesthetics may be administered in a variety of ways to reduce the transmission of pain to the CNS.</td></tr><tr><td></td><td></td><td></td><td>Lidocaine,</td><td></td></tr><tr><td></td><td></td><td></td><td>bupivacaine,</td><td></td></tr><tr><td></td><td></td><td></td><td>tetracaine</td><td></td></tr><tr><td></td><td>Lidocaine,</td><td>Lidocaine,</td><td>Lidocaine,</td><td></td></tr><tr><td></td><td>bupivacaine,</td><td>bupivacaine,</td><td>bupivacaine,</td><td></td></tr><tr><td></td><td>ropivacaine</td><td>ropivacaine</td><td>ropivacaine</td><td></td></tr><tr><td></td><td></td><td>Nerve</td><td></td><td></td></tr><tr><td></td><td></td><td>block</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Spinal</td></tr><tr><td>Lidocaine, EMLA,</td><td></td><td></td><td>Epidural</td><td>anaesthesia</td></tr><tr><td>tetracaine, cocaine,</td><td>Infiltration</td><td></td><td>anaesthesia</td><td></td></tr><tr><td></td><td>anaesthesia</td><td></td><td></td><td></td></tr><tr><td>Surface</td><td></td><td></td><td></td><td></td></tr><tr><td>anaesthesia</td><td></td><td>Sensory</td><td></td><td></td></tr><tr><td></td><td></td><td>nerve</td><td>Arachnoid mater</td><td></td></tr><tr><td></td><td></td><td></td><td>Dura mater</td><td></td></tr><tr><td></td><td></td><td></td><td>Vertebra</td><td></td></tr></table>
</page>
<page number="465">
<table id="p465t1" data-filename="pdftables_fromstorage_023782248" data-page="465" data-table="1"><tr><td></td><td>Local anaesthetic</td><td>Benzocaine</td><td></td></tr><tr><td>Actions</td><td colspan="3">Prevents the propagation of nerve action potentials. Blocks small-diameter pain fibres at lower</td></tr><tr><td></td><td>concentration than large fibres.</td><td></td><td>Unionised</td></tr><tr><td></td><td></td><td></td><td>benzocaine</td></tr><tr><td></td><td></td><td>out</td><td></td></tr><tr><td>MOA</td><td>Benzocaine (pKa = 2.5) is a much weaker base than most LAs and</td><td>α</td><td></td></tr><tr><td></td><td>is mainly unionised in the body. It is not use-dependent and can</td><td>β</td><td>β</td></tr><tr><td></td><td>gain access to the Na+ channel via the membrane lipid (See fig.).</td><td></td><td></td></tr><tr><td></td><td></td><td>in</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Topical application as gel, ointment or powder (low aqueous solubility).</td><td></td><td></td></tr><tr><td></td><td>High lipid solubility allows rapid penetration of mucous membranes.</td><td></td><td></td></tr><tr><td>Clinical use</td><td colspan="3">Used only for surface anaesthesia (e.g. for placement of nasogastric tubes, pain relief for wounds and</td></tr><tr><td></td><td>burns). Also in throat lozenges.</td><td></td><td></td></tr><tr><td>Adverse effects</td><td>Allergic reactions, but generally safe and available in many OTC preparations.</td><td></td><td></td></tr><tr><td></td><td colspan="3">R&amp;D 7e Ch 42, p 529; D&amp;H 2e Ch 44, p 100</td></tr></table>
</page>
<page number="466">
<table id="p466t1" data-filename="pdftables_fromstorage_023782248" data-page="466" data-table="1"><tr><td style="text-align: right">28.05</td><td>Articaine</td><td>Local anaesthetics</td><td></td><td></td><td></td></tr><tr><td colspan="6">Local anaesthetics may be administered in a variety of ways to reduce the transmission of pain to the CNS.</td></tr><tr><td></td><td></td><td></td><td></td><td>Lidocaine,</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>bupivacaine,</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>tetracaine</td><td></td></tr><tr><td></td><td colspan="2">Lidocaine,</td><td>Lidocaine,</td><td>Lidocaine,</td><td></td></tr><tr><td></td><td colspan="2">bupivacaine,</td><td>bupivacaine,</td><td>bupivacaine,</td><td></td></tr><tr><td></td><td colspan="2">ropivacaine</td><td>ropivacaine</td><td>ropivacaine</td><td></td></tr><tr><td></td><td></td><td></td><td>Nerve</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>block</td><td></td><td></td></tr><tr><td>Lidocaine, EMLA,</td><td></td><td></td><td></td><td></td><td>Spinal</td></tr><tr><td>tetracaine, cocaine,</td><td></td><td></td><td></td><td>Epidural</td><td>anaesthesia</td></tr><tr><td>benzocaine</td><td></td><td>Infiltration</td><td></td><td>anaesthesia</td><td></td></tr><tr><td></td><td></td><td>anaesthesia</td><td></td><td></td><td></td></tr><tr><td>Surface</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>anaesthesia</td><td></td><td></td><td>Sensory</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>nerve</td><td>Arachnoid mater</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Dura mater</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Vertebra</td><td></td></tr></table>
</page>
<page number="467">
<table id="p467t1" data-filename="pdftables_fromstorage_023782248" data-page="467" data-table="1"><tr><td></td><td></td><td>Local anaesthetic</td><td colspan="3">Articaine</td><td></td></tr><tr><td>Actions</td><td colspan="6">Prevents the propagation of nerve action potentials. Blocks small-diameter pain fibres at lower</td></tr><tr><td></td><td>concentration than large fibres.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">B + H +</td><td>BH+</td></tr><tr><td></td><td></td><td>out</td><td></td><td></td><td></td><td></td></tr><tr><td>MOA</td><td>Use-dependent block of voltage-gated Na+ channels from inside</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>of cell membrane. Penetrates cell membrane in its lipid-soluble,</td><td></td><td></td><td>β</td><td>α</td><td>β</td></tr><tr><td></td><td>uncharged form. (See fig.) Less active in inflamed tissue, where</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>the lower pH increases ionisation of the weakly basic local</td><td>in</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>anaesthetic (LA).</td><td></td><td colspan="2">B + H+</td><td>BH+</td><td></td></tr><tr><td></td><td></td><td></td><td colspan="4">(B = unionised drug;</td></tr><tr><td>Abs/Distrb/Elim</td><td>Articaine is an amide-type LA (like lidocaine) but has an additional</td><td></td><td>BH</td><td colspan="3">= ionised drug)</td></tr><tr><td></td><td>ester group which can be rapidly hydrolysed to give a short plasma</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>half-life (30min).</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Clinical use</td><td colspan="6">Articaine, usually combined with epinephrine, is the favoured LA for dentistry in many countries.</td></tr><tr><td>Adverse effects</td><td colspan="6">Low toxicity due to rapid breakdown in blood. Potential paresthesia if used for mandibular nerve</td></tr><tr><td></td><td>block.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="5">R&amp;D 7e Ch 42, pp 527-528; D&amp;H 2e Ch 44, p 100</td></tr></table>
</page>
<page number="468">
<table id="p468t1" data-filename="pdftables_fromstorage_023782248" data-page="468" data-table="1"><tr><td></td><td colspan="3">Benzylpenicillin</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">29.01</td><td colspan="3">(Penicillin G)</td><td colspan="4">Antibacterial agents</td><td></td><td></td><td></td></tr><tr><td colspan="8">Peptidoglycan synthesis and the site of action of drugs</td><td></td><td></td><td></td></tr><tr><td>M</td><td></td><td></td><td colspan="8">Acetylmuramic acid (M), with a side-chain of 5 amino acids, is attached to a large carrier</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="7">lipid by a pyrophosphate bridge (-P-P-) and towed across the membrane</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Interior of bacterium</td></tr><tr><td></td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td><td></td><td></td><td></td><td>Bacterial cell membrane</td></tr><tr><td></td><td></td><td></td><td></td><td>G</td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>P</td><td>P</td><td>Carrier lipid</td></tr><tr><td colspan="4">N-Acetylglucosamine (G)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">is attached as are five</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">glycine residues. This is</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">the basic building block</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">of the peptidoglycan</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">On the outside, this building block is enzymically linked to 'the acceptor' – here shown as a small section</td></tr><tr><td></td><td colspan="10">of the preformed peptidoglycan. There is then cross-linking between the side-chains, the hydrolytic</td></tr><tr><td colspan="11">removal of one of the five amino acids (o) providing the energy. Beta-lactams inhibit this cross-linking.</td></tr></table>
</page>
<page number="469">
<table id="p469t1" data-filename="pdftables_fromstorage_023782248" data-page="469" data-table="1"><tr><td></td><td>A beta-lactam antibacterial agent (Similar agent: phenoxymethylpenicillin)</td><td>Benzylpenicillin</td></tr><tr><td>Actions</td><td>Bactericidal; interferes with cell wall synthesis in dividing bacteria.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Binds to and inhibits the enzyme that cross-links the peptide chain of the newly formed ‘building</td></tr><tr><td></td><td>block’ to the peptidoglycan cell wall backbone.</td><td></td></tr><tr><td>Special points</td><td>Inactivated by bacterial beta-lactamases.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given i.m. or i.v. Passes into all body fluids; crosses the placenta but not the blood-brain barrier</td></tr><tr><td></td><td colspan="2">unless the meninges are inflamed. Excreted in the urine (blocked by probenecid). The less active</td></tr><tr><td></td><td>phenoxymethyl penicillin can be given orally.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Streptococcal, gonococcal, meningococcal infections; also anthrax, dipththeria, gas gangrene.</td></tr><tr><td>Resistance</td><td colspan="2">Staphylococci are generally resistant (mainly because they produce beta-lactamase); some</td></tr><tr><td></td><td colspan="2">pneumococci, meningococci and gonococci have decreased sensitivity.</td></tr><tr><td>Adverse effects</td><td colspan="2">Hypersensitivity reactions (rashes, urticaria, angioedema, fever, arthralgia, anaphylaxis).</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 50, p 627; D&amp;H 2e Ch 47, pp 107-108</td></tr></table>
</page>
<page number="470">
<table id="p470t1" data-filename="pdftables_fromstorage_023782248" data-page="470" data-table="1"><tr><td style="text-align: right">29.02</td><td colspan="3">Flucloxacillin</td><td colspan="3">Antibacterial agents</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">Peptidoglycan synthesis and the site of action of drugs</td><td></td><td></td><td></td></tr><tr><td>M</td><td></td><td></td><td colspan="8">Acetylmuramic acid (M), with a side-chain of 5 amino acids, is attached to a large carrier</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="7">lipid by a pyrophosphate bridge (-P-P-) and towed across the membrane</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Interior of bacterium</td></tr><tr><td></td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td><td></td><td></td><td></td><td>Bacterial cell membrane</td></tr><tr><td></td><td></td><td></td><td></td><td>G</td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>P</td><td>P</td><td>Carrier lipid</td></tr><tr><td colspan="4">N-Acetylglucosamine (G)</td><td></td><td></td><td></td><td></td><td></td><td></td><td>Beta-lactams</td></tr><tr><td colspan="4">is attached as are five</td><td></td><td></td><td></td><td></td><td></td><td></td><td>e.g Penicillin G</td></tr><tr><td colspan="4">glycine residues. This is</td><td></td><td></td><td></td><td></td><td></td><td></td><td>inhibit the formation</td></tr><tr><td colspan="4">the basic building block</td><td></td><td></td><td></td><td></td><td></td><td></td><td>of this link</td></tr><tr><td colspan="4">of the peptidoglycan</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">On the outside, this building block is enzymically linked to 'the acceptor' – here shown as a small section</td></tr><tr><td></td><td colspan="10">of the preformed peptidoglycan. There is then cross-linking between the side-chains, the hydrolytic</td></tr><tr><td colspan="11">removal of one of the five amino acids (o) providing the energy. Beta-lactams inhibit this cross-linking.</td></tr></table>
</page>
<page number="471">
<table id="p471t1" data-filename="pdftables_fromstorage_023782248" data-page="471" data-table="1"><tr><td></td><td>A β-lactamase-resistant penicillin antibacterial agent (Similar drug: temocillin)</td><td>Flucloxacillin</td></tr><tr><td>Actions</td><td>Bactericidal; interferes with cell wall synthesis in dividing bacteria.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Binds to and inhibits the enzyme that cross-links the peptide chain of the newly formed ‘building</td></tr><tr><td></td><td>block’ to the peptidoglycan cell wall backbone.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally, i.m. or i.v. or by slow i.v. infusion. Passes into all body fluids; excreted in the urine</td></tr><tr><td></td><td>(blocked by probenecid).</td><td></td></tr><tr><td>Clinical use</td><td>Penicillin-resistant staphylococci infections.</td><td></td></tr><tr><td>Resistance</td><td colspan="2">Some pneumococci, meningococci and gonococci have decreased sensitivity.</td></tr><tr><td>Adverse effects</td><td colspan="2">Hypersensitivity reactions (rashes, urticaria, angioedema, fever, arthralgia, anaphylaxis); GIT</td></tr><tr><td></td><td>disturbances. Rarely: hepatitis and cholestatic jaundice.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 50, p 627; D&amp;H 2e Ch 47, pp 107-108</td></tr></table>
</page>
<page number="472">
<table id="p472t1" data-filename="pdftables_fromstorage_023782248" data-page="472" data-table="1"><tr><td style="text-align: right">29.03</td><td colspan="3">Amoxicillin</td><td colspan="2">Antibacterial agents</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">Peptidoglycan synthesis and the site of action of drugs</td><td></td><td></td><td></td></tr><tr><td>M</td><td></td><td></td><td colspan="8">Acetylmuramic acid (M), with a side-chain of 5 amino acids, is attached to a large carrier</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="7">lipid by a pyrophosphate bridge (-P-P-) and towed across the membrane</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Interior of bacterium</td></tr><tr><td></td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td><td></td><td></td><td></td><td>Bacterial cell membrane</td></tr><tr><td></td><td></td><td></td><td></td><td>G</td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>P</td><td>P</td><td>Carrier lipid</td></tr><tr><td colspan="4">N-Acetylglucosamine (G)</td><td></td><td></td><td></td><td></td><td></td><td></td><td>Beta-lactams</td></tr><tr><td colspan="4">is attached as are five</td><td></td><td></td><td></td><td></td><td></td><td></td><td>e.g Penicillin G,</td></tr><tr><td colspan="4">glycine residues. This is</td><td></td><td></td><td></td><td></td><td></td><td></td><td>flucloxacillin inhibit</td></tr><tr><td colspan="4">the basic building block</td><td></td><td></td><td></td><td></td><td></td><td></td><td>the formation of this link</td></tr><tr><td colspan="4">of the peptidoglycan</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">On the outside, this building block is enzymically linked to 'the acceptor' – here shown as a small section</td></tr><tr><td></td><td colspan="10">of the preformed peptidoglycan. There is then cross-linking between the side-chains, the hydrolytic</td></tr><tr><td colspan="11">removal of one of the five amino acids (o) providing the energy. Beta-lactams inhibit this cross-linking.</td></tr></table>
</page>
<page number="473">
<table id="p473t1" data-filename="pdftables_fromstorage_023782248" data-page="473" data-table="1"><tr><td></td><td>A broad-spectrum penicillin antibacterial agent (Similar drug: ampicillin)</td><td>Amoxicillin</td></tr><tr><td>Actions</td><td>Bactericidal; interferes with cell wall synthesis in dividing bacteria.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Binds to and inhibits the enzyme that cross-links the peptide chain of the newly formed ‘building</td></tr><tr><td></td><td>blocks’ to the peptidoglycan cell wall backbone.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Inactivated by bacterial β-lactamases; usually given with clavulanic acid which inhibits β-lactamases.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given i.m. or i.v. or by slow i.v. infusion. Passes into all body fluids; excreted in the urine (blocked by</td></tr><tr><td></td><td>probenecid). Ampicillin is given i.v.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Gram-negative bacteria as well as streptococcal, gonococcal, meningococcal infections, anthrax,</td></tr><tr><td></td><td>dipththeria, gas gangrene.</td><td></td></tr><tr><td>Resistance</td><td colspan="2">Not effective against staphylococci (due to β-lactamase) and to streptococci which have impaired</td></tr><tr><td></td><td>β-lactam binding due to mutation of the transpeptidase enzyme.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Hypersensitivity reactions (rashes, urticaria, angioedema, fever, arthralgia, anaphylaxis); GIT</td></tr><tr><td></td><td>disturbances; rarely colitis.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 50, p 627; D&amp;H 2e Ch 47, pp 107-108</td></tr></table>
</page>
<page number="474">
<table id="p474t1" data-filename="pdftables_fromstorage_023782248" data-page="474" data-table="1"><tr><td style="text-align: right">29.04</td><td colspan="3">Piperacillin</td><td colspan="2">Antibacterial agents</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">Peptidoglycan synthesis and the site of action of drugs</td><td></td><td></td><td></td></tr><tr><td>M</td><td></td><td></td><td colspan="8">Acetylmuramic acid (M), with a side-chain of 5 amino acids, is attached to a large carrier</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="7">lipid by a pyrophosphate bridge (-P-P-) and towed across the membrane</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Interior of bacterium</td></tr><tr><td></td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td><td></td><td></td><td></td><td>Bacterial cell membrane</td></tr><tr><td></td><td></td><td></td><td></td><td>G</td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>P</td><td>P</td><td>Carrier lipid</td></tr><tr><td colspan="4">N-Acetylglucosamine (G)</td><td></td><td></td><td></td><td></td><td></td><td></td><td>Beta-lactams</td></tr><tr><td colspan="4">is attached as are five</td><td></td><td></td><td></td><td></td><td></td><td></td><td>e.g Penicillin G,</td></tr><tr><td colspan="4">glycine residues. This is</td><td></td><td></td><td></td><td></td><td></td><td></td><td>flucloxacillin, amoxicillin</td></tr><tr><td colspan="4">the basic building block</td><td></td><td></td><td></td><td></td><td></td><td></td><td>inhibit the formation of this link</td></tr><tr><td colspan="4">of the peptidoglycan</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">On the outside, this building block is enzymically linked to 'the acceptor' – here shown as a small section</td></tr><tr><td></td><td colspan="10">of the preformed peptidoglycan. There is then cross-linking between the side-chains, the hydrolytic</td></tr><tr><td colspan="11">removal of one of the five amino acids (o) providing the energy. Beta-lactams inhibit this cross-linking.</td></tr></table>
</page>
<page number="475">
<table id="p475t1" data-filename="pdftables_fromstorage_023782248" data-page="475" data-table="1"><tr><td></td><td>An antipseudomonal penicillin antibacterial agent (Similar drug: ticarcillin)</td><td>Piperacillin</td></tr><tr><td>Actions</td><td>Bactericidal; interferes with cell wall synthesis in dividing bacteria.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Binds to and inhibits the enzyme that cross-links the peptide chain of the newly formed ‘building</td></tr><tr><td></td><td>blocks’ to the peptidoglycan cell wall backbone.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Inactivated by bacterial β-lactamases; usually given with tazobactam which inhibits β-lactamases.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given by i.v. injection or infusion. Passes into all body fluids; excreted in the urine (blocked by</td></tr><tr><td></td><td>probenecid).</td><td></td></tr><tr><td>Clinical use</td><td>Gram-negative bacterial and Pseudomonas aeruginosa infections.</td><td></td></tr><tr><td>Resistance</td><td colspan="2">Ineffective against staphylococci due to β-lactamase (unless given with the β-lactamase inhibitor</td></tr><tr><td></td><td colspan="2">tazobactam) and to streptococci which have impaired β-lactam binding due to mutation of the</td></tr><tr><td></td><td>transpeptidase enzyme.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Hypersensitivity reactions (rashes, urticaria, angioedema, fever, arthralgia, anaphylaxis); GIT</td></tr><tr><td></td><td>disturbances, pseudomembranous colitis.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 50, p 627; D&amp;H 2e Ch 47, pp 107-108</td></tr></table>
</page>
<page number="476">
<table id="p476t1" data-filename="pdftables_fromstorage_023782248" data-page="476" data-table="1"><tr><td style="text-align: right">29.05</td><td colspan="3">Cefuroxime</td><td colspan="2">Antibacterial agents</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">Peptidoglycan synthesis and the site of action of drugs</td><td></td><td></td><td></td></tr><tr><td>M</td><td></td><td></td><td colspan="8">Acetylmuramic acid (M), with a side-chain of 5 amino acids, is attached to a large carrier</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="7">lipid by a pyrophosphate bridge (-P-P-) and towed across the membrane</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Interior of bacterium</td></tr><tr><td></td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td><td></td><td></td><td></td><td>Bacterial cell membrane</td></tr><tr><td></td><td></td><td></td><td></td><td>G</td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>P</td><td>P</td><td>Carrier lipid</td></tr><tr><td colspan="4">N-Acetylglucosamine (G)</td><td></td><td></td><td></td><td></td><td></td><td></td><td>Beta-lactams</td></tr><tr><td colspan="4">is attached as are five</td><td></td><td></td><td></td><td></td><td></td><td></td><td>e.g Penicillin G, flucloxacillin,</td></tr><tr><td colspan="4">glycine residues. This is</td><td></td><td></td><td></td><td></td><td></td><td></td><td>amoxicillin, piperacillin</td></tr><tr><td colspan="4">the basic building block</td><td></td><td></td><td></td><td></td><td></td><td></td><td>inhibit the formation of this link</td></tr><tr><td colspan="4">of the peptidoglycan</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">On the outside, this building block is enzymically linked to 'the acceptor' – here shown as a small section</td></tr><tr><td></td><td colspan="10">of the preformed peptidoglycan. There is then cross-linking between the side-chains, the hydrolytic</td></tr><tr><td colspan="11">removal of one of the five amino acids (o) providing the energy. Beta-lactams inhibit this cross-linking.</td></tr></table>
</page>
<page number="477">
<table id="p477t1" data-filename="pdftables_fromstorage_023782248" data-page="477" data-table="1"><tr><td></td><td>A second-generation cephalosporin β-lactam antibiotic (Similar drug: cefaclor)</td><td>Cefuroxime</td></tr><tr><td>Actions</td><td>Bactericidal; interferes with cell wall synthesis in dividing bacteria.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Binds to and inhibits the enzyme that cross-links the peptide chain of the newly formed ‘building</td></tr><tr><td></td><td>blocks’ to the peptidoglycan cell wall backbone.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally. i.m. or i.v. Passes into all body fluids; excreted in the urine (blocked by probenecid).</td></tr><tr><td>Clinical use</td><td colspan="2">Active against β-lactamase-producing H. influenzae &amp; N. gonorrhoea. Used to treat sinusitis, ear</td></tr><tr><td></td><td>infections, lower respiratory tract infections, urinary infections.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Hypersensitivity reactions (rashes, urticaria, angioedema, fever, arthralgia, anaphylaxis); GIT</td></tr><tr><td></td><td>disturbances, pseudomembranous colitis; superinfection.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 50, p 627-628; D&amp;H 2e Ch 47, pp 107-108</td></tr></table>
</page>
<page number="478">
<table id="p478t1" data-filename="pdftables_fromstorage_023782248" data-page="478" data-table="1"><tr><td style="text-align: right">29.06</td><td colspan="3">Ceftazidime</td><td colspan="3">Antibacterial agents</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">Peptidoglycan synthesis and the site of action of drugs</td><td></td><td></td><td></td></tr><tr><td>M</td><td></td><td></td><td colspan="8">Acetylmuramic acid (M), with a side-chain of 5 amino acids, is attached to a large carrier</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="7">lipid by a pyrophosphate bridge (-P-P-) and towed across the membrane</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Interior of bacterium</td></tr><tr><td></td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td><td></td><td></td><td></td><td>Bacterial cell membrane</td></tr><tr><td></td><td></td><td></td><td></td><td>G</td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>P</td><td>P</td><td>Carrier lipid</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Beta-lactams</td></tr><tr><td colspan="4">N-Acetylglucosamine (G)</td><td></td><td></td><td></td><td></td><td></td><td></td><td>e.g Penicillin G, flucloxacillin,</td></tr><tr><td colspan="4">is attached as are five</td><td></td><td></td><td></td><td></td><td></td><td></td><td>amoxicillin, piperacillin,</td></tr><tr><td colspan="4">glycine residues. This is</td><td></td><td></td><td></td><td></td><td></td><td></td><td>cefuroxime</td></tr><tr><td colspan="4">the basic building block</td><td></td><td></td><td></td><td></td><td></td><td></td><td>inhibit the formation of this link</td></tr><tr><td colspan="4">of the peptidoglycan</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">On the outside, this building block is enzymically linked to 'the acceptor' – here shown as a small section</td></tr><tr><td></td><td colspan="10">of the preformed peptidoglycan. There is then cross-linking between the side-chains, the hydrolytic</td></tr><tr><td colspan="11">removal of one of the five amino acids (o) providing the energy. Beta-lactams inhibit this cross-linking.</td></tr></table>
</page>
<page number="479">
<table id="p479t1" data-filename="pdftables_fromstorage_023782248" data-page="479" data-table="1"><tr><td></td><td>A third-generation cephalosporin β-lactam antibiotic</td><td>Ceftazidime</td></tr><tr><td>Actions</td><td>Bactericidal; interferes with cell wall synthesis in dividing bacteria.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Binds to and inhibits the enzyme that cross-links the peptide chain of the newly formed ‘building</td></tr><tr><td></td><td>blocks’ to the peptidoglycan cell wall backbone.</td><td></td></tr><tr><td>Resistance</td><td>Susceptible to bacterial β-lactamases.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given by deep i.m. or by i.v. injection or by i.v. infusion. Passes into all body fluids; excreted in the</td></tr><tr><td></td><td>urine (blocked by probenecid). Half-life 1–1.5h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Gram-positive &amp; Gram-negative bacterial and Pseudomonas aeruginosa infections.</td></tr><tr><td>Adverse effects</td><td colspan="2">Hypersensitivity reactions (rashes, urticaria, angioedema, fever, arthralgia, anaphylaxis); GIT</td></tr><tr><td></td><td>disturbances, pseudomembranous colitis; superinfection.</td><td></td></tr><tr><td>Similar drugs</td><td>Ceftriaxone (half-life 7–8h), cefoperazone (half-life 2h).</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 50, p 627-628; D&amp;H 2e Ch 47, pp 107-108</td></tr></table>
</page>
<page number="480">
<table id="p480t1" data-filename="pdftables_fromstorage_023782248" data-page="480" data-table="1"><tr><td style="text-align: right">29.07</td><td colspan="3">Imipenem</td><td colspan="2">Antibacterial agents</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">Peptidoglycan synthesis and the site of action of drugs</td><td></td><td></td><td></td></tr><tr><td>M</td><td></td><td></td><td colspan="8">Acetylmuramic acid (M), with a side-chain of 5 amino acids, is attached to a large carrier</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="7">lipid by a pyrophosphate bridge (-P-P-) and towed across the membrane</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Interior of bacterium</td></tr><tr><td></td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td><td></td><td></td><td></td><td>Bacterial cell membrane</td></tr><tr><td></td><td></td><td></td><td></td><td>G</td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>P</td><td>P</td><td>Carrier lipid</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Beta-lactams</td></tr><tr><td colspan="4">N-Acetylglucosamine (G)</td><td></td><td></td><td></td><td></td><td></td><td></td><td>e.g Penicillin G, flucloxacillin,</td></tr><tr><td colspan="4">is attached as are five</td><td></td><td></td><td></td><td></td><td></td><td></td><td>amoxicillin, piperacillin,</td></tr><tr><td colspan="4">glycine residues. This is</td><td></td><td></td><td></td><td></td><td></td><td></td><td>cefuroxime, ceftazidime</td></tr><tr><td colspan="4">the basic building block</td><td></td><td></td><td></td><td></td><td></td><td></td><td>inhibit the formation of this link</td></tr><tr><td colspan="4">of the peptidoglycan</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">On the outside, this building block is enzymically linked to 'the acceptor' – here shown as a small section</td></tr><tr><td></td><td colspan="10">of the preformed peptidoglycan. There is then cross-linking between the side-chains, the hydrolytic</td></tr><tr><td colspan="11">removal of one of the five amino acids (o) providing the energy. Beta-lactams inhibit this cross-linking.</td></tr></table>
</page>
<page number="481">
<table id="p481t1" data-filename="pdftables_fromstorage_023782248" data-page="481" data-table="1"><tr><td></td><td>A carbapenem β-lactam antibiotic</td><td>Imipenem</td></tr><tr><td>Actions</td><td>Bactericidal; interferes with cell wall synthesis in dividing bacteria.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Binds to and inhibits the enzyme that cross-links the peptide chain of the newly formed ‘building</td></tr><tr><td></td><td>blocks’ to the peptidoglycan cell wall backbone.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given by i.v. infusion. Passes into all body fluids including the CSF. Inactivated by renal enzymes so</td></tr><tr><td></td><td>must be given with cilastatin which inhibits the relevant enzymes.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Broad spectrum: active against Gram-positive, Gram-negative and anaerobic bacteria. Not active</td></tr><tr><td></td><td colspan="2">against MRSA. Used to treat severe polymicrobial hospital-acquired infections, e.g. septicaemia,</td></tr><tr><td></td><td>pneumonia, complicated urinary infections.</td><td></td></tr><tr><td>Adverse effects</td><td>GIT disturbances, rashes, injection site reactions.</td><td></td></tr><tr><td>Similar drugs</td><td>Meropenem.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 50, p 628; D&amp;H 2e Ch 47, pp 107-108</td></tr></table>
</page>
<page number="482">
<table id="p482t1" data-filename="pdftables_fromstorage_023782248" data-page="482" data-table="1"><tr><td style="text-align: right">29.08</td><td colspan="3">Vancomycin</td><td colspan="3">Antibacterial agents</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">Peptidoglycan synthesis and the site of action of drugs</td><td></td><td></td><td></td></tr><tr><td>M</td><td></td><td></td><td colspan="8">Acetylmuramic acid (M), with a side-chain of 5 amino acids, is attached to a large carrier</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="7">lipid by a pyrophosphate bridge (-P-P-) and towed across the membrane</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Interior of bacterium</td></tr><tr><td></td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td><td></td><td></td><td></td><td>Bacterial cell membrane</td></tr><tr><td></td><td></td><td></td><td></td><td>G</td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>P</td><td>P</td><td>Carrier lipid</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Beta-lactams</td></tr><tr><td colspan="4">N-Acetylglucosamine (G)</td><td></td><td></td><td></td><td></td><td></td><td></td><td>e.g Penicillin G, flucloxacillin,</td></tr><tr><td colspan="4">is attached as are five</td><td></td><td></td><td></td><td></td><td></td><td></td><td>amoxicillin, cefuroxime,</td></tr><tr><td colspan="4">glycine residues. This is</td><td></td><td></td><td></td><td></td><td></td><td></td><td>ceftazidime, imipenem</td></tr><tr><td colspan="4">the basic building block</td><td></td><td></td><td></td><td></td><td></td><td></td><td>inhibit the formation of this link</td></tr><tr><td colspan="4">of the peptidoglycan</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">On the outside, this building block is enzymically linked to 'the acceptor' – here shown as a small section</td></tr><tr><td></td><td colspan="10">of the preformed peptidoglycan. There is then cross-linking between the side-chains, the hydrolytic</td></tr><tr><td colspan="11">removal of one of the five amino acids (o) providing the energy. Beta-lactams inhibit this cross-linking.</td></tr></table>
</page>
<page number="483">
<table id="p483t1" data-filename="pdftables_fromstorage_023782248" data-page="483" data-table="1"><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">A glycopeptide antibiotic</td><td>Vancomycin</td></tr><tr><td>M</td><td></td><td></td><td colspan="8">Acetylmuramic acid (M), with a side-chain of 5 amino acids, is attached to a large carrier</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="7">lipid by a pyrophosphate bridge (-P-P-) and towed across the membrane</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Interior of bacterium</td></tr><tr><td></td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td><td></td><td></td><td></td><td>Bacterial cell membrane</td></tr><tr><td></td><td></td><td></td><td></td><td>G</td><td>M</td><td>P</td><td>P</td><td>Carrier lipid</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Building block</td><td></td><td></td><td></td><td></td><td>P</td><td>P</td><td>Carrier lipid</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Vancomycin</td><td></td><td></td><td>Beta-lactams</td></tr><tr><td>Action &amp; MOA</td><td colspan="6">Bactericidal; interferes with cell wall</td><td></td><td></td><td></td><td>e.g Penicillin G, flucloxacillin,</td></tr><tr><td></td><td colspan="5">synthesis in dividing bacteria.</td><td></td><td></td><td></td><td></td><td>amoxicillin, cefuroxime,</td></tr><tr><td>Abs/Distrb/</td><td colspan="5">Given orally for local effect in the</td><td></td><td></td><td></td><td></td><td>ceftazidime, imipenem</td></tr><tr><td>Elim</td><td colspan="6">mouth,otherwise i-v; renal excretion</td><td></td><td></td><td></td><td>inhibit the formation of this link</td></tr><tr><td>Clinical use</td><td colspan="4">MRSA infections, pseudo-</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="3">membranous colitis</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Advers</td><td colspan="6">Reversible hearing loss; rarely: renal</td><td></td><td></td><td></td><td></td></tr><tr><td>effects</td><td colspan="2">failure</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10">On the outside, this building block is enzymically linked to 'the acceptor' – here shown as</td><td></td></tr><tr><td colspan="10">a small section of the preformed peptidoglycan. There is then cross-linking between the</td><td></td></tr><tr><td colspan="10">side-chains, the hydrolytic removal of one of the five amino acids (o) providing the energy.</td><td></td></tr><tr><td colspan="9">Vancomycin inhibits this removal and thus the attachment of the building block.</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>R&amp;D 7e Ch 50, p 628; D&amp;H 2e Ch 47, p 108</td></tr></table>
</page>
<page number="484">
<table id="p484t1" data-filename="pdftables_fromstorage_023782248" data-page="484" data-table="1"><tr><td style="text-align: right">29.09</td><td>Doxycycline</td><td>Antibacterial agents</td><td></td><td></td><td></td></tr><tr><td colspan="5">Bacterial protein synthesis and the antibiotics that act thereon</td><td></td></tr><tr><td></td><td></td><td colspan="3">Anticodon for relevant</td><td></td></tr><tr><td></td><td></td><td colspan="3">amino acid (V)</td><td>V</td></tr><tr><td></td><td></td><td>M</td><td>L</td><td></td><td>tRNA</td></tr><tr><td></td><td></td><td></td><td>T</td><td></td><td></td></tr><tr><td></td><td></td><td>50S subunit</td><td>P</td><td>A</td><td></td></tr><tr><td></td><td></td><td>of ribosome</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Ribosome</td></tr><tr><td></td><td></td><td>Codons</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>} mRNA</td></tr><tr><td></td><td></td><td>30S subunit</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>of ribosome</td><td></td><td></td><td></td></tr><tr><td colspan="6">The ribosome moves along the messenger RNA (mRNA) which has been transcribed from DNA. Codons pass</td></tr><tr><td colspan="6">along the ribosome from the A site to the P site. A transfer RNA (tRNA) with growing peptide chain is in the P site.</td></tr><tr><td colspan="3">The incoming tRNA carries valine (V).</td><td></td><td></td><td></td></tr></table>
</page>
<page number="485">
<table id="p485t1" data-filename="pdftables_fromstorage_023782248" data-page="485" data-table="1"><tr><td></td><td>Broad-spectrum bacteriostatic tetracycline antibiotic</td><td>Doxycycline</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Interferes with bacterial protein synthesis by competing with tRNA for the A site of the</td></tr><tr><td></td><td colspan="2">ribosome and reversibly inhibiting its binding to the mRNA codons in the 30s subunit.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally, absorption impaired by milk and by calcium, magnesium and iron</td></tr><tr><td></td><td>preparations.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">A drug of choice for chlamydial, rickettsial and brucella infections. Effective in infections</td></tr><tr><td></td><td colspan="2">with mycoplasma and Haemophilus influenzae. Used in sinusitis, prostatitis, syphilis, Lyme</td></tr><tr><td></td><td>disease and in treatment/prevention of malaria (see card 31.02).</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Staining of the teeth, GIT disturbances, anorexia, flushing, tinnitus. Rare: hepatotoxicity pancreatitis,</td></tr><tr><td></td><td>hypersensitivity reactions.</td><td></td></tr><tr><td>Similar drug:</td><td>Minocycline (has broader spectrum), demeclocycline.</td><td>R&amp;D 7e Ch 50, p 629; D&amp;H 2e Ch 47, p 110</td></tr></table>
</page>
<page number="486">
<table id="p486t1" data-filename="pdftables_fromstorage_023782248" data-page="486" data-table="1"><tr><td style="text-align: right">29.10</td><td>Gentamicin</td><td>Antibacterial agents</td><td></td><td></td><td></td></tr><tr><td colspan="5">Bacterial protein synthesis and the antibiotics that act thereon</td><td></td></tr><tr><td></td><td colspan="4">Tetracyclines (e.g. doxycycline) compete with tRNA for the</td><td></td></tr><tr><td></td><td colspan="5">A site and prevent binding to the mRNA/ribosome complex</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>V</td></tr><tr><td></td><td></td><td>M</td><td>L</td><td></td><td>tRNA</td></tr><tr><td></td><td></td><td></td><td>T</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>P</td><td>A</td><td>Anticodon for relevant</td></tr><tr><td></td><td></td><td>50S subunit</td><td></td><td></td><td>amino acid (V)</td></tr><tr><td></td><td></td><td>of ribosome</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Codons</td><td></td><td></td><td>Ribosome</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>} mRNA</td></tr><tr><td></td><td></td><td>30S subunit</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>of ribosome</td><td></td><td></td><td></td></tr><tr><td colspan="6">The ribosome moves along the messenger RNA (mRNA) which has been transcribed from DNA. Codons pass</td></tr><tr><td colspan="6">along the ribosome from the A site to the P site. A transfer RNA (tRNA) with growing peptide chain is in the P site.</td></tr><tr><td colspan="3">The incoming tRNA carries valine (V).</td><td></td><td></td><td></td></tr></table>
</page>
<page number="487">
<table id="p487t1" data-filename="pdftables_fromstorage_023782248" data-page="487" data-table="1"><tr><td></td><td></td><td>A bactericidal aminoglycoside antibiotic</td><td>Gentamicin</td></tr><tr><td>Actions</td><td>Inhibits bacterial protein synthesis.</td><td></td><td></td></tr><tr><td>MOA</td><td colspan="3">Causes misreading of the mRNA message due to abnormal codon:anticodon recognition with the</td></tr><tr><td></td><td>production of abnormal proteins.</td><td></td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="3">Given i.m. or by slow i.v. injection or infusion. Can be given intrathecally. Renal excretion.</td></tr><tr><td>Clinical use</td><td colspan="3">Infections with staphylococci (with a β-lactam antibiotic), streptococci, enterococci, Gram-negative</td></tr><tr><td></td><td colspan="3">bacilli (including P. aeruginosa). Used for septicaemia, meningitis, pyelonephritis, endocarditis,</td></tr><tr><td></td><td>pneumonia.</td><td></td><td></td></tr><tr><td>Adverse effects</td><td colspan="3">Dose-related ototoxicity and nephrotoxicity. GIT disturbances, rash, blood disorders can occur;</td></tr><tr><td></td><td colspan="2">↑ototoxicity with loop diuretics;↑ effect of neuromuscular blockers.</td><td></td></tr><tr><td>Special points</td><td>Serum levels should be monitored.</td><td></td><td></td></tr><tr><td>Similar drugs:</td><td>Amikacin, tobramycin.</td><td colspan="2">R&amp;D 7e Ch 50, p 630; D&amp;H 2e Ch 47, pp 108-110</td></tr></table>
</page>
<page number="488">
<table id="p488t1" data-filename="pdftables_fromstorage_023782248" data-page="488" data-table="1"><tr><td style="text-align: right">29.11</td><td>Chloramphenicol</td><td colspan="2">Antibacterial agents</td><td></td><td></td></tr><tr><td colspan="5">Bacterial protein synthesis and the antibiotics that act thereon</td><td></td></tr><tr><td></td><td colspan="4">Tetracyclines (e.g. doxycycline) compete with tRNA for the</td><td></td></tr><tr><td></td><td colspan="5">A site and prevent binding to the mRNA/ribosome complex</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>V</td></tr><tr><td></td><td></td><td>M</td><td>L</td><td></td><td>tRNA</td></tr><tr><td></td><td></td><td></td><td>T</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>P</td><td>A</td><td>Anticodon for relevant</td></tr><tr><td></td><td colspan="2">50S subunit</td><td></td><td></td><td>amino acid (V)</td></tr><tr><td></td><td colspan="2">of ribosome</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Codons</td><td></td><td></td><td>Ribosome</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>} mRNA</td></tr><tr><td></td><td colspan="2">30S subunit</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">of ribosome</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="4">Aminoglycosides (e.g. gentamicin) cause misreading of mRNA</td></tr><tr><td></td><td></td><td colspan="4">message due to abnormal codon: anticodon recognition</td></tr><tr><td colspan="6">The ribosome moves along the messenger RNA (mRNA) which has been transcribed from DNA. Codons pass</td></tr><tr><td colspan="6">along the ribosome from the A site to the P site. A transfer RNA (tRNA) with growing peptide chain is in the P site.</td></tr><tr><td colspan="3">The incoming tRNA carries valine (V).</td><td></td><td></td><td></td></tr></table>
</page>
<page number="489">
<table id="p489t1" data-filename="pdftables_fromstorage_023782248" data-page="489" data-table="1"><tr><td></td><td>Broad-spectrum antibiotic</td><td>Chloramphenicol</td></tr><tr><td>Actions</td><td>Inhibits bacterial protein synthesis.</td><td></td></tr><tr><td>MOA</td><td>Inhibits transpeptidation.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally or by i.v. injection or infusion; enters CSF and CNS; inactivated in the liver; excreted in</td></tr><tr><td></td><td>the urine.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Used mainly for life-threatening H. influenzae infections, for meningitis resistant to penicillin and for</td></tr><tr><td></td><td>typhoid. Used topically for bacterial eye infections.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Dose-related bone marrow depression. ‘Grey baby’ syndrome in neonates who lack the relevant</td></tr><tr><td></td><td colspan="2">inactivating enzyme: circulatory collapse, flaccidity, vomiting. Aplastic anaemia in a few genetically</td></tr><tr><td></td><td>predisposed individuals.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 50, p 630; D&amp;H 2e Ch 47, p 110</td></tr></table>
</page>
<page number="490">
<table id="p490t1" data-filename="pdftables_fromstorage_023782248" data-page="490" data-table="1"><tr><td style="text-align: right">29.12</td><td colspan="2">Erythromycin</td><td>Antibacterial agents</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">Bacterial protein synthesis and the antibiotics that act thereon</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="3">Tetracyclines (e.g. doxycycline)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="3">compete with tRNA for the A</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="3">site and prevent binding</td><td></td><td></td><td colspan="2">Chloramphenicol</td></tr><tr><td></td><td colspan="3">to the mRNA/ribosome complex</td><td></td><td></td><td></td><td>inhibits</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">transpeptidation</td></tr><tr><td></td><td></td><td></td><td>V</td><td></td><td></td><td></td><td></td></tr><tr><td>A transfer</td><td>M</td><td>L</td><td></td><td>Transpeptidation</td><td></td><td></td><td></td></tr><tr><td>RNA with</td><td></td><td>T</td><td>tRNA</td><td>occurs, linking</td><td></td><td></td><td></td></tr><tr><td>growing</td><td></td><td></td><td>A</td><td>the peptide chain</td><td>M</td><td>L</td><td></td></tr><tr><td></td><td></td><td>P</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>peptide</td><td></td><td></td><td></td><td>on the tRNA at</td><td></td><td>T</td><td>V</td></tr><tr><td>chain is in</td><td></td><td></td><td></td><td>the P site to the</td><td></td><td></td><td></td></tr><tr><td>the P site.</td><td></td><td></td><td></td><td>amino acid on the</td><td></td><td></td><td></td></tr><tr><td>The Incoming</td><td></td><td></td><td></td><td>incoming tRNA at</td><td></td><td></td><td></td></tr><tr><td>tRNA carries</td><td></td><td></td><td></td><td>the A site</td><td></td><td></td><td></td></tr><tr><td>valine (V).</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Aminoglycosides (e.g. gentamicin)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">cause misreading of message due to</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">abnormal codon: anticodon recognition</td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="491">
<table id="p491t1" data-filename="pdftables_fromstorage_023782248" data-page="491" data-table="1"><tr><td></td><td>A macrolide antibiotic</td><td>Erythromycin</td></tr><tr><td>Actions</td><td>Inhibits bacterial protein synthesis.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits the translocation of the transfer RNA (with its attached peptide) from the A site to</td></tr><tr><td></td><td>the P site.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally or by i.v. infusion. Half-life 1.5h. Distributed widely but doesn’t enter brain or CSF.</td></tr><tr><td>Clinical use</td><td colspan="2">For pneumococcal &amp; streptococcal infections in patients allergic to penicillin. For chlamydial and</td></tr><tr><td></td><td colspan="2">mycoplasma infections. For infections of the skin and the respiratory tract; for syphilis, diptheria,</td></tr><tr><td></td><td>prostatitis, whooping cough, campylobacter enteritis.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances. Less frequent: allergic reactions, cholestatic jaundice.</td></tr><tr><td>Similar drugs</td><td>Clarithromycin and azithromycin.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 50, p 631; D&amp;H 2e Ch 47, pp 108-110</td></tr></table>
</page>
<page number="492">
<table id="p492t1" data-filename="pdftables_fromstorage_023782248" data-page="492" data-table="1"><tr><td style="text-align: right">29.13</td><td colspan="3">Clindamycin</td><td colspan="4">Antibacterial agents</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">Bacterial protein synthesis and the antibiotics that act thereon</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">Tetracyclines (e.g. doxycycline) compete with tRNA for the</td><td></td><td></td><td></td><td>Macrolides (e.g.</td></tr><tr><td colspan="8">A site and prevent binding to the mRNA/ribosome complex</td><td></td><td></td><td></td><td>erythromycin)</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>inhibit</td></tr><tr><td>A transfer</td><td></td><td></td><td></td><td>V</td><td></td><td></td><td></td><td></td><td></td><td></td><td>translocation</td></tr><tr><td>M</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>RNA with</td><td>L</td><td>T</td><td></td><td></td><td></td><td></td><td></td><td>The tRNA denuded of</td><td></td><td></td><td></td></tr><tr><td>growing</td><td></td><td></td><td></td><td colspan="2">tRNA</td><td></td><td></td><td>its peptide chain is</td><td></td><td></td><td></td></tr><tr><td>peptide</td><td></td><td>P</td><td>A</td><td></td><td></td><td></td><td></td><td>ejected and the tRNA</td><td></td><td></td><td></td></tr><tr><td>chain is in</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>(with peptide attached)</td><td></td><td></td><td></td></tr><tr><td>the P site.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>in the A site is</td><td></td><td></td><td></td></tr><tr><td>The Incoming</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>translocated to the P</td><td>M</td><td>L</td><td>T</td></tr><tr><td>tRNA carries</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">site. The ribosome then</td><td></td><td>V</td></tr><tr><td>valine (V).</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>moves on one codon</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>on the mRNA.</td><td></td><td></td><td></td></tr><tr><td colspan="8">Aminoglycosides (e.g. gentamicin) cause misreading of</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">message due to abnormal codon: anticodon recognition</td><td>A new tRNA with</td><td></td><td></td><td></td></tr><tr><td colspan="4">Transpeptidation</td><td></td><td></td><td></td><td>Chloramphenicol</td><td>attached amino acid</td><td></td><td></td><td></td></tr><tr><td colspan="4">occurs, linking</td><td>M</td><td>L</td><td>T</td><td>inhibits</td><td>can now move into the</td><td></td><td></td><td></td></tr><tr><td colspan="4">the peptide chain</td><td></td><td></td><td>V</td><td>transpeptidation</td><td>A site.</td><td></td><td></td><td></td></tr><tr><td colspan="4">on the tRNA at</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">the P site to the</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">amino acid on the</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">incoming tRNA at</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">the A site</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="493">
<table id="p493t1" data-filename="pdftables_fromstorage_023782248" data-page="493" data-table="1"><tr><td></td><td>A lincosamide antibiotic</td><td>Clindamycin</td></tr><tr><td>Actions</td><td>Inhibits bacterial protein synthesis.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits the translocation of the transfer RNA (with its attached peptide) from the A site to</td></tr><tr><td></td><td>the P site.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally or by deep i.m. injection or by i.v. infusion. Half-life 2.5h. Distributed widely, entering</td></tr><tr><td></td><td colspan="2">abscesses but doesn’t penetrate brain or CSF. Is concentrated in bone. Metabolised in liver to give</td></tr><tr><td></td><td>active metabolite, excreted in urine.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Effective against streptococci, penicillin-resistant staphylococci and many anaerobes (except</td></tr><tr><td></td><td colspan="2">Clostridium difficile). Used for lung abscesses, and for bone, joint, skin and soft tissue infections.</td></tr><tr><td colspan="2">Adverse effects GIT disturbances, skin rashes, jaundice, pseudomembranous colitis.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 50, p 633; D&amp;H 2e Ch 47, p 110</td></tr></table>
</page>
<page number="494">
<table id="p494t1" data-filename="pdftables_fromstorage_023782248" data-page="494" data-table="1"><tr><td></td><td colspan="4">Quinupristin +</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">29.14</td><td colspan="3">dalfopristin</td><td></td><td colspan="3">Antibacterial agents</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">Bacterial protein synthesis and the antibiotics that act thereon</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">Tetracyclines (e.g. doxycycline) compete with tRNA for the</td><td></td><td></td><td></td><td>Clindamycin</td></tr><tr><td colspan="8">A site and prevent binding to the mRNA/ribosome complex</td><td></td><td></td><td></td><td>and erythromycin</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>inhibit</td></tr><tr><td>A transfer</td><td></td><td></td><td></td><td>V</td><td></td><td></td><td></td><td></td><td></td><td></td><td>translocation</td></tr><tr><td>M</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>L</td><td>T</td><td></td><td></td><td></td><td></td><td></td><td>The tRNA denuded of</td><td></td><td></td><td></td></tr><tr><td>RNA with</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">tRNA</td><td></td><td></td><td>its peptide chain is</td><td></td><td></td><td></td></tr><tr><td>growing</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>P</td><td>A</td><td></td><td></td><td></td><td></td><td>ejected and the tRNA</td><td></td><td></td><td></td></tr><tr><td>peptide</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>(with peptide attached)</td><td></td><td></td><td></td></tr><tr><td>chain is in</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>in the A site is</td><td></td><td></td><td></td></tr><tr><td>the P site.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>translocated to the P</td><td>M</td><td>L</td><td>T</td></tr><tr><td>The Incoming</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">site. The ribosome then</td><td></td><td>V</td></tr><tr><td>tRNA carries</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>moves on one codon</td><td></td><td></td><td></td></tr><tr><td>valine (V).</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>on the mRNA.</td><td></td><td></td><td></td></tr><tr><td colspan="8">Aminoglycosides (e.g. gentamicin) cause misreading of</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">message due to abnormal codon: anticodon recognition</td><td>A new tRNA with</td><td></td><td></td><td></td></tr><tr><td colspan="4">Transpeptidation</td><td></td><td></td><td></td><td>Chloramphenicol</td><td>attached amino acid</td><td></td><td></td><td></td></tr><tr><td colspan="4">occurs, linking</td><td>M</td><td>L</td><td>T</td><td>inhibits</td><td>can now move into the</td><td></td><td></td><td></td></tr><tr><td colspan="4">the peptide chain</td><td></td><td></td><td>V</td><td>transpeptidation</td><td>A site.</td><td></td><td></td><td></td></tr><tr><td colspan="4">on the tRNA at</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">the P site to the</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">amino acid on the</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">incoming tRNA at</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="4">the A site</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="495">
<table id="p495t1" data-filename="pdftables_fromstorage_023782248" data-page="495" data-table="1"><tr><td></td><td></td><td colspan="3">Quinupristin +</td><td></td></tr><tr><td></td><td>Streptogramin antibiotics</td><td></td><td colspan="2">dalfopristin</td><td></td></tr><tr><td>Actions</td><td>Inhibit bacterial protein synthesis by disrupting the</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>translation of mRNA into protein.</td><td colspan="4">Tetracyclines (e.g. doxycycline)</td></tr><tr><td></td><td></td><td colspan="4">compete with tRNA for the A</td></tr><tr><td>MOA</td><td>Dalfopristin inhibits the binding of the aa-tRNA to the</td><td colspan="4">site and prevent binding</td></tr><tr><td></td><td>ribosome and the formation of the peptide</td><td colspan="4">to the mRNA/ribosome complex</td></tr><tr><td></td><td>bonds; quinupristin causes dissociation of the</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>peptidyl-tRNA.</td><td></td><td></td><td></td><td>V</td></tr><tr><td></td><td></td><td>A transfer</td><td>M</td><td>L</td><td></td></tr><tr><td>Abs/Distrib/Elim</td><td>Given by i.v. infusion, metabolised in the liver; T0.51–3h.</td><td>RNA with</td><td></td><td>T</td><td>tRNA</td></tr><tr><td></td><td></td><td>growing</td><td></td><td></td><td></td></tr><tr><td>Clinical use</td><td>Serious Gram-positive infections unresponsive to other</td><td>peptide</td><td></td><td>P</td><td>A</td></tr><tr><td></td><td>antibacterials, e.g. MRSA, infections of the skin &amp; soft</td><td>chain is in</td><td></td><td></td><td></td></tr><tr><td></td><td>tissues, hospital-acquired pneumonia, vancomycin-</td><td>the P site.</td><td></td><td></td><td></td></tr><tr><td></td><td>resistant Enterococcus faecium.</td><td colspan="2">The Incoming</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">tRNA carries</td><td></td><td></td></tr><tr><td>Adverse effects</td><td>GIT disturbances, headache, joint and muscle pain,</td><td>valine (V).</td><td></td><td></td><td></td></tr><tr><td></td><td>rash, pruritis, infusion site reactions, anaemia,</td><td></td><td></td><td></td><td>Quinupristin</td></tr><tr><td></td><td>leucopenia.</td><td></td><td></td><td></td><td>+ dalfopristin</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">interfere with tRNA</td></tr><tr><td>Special points</td><td>Inhibits the metabolism and thus increases action</td><td></td><td></td><td colspan="2">binding and peptide</td></tr><tr><td></td><td>of ciclosporin, midazolam, nifedipine,</td><td></td><td></td><td colspan="2">bond formation</td></tr><tr><td></td><td>antidysrhythmics (lidocaine, disopyramide).</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>R&amp;D 7e Ch 50, p 633</td></tr></table>
</page>
<page number="496">
<table id="p496t1" data-filename="pdftables_fromstorage_023782248" data-page="496" data-table="1"><tr><td style="text-align: right">29.15</td><td>Ciprofloxacin</td><td>Antibacterial agents</td><td></td></tr><tr><td colspan="2">The bacterial chromosome</td><td></td><td>Folate metabolism</td></tr><tr><td colspan="2">Cell wall</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>PABA</td></tr><tr><td></td><td></td><td>Portion of the</td><td></td></tr><tr><td></td><td></td><td>chromosomal</td><td></td></tr><tr><td></td><td></td><td>double helix</td><td>Dihydropteroate</td></tr><tr><td></td><td></td><td></td><td>synthetase</td></tr><tr><td colspan="2">Chromosome</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Folate</td></tr><tr><td colspan="2">Chromosome</td><td></td><td></td></tr><tr><td colspan="2">folded round</td><td>RNA core</td><td></td></tr><tr><td>RNA core</td><td></td><td></td><td>Dihydrofolate</td></tr><tr><td></td><td></td><td></td><td>reductase</td></tr><tr><td></td><td>DNA gyrase</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Tetrahydrofolate</td></tr><tr><td></td><td></td><td>Portion of the</td><td></td></tr><tr><td></td><td></td><td>double helix in</td><td></td></tr><tr><td></td><td>RNA core</td><td>supercoiled</td><td>Synthesis of</td></tr><tr><td></td><td></td><td>form</td><td>thymidylate etc.</td></tr><tr><td></td><td></td><td></td><td>DNA</td></tr></table>
</page>
<page number="497">
<table id="p497t1" data-filename="pdftables_fromstorage_023782248" data-page="497" data-table="1"><tr><td></td><td>Bactericidal fluoroquinolone</td><td>Ciprofloxacin</td></tr><tr><td>Actions</td><td>Interferes with bacterial DNA function.</td><td></td></tr><tr><td colspan="3">MOA Inhibits DNA gyrase (aka topoisomerase II) – the enzyme that produces the supercoil in the</td></tr><tr><td></td><td>chromosome that is essential for transcription and replication.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally or by i.v. infusion. Not absorbed from GIT in the presence of magnesium or aluminium</td></tr><tr><td></td><td colspan="2">salts. Accumulates in the kidney, prostate and lung and concentrates in phagocytes. Partly</td></tr><tr><td></td><td>metabolised in the liver and partly excreted in urine.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Active against Gram-positive organisms; particularly effective against Gram-negative bacteria. Used</td></tr><tr><td></td><td colspan="2">for infections of the urinary tract, the GIT and bones &amp; joints; for respiratory tract infections not</td></tr><tr><td></td><td colspan="2">caused by pneumococci; for gonorrhoea and septicaemia caused by sensitive organisms.</td></tr><tr><td>Adverse effects</td><td colspan="2">GIT upsets, headache, dizziness, rashes. Rare: tendon damage, CNS effects (seizures, insomnia) due</td></tr><tr><td></td><td>to competition with GABA binding to its receptors.</td><td></td></tr><tr><td>Similar drugs:</td><td>Norfloxacin, levofloxacin.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 50, p 632; D&amp;H 2e Ch 47, p 110</td></tr></table>
</page>
<page number="498">
<table id="p498t1" data-filename="pdftables_fromstorage_023782248" data-page="498" data-table="1"><tr><td style="text-align: right">29.16</td><td>Co-trimoxazole</td><td colspan="2">Antibacterial agents</td><td></td></tr><tr><td colspan="2">The bacterial chromosome</td><td></td><td></td><td>Folate metabolism</td></tr><tr><td colspan="2">Cell wall</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>PABA</td></tr><tr><td></td><td></td><td></td><td>Portion of the</td><td></td></tr><tr><td></td><td></td><td></td><td>chromosomal</td><td></td></tr><tr><td></td><td></td><td></td><td>double helix</td><td>Dihydropteroate</td></tr><tr><td></td><td></td><td></td><td></td><td>synthetase</td></tr><tr><td colspan="2">Chromosome</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Folate</td></tr><tr><td colspan="2">Chromosome</td><td></td><td></td><td></td></tr><tr><td colspan="2">folded round</td><td></td><td>RNA core</td><td></td></tr><tr><td>RNA core</td><td></td><td></td><td></td><td>Dihydrofolate</td></tr><tr><td></td><td></td><td></td><td></td><td>reductase</td></tr><tr><td></td><td>DNA gyrase</td><td>-–</td><td>Ciprofloxacin</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Tetrahydrofolate</td></tr><tr><td></td><td></td><td></td><td>Portion of the</td><td></td></tr><tr><td></td><td></td><td></td><td>double helix in</td><td></td></tr><tr><td></td><td>RNA core</td><td></td><td>supercoiled</td><td>Synthesis of</td></tr><tr><td></td><td></td><td></td><td>form</td><td>thymidylate etc.</td></tr><tr><td></td><td></td><td></td><td></td><td>DNA</td></tr></table>
</page>
<page number="499">
<table id="p499t1" data-filename="pdftables_fromstorage_023782248" data-page="499" data-table="1"><tr><td></td><td>Bacteriostatic antibacterial agent consisting of sulfamethoxazole + trimethoprim</td><td colspan="2">Co-trimoxazole</td></tr><tr><td>Actions</td><td colspan="3">Both sulfamethoxazole and trimethoprim interfere with bacterial folate metabolism and thus with</td></tr><tr><td></td><td>DNA synthesis.</td><td>Folate metabolism</td><td></td></tr><tr><td>MOA</td><td>Sulfamethoxazole competitively inhibits the enzyme</td><td>PABA</td><td></td></tr><tr><td></td><td>dihydropteroate synthetase. Trimethoprim inhibits</td><td></td><td></td></tr><tr><td></td><td>dihydrofolate reductase and thus the conversion of</td><td>Dihydropteroate</td><td>-–</td></tr><tr><td></td><td>folate to tetrahydrofolate.</td><td>synthetase</td><td></td></tr><tr><td></td><td></td><td>Folate</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally or by i.v. infusion. Sulfa drugs pass into</td><td></td><td></td></tr><tr><td></td><td>inflammatory exudates, but are inactive in the</td><td></td><td></td></tr><tr><td></td><td>presence of pus.</td><td>Dihydrofolate</td><td>-–</td></tr><tr><td></td><td></td><td>reductase</td><td></td></tr><tr><td>Clinical use</td><td>Pneumocystis pneumonia, toxoplasmosis and</td><td></td><td></td></tr><tr><td></td><td>nocardiasis, urinary infections, acute exacerbations</td><td colspan="2">Tetrahydrofolate</td></tr><tr><td></td><td>of chronic bronchitis. Trimethoprim alone used for</td><td></td><td></td></tr><tr><td></td><td>prostatitis, and for urinary and respiratory infections .</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Synthesis of thymidylate etc.</td></tr><tr><td>Adverse effects</td><td>GIT upsets, rashes. Very rare but serious:</td><td></td><td></td></tr><tr><td></td><td>Stevens-Johnson syndrome, blood dyscrasias,</td><td></td><td></td></tr><tr><td></td><td>toxic epidermal necrolysis, photosensitivity.</td><td colspan="2">R&amp;D 7e Ch 50, pp 625-626; D&amp;H 2e Ch 47, p 111</td></tr></table>
</page>
<page number="500">
<table id="p500t1" data-filename="pdftables_fromstorage_023782248" data-page="500" data-table="1"><tr><td style="text-align: right">29.17</td><td>Isoniazid</td><td>Antibacterial agents</td></tr><tr><td></td><td colspan="2">Regimen of directly observed treatment (DOT) for tuberculosis</td></tr><tr><td></td><td></td><td>Drug 1 given for 2-month initial and 4-month continuation therapy .</td></tr><tr><td></td><td></td><td>Drug 2 given for 2-month initial and 4-month continuation therapy.</td></tr><tr><td></td><td></td><td>Drug 3 given for 2-month initial phase only.</td></tr><tr><td></td><td></td><td>Drug 4 given for 2-month initial phase only.</td></tr><tr><td></td><td colspan="2">Different countries may have different regimens.</td></tr></table>
</page>
<page number="501">
<table id="p501t1" data-filename="pdftables_fromstorage_023782248" data-page="501" data-table="1"><tr><td></td><td>A nicotinic acid derivative that is an antituberculosis drug</td><td>Isoniazid</td></tr><tr><td>Actions</td><td colspan="2">Bacteriostatic for resting mycobacteria, bactericidal for proliferating mycobacteria.</td></tr><tr><td>MOA</td><td colspan="2">Disrupts the synthesis of mycolic acids – major components of mycobacterial cell walls.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally, well absorbed. Passes into CSF and tuberculous lesions. Enters cells and is taken up by</td></tr><tr><td></td><td colspan="2">tubercle bacilli. Acetylated in liver – slowly by some individuals (genetically ‘slow metabolisers’),</td></tr><tr><td></td><td>fast by others who thus respond less efficiently to the drug.</td><td></td></tr><tr><td>Clinical use</td><td>Tuberculosis.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances, hypersensitivity reactions, peripheral neuritis (with high doses, pyridoxine</td></tr><tr><td></td><td>prophylaxis required).</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 50, p 634; D&amp;H 2e Ch 47, p 111-112</td></tr></table>
</page>
<page number="502">
<table id="p502t1" data-filename="pdftables_fromstorage_023782248" data-page="502" data-table="1"><tr><td style="text-align: right">29.18</td><td>Rifampicin</td><td>Antibacterial agents</td></tr><tr><td></td><td colspan="2">Regimen of directly observed treatment (DOT) for tuberculosis</td></tr><tr><td></td><td></td><td>Drug 1 given for 2-month initial and 4-month continuation therapy.</td></tr><tr><td></td><td></td><td>Isoniazid</td></tr><tr><td></td><td></td><td>Drug 2 given for 2-month initial and 4-month continuation therapy.</td></tr><tr><td></td><td></td><td>Drug 3 given for 2-month initial phase only.</td></tr><tr><td></td><td></td><td>Drug 4 given for 2-month initial phase only.</td></tr><tr><td></td><td colspan="2">Different countries may have different regimens.</td></tr></table>
</page>
<page number="503">
<table id="p503t1" data-filename="pdftables_fromstorage_023782248" data-page="503" data-table="1"><tr><td></td><td>An antituberculosis drug</td><td>Rifampicin</td></tr><tr><td>Actions</td><td colspan="2">Bactericidal for mycobacteria; also effective against most Gram-positive and many Gram-negative</td></tr><tr><td></td><td>bacteria.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits bacterial but not human DNA-dependent RNA polymerase leading to reduced RNA</td></tr><tr><td></td><td>synthesis in the bacterial cell.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally, widely distributed excreted in urine and bile.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Tuberculosis (in combination with other drugs). Leprosy. Prophylaxis for meningococcal meningitis,</td></tr><tr><td></td><td colspan="2">and Haemophilus influenzae. Also used (combined with other drugs) for brucellosis, endocarditis,</td></tr><tr><td></td><td>legionnaires’ disease, serious staphylococcal infections.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances, hepatitis, rash, harmless orange tint to saliva, sweat &amp; tears. If treatment is</td></tr><tr><td></td><td colspan="2">intermittent patients can develop influenza-like and respiratory symptoms, shock, renal problems</td></tr><tr><td></td><td>and thrombocytopenic purpura.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Induction of metabolising enzymes results in decreased action of anticoagulants, narcotic analgesics,</td></tr><tr><td></td><td>phenytoin, glucocorticoids, oral contraceptives.</td><td>R&amp;D 7e Ch 50, p 634; D&amp;H 2e Ch 47, p 112</td></tr></table>
</page>
<page number="504">
<table id="p504t1" data-filename="pdftables_fromstorage_023782248" data-page="504" data-table="1"><tr><td style="text-align: right">29.19</td><td>Pyrazinamide</td><td>Antibacterial agents</td></tr><tr><td></td><td colspan="2">Regimen of directly observed treatment (DOT) for tuberculosis</td></tr><tr><td></td><td></td><td>Drug 1 given for 2-month initial and 4-month continuation therapy.</td></tr><tr><td></td><td></td><td>Isoniazid</td></tr><tr><td></td><td></td><td>Drug 2 given for 2-month initial and 4-month continuation therapy.</td></tr><tr><td></td><td></td><td>Rifampicin</td></tr><tr><td></td><td></td><td>Drug 3 given for 2-month initial phase only.</td></tr><tr><td></td><td></td><td>Drug 4 given for 2-month initial phase only.</td></tr><tr><td></td><td colspan="2">Different countries may have different regimens.</td></tr></table>
</page>
<page number="505">
<table id="p505t1" data-filename="pdftables_fromstorage_023782248" data-page="505" data-table="1"><tr><td></td><td>An antituberculosis drug</td><td>Pyrazinamide</td></tr><tr><td>Actions</td><td colspan="2">Bactericidal for actively dividing intracellular mycobacteria. Main effects occur in first few months.</td></tr><tr><td>MOA</td><td colspan="2">Is converted to pyrazinoic acid which disrupts membrane energetics and inhibits membrane</td></tr><tr><td></td><td>transport function in Mycobacterium tuberculosis.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally, widely distributed, crosses into the CSF, excreted in urine.</td></tr><tr><td>Clinical use</td><td colspan="2">Tuberculosis (in combination with other drugs). Tuberculous meningitis.</td></tr><tr><td>Adverse effects</td><td colspan="2">Joint pains, GIT disturbances, sideroblastic anemia, rash; sometimes serious hepatotoxicity.</td></tr><tr><td>Special points</td><td colspan="2">Induction of metabolising enzymes results in decreased action of anticoagulants, narcotic analgesics,</td></tr><tr><td></td><td>phenytoin, glucocorticoids, oral contraceptives.</td><td>R&amp;D 7e Ch 50, p 635; D&amp;H 2e Ch 47, pp 111-112</td></tr></table>
</page>
<page number="506">
<table id="p506t1" data-filename="pdftables_fromstorage_023782248" data-page="506" data-table="1"><tr><td style="text-align: right">29.20</td><td>Ethambutol</td><td>Antibacterial agents</td></tr><tr><td></td><td colspan="2">Regimen of directly observed treatment (DOT) for tuberculosis</td></tr><tr><td></td><td></td><td>Drug 1 given for 2-month initial and 4-month continuation therapy.</td></tr><tr><td></td><td></td><td>Isoniazid</td></tr><tr><td></td><td></td><td>Drug 2 given for 2-month initial and 4-month continuation therapy.</td></tr><tr><td></td><td></td><td>Rifampicin</td></tr><tr><td></td><td></td><td>Drug 3 given for 2-month initial phase only.</td></tr><tr><td></td><td></td><td>Pyrazinamide</td></tr><tr><td></td><td></td><td>Drug 4 given for 2-month initial phase only.</td></tr><tr><td></td><td colspan="2">Different countries may have different regimens.</td></tr></table>
</page>
<page number="507">
<table id="p507t1" data-filename="pdftables_fromstorage_023782248" data-page="507" data-table="1"><tr><td></td><td>An antituberculosis drug</td><td>Ethambutol</td></tr><tr><td>Actions</td><td>Bacteriostatic for rapidly growing TB bacilli.</td><td></td></tr><tr><td>MOA</td><td>It obstructs the formation of the cell wall in dividing TB bacilli.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally; can cross into the CSF; some is metabolised, some is excreted in the urine.</td></tr><tr><td>Clinical use</td><td>Tuberculosis (in combination with other drugs).</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Visual disturbances (e.g. colour blindness, loss of acuity), peripheral neuritis, rash, fever.</td></tr><tr><td>Regimen of directly observed treatment (DOT) for tuberculosis</td><td></td><td></td></tr><tr><td colspan="3">Drug 1 given for 2-month initial and 4-month continuation therapy: Isoniazid</td></tr><tr><td colspan="3">Drug 2 given for 2-month initial and 4-month continuation therapy: Rifampicin</td></tr><tr><td>Drug 3 given for 2-month initial phase only: Pyrazinamide</td><td></td><td></td></tr><tr><td>Drug 4 given for 2-month initial phase only: Ethambutol</td><td></td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 50, p 635; D&amp;H 2e Ch 47, pp 111-112</td></tr></table>
</page>
<page number="508">
<table id="p508t1" data-filename="pdftables_fromstorage_023782248" data-page="508" data-table="1"><tr><td style="text-align: right">30.01</td><td>Zidovudine</td><td>Antiviral agents</td><td></td><td></td></tr><tr><td colspan="4">A schematic diagram of virus infection of a mammalian cell</td><td></td></tr><tr><td></td><td></td><td></td><td>CMV = Cytomegalovirus</td><td>HIV = Human immunodeficiency virus</td></tr><tr><td></td><td></td><td></td><td>HBV = Hepatitis B virus</td><td>HV = Herpes viruses</td></tr><tr><td></td><td></td><td>2. Entry</td><td>HCV = Hepatitis C virus</td><td>RSV = Respiratory syncytial virus</td></tr><tr><td></td><td></td><td>and ...</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>4. Transfer of viral</td><td></td></tr><tr><td></td><td></td><td>3.Uncoating</td><td>DNA to nucleus</td><td></td></tr><tr><td>1. Attachment</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5. Viral nucleic</td></tr><tr><td></td><td></td><td></td><td></td><td>acid synthesis</td></tr><tr><td></td><td></td><td>5. Assembly and</td><td></td><td></td></tr><tr><td></td><td></td><td>budding</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>5. Protein</td><td></td></tr><tr><td></td><td></td><td></td><td>synthesis</td><td></td></tr><tr><td></td><td colspan="2">New virions</td><td></td><td></td></tr></table>
</page>
<page number="509">
<table id="p509t1" data-filename="pdftables_fromstorage_023782248" data-page="509" data-table="1"><tr><td></td><td>A nucleoside antiretroviral agent (Similar drug: didanosine)</td><td>Zidovudine</td></tr><tr><td>Actions</td><td>Inhibits the action of the viral reverse transcriptase of HIV viruses.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Phosphorylated by host cell enzymes to give zidovudine trisphosphate which</td></tr><tr><td></td><td>interferes with viral DNA synthesis.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally but can be given by i.v. infusion; the concentration in the CSF is 65% of the</td></tr><tr><td></td><td>blood level. The T0.5 of the false trisphosphate is 3h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Human immunodeficiency virus infection in combination with other agents. Slows</td></tr><tr><td></td><td>progress of the disease without curing the infection.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">With long-term use: blood dyscrasias, GIT disturbances, myopathy, rashes, fever and a</td></tr><tr><td></td><td>flulike syndrome.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Resistance is likely to occur. To reduce this possibility, the drug is used in combination</td></tr><tr><td></td><td>with other antiretrovirals.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 51, pp 641-643; D&amp;H 2e Ch 48, pp 113-114</td></tr></table>
</page>
<page number="510">
<table id="p510t1" data-filename="pdftables_fromstorage_023782248" data-page="510" data-table="1"><tr><td style="text-align: right">30.02</td><td>Nevirapine</td><td>Antiviral agents</td><td></td><td></td></tr><tr><td colspan="4">A schematic diagram of virus infection of a mammalian cell</td><td></td></tr><tr><td></td><td></td><td></td><td>CMV = Cytomegalovirus</td><td>HIV = Human immunodeficiency virus</td></tr><tr><td></td><td></td><td></td><td>HBV = Hepatitis B virus</td><td>HV = Herpes viruses</td></tr><tr><td></td><td></td><td>2. Entry</td><td>HCV = Hepatitis C virus</td><td>RSV = Respiratory syncytial virus</td></tr><tr><td></td><td></td><td>and ...</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>4. Transfer of viral</td><td></td></tr><tr><td></td><td></td><td>3.Uncoating</td><td>DNA to nucleus</td><td></td></tr><tr><td>1. Attachment</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5. Viral nucleic</td></tr><tr><td></td><td></td><td></td><td></td><td>acid synthesis</td></tr><tr><td></td><td></td><td></td><td>Zidovudine (HIV)</td><td></td></tr><tr><td></td><td></td><td>5. Assembly and</td><td></td><td></td></tr><tr><td></td><td></td><td>budding</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>5. Protein</td><td></td></tr><tr><td></td><td></td><td></td><td>synthesis</td><td></td></tr><tr><td></td><td colspan="2">New virions</td><td></td><td></td></tr></table>
</page>
<page number="511">
<table id="p511t1" data-filename="pdftables_fromstorage_023782248" data-page="511" data-table="1"><tr><td></td><td>A non-nucleoside antiretroviral agent (Simliar drug: efavirenz)</td><td>Nevirapine</td></tr><tr><td>Actions</td><td colspan="2">Inhibits the action of the viral reverse transcriptase of the immunodeficiency virus.</td></tr><tr><td></td><td>Active against HIV-1 but not HIV-2.</td><td></td></tr><tr><td>MOA</td><td>Binds to and denatures the viral reverse transcriptase enzyme.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally; the concentration in the CSF is 45% of the plasma level.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">HIV-1 infection in combination with other antiretrovirals. Can reduce mother-to-foetus</td></tr><tr><td></td><td>transmission of the virus by ~50%.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Hepatotoxicity. Rash, Stevens-Johnson syndrome. Less common: GIT disturbances, myalgia.</td></tr><tr><td></td><td>Efavirenz can cause disturbances of sleep and dreaming.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 51, p 643; D&amp;H 2e Ch 48, pp 113-114</td></tr></table>
</page>
<page number="512">
<table id="p512t1" data-filename="pdftables_fromstorage_023782248" data-page="512" data-table="1"><tr><td style="text-align: right">30.03</td><td>Saquinavir</td><td>Antiviral agents</td><td></td><td></td></tr><tr><td colspan="4">A schematic diagram of virus infection of a mammalian cell</td><td></td></tr><tr><td></td><td></td><td></td><td>CMV = Cytomegalovirus</td><td>HIV = Human immunodeficiency virus</td></tr><tr><td></td><td></td><td></td><td>HBV = Hepatitis B virus</td><td>HV = Herpes viruses</td></tr><tr><td></td><td></td><td>2. Entry</td><td>HCV = Hepatitis C virus</td><td>RSV = Respiratory syncytial virus</td></tr><tr><td></td><td></td><td>and ...</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>4. Transfer of viral</td><td></td></tr><tr><td></td><td></td><td>3.Uncoating</td><td>DNA to nucleus</td><td></td></tr><tr><td>1. Attachment</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5. Viral nucleic</td></tr><tr><td></td><td></td><td></td><td></td><td>acid synthesis</td></tr><tr><td></td><td></td><td></td><td>Zidovudine (HIV)</td><td></td></tr><tr><td></td><td></td><td>5. Assembly and</td><td>nevirapine (HIV)</td><td></td></tr><tr><td></td><td></td><td>budding</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>5. Protein</td><td></td></tr><tr><td></td><td></td><td></td><td>synthesis</td><td></td></tr><tr><td></td><td colspan="2">New virions</td><td></td><td></td></tr></table>
</page>
<page number="513">
<table id="p513t1" data-filename="pdftables_fromstorage_023782248" data-page="513" data-table="1"><tr><td></td><td>A protease inhibitor antiretroviral agent (Simliar drug: atazanavir)</td><td>Saquinavir</td></tr><tr><td>Action &amp; MOA</td><td colspan="2">Reversibly inhibits the viral-specific protease that, during assembly &amp; budding, cleaves</td></tr><tr><td></td><td colspan="2">precursor viral proteins to give the structural and functional proteins of the new virions.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally, extensive first-pass metabolism. Elimination t1⁄2 12h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">HIV-1 infection in combination with other antiretrovirals. Can reduce mother-to-foetus</td></tr><tr><td></td><td>transmission of the virus by ~50%.</td><td></td></tr><tr><td>Adverse effects</td><td>GIT disturbances, rhinitis, insulin resistance, lipodystrophy.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 51, p 643; D&amp;H 2e Ch 48, p 114</td></tr></table>
</page>
<page number="514">
<table id="p514t1" data-filename="pdftables_fromstorage_023782248" data-page="514" data-table="1"><tr><td style="text-align: right">30.04</td><td>Enfuvirtide</td><td>Antiviral agents</td><td></td><td></td></tr><tr><td colspan="4">A schematic diagram of virus infection of a mammalian cell</td><td></td></tr><tr><td></td><td></td><td></td><td>CMV = Cytomegalovirus</td><td>HIV = Human immunodeficiency virus</td></tr><tr><td></td><td></td><td></td><td>HBV = Hepatitis B virus</td><td>HV = Herpes viruses</td></tr><tr><td></td><td></td><td>2. Entry</td><td>HCV = Hepatitis C virus</td><td>RSV = Respiratory syncytial virus</td></tr><tr><td></td><td></td><td>and ...</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>4. Transfer of viral</td><td></td></tr><tr><td></td><td></td><td>3.Uncoating</td><td>DNA to nucleus</td><td></td></tr><tr><td>1. Attachment</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5. Viral nucleic</td></tr><tr><td></td><td></td><td></td><td></td><td>acid synthesis</td></tr><tr><td></td><td></td><td></td><td>Zidovudine (HIV)</td><td></td></tr><tr><td></td><td></td><td>5. Assembly and</td><td>nevirapine (HIV)</td><td></td></tr><tr><td></td><td></td><td>budding</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>5. Protein</td><td></td></tr><tr><td></td><td></td><td></td><td>synthesis</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Saquinavir (HIV)</td></tr><tr><td></td><td colspan="2">New virions</td><td></td><td></td></tr></table>
</page>
<page number="515">
<table id="p515t1" data-filename="pdftables_fromstorage_023782248" data-page="515" data-table="1"><tr><td></td><td>An antiretroviral agent</td><td>Enfuvirtide</td></tr><tr><td>Action</td><td>Inhibits HIV entry into host cells.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Binds to a subunit on the HIV envelope preventing fusion of the virus with the target cell</td></tr><tr><td></td><td>membrane, thus inhibiting infection of the mammalian cell.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given by subcut. injection. Elimination t1⁄2 ~4h.</td><td></td></tr><tr><td>Clinical use</td><td>HIV-1 infection in combination with other antiretrovirals.</td><td></td></tr><tr><td>Adverse effects</td><td>Hypersensitivity reactions.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 51, p 645; D&amp;H 2e Ch 48, p 114</td></tr></table>
</page>
<page number="516">
<table id="p516t1" data-filename="pdftables_fromstorage_023782248" data-page="516" data-table="1"><tr><td style="text-align: right">30.05</td><td>Aciclovir</td><td>Antiviral agents</td><td></td><td></td></tr><tr><td colspan="4">A schematic diagram of virus infection of a mammalian cell</td><td></td></tr><tr><td></td><td></td><td></td><td>CMV = Cytomegalovirus</td><td>HIV = Human immunodeficiency virus</td></tr><tr><td></td><td></td><td></td><td>HBV = Hepatitis B virus</td><td>HV = Herpes viruses</td></tr><tr><td colspan="2">Enfuvirtide (HIV)</td><td>2. Entry</td><td>HCV = Hepatitis C virus</td><td>RSV = Respiratory syncytial virus</td></tr><tr><td></td><td></td><td>and ...</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>4. Transfer of viral</td><td></td></tr><tr><td></td><td></td><td>3.Uncoating</td><td>DNA to nucleus</td><td></td></tr><tr><td colspan="2">1. Attachment</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5. Viral nucleic</td></tr><tr><td></td><td></td><td></td><td></td><td>acid synthesis</td></tr><tr><td></td><td></td><td></td><td>Zidovudine (HIV)</td><td></td></tr><tr><td></td><td></td><td>5. Assembly and</td><td>nevirapine (HIV)</td><td></td></tr><tr><td></td><td></td><td>budding</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>5. Protein</td><td></td></tr><tr><td></td><td></td><td></td><td>synthesis</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Saquinavir (HIV)</td></tr><tr><td></td><td></td><td>New virions</td><td></td><td></td></tr></table>
</page>
<page number="517">
<table id="p517t1" data-filename="pdftables_fromstorage_023782248" data-page="517" data-table="1"><tr><td></td><td>An antiviral agent (Similar drugs: famciclovir, valaciclovir)</td><td>Aciclovir</td></tr><tr><td>Actions</td><td>Interferes with viral nucleic acid synthesis.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Converted by viral and host cell kinases to aciclovir triphosphate which selectively inhibits</td></tr><tr><td></td><td>viral DNA polymerase.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally, i.v. (slowly) or topically; is degraded fairly rapidly within the host cell. CSF</td></tr><tr><td></td><td>concentration is ~50% of plasma level.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Herpes simplex infections (cold sores, mouth ulcers, conjunctivitis, genital infections and,</td></tr><tr><td></td><td colspan="2">more seriously, encephalitis). Herpes zoster infections (shingles, chickenpox).</td></tr><tr><td>Adverse effects</td><td>Usually minimal; sometimes nausea, headache; rarely encephalitis.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 51, pp 644-645; D&amp;H 2e Ch 48, p 114</td></tr></table>
</page>
<page number="518">
<table id="p518t1" data-filename="pdftables_fromstorage_023782248" data-page="518" data-table="1"><tr><td style="text-align: right">30.06</td><td>Ganciclovir</td><td>Antiviral agents</td><td></td><td></td></tr><tr><td colspan="4">A schematic diagram of virus infection of a mammalian cell</td><td></td></tr><tr><td></td><td></td><td></td><td>CMV = Cytomegalovirus</td><td>HIV = Human immunodeficiency virus</td></tr><tr><td></td><td></td><td></td><td>HBV = Hepatitis B virus</td><td>HV = Herpes viruses</td></tr><tr><td>Enfuvirtide (HIV)</td><td></td><td>2. Entry</td><td>HCV = Hepatitis C virus</td><td>RSV = Respiratory syncytial virus</td></tr><tr><td></td><td></td><td>and ...</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>4. Transfer of viral</td><td></td></tr><tr><td></td><td></td><td>3.Uncoating</td><td>DNA to nucleus</td><td></td></tr><tr><td>1. Attachment</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Aciclovir (HV)</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5. Viral nucleic</td></tr><tr><td></td><td></td><td></td><td></td><td>acid synthesis</td></tr><tr><td></td><td></td><td></td><td>Zidovudine (HIV)</td><td></td></tr><tr><td></td><td></td><td>5. Assembly and</td><td>nevirapine (HIV)</td><td></td></tr><tr><td></td><td></td><td>budding</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>5. Protein</td><td></td></tr><tr><td></td><td></td><td></td><td>synthesis</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Saquinavir (HIV)</td></tr><tr><td></td><td colspan="2">New virions</td><td></td><td></td></tr></table>
</page>
<page number="519">
<table id="p519t1" data-filename="pdftables_fromstorage_023782248" data-page="519" data-table="1"><tr><td></td><td>An antiviral agent (Similar agent: foscarnet)</td><td>Ganciclovir</td></tr><tr><td>Actions</td><td>Interferes with viral nucleic acid synthesis.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Converted by viral and host cell kinases to ganciclovir triphosphate which competes</td></tr><tr><td></td><td colspan="2">with guanosine triphosphate for incorporation into viral DNA, and suppresses viral DNA</td></tr><tr><td></td><td>replication.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given intravenously; t1⁄2 4h but persists in host cells for 18-20h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Cytomegalovirus infection (common in AIDS &amp; immunocompromised patients).</td></tr><tr><td>Adverse effects</td><td colspan="2">Bone marrow depression; therefore used only for life-threatening infections.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 51, p 645; D&amp;H 2e Ch 48, p 114</td></tr></table>
</page>
<page number="520">
<table id="p520t1" data-filename="pdftables_fromstorage_023782248" data-page="520" data-table="1"><tr><td style="text-align: right">30.07</td><td>Oseltamivir</td><td>Antiviral agents</td><td></td><td></td></tr><tr><td colspan="4">A schematic diagram of virus infection of a mammalian cell</td><td></td></tr><tr><td></td><td></td><td></td><td>CMV = Cytomegalovirus</td><td>HIV = Human immunodeficiency virus</td></tr><tr><td></td><td></td><td></td><td>HBV = Hepatitis B virus</td><td>HV = Herpes viruses</td></tr><tr><td>Enfuvirtide (HIV)</td><td></td><td>2. Entry</td><td>HCV = Hepatitis C virus</td><td>RSV = Respiratory syncytial virus</td></tr><tr><td></td><td></td><td>and ...</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>4. Transfer of viral</td><td></td></tr><tr><td></td><td></td><td>3.Uncoating</td><td>DNA to nucleus</td><td></td></tr><tr><td>1. Attachment</td><td></td><td></td><td>Acyclovir (HV)</td><td></td></tr><tr><td></td><td></td><td></td><td>Ganciclovir</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5. Viral nucleic</td></tr><tr><td></td><td></td><td></td><td></td><td>acid synthesis</td></tr><tr><td></td><td></td><td></td><td>Zidovudine (HIV)</td><td></td></tr><tr><td></td><td></td><td>5. Assembly and</td><td>nevirapine (HIV)</td><td></td></tr><tr><td></td><td></td><td>budding</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>5. Protein</td><td></td></tr><tr><td></td><td></td><td></td><td>synthesis</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Saquinavir (HIV)</td></tr><tr><td></td><td colspan="2">New virions</td><td></td><td></td></tr></table>
</page>
<page number="521">
<table id="p521t1" data-filename="pdftables_fromstorage_023782248" data-page="521" data-table="1"><tr><td></td><td>Antiflu antiviral agent (Similar agent: zanamivir)</td><td>Oseltamivir</td></tr><tr><td>Actions</td><td>Reduces viral replication.</td><td></td></tr><tr><td>MOA</td><td>Inhibits neuraminidase which is necessary for virion release.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally – within 48h of onset of symptoms for post-exposure prophylaxis.</td></tr><tr><td></td><td>Zanamivir is given intranasally.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Prevention and treatment of infections with influenza viruses A and B.</td></tr><tr><td>Adverse effects</td><td>GIT disturbances, headache, dizziness, rashes; very rarely hepatitis.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 51, p 645; D&amp;H 2e Ch 48, p 114</td></tr></table>
</page>
<page number="522">
<table id="p522t1" data-filename="pdftables_fromstorage_023782248" data-page="522" data-table="1"><tr><td style="text-align: right">30.08</td><td>Palivizumab</td><td>Antiviral agents</td><td></td><td></td></tr><tr><td colspan="4">A schematic diagram of virus infection of a mammalian cell</td><td></td></tr><tr><td></td><td></td><td></td><td>CMV = Cytomegalovirus</td><td>HIV = Human immunodeficiency virus</td></tr><tr><td></td><td></td><td></td><td>HBV = Hepatitis B virus</td><td>HV = Herpes viruses</td></tr><tr><td>Enfuvirtide (HIV)</td><td></td><td>2. Entry</td><td>HCV = Hepatitis C virus</td><td>RSV = Respiratory syncytial virus</td></tr><tr><td></td><td></td><td>and ...</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>4. Transfer of viral</td><td></td></tr><tr><td></td><td></td><td>3.Uncoating</td><td>DNA to nucleus</td><td></td></tr><tr><td>1. Attachment</td><td></td><td></td><td>Acyclovir (HV)</td><td></td></tr><tr><td></td><td></td><td></td><td>Ganciclovir</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5. Viral nucleic</td></tr><tr><td></td><td></td><td></td><td></td><td>acid synthesis</td></tr><tr><td></td><td></td><td></td><td>Zidovudine (HIV)</td><td></td></tr><tr><td></td><td></td><td>5. Assembly and</td><td>nevirapine (HIV)</td><td></td></tr><tr><td>Oseltamivir</td><td></td><td>budding</td><td></td><td></td></tr><tr><td>&amp; zanamivir</td><td></td><td></td><td></td><td></td></tr><tr><td>(flu virus)</td><td></td><td></td><td>5. Protein</td><td></td></tr><tr><td></td><td></td><td></td><td>synthesis</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Saquinavir (HIV)</td></tr><tr><td></td><td colspan="2">New virions</td><td></td><td></td></tr></table>
</page>
<page number="523">
<table id="p523t1" data-filename="pdftables_fromstorage_023782248" data-page="523" data-table="1"><tr><td></td><td>A monoclonal antibody antiviral agent</td><td>Palivizumab</td></tr><tr><td>Actions</td><td>Inhibits viral entry into host cells.</td><td></td></tr><tr><td>MOA</td><td colspan="2">It is a humanized monoclonal antibody against a protein on the surface of the respiratory</td></tr><tr><td></td><td>syncytial virus.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given by intramuscular injection.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">For respiratory syncytial virus infection in children. (Needs specialist prescription and</td></tr><tr><td></td><td>administration.)</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Hypersensitivity reactions against the monoclonal antibody are possible.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 51, p 646; D&amp;H 2e Ch 48, p 114</td></tr></table>
</page>
<page number="524">
<table id="p524t1" data-filename="pdftables_fromstorage_023782248" data-page="524" data-table="1"><tr><td style="text-align: right">30.09</td><td>Interferon alpha</td><td>Antiviral agents</td><td></td><td></td></tr><tr><td colspan="4">A schematic diagram of virus infection of a mammalian cell</td><td></td></tr><tr><td></td><td></td><td></td><td>CMV = Cytomegalovirus</td><td>HIV = Human immunodeficiency virus</td></tr><tr><td>Enfuvirtide (HIV)</td><td></td><td></td><td>HBV = Hepatitis B virus</td><td>HV = Herpes viruses</td></tr><tr><td>palivizumab (RSV)</td><td></td><td>2. Entry</td><td>HCV = Hepatitis C virus</td><td>RSV = Respiratory syncytial virus</td></tr><tr><td></td><td></td><td>and ...</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>4. Transfer of viral</td><td></td></tr><tr><td></td><td></td><td>3.Uncoating</td><td>DNA to nucleus</td><td></td></tr><tr><td>1. Attachment</td><td></td><td></td><td>Aciclovir (HV)</td><td></td></tr><tr><td></td><td></td><td></td><td>Ganciclovir</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5. Viral nucleic</td></tr><tr><td></td><td></td><td></td><td></td><td>acid synthesis</td></tr><tr><td></td><td></td><td></td><td>Zidovudine (HIV)</td><td></td></tr><tr><td></td><td colspan="2">5. Assembly and</td><td>nevirapine (HIV)</td><td></td></tr><tr><td>Oseltamivir</td><td></td><td>budding</td><td></td><td></td></tr><tr><td>&amp; zanamivir</td><td></td><td></td><td></td><td></td></tr><tr><td>(flu virus)</td><td></td><td></td><td>5. Protein</td><td></td></tr><tr><td></td><td></td><td></td><td>synthesis</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Saquinavir (HIV)</td></tr><tr><td></td><td colspan="2">New virions</td><td></td><td></td></tr></table>
</page>
<page number="525">
<table id="p525t1" data-filename="pdftables_fromstorage_023782248" data-page="525" data-table="1"><tr><td colspan="2">A modified recombinant DNA version of an antiviral cytokine produced by mammalian cells</td><td>Interferon-alpha</td></tr><tr><td>Actions</td><td>Kills viruses and virus-infected cells.</td><td></td></tr><tr><td>MOA</td><td colspan="2">It stimulates the production of host enzymes that degrade both viral mRNA (thus inhibiting viral</td></tr><tr><td></td><td colspan="2">protein synthesis and halting replication) and host cell mRNA in the infected cell, thus killing it.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given i.v.; T0.5 2–4h. Peginterferon-alfa2a has a longer t1⁄2 .</td><td></td></tr><tr><td>Clinical use</td><td>For viral hepatitis B; with ribavirin for chronic viral hepatitis C.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Fever, headache and myalgia are common. CVS and liver dysfunction and bone marrow depression</td></tr><tr><td></td><td>can also occur.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 51, p 646; D&amp;H 2e Ch 48, p 114</td></tr></table>
</page>
<page number="526">
<table id="p526t1" data-filename="pdftables_fromstorage_023782248" data-page="526" data-table="1"><tr><td style="text-align: right">30.10</td><td colspan="2">Why are combinations of drugs used to treat HIV infection?</td><td>Antiviral agents</td></tr><tr><td></td><td>What combinations are used?</td><td></td><td></td></tr><tr><td colspan="3">A schematic diagram of virus infection of a mammalian cell</td><td></td></tr><tr><td></td><td></td><td>CMV = Cytomegalovirus</td><td>HIV = Human immunodeficiency virus</td></tr><tr><td>Enfuvirtide (HIV)</td><td></td><td>HBV = Hepatitis B virus</td><td>HV = Herpes viruses</td></tr><tr><td>palivizumab (RSV)</td><td>2. Entry</td><td>HCV = Hepatitis C virus</td><td>RSV = Respiratory syncytial virus</td></tr><tr><td></td><td>and ...</td><td></td><td></td></tr><tr><td></td><td></td><td>4. Transfer of viral</td><td></td></tr><tr><td></td><td>3.Uncoating</td><td>DNA to nucleus</td><td></td></tr><tr><td>1. Attachment</td><td></td><td>Aciclovir (HV)</td><td></td></tr><tr><td></td><td></td><td>Ganciclovir</td><td></td></tr><tr><td></td><td></td><td></td><td>5. Viral nucleic</td></tr><tr><td></td><td></td><td></td><td>acid synthesis</td></tr><tr><td></td><td></td><td>Zidovudine (HIV)</td><td></td></tr><tr><td></td><td>5. Assembly and</td><td>nevirapine (HIV)</td><td></td></tr><tr><td>Oseltamivir</td><td>budding</td><td></td><td></td></tr><tr><td>&amp; zanamivir</td><td></td><td></td><td></td></tr><tr><td>(flu virus)</td><td></td><td>5. Protein</td><td></td></tr><tr><td></td><td></td><td>synthesis</td><td>Interferon-α</td></tr><tr><td></td><td></td><td></td><td>(HBV, HCV)</td></tr><tr><td></td><td></td><td></td><td>Saquinavir (HIV)</td></tr><tr><td></td><td>New virions</td><td></td><td></td></tr></table>
</page>
<page number="527">
<table id="p527t1" data-filename="pdftables_fromstorage_023782248" data-page="527" data-table="1"><tr><td>Drug combinations used to treat HIV infection</td></tr><tr><td>Combinations of anti-HIV drugs* are used to reduce the development of resistance.</td></tr><tr><td>The drugs combined should have additive antiviral action but not additive adverse reactions.</td></tr><tr><td>A frequently used combination is:</td></tr><tr><td>Two nucleoside reverse transcriptase inhibitors e.g. zidovudine, didanosine, lamivudine</td></tr><tr><td>PLUS</td></tr><tr><td>Either a non-nucleoside reverse transcriptase inhibitor, e.g. nevirapine, enfuvirtide</td></tr><tr><td>OR a protease inhibitor, e.g. saquinavir, atazanavir.</td></tr><tr><td>*referred to as highly active antiretroviral therapy (HAART).</td></tr><tr><td>R&amp;D 7e Ch 51, pp 646-647; D&amp;H 2e Ch 48, p 114</td></tr></table>
</page>
<page number="528">
<table id="p528t1" data-filename="pdftables_fromstorage_023782248" data-page="528" data-table="1"><tr><td style="text-align: right">31.01</td><td>Chloroquine</td><td colspan="2">Antiprotozoal drugs – Malaria</td><td></td><td></td></tr><tr><td colspan="4">The malarial cycle and the sites at which drugs can affect it</td><td></td><td></td></tr><tr><td></td><td colspan="3">C. Chemoprophylactic drugs</td><td>5. Merozoite enters</td><td>6. ... then forms</td></tr><tr><td>HUMAN</td><td colspan="2">(prevent clinical attack)</td><td></td><td>erythrocyte and</td><td>motile trophozoite</td></tr><tr><td></td><td></td><td></td><td></td><td>forms schizont ...</td><td>and starts to divide</td></tr><tr><td>4. Merozoites</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>released</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Liver</td><td></td><td></td></tr><tr><td></td><td colspan="3">B. Drugs of radical cure</td><td></td><td></td></tr><tr><td>3. Schizonts</td><td colspan="2">inhibit hypnozoites</td><td></td><td></td><td></td></tr><tr><td>divide to form</td><td></td><td></td><td></td><td></td><td>A. Blood</td></tr><tr><td></td><td></td><td>Reactivation</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>schizonticides</td></tr><tr><td>merozoites</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Erythrocytic stage</td><td>treat the</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>acute attack</td></tr><tr><td>2. Schizonts</td><td></td><td colspan="2">2a. Hypnozoites of Plasmodium</td><td></td><td></td></tr><tr><td>in liver cells</td><td></td><td colspan="2">vivax &amp; P. ovale lie dormant</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">(Exo-erythrocytic stage)</td><td></td><td></td></tr><tr><td>1. Sporozoites</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>injected by bite</td><td></td><td colspan="2">D. Drugs preventing</td><td>7. Merozoites</td><td></td></tr><tr><td>and enter liver</td><td></td><td colspan="2">transmission destroy</td><td></td><td></td></tr><tr><td>(Pre-erythrocytic</td><td></td><td>gametocytes</td><td></td><td colspan="2">8. Release of merozoites causes fever</td></tr><tr><td>stage)</td><td></td><td></td><td></td><td colspan="2">9. Some merozoites form gametocytes</td></tr><tr><td>MOSQUITO</td><td>Sporozoites</td><td>Oocyst</td><td>Zygote</td><td>10. Taken up in insect bite</td><td></td></tr></table>
</page>
<page number="529">
<table id="p529t1" data-filename="pdftables_fromstorage_023782248" data-page="529" data-table="1"><tr><td></td><td>An antimalarial drug</td><td>Chloroquine</td></tr><tr><td>Actions</td><td>A schizonticidal drug that kills malarial parasites in red blood cells.</td><td></td></tr><tr><td>MOA</td><td colspan="2">It inhibits haem polymerase which would normally degrade haem, rendering it harmless</td></tr><tr><td></td><td colspan="2">to the parasite. The toxic haem molecules accumulate and kill the parasite.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally (or in severe falciparum malaria subcut. or i.v.) it concentrates in parasitised</td></tr><tr><td></td><td colspan="2">erythrocytes. Slowly eliminated; T0.5 50h, but a residue persists for longer.</td></tr><tr><td>Clinical use</td><td colspan="2">To treat acute attacks of benign malaria (Plasmodium vivax, P. ovale, P. malariae).</td></tr><tr><td></td><td colspan="2">For chemoprophylaxis of benign malaria and of chloroquine-sensitive falciparum malaria.</td></tr><tr><td></td><td colspan="2">To treat rheumatoid arthritis and lupus erythematosus (see card 3.10).</td></tr><tr><td>Adverse effects</td><td colspan="2">Few when used for chemoprophylaxis. The larger doses used to treat the acute attack</td></tr><tr><td></td><td colspan="2">can cause GIT disturbances, dizziness, urticaria. Bolus i.v. injections can cause dysrhythmias.</td></tr><tr><td>Special points</td><td>Chloroquine resistance is spreading.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 53, pp 659-660; D&amp;H 2e Ch 49, pp 115-116</td></tr></table>
</page>
<page number="530">
<table id="p530t1" data-filename="pdftables_fromstorage_023782248" data-page="530" data-table="1"><tr><td style="text-align: right">31.02</td><td>Quinine</td><td colspan="2">Antiprotozoal drugs – Malaria</td><td></td><td></td></tr><tr><td colspan="4">The malarial cycle and the sites at which drugs can affect it</td><td></td><td></td></tr><tr><td></td><td colspan="3">C. Chemoprophylactic drugs</td><td>5. Merozoite enters</td><td>6. ... then forms</td></tr><tr><td>HUMAN</td><td></td><td></td><td></td><td>erythrocyte and</td><td>motile trophozoite</td></tr><tr><td></td><td colspan="3">(prevent clinical attack): chloroquine</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>forms schizont ...</td><td>and starts to divide</td></tr><tr><td>4. Merozoites</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>released</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Liver</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">B. Drugs of radical cure</td><td></td><td></td></tr><tr><td>3. Schizonts</td><td></td><td>inhibit hypnozoites</td><td></td><td></td><td>A. Blood</td></tr><tr><td>divide to form</td><td></td><td></td><td></td><td></td><td>schizonticides</td></tr><tr><td></td><td></td><td>Reactivation</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>treat the</td></tr><tr><td>merozoites</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Erythrocytic stage</td><td>acute attack:</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>chloroquine</td></tr><tr><td>2. Schizonts</td><td></td><td colspan="2">2a. Hypnozoites of P. vivax</td><td></td><td></td></tr><tr><td>in liver cells</td><td></td><td colspan="2">&amp; P. ovale lie dormant</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">(Exo-erythrocytic stage)</td><td></td><td></td></tr><tr><td>1. Sporozoites</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>injected by bite</td><td></td><td colspan="2">D. Drugs preventing</td><td>7. Merozoites</td><td></td></tr><tr><td>and enter liver</td><td></td><td colspan="2">transmission destroy</td><td></td><td></td></tr><tr><td>(Pre-erythrocytic</td><td></td><td>gametocytes</td><td></td><td colspan="2">8. Release of merozoites causes fever</td></tr><tr><td>stage)</td><td></td><td></td><td></td><td colspan="2">9. Some merozoites form gametocytes</td></tr><tr><td>MOSQUITO</td><td>Sporozoites</td><td>Oocyst</td><td>Zygote</td><td>10. Taken up in insect bite</td><td></td></tr></table>
</page>
<page number="531">
<table id="p531t1" data-filename="pdftables_fromstorage_023782248" data-page="531" data-table="1"><tr><td></td><td>An antimalarial drug</td><td>Quinine</td></tr><tr><td>Actions</td><td>A schizonticidal drug that kills malarial parasites in red blood cells.</td><td></td></tr><tr><td>MOA</td><td colspan="2">It is thought to inhibit haem polymerase which would normally degrade haem, rendering</td></tr><tr><td></td><td colspan="2">it harmless to the parasite. The toxic haem molecules accumulate and kill the parasite.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally, t1⁄2 10h but can be given by i.v. infusion. It partially concentrates in parasitised</td></tr><tr><td></td><td>red blood cells. Metabolised in liver; t 1⁄2 10h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">To treat acute attacks of malignant malaria (P. falciparum). Often given in combination</td></tr><tr><td></td><td colspan="2">with (or followed by) doxycycline or clindamycin or pyrimethamine + sulfadoxine</td></tr><tr><td></td><td>(see cards 29.09 &amp; 31.06).</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances, tinnitus, blurred vision. With large doses: hypotension, dysrhythmias</td></tr><tr><td></td><td colspan="2">and CNS disturbances. Black water fever (intravascular haemolysis, haemoglobinuria,</td></tr><tr><td></td><td>kidney failure) can be associated with quinine.</td><td></td></tr><tr><td>Special points</td><td>Not suitable for chemoprophylaxis.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 53, pp 660-661; D&amp;H 2e Ch 49, pp 115-116</td></tr></table>
</page>
<page number="532">
<table id="p532t1" data-filename="pdftables_fromstorage_023782248" data-page="532" data-table="1"><tr><td style="text-align: right">31.03</td><td>Mefloquine</td><td colspan="2">Antiprotozoal drugs – Malaria</td><td></td><td></td></tr><tr><td colspan="4">The malarial cycle and the sites at which drugs can affect it</td><td></td><td></td></tr><tr><td></td><td colspan="3">C. Chemoprophylactic drugs</td><td>5. Merozoite enters</td><td>6. ... then forms</td></tr><tr><td></td><td colspan="3">(prevent clinical attack): chloroquine</td><td>erythrocyte and</td><td>motile trophozoite</td></tr><tr><td></td><td></td><td></td><td></td><td>forms schizont ...</td><td>and starts to divide</td></tr><tr><td>4. Merozoites</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>released</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Liver</td><td></td><td>A. Blood</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>schizonticides</td></tr><tr><td></td><td colspan="3">B. Drugs of radical cure</td><td></td><td>treat the</td></tr><tr><td>3. Schizonts</td><td colspan="2">inhibit hypnozoites</td><td></td><td></td><td>acute attack:</td></tr><tr><td>divide to form</td><td></td><td>Reactivation</td><td></td><td></td><td>chloroquine</td></tr><tr><td>merozoites</td><td></td><td></td><td></td><td>Erythrocytic stage</td><td>(benign malaria),</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>quinine +</td></tr><tr><td>2. Schizonts</td><td></td><td colspan="2">2a. Hypnozoites of P. vivax</td><td></td><td>doxycycline</td></tr><tr><td>in liver cells</td><td></td><td colspan="2">&amp; P. ovale lie dormant</td><td></td><td>(falciparum</td></tr><tr><td></td><td></td><td colspan="2">(Exo-erythrocytic stage)</td><td></td><td>malaria)</td></tr><tr><td>1. Sporozoites</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>injected by bite</td><td></td><td colspan="2">D. Drugs preventing</td><td>7. Merozoites</td><td></td></tr><tr><td>and enter liver</td><td></td><td colspan="2">transmission destroy</td><td></td><td></td></tr><tr><td>(Pre-erythrocytic</td><td></td><td>gametocytes</td><td></td><td colspan="2">8. Release of merozoites causes fever</td></tr><tr><td>stage)</td><td></td><td></td><td></td><td colspan="2">9. Some merozoites form gametocytes</td></tr><tr><td>MOSQUITO</td><td>Sporozoites</td><td>Oocyst</td><td>Zygote</td><td>10. Taken up in insect bite</td><td></td></tr></table>
</page>
<page number="533">
<table id="p533t1" data-filename="pdftables_fromstorage_023782248" data-page="533" data-table="1"><tr><td></td><td>An antimalarial drug</td><td>Mefloquine</td></tr><tr><td>Actions</td><td>A schizonticidal drug that kills malarial parasites in red blood cells.</td><td></td></tr><tr><td>MOA</td><td colspan="2">It is thought to inhibit haem polymerase which would normally degrade haem, rendering</td></tr><tr><td></td><td colspan="2">it harmless to the parasite. The toxic haem molecules accumulate and kill the parasite.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally, onset of action is slow, T0.5 16h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">For chemoprophylaxis of falciparum malaria in areas where it is chloroquine resistant.</td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances, neuropsychiatric reactions (e.g. ataxia, confusion, hallucinations, convulsions),</td></tr><tr><td></td><td>CVS disorders, rash, fever, leucopenia.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Not used for treatment of falciparum malaria because of resistance; not used for the</td></tr><tr><td></td><td>benign malarias because less toxic drugs are available.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 53, p 661; D&amp;H 2e Ch 49, pp 115-116</td></tr></table>
</page>
<page number="534">
<table id="p534t1" data-filename="pdftables_fromstorage_023782248" data-page="534" data-table="1"><tr><td style="text-align: right">31.04</td><td>Primaquine</td><td colspan="2">Antiprotozoal drugs – Malaria</td><td></td><td></td></tr><tr><td colspan="4">The malarial cycle and the sites at which drugs can affect it</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5. Merozoite enters</td><td>6. ... then forms</td></tr><tr><td></td><td colspan="3">C. Chemoprophylactic drugs (prevent</td><td></td><td></td></tr><tr><td>HUMAN</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="3">clinical attack): chloroquine, mefloquine</td><td>erythrocyte and</td><td>motile trophozoite</td></tr><tr><td></td><td></td><td></td><td></td><td>forms schizont ...</td><td>and starts to divide</td></tr><tr><td>4. Merozoites</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>released</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Liver</td><td></td><td>A. Blood</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>schizonticides</td></tr><tr><td></td><td colspan="3">B. Drugs of radical cure</td><td></td><td>treat the</td></tr><tr><td>3. Schizonts</td><td colspan="2">inhibit hypnozoites</td><td></td><td></td><td>acute attack:</td></tr><tr><td>divide to form</td><td></td><td>Reactivation</td><td></td><td></td><td>chloroquine</td></tr><tr><td>merozoites</td><td></td><td></td><td></td><td>Erythrocytic stage</td><td>(benign malaria),</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>quinine +</td></tr><tr><td>2. Schizonts</td><td></td><td colspan="2">2a. Hypnozoites of P. vivax</td><td></td><td>doxycycline</td></tr><tr><td>in liver cells</td><td></td><td colspan="2">&amp; P. ovale lie dormant</td><td></td><td>(falciparum</td></tr><tr><td></td><td></td><td colspan="2">(Exo-erythrocytic stage)</td><td></td><td>malaria)</td></tr><tr><td>1. Sporozoites</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>injected by bite</td><td></td><td colspan="2">D. Drugs preventing</td><td>7. Merozoites</td><td></td></tr><tr><td>and enter liver</td><td></td><td colspan="2">transmission destroy</td><td></td><td></td></tr><tr><td>(Pre-erythrocytic</td><td></td><td>gametocytes</td><td></td><td colspan="2">8. Release of merozoites causes fever</td></tr><tr><td>stage)</td><td></td><td></td><td></td><td colspan="2">9. Some merozoites form gametocytes</td></tr><tr><td>MOSQUITO</td><td>Sporozoites</td><td>Oocyst</td><td>Zygote</td><td>10. Taken up in insect bite</td><td></td></tr></table>
</page>
<page number="535">
<table id="p535t1" data-filename="pdftables_fromstorage_023782248" data-page="535" data-table="1"><tr><td></td><td>An antimalarial drug</td><td>Primaquine</td></tr><tr><td>Actions</td><td>Kills hypnozoites in the liver. Kills gametocytes.</td><td></td></tr><tr><td>MOA</td><td>Not really known.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally, rapidly metabolised; t1⁄2 3–6h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">For radical cure of P. vivax and P. ovale by eliminating the exo-erythrocytic stage. Given as adjuct</td></tr><tr><td></td><td>to chloroquine treatment of the acute attack.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Dose-related GIT disturbances and methaemoglobinaemia. Causes haemolytic anaemia in patients</td></tr><tr><td></td><td colspan="2">with genetic glucose 6-phosphate dehydrogenase deficiency (G6PD).</td></tr><tr><td>Special points</td><td>Test for G6PD.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 53, p 662; D&amp;H 2e Ch 49, pp 115-116</td></tr></table>
</page>
<page number="536">
<table id="p536t1" data-filename="pdftables_fromstorage_023782248" data-page="536" data-table="1"><tr><td style="text-align: right">31.05</td><td>Proguanil</td><td colspan="2">Antiprotozoal drugs – Malaria</td><td></td><td></td></tr><tr><td colspan="4">The malarial cycle and the sites at which drugs can affect it</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>5. Merozoite enters</td><td>6. ... then forms</td></tr><tr><td></td><td colspan="3">C. Chemoprophylactic drugs (prevent</td><td></td><td></td></tr><tr><td>HUMAN</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="3">clinical attack): chloroquine, mefloquine</td><td>erythrocyte and</td><td>motile trophozoite</td></tr><tr><td></td><td></td><td></td><td></td><td>forms schizont ...</td><td>and starts to divide</td></tr><tr><td>4. Merozoites</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>released</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Liver</td><td></td><td>A. Blood</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>schizonticides</td></tr><tr><td></td><td></td><td colspan="2">B. Drugs of radical cure inhibit</td><td></td><td>treat the</td></tr><tr><td>3. Schizonts</td><td></td><td colspan="2">hypnozoites: primaquine</td><td></td><td>acute attack:</td></tr><tr><td>divide to form</td><td></td><td>Reactivation</td><td></td><td></td><td>chloroquine</td></tr><tr><td>merozoites</td><td></td><td></td><td></td><td>Erythrocytic stage</td><td>(benign malaria),</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>quinine +</td></tr><tr><td>2. Schizonts</td><td></td><td colspan="2">2a. Hypnozoites of P. vivax</td><td></td><td>doxycycline</td></tr><tr><td>in liver cells</td><td></td><td colspan="2">&amp; P. ovale lie dormant</td><td></td><td>(falciparum</td></tr><tr><td></td><td></td><td colspan="2">(Exo-erythrocytic stage)</td><td></td><td>malaria)</td></tr><tr><td>1. Sporozoites</td><td></td><td colspan="2">D. Drugs preventing</td><td></td><td></td></tr><tr><td>injected by bite</td><td></td><td colspan="2">transmission destroy</td><td>7. Merozoites</td><td></td></tr><tr><td>and enter liver</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(Pre-erythrocytic</td><td></td><td>gametocytes:</td><td></td><td colspan="2">8. Release of merozoites causes fever</td></tr><tr><td>stage)</td><td></td><td></td><td></td><td colspan="2">9. Some merozoites form gametocytes</td></tr><tr><td>MOSQUITO</td><td>Sporozoites</td><td>Oocyst</td><td>Zygote</td><td>10. Taken up in insect bite</td><td></td></tr></table>
</page>
<page number="537">
<table id="p537t1" data-filename="pdftables_fromstorage_023782248" data-page="537" data-table="1"><tr><td></td><td>An antimalarial drug</td><td>Proguanil</td></tr><tr><td>Actions</td><td>A slow blood schizonticide.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits the malaria parasite’s dihydrofolate reductase (DHFR) and thus interferes with its</td></tr><tr><td></td><td>thymidylate synthesis.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally, T0.5 16h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">For chemoprophylaxis of malaria usually in combination with chloroquine.</td></tr><tr><td></td><td colspan="2">Proguanil + atovaquone is used for both chemoprophylaxis and treatment of falciparum</td></tr><tr><td></td><td>malaria in some regions.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Few since the drug does not inhibit host DHFR. Rare: GIT disturbances, rash, mouth ulcers,</td></tr><tr><td></td><td>hair loss.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 53, pp 661-662; D&amp;H 2e Ch 49, pp 115-116</td></tr></table>
</page>
<page number="538">
<table id="p538t1" data-filename="pdftables_fromstorage_023782248" data-page="538" data-table="1"><tr><td style="text-align: right">31.06</td><td>Pyrimethamine</td><td colspan="2">Antiprotozoal drugs – Malaria</td><td></td><td></td></tr><tr><td colspan="4">The malarial cycle and the sites at which drugs can affect it</td><td></td><td></td></tr><tr><td>HUMAN</td><td colspan="3">C. Chemoprophylactic drugs (prevent clinical</td><td>5. Merozoite enters</td><td>6. ... then forms</td></tr><tr><td></td><td colspan="3">attack): chloroquine, mefloquine, proguanil</td><td>erythrocyte and</td><td>motile trophozoite</td></tr><tr><td></td><td></td><td></td><td></td><td>forms schizont ...</td><td>and starts to divide</td></tr><tr><td>4. Merozoites</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>released</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Liver</td><td></td><td>A. Blood</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>schizonticides</td></tr><tr><td></td><td></td><td colspan="2">B. Drugs of radical cure inhibit</td><td></td><td>treat the</td></tr><tr><td>3. Schizonts</td><td></td><td colspan="2">hypnozoites: primaquine</td><td></td><td>acute attack:</td></tr><tr><td>divide to form</td><td></td><td>Reactivation</td><td></td><td></td><td>chloroquine</td></tr><tr><td>merozoites</td><td></td><td></td><td></td><td>Erythrocytic stage</td><td>(benign malaria),</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>quinine +</td></tr><tr><td>2. Schizonts</td><td></td><td colspan="2">2a. Hypnozoites of P. vivax</td><td></td><td>doxycycline</td></tr><tr><td>in liver cells</td><td></td><td colspan="2">&amp; P. ovale lie dormant</td><td></td><td>(falciparum</td></tr><tr><td></td><td></td><td colspan="2">(Exo-erythrocytic stage)</td><td></td><td>malaria)</td></tr><tr><td>1. Sporozoites</td><td></td><td colspan="2">D. Drugs preventing</td><td></td><td></td></tr><tr><td>injected by bite</td><td></td><td colspan="2">transmission destroy</td><td>7. Merozoites</td><td></td></tr><tr><td>and enter liver</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(Pre-erythrocytic</td><td></td><td>gametocytes:</td><td></td><td colspan="2">8. Release of merozoites causes fever</td></tr><tr><td>stage)</td><td></td><td></td><td></td><td colspan="2">9. Some merozoites form gametocytes</td></tr><tr><td>MOSQUITO</td><td>Sporozoites</td><td>Oocyst</td><td>Zygote</td><td>10. Taken up in insect bite</td><td></td></tr></table>
</page>
<page number="539">
<table id="p539t1" data-filename="pdftables_fromstorage_023782248" data-page="539" data-table="1"><tr><td></td><td>An antimalarial drug</td><td>Pyrimethamine</td></tr><tr><td>Actions</td><td>A slow blood schizonticide.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Pyrimethamine inhibits the malaria parasite’s dihydrofolate reductase (DHFR) and thus interferes</td></tr><tr><td></td><td colspan="2">with its thymidylate synthesis. Sulfadoxine inhibits dihydropteroate synthetase – an earlier step</td></tr><tr><td></td><td>in thymidylate synthesis.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Used in combination tablet with sulfadoxine for the treatment of falciparum malaria.</td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances, moderate depression of haemopoiesis, rashes, allergic alveolitis.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 53, p 661-662; D&amp;H 2e Ch 49, pp 115-116</td></tr></table>
</page>
<page number="540">
<table id="p540t1" data-filename="pdftables_fromstorage_023782248" data-page="540" data-table="1"><tr><td></td><td>Artemether +</td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">31.07</td><td>lumefantrine</td><td colspan="2">Antiprotozoal drugs – Malaria</td><td></td><td></td></tr><tr><td colspan="4">The malarial cycle and the sites at which drugs can affect it</td><td></td><td></td></tr><tr><td>HUMAN</td><td colspan="3">C. Chemoprophylactic drugs (prevent clinical</td><td>5. Merozoite enters</td><td>6. ... then forms</td></tr><tr><td></td><td colspan="3">attack): chloroquine, mefloquine, proguanil</td><td>erythrocyte and</td><td>motile trophozoite</td></tr><tr><td></td><td></td><td></td><td></td><td>forms schizont ...</td><td>and starts to divide</td></tr><tr><td>4. Merozoites</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>released</td><td></td><td></td><td></td><td></td><td>A. Blood</td></tr><tr><td></td><td></td><td></td><td>Liver</td><td></td><td>schizonticides</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>treat the</td></tr><tr><td></td><td></td><td colspan="2">B. Drugs of radical cure inhibit</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>acute attack:</td></tr><tr><td>3. Schizonts</td><td></td><td colspan="2">hypnozoites: primaquine</td><td></td><td></td></tr><tr><td>divide to form</td><td></td><td>Reactivation</td><td></td><td></td><td>(benign malaria),</td></tr><tr><td>merozoites</td><td></td><td></td><td></td><td>Erythrocytic stage</td><td>quinine +</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>doxycycline; or</td></tr><tr><td>2. Schizonts</td><td></td><td colspan="2">2a. Hypnozoites of P. vivax</td><td></td><td>pyrimethamine</td></tr><tr><td>in liver cells</td><td></td><td colspan="2">&amp; P. ovale lie dormant</td><td></td><td>+ sulfadoxine</td></tr><tr><td></td><td></td><td colspan="2">(Exo-erythrocytic stage)</td><td></td><td>(falciparum</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>malaria)</td></tr><tr><td>1. Sporozoites</td><td></td><td colspan="2">D. Drugs preventing</td><td></td><td></td></tr><tr><td>injected by bite</td><td></td><td colspan="2">transmission destroy</td><td>7. Merozoites</td><td></td></tr><tr><td>and enter liver</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(Pre-erythrocytic</td><td></td><td>gametocytes:</td><td></td><td colspan="2">8. Release of merozoites causes fever</td></tr><tr><td>stage)</td><td></td><td></td><td></td><td colspan="2">9. Some merozoites form gametocytes</td></tr><tr><td>MOSQUITO</td><td>Sporozoites</td><td>Oocyst</td><td>Zygote</td><td>10. Taken up in insect bite</td><td></td></tr></table>
</page>
<page number="541">
<table id="p541t1" data-filename="pdftables_fromstorage_023782248" data-page="541" data-table="1"><tr><td></td><td></td><td>Artemether +</td></tr><tr><td></td><td>An antimalarial drug combination</td><td>lumefantrine</td></tr><tr><td>Actions</td><td>A blood schizonticide combination.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Artemether inhibits falciparum sarcoplasmic-endoplasmic reticulum calcium ATPase.</td></tr><tr><td></td><td colspan="2">Lumefantrine inhibits the metabolism of haem within the parasite food vacuole.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally. Artemether: T0.5 3–7h. Lumefantrine: T0.5 4–7 days.</td><td></td></tr><tr><td>Clinical use</td><td>To treat acute uncomplicated falciparum malaria.</td><td></td></tr><tr><td>Adverse effects</td><td>GIT disturbances, headache, dizziness, parasthesia, myalgia, rash.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 53, p 661; D&amp;H 2e Ch 49, pp 115-116</td></tr></table>
</page>
<page number="542">
<table id="p542t1" data-filename="pdftables_fromstorage_023782248" data-page="542" data-table="1"><tr><td style="text-align: right">31.08</td><td colspan="4">A patient is due to go to an area with a high risk of falciparum malaria.</td><td>Antiprotozoal drugs –</td></tr><tr><td></td><td colspan="4">What drugs could be used for chemoprophylaxis?</td><td>Malaria</td></tr><tr><td colspan="4">The malarial cycle and the sites at which drugs can affect it</td><td></td><td></td></tr><tr><td>HUMAN</td><td colspan="3">C. Chemoprophylactic drugs (prevent clinical</td><td>5. Merozoite enters</td><td>6. ... then forms</td></tr><tr><td></td><td colspan="3">attack): chloroquine, mefloquine, proguanil</td><td>erythrocyte and</td><td>motile trophozoite</td></tr><tr><td></td><td></td><td></td><td></td><td>forms schizont ...</td><td>and starts to divide</td></tr><tr><td>4. Merozoites</td><td></td><td></td><td></td><td></td><td>A. Blood</td></tr><tr><td>released</td><td></td><td></td><td></td><td></td><td>schizonticides</td></tr><tr><td></td><td></td><td></td><td>Liver</td><td></td><td>treat the</td></tr><tr><td></td><td></td><td colspan="2">B. Drugs of radical cure inhibit</td><td></td><td>acute attack:</td></tr><tr><td>3. Schizonts</td><td></td><td colspan="2">hypnozoites: primaquine</td><td></td><td>chloroquine</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>(benign malaria),</td></tr><tr><td>divide to form</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Reactivation</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>quinine +</td></tr><tr><td>merozoites</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Erythrocytic stage</td><td>doxycycline; or</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>pyrimethamine</td></tr><tr><td>2. Schizonts</td><td></td><td colspan="2">2a. Hypnozoites of P. vivax</td><td></td><td>+ sulfadoxine or</td></tr><tr><td>in liver cells</td><td></td><td colspan="2">&amp; P. ovale lie dormant</td><td></td><td>artemether with</td></tr><tr><td></td><td></td><td colspan="2">(Exo-erythrocytic stage)</td><td></td><td>lumefantrine</td></tr><tr><td>1. Sporozoites</td><td></td><td></td><td></td><td></td><td>(falciparum</td></tr><tr><td></td><td></td><td colspan="2">D. Drugs preventing</td><td></td><td></td></tr><tr><td>injected by bite</td><td></td><td colspan="2">transmission destroy</td><td>7. Merozoites</td><td>malaria)</td></tr><tr><td>and enter liver</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(Pre-erythrocytic</td><td></td><td>gametocytes:</td><td></td><td colspan="2">8. Release of merozoites causes fever</td></tr><tr><td>stage)</td><td></td><td></td><td></td><td colspan="2">9. Some merozoites form gametocytes</td></tr><tr><td>MOSQUITO</td><td>Sporozoites</td><td>Oocyst</td><td>Zygote</td><td>10. Taken up in insect bite</td><td></td></tr></table>
</page>
<page number="543">
<table id="p543t1" data-filename="pdftables_fromstorage_023782248" data-page="543" data-table="1"><tr><td></td><td></td><td colspan="3">A patient is due to go to an area with a high risk of falciparum malaria.</td></tr><tr><td></td><td></td><td></td><td></td><td>What drugs could be used for chemoprophylaxis?</td></tr><tr><td colspan="5">If falciparum malaria in the region is chloroquine resistant, the drugs to be used could be:</td></tr><tr><td>Mefloquine</td><td>or</td><td>doxycycline</td><td>or</td><td>proguanil + atovaquone</td></tr><tr><td colspan="5">If it is known that the falciparum malaria in the relevant region is sensitive to chloroquine,</td></tr><tr><td></td><td></td><td colspan="2">the drugs used could be:</td><td></td></tr><tr><td></td><td></td><td colspan="2">Chloroquine + proguanil</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>R&amp;D 7e Ch 53, pp 659-663; D&amp;H 2e Ch 49, pp 115-116</td></tr></table>
</page>
<page number="544">
<table id="p544t1" data-filename="pdftables_fromstorage_023782248" data-page="544" data-table="1"><tr><td style="text-align: right">31.09</td><td>Metronidazole</td><td>Antiprotozoal drugs Amoebiasis</td></tr><tr><td colspan="2">Amoebiasis is caused by the ingestion of the cysts of Entamoeba histolytica.</td><td></td></tr><tr><td></td><td></td><td>2. In the GI tract, the cysts develop</td></tr><tr><td></td><td>1. Ingestion of cysts</td><td>into motile trophozoites,</td></tr><tr><td></td><td></td><td>which invade the intestinal wall</td></tr><tr><td></td><td></td><td>causing amoebic dysentery</td></tr><tr><td colspan="2">6. Cysts in contaminated</td><td></td></tr><tr><td></td><td>food or water</td><td></td></tr><tr><td></td><td></td><td>3. Rarely, the trophozoites</td></tr><tr><td></td><td>5. Cysts in faeces</td><td></td></tr><tr><td></td><td></td><td>migrate to the liver causing</td></tr><tr><td></td><td></td><td>amoebic liver abscess</td></tr><tr><td colspan="2">Some individuals remain</td><td></td></tr><tr><td colspan="2">symptom-free ‘carriers’ who</td><td>4. Some trophozoites</td></tr><tr><td colspan="2">excrete cysts that can infect others.</td><td>become encysted and</td></tr><tr><td></td><td></td><td>are excreted</td></tr></table>
</page>
<page number="545">
<table id="p545t1" data-filename="pdftables_fromstorage_023782248" data-page="545" data-table="1"><tr><td></td><td>An amoebicide (Similar drug: tinidazole)</td><td>Metronidazole</td></tr><tr><td>Actions</td><td>Kills the motile forms of Entamoeba histolytica.</td><td></td></tr><tr><td>MOA</td><td colspan="2">The trophozoite generates, from the drug, free radicals that damage the trophozoite’s DNA.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally, can be given i.v. and rectally; t1⁄2 7h. Tinidazole has longer action.</td></tr><tr><td>Clinical use</td><td colspan="2">To treat amoebic dystery (followed by treatment with diloxanide); to treat amoebic liver abscess.</td></tr><tr><td></td><td>Also used for trichomoniasis, and giardiasis.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances; anorexia. Occasionally dizziness, ataxia, myalgia, hepatitis, blood dyscrasias,</td></tr><tr><td></td><td>Can cause disulfiram reactions after alcohol.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 53, p 664; D&amp;H 2e Ch 49, p 116</td></tr></table>
</page>
<page number="546">
<table id="p546t1" data-filename="pdftables_fromstorage_023782248" data-page="546" data-table="1"><tr><td style="text-align: right">31.10</td><td>Diloxanide</td><td>Antiprotozoal drugs – Amoebiasis</td></tr><tr><td colspan="2">Amoebiasis is caused by the ingestion of the cysts of Entamoeba histolytica.</td><td></td></tr><tr><td></td><td></td><td>2. In the GI tract, the cysts develop</td></tr><tr><td></td><td>1. Ingestion of cysts</td><td>into motile trophozoites,</td></tr><tr><td></td><td></td><td>which invade the intestinal wall</td></tr><tr><td></td><td></td><td>causing amoebic dysentery</td></tr><tr><td colspan="2">6. Cysts in contaminated</td><td></td></tr><tr><td></td><td>food or water</td><td></td></tr><tr><td></td><td></td><td>Metronidazole,</td></tr><tr><td></td><td></td><td>tinidazole</td></tr><tr><td></td><td></td><td>3. Rarely, the trophozoites</td></tr><tr><td></td><td>5. Cysts in faeces</td><td></td></tr><tr><td></td><td></td><td>migrate to the liver causing</td></tr><tr><td></td><td></td><td>amoebic liver abscess</td></tr><tr><td colspan="2">Some individuals remain</td><td></td></tr><tr><td colspan="2">symptom-free ‘carriers’ who</td><td>4. Some trophozoites</td></tr><tr><td colspan="2">excrete cysts that can infect others.</td><td>become encysted and</td></tr><tr><td></td><td></td><td>are excreted</td></tr></table>
</page>
<page number="547">
<table id="p547t1" data-filename="pdftables_fromstorage_023782248" data-page="547" data-table="1"><tr><td></td><td></td><td>An amoebicide</td><td>Diloxanide</td></tr><tr><td>Actions</td><td colspan="2">Acts against the non-motile forms of Entamoeba histolytica.</td><td></td></tr><tr><td>MOA</td><td>Not clearly known.</td><td></td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally, can be given i.v. and rectally; t1⁄2 7h.</td><td></td><td></td></tr><tr><td></td><td></td><td>Diloxanide</td><td>Metronidazole,</td></tr><tr><td></td><td></td><td></td><td>tinidazole</td></tr><tr><td></td><td></td><td></td><td>diloxanide</td></tr><tr><td></td><td></td><td>5. Cysts in faeces</td><td></td></tr><tr><td colspan="2">Some individuals remain</td><td></td><td></td></tr><tr><td colspan="2">symptom-free ‘carriers’</td><td></td><td></td></tr><tr><td colspan="2">who excrete cysts that can</td><td></td><td></td></tr><tr><td>infect others.</td><td></td><td></td><td></td></tr><tr><td>Clinical use</td><td colspan="3">To treat amoebic dysentery (after treatment with metronidazole); to treat asymptomatic cyst carriers.</td></tr><tr><td>Adverse effects</td><td colspan="3">GIT disturbances; anorexia. Occasionally dizziness, ataxia, myalgia, hepatitis, blood dyscrasias,</td></tr><tr><td></td><td>Can cause disulfiram reactions after alcohol.</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">R&amp;D 7e Ch 53, p 664; D&amp;H 2e Ch 49, p 116</td></tr></table>
</page>
<page number="548">
<table id="p548t1" data-filename="pdftables_fromstorage_023782248" data-page="548" data-table="1"><tr><td></td><td>Sodium</td><td></td></tr><tr><td style="text-align: right">31.11</td><td>stibogluconate</td><td>Antiprotozoal drugs – Leishmaniasis</td></tr><tr><td colspan="3">Leishmaniasis is a disease of the skin and viscera caused by leishmania protozoa transmitted by the bite of a sandfly.</td></tr><tr><td colspan="2">1. Sandfly bite tranfers</td><td></td></tr><tr><td colspan="2">the flagellated form of</td><td>2. Macrophages phagocytose them</td></tr><tr><td colspan="2">the protozoa to host</td><td></td></tr><tr><td></td><td></td><td>3. The parasites multiply and</td></tr><tr><td></td><td></td><td>transform into non-flagellated</td></tr><tr><td colspan="2">7. Flagellated forms</td><td>amastigotes in the macrophages</td></tr><tr><td colspan="2">(promastigotes)</td><td>which rupture releasing</td></tr><tr><td colspan="2">develop in the sandfly</td><td>the protozoa ...</td></tr><tr><td colspan="2">6. Sandfly sucks blood</td><td>4. ... which cause chronic inflammatory</td></tr><tr><td colspan="2">containing parasitised</td><td>lesions of the skin, and sometimes</td></tr><tr><td colspan="2">macrophages</td><td>the viscera (spleen, liver) ...</td></tr><tr><td></td><td></td><td>5. ... and also parasitise</td></tr><tr><td></td><td></td><td>other macrophages</td></tr></table>
</page>
<page number="549">
<table id="p549t1" data-filename="pdftables_fromstorage_023782248" data-page="549" data-table="1"><tr><td></td><td></td><td>Sodium</td></tr><tr><td></td><td>A leishmaniacide</td><td>stibogluconate</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Inactivates the protozoa within the macrophage, possibly by triggering toxic oxygen radicals.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given i.m. (painful) or by slow i.v. injection daily for 10–20 days.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">To treat visceral leishmaniasis (kala-azar) and, if necessary, cutaneous leishmaniasis.</td></tr><tr><td></td><td>Specialist supervision needed.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances, ECG changes, headache, coughing, arthralgia, myalgia.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 53, p 666; D&amp;H 2e Ch 49 p 116</td></tr></table>
</page>
<page number="550">
<table id="p550t1" data-filename="pdftables_fromstorage_023782248" data-page="550" data-table="1"><tr><td style="text-align: right">32.01</td><td>Amphotericin</td><td></td><td>Antifungal agents</td><td></td></tr><tr><td colspan="2">Simplified diagram of a fungal cell</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Ergosterol</td><td>Microtubule system</td></tr><tr><td></td><td></td><td></td><td>14α</td><td></td></tr><tr><td></td><td></td><td>demethylase</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Lanosterol</td><td></td></tr><tr><td></td><td></td><td></td><td>DNA</td><td></td></tr><tr><td></td><td></td><td>Squalene</td><td></td><td></td></tr><tr><td></td><td></td><td>epoxidase</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Nucleus</td><td></td></tr><tr><td></td><td></td><td></td><td>Squalene</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Fungal cell wall</td></tr><tr><td></td><td></td><td colspan="2">Ergosterol-rich fungal cell membrane</td><td></td></tr></table>
</page>
<page number="551">
<table id="p551t1" data-filename="pdftables_fromstorage_023782248" data-page="551" data-table="1"><tr><td></td><td>A broad-spectrum antifungal agent</td><td>Amphotericin</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Kills fungi by binding to the ergosterol in the fungal cell membane (missing in mammalian</td></tr><tr><td></td><td>cells) and increasing membrane permeability.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Not absorbed in the GIT. Given by i.v. infusion in a lipid formulation; can cross the blood–</td></tr><tr><td></td><td colspan="2">brain barrier in meningitis; given topically by lozenge for oral fungal infections.</td></tr><tr><td>Clinical use</td><td colspan="2">Candidiasis; cryptococcal meningitis; histoplasmosis; apergillosis; blastomycosis; coccidio-</td></tr><tr><td></td><td>mycosis; mucormycosis.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">When given i.v.: renal toxicity; CVS toxicity; GIT disturbances; neurological disturbances;</td></tr><tr><td></td><td colspan="2">anaphylactoid reactions; infusion reactions (fever, headache, chills); myalgia, arthralgia.</td></tr><tr><td>Drug with</td><td>Nystatin. Given orally for GIT candidiasis.</td><td></td></tr><tr><td>similar action</td><td></td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 52, pp 650-651; D&amp;H 2e Ch 50, p 117</td></tr></table>
</page>
<page number="552">
<table id="p552t1" data-filename="pdftables_fromstorage_023782248" data-page="552" data-table="1"><tr><td style="text-align: right">32.02</td><td>Fluconazole</td><td></td><td>Antifungal agents</td><td></td></tr><tr><td colspan="2">Simplified diagram of a fungal cell</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Amphotericin</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Ergosterol</td><td>Microtubule system</td></tr><tr><td></td><td></td><td></td><td>14α</td><td></td></tr><tr><td></td><td></td><td>demethylase</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Lanosterol</td><td></td></tr><tr><td></td><td></td><td></td><td>DNA</td><td></td></tr><tr><td></td><td></td><td>Squalene</td><td></td><td></td></tr><tr><td></td><td></td><td>epoxidase</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Nucleus</td><td></td></tr><tr><td></td><td></td><td></td><td>Squalene</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Fungal cell wall</td></tr><tr><td></td><td></td><td colspan="2">Ergosterol-rich fungal cell membrane</td><td></td></tr></table>
</page>
<page number="553">
<table id="p553t1" data-filename="pdftables_fromstorage_023782248" data-page="553" data-table="1"><tr><td></td><td>A triazole antifungal agent</td><td>Fluconazole</td></tr><tr><td>Action</td><td colspan="2">Fungistatic by inhibiting the synthesis of ergosterol – a crucial component of fungal cell</td></tr><tr><td></td><td>membranes (missing in mammalian cells).</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits 14α demethylase – a p450-dependent enzyme important in the conversion of</td></tr><tr><td></td><td>lanosterol to ergosterol.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally or i.v., widely distributed, passing into CSF, ocular fluids, vaginal tissue, nails,</td></tr><tr><td></td><td>saliva, skin. Half-life ~25h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Candidiasis: local (dermal, mucosal) and invasive; tinea corporis, tinea cruris &amp; tinea pedis;</td></tr><tr><td></td><td colspan="2">cryptococcal meningitis; histoplasmosis; blastomycosis; coccidiomycosis.</td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances; headache, rash. Less frequently liver disorders, hypersensitivity reactions.</td></tr><tr><td>Drug with</td><td>Itraconazole (used for fungal skin infections); hepatotoxicity.</td><td></td></tr><tr><td>similar action</td><td colspan="2">Voriconazole: broad spectrum; used for life-threatening fungal infections.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 52, p 652; D&amp;H 2e Ch 50, p 117</td></tr></table>
</page>
<page number="554">
<table id="p554t1" data-filename="pdftables_fromstorage_023782248" data-page="554" data-table="1"><tr><td style="text-align: right">32.03</td><td>Terbinafine</td><td></td><td>Antifungal agents</td><td></td></tr><tr><td colspan="2">Simplified diagram of a fungal cell</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Amphotericin</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Ergosterol</td><td>Microtubule system</td></tr><tr><td></td><td>Fluconazole,</td><td></td><td>14α</td><td></td></tr><tr><td></td><td>itraconazole</td><td>demethylase</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Lanosterol</td><td></td></tr><tr><td></td><td></td><td></td><td>DNA</td><td></td></tr><tr><td></td><td></td><td>Squalene</td><td></td><td></td></tr><tr><td></td><td></td><td>epoxidase</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Nucleus</td><td></td></tr><tr><td></td><td></td><td></td><td>Squalene</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Fungal cell wall</td></tr><tr><td></td><td></td><td colspan="2">Ergosterol-rich fungal cell membrane</td><td></td></tr></table>
</page>
<page number="555">
<table id="p555t1" data-filename="pdftables_fromstorage_023782248" data-page="555" data-table="1"><tr><td></td><td>A broad-spectrum antifungal agent</td><td>Terbinafine</td></tr><tr><td>Action</td><td colspan="2">Fungicidal by inhibiting the synthesis of ergosterol – a crucial component of fungal cell</td></tr><tr><td></td><td>membranes (missing in mammalian cells).</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits squalene epoxidase which is responsible for the conversion of squalene to</td></tr><tr><td></td><td>lanostreol.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally it is taken up into skin, nails and fatty tissue. Can be given topically.</td></tr><tr><td>Clinical use</td><td colspan="2">Fungal infections of the nails &amp; skin (tinea corporis, tinea cruris &amp; tinea pedis, aka ‘ringworm’)</td></tr><tr><td>Adverse effects</td><td>GIT disturbances; headache, dizziness, rash.</td><td></td></tr><tr><td>Drug with</td><td>Amorolfine; used topically on the nails.</td><td></td></tr><tr><td>similar action</td><td></td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 52, p 653; D&amp;H 2e Ch 50, p 117</td></tr></table>
</page>
<page number="556">
<table id="p556t1" data-filename="pdftables_fromstorage_023782248" data-page="556" data-table="1"><tr><td style="text-align: right">32.04</td><td>Caspofungin</td><td>Antifungal agents</td><td></td><td></td><td></td></tr><tr><td colspan="3">Simplified diagram of a fungal cell</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Amphotericin</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Ergosterol</td><td>Microtubule system</td></tr><tr><td></td><td>Fluconazole,</td><td></td><td></td><td>14α</td><td></td></tr><tr><td></td><td>itraconazole</td><td></td><td>demethylase</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Lanosterol</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>DNA</td><td></td></tr><tr><td></td><td colspan="2">Terbinafine</td><td>eSpqouxaildeansee</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Nucleus</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Squalene</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Fungal cell wall</td></tr><tr><td></td><td></td><td></td><td colspan="2">Ergosterol-rich fungal cell membrane</td><td></td></tr></table>
</page>
<page number="557">
<table id="p557t1" data-filename="pdftables_fromstorage_023782248" data-page="557" data-table="1"><tr><td></td><td>An antifungal agent</td><td>Caspofungin</td></tr><tr><td>Action</td><td>Fungicidal by weakening the fungal cell wall.</td><td></td></tr><tr><td>MOA</td><td colspan="2">Inhibits the synthesis of 1,3-β-D-glucan, a crucial component of the fungal cell wall that is</td></tr><tr><td></td><td>missing from mammalian cells.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given i.v. Half-life ~9h.</td><td></td></tr><tr><td>Clinical use</td><td>Candidiasis; aspergillosis.</td><td></td></tr><tr><td>Adverse effects</td><td>GIT disturbances; headache, dizziness, rash.</td><td></td></tr><tr><td>Drug with</td><td>Micafungin. Used for invasive candidiasis.</td><td></td></tr><tr><td>similar action</td><td></td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 52, p 652; D&amp;H 2e Ch 50, p 117</td></tr></table>
</page>
<page number="558">
<table id="p558t1" data-filename="pdftables_fromstorage_023782248" data-page="558" data-table="1"><tr><td style="text-align: right">32.05</td><td>Griseofulvin</td><td>Antifungal agents</td><td></td><td></td><td></td></tr><tr><td colspan="3">Simplified diagram of a fungal cell</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Amphotericin</td><td></td><td></td></tr><tr><td></td><td colspan="2">Caspofungin</td><td></td><td>Ergosterol</td><td>Microtubule system</td></tr><tr><td></td><td>Fluconazole,</td><td></td><td></td><td>14α</td><td></td></tr><tr><td></td><td>itraconazole</td><td></td><td>demethylase</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Lanosterol</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>DNA</td><td></td></tr><tr><td></td><td colspan="2">Terbinafine</td><td>eSpqouxaildeansee</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Nucleus</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Squalene</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Fungal cell wall</td></tr><tr><td></td><td></td><td></td><td colspan="2">Ergosterol-rich fungal cell membrane</td><td></td></tr></table>
</page>
<page number="559">
<table id="p559t1" data-filename="pdftables_fromstorage_023782248" data-page="559" data-table="1"><tr><td></td><td>A narrow-spectrum antifungal agent</td><td>Griseofulvin</td></tr><tr><td>Action</td><td>Fungistatic by interefering with mitosis of fungal cells.</td><td></td></tr><tr><td>MOA</td><td>Interacts with polymerized microtubules inhibiting spindle formation.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally; taken up by proliferating skin cells, binds to the keratin. Half-life ~24h.</td></tr><tr><td>Clinical use</td><td colspan="2">Fungal infections of skin, hair and scalp; trichophyton infections in children.</td></tr><tr><td>Adverse effects</td><td>Infrequent: GIT disturbances; headache.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 52, p 651; D&amp;H 2e Ch 50, p 117</td></tr></table>
</page>
<page number="560">
<table id="p560t1" data-filename="pdftables_fromstorage_023782248" data-page="560" data-table="1"><tr><td style="text-align: right">32.06</td><td>Flucytosine</td><td>Antifungal agents</td><td></td><td></td><td></td></tr><tr><td colspan="3">Simplified diagram of a fungal cell</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Amphotericin</td><td></td><td></td></tr><tr><td></td><td colspan="2">Caspofungin</td><td></td><td>Ergosterol</td><td>Microtubule system</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Griseofulvin</td></tr><tr><td></td><td>Fluconazole,</td><td></td><td></td><td>14α</td><td></td></tr><tr><td></td><td>itraconazole</td><td></td><td>demethylase</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Lanosterol</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>DNA</td><td></td></tr><tr><td></td><td colspan="2">Terbinafine</td><td>eSpqouxaildeansee</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Nucleus</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Squalene</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Fungal cell wall</td></tr><tr><td></td><td></td><td></td><td colspan="2">Ergosterol-rich fungal cell membrane</td><td></td></tr></table>
</page>
<page number="561">
<table id="p561t1" data-filename="pdftables_fromstorage_023782248" data-page="561" data-table="1"><tr><td></td><td>A synthetic antifungal agent</td><td>Flucytosine</td></tr><tr><td>Action &amp; MOA</td><td colspan="2">Is converted in fungal cells (but not mammalian cells) into the antimetabolite, 5-fluorouracil ,</td></tr><tr><td></td><td colspan="2">which Interrupts DNA synthesis by inhibiting thymidylate synthetase.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given by i.v. infusion, but can be given orally. Plasma half-life ~4h.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Systemic fungal &amp; yeast infections: systemic candidiasis, cryptococcal meningitis.</td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances; rashes. Less commonly: blood dyscrasias, headaches, confusion,</td></tr><tr><td></td><td>cardiotoxicity.</td><td></td></tr><tr><td>Special points</td><td>Resistance can occur, therefore usually given with amphotericin.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 52, p 653; D&amp;H 2e Ch 50, p 117</td></tr></table>
</page>
<page number="562">
<table id="p562t1" data-filename="pdftables_fromstorage_023782248" data-page="562" data-table="1"><tr><td></td><td>Notes on</td><td></td><td></td><td></td></tr><tr><td style="text-align: right">32.07</td><td>antifungal drugs</td><td></td><td>Antifungal agents</td><td></td></tr><tr><td colspan="2">Simplified diagram of a fungal cell</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Amphotericin</td><td></td><td></td></tr><tr><td></td><td>Caspofungin</td><td></td><td>Ergosterol</td><td>Microtubule system</td></tr><tr><td></td><td></td><td></td><td></td><td>Griseofulvin</td></tr><tr><td></td><td>Fluconazole,</td><td></td><td>14α</td><td></td></tr><tr><td></td><td>itraconazole</td><td>demethylase</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Lanosterol</td><td></td></tr><tr><td></td><td></td><td></td><td>DNA</td><td>Flucytosine</td></tr><tr><td></td><td>Terbinafine</td><td>eSpqouxaildeansee</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Nucleus</td><td></td></tr><tr><td></td><td></td><td></td><td>Squalene</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Fungal cell wall</td></tr><tr><td></td><td></td><td colspan="2">Ergosterol-rich fungal cell membrane</td><td></td></tr></table>
</page>
<page number="563">
<table id="p563t1" data-filename="pdftables_fromstorage_023782248" data-page="563" data-table="1"><tr><td>Notes</td></tr><tr><td>Notes</td></tr></table>
</page>
<page number="564">
<table id="p564t1" data-filename="pdftables_fromstorage_023782248" data-page="564" data-table="1"><tr><td style="text-align: right">33.01</td><td>Mebendazole</td><td>Anthelminthic drugs</td><td></td></tr><tr><td></td><td colspan="2">Disease/worm</td><td>Drugs used</td></tr><tr><td colspan="3">‘Thread’ worm infection (Enterobius vermicularis in UK, Strongyloides</td><td></td></tr><tr><td colspan="2">stercoralis in US)</td><td></td><td></td></tr><tr><td colspan="3">Common round worm (Ascaris lumbricoides)</td><td></td></tr><tr><td colspan="2">Whip worm (Trichuris trichiura)</td><td></td><td></td></tr><tr><td colspan="3">Tape worm infection: Taenia saginata (beef tapeworm), Taenia solium</td><td></td></tr><tr><td colspan="2">(pork tape worm)</td><td></td><td></td></tr><tr><td colspan="3">Cysticercosis (infection with larval Taenia solium)</td><td></td></tr><tr><td colspan="3">Hydatid disease (Echinococcus granulosus)</td><td></td></tr><tr><td colspan="3">Bilharziasis caused by blood flukes /schistosomes (Schistosoma</td><td></td></tr><tr><td colspan="3">haematobium, S. mansoni, S. japonicum)</td><td></td></tr><tr><td colspan="3">Hookworm infection (Ankylostoma duodenale, Necator americanus)</td><td></td></tr><tr><td colspan="3">Cutaneous larva migrans (Ankylostoma caninum)</td><td></td></tr><tr><td colspan="3">Visceral larva migrans (Toxacara canis)</td><td></td></tr></table>
</page>
<page number="565">
<table id="p565t1" data-filename="pdftables_fromstorage_023782248" data-page="565" data-table="1"><tr><td></td><td>A broad-spectrum anthelminthic agent</td><td>Mebendazole</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Inhibits microtubule synthesis, impairing microtubule functions such as glucose uptake.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally; poor uptake is improved by fatty foods.</td><td></td></tr><tr><td>Clinical use</td><td>Thread worm, round worm, whip worm and hookworm infections.</td><td></td></tr><tr><td>Adverse effects</td><td>GIT disturbances, rash. Rarely convulsions in infants.</td><td></td></tr><tr><td>Drugs with</td><td colspan="2">Albendazole: also used for cutaneous larva migrans, cystercercosis, strongyloidiasis.</td></tr><tr><td>similar action</td><td></td><td></td></tr><tr><td>Special points</td><td colspan="2">Albendazole is only available in the UK from the pharmaceutical company on a ‘named patient’</td></tr><tr><td></td><td>basis.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 54, p 670; D&amp;H 2e Ch 50, p 117</td></tr></table>
</page>
<page number="566">
<table id="p566t1" data-filename="pdftables_fromstorage_023782248" data-page="566" data-table="1"><tr><td style="text-align: right">33.02</td><td>Levamisole</td><td>Anthelminthic drugs</td><td></td></tr><tr><td></td><td></td><td>Disease/worm</td><td>Drugs used</td></tr><tr><td colspan="3">‘Thread’ worm infection (Enterobius vermicularis in UK, Strongyloides</td><td>Mebendazole</td></tr><tr><td colspan="2">stercoralis in US)</td><td></td><td></td></tr><tr><td colspan="3">Common round worm (Ascaris lumbricoides)</td><td>Mebendazole</td></tr><tr><td colspan="3">Whip worm (Trichuris trichiura)</td><td>Mebendazole</td></tr><tr><td colspan="3">Tape worm infection: Taenia saginata (beef tapeworm), Taenia solium</td><td></td></tr><tr><td colspan="2">(pork tape worm)</td><td></td><td></td></tr><tr><td colspan="3">Cysticercosis (infection with larval Taenia solium)</td><td>Albendazole</td></tr><tr><td colspan="3">Hydatid disease (Echinococcus granulosus)</td><td></td></tr><tr><td colspan="3">Bilharziasis caused by blood flukes /schistosomes (Schistosoma</td><td></td></tr><tr><td colspan="3">haematobium, S. mansoni, S. japonicum)</td><td></td></tr><tr><td colspan="3">Hookworm infection (Ankylostoma duodenale, Necator americanus)</td><td>Mebendazole</td></tr><tr><td colspan="3">Cutaneous larva migrans (Ankylostoma caninum)</td><td>Albendazole</td></tr><tr><td colspan="3">Visceral larva migrans (Toxacara canis)</td><td>Albendazole</td></tr></table>
</page>
<page number="567">
<table id="p567t1" data-filename="pdftables_fromstorage_023782248" data-page="567" data-table="1"><tr><td></td><td>A narrow-spectrum anthelminthic agent</td><td>Levamisole</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Causes tonic paralysis of the worm by stimulating nicotinic receptors at the neuromuscular junction.</td></tr><tr><td></td><td>The paralysed worms (but not the ova) are expelled in the faeces.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally; plasma half-life is 4h.</td><td></td></tr><tr><td>Clinical use</td><td>Common round worm infection.</td><td></td></tr><tr><td>Adverse effects</td><td>Mild GIT disturbances.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Only available in the UK from the relevant pharmaceutical company on a ‘named patient’ basis.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 54, p 671; D&amp;H 2e Ch 50, p 117</td></tr></table>
</page>
<page number="568">
<table id="p568t1" data-filename="pdftables_fromstorage_023782248" data-page="568" data-table="1"><tr><td style="text-align: right">33.03</td><td>Piperazine</td><td>Anthelminthic drugs</td><td></td></tr><tr><td></td><td></td><td>Disease/worm</td><td>Drugs used</td></tr><tr><td colspan="3">‘Thread’ worm infection (Enterobius vermicularis in UK, Strongyloides</td><td>Mebendazole, Albendazole</td></tr><tr><td colspan="3">Common round worm (Ascaris lumbricoides)</td><td>Mebendazole, Levamisole</td></tr><tr><td colspan="3">Whip worm (Trichuris trichiura)</td><td>Mebendazole</td></tr><tr><td colspan="3">Tape worm infection: Taenia saginata (beef tapeworm), Taenia solium</td><td></td></tr><tr><td colspan="2">(pork tape worm)</td><td></td><td></td></tr><tr><td colspan="3">Cysticercosis (infection with larval Taenia solium)</td><td>Albendazole</td></tr><tr><td colspan="3">Hydatid disease (Echinococcus granulosus)</td><td></td></tr><tr><td colspan="3">Bilharziasis caused by blood flukes /schistosomes (Schistosoma</td><td></td></tr><tr><td colspan="3">haematobium, S. mansoni, S. japonicum)</td><td></td></tr><tr><td colspan="3">Hookworm infection (Ankylostoma duodenale, Necator americanus)</td><td>Mebendazole</td></tr><tr><td colspan="3">Cutaneous larva migrans (Ankylostoma caninum)</td><td>Albendazole</td></tr><tr><td colspan="3">Visceral larva migrans (Toxacara canis)</td><td>Albendazole</td></tr></table>
</page>
<page number="569">
<table id="p569t1" data-filename="pdftables_fromstorage_023782248" data-page="569" data-table="1"><tr><td></td><td>A narrow-spectrum anthelminthic agent</td><td>Piperazine</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">It reverses neuromuscular transmission in the worm. The paralysed worms are expelled alive in the</td></tr><tr><td></td><td>faeces.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally.</td><td></td></tr><tr><td>Clinical use</td><td>Common round worm infection.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances. Rash, bronchospasm. Some patients experience CNS symptoms, e.g. dizziness,</td></tr><tr><td></td><td>paraesthesias.</td><td></td></tr><tr><td>Special points</td><td colspan="2">Only available in the UK from the relevant pharmaceutical company on a ‘named patient’ basis.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 54, p 670; D&amp;H 2e Ch 50, p 117</td></tr></table>
</page>
<page number="570">
<table id="p570t1" data-filename="pdftables_fromstorage_023782248" data-page="570" data-table="1"><tr><td style="text-align: right">33.04</td><td>Praziquantel</td><td>Anthelminthic drugs</td><td></td></tr><tr><td></td><td colspan="2">Disease/worm</td><td>Drugs used</td></tr><tr><td colspan="3">‘Thread’ worm infection (Enterobius vermicularis in UK, Strongyloides</td><td>Mebendazole, Albendazole, Piperazine</td></tr><tr><td colspan="3">Common round worm (Ascaris lumbricoides)</td><td>Mebendazole, Levamisole, Piperazine</td></tr><tr><td colspan="2">Whip worm (Trichuris trichiura)</td><td></td><td>Mebendazole</td></tr><tr><td colspan="3">Tape worm infection: Taenia saginata (beef tapeworm), Taenia solium</td><td>Albendazole</td></tr><tr><td colspan="2">(pork tape worm)</td><td></td><td></td></tr><tr><td colspan="3">Cysticercosis (infection with larval Taenia solium)</td><td></td></tr><tr><td colspan="3">Hydatid disease (Echinococcus granulosus)</td><td>Albendazole</td></tr><tr><td colspan="3">Bilharziasis caused by blood flukes /schistosomes (Schistosoma</td><td></td></tr><tr><td colspan="3">haematobium, S. mansoni, S. japonicum)</td><td></td></tr><tr><td colspan="3">Hookworm infection (Ankylostoma duodenale, Necator americanus)</td><td>Mebendazole</td></tr><tr><td colspan="3">Cutaneous larva migrans (Ankylostoma caninum)</td><td>Albendazole</td></tr><tr><td colspan="3">Visceral larva migrans (Toxacara canis)</td><td>Albendazole</td></tr></table>
</page>
<page number="571">
<table id="p571t1" data-filename="pdftables_fromstorage_023782248" data-page="571" data-table="1"><tr><td></td><td>A broad-spectrum anthelminthic agent</td><td>Praziquantel</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">It causes an increase in the calcium permeability of the cell membranes, promoting calcium influx,</td></tr><tr><td></td><td colspan="2">resulting in prolonged contraction of muscle with eventual paralysis and death.</td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally, well absorbrd, metabolised to inactive products. Plasma half-life 60–90min.</td></tr><tr><td>Clinical use</td><td>Schistosomiasis, cysticercosis.</td><td></td></tr><tr><td>Adverse effects</td><td>Few and minor: sometimes GIT disturbances.</td><td></td></tr><tr><td>Special points</td><td>Available in the UK from special-order manufacturers.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 54, pp 669-670; D&amp;H 2e Ch 50, p 117</td></tr></table>
</page>
<page number="572">
<table id="p572t1" data-filename="pdftables_fromstorage_023782248" data-page="572" data-table="1"><tr><td style="text-align: right">33.05</td><td>Ivermectin</td><td>Antheminthic drugs</td><td></td></tr><tr><td></td><td></td><td>Disease/worm</td><td>Drugs used</td></tr><tr><td colspan="3">‘Thread’ worm infection (Enterobius vermicularis in UK, Strongyloides</td><td>Mebendazole, Albendazole, Piperazine</td></tr><tr><td colspan="2">stercoralis in US)</td><td></td><td></td></tr><tr><td colspan="3">Common round worm (Ascaris lumbricoides)</td><td>Mebendazole, Levamisole, Piperazine</td></tr><tr><td colspan="3">Whip worm (Trichuris trichiura)</td><td>Mebendazole</td></tr><tr><td colspan="3">Tape worm infection: Taenia saginata (beef tapeworm), Taenia solium</td><td>Praziquantel</td></tr><tr><td colspan="2">(pork tape worm)</td><td></td><td></td></tr><tr><td colspan="3">Cysticercosis (infection with larval Taenia solium)</td><td>Albendazole, Praziquantel</td></tr><tr><td colspan="3">Hydatid disease (Echinococcus granulosus)</td><td>Albendazole</td></tr><tr><td colspan="3">Bilharziasis caused by blood flukes /schistosomes (Schistosoma</td><td>Praziquantel</td></tr><tr><td colspan="3">haematobium, S. mansoni, S. japonicum)</td><td></td></tr><tr><td colspan="3">Hookworm infection (Ankylostoma duodenale, Necator americanus)</td><td>Mebendazole</td></tr><tr><td colspan="3">Cutaneous larva migrans (Ankylostoma caninum)</td><td>Albendazole</td></tr><tr><td colspan="3">Visceral larva migrans (Toxacara canis)</td><td>Albendazole</td></tr></table>
</page>
<page number="573">
<table id="p573t1" data-filename="pdftables_fromstorage_023782248" data-page="573" data-table="1"><tr><td></td><td>A broad-spectrum anthelminthic agent</td><td>Ivermectin</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Acts at the worm’s neuromuscular junction, causing paralysis either by intensifying GABA-mediated</td></tr><tr><td></td><td colspan="2">inhibition or by activating an invertebrate-specific glutamate-gated chloride channel.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally.</td><td></td></tr><tr><td>Clinical use</td><td>Onchocerciasis (drug of choice); strongyloidiasis.</td><td></td></tr><tr><td>Adverse effects</td><td>Infrequent: itching, rash, GIT disturbances, dizziness, fatigue.</td><td></td></tr><tr><td>Special points</td><td>Available in the UK from special-order manufacturers.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 54, p 671; D&amp;H 2e Ch 50, p 117</td></tr></table>
</page>
<page number="574">
<table id="p574t1" data-filename="pdftables_fromstorage_023782248" data-page="574" data-table="1"><tr><td style="text-align: right">33.06</td><td>Antheminthic drugs</td><td></td></tr><tr><td></td><td>Disease/worm</td><td>Drugs used</td></tr><tr><td colspan="2">‘Thread’ worm infection (Enterobius vermicularis in UK, Strongyloides</td><td>Mebendazole, Albendazole, Piperazine</td></tr><tr><td colspan="2">stercoralis in US)</td><td>For US ‘threadworm’: ivermectin</td></tr><tr><td colspan="2">Common round worm (Ascaris lumbricoides)</td><td>Mebendazole, Levamisole, Piperazine</td></tr><tr><td colspan="2">Whip worm (Trichuris trichiura)</td><td>Mebendazole</td></tr><tr><td colspan="2">Tape worm infection: Taenia saginata (beef tapeworm), Taenia solium</td><td>Praziquantel</td></tr><tr><td colspan="2">(pork tape worm)</td><td></td></tr><tr><td colspan="2">Cysticercosis (infection with larval Taenia solium)</td><td>Albendazole, Praziquantel</td></tr><tr><td colspan="2">Hydatid disease (Echinococcus granulosus)</td><td>Albendazole</td></tr><tr><td colspan="2">Bilharziasis caused by blood flukes /schistosomes (Schistosoma</td><td>Praziquantel</td></tr><tr><td colspan="2">haematobium, S. mansoni, S. japonicum)</td><td></td></tr><tr><td colspan="2">Hookworm infection (Ankylostoma duodenale, Necator americanus)</td><td>Mebendazole</td></tr><tr><td colspan="2">Cutaneous larva migrans (Ankylostoma caninum)</td><td>Albendazole, ivermectin</td></tr><tr><td colspan="2">Visceral larva migrans (Toxacara canis)</td><td>Albendazole</td></tr></table>
</page>
<page number="575">
<table id="p575t1" data-filename="pdftables_fromstorage_023782248" data-page="575" data-table="1"><tr><td>Notes</td></tr><tr><td>Notes</td></tr></table>
</page>
<page number="576">
<table id="p576t1" data-filename="pdftables_fromstorage_023782248" data-page="576" data-table="1"><tr><td style="text-align: right">34.01</td><td>Methotrexate</td><td>Anticancer drugs</td><td></td></tr><tr><td></td><td>Diagram of the main targets for anticancer drug therapy</td><td></td><td></td></tr><tr><td></td><td></td><td>Purine synthesis</td><td>Pyrimidine synthesis</td></tr><tr><td></td><td></td><td colspan="2">Ribonucleotides</td></tr><tr><td></td><td></td><td colspan="2">Deoxyribonucleotides</td></tr><tr><td></td><td></td><td>DNA</td><td></td></tr><tr><td></td><td></td><td>RNA</td><td></td></tr><tr><td></td><td></td><td colspan="2">(transfer, messenger, ribosomal)</td></tr><tr><td></td><td></td><td>Proteins</td><td>Receptors</td></tr><tr><td></td><td></td><td>Enzymes</td><td>Microtubules</td></tr></table>
</page>
<page number="577">
<table id="p577t1" data-filename="pdftables_fromstorage_023782248" data-page="577" data-table="1"><tr><td></td><td></td><td>Antimetabolite anticancer drug</td><td colspan="2">Methotrexate</td><td></td></tr><tr><td>Actions</td><td>Interferes with purine synthesis and the</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>synthesis of thymidylate and thus with</td><td colspan="2">Methotrexate</td><td></td><td></td></tr><tr><td></td><td>DNA synthesis.</td><td></td><td></td><td></td><td></td></tr><tr><td>MOA</td><td>Competitively inhibits dihydrofolate</td><td>DHFR</td><td></td><td>DHFR</td><td></td></tr><tr><td></td><td>reductase (DHFR).</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>FH4</td><td></td></tr><tr><td></td><td></td><td>Folic acid</td><td>FH</td><td colspan="2">FH 4 + 1-carbon unit</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally, i.v., i.m., or intrathecally; taken</td><td></td><td style="text-align: right">2</td><td></td><td></td></tr><tr><td></td><td>up into cells by the folate transport system.</td><td></td><td></td><td></td><td></td></tr><tr><td>Clinical use</td><td>Acute lymphoblastic leukemia in children;</td><td></td><td></td><td>Thymidylate</td><td></td></tr><tr><td></td><td>choriocarcinoma; tumours of head, neck</td><td>dTMP</td><td></td><td>synthetase</td><td>dUMP</td></tr><tr><td></td><td>breast &amp; lung.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>FH 2 = dihydrofolate</td><td></td><td></td><td></td></tr><tr><td>Adverse effects</td><td>Myelosupression, GIT disturbances,</td><td>FH 4 = tetrahydrofolate</td><td></td><td></td><td></td></tr><tr><td></td><td>mucositis and sometimes pneumonitis.</td><td>dTMP = thymidylate</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>dUMP = uridylate</td><td></td><td></td><td></td></tr><tr><td>Special points</td><td colspan="5">High-dose regimens should be followed by ‘rescue’ with folinic acid – a form of tetrahydrofolate –</td></tr><tr><td></td><td>to minimise toxic effects on the bone marrow and GIT mucosa.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="4">R&amp;D 7e Ch 55, p 680; D&amp;H 2e Ch 46, p 105</td></tr></table>
</page>
<page number="578">
<table id="p578t1" data-filename="pdftables_fromstorage_023782248" data-page="578" data-table="1"><tr><td style="text-align: right">34.02</td><td>Fluorouracil</td><td>Anticancer drugs</td><td></td></tr><tr><td></td><td>Diagram of the main targets for anticancer drug therapy</td><td></td><td></td></tr><tr><td></td><td></td><td>Purine synthesis</td><td>Pyrimidine synthesis</td></tr><tr><td></td><td></td><td colspan="2">Ribonucleotides</td></tr><tr><td></td><td>Methotrexate</td><td></td><td></td></tr><tr><td></td><td>inhibits purine synthesis</td><td colspan="2">Deoxyribonucleotides</td></tr><tr><td></td><td>and dTMP synthesis</td><td></td><td></td></tr><tr><td></td><td></td><td>DNA</td><td></td></tr><tr><td></td><td></td><td>RNA</td><td></td></tr><tr><td></td><td></td><td colspan="2">(transfer, messenger, ribosomal)</td></tr><tr><td></td><td></td><td>Proteins</td><td>Receptors</td></tr><tr><td></td><td></td><td>Enzymes</td><td>Microtubules</td></tr></table>
</page>
<page number="579">
<table id="p579t1" data-filename="pdftables_fromstorage_023782248" data-page="579" data-table="1"><tr><td></td><td></td><td>Antimetabolite anticancer drug</td><td colspan="2">Fluorouracil</td><td></td></tr><tr><td>Actions</td><td>Interferes with the synthesis of dTMP and</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>thus with DNA synthesis.</td><td colspan="2">Methotrexate</td><td></td><td></td></tr><tr><td>MOA</td><td>Gives rise to a fraudulent nucleotide and</td><td>DHFR</td><td></td><td>DHFR</td><td></td></tr><tr><td></td><td>Inhibits thymidylate synthetase.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>FH4</td><td></td></tr><tr><td></td><td></td><td>Folic acid</td><td>FH</td><td colspan="2">FH 4 + 1-carbon unit</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given i.v.</td><td></td><td style="text-align: right">2</td><td></td><td></td></tr><tr><td>Clinical use</td><td>Cancers of GIT (gastric, colorectal ), pancreas,</td><td></td><td></td><td>Thymidylate</td><td></td></tr><tr><td></td><td>breast; malignant skin conditions.</td><td>dTMP</td><td></td><td>synthetase</td><td>dUMP</td></tr><tr><td></td><td></td><td>FH2 = dihydrofolate</td><td></td><td></td><td></td></tr><tr><td>Adverse effects</td><td>Not common: myelosuppression,</td><td>FH 4 = tetrahydrofolate</td><td></td><td></td><td></td></tr><tr><td></td><td>GIT disturbances, mucositis. Given long term:</td><td>dTMP = thymidylate</td><td></td><td>Fluorouracil</td><td></td></tr><tr><td></td><td>desquamation of feet &amp; hands.</td><td>dUMP = uridylate</td><td></td><td></td><td></td></tr><tr><td>Special points</td><td colspan="5">High-dose regimens should be followed by ‘rescue’ with folinic acid – a form of tetrahydrofolate –</td></tr><tr><td></td><td>to minimise toxic effects on the bone marrow and GIT mucosa.</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="4">R&amp;D 7e Ch 55, p 681; D&amp;H 2e Ch 46, p 105</td></tr></table>
</page>
<page number="580">
<table id="p580t1" data-filename="pdftables_fromstorage_023782248" data-page="580" data-table="1"><tr><td style="text-align: right">34.03</td><td>Mercaptopurine</td><td>Anticancer drugs</td><td></td></tr><tr><td colspan="2">Diagram of the main targets for anticancer drug therapy</td><td></td><td></td></tr><tr><td></td><td></td><td>Purine synthesis</td><td>Pyrimidine synthesis</td></tr><tr><td></td><td></td><td>Ribonucleotides</td><td></td></tr><tr><td>Methotrexate</td><td></td><td></td><td></td></tr><tr><td>inhibits purine synthesis</td><td></td><td></td><td>Fluorouracil inhibits</td></tr><tr><td></td><td></td><td>Deoxyribonucleotides</td><td></td></tr><tr><td></td><td></td><td></td><td>dTMP synthesis</td></tr><tr><td>and dTMP synthesis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>DNA</td><td></td></tr><tr><td></td><td></td><td>RNA</td><td></td></tr><tr><td></td><td></td><td>(transfer, messenger, ribosomal)</td><td></td></tr><tr><td></td><td></td><td>Proteins</td><td>Receptors</td></tr><tr><td></td><td></td><td>Enzymes</td><td>Microtubules</td></tr></table>
</page>
<page number="581">
<table id="p581t1" data-filename="pdftables_fromstorage_023782248" data-page="581" data-table="1"><tr><td></td><td>Antimetabolite anticancer drug</td><td>Mercaptopurine</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Purine analogue that inhibits purine synthesis and gives rise to a fraudulent nucleotide.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally.</td><td></td></tr><tr><td>Clinical use</td><td>Acute leukemias and chronic myeloid leukemia.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Myelosuppression, hepatotoxicity, immunosuppression. Rare: pancreatitis, GIT ulceration.</td></tr><tr><td>Special points</td><td colspan="2">Note that azathioprine, an immunosuppressant agent, is metabolised to mercaptopurine.</td></tr><tr><td>Similar drug</td><td colspan="2">Pentostatin, also a purine analogue, inhibits adenosine deaminase – important in generation of</td></tr><tr><td></td><td>inosine, an early stage of ribonucleic acid synthesis.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 55, p 681; D&amp;H 2e Ch 46, p 104</td></tr></table>
</page>
<page number="582">
<table id="p582t1" data-filename="pdftables_fromstorage_023782248" data-page="582" data-table="1"><tr><td style="text-align: right">34.04</td><td>Cytarabine</td><td>Anticancer drugs</td><td></td></tr><tr><td colspan="2">Diagram of the main targets for anticancer drug therapy</td><td></td><td></td></tr><tr><td colspan="2">Pentostatin,</td><td>Purine synthesis</td><td>Pyrimidine synthesis</td></tr><tr><td colspan="2">mercaptopurine</td><td></td><td></td></tr><tr><td colspan="2">inhibit purine &amp; ribo-</td><td></td><td></td></tr><tr><td colspan="2">nucleotide synthesis</td><td></td><td></td></tr><tr><td></td><td></td><td>Ribonucleotides</td><td></td></tr><tr><td colspan="2">Methotrexate</td><td></td><td></td></tr><tr><td colspan="2">inhibits purine synthesis</td><td></td><td>Fluorouracil inhibits</td></tr><tr><td></td><td></td><td>Deoxyribonucleotides</td><td></td></tr><tr><td></td><td></td><td></td><td>dTMP synthesis</td></tr><tr><td colspan="2">and dTMP synthesis</td><td></td><td></td></tr><tr><td></td><td></td><td>DNA</td><td></td></tr><tr><td></td><td></td><td>RNA</td><td></td></tr><tr><td></td><td></td><td>(transfer, messenger, ribosomal)</td><td></td></tr><tr><td></td><td></td><td>Proteins</td><td>Receptors</td></tr><tr><td></td><td></td><td>Enzymes</td><td>Microtubules</td></tr></table>
</page>
<page number="583">
<table id="p583t1" data-filename="pdftables_fromstorage_023782248" data-page="583" data-table="1"><tr><td></td><td>Antimetabolite anticancer drug</td><td>Cytarabine</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Pyrimidine analogue that is converted in the cell to the trisphosphate which inhibits DNA</td></tr><tr><td></td><td>polymerase.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given i.v., subcut. or intrathecally.</td><td></td></tr><tr><td>Clinical use</td><td>Acute myeloblastic leukemia.</td><td></td></tr><tr><td>Adverse effects</td><td>Marked myelosuppression. GIT disturbances; cerebellar ataxia.</td><td></td></tr><tr><td>Special points</td><td>Careful haematological monitoring necessary.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 55, p 681; D&amp;H 2e Ch 46, pp 104-105</td></tr></table>
</page>
<page number="584">
<table id="p584t1" data-filename="pdftables_fromstorage_023782248" data-page="584" data-table="1"><tr><td style="text-align: right">34.05</td><td>Bleomycin</td><td>Anticancer drugs</td><td></td></tr><tr><td colspan="2">Diagram of the main targets for anticancer drug therapy</td><td></td><td></td></tr><tr><td colspan="2">Pentostatin,</td><td>Purine synthesis</td><td>Pyrimidine synthesis</td></tr><tr><td colspan="2">mercaptopurine</td><td></td><td></td></tr><tr><td colspan="2">inhibit purine &amp; ribo-</td><td></td><td></td></tr><tr><td colspan="2">nucleotide synthesis</td><td></td><td></td></tr><tr><td></td><td></td><td>Ribonucleotides</td><td></td></tr><tr><td colspan="2">Methotrexate</td><td></td><td></td></tr><tr><td colspan="2">inhibits purine synthesis</td><td></td><td>Fluorouracil inhibits</td></tr><tr><td></td><td></td><td>Deoxyribonucleotides</td><td></td></tr><tr><td></td><td></td><td></td><td>dTMP synthesis</td></tr><tr><td colspan="2">and dTMP synthesis</td><td></td><td></td></tr><tr><td colspan="2">Cytarabine</td><td></td><td></td></tr><tr><td colspan="2">inhibits DNA synthesis</td><td></td><td></td></tr><tr><td></td><td></td><td>DNA</td><td></td></tr><tr><td></td><td></td><td>RNA</td><td></td></tr><tr><td></td><td></td><td>(transfer, messenger, ribosomal)</td><td></td></tr><tr><td></td><td></td><td>Proteins</td><td>Receptors</td></tr><tr><td></td><td></td><td>Enzymes</td><td>Microtubules</td></tr></table>
</page>
<page number="585">
<table id="p585t1" data-filename="pdftables_fromstorage_023782248" data-page="585" data-table="1"><tr><td></td><td>Cytotoxic antibiotic anticancer drug</td><td>Bleomycin</td></tr><tr><td>Actions &amp; MOA</td><td>Causes DNA fragmentation.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given i.v. or i.m.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Squamous cell cancer, metastatic germ cell cancer. Non-Hodgkin’s lymphoma.</td></tr><tr><td>Adverse effects</td><td colspan="2">Dose-related pulmonary fibrosis; skin toxicity (pigmentation, subcutaneous sclerotic plaques);</td></tr><tr><td></td><td colspan="2">mucositis; transient hypersensitivity reactions. Minimal myelosuppression.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 55, p 682; D&amp;H 2e Ch 46, pp 104-105</td></tr></table>
</page>
<page number="586">
<table id="p586t1" data-filename="pdftables_fromstorage_023782248" data-page="586" data-table="1"><tr><td style="text-align: right">34.06</td><td>Cisplatin</td><td>Anticancer drugs</td><td></td></tr><tr><td colspan="2">Diagram of the main targets for anticancer drug therapy</td><td></td><td></td></tr><tr><td colspan="2">Pentostatin,</td><td>Purine synthesis</td><td>Pyrimidine synthesis</td></tr><tr><td colspan="2">mercaptopurine</td><td></td><td></td></tr><tr><td colspan="2">inhibit purine &amp; ribo-</td><td></td><td></td></tr><tr><td colspan="2">nucleotide synthesis</td><td></td><td></td></tr><tr><td></td><td></td><td>Ribonucleotides</td><td></td></tr><tr><td colspan="2">Methotrexate</td><td></td><td></td></tr><tr><td colspan="2">inhibits purine synthesis</td><td></td><td>Fluorouracil inhibits</td></tr><tr><td></td><td></td><td>Deoxyribonucleotides</td><td></td></tr><tr><td></td><td></td><td></td><td>dTMP synthesis</td></tr><tr><td colspan="2">and dTMP synthesis</td><td></td><td></td></tr><tr><td colspan="2">Cytarabine</td><td></td><td>Bleomycin</td></tr><tr><td colspan="2">inhibits DNA synthesis</td><td></td><td>damages DNA</td></tr><tr><td></td><td></td><td>DNA</td><td></td></tr><tr><td></td><td></td><td>RNA</td><td></td></tr><tr><td></td><td></td><td>(transfer, messenger, ribosomal)</td><td></td></tr><tr><td></td><td></td><td>Proteins</td><td>Receptors</td></tr><tr><td></td><td></td><td>Enzymes</td><td>Microtubules</td></tr></table>
</page>
<page number="587">
<table id="p587t1" data-filename="pdftables_fromstorage_023782248" data-page="587" data-table="1"><tr><td></td><td>Cytotoxic anticancer drug</td><td>Cisplatin</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Forms a reactive complex that causes intrastrand cross-linking and denaturation of the DNA.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given by i.v. infusion. Can be given to outpatients.</td><td></td></tr><tr><td>Clinical use</td><td>Cancers of testes, ovaries, cervix, bladder, lung and head &amp; neck.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Nephrotoxicity, ototoxicity, severe nausea &amp; vomiting, myelosuppression, peripheral neuropathy,</td></tr><tr><td></td><td>hypomagnesaemia.</td><td></td></tr><tr><td>Drug with</td><td colspan="2">Carboplatin: more myelosuppressive but other adverse effects less marked so better tolerated;</td></tr><tr><td>similar action</td><td>preferred for ovarian cancer.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 55, p 679; D&amp;H 2e Ch 46, pp 104-105</td></tr></table>
</page>
<page number="588">
<table id="p588t1" data-filename="pdftables_fromstorage_023782248" data-page="588" data-table="1"><tr><td style="text-align: right">34.07</td><td>Cyclophosphamide</td><td>Anticancer drugs</td><td></td></tr><tr><td colspan="2">Diagram of the main targets for anticancer drug therapy</td><td></td><td></td></tr><tr><td>Pentostatin,</td><td>Purine synthesis</td><td></td><td>Pyrimidine synthesis</td></tr><tr><td>mercaptopurine</td><td></td><td></td><td></td></tr><tr><td>inhibit purine &amp; ribo-</td><td></td><td></td><td></td></tr><tr><td>nucleotide synthesis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Ribonucleotides</td><td></td></tr><tr><td>Methotrexate</td><td></td><td></td><td></td></tr><tr><td>inhibits purine synthesis</td><td></td><td></td><td>Fluorouracil inhibits</td></tr><tr><td></td><td></td><td>Deoxyribonucleotides</td><td></td></tr><tr><td></td><td></td><td></td><td>dTMP synthesis</td></tr><tr><td>and dTMP synthesis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Bleomycin</td></tr><tr><td>Cytarabine</td><td></td><td></td><td>damages DNA</td></tr><tr><td>inhibits DNA synthesis</td><td></td><td></td><td>Cisplatin cross-</td></tr><tr><td></td><td></td><td></td><td>links DNA strands</td></tr><tr><td></td><td></td><td>RNA</td><td></td></tr><tr><td></td><td></td><td>(transfer, messenger, ribosomal)</td><td></td></tr><tr><td></td><td></td><td>Proteins</td><td>Receptors</td></tr><tr><td></td><td></td><td>Enzymes</td><td>Microtubules</td></tr></table>
</page>
<page number="589">
<table id="p589t1" data-filename="pdftables_fromstorage_023782248" data-page="589" data-table="1"><tr><td></td><td>Alkylating anticancer drug</td><td>Cyclophosphamide</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Cross-links DNA by forming covalent bonds with guanine residues on each strand, interfering with cell</td></tr><tr><td></td><td>division and triggering apoptosis.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given orally or i.v. Metabolised in the liver to phosphoramide mustard (the active moiety) and</td></tr><tr><td></td><td>acrolein.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Chronic lymphocytic leukemia, soft tissue sarcoma, osteogenic sarcoma, ovarian &amp; breast cancers.</td></tr><tr><td>Adverse effects</td><td colspan="2">Nausea &amp; vomiting; myelosuppression; acrolein-mediated haemorrhagic cystitis; alopecia.</td></tr><tr><td></td><td colspan="2">Gametogenesis can be affected. Prolonged use can result in acute non-lymphocytic leukemia.</td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 55, p 678; D&amp;H 2e Ch 46, pp 104-105</td></tr></table>
</page>
<page number="590">
<table id="p590t1" data-filename="pdftables_fromstorage_023782248" data-page="590" data-table="1"><tr><td style="text-align: right">34.08</td><td>Doxorubicin</td><td>Anticancer drugs</td><td></td></tr><tr><td colspan="3">Diagram of the main targets for anticancer drug therapy</td><td></td></tr><tr><td>Pentostatin,</td><td></td><td>Purine synthesis</td><td>Pyrimidine synthesis</td></tr><tr><td>mercaptopurine</td><td></td><td></td><td></td></tr><tr><td>inhibit purine &amp; ribo-</td><td></td><td></td><td></td></tr><tr><td>nucleotide synthesis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Ribonucleotides</td><td></td></tr><tr><td></td><td></td><td></td><td>Fluorouracil inhibits</td></tr><tr><td>Methotrexate</td><td></td><td></td><td>dTMP synthesis</td></tr><tr><td>inhibits purine synthesis</td><td></td><td>Deoxyribonucleotides</td><td></td></tr><tr><td>and dTMP synthesis</td><td></td><td></td><td>Bleomycin</td></tr><tr><td></td><td></td><td></td><td>damages DNA</td></tr><tr><td>Cytarabine</td><td></td><td></td><td>Cisplatin cross-</td></tr><tr><td>inhibits DNA synthesis</td><td></td><td></td><td>links DNA strands</td></tr><tr><td></td><td></td><td>DNA</td><td></td></tr><tr><td></td><td></td><td></td><td>Cyclophosphamide</td></tr><tr><td></td><td></td><td></td><td>intercalates &amp; cross-links</td></tr><tr><td></td><td></td><td>RNA</td><td></td></tr><tr><td></td><td></td><td>(transfer, messenger, ribosomal)</td><td></td></tr><tr><td></td><td></td><td>Proteins</td><td>Receptors</td></tr><tr><td></td><td></td><td>Enzymes</td><td>Microtubules</td></tr></table>
</page>
<page number="591">
<table id="p591t1" data-filename="pdftables_fromstorage_023782248" data-page="591" data-table="1"><tr><td></td><td>Cytotoxic anticancer drug</td><td>Doxorubicin</td></tr><tr><td>Actions &amp; MOA</td><td>Inhibits DNA and RNA synthesis through an effect on topoisomerase II.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td colspan="2">Given by infusion (extravasation can cause tissue damage); by bladder instillation for</td></tr><tr><td></td><td>bladder cancers.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Acute leukemias; Hodgkin &amp; non-Hodgkin lymphomas; tumours of breast, ovary, bladder, bronchi.</td></tr><tr><td>Adverse effects</td><td colspan="2">Dose-related cardiac damage; nausea &amp; vomiting; myelosuppression; hair loss.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 55, pp 681-682; D&amp;H 2e Ch 46, pp 104-105</td></tr></table>
</page>
<page number="592">
<table id="p592t1" data-filename="pdftables_fromstorage_023782248" data-page="592" data-table="1"><tr><td style="text-align: right">34.09</td><td>Irinotecan</td><td>Anticancer drugs</td><td></td></tr><tr><td colspan="3">Diagram of the main targets for anticancer drug therapy</td><td></td></tr><tr><td colspan="2">Pentostatin,</td><td>Purine synthesis</td><td>Pyrimidine synthesis</td></tr><tr><td colspan="2">mercaptopurine</td><td></td><td>Fluorouracil inhibits</td></tr><tr><td colspan="2">inhibit purine &amp; ribo-</td><td></td><td>dTMP synthesis</td></tr><tr><td colspan="2">nucleotide synthesis</td><td></td><td></td></tr><tr><td></td><td></td><td>Ribonucleotides</td><td></td></tr><tr><td></td><td></td><td></td><td>Bleomycin</td></tr><tr><td colspan="2">Methotrexate</td><td></td><td>damages DNA</td></tr><tr><td colspan="2">inhibits purine synthesis</td><td>Deoxyribonucleotides</td><td></td></tr><tr><td colspan="2">and dTMP synthesis</td><td></td><td>Cisplatin cross-</td></tr><tr><td></td><td></td><td></td><td>links DNA strands</td></tr><tr><td colspan="2">Cytarabine</td><td></td><td>Cyclophosphamide</td></tr><tr><td colspan="2">inhibits DNA synthesis</td><td></td><td>intercalates &amp; cross-links</td></tr><tr><td></td><td></td><td>DNA</td><td></td></tr><tr><td></td><td></td><td></td><td>Doxorubicin</td></tr><tr><td></td><td></td><td></td><td>intercalates &amp; inhibits</td></tr><tr><td></td><td></td><td></td><td>topoisomerase II</td></tr><tr><td></td><td></td><td>RNA</td><td></td></tr><tr><td></td><td></td><td>(transfer, messenger, ribosomal)</td><td></td></tr><tr><td></td><td></td><td>Proteins</td><td>Receptors</td></tr><tr><td></td><td></td><td>Enzymes</td><td>Microtubules</td></tr></table>
</page>
<page number="593">
<table id="p593t1" data-filename="pdftables_fromstorage_023782248" data-page="593" data-table="1"><tr><td></td><td>Cytotoxic anticancer drug (plant derived)</td><td>Irinotecan</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Binds to and inhibits topoisomerase I, thus interfering with cell proliferation.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given by i.v. infusion</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Metastatic tumours of colon and rectum (in combination with other agents).</td></tr><tr><td>Adverse effects</td><td>GIT disturbances, interstitial pulmonary disease.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 55, p 682; D&amp;H 2e Ch 46, pp 104-105</td></tr></table>
</page>
<page number="594">
<table id="p594t1" data-filename="pdftables_fromstorage_023782248" data-page="594" data-table="1"><tr><td style="text-align: right">34.10</td><td>Dactinomycin</td><td>Anticancer drugs</td><td></td><td></td></tr><tr><td colspan="3">Diagram of the main targets for anticancer drug therapy</td><td></td><td></td></tr><tr><td>Pentostatin,</td><td></td><td>Purine synthesis</td><td>Pyrimidine synthesis</td><td></td></tr><tr><td>mercaptopurine</td><td></td><td></td><td></td><td>Fluorouracil inhibits</td></tr><tr><td>inhibit purine &amp; ribo-</td><td></td><td></td><td></td><td>dTMP synthesis</td></tr><tr><td>nucleotide synthesis</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Ribonucleotides</td><td>Bleomycin</td></tr><tr><td>Methotrexate</td><td></td><td></td><td></td><td>damages DNA</td></tr><tr><td>inhibits purine synthesis</td><td></td><td colspan="2">Deoxyribonucleotides</td><td>Cisplatin cross-</td></tr><tr><td>and dTMP synthesis</td><td></td><td></td><td></td><td>links DNA strands</td></tr><tr><td></td><td></td><td></td><td></td><td>Cyclophosphamide</td></tr><tr><td></td><td></td><td></td><td></td><td>intercalates &amp; cross-links</td></tr><tr><td>Cytarabine</td><td></td><td></td><td></td><td></td></tr><tr><td>inhibits DNA synthesis</td><td></td><td></td><td></td><td>Doxorubicin</td></tr><tr><td></td><td></td><td>DNA</td><td></td><td>intercalates &amp; inhibits</td></tr><tr><td></td><td></td><td></td><td></td><td>topoisomerase II</td></tr><tr><td></td><td></td><td></td><td></td><td>Irinotecan inhibits</td></tr><tr><td></td><td></td><td></td><td></td><td>topoisomerase I</td></tr><tr><td></td><td></td><td>RNA</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">(transfer, messenger, ribosomal)</td><td></td></tr><tr><td></td><td></td><td>Proteins</td><td>Receptors</td><td></td></tr><tr><td></td><td></td><td>Enzymes</td><td>Microtubules</td><td></td></tr></table>
</page>
<page number="595">
<table id="p595t1" data-filename="pdftables_fromstorage_023782248" data-page="595" data-table="1"><tr><td></td><td>Anticancer antibiotic</td><td>Dactinomycin</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Intercalates in the DNA and inhibits RNA polymerase and topoisomerase II.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given by i.v. injection.</td><td></td></tr><tr><td>Clinical use</td><td>Paediatric cancers.</td><td></td></tr><tr><td>Adverse effects</td><td>Nausea &amp; vomiting; myelosuppression; hair loss.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 55, p 682; D&amp;H 2e Ch 46, pp 104-105</td></tr></table>
</page>
<page number="596">
<table id="p596t1" data-filename="pdftables_fromstorage_023782248" data-page="596" data-table="1"><tr><td style="text-align: right">34.11</td><td>Vincristine</td><td>Anticancer drugs</td><td></td><td></td></tr><tr><td colspan="3">Diagram of the main targets for anticancer drug therapy</td><td></td><td></td></tr><tr><td colspan="2">Pentostatin,</td><td>Purine synthesis</td><td>Pyrimidine synthesis</td><td></td></tr><tr><td colspan="2">mercaptopurine</td><td></td><td></td><td>Fluorouracil inhibits</td></tr><tr><td colspan="2">inhibit purine &amp; ribo-</td><td></td><td></td><td>dTMP synthesis</td></tr><tr><td colspan="2">nucleotide synthesis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Ribonucleotides</td><td>Bleomycin</td></tr><tr><td colspan="2">Methotrexate</td><td></td><td></td><td>damages DNA</td></tr><tr><td colspan="2">inhibits purine synthesis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Cisplatin cross-</td></tr><tr><td></td><td></td><td colspan="2">Deoxyribonucleotides</td><td></td></tr><tr><td colspan="2">and dTMP synthesis</td><td></td><td></td><td>links DNA strands</td></tr><tr><td colspan="2">Cytarabine</td><td></td><td></td><td>Cyclophosphamide</td></tr><tr><td colspan="2">inhibits DNA synthesis</td><td></td><td></td><td>intercalates &amp; cross-links</td></tr><tr><td></td><td></td><td></td><td></td><td>Doxorubicin</td></tr><tr><td colspan="2">Dactinomycin</td><td>DNA</td><td></td><td>intercalates &amp; inhibits</td></tr><tr><td colspan="2">inhibits topoisomerase II</td><td></td><td></td><td>topoisomerase II</td></tr><tr><td colspan="2">and RNA polymerase</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Irinotecan inhibits</td></tr><tr><td></td><td></td><td></td><td></td><td>topoisomerase I</td></tr><tr><td></td><td></td><td>RNA</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">(transfer, messenger, ribosomal)</td><td></td></tr><tr><td></td><td></td><td>Proteins</td><td>Receptors</td><td></td></tr><tr><td></td><td></td><td>Enzymes</td><td>Microtubules</td><td></td></tr></table>
</page>
<page number="597">
<table id="p597t1" data-filename="pdftables_fromstorage_023782248" data-page="597" data-table="1"><tr><td></td><td>Anticancer vinca alkaloid</td><td>Vincristine</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Binds to tubulin, preventing spindle formation in dividing cells stopping them in mitosis.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given by i.v. injection.</td><td></td></tr><tr><td>Clinical use</td><td>Leukemias, lymphomas, breast and lung cancers.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Nausea &amp; vomiting; hair loss; neurotoxicity (peripheral &amp; autonomic); negligible myelosuppression.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 55, p 682; D&amp;H 2e Ch 46, pp 104-105</td></tr></table>
</page>
<page number="598">
<table id="p598t1" data-filename="pdftables_fromstorage_023782248" data-page="598" data-table="1"><tr><td style="text-align: right">34.12</td><td>Paclitaxel</td><td>Anticancer drugs</td><td></td><td></td></tr><tr><td colspan="3">Diagram of the main targets for anticancer drug therapy</td><td></td><td></td></tr><tr><td colspan="2">Pentostatin,</td><td>Purine synthesis</td><td>Pyrimidine synthesis</td><td></td></tr><tr><td colspan="2">mercaptopurine</td><td></td><td></td><td>Fluorouracil inhibits</td></tr><tr><td colspan="2">inhibit purine &amp; ribo-</td><td></td><td></td><td>dTMP synthesis</td></tr><tr><td colspan="2">nucleotide synthesis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Ribonucleotides</td><td>Bleomycin</td></tr><tr><td colspan="2">Methotrexate</td><td></td><td></td><td>damages DNA</td></tr><tr><td colspan="2">inhibits purine synthesis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Cisplatin cross-</td></tr><tr><td></td><td></td><td colspan="2">Deoxyribonucleotides</td><td></td></tr><tr><td colspan="2">and dTMP synthesis</td><td></td><td></td><td>links DNA strands</td></tr><tr><td colspan="2">Cytarabine</td><td></td><td></td><td>Cyclophosphamide</td></tr><tr><td colspan="2">inhibits DNA synthesis</td><td></td><td></td><td>intercalates &amp; cross-links</td></tr><tr><td></td><td></td><td></td><td></td><td>Doxorubicin</td></tr><tr><td colspan="2">Dactinomycin</td><td>DNA</td><td></td><td>intercalates &amp; inhibits</td></tr><tr><td colspan="2">inhibits topoisomerase II</td><td></td><td></td><td>topoisomerase II</td></tr><tr><td colspan="2">and RNA polymerase</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Irinotecan inhibits</td></tr><tr><td></td><td></td><td></td><td></td><td>topoisomerase I</td></tr><tr><td></td><td></td><td>RNA</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">(transfer, messenger, ribosomal)</td><td></td></tr><tr><td></td><td></td><td>Proteins</td><td>Receptors</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Vincristine inhibits</td></tr><tr><td></td><td></td><td>Enzymes</td><td>Microtubules</td><td>microtubule function</td></tr></table>
</page>
<page number="599">
<table id="p599t1" data-filename="pdftables_fromstorage_023782248" data-page="599" data-table="1"><tr><td></td><td>Anticancer yew tree derivative</td><td>Paclitaxel</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Binds to tubulin, keeping microtubules polymerised (‘frozen’), preventing spindle formation in</td></tr><tr><td></td><td>dividing cells and stopping them in mitosis.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given by i.v. infusion.</td><td></td></tr><tr><td>Clinical use</td><td>Cancers of ovary and breast, non-small-cell lung cancer.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Hypersensitivity reactions, myelosuppression, peripheral neuropathy, bradycardia, muscle &amp; joint</td></tr><tr><td></td><td>pain, hair loss. GIT disturbance: moderate.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 55, p 682; D&amp;H 2e Ch 46, pp 104-105</td></tr></table>
</page>
<page number="600">
<table id="p600t1" data-filename="pdftables_fromstorage_023782248" data-page="600" data-table="1"><tr><td style="text-align: right">34.13</td><td>Imatinib</td><td>Anticancer drugs</td><td></td><td></td></tr><tr><td colspan="3">Diagram of the main targets for anticancer drug therapy</td><td></td><td></td></tr><tr><td colspan="2">Pentostatin,</td><td>Purine synthesis</td><td>Pyrimidine synthesis</td><td></td></tr><tr><td colspan="2">mercaptopurine</td><td></td><td></td><td>Fluorouracil inhibits</td></tr><tr><td colspan="2">inhibit purine &amp; ribo-</td><td></td><td></td><td>dTMP synthesis</td></tr><tr><td colspan="2">nucleotide synthesis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Ribonucleotides</td><td>Bleomycin</td></tr><tr><td colspan="2">Methotrexate</td><td></td><td></td><td>damages DNA</td></tr><tr><td colspan="2">inhibits purine synthesis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Cisplatin cross-</td></tr><tr><td></td><td></td><td colspan="2">Deoxyribonucleotides</td><td></td></tr><tr><td colspan="2">and dTMP synthesis</td><td></td><td></td><td>links DNA strands</td></tr><tr><td colspan="2">Cytarabine</td><td></td><td></td><td>Cyclophosphamide</td></tr><tr><td colspan="2">inhibits DNA synthesis</td><td></td><td></td><td>intercalates &amp; cross-links</td></tr><tr><td></td><td></td><td></td><td></td><td>Doxorubicin</td></tr><tr><td colspan="2">Dactinomycin</td><td>DNA</td><td></td><td>intercalates &amp; inhibits</td></tr><tr><td colspan="2">inhibits topoisomerase II</td><td></td><td></td><td>topoisomerase II</td></tr><tr><td colspan="2">and RNA polymerase</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Irinotecan inhibits</td></tr><tr><td></td><td></td><td></td><td></td><td>topoisomerase I</td></tr><tr><td></td><td></td><td>RNA</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">(transfer, messenger, ribosomal)</td><td></td></tr><tr><td></td><td></td><td>Proteins</td><td>Receptors</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Vincristine, paclitaxel</td></tr><tr><td></td><td></td><td>Enzymes</td><td>Microtubules</td><td>inhibit microtubule function</td></tr></table>
</page>
<page number="601">
<table id="p601t1" data-filename="pdftables_fromstorage_023782248" data-page="601" data-table="1"><tr><td></td><td>Anticancer protein kinase inhibitor</td><td>Imatinib</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Inhibits protein kinases important in chronic myeloid leukemia and other malignancies.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally, well absorbed.</td><td></td></tr><tr><td>Clinical use</td><td colspan="2">Chronic myeloid leukemia, acute lymphoblastic leukemia, GIT stromal tumours, chronic</td></tr><tr><td></td><td>eosinophilic leukemia, myeloproliferative diseases.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances, abdominal pain, oedema, haemorrhage, cough, dyspnoea, paraesthesia, arthralgia,</td></tr><tr><td></td><td>conjunctivitis, photosensitivity, headache, dizziness, sweating, rash.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 55, p 684; D&amp;H 2e Ch 46, pp 104-105</td></tr></table>
</page>
<page number="602">
<table id="p602t1" data-filename="pdftables_fromstorage_023782248" data-page="602" data-table="1"><tr><td style="text-align: right">34.14</td><td>Trastuzumab</td><td>Anticancer drugs</td><td></td><td></td></tr><tr><td colspan="3">Diagram of the main targets for anticancer drug therapy</td><td></td><td></td></tr><tr><td>Pentostatin,</td><td></td><td>Purine synthesis</td><td>Pyrimidine synthesis</td><td></td></tr><tr><td>mercaptopurine</td><td></td><td></td><td></td><td>Fluorouracil inhibits</td></tr><tr><td>inhibit purine &amp; ribo-</td><td></td><td></td><td></td><td>dTMP synthesis</td></tr><tr><td>nucleotide synthesis</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Ribonucleotides</td><td>Bleomycin</td></tr><tr><td>Methotrexate</td><td></td><td></td><td></td><td>damages DNA</td></tr><tr><td>inhibits purine synthesis</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Cisplatin cross-</td></tr><tr><td></td><td></td><td colspan="2">Deoxyribonucleotides</td><td></td></tr><tr><td>and dTMP synthesis</td><td></td><td></td><td></td><td>links DNA strands</td></tr><tr><td>Cytarabine</td><td></td><td></td><td></td><td>Cyclophosphamide</td></tr><tr><td>inhibits DNA synthesis</td><td></td><td></td><td></td><td>intercalates &amp; cross-links</td></tr><tr><td></td><td></td><td></td><td></td><td>Doxorubicin</td></tr><tr><td>Dactinomycin</td><td></td><td>DNA</td><td></td><td>intercalates &amp; inhibits</td></tr><tr><td>inhibits topoisomerase II</td><td></td><td></td><td></td><td>topoisomerase II</td></tr><tr><td>and RNA polymerase</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Irinotecan inhibits</td></tr><tr><td></td><td></td><td></td><td></td><td>topoisomerase I</td></tr><tr><td></td><td></td><td>RNA</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">(transfer, messenger, ribosomal)</td><td></td></tr><tr><td></td><td></td><td>Proteins</td><td>Receptors</td><td></td></tr><tr><td>Imatinib protein</td><td></td><td></td><td></td><td>Vincristine, paclitaxel</td></tr><tr><td></td><td></td><td>Enzymes</td><td>Microtubules</td><td></td></tr><tr><td>kinase inhibitor</td><td></td><td></td><td></td><td>inhibit microtubule function</td></tr></table>
</page>
<page number="603">
<table id="p603t1" data-filename="pdftables_fromstorage_023782248" data-page="603" data-table="1"><tr><td></td><td>Monoclonal antibody anticancer agent</td><td>Trastuzumab</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Binds to and inhibits the epidermal growth factor receptor (a tyrosine kinase receptor), preventing</td></tr><tr><td></td><td>its activation and inhibiting cell proliferation.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given by i.v. infusion.</td><td></td></tr><tr><td>Clinical use</td><td>Breast cancers.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">GIT disturbances, abdominal pain, hypersensitivity reactions, cardiac toxicity, paraesthesia,</td></tr><tr><td></td><td colspan="2">headache, dizziness, anxiety, depression, oedema, arthralgia, bruising, bone pain, leg cramps,</td></tr><tr><td></td><td>rash, alopecia.</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 55, p 684; D&amp;H 2e Ch 46, pp 104-105</td></tr></table>
</page>
<page number="604">
<table id="p604t1" data-filename="pdftables_fromstorage_023782248" data-page="604" data-table="1"><tr><td style="text-align: right">34.15</td><td>Tamoxifen</td><td>Anticancer drugs</td><td></td><td></td></tr><tr><td colspan="3">Diagram of the main targets for anticancer drug therapy</td><td></td><td></td></tr><tr><td colspan="2">Pentostatin,</td><td>Purine synthesis</td><td>Pyrimidine synthesis</td><td></td></tr><tr><td colspan="2">mercaptopurine</td><td></td><td></td><td>Fluorouracil inhibits</td></tr><tr><td colspan="2">inhibit purine &amp; ribo-</td><td></td><td></td><td>dTMP synthesis</td></tr><tr><td colspan="2">nucleotide synthesis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Ribonucleotides</td><td>Bleomycin</td></tr><tr><td colspan="2">Methotrexate</td><td></td><td></td><td>damages DNA</td></tr><tr><td colspan="2">inhibits purine synthesis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Cisplatin cross-</td></tr><tr><td></td><td></td><td colspan="2">Deoxyribonucleotides</td><td></td></tr><tr><td colspan="2">and dTMP synthesis</td><td></td><td></td><td>links DNA strands</td></tr><tr><td colspan="2">Cytarabine</td><td></td><td></td><td>Cyclophosphamide</td></tr><tr><td colspan="2">inhibits DNA synthesis</td><td></td><td></td><td>intercalates &amp; cross-links</td></tr><tr><td></td><td></td><td></td><td></td><td>Doxorubicin</td></tr><tr><td colspan="2">Dactinomycin</td><td>DNA</td><td></td><td>intercalates &amp; inhibits</td></tr><tr><td colspan="2">inhibits topoisomerase II</td><td></td><td></td><td>topoisomerase II</td></tr><tr><td colspan="2">and RNA polymerase</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Irinotecan inhibits</td></tr><tr><td></td><td></td><td></td><td></td><td>topoisomerase I</td></tr><tr><td></td><td></td><td>RNA</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">(transfer, messenger, ribosomal)</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Trastuzumab antibody</td></tr><tr><td></td><td></td><td>Proteins</td><td>Receptors</td><td>v EGRF 2 (epidermal</td></tr><tr><td></td><td></td><td></td><td></td><td>growth factor receptor 2)</td></tr><tr><td colspan="2">Imatinib protein</td><td></td><td></td><td>Vincristine, paclitaxel</td></tr><tr><td></td><td></td><td>Enzymes</td><td>Microtubules</td><td></td></tr><tr><td colspan="2">kinase inhibitor</td><td></td><td></td><td>inhibit microtubule function</td></tr></table>
</page>
<page number="605">
<table id="p605t1" data-filename="pdftables_fromstorage_023782248" data-page="605" data-table="1"><tr><td></td><td>Oestrogen receptor agonist</td><td>Tamoxifen</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Competes with endogenous oestrogen for the oestrogen receptor, preventing cell activation and</td></tr><tr><td></td><td>proliferation.</td><td></td></tr><tr><td>Abs/Distrb/Elim</td><td>Given orally.</td><td></td></tr><tr><td>Clinical use</td><td>Breast cancer.</td><td></td></tr><tr><td>Adverse effects</td><td>Hot flushes, GIT disturbances, headache, menstrual irregularities.</td><td></td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 55, p 683; D&amp;H 2e Ch 46, pp 104-105</td></tr></table>
</page>
<page number="606">
<table id="p606t1" data-filename="pdftables_fromstorage_023782248" data-page="606" data-table="1"><tr><td style="text-align: right">34.16</td><td>Crisantaspase</td><td>Anticancer drugs</td><td></td><td></td></tr><tr><td colspan="3">Diagram of the main targets for anticancer drug therapy</td><td></td><td></td></tr><tr><td>Pentostatin,</td><td></td><td>Purine synthesis</td><td>Pyrimidine synthesis</td><td></td></tr><tr><td>mercaptopurine</td><td></td><td></td><td></td><td>Fluorouracil inhibits</td></tr><tr><td>inhibit purine &amp; ribo-</td><td></td><td></td><td></td><td>dTMP synthesis</td></tr><tr><td>nucleotide synthesis</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Ribonucleotides</td><td>Bleomycin</td></tr><tr><td>Methotrexate</td><td></td><td></td><td></td><td>damages DNA</td></tr><tr><td>inhibits purine synthesis</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Cisplatin cross-</td></tr><tr><td></td><td></td><td colspan="2">Deoxyribonucleotides</td><td></td></tr><tr><td>and dTMP synthesis</td><td></td><td></td><td></td><td>links DNA strands</td></tr><tr><td>Cytarabine</td><td></td><td></td><td></td><td>Cyclophosphamide</td></tr><tr><td>inhibits DNA synthesis</td><td></td><td></td><td></td><td>intercalates &amp; cross-links</td></tr><tr><td></td><td></td><td></td><td></td><td>Doxorubicin</td></tr><tr><td>Dactinomycin</td><td></td><td>DNA</td><td></td><td>intercalates &amp; inhibits</td></tr><tr><td>inhibits topoisomerase II</td><td></td><td></td><td></td><td>topoisomerase II</td></tr><tr><td>and RNA polymerase</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Irinotecan inhibits</td></tr><tr><td></td><td></td><td></td><td></td><td>topoisomerase I</td></tr><tr><td></td><td></td><td>RNA</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Trastuzumab antibody</td></tr><tr><td></td><td></td><td colspan="2">(transfer, messenger, ribosomal)</td><td>v EGRF 2 (epidermal</td></tr><tr><td></td><td></td><td></td><td></td><td>growth factor receptor 2)</td></tr><tr><td></td><td></td><td>Proteins</td><td>Receptors</td><td>Tamoxifen, an</td></tr><tr><td></td><td></td><td></td><td></td><td>antioestrogen</td></tr><tr><td>Imatinib protein</td><td></td><td></td><td></td><td>Vincristine, paclitaxel</td></tr><tr><td></td><td></td><td>Enzymes</td><td>Microtubules</td><td></td></tr><tr><td>kinase inhibitor</td><td></td><td></td><td></td><td>inhibit microtubule function</td></tr></table>
</page>
<page number="607">
<table id="p607t1" data-filename="pdftables_fromstorage_023782248" data-page="607" data-table="1"><tr><td></td><td>A preparation of the enzyme asparaginase used as an anticancer agent</td><td>Crisantaspase</td></tr><tr><td>Actions &amp; MOA</td><td colspan="2">Breaks down asparagine and is active in tumours (e.g. acute lymphoblastic leukemia) that have lost</td></tr><tr><td></td><td colspan="2">the ability to synthesise asparagine and require an external source.</td></tr><tr><td>Abs/Distrb/Elim</td><td>Given i.v., i.m. or subcut.</td><td></td></tr><tr><td>Clinical use</td><td>Acute lymphoblastic leukemia.</td><td></td></tr><tr><td>Adverse effects</td><td colspan="2">Nausea &amp; vomiting, CNS depression, liver disorder, anaphylactic reactions, risk of hyperglycaemia.</td></tr><tr><td></td><td colspan="2">R&amp;D 7e Ch 55, p 685; D&amp;H 2e Ch 46, pp 104-105</td></tr></table>
</page>
<page number="608">
<table id="p608t1" data-filename="pdftables_fromstorage_023782248" data-page="608" data-table="1"><tr><td style="text-align: right">34.17</td><td>Anticancer drugs</td><td colspan="2">What are the main adverse effects of anticancer drugs?</td><td></td></tr><tr><td colspan="3">Diagram of the main targets for anticancer drug therapy</td><td></td><td></td></tr><tr><td>Pentostatin,</td><td>Purine synthesis</td><td></td><td>Pyrimidine synthesis</td><td></td></tr><tr><td>mercaptopurine</td><td></td><td></td><td></td><td>Fluorouracil inhibits</td></tr><tr><td>inhibit purine &amp; ribo-</td><td></td><td></td><td></td><td>dTMP synthesis</td></tr><tr><td>nucleotide synthesis</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Ribonucleotides</td><td>Bleomycin</td></tr><tr><td>Methotrexate</td><td></td><td></td><td></td><td>damages DNA</td></tr><tr><td>inhibits purine synthesis</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Cisplatin cross-</td></tr><tr><td></td><td></td><td colspan="2">Deoxyribonucleotides</td><td></td></tr><tr><td>and dTMP synthesis</td><td></td><td></td><td></td><td>links DNA strands</td></tr><tr><td>Cytarabine</td><td></td><td></td><td></td><td>Cyclophosphamide</td></tr><tr><td>inhibits DNA synthesis</td><td></td><td></td><td></td><td>intercalates &amp; cross-links</td></tr><tr><td></td><td></td><td></td><td></td><td>Doxorubicin</td></tr><tr><td>Dactinomycin</td><td></td><td>DNA</td><td></td><td>intercalates &amp; inhibits</td></tr><tr><td>inhibits topoisomerase II</td><td></td><td></td><td></td><td>topoisomerase II</td></tr><tr><td>and RNA polymerase</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Irinotecan inhibits</td></tr><tr><td></td><td></td><td></td><td></td><td>topoisomerase I</td></tr><tr><td></td><td></td><td>RNA</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Trastuzumab antibody</td></tr><tr><td></td><td></td><td colspan="2">(transfer, messenger, ribosomal)</td><td></td></tr><tr><td>Crisantaspase</td><td></td><td></td><td></td><td>v EGRF 2 (epidermal</td></tr><tr><td>deaminates asparagine,</td><td></td><td></td><td></td><td>growth factor receptor 2)</td></tr><tr><td>inhibits protein synthesis</td><td></td><td>Proteins</td><td>Receptors</td><td>Tamoxifen, an</td></tr><tr><td></td><td></td><td></td><td></td><td>antioestrogen</td></tr><tr><td>Imatinib protein</td><td></td><td></td><td></td><td>Vincristine, paclitaxel</td></tr><tr><td></td><td></td><td>Enzymes</td><td>Microtubules</td><td></td></tr><tr><td>kinase inhibitor</td><td></td><td></td><td></td><td>inhibit microtubule function</td></tr></table>
</page>
<page number="609">
<table id="p609t1" data-filename="pdftables_fromstorage_023782248" data-page="609" data-table="1"><tr><td>The main adverse effects of anticancer drugs</td></tr><tr><td>Most anticancer drugs are cytotoxic (they damage or kill cells) and they are antiproliferative (they</td></tr><tr><td>stop cells from dividing – both cancer cells and rapidly dividing normal cells). Thus they can:</td></tr><tr><td>• depress the bone marrow</td></tr><tr><td>• impair healing</td></tr><tr><td>• interfere with normal growth (in children)</td></tr><tr><td>• cause sterility</td></tr><tr><td>• result in hair loss</td></tr><tr><td>• be teratogenic</td></tr><tr><td>Most also cause nausea and vomiting.</td></tr><tr><td>Different cytotoxic drugs manifest the above adverse effects to different degrees.</td></tr><tr><td>Examples are the drugs that affect DNA &amp; RNA synthesis and actions (see figure on the face of this card)</td></tr><tr><td>Newer, non-proliferative agents target the underlying pathogenic mechanisms such as changes in:</td></tr><tr><td>• the relevant growth factors and/or their receptors</td></tr><tr><td>• cell cycle control mechanisms</td></tr><tr><td>• apoptotic pathways</td></tr><tr><td>• telomerase expression</td></tr><tr><td>• tumour-related angiogenesis</td></tr><tr><td>These agents are less likely to have the above cytotoxic actions but have their own adverse effects.</td></tr><tr><td>Examples are the drugs that don’t affect DNA &amp; RNA synthesis (see the face of this card)</td></tr><tr><td>R&amp;D 7e Ch 55 p 676; D&amp;H 2e Ch 46, pp 104-105</td></tr></table>
</page>
<page number="610">
<table id="p610t1" data-filename="pdftables_fromstorage_023782248" data-page="610" data-table="1"><tr><td></td><td>Agonists and</td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">35.01</td><td>antagonists</td><td>General principles</td><td></td><td></td><td></td></tr><tr><td colspan="2">Panel A shows the response of a</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">tissue to drugs A, B and C. Panels B and C</td><td></td><td></td><td></td></tr><tr><td colspan="3">show the effects that drugs D and E have</td><td>B</td><td></td><td></td></tr><tr><td colspan="3">on the log.dose/response curves to drug A.</td><td></td><td></td><td>Drug A + fixed</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>concentration</td></tr><tr><td colspan="3">Which drugs are agonists and which antagonists?</td><td></td><td>Drug A</td><td>of drug D</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Drug A + higher</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>fixed concentration</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>of drug D</td></tr><tr><td>A</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>C</td><td></td><td></td></tr><tr><td></td><td>Drug A</td><td>Drug B</td><td></td><td></td><td>Drug A + fixed</td></tr><tr><td></td><td></td><td></td><td>nse</td><td></td><td>concentration</td></tr><tr><td></td><td></td><td></td><td>po</td><td>Drug A</td><td>of drug E</td></tr><tr><td></td><td></td><td></td><td>e</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>r</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Drug A + higher</td></tr><tr><td></td><td></td><td>Drug C</td><td></td><td></td><td>fixed concentration</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>of drug E</td></tr><tr><td></td><td>Log of drug concentration</td><td></td><td></td><td>Log of concentration of drug A</td><td></td></tr></table>
</page>
<page number="611">
<table id="p611t1" data-filename="pdftables_fromstorage_023782248" data-page="611" data-table="1"><tr><td>Agonists and</td></tr><tr><td>antagonists</td></tr><tr><td>An agonist binds to a receptor to elicit a response (e.g. increase in heart rate; contraction of smooth muscle).</td></tr><tr><td>The log.dose/response curves to three different agonists, which work through the same receptor, are shown</td></tr><tr><td>in panel A.</td></tr><tr><td>An antagonist prevents the action of an agonist. In panels B and C drugs D and E, both antagonists, reduce</td></tr><tr><td>responses to the agonist A. They move the log.dose/response curve for the agonist to the right.</td></tr><tr><td>There are several ways in which antagonism can occur:</td></tr><tr><td>Competitive receptor antagonism – the antagonist binds to the receptor to prevent the agonist binding (see card 35.04).</td></tr><tr><td>Non-competitive antagonism – the antagonist interferes with the transduction process between agonist binding</td></tr><tr><td>and response.</td></tr><tr><td>Physiological antagonism – the antagonist (in fact an agonist) produces a response which opposes the action of</td></tr><tr><td>the agonist.</td></tr><tr><td>Pharmacokinetic antagonism – the antagonist reduces the concentration of the agonist at its site of action.</td></tr><tr><td>This might be due to reduced drug absorption or an enhanced rate of elimination.</td></tr><tr><td>Chemical antagonism – the antagonist combines with the agonist. Very uncommon.</td></tr><tr><td>R&amp;D 7e Ch 2, pp 8-14; D&amp;H 2e Ch 1, pp 2-6</td></tr></table>
</page>
<page number="612">
<table id="p612t1" data-filename="pdftables_fromstorage_023782248" data-page="612" data-table="1"><tr><td style="text-align: right">35.02</td><td>Affinity</td><td>General principles</td><td></td><td></td><td></td></tr><tr><td colspan="2">Panel A shows the response of a</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">tissue to drugs A, B and C. Panels B and C</td><td></td><td></td><td></td></tr><tr><td colspan="3">show the effects that drugs D and E have</td><td>B</td><td></td><td></td></tr><tr><td colspan="3">on the log.dose/response curves to drug A.</td><td></td><td></td><td>Drug A + fixed</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>concentration</td></tr><tr><td colspan="2">How does the affinity of a drug for its receptor</td><td></td><td></td><td>Drug A</td><td>of drug D</td></tr><tr><td colspan="2">influence its log.dose/response curve?</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Drug A + higher</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>fixed concentration</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>of drug D</td></tr><tr><td></td><td>A, B and C are agonists</td><td></td><td></td><td></td><td></td></tr><tr><td>A</td><td></td><td></td><td></td><td>D and E are antagonists</td><td></td></tr><tr><td></td><td></td><td></td><td>C</td><td></td><td></td></tr><tr><td></td><td>Drug A</td><td>Drug B</td><td></td><td></td><td>Drug A + fixed</td></tr><tr><td></td><td></td><td></td><td>nse</td><td></td><td>concentration</td></tr><tr><td></td><td></td><td></td><td>po</td><td>Drug A</td><td>of drug E</td></tr><tr><td></td><td></td><td></td><td>e</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>r</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Drug A + higher</td></tr><tr><td></td><td></td><td>Drug C</td><td></td><td></td><td>fixed concentration</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>of drug E</td></tr><tr><td></td><td>Log of drug concentration</td><td></td><td></td><td>Log of concentration of drug A</td><td></td></tr></table>
</page>
<page number="613">
<table id="p613t1" data-filename="pdftables_fromstorage_023782248" data-page="613" data-table="1"><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Affinity</td></tr><tr><td colspan="9">The affinity of a drug, D (agonist or antagonist), for its receptor, R, determines the proportion of receptors which</td></tr><tr><td colspan="9">are occupied by the drug, DR. The interaction follows the law of mass action:</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>D + R</td><td>DR</td><td>KD = ([D] x [R])/[DR]</td></tr><tr><td colspan="9">where [D], [R] and [DR] are the concentrations of D, R and DR respectively and K D is the equilibrium dissociation</td></tr><tr><td colspan="9">constant. Occupancy of receptors by D is given by the equation:</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>[D]</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">% occupancy = 100*</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>[D] + K D</td></tr><tr><td colspan="9">This equation predicts the relationship between occupancy and drug concentration will be a rectangular hyperbola,</td></tr><tr><td colspan="9">which will appear as a sigmoid curve if the drug concentration is plotted on a log scale:</td></tr><tr><td style="text-align: right">100</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">80</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">The tissue log.dose/response curve is also invariably sigmoidal.</td></tr><tr><td style="text-align: right">60</td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">A low K D value represents a high affinity and the curve will rise at</td></tr><tr><td style="text-align: right">40</td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">low drug concentrations. If K D is higher (lower affinity) the curve</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">will appear at higher drug concentrations. Thus in panel A overleaf,</td></tr><tr><td style="text-align: right">20</td><td></td><td></td><td></td><td>KD</td><td></td><td></td><td colspan="2">drug A would have a higher affinity for the receptor than drug B –</td></tr><tr><td style="text-align: right">0</td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">assuming they have the same efficacy (see card 35.03)</td></tr><tr><td style="text-align: right">0.0</td><td style="text-align: right">0.5</td><td style="text-align: right">1.0</td><td style="text-align: right">1.5</td><td style="text-align: right">2.0</td><td style="text-align: right">2.5</td><td style="text-align: right">3.0</td><td></td><td></td></tr><tr><td></td><td></td><td colspan="2">Log [D]</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>R&amp;D 7e Ch 2, p 8; D&amp;H 2e Ch 1, pp 2-6</td></tr></table>
</page>
<page number="614">
<table id="p614t1" data-filename="pdftables_fromstorage_023782248" data-page="614" data-table="1"><tr><td style="text-align: right">35.03</td><td>Efficacy</td><td>General principles</td><td></td><td></td><td></td></tr><tr><td colspan="2">Panel A shows the response of a</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">tissue to drugs A, B and C. Panels B and C</td><td></td><td></td><td></td></tr><tr><td colspan="3">show the effects that drugs D and E have</td><td>B</td><td></td><td></td></tr><tr><td colspan="3">on the log.dose/response curves to drug A.</td><td></td><td></td><td>Drug A + fixed</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>concentration</td></tr><tr><td colspan="2">How does the efficacy of a drug influence</td><td></td><td></td><td>Drug A</td><td>of drug D</td></tr><tr><td colspan="2">its log.dose/response curve?</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Drug A + higher</td></tr><tr><td colspan="3">Assuming equal efficacy agonist A has a</td><td></td><td></td><td>fixed concentration</td></tr><tr><td colspan="3">higher affinity for receptor than agonist B</td><td></td><td></td><td>of drug D</td></tr><tr><td>A</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>C</td><td></td><td></td></tr><tr><td></td><td>Drug A</td><td>Drug B</td><td></td><td></td><td>Drug A + fixed</td></tr><tr><td></td><td></td><td></td><td>nse</td><td></td><td>concentration</td></tr><tr><td></td><td></td><td></td><td>po</td><td>Drug A</td><td>of drug E</td></tr><tr><td></td><td></td><td></td><td>e</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>r</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Drug A + higher</td></tr><tr><td></td><td></td><td>Drug C</td><td></td><td></td><td>fixed concentration</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>of drug E</td></tr><tr><td></td><td>Log of drug concentration</td><td></td><td></td><td>Log of concentration of drug A</td><td></td></tr></table>
</page>
<page number="615">
<table id="p615t1" data-filename="pdftables_fromstorage_023782248" data-page="615" data-table="1"><tr><td></td><td></td><td>Efficacy</td></tr><tr><td colspan="2">Efficacy describes the ability of an agonist, once bound to its receptor, to elicit a response.</td><td></td></tr><tr><td colspan="2">A full agonist produces the maximum response which a tissue is capable of.</td><td></td></tr><tr><td colspan="3">A partial agonist cannot produce such a large response, even when occupying all the receptors.</td></tr><tr><td colspan="2">In panel A overleaf drugs A and B are full agonists whereas drug C is a partial agonist.</td><td></td></tr><tr><td colspan="3">The distinction between full and partial agonists is best illustrated in the context of agonists acting on</td></tr><tr><td colspan="3">ligand-gated ion channels (e.g. the NMDA receptor). The following reaction scheme indicates an agonist, A,</td></tr><tr><td>binding to a receptor, R, to give AR;</td><td></td><td></td></tr><tr><td>k +1</td><td>β</td><td></td></tr><tr><td>A + R</td><td>AR</td><td>AR*</td></tr><tr><td>k -1</td><td>α</td><td></td></tr><tr><td colspan="3">k +1 and k -1 are the forward and reverse rate constants for agonist binding.</td></tr><tr><td colspan="3">The agonist–receptor complex isomerises to AR* which is the active, open channel form of the receptor, β and α are</td></tr><tr><td colspan="3">the forward and reverse rate constants for the isomerisation reaction. It is now easy, for this receptor mechanism,</td></tr><tr><td colspan="3">to understand full and partial agonism. For a full agonist β is much greater than α so that many of the channels open.</td></tr><tr><td colspan="3">For a partial agonist, with low efficacy, α is greater than β so that few of the receptors isomerise to AR*.</td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 2, p 8; D&amp;H 2e Ch 1, pp 2-6</td></tr></table>
</page>
<page number="616">
<table id="p616t1" data-filename="pdftables_fromstorage_023782248" data-page="616" data-table="1"><tr><td></td><td>Competitive</td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">35.04</td><td>antagonism</td><td>General principles</td><td></td><td></td><td></td></tr><tr><td colspan="2">Panel A shows the response of a</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">tissue to drugs A, B and C. Panels B and C</td><td></td><td></td><td></td></tr><tr><td colspan="3">show the effects that drugs D and E have</td><td>B</td><td></td><td></td></tr><tr><td colspan="3">on the log.dose/response curves to drug A.</td><td></td><td></td><td>Drug A + fixed</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>concentration</td></tr><tr><td colspan="2">How does a competitive antagonist influence</td><td></td><td></td><td>Drug A</td><td>of drug D</td></tr><tr><td colspan="2">the dose/response curve for an agonist?</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Drug A + higher</td></tr><tr><td></td><td>Full agonists</td><td></td><td></td><td></td><td>fixed concentration</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>of drug D</td></tr><tr><td>A</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Drug A</td><td>Drug B</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Partial agonist</td><td>C</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Drug A + fixed</td></tr><tr><td></td><td></td><td></td><td>nse</td><td></td><td>concentration</td></tr><tr><td></td><td></td><td>Drug C</td><td>spo</td><td>Drug A</td><td>of drug E</td></tr><tr><td></td><td></td><td></td><td>e</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>r</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Drug A + higher</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>fixed concentration</td></tr><tr><td></td><td>Log of drug concentration</td><td></td><td></td><td></td><td>of drug E</td></tr><tr><td></td><td colspan="2">Partial agonists have a low efficacy</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Log of concentration of drug A</td><td></td></tr></table>
</page>
<page number="617">
<table id="p617t1" data-filename="pdftables_fromstorage_023782248" data-page="617" data-table="1"><tr><td></td><td></td><td>Competitive</td></tr><tr><td></td><td></td><td>antagonism</td></tr><tr><td colspan="3">A competitive antagonist binds to the receptor and in so doing prevents the binding of an agonist molecule.</td></tr><tr><td colspan="3">If the antagonist binds reversibly, the effect of the antagonist can be overcome by increasing the concentration</td></tr><tr><td>of the agonist.</td><td></td><td></td></tr><tr><td colspan="3">Reversible competitive antagonism shifts the log.dose/response curve to the right in a parallel fashion (drug D in</td></tr><tr><td colspan="3">panel B overleaf). The shift is expressed as a ‘dose ratio’, r, – the factor by which the concentration of agonist must</td></tr><tr><td colspan="3">be increased to make any response in the presence of the antagonist the same as that in its absence. The Schild</td></tr><tr><td colspan="3">equation then allows the affinity of the antagonist for the receptor to be determined:</td></tr><tr><td>r-1 =</td><td>[B]</td><td>Where [B] is the antagonist concentration and K B is the dissociation equilibrium</td></tr><tr><td></td><td>KB</td><td>constant for antagonist binding.</td></tr><tr><td colspan="3">If the competitive antagonist binds irreversibly then raising the agonist concentration may not allow sufficient</td></tr><tr><td colspan="3">agonist occupancy for a maximum response. Irreversible competitive antagonism is shown by drug E in Panel C</td></tr><tr><td colspan="3">overleaf, where, with the higher concentration of antagonist, no amount of increase in [A] allows the maximum</td></tr><tr><td colspan="3">response to be regained. Often a maximum response does not need the agonist to occupy all of the receptors.</td></tr><tr><td colspan="3">There are said to be ‘spare receptors’. A low dose of irreversible competitive antagonist may then appear to</td></tr><tr><td colspan="3">produce a parallel shift of the log.dose/response curve (suggested by the change in the log.dose/response</td></tr><tr><td colspan="2">curve with the lower concentration of E).</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 2, pp 10-11; D&amp;H 2e Ch 1, pp 2-6</td></tr></table>
</page>
<page number="618">
<table id="p618t1" data-filename="pdftables_fromstorage_023782248" data-page="618" data-table="1"><tr><td style="text-align: right">35.05</td><td>Summary</td><td>General principles</td><td></td><td></td><td></td></tr><tr><td colspan="2">Panel A shows the response of a</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="3">tissue to drugs A, B and C. Panels B and C</td><td></td><td></td><td>D, Reversible competitive antagonist</td></tr><tr><td colspan="3">show the effects that drugs D and E have</td><td>B</td><td></td><td></td></tr><tr><td colspan="3">on the log.dose/response curves to drug A.</td><td></td><td></td><td>Drug A + fixed</td></tr><tr><td></td><td></td><td></td><td></td><td>Drug A</td><td>concentration</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>of drug D</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Drug A + higher</td></tr><tr><td></td><td>Full agonists</td><td></td><td></td><td></td><td>fixed concentration</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>of drug D</td></tr><tr><td>A</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Drug A</td><td>Drug B</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>C</td><td></td><td>E, Irreversible competitive antagonist</td></tr><tr><td></td><td></td><td>Partial agonist</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Drug A + fixed</td></tr><tr><td></td><td></td><td></td><td>nse</td><td></td><td>concentration</td></tr><tr><td></td><td></td><td>Drug C</td><td>spo</td><td>Drug A</td><td>of drug E</td></tr><tr><td></td><td></td><td></td><td>e</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>r</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Drug A + higher</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>fixed concentration</td></tr><tr><td></td><td>Log of drug concentration</td><td></td><td></td><td></td><td>of drug E</td></tr><tr><td></td><td></td><td></td><td></td><td>Log of concentration of drug A</td><td></td></tr></table>
</page>
<page number="619">
<table id="p619t1" data-filename="pdftables_fromstorage_023782248" data-page="619" data-table="1"><tr><td>Notes</td></tr><tr><td>Notes</td></tr></table>
</page>
<page number="620">
<table id="p620t1" data-filename="pdftables_fromstorage_023782248" data-page="620" data-table="1"><tr><td></td><td>Ethical considerations</td><td></td><td></td></tr><tr><td style="text-align: right">36.01</td><td>in drug development</td><td>The introduction of new drugs</td><td></td></tr><tr><td colspan="3">Key stages in the development and introduction of a new drug</td><td></td></tr><tr><td colspan="2">Identification of novel chemical</td><td></td><td></td></tr><tr><td colspan="2">with therapeutic potential</td><td></td><td>Pharmacological actions</td></tr><tr><td></td><td></td><td>Preclinical studies in animals</td><td>Pharmacokinetics</td></tr><tr><td></td><td></td><td></td><td>Toxicology</td></tr><tr><td></td><td></td><td></td><td>Pharmacological actions</td></tr><tr><td></td><td></td><td>Phase I – Studies in healthy volunteers</td><td>Pharmacokinetics</td></tr><tr><td></td><td></td><td></td><td>Tolerability/side effects</td></tr><tr><td></td><td></td><td></td><td>Efficacy in target conditon(s)</td></tr><tr><td></td><td>Clinical studies</td><td>Phase II – Small-scale trials in patients</td><td>Dosage regimen</td></tr><tr><td></td><td></td><td></td><td>Toxicity</td></tr><tr><td></td><td></td><td></td><td>Comparison with established</td></tr><tr><td></td><td></td><td>Phase III – Large-scale, formal clinical trial</td><td>treatments</td></tr><tr><td></td><td></td><td></td><td>Discovery of rare or long-term/</td></tr><tr><td></td><td></td><td>Phase IV – Postmarketing surveillance</td><td>delayed adverse effects</td></tr><tr><td></td><td></td><td></td><td>Identification of sensitive/</td></tr><tr><td></td><td></td><td></td><td>insensitive populations</td></tr><tr><td></td><td></td><td>NEW DRUG !!</td><td></td></tr></table>
</page>
<page number="621">
<table id="p621t1" data-filename="pdftables_fromstorage_023782248" data-page="621" data-table="1"><tr><td></td><td>Ethical considerations</td></tr><tr><td></td><td>in drug development</td></tr><tr><td>Human studies</td><td>Trials must ask a particular, relevant question and be designed so that an unambiguous answer</td></tr><tr><td></td><td>can be provided. Independent ethical committees must approve the study.</td></tr><tr><td></td><td>A new drug can only be compared to the best treatment currently available (i.e. the use of a</td></tr><tr><td></td><td>placebo may be unethical).</td></tr><tr><td></td><td>A comparative trial should be terminated early if data indicate one treatment is clearly better</td></tr><tr><td></td><td>(so that all may benefit).</td></tr><tr><td></td><td>All patients (or guardian) should provide informed consent for participation.</td></tr><tr><td></td><td>Drugs known to be toxic (e.g. from animal studies) should not be tested in healthy volunteers.</td></tr><tr><td>Animal studies</td><td>The minimum number of animals, consistent with achieving a statistically valid assessment of</td></tr><tr><td></td><td>the drug action under study, should be used. Suffering must also be minimised.</td></tr><tr><td></td><td>R&amp;D 7e Ch 7, pp 94-98; D&amp;H 2e Ch 5, p 19</td></tr></table>
</page>
<page number="622">
<table id="p622t1" data-filename="pdftables_fromstorage_023782248" data-page="622" data-table="1"><tr><td></td><td>Randomisation</td><td></td><td></td></tr><tr><td style="text-align: right">36.02</td><td>in clinical trials</td><td>The introduction of new drugs</td><td></td></tr><tr><td colspan="3">Key stages in the development and introduction of a new drug</td><td></td></tr><tr><td colspan="2">Identification of novel chemical</td><td></td><td></td></tr><tr><td colspan="2">with therapeutic potential</td><td></td><td>Pharmacological actions</td></tr><tr><td></td><td></td><td>Preclinical studies in animals</td><td>Pharmacokinetics</td></tr><tr><td></td><td></td><td></td><td>Toxicology</td></tr><tr><td></td><td>Ethics</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Pharmacological actions</td></tr><tr><td></td><td></td><td>Phase I – Studies in healthy volunteers</td><td>Pharmacokinetics</td></tr><tr><td></td><td></td><td></td><td>Tolerability/side effects</td></tr><tr><td></td><td></td><td></td><td>Efficacy in target conditon(s)</td></tr><tr><td colspan="2">Clinical studies</td><td>Phase II – Small-scale trials in patients</td><td>Dosage regimen</td></tr><tr><td></td><td></td><td></td><td>Toxicity</td></tr><tr><td></td><td></td><td></td><td>Comparison with established</td></tr><tr><td></td><td></td><td>Phase III – Large-scale, formal clinical trial</td><td>treatments</td></tr><tr><td></td><td></td><td></td><td>Discovery of rare or long-term/</td></tr><tr><td></td><td></td><td>Phase IV – Postmarketing surveillance</td><td>delayed adverse effects</td></tr><tr><td></td><td></td><td></td><td>Identification of sensitive/</td></tr><tr><td></td><td></td><td></td><td>insensitive populations</td></tr><tr><td></td><td></td><td>NEW DRUG !!</td><td></td></tr></table>
</page>
<page number="623">
<table id="p623t1" data-filename="pdftables_fromstorage_023782248" data-page="623" data-table="1"><tr><td>Randomisation and the allocation of</td></tr><tr><td>patients to treatment groups</td></tr><tr><td>Random allocation to treatment groups</td></tr><tr><td>The main aim is to avoid bias in selecting patients for particular treatments yet to ensure the groups</td></tr><tr><td>are essentially similar in composition. In a large trial, with many participants, simple, random</td></tr><tr><td>allocation will generally ensure the treatment groups are similar.</td></tr><tr><td>Stratified randomisation</td></tr><tr><td>In a small trial, randomisation may not ensure similarity. It may be desirable to make sure that each</td></tr><tr><td>group has broadly the same numbers of each sex, a similar age spread and that disease severity is</td></tr><tr><td>comparable. Stratification may also allow groups of individuals who respond more favourably to a</td></tr><tr><td>particular treatment to be identified.</td></tr><tr><td>Cross-over design</td></tr><tr><td>With stable, chronic conditions it is possible that all subjects may be able take both treatments at</td></tr><tr><td>different times. Each patient effectively serves as their own control and the outcome may be</td></tr><tr><td>recorded as a preference.</td></tr><tr><td>R&amp;D 7e Ch 7, p 95; D&amp;H 2e Ch 5, p 19</td></tr></table>
</page>
<page number="624">
<table id="p624t1" data-filename="pdftables_fromstorage_023782248" data-page="624" data-table="1"><tr><td style="text-align: right">36.03</td><td>Blinding</td><td>The introduction of new drugs</td><td></td></tr><tr><td colspan="3">Key stages in the development and introduction of a new drug</td><td></td></tr><tr><td colspan="2">Identification of novel chemical</td><td></td><td></td></tr><tr><td colspan="2">with therapeutic potential</td><td></td><td>Pharmacological actions</td></tr><tr><td></td><td></td><td>Preclinical studies in animals</td><td>Pharmacokinetics</td></tr><tr><td></td><td></td><td></td><td>Toxicology</td></tr><tr><td></td><td>Ethics</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Pharmacological actions</td></tr><tr><td></td><td></td><td>Phase I – Studies in healthy volunteers</td><td>Pharmacokinetics</td></tr><tr><td></td><td></td><td></td><td>Tolerability/side effects</td></tr><tr><td></td><td></td><td></td><td>Efficacy in target conditon(s)</td></tr><tr><td>Clinical studies</td><td></td><td>Phase II – Small-scale trials in patients</td><td>Dosage regimen</td></tr><tr><td></td><td></td><td></td><td>Toxicity</td></tr><tr><td></td><td></td><td></td><td>Comparison with established</td></tr><tr><td></td><td></td><td>Phase III – Large-scale, formal clinical trial</td><td>treatments</td></tr><tr><td></td><td></td><td></td><td>Discovery of rare or long-term/</td></tr><tr><td></td><td></td><td>Phase IV – Postmarketing surveillance</td><td>delayed adverse effects</td></tr><tr><td></td><td></td><td></td><td>Identification of sensitive/</td></tr><tr><td></td><td></td><td>Randomisation</td><td>insensitive populations</td></tr><tr><td></td><td></td><td>NEW DRUG !!</td><td></td></tr></table>
</page>
<page number="625">
<table id="p625t1" data-filename="pdftables_fromstorage_023782248" data-page="625" data-table="1"><tr><td></td><td>Blinding</td></tr><tr><td>Single blind</td><td>In single-blind trials patients are not told which treatment they are to receive. The aim is to</td></tr><tr><td></td><td>ensure that any expectations that the patient has does not generate or modify a placebo effect</td></tr><tr><td></td><td>or otherwise influence their assessment of the treatment.</td></tr><tr><td>Double blind</td><td>‘Double blind’ is where neither patient nor doctor knows which treatment is being administered.</td></tr><tr><td></td><td>Bias in allocating patients to a treatment can be avoided if the trial organiser does not know which</td></tr><tr><td></td><td>treatment a patient is to receive. This ensures that, for example, the more seriously ill patients are</td></tr><tr><td></td><td>not given the new treatment, perhaps in the expectation that ‘new is better’. It should also prevent</td></tr><tr><td></td><td>bias affecting the clinician’s assessment of the comparative effectiveness of the treatments.</td></tr><tr><td></td><td>R&amp;D 7e Ch 7, p 95; D&amp;H Ch 5, p 19</td></tr></table>
</page>
<page number="626">
<table id="p626t1" data-filename="pdftables_fromstorage_023782248" data-page="626" data-table="1"><tr><td style="text-align: right">36.04</td><td>Therapeutic index</td><td>The introduction of new drugs</td><td></td></tr><tr><td colspan="3">Key stages in the development and introduction of a new drug</td><td></td></tr><tr><td colspan="2">Identification of novel chemical</td><td></td><td></td></tr><tr><td colspan="2">with therapeutic potential</td><td></td><td>Pharmacological actions</td></tr><tr><td></td><td></td><td>Preclinical studies in animals</td><td>Pharmacokinetics</td></tr><tr><td></td><td></td><td></td><td>Toxicology</td></tr><tr><td></td><td>Ethics</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Pharmacological actions</td></tr><tr><td></td><td></td><td>Phase I – Studies in healthy volunteers</td><td>Pharmacokinetics</td></tr><tr><td></td><td></td><td></td><td>Tolerability/side effects</td></tr><tr><td></td><td></td><td></td><td>Efficacy in target conditon(s)</td></tr><tr><td>Clinical studies</td><td></td><td>Phase II – Small-scale trials in patients</td><td>Dosage regimen</td></tr><tr><td></td><td></td><td></td><td>Toxicity</td></tr><tr><td></td><td></td><td></td><td>Comparison with established</td></tr><tr><td></td><td></td><td>Phase III – Large-scale, formal clinical trial</td><td>treatments</td></tr><tr><td></td><td>Blinding</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Discovery of rare or long-term/</td></tr><tr><td></td><td></td><td>Phase IV – Postmarketing surveillance</td><td>delayed adverse effects</td></tr><tr><td></td><td></td><td></td><td>Identification of sensitive/</td></tr><tr><td></td><td>Randomisation</td><td></td><td>insensitive populations</td></tr><tr><td></td><td></td><td>NEW DRUG !!</td><td></td></tr></table>
</page>
<page number="627">
<table id="p627t1" data-filename="pdftables_fromstorage_023782248" data-page="627" data-table="1"><tr><td></td><td>Therapeutic index</td></tr><tr><td colspan="2">The therapeutic index (TI) is a simple attempt to quantify the benefit versus risk ratio of a drug.</td></tr><tr><td>TD 50</td><td>LD50</td></tr><tr><td>TI =</td><td>or</td></tr><tr><td>ED50</td><td>ED50</td></tr><tr><td colspan="2">The TD50 is the dose required to produce a toxic effect in 50% of the subjects (the median toxic dose) and the</td></tr><tr><td colspan="2">ED 50 is the median effective dose. In animal studies, toxicity may be measured by death, in which case the median</td></tr><tr><td colspan="2">lethal dose (LD 50) replaces the TD50. Clearly, if the TD50 or LD 50 is much greater than the ED50 then the TI will be</td></tr><tr><td colspan="2">large and the drug might be considered to have a large safety margin. The LD50 , necessarily measured in animals,</td></tr><tr><td>is a poor measure of human toxicity.</td><td></td></tr><tr><td colspan="2">The risk which is accepted in taking a drug will obviously be affected by the severity of the condition being treated.</td></tr><tr><td>Many quite toxic drugs are used for life-threatening illnesses.</td><td></td></tr><tr><td></td><td>R&amp;D 7e Ch 7, p 97; D&amp;H Ch 5, p 19</td></tr></table>
</page>
<page number="628">
<table id="p628t1" data-filename="pdftables_fromstorage_023782248" data-page="628" data-table="1"><tr><td></td><td>Lipid solubility</td><td></td><td></td></tr><tr><td style="text-align: right">37.01</td><td>and ionisation</td><td>Absorption and distribution of drugs</td><td></td></tr><tr><td colspan="3">Simple diagram of absorption and distribution of a drug</td><td></td></tr><tr><td colspan="4">How do lipid solubility and ionisation influence the passage of drugs through cell membranes?</td></tr><tr><td></td><td></td><td>Drug in brain</td><td></td></tr><tr><td colspan="2">Drug administration</td><td>Drug in plasma</td><td>Drug elimination</td></tr><tr><td></td><td></td><td>Drug in peripheral</td><td></td></tr><tr><td></td><td></td><td>tissues</td><td></td></tr></table>
</page>
<page number="629">
<table id="p629t1" data-filename="pdftables_fromstorage_023782248" data-page="629" data-table="1"><tr><td>Lipid solubility</td></tr><tr><td>and ionisation</td></tr><tr><td>• Passive diffusion of drug through a cell membrane depends on its concentration gradient across the membrane</td></tr><tr><td>and its diffusion coefficient.</td></tr><tr><td>• Concentration gradient established within the cell membrane depends on the drug's lipid/water partition</td></tr><tr><td>coefficient.</td></tr><tr><td>• Most drugs ionise to some extent in aqueous solution.</td></tr><tr><td>• The ionised form is lipophobic, so that ionisation impedes passive membrane permeation.</td></tr><tr><td>• The fractional ionisation can be determined from the Henderson-Hasselbalch equation:</td></tr><tr><td>for a weak acid: log 10 c i/c u = pH - pKa</td></tr><tr><td>for a weak base: log10 c i /c u = pK a - pH</td></tr><tr><td>[Where ci is the concentration of drug in ionised form, cu is that in unionised form, pKa is -log10 of the acid dissociation</td></tr><tr><td>constant for the drug and pH is -log10 of the hydrogen ion concentration.]</td></tr><tr><td>• Ionisation thus depends on the pH of the aqueous environment and the drug's acid dissociation constant</td></tr><tr><td>(a strong acid has a low pKa and a strong base has a high pKa).</td></tr><tr><td>R&amp;D 7e Ch 8, pp 99-101; D&amp;H 2e Ch 6, pp 20-21</td></tr></table>
</page>
<page number="630">
<table id="p630t1" data-filename="pdftables_fromstorage_023782248" data-page="630" data-table="1"><tr><td></td><td>Routes of drug</td><td></td><td></td></tr><tr><td style="text-align: right">37.02</td><td>administration</td><td>Absorption and distribution of drugs</td><td></td></tr><tr><td colspan="2">Simple diagram of absorption and distribution of a drug</td><td></td><td></td></tr><tr><td colspan="4">What are the features, advantages and disadvantages of the different routes of drug administration?</td></tr><tr><td></td><td>Passage across the</td><td>Drug in brain</td><td></td></tr><tr><td>Lipid solubility</td><td>blood–brain barrier</td><td></td><td></td></tr><tr><td>and ionisation</td><td></td><td></td><td></td></tr><tr><td>Absorption across the</td><td></td><td></td><td></td></tr><tr><td colspan="2">mucosa of the intestine</td><td></td><td></td></tr><tr><td colspan="2">Drug administration</td><td>Drug in plasma</td><td>Drug elimination</td></tr><tr><td></td><td></td><td></td><td>Passive reabsorption</td></tr><tr><td></td><td></td><td></td><td>from the renal tubules</td></tr><tr><td></td><td></td><td>Penetration</td><td>Lipid solubility</td></tr><tr><td></td><td></td><td>into cells</td><td>and ionisation</td></tr><tr><td></td><td></td><td>Drug in peripheral</td><td></td></tr><tr><td></td><td></td><td>tissues</td><td></td></tr></table>
</page>
<page number="631">
<table id="p631t1" data-filename="pdftables_fromstorage_023782248" data-page="631" data-table="1"><tr><td></td><td>Routes of drug</td></tr><tr><td></td><td>administration</td></tr><tr><td>Enteral, i.e.</td><td>Easy, requires no skill, and little need for sterility. Many drugs, however, are poorly absorbed from</td></tr><tr><td>oral, rectal,</td><td>the gut and bioavailability (see card 37.03) may be low. Rectal and sublingual admin. largely avoid</td></tr><tr><td>sublingual</td><td>first-pass metabolism. Rectal route useful for irritant medicines or if the patient is vomiting or</td></tr><tr><td></td><td>comatose.</td></tr><tr><td>Intravenous,</td><td>100% of dose is immediately available within the circulation (though injection is often made slowly</td></tr><tr><td>i.v.</td><td>to avoid an excessive, transient concentration in the blood.) Skill and sterility required.</td></tr><tr><td>Intramuscular,</td><td>Requires less skill and all the drug enters the circulation. Depot preparations can be used for drug</td></tr><tr><td>i.m.</td><td>action over periods of days to weeks.</td></tr><tr><td>Subcutaneous,</td><td>Requires little skill. Depots can be used.</td></tr><tr><td>s.c.</td><td></td></tr><tr><td>Percutaneous</td><td>Very lipid-soluble substances can be usefully administered this way, e.g. nicotine/fentanyl/glyceryl</td></tr><tr><td></td><td>trinitrate as patches.</td></tr><tr><td>Inhalation</td><td>Rapid absorption – large surface area, rich blood supply, thin membranes. Used for systemic action,</td></tr><tr><td></td><td>esp. gaseous anaesthetics, or local action, e.g. bronchodilators and antiasthmatic glucocorticoids.</td></tr><tr><td>Intrathecal</td><td>For drugs which do not readily cross the blood–brain barrier.</td></tr><tr><td>Local/topical</td><td>To provide local treatment (eye, joint etc.) and minimise effects elsewhere in body.</td></tr><tr><td></td><td>R&amp;D 7e Ch 8, pp 106-110; D&amp;H 2e Ch 6, pp 20-21</td></tr></table>
</page>
<page number="632">
<table id="p632t1" data-filename="pdftables_fromstorage_023782248" data-page="632" data-table="1"><tr><td style="text-align: right">37.03</td><td>Bioavailability</td><td>Absorption and distribution of drugs</td><td></td></tr><tr><td colspan="2">Simple diagram of absorption and distribution of a drug</td><td></td><td></td></tr><tr><td colspan="2">What is meant by the term ‘bioavailability’?</td><td></td><td></td></tr><tr><td></td><td>Passage across the</td><td>Drug in brain</td><td></td></tr><tr><td>Lipid solubility</td><td>blood–brain barrier</td><td></td><td></td></tr><tr><td>and ionisation</td><td></td><td></td><td></td></tr><tr><td>Absorption across the</td><td></td><td></td><td></td></tr><tr><td colspan="2">mucosa of the intestine</td><td></td><td></td></tr><tr><td colspan="2">Drug administration</td><td>Drug in plasma</td><td>Drug elimination</td></tr><tr><td></td><td></td><td></td><td>Passive reabsorption</td></tr><tr><td>Routes of</td><td></td><td></td><td>from the renal tubules</td></tr><tr><td>administration</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Penetration</td><td>Lipid solubility</td></tr><tr><td></td><td></td><td>into cells</td><td>and ionisation</td></tr><tr><td></td><td></td><td>Drug in peripheral</td><td></td></tr><tr><td></td><td></td><td>tissues</td><td></td></tr></table>
</page>
<page number="633">
<table id="p633t1" data-filename="pdftables_fromstorage_023782248" data-page="633" data-table="1"><tr><td></td><td></td><td></td><td>Bioavailability</td></tr><tr><td colspan="4">The most useful definition is ‘the proportion of the administered dose that reaches the systemic circulation’.</td></tr><tr><td colspan="4">Incomplete release from the dosage form, destruction within the gut, poor absorption and first-pass elimination</td></tr><tr><td colspan="4">are important causes of low bioavailability. For drugs with a low therapeutic index it is important that repeat</td></tr><tr><td colspan="3">prescriptions provide medicines of equivalent bioavailability (bioequivalence).</td><td></td></tr><tr><td colspan="2">Diagram showing factors influencing bioavailability</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Only a fraction of</td></tr><tr><td>Drug in solution</td><td></td><td></td><td>dose may reach</td></tr><tr><td>in the gut</td><td></td><td></td><td>general circulation</td></tr><tr><td>Disintegration and</td><td></td><td></td><td></td></tr><tr><td>dissolution of tablet</td><td>Destruction in gut.</td><td>Partial absorption</td><td>Metabolism by gut mucosa</td></tr><tr><td></td><td>Peptides and proteins</td><td>-Low lipid solubility.</td><td>or liver in ‘first pass’;</td></tr><tr><td></td><td>subject to proteolytic</td><td>-Ionisation.</td><td>90% or more of a drug</td></tr><tr><td></td><td>enzymes. Some drugs</td><td>-Complexation with</td><td>dose may be metabolised</td></tr><tr><td></td><td>acid labile.</td><td>gut contents (e.g.</td><td>during its first passage</td></tr><tr><td>Drug formulation: the</td><td></td><td>tetracycline/Ca2+ salts)</td><td>through the liver.</td></tr><tr><td>main factor determining</td><td></td><td>-Rapid loss from gut</td><td></td></tr><tr><td>differences between</td><td></td><td>(diarrhoea).</td><td></td></tr><tr><td>preparations.</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>R&amp;D 7e Ch 8, p 108; D&amp;H Ch 6, pp 20-21</td></tr></table>
</page>
<page number="634">
<table id="p634t1" data-filename="pdftables_fromstorage_023782248" data-page="634" data-table="1"><tr><td></td><td>Measurement of</td><td></td><td></td></tr><tr><td style="text-align: right">37.04</td><td>bioavailability</td><td>Absorption and distribution of drugs</td><td></td></tr><tr><td colspan="2">Simple diagram of absorption and distribution of a drug</td><td></td><td></td></tr><tr><td colspan="2">How can the bioavailability of a drug preparation be established?</td><td></td><td></td></tr><tr><td></td><td>Passage across the</td><td>Drug in brain</td><td></td></tr><tr><td>Lipid solubility</td><td>blood–brain barrier</td><td></td><td></td></tr><tr><td>and ionisation</td><td></td><td></td><td></td></tr><tr><td>Absorption across the</td><td></td><td></td><td></td></tr><tr><td colspan="2">mucosa of the intestine</td><td></td><td></td></tr><tr><td colspan="2">Drug administration</td><td>Drug in plasma</td><td>Drug elimination</td></tr><tr><td></td><td></td><td></td><td>Passive reabsorption</td></tr><tr><td>Routes of</td><td></td><td></td><td>from the renal tubules</td></tr><tr><td>administration</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Penetration</td><td>Lipid solubility</td></tr><tr><td></td><td></td><td>into cells</td><td>and ionisation</td></tr><tr><td></td><td>Bioavailability</td><td>Drug in peripheral</td><td></td></tr><tr><td></td><td></td><td>tissues</td><td></td></tr></table>
</page>
<page number="635">
<table id="p635t1" data-filename="pdftables_fromstorage_023782248" data-page="635" data-table="1"><tr><td></td><td></td><td>Measurement of</td></tr><tr><td></td><td></td><td>bioavailability</td></tr><tr><td colspan="3">Bioavailability may be quantified by measuring the area under the curve of plasma concentration versus time.</td></tr><tr><td colspan="3">For intravenous administration, bioavailability is 100%. If the same dose is given by another route, the area under</td></tr><tr><td colspan="3">the curve, expressed as a percentage of the area for i.v. administration, gives the bioavailability. In the illustration</td></tr><tr><td colspan="3">below the relative areas would suggest a bioavailability of approximately 50% for the oral dosage form.</td></tr><tr><td>g</td><td></td><td></td></tr><tr><td>u</td><td></td><td></td></tr><tr><td>r</td><td></td><td></td></tr><tr><td>d</td><td></td><td></td></tr><tr><td>a</td><td>Intravenous</td><td></td></tr><tr><td>m</td><td></td><td></td></tr><tr><td>s</td><td></td><td></td></tr><tr><td>a</td><td></td><td></td></tr><tr><td>l</td><td></td><td></td></tr><tr><td>p</td><td></td><td></td></tr><tr><td></td><td></td><td>Oral</td></tr><tr><td></td><td></td><td>Time</td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 8, p 108; D&amp;H Ch 6, pp 20-21</td></tr></table>
</page>
<page number="636">
<table id="p636t1" data-filename="pdftables_fromstorage_023782248" data-page="636" data-table="1"><tr><td></td><td>Binding of drugs to non-target proteins</td><td></td><td></td></tr><tr><td style="text-align: right">37.05</td><td>and other tissue components</td><td>Absorption and distribution of drugs</td><td></td></tr><tr><td colspan="2">Simple diagram of absorption and distribution of a drug</td><td></td><td></td></tr><tr><td colspan="4">What are the features and consequences of drug binding to plasma proteins and other tissue components?</td></tr><tr><td></td><td>Passage across the</td><td>Drug in brain</td><td></td></tr><tr><td>Lipid solubility</td><td>blood–brain barrier</td><td></td><td></td></tr><tr><td>and ionisation</td><td></td><td></td><td></td></tr><tr><td>Absorption across the</td><td></td><td></td><td></td></tr><tr><td>mucosa of the intestine</td><td></td><td></td><td></td></tr><tr><td>Drug administration</td><td></td><td>Drug in plasma</td><td>Drug elimination</td></tr><tr><td></td><td></td><td></td><td>Passive reabsorption</td></tr><tr><td>Routes of</td><td></td><td></td><td>from the renal tubules</td></tr><tr><td>administration</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Penetration</td><td>Lipid solubility</td></tr><tr><td></td><td></td><td>into cells</td><td>and ionisation</td></tr><tr><td></td><td>Bioavailability</td><td>Drug in peripheral</td><td></td></tr><tr><td></td><td></td><td>tissues</td><td></td></tr></table>
</page>
<page number="637">
<table id="p637t1" data-filename="pdftables_fromstorage_023782248" data-page="637" data-table="1"><tr><td>Protein binding</td></tr><tr><td>Many drugs bind to plasma proteins, albumin in general being the most important. α-Acid glycoprotein is more</td></tr><tr><td>important for some basic drugs (e.g. propranolol). Binding to plasma proteins is usually reversible, of finite</td></tr><tr><td>capacity and of low specificity and has several consequences:</td></tr><tr><td>• Bound drug is usually inactive.</td></tr><tr><td>• The reduction in free drug concentration may reduce elimination (by reducing glomerular filtration) or,</td></tr><tr><td>conversely, protein binding may act to deliver drug to the kidney and liver, and so enhance elimination.</td></tr><tr><td>• One drug may prevent the binding of another, and so enhance drug action (significant only for highly</td></tr><tr><td>bound drugs such as warfarin, whose displacement and resulting increased activity can cause bleeding).</td></tr><tr><td>Tetracyclines bind to calcium in bones and teeth (which can produce abnormalities in tooth development</td></tr><tr><td>in children).</td></tr><tr><td>R&amp;D 7e Ch 8, pp 103-106; D&amp;H Ch 6, pp 20-21</td></tr></table>
</page>
<page number="638">
<table id="p638t1" data-filename="pdftables_fromstorage_023782248" data-page="638" data-table="1"><tr><td></td><td>Volume of</td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">37.06</td><td>distribution, Vd</td><td colspan="2">Absorption and distribution of drugs</td><td></td><td></td></tr><tr><td colspan="4">Simple diagram of absorption and distribution of a drug</td><td></td><td></td></tr><tr><td colspan="5">How can the same dose of different drugs result in different concentrations in the body?</td><td></td></tr><tr><td></td><td colspan="2">Passage across the</td><td></td><td colspan="2">Drug bound</td></tr><tr><td></td><td></td><td></td><td>Drug in brain</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">in brain</td></tr><tr><td>Lipid solubility</td><td colspan="2">blood–brain barrier</td><td></td><td></td><td></td></tr><tr><td>and ionisation</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Absorption across the</td><td></td><td></td><td></td><td colspan="2">Drug bound to</td></tr><tr><td colspan="2">mucosa of the intestine</td><td></td><td></td><td colspan="2">plasma proteins</td></tr><tr><td colspan="2">Drug administration</td><td></td><td>Drug in plasma</td><td></td><td>Drug elimination</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Passive reabsorption</td></tr><tr><td>Routes of</td><td></td><td></td><td></td><td></td><td>from the renal tubules</td></tr><tr><td>administration</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Penetration</td><td>Lipid solubility</td></tr><tr><td></td><td></td><td></td><td></td><td>into cells</td><td>and ionisation</td></tr><tr><td></td><td></td><td>Bioavailability</td><td>Drug in peripheral</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>tissues</td><td colspan="2">Drug bound</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">in tissues</td></tr></table>
</page>
<page number="639">
<table id="p639t1" data-filename="pdftables_fromstorage_023782248" data-page="639" data-table="1"><tr><td></td><td>Volume of</td></tr><tr><td></td><td>distribution</td></tr><tr><td colspan="2">After absorption, drugs do not spread rapidly throughout the whole of body water to achieve a uniform</td></tr><tr><td colspan="2">concentration. Large molecules (heparin, insulin) cannot easily enter interstitial and intracellular spaces, whereas</td></tr><tr><td colspan="2">smaller and lipid-soluble molecules can. A drug's penetration into these compartments is indicated by its apparent</td></tr><tr><td colspan="2">volume of distribution Vd : the volume of fluid that would be required to hold the amount of drug in the body at</td></tr><tr><td colspan="2">the measured plasma concentration. It can be estimated by the equation:</td></tr><tr><td>Vd = Dose/cp</td><td></td></tr><tr><td colspan="2">Where cp is the concentration of drug in the plasma after it has equilibrated in its distribution volume but before a</td></tr><tr><td colspan="2">significant fraction has been eliminated. Examples of Vd values (l/kg) are:</td></tr><tr><td>Heparin</td><td>0.05– 0.1</td></tr><tr><td>Tubocurarine</td><td>0.2–0.4</td></tr><tr><td>Ethanol</td><td style="text-align: right">1.0</td></tr><tr><td>Propranolol</td><td>2–5</td></tr><tr><td>Nortriptyline</td><td style="text-align: right">&gt;20</td></tr><tr><td colspan="2">A drug with a large V d will clearly require a larger dose to achieve a given plasma concentration than one with a</td></tr><tr><td>small Vd (given the same degree of binding to plasma protein).</td><td></td></tr><tr><td></td><td>R&amp;D 7e Ch 8, p 111; D&amp;H Ch 6, p 21</td></tr></table>
</page>
<page number="640">
<table id="p640t1" data-filename="pdftables_fromstorage_023782248" data-page="640" data-table="1"><tr><td></td><td colspan="2">Phase I and phase</td><td></td><td></td><td></td></tr><tr><td style="text-align: right">38.01</td><td colspan="2">II metabolism</td><td>Drug metabolism and excretion</td><td></td><td></td></tr><tr><td colspan="6">The concentration of a drug in the body is reduced either by its metabolism or by its excretion unchanged.</td></tr><tr><td></td><td></td><td></td><td></td><td>n via lungs</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Excretio</td><td>Drug in exhaled air</td></tr><tr><td></td><td></td><td>n</td><td>Drug in body</td><td>Unchanged drug</td><td></td></tr><tr><td></td><td></td><td>excretio</td><td></td><td>excre</td><td>tion</td></tr><tr><td></td><td></td><td>y</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>r</td><td></td><td></td><td>by</td></tr><tr><td></td><td>Bilia</td><td></td><td></td><td></td><td>kidney</td></tr><tr><td colspan="2">Drug or metabolite</td><td></td><td></td><td></td><td>Unchanged drug or</td></tr><tr><td>in faeces</td><td></td><td></td><td></td><td></td><td>metabolite in urine</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>idney</td></tr><tr><td></td><td></td><td>Bil</td><td></td><td></td><td></td></tr><tr><td></td><td>iary</td><td></td><td></td><td></td><td>by k</td></tr><tr><td></td><td></td><td>excretion</td><td>Drug metabolite</td><td>tion excre</td><td></td></tr><tr><td></td><td></td><td></td><td>in body</td><td>Drug metabolite</td><td></td></tr></table>
</page>
<page number="641">
<table id="p641t1" data-filename="pdftables_fromstorage_023782248" data-page="641" data-table="1"><tr><td></td><td></td><td></td><td>Phase I and phase</td></tr><tr><td></td><td></td><td></td><td>II metabolism</td></tr><tr><td></td><td colspan="3">Drug metabolism often occurs in two steps; phase I generally adds a reactive group to the molecule which</td></tr><tr><td></td><td colspan="3">provides a point of attack for the group added by a phase II, conjugation, reaction. Drug conjugates are nearly</td></tr><tr><td></td><td colspan="3">always biologically inactive (an exception is morphine 6-glucuronide) whereas phase I products may retain the</td></tr><tr><td></td><td colspan="2">therapeutic action or be toxic.</td><td></td></tr><tr><td>Phase I Reactions</td><td>Oxidation</td><td colspan="2">Mainly carried out by the P450 system (see card 38.02) in the liver. Examples:</td></tr><tr><td></td><td></td><td>propranolol</td><td>4-hydroxypropranolol (retains β-blocking activity)</td></tr><tr><td></td><td></td><td>paracetamol</td><td>N-acetyl-p-benzoquinone imine (responsible for hepatotoxicity)</td></tr><tr><td></td><td>Reduction</td><td>Nitrazepam</td><td>7-amino-nitrazepam (nitro reduction)</td></tr><tr><td></td><td></td><td>prednisone</td><td>prednisolone</td></tr><tr><td></td><td>Hydrolysis</td><td colspan="2">Often carrried out by esterases in liver or blood. Examples:</td></tr><tr><td></td><td></td><td>procaine</td><td></td></tr><tr><td></td><td></td><td>succinylcholine</td><td></td></tr><tr><td>Phase II Reactions</td><td colspan="2">These are the (mostly hepatic) conjugation reactions.</td><td></td></tr><tr><td></td><td>Glucuronidation</td><td>E.g. morphine, valproate</td><td></td></tr><tr><td></td><td>Sulfation</td><td>E.g. paracetamol, salbutamol</td><td></td></tr><tr><td></td><td>Methylation</td><td>E.g. o-methylation of catecholamines</td><td></td></tr><tr><td></td><td>Acetylation</td><td>E.g. sulphonamides, isoniazid</td><td></td></tr><tr><td></td><td>Amino acid</td><td>Especially with glycine. E.g. aspirin</td><td></td></tr><tr><td></td><td>Glutathione</td><td>E.g. busulfan and toxic metabolite of paracetamol</td><td></td></tr><tr><td></td><td></td><td></td><td>R&amp;D 7e Ch 9, pp 115-117; D&amp;H Ch 7, p 22</td></tr></table>
</page>
<page number="642">
<table id="p642t1" data-filename="pdftables_fromstorage_023782248" data-page="642" data-table="1"><tr><td></td><td>Cytochrome</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">38.02</td><td colspan="2">P450 system</td><td>Drug metabolism and excretion</td><td></td><td></td><td></td></tr><tr><td colspan="7">The concentration of a drug in the body is reduced either by its metabolism or by its excretion unchanged.</td></tr><tr><td></td><td></td><td></td><td></td><td>n via lungs</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Excretio</td><td>Drug in exhaled air</td></tr><tr><td></td><td></td><td>n</td><td>Drug in body</td><td></td><td>Unchanged drug</td><td></td></tr><tr><td></td><td></td><td>excretio</td><td></td><td></td><td>excretion</td><td></td></tr><tr><td></td><td></td><td>Biliary</td><td>Oxidation</td><td></td><td>by</td><td>kidney</td></tr><tr><td></td><td colspan="2">Reduction</td><td>Phase I</td><td></td><td></td><td></td></tr><tr><td>Drug or metabolite</td><td></td><td></td><td></td><td></td><td></td><td>Unchanged drug or</td></tr><tr><td>in faeces</td><td></td><td>Hydrolysis</td><td></td><td></td><td></td><td>metabolite in urine</td></tr><tr><td></td><td></td><td></td><td>Phase II</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Conjugation</td><td></td><td></td><td></td><td>idney</td></tr><tr><td></td><td></td><td>Bil</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>iary</td><td></td><td></td><td>by k</td><td></td></tr><tr><td></td><td></td><td>excretion</td><td>Drug metabolite</td><td colspan="2">tion excre</td><td></td></tr><tr><td></td><td></td><td></td><td>in body</td><td></td><td>Drug metabolite</td><td></td></tr></table>
</page>
<page number="643">
<table id="p643t1" data-filename="pdftables_fromstorage_023782248" data-page="643" data-table="1"><tr><td></td><td>Cytochrome</td></tr><tr><td></td><td>P450</td></tr><tr><td colspan="2">Drug oxidation, usually carried out by the P450 monooxygenase system, is a major route of drug metabolism.</td></tr><tr><td colspan="2">The P450 haem proteins are found particularly in the smooth endoplasmic reticulum of the liver.</td></tr><tr><td colspan="2">NADPH/cytochrome P450 reductase is generally an essential component of the system.</td></tr><tr><td colspan="2">There is a large family of P450 enzymes, only some of which are important for drug metabolism.</td></tr><tr><td colspan="2">These demonstrate selectivity in the drugs which act as substrates:</td></tr><tr><td>CYP1A2</td><td>caffeine, paracetamol</td></tr><tr><td>CYP2B6</td><td>cyclophosphamide, methadone</td></tr><tr><td>CYP2C8</td><td>paclitaxel, repaglinide</td></tr><tr><td>CYP2C19</td><td>omeprazole, phenytoin</td></tr><tr><td>CYP2C9</td><td>ibuprofen, tolbutamide</td></tr><tr><td>CYP2D6</td><td>codeine, propranolol</td></tr><tr><td>CYP2E1</td><td>alcohol, paracetamol</td></tr><tr><td>CYP3A4,5,7</td><td>ciclosporin, nifedipine</td></tr><tr><td colspan="2">Reactions catalysed by P450 include: O-dealkylation (codeine), aliphatic hydroxylation (ciclosporin),</td></tr><tr><td colspan="2">deamination (amfetamine), N-dealkylation (morphine), N-oxidation (dapsone), s-oxidation (cimetidine) and</td></tr><tr><td>aromatic hydroxylation (propranolol).</td><td></td></tr><tr><td></td><td>R&amp;D 7e Ch 9, pp 115-117; D&amp;H Ch 7, p 22</td></tr></table>
</page>
<page number="644">
<table id="p644t1" data-filename="pdftables_fromstorage_023782248" data-page="644" data-table="1"><tr><td></td><td colspan="2">P450 inducers/</td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">38.03</td><td>inhibitors</td><td></td><td>Drug metabolism and excretion</td><td></td><td></td><td></td></tr><tr><td colspan="7">The concentration of a drug in the body is reduced either by its metabolism or by its excretion unchanged.</td></tr><tr><td></td><td></td><td></td><td></td><td>n via lungs</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Excretio</td><td></td><td>Drug in exhaled air</td></tr><tr><td></td><td></td><td>n</td><td>Drug in body</td><td>Unchanged drug</td><td></td><td></td></tr><tr><td></td><td></td><td>excretio</td><td></td><td></td><td>excretion</td><td></td></tr><tr><td></td><td></td><td>Biliary</td><td>Oxidation</td><td></td><td>by</td><td>kidney</td></tr><tr><td></td><td>CytP450</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Reduction</td><td>Phase I</td><td></td><td></td><td></td></tr><tr><td>Drug or metabolite</td><td></td><td></td><td></td><td></td><td></td><td>Unchanged drug or</td></tr><tr><td>in faeces</td><td></td><td>Hydrolysis</td><td></td><td></td><td></td><td>metabolite in urine</td></tr><tr><td></td><td></td><td></td><td>Phase II</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Conjugation</td><td></td><td></td><td></td><td>idney</td></tr><tr><td></td><td></td><td>Bil</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>iary</td><td></td><td></td><td>by k</td><td></td></tr><tr><td></td><td></td><td>excretion</td><td>Drug metabolite</td><td>bolite</td><td>tion excre</td><td></td></tr><tr><td></td><td></td><td></td><td>in body</td><td>Drug meta</td><td></td><td></td></tr></table>
</page>
<page number="645">
<table id="p645t1" data-filename="pdftables_fromstorage_023782248" data-page="645" data-table="1"><tr><td></td><td></td><td></td><td>P450 induction</td></tr><tr><td></td><td></td><td></td><td>and inhibition</td></tr><tr><td></td><td colspan="3">The activity of the P450 system can be increased (induced) or inhibited by drugs or by dietary constituents.</td></tr><tr><td></td><td colspan="3">This is an important cause of drug interactions. The induction or inhibition of particular P450 isoenzymes will</td></tr><tr><td></td><td colspan="3">either reduce or enhance the activity of drugs metabolised by the enzyme. Just a few examples are:</td></tr><tr><td>Drug metabolising</td><td>Inducers</td><td>Inhibitors</td><td>Substrates affected</td></tr><tr><td>P450s</td><td></td><td></td><td></td></tr><tr><td>CYP1A2</td><td>Omeprazole, modafinil</td><td>Fluvoxamine, ciprofloxacin,</td><td>Clomipramine, clozapine,</td></tr><tr><td></td><td></td><td>cimetidine, amiodarone</td><td>paracetamol</td></tr><tr><td>CYP2B6</td><td>Phenobarbital, rifampin</td><td>Ticlopidine</td><td>Bupropion, cyclophosphamide,</td></tr><tr><td></td><td></td><td></td><td>methadone</td></tr><tr><td>CYP2C8</td><td>Rifampin</td><td>Gemfibrozil, trimethoprim</td><td>Paclitaxel, repaglinide</td></tr><tr><td>CYP2C19</td><td>Carbamazepine, prednisone</td><td>Omeprazole, fluoxetine,</td><td>Omeprazole, diazepam,</td></tr><tr><td></td><td>rifampin</td><td>topiramate</td><td>phenytoin</td></tr><tr><td>CYP2C9</td><td>Rifampin, secobarbital</td><td>Fluconazole, amiodarone</td><td>Ibuprofen, tolbutamide,</td></tr><tr><td></td><td></td><td></td><td>losartan, tamoxifen</td></tr><tr><td>CYP2D6</td><td>Dexamethasone, rifampin</td><td>Fluoxetine, quinidine,</td><td>Codeine, lidocaine,</td></tr><tr><td></td><td></td><td>terbinafine</td><td>propranolol</td></tr><tr><td>CYP2E1</td><td>Ethanol, isoniazid</td><td>Disulfiram</td><td>Ethanol, paracetamol,</td></tr><tr><td></td><td></td><td></td><td>halothane</td></tr><tr><td>CYP3A4,5,7</td><td>Nevirapine, barbiturates,</td><td>Indinavir, clarithromycin,</td><td>Ciclosporin, terfenadine,</td></tr><tr><td></td><td>carbamazepine, rifampin</td><td>itraconazole, grapefruit juice</td><td>simvastatin, buspirone</td></tr><tr><td></td><td></td><td></td><td>R&amp;D 7e Ch 9, p 117-118; D&amp;H Ch 7, p 22</td></tr></table>
</page>
<page number="646">
<table id="p646t1" data-filename="pdftables_fromstorage_023782248" data-page="646" data-table="1"><tr><td></td><td colspan="2">Renal excretion</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">38.04</td><td colspan="2">of drugs</td><td>Drug metabolism and excretion</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">The concentration of a drug in the body is reduced either by its metabolism or by its excretion unchanged.</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">n via lungs</td><td></td><td></td></tr><tr><td></td><td colspan="2">P450</td><td></td><td>Excretio</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">inducers</td><td></td><td></td><td></td><td></td><td>Drug in exhaled air</td></tr><tr><td>P450</td><td></td><td></td><td>Drug in body</td><td>Unchanged</td><td></td><td></td><td></td></tr><tr><td>inhibitors</td><td></td><td>retion</td><td></td><td>drug</td><td>excre</td><td>tion</td><td></td></tr><tr><td></td><td>Biliary</td><td></td><td>Oxidation</td><td></td><td></td><td>by</td><td>kidney</td></tr><tr><td></td><td colspan="2">CytP450</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Reduction</td><td>Phase I</td><td></td><td></td><td></td><td></td></tr><tr><td>Drug or metabolite</td><td></td><td></td><td></td><td></td><td></td><td></td><td>Unchanged drug or</td></tr><tr><td>in faeces</td><td></td><td>Hydrolysis</td><td></td><td></td><td></td><td></td><td>metabolite in urine</td></tr><tr><td></td><td></td><td></td><td>Phase II</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Conjugation</td><td></td><td></td><td></td><td></td><td>idney</td></tr><tr><td></td><td></td><td>Bil</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>iary</td><td></td><td></td><td></td><td>by k</td><td></td></tr><tr><td></td><td></td><td>excretion</td><td>Drug metabolite</td><td></td><td colspan="2">tion excre</td><td></td></tr><tr><td></td><td></td><td></td><td>in body</td><td>Drug metabolite</td><td></td><td></td><td></td></tr></table>
</page>
<page number="647">
<table id="p647t1" data-filename="pdftables_fromstorage_023782248" data-page="647" data-table="1"><tr><td></td><td>Renal excretion</td></tr><tr><td></td><td>of drugs</td></tr><tr><td></td><td>Most are excreted into the urine, either in an unchanged form or as a metabolite.</td></tr><tr><td></td><td>Three renal processes are involved:</td></tr><tr><td>Glomerular</td><td>Small drug molecules are forced across the glomerular membrane by the pressure in the renal</td></tr><tr><td>filtration</td><td>arteries, entering the renal tubule at a concentration equal to that in the plasma. Drug bound to</td></tr><tr><td></td><td>plasma proteins will not be filtered.</td></tr><tr><td>Tubular</td><td>Drug molecules which are not filtered pass to capillaries surrounding the proximal convoluted</td></tr><tr><td>secretion</td><td>tubule. Here separate anion and cation transporters secrete drugs into the urine. This process can be</td></tr><tr><td></td><td>very effective, possibly removing most of a drug (e.g. benzylpenicillin) from the blood in a single</td></tr><tr><td></td><td>passage. The process is saturable and subject to competition. Thus probenecid inhibits the transport</td></tr><tr><td></td><td>of the weak acid penicillin.</td></tr><tr><td>Tubular</td><td>As water is reabsorbed from the filtrate, the concentration of drug in the urine rises and unionised,</td></tr><tr><td>reabsorption</td><td>lipid-soluble drug is also reabsorbed. Excretion of suitable drugs can be modified by manipulating</td></tr><tr><td></td><td>urinary pH to change the fraction of drug ionised. In forced alkaline diuresis the ionisation of acidic</td></tr><tr><td></td><td>drugs, e.g. salicylate, is increased, so reducing reabsorption and increasing clearance. (May be useful</td></tr><tr><td></td><td>in drug overdose.)</td></tr><tr><td></td><td>R&amp;D 7e Ch 9, p 119-121; D&amp;H Ch 7, p 23</td></tr></table>
</page>
<page number="648">
<table id="p648t1" data-filename="pdftables_fromstorage_023782248" data-page="648" data-table="1"><tr><td></td><td colspan="2">Other routes</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">38.05</td><td colspan="2">of excretion</td><td>Drug metabolism and excretion</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="8">The concentration of a drug in the body is reduced either by its metabolism or by its excretion unchanged.</td></tr><tr><td></td><td></td><td></td><td></td><td>n via lungs</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">P450</td><td></td><td>Excretio</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Drug in exhaled air</td></tr><tr><td></td><td colspan="2">inducers</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P450</td><td></td><td></td><td>Drug in body</td><td>Unchanged</td><td></td><td></td><td></td></tr><tr><td>inhibitors</td><td></td><td>retion</td><td></td><td>drug</td><td>excre</td><td>tion</td><td></td></tr><tr><td></td><td>Biliary</td><td></td><td>Oxidation</td><td></td><td></td><td>by</td><td>kidney</td></tr><tr><td></td><td colspan="2">CytP450</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">Reduction</td><td>Phase I</td><td>Glomerular filtration</td><td></td><td></td><td></td></tr><tr><td>Drug or metabolite</td><td></td><td></td><td></td><td>Tubular reabsorption</td><td></td><td></td><td>Unchanged drug or</td></tr><tr><td>in faeces</td><td></td><td>Hydrolysis</td><td></td><td></td><td></td><td></td><td>metabolite in urine</td></tr><tr><td></td><td></td><td></td><td></td><td>Tubular secretion</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Phase II</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Prob-enecid</td><td></td><td></td><td>ey</td></tr><tr><td></td><td></td><td>Conjugation</td><td></td><td></td><td></td><td></td><td>idn</td></tr><tr><td></td><td></td><td>Bil</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>iary</td><td></td><td></td><td></td><td>by k</td><td></td></tr><tr><td></td><td></td><td>excretion</td><td>Drug metabolite</td><td></td><td colspan="2">tion excre</td><td></td></tr><tr><td></td><td></td><td></td><td>in body</td><td>Drug metabolite</td><td></td><td></td><td></td></tr></table>
</page>
<page number="649">
<table id="p649t1" data-filename="pdftables_fromstorage_023782248" data-page="649" data-table="1"><tr><td></td><td>Other routes</td></tr><tr><td></td><td>of excretion</td></tr><tr><td>Biliary excretion</td><td>For some drugs (e.g. cromoglicate, vecuronium) biliary excretion of drug or metabolite is more</td></tr><tr><td></td><td>important than renal excretion. Biliary excretion is by active transport, which is saturable and</td></tr><tr><td></td><td>subject to competition. Drug excreted in bile may be reabsorbed from the intestine and enter</td></tr><tr><td></td><td>an ‘enterohepatic circulation’. Drug tied up in this ‘enteric pool’ acts as a reservoir which</td></tr><tr><td></td><td>may increase the drug’s half-life.</td></tr><tr><td>Excretion via</td><td>Volatile/gaseous agents can be readily excreted via the lungs, which receive the whole of the</td></tr><tr><td>lungs</td><td>cardiac output and which have thin membranes which are very permeable to small gas</td></tr><tr><td></td><td>molecules. The main agents lost via the lungs are the gaseous/volatile anaesthetics.</td></tr><tr><td></td><td>R&amp;D 7e Ch 9, p 119; D&amp;H Ch 7, p 23</td></tr></table>
</page>
<page number="650">
<table id="p650t1" data-filename="pdftables_fromstorage_023782248" data-page="650" data-table="1"><tr><td></td><td>First-order</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">39.01</td><td>elimination</td><td colspan="4">Pharmacokinetics</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6">The time-course of drug concentrations in the plasma</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10">A1 and A2 illustrate an exponential fall in plasma concentration after i.v. administration (A1 uses a linear</td><td></td><td></td></tr><tr><td colspan="10">concentration scale, A2 a logarithmic scale). B shows a drug whose concentration falls in a linear fashion.</td><td></td><td></td></tr><tr><td></td><td>A1</td><td></td><td></td><td></td><td></td><td>B</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3">Linear decline</td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.8</td><td></td><td></td><td></td><td></td><td style="text-align: right">0.8</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.6</td><td></td><td></td><td></td><td></td><td style="text-align: right">0.6</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.4</td><td></td><td></td><td></td><td></td><td style="text-align: right">0.4</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Exponential decline</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.2</td><td></td><td></td><td></td><td></td><td style="text-align: right">0.2</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">0</td><td style="text-align: right">20</td><td style="text-align: right">40</td><td style="text-align: right">60</td><td style="text-align: right">80</td><td style="text-align: right">100</td></tr><tr><td></td><td>A2</td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Time, min</td><td></td><td></td></tr><tr><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.5</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.25</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.125</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0</td><td style="text-align: right">20</td><td style="text-align: right">40</td><td style="text-align: right">60</td><td style="text-align: right">80</td><td style="text-align: right">100</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Time, min</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="651">
<table id="p651t1" data-filename="pdftables_fromstorage_023782248" data-page="651" data-table="1"><tr><td>First-order</td></tr><tr><td>elimination</td></tr><tr><td>Where passive diffusion is responsible for absorption or excretion, drug transport is often first order, i.e. the</td></tr><tr><td>rate is proportional to the concentration gradient. First-order kinetics is exemplified by the exponentially</td></tr><tr><td>declining plasma concentration of the drug, cp, which follows first-order elimination after i.v. administration</td></tr><tr><td>(Fig. A1 overleaf)*. The equation describing this decline is:</td></tr><tr><td>c p = cp (0)e – kelt</td></tr><tr><td>Where cp is the drug concentration in the plasma, cp (0) is the initial drug concentration at time t = 0 and kel</td></tr><tr><td>is the elimination rate constant.</td></tr><tr><td>The relationship can be linearised by taking logarithms (Fig. A2 overleaf). For natural logarithms (ln):</td></tr><tr><td>In cp = In c p (0) – kel t</td></tr><tr><td>A plot of ln c p against time gives a straight line of slope –kel .</td></tr><tr><td>*Note: A simple exponential decline will only be observed where the body behaves as one compartment – see D&amp;H ref.</td></tr><tr><td>R&amp;D 7e Ch 10, pp 124-126; D&amp;H 2e Ch 8, pp 24-25</td></tr></table>
</page>
<page number="652">
<table id="p652t1" data-filename="pdftables_fromstorage_023782248" data-page="652" data-table="1"><tr><td></td><td>Zero-order</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">39.02</td><td>elimination</td><td colspan="4">Pharmacokinetics</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6">The time-course of drug concentrations in the plasma</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10">A1 and A2 illustrate an exponential fall in plasma concentration after i.v. administration (A1 uses a linear</td><td></td><td></td></tr><tr><td colspan="10">concentration scale, A2 a logarithmic scale). B shows a drug whose concentration falls in a linear fashion.</td><td></td><td></td></tr><tr><td></td><td>A1</td><td></td><td></td><td></td><td></td><td>B</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="3">First-order</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="3">elimination</td><td></td><td></td><td colspan="3">Linear decline</td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.8</td><td></td><td></td><td></td><td></td><td style="text-align: right">0.8</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Elimination rate</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.6</td><td></td><td></td><td colspan="2">constant = 0.03min-1</td><td style="text-align: right">0.6</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.4</td><td></td><td></td><td></td><td></td><td style="text-align: right">0.4</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Exponential decline</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.2</td><td></td><td></td><td></td><td></td><td style="text-align: right">0.2</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">0</td><td style="text-align: right">20</td><td style="text-align: right">40</td><td style="text-align: right">60</td><td style="text-align: right">80</td><td style="text-align: right">100</td></tr><tr><td></td><td>A2</td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Time, min</td><td></td><td></td></tr><tr><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.5</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.25</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.125</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0</td><td style="text-align: right">20</td><td style="text-align: right">40</td><td style="text-align: right">60</td><td style="text-align: right">80</td><td style="text-align: right">100</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Time, min</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="653">
<table id="p653t1" data-filename="pdftables_fromstorage_023782248" data-page="653" data-table="1"><tr><td></td><td>Zero-order</td></tr><tr><td></td><td>elimination</td></tr><tr><td colspan="2">Zero-order kinetics applies when the rate of a process (e.g. drug metabolism) is independent of the drug’s</td></tr><tr><td colspan="2">concentration (Fig. B overleaf). Zero-order kinetics will be found where an enzyme reaction or membrane</td></tr><tr><td colspan="2">transport process has been saturated. These processes follow Michaelis-Menten kinetics.</td></tr><tr><td colspan="2">Where the process lowers the drug concentration in the plasma (cp ):</td></tr><tr><td>dc p</td><td>Vmax • cp</td></tr><tr><td>–</td><td>=</td></tr><tr><td>dt</td><td>c p + K M</td></tr><tr><td colspan="2">Where Vmax is the maximum rate of transport or biotransformation and KM is the Michaelis constant.</td></tr><tr><td colspan="2">When the drug concentration is high (relative to K M), and the process effectively saturated, the equation reduces to:</td></tr><tr><td>dc</td><td></td></tr><tr><td>p</td><td></td></tr><tr><td>–</td><td>≈ V</td></tr><tr><td></td><td>max</td></tr><tr><td>dt</td><td></td></tr><tr><td colspan="2">The rate of change of concentration has reached a maximum and is now unaffected by the drug concentration.</td></tr><tr><td colspan="2">(Cp declines at a fixed rate (Fig. B overleaf)).</td></tr><tr><td colspan="2">Ethanol is a well-known example of a substance subject to first-order elimination.</td></tr><tr><td></td><td>R&amp;D 7e Ch 10, pp 128-129; D&amp;H 2e Ch 8, pp 24-25</td></tr></table>
</page>
<page number="654">
<table id="p654t1" data-filename="pdftables_fromstorage_023782248" data-page="654" data-table="1"><tr><td></td><td></td><td colspan="2">Plasma</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td style="text-align: right">39.03</td><td></td><td colspan="2">half-life</td><td colspan="2">Pharmacokinetics</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6">The time-course of drug concentrations in the plasma</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="11">A1 and A2 illustrate an exponential fall in plasma concentration after i.v. administration (A1 uses a linear</td><td></td></tr><tr><td colspan="11">concentration scale, A2 a logarithmic scale). B shows a drug whose concentration falls in a linear fashion.</td><td></td></tr><tr><td></td><td>A1</td><td></td><td></td><td></td><td></td><td>B</td><td></td><td></td><td></td><td>Zero-order</td><td></td></tr><tr><td></td><td></td><td colspan="3">First-order</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="3">elimination</td><td></td><td></td><td colspan="3">Linear decline</td><td>elimination</td><td></td></tr><tr><td></td><td style="text-align: right">0.8</td><td></td><td></td><td></td><td></td><td style="text-align: right">0.8</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Elimination rate</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.6</td><td></td><td></td><td colspan="2">constant = 0.03min -1</td><td style="text-align: right">0.6</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Constant</td></tr><tr><td></td><td style="text-align: right">0.4</td><td></td><td></td><td></td><td></td><td style="text-align: right">0.4</td><td></td><td></td><td></td><td></td><td>elimination rate</td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Exponential decline</td><td></td><td></td><td></td><td></td><td></td><td>of 0.006</td></tr><tr><td></td><td style="text-align: right">0.2</td><td></td><td></td><td></td><td></td><td style="text-align: right">0.2</td><td></td><td></td><td></td><td></td><td>units min-1</td></tr><tr><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">0</td><td style="text-align: right">20</td><td style="text-align: right">40</td><td style="text-align: right">60</td><td style="text-align: right">80</td><td style="text-align: right">100</td></tr><tr><td></td><td>A2</td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Time, min</td><td></td><td></td></tr><tr><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.5</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.25</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.125</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0</td><td style="text-align: right">20</td><td style="text-align: right">40</td><td style="text-align: right">60</td><td style="text-align: right">80</td><td style="text-align: right">100</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Time, min</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="655">
<table id="p655t1" data-filename="pdftables_fromstorage_023782248" data-page="655" data-table="1"><tr><td></td><td></td><td></td><td colspan="2">Plasma</td></tr><tr><td></td><td></td><td></td><td colspan="2">half-life</td></tr><tr><td colspan="5">A feature of exponential decline in cp according to first-order elimination is that in a given period of time</td></tr><tr><td colspan="5">the concentration will reduce by the same proportion. (One-compartment system is assumed.) In particular,</td></tr><tr><td colspan="4">the plasma half-life, T0.5, is the time taken for any given plasma concentration to fall by 50%.</td><td></td></tr><tr><td colspan="3">It is relatively easy to show that in the equation (from card 39.01):</td><td colspan="2">Representative plasma</td></tr><tr><td></td><td></td><td></td><td colspan="2">half-lives of drugs, h</td></tr><tr><td></td><td></td><td></td><td>Insulin</td><td style="text-align: right">0.1</td></tr><tr><td>c</td><td>= c</td><td>(0)e– k elt</td><td></td><td></td></tr><tr><td>p</td><td colspan="2">p</td><td>Aspirin</td><td style="text-align: right">0.25</td></tr><tr><td></td><td></td><td></td><td>Penicillin G</td><td style="text-align: right">0.7</td></tr><tr><td colspan="3">When t is made equal to t 1⁄2 and cp is made equal to a half of cp(0) then:</td><td>Lidocaine</td><td style="text-align: right">2.0</td></tr><tr><td></td><td></td><td></td><td>Salicylate</td><td style="text-align: right">4.0</td></tr><tr><td></td><td></td><td></td><td>Sulfadiazine</td><td>13–25</td></tr><tr><td colspan="3">t1⁄2 = 0.693/ kel</td><td>Atropine</td><td>12–38</td></tr><tr><td></td><td></td><td></td><td>Chlorpromazine</td><td style="text-align: right">30</td></tr><tr><td></td><td></td><td></td><td>Phenobarbitone</td><td>48–120</td></tr><tr><td colspan="3">Thus in the example given here T0.5 = 0.693/0.03, i.e. 23min.</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Digitoxin</td><td style="text-align: right">200</td></tr><tr><td></td><td></td><td></td><td colspan="2">R&amp;D 7e Ch 10, p 127; D&amp;H 2e Ch 8, pp 24-25</td></tr></table>
</page>
<page number="656">
<table id="p656t1" data-filename="pdftables_fromstorage_023782248" data-page="656" data-table="1"><tr><td style="text-align: right">39.04</td><td colspan="2">Clearance</td><td colspan="3">Pharmacokinetics</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6">The time-course of drug concentrations in the plasma</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10">A1 and A2 illustrate an exponential fall in plasma concentration after i.v. administration (A1 uses a linear</td><td></td><td></td></tr><tr><td colspan="10">concentration scale, A2 a logarithmic scale). B shows a drug whose concentration falls in a linear fashion.</td><td></td><td></td></tr><tr><td>A1</td><td></td><td></td><td></td><td></td><td></td><td>B</td><td></td><td></td><td></td><td colspan="2">Zero-order</td></tr><tr><td></td><td></td><td colspan="3">First-order</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td colspan="3">elimination</td><td></td><td></td><td colspan="3">Linear decline</td><td colspan="2">elimination</td></tr><tr><td></td><td style="text-align: right">0.8</td><td></td><td></td><td></td><td></td><td style="text-align: right">0.8</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Elimination rate</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.6</td><td></td><td></td><td colspan="2">constant = 0.03min -1</td><td style="text-align: right">0.6</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.4</td><td></td><td></td><td></td><td></td><td style="text-align: right">0.4</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="2">Exponential decline</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.2</td><td></td><td></td><td></td><td></td><td style="text-align: right">0.2</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td style="text-align: right">0</td><td style="text-align: right">20</td><td style="text-align: right">40</td><td style="text-align: right">60</td><td style="text-align: right">80</td><td style="text-align: right">100</td></tr><tr><td>A2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2">Time, min</td><td></td><td></td></tr><tr><td></td><td style="text-align: right">1.0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.5</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.25</td><td></td><td></td><td></td><td>Half-life</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>T 0.5 = 23min.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td style="text-align: right">0.125</td><td></td><td></td><td></td><td></td><td colspan="6">In this example, the plasma concentration of drug reduces</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="6">from 1 to 0.5 to 0.25 to 0.125 units in successive half-lives.</td></tr><tr><td></td><td style="text-align: right">0</td><td style="text-align: right">20</td><td style="text-align: right">40</td><td style="text-align: right">60</td><td style="text-align: right">80</td><td style="text-align: right">100</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="2">Time, min</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table>
</page>
<page number="657">
<table id="p657t1" data-filename="pdftables_fromstorage_023782248" data-page="657" data-table="1"><tr><td></td><td></td><td>Clearance</td></tr><tr><td colspan="3">Another useful way of quantifying drug elimination is by its clearance. Drug clearance (CI) is defined as the</td></tr><tr><td colspan="3">volume of plasma cleared of drug per unit time. Thus (assuming first-order, one-compartment behaviour):</td></tr><tr><td></td><td></td><td>elimination rate</td></tr><tr><td></td><td>Clearance =</td><td></td></tr><tr><td></td><td>plasma concentration</td><td></td></tr><tr><td colspan="3">The elimination rate is also given by the amount of drug in body cp V d multiplied by kel . Vd = volume of distribution.</td></tr><tr><td></td><td>Therefore:</td><td></td></tr><tr><td></td><td>k elcp V d</td><td></td></tr><tr><td></td><td>Cl =</td><td>= k el Vd</td></tr><tr><td>As kel = 0.693/t1⁄2, clearance = 0.693Vd /t1⁄2</td><td></td><td></td></tr><tr><td colspan="3">Total body clearance is the sum of the clearances occurring by whatever routes are applicable to the drug in question;</td></tr><tr><td colspan="2">often only renal and hepatic clearances are important.</td><td></td></tr><tr><td colspan="3">A drug’s clearance can be used to determine the expected steady-state concentration in the plasma, css,</td></tr><tr><td colspan="3">during infusion or regular intermittent dosing. In the steady state, the rate of drug administration</td></tr><tr><td colspan="3">(e.g. 500mg/day) will equal the rate of loss (elimination rate, i.e. Cl x css ). Therefore, css is given by the dose rate</td></tr><tr><td colspan="3">divided by the clearance. Alternatively, by knowing the clearance of a drug and the desired target plasma</td></tr><tr><td colspan="2">concentration, it is possible to calculate the required dose rate (Cl x css ).</td><td></td></tr><tr><td></td><td></td><td>R&amp;D 7e Ch 10, p 124; D&amp;H 2e Ch 8, pp 24-25</td></tr><tr><td colspan="2">6QMPBEFECZ&lt;4UPSN3(&gt;</td><td></td></tr></table>
</page>
</document>
